U.S. patent application number 11/592127 was filed with the patent office on 2007-03-01 for molecular antigen array.
This patent application is currently assigned to Cytos Biotechnology AG. Invention is credited to Martin Bachmann, Franziska Lechner, Patrick Maurer, Christine Piossek, Wolfgang A. Renner, Peter Sebbel, Alain Tissot.
Application Number | 20070048287 11/592127 |
Document ID | / |
Family ID | 27500737 |
Filed Date | 2007-03-01 |
United States Patent
Application |
20070048287 |
Kind Code |
A1 |
Renner; Wolfgang A. ; et
al. |
March 1, 2007 |
Molecular antigen array
Abstract
The present invention is related to the fields of molecular
biology, virology, immunology and medicine. The invention provides
a composition comprising an ordered and repetitive antigen or
antigenic determinant array. The invention also provides a process
for producing an antigen or antigenic determinant in an ordered and
repetitive array. The ordered and repetitive antigen or antigenic
determinant is useful in the production of vaccines for the
treatment of infectious diseases, the treatment of allergies and as
a pharmaccine to prevent or cure cancer and to efficiently induce
self-specific immune responses, in particular antibody
responses.
Inventors: |
Renner; Wolfgang A.;
(Zurich, CH) ; Bachmann; Martin; (Winterthur,
CH) ; Tissot; Alain; (Zurich, CH) ; Maurer;
Patrick; (Winterthur, CH) ; Lechner; Franziska;
(Zurich, CH) ; Sebbel; Peter; (Zurich, CH)
; Piossek; Christine; (Winterthur, CH) |
Correspondence
Address: |
STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVENUE, N.W.
WASHINGTON
DC
20005
US
|
Assignee: |
Cytos Biotechnology AG
Zurich-Schlieren
CH
|
Family ID: |
27500737 |
Appl. No.: |
11/592127 |
Filed: |
November 3, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10050902 |
Jan 18, 2002 |
|
|
|
11592127 |
Nov 3, 2006 |
|
|
|
60262379 |
Jan 19, 2001 |
|
|
|
60288549 |
May 4, 2001 |
|
|
|
60326998 |
Oct 5, 2001 |
|
|
|
60331045 |
Nov 7, 2001 |
|
|
|
Current U.S.
Class: |
424/93.2 ;
435/456; 977/802 |
Current CPC
Class: |
A61K 39/12 20130101;
C12N 2795/18134 20130101; A61P 33/12 20180101; A61P 37/08 20180101;
C07K 14/005 20130101; C07K 2317/34 20130101; C12N 2730/10123
20130101; C12N 2795/18122 20130101; A61P 31/18 20180101; A61K
2039/5258 20130101; A61P 29/00 20180101; A61P 37/00 20180101; A61K
39/35 20130101; C07K 2317/52 20130101; C07K 14/5437 20130101; C07K
16/00 20130101; C07K 16/4291 20130101; C07K 14/523 20130101; C12N
7/00 20130101; C07K 2319/00 20130101; A61P 39/00 20180101; A61K
47/6901 20170801; A61P 37/02 20180101; C07K 16/22 20130101; A61K
39/0005 20130101; A61K 39/385 20130101; C07K 16/2875 20130101; Y02A
50/412 20180101; A61K 39/001 20130101; A61K 39/39 20130101; C07K
16/082 20130101; C07K 2317/55 20130101; A61P 25/28 20180101; A61P
31/16 20180101; A61P 31/00 20180101; A61P 31/12 20180101; C07K
14/5409 20130101; A61P 37/04 20180101; C12N 2730/10122 20130101;
A61K 38/00 20130101; A61K 2039/627 20130101; C07K 2319/30 20130101;
A61K 39/0008 20130101; A61K 39/0007 20130101; A61K 2039/5256
20130101; A61P 35/00 20180101; C07K 16/2863 20130101; Y02A 50/467
20180101; A61K 2039/6075 20130101; C07K 16/40 20130101; Y02A 50/30
20180101 |
Class at
Publication: |
424/093.2 ;
435/456; 977/802 |
International
Class: |
A61K 48/00 20060101
A61K048/00; C12N 15/86 20060101 C12N015/86 |
Claims
1. A composition comprising: (a) a non-natural molecular scaffold
comprising: (i) a core particle comprising a virus-like particle of
an RNA bacteriophage; and (ii) an organizer comprising at least one
first attachment site, wherein said organizer is connected to said
core particle by at least one covalent bond; and wherein said first
attachment site is not a sulfhydryl group; and (b) an antigen or
antigenic determinant with at least one second attachment site,
wherein said second attachment site is capable of association
through at least one non-peptide bond to said first attachment
site; and wherein said antigen or antigenic determinant and said
scaffold interact through said association to form an ordered and
repetitive antigen array.
2. The composition of claim 1, wherein said RNA bacteriophage is
selected from the group consisting of: (a) bacteriophage Q.beta.;
(b) bacteriophage R17; (c) bacteriophage fr; (d) bacteriophage GA;
(e) bacteriophage SP; (f) bacteriophage MS2; (g) bacteriophage M11;
(h) bacteriophage MX1; (i) bacteriophage NL95; (j) bacteriophage
f2; and (k) bacteriophage PP7.
3. The composition of claim 1, wherein said bacteriophage is
bacteriophage Q.beta..
4. The composition of claim 1, wherein said virus-like particle of
an RNA bacteriophage comprises recombinant proteins, or fragments
thereof, of an RNA bacteriophage.
5. The composition of claim 4, wherein said bacteriophage is
bacteriophage Q.beta..
6. The composition of claim 1, wherein said virus-like particle of
an RNA bacteriophage comprises recombinant coat proteins comprising
an amino acid sequence selected from the group consisting of: (a)
SEQ ID NO:159; (b) SEQ ID NO:160; (c) SEQ ID NO:161; (d) SEQ ID
NO:162; (e) SEQ ID NO:163; (f) SEQ ID NO:164; (g) SEQ ID NO:165;
(h) SEQ ID NO:166; (i) SEQ ID NO:167; (j) SEQ ID NO:215; (k) SEQ ID
NO:253; (l) SEQ ID NO:217; and (m) SEQ ID NO:254.
7. The composition of claim 1, wherein said virus-like particle of
an RNA bacteriophage comprises recombinant coat proteins having an
amino acid sequence of SEQ ID NO:159, or a mixture of coat proteins
having amino acid sequences of SEQ ID NO:159 and of SEQ ID
NO:217.
8. The composition of claim 1, wherein said virus-like particle of
an RNA bacteriophage comprises one or more coat proteins of said
RNA bacteriophage that have been modified by deletion or
substitution to remove at least one naturally occurring lysine
residue, or that have been modified by insertion or substitution to
add at least one lysine residue.
9. The composition of claim 8, wherein said RNA bacteriophage is
Q.beta..
10. The composition of claim 1, wherein said virus-like particle of
an RNA bacteriophage comprises one or more coat proteins comprising
an amino acid sequence selected from the group consisting of: (a)
SEQ ID NO:255; (b) SEQ ID NO:256; (c) SEQ ID NO:257; (d) SEQ ID
NO:258; (e) SEQ ID NO:259; and (f) a mixture of any one of (a)-(e)
and the corresponding A1 protein.
11. The composition of claim 1, wherein said organizer is an
integral part of said RNA bacteriophage.
12. The composition of claim 1, wherein said association is by way
of at least one covalent bond.
13. The composition of claim 1 further comprising an amino acid
linker.
14. The composition of claim 13, wherein said amino acid linker is
bound to said antigen or said antigenic determinant by way of at
least one covalent bond.
15. The composition of claim 14, wherein said covalent bond is a
peptide bond.
16. The composition of claim 13, wherein said amino acid linker
comprises said second attachment site.
17. The composition of claim 13, wherein said amino acid linker
comprises a sulfhydryl group.
18. The composition of claim 13, wherein said amino acid linker
comprises a cysteine residue.
19. The composition of claim 1, wherein said first attachment site
comprises: (a) an amino group; (b) a chemical group reactive to an
amino group; (c) a carboxyl group; (d) a chemical group reactive to
a carboxyl group; (e) biotin; (f) avidin; (g) strepavidin; or (h)
interacting leucine zipper polypeptide.
20. The composition of claim 1, wherein said second attachment site
comprises: (a) an amino group; (b) a chemical group reactive to an
amino group; (c) a carboxyl group; (d) a chemical group reactive to
a carboxyl group; (e) a sulfhydryl group; (f) a chemical group
reactive to a sulfhydryl group. (g) biotin; (h) avidin; (i)
strepavidin; or (j) interacting leucine zipper polypeptide.
21. The composition of claim 1, wherein said first attachment site
and said second attachment site are associated through a
heterobifunctional linker.
22. The composition of claim 21, wherein said heterobifunctional
linker is selected from the group consisting of: (a) a
maleimidocaproic acid N-hydroxysuccinimide ester; (b)
N-Succinimidyl 3-(2-pyridyldithio)propionate (SPDP); and (c)
Sulfo-MBS.
23. The composition of claim 1, wherein said first attachment site
comprises an amino group.
24. The composition of claim 1, wherein said first attachment site
is an amino group or is a lysine residue.
25. The composition of claim 1, wherein said second attachment site
comprises a sulfhydryl group.
26. The composition of claim 1, wherein said second attachment site
is a sulfhydryl group or is a cysteine residue.
27. The composition of claim 1, wherein said second attachment site
does not naturally occur within said antigen or antigenic
determinant.
28. The composition of claim 1, wherein said first attachment site
comprises an amino group and said second attachment site comprises
a sulfhydryl group.
29. The composition of claim 1, wherein said first attachment site
is an amino group and said second attachment site is a sulfhydryl
group.
30. The composition of claim 1, wherein said first attachment site
is a lysine residue and said second attachment site is a cysteine
residue.
31. The composition of claim 1, wherein only one of said second
attachment sites associates with said first attachment site through
at least one non-peptide covalent bond leading to a single and
uniform type of binding of said antigen to said core particle,
wherein said only one second attachment site that associates with
said first attachment site is a sulfhydryl group.
32. The composition of claim 1, wherein said antigen is a protein
or a fragment thereof, being selected from the group consisting of:
(a) proteins suitable to induce an immune response against
allergens, (b) proteins suitable to induce an immune response
against cancer cells, (c) proteins suitable to induce an immune
response against infectious diseases, and (d) proteins suitable to
induce an immune response in farm animals or pets.
33. The composition of claim 1, wherein said antigen is: a
recombinant protein of bee sting allergy, a recombinant protein of
nut allergy, a recombinant protein of food allergies, a recombinant
protein of asthma, a recombinant protein of breast cancer cells, a
recombinant protein of kidney cancer cells, a recombinant protein
of prostate cancer cells, a recombinant protein of skin cancer
cells, a recombinant protein of brain cancer cells, a recombinant
protein of leukemia cells, a recombinant protein of Influenza
virus, a recombinant protein of HIV, a recombinant protein of
Hepatitis C virus, a recombinant protein of Toxoplasma, a
recombinant protein of Plasmodium falciparum, a recombinant protein
of Plasmodium vivax, a recombinant protein of Plasmodium ovale, a
recombinant protein of Plasmodium malariae, a recombinant protein
of Chlamydia.
34. The composition of claim 1, wherein said antigen is suitable to
prevent or treat an infectious disease of viral etiology.
35. The composition of claim 34, wherein said infectious disease of
viral etiology is selected from the group consisting of: HIV,
influenza, herpes, viral hepatitis, Epstein Bar, or viral
encephalitis.
36. The composition of claim 1, wherein said antigen is suitable to
prevent or treat an infectious disease of bacterial etiology.
37. The composition of claim 36, wherein said infectious disease of
bacterial etiology is a pneumonia, syphillis or tuberculosis.
38. The composition of claim 1, wherein said antigen is suitable to
prevent or treat an infectious disease of parasitic etiology.
39. The composition of claim 38, wherein said infectious disease of
parasitic etiology is malaria, trypanosomiasis, leishmaniasis,
trichomoniasis or amoebiasis.
40. The composition of claim 1, wherein said antigen or antigenic
determinant is a peptide, a protein, or a fragment of a protein,
selected from the group consisting of: (a) an Influenza M2 protein;
(b) a phospholipase A2 protein; and (c) a Der p I peptide.
41. The composition of claim 1, wherein said antigen or said
antigenic determinant is an influenza M2 protein, or a fragment
thereof.
42. The composition of claim 1, wherein said antigen or antigenic
determinant is the M2 protein of SEQ ID NO: 213 or a fragment
thereof being at least 6 amino acids in length.
43. The composition of claim 1, wherein said antigen or antigenic
determinant is a peptide comprising the amino acids 2 to 24 of SEQ
ID NO: 213 or a fragment thereof being at least 6 amino acids in
length.
44. The composition of claim 1, wherein said antigen or antigenic
determinant is a peptide consisting of the amino acids 2 to 24 of
SEQ ID NO: 171 or a fragment thereof being at least 6 amino acids
in length.
45. The composition of claim 1, wherein said antigen or antigenic
determinant with said second attachment site is the M2 peptide of
SEQ ID NO: 170.
46. The composition of claim 1, wherein said antigen or antigenic
determinant is Der p I peptide, or a fragment thereof comprising an
amino acid sequence selected from the group consisting of:
TABLE-US-00039 (a) CGNQSLDLAEQELVDCASQHGCH; and (b)
CQIYPPNANKIREALAQTHSA.
47. The composition of claim 1, wherein said antigen or said
antigenic determinant is a phospholipase A2 protein, or a fragment
thereof.
48. The composition of claim 1, wherein said antigen or antigenic
determinant is a phospholipase A2 protein or fragment thereof
comprising an amino acid sequence selected from the group
consisting of: (a) the amino acid sequence of SEQ ID NO:168; (b)
the amino acid sequence of SEQ ID NO:169; (c) the amino acid
sequence of SEQ ID NO:170; (d) the amino acid sequence of SEQ ID
NO:171; (e) the amino acid sequence of SEQ ID NO:172; (f) the amino
acid sequence of SEQ ID NO:173; (g) the amino acid sequence of SEQ
ID NO:174; and (h) the amino acid sequence of SEQ ID NO:175.
49. A pharmaceutical composition comprising: (a) the composition of
claim 1; and (b) an acceptable pharmaceutical carrier.
50. A method of immunization of an animal comprising administering
to said animal the composition of claim 1, wherein an immune
response against said antigen or antigenic determinant is produced
in said animal.
51. An immunogenic composition comprising the composition of claim
1 and an adjuvant.
52. A process for producing a non-naturally occurring, ordered and
repetitive antigen array comprising: (a) providing a non-natural
molecular scaffold comprising: (i) a core particle comprising a
virus-like particle of an RNA bacteriophage; and (ii) an organizer
comprising at least one first attachment site, wherein said
organizer is connected to said core particle by at least one
covalent bond; and wherein said first attachment site is not a
sulfhydryl group; and (b) providing an antigen or antigenic
determinant with at least one second attachment site, wherein said
second attachment site is capable of association through at least
one non-peptide bond to said first attachment site; and (c)
combining said non-natural molecular scaffold and said antigen to
form an ordered and repetitive antigen array.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 10/050,902, filed Jan. 18, 2002, which claims priority benefit
of U.S. provisional application No. 60/262,379, filed Jan. 19,
2001, U.S. provisional application No. 60/288,549, filed May 4,
2001, U.S. provisional application No. 60/326,998, filed Oct. 5,
2001, and U.S. provisional application No. 60/331,045, filed Nov.
7, 2001, which are incorporated herein by reference in their
entireties.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention is related to the fields of molecular
biology, virology, immunology and medicine. The invention provides
a composition comprising an ordered and repetitive antigen or
antigenic determinant array. The invention also provides a process
for producing an antigen or antigenic determinant in an ordered and
repetitive array. The ordered and repetitive antigen or antigenic
determinant is useful in the production of vaccines for the
treatment of infectious diseases, the treatment of allergies and as
a pharmaccine to prevent or cure cancer and to efficiently induce
self-specific immune responses, in particular antibody
responses.
[0004] 2. Background Art
[0005] WO 00/3227 describes compositions and processes for the
production of ordered and repetitive antigen or antigenic
determinant arrays. The compositions are useful for the production
of vaccines for the prevention of infectious diseases, the
treatment of allergies and the treatment of cancers. The
compositions comprise a core particle, such as a virus or a
virus-like particle, to which at least one antigen or one antigenic
determinant, is associated by way of at least one non-peptide bond
leading to the ordered and repetitive antigen array.
[0006] Virus-like particles (VLPs) are being exploited in the area
of vaccine production because of both their structural properties
and their non-infectious nature. VLPs are supermolecular structures
built in a symmetric manner from many protein molecules of one or
more types. They lack the viral genome and, therefore, are
noninfectious. VLPs can often be produced in large quantities by
heterologous expression and can be easily be purified.
[0007] Examples of VLPs include the capsid proteins of Hepatitis B
virus (Ulrich, et al., Virus Res. 50:141-182 (1998)), measles virus
(Warnes, et al., Gene 160:173-178 (1995)), Sindbis virus, rotavirus
(U.S. Pat. No. 5,071,651 and U.S. Pat. No. 5,374,426),
foot-and-mouth-disease virus (Twomey, et al., Vaccine 13:1603-1610,
(1995)), Norwalk virus (Jiang, X., et al., Science 250:1580-1583
(1990); Matsui, S. M., et al., J. Clin. Invest. 87:1456-1461
(1991)), the retroviral GAG protein (WO 96/30523), the
retrotransposon Ty protein p1, the surface protein of Hepatitis B
virus (WO 92/11291) and human papilloma virus (WO 98/15631).
[0008] It is generally difficult to induce immune responses against
self-molecules due to immunological tolerance. Specifically,
lymphocytes with a specificity for self-molecules are usually hypo-
or even unresponsive if triggered by conventional vaccination
strategies.
[0009] The amyloid B peptide (A.beta..sub.1-42) has a central role
in the neuropathology of Alzheimers disease. Region specific,
extracellular accumulation of A.beta. peptide is accompanied by
microgliosis, cytoskeletal changes, dystrophic neuritis and
synaptic loss. These pathological alterations are thought to be
linked to the cognitive decline that defines the disease.
[0010] In a mouse model of Alzheimer disease, transgenic animals
engineered to produce A.beta..sub.1-42 (PDAPP-mice), develop
plaques and neuron damage in their brains. Recent work has shown
immunization of young PDAPP-mice, using A.beta..sub.1-42, resulted
in inhibition of plaque formation and associated dystrophic
neuritis (Schenk, D. et al., Nature 400:173-77 (1999)).
[0011] Furthermore immunization of older PDAPP mice that had
already developed AD-like neuropathologies, reduced the extent and
progression of the neuropathologies. The immunization protocol for
these studies was as follows; peptide was dissolved in aqueous
buffer and mixed 1:1 with complete Freunds adjuvant (for primary
dose) to give a peptide concentration of 100 .mu.g/dose. Subsequent
boosts used incomplete Freunds adjuvant. Mice received 11
immunizations over an 11 month period. Antibodies titres greater
than 1:10 000 were achieved and maintained. Hence, immunization may
be an effective prophylactic and therapeutic action against
Alzheimer disease.
[0012] In another study, peripherally administered antibodies
raised against A.beta..sub.1-42, were able to cross the blood-brain
barrier, bind A.beta. peptide, and induce clearance of pre-existing
amyloid (Bard, F. et al., Nature Medicine 6:916-19 (2000)). This
study utilized either polyclonal antibodies raised against
A.beta..sub.1-42, or monoclonal antibodies raised against synthetic
fragments derived from different regions of A.beta.. Thus induction
of antibodies can be considered as a potential therapeutic
treatment for Alzheimer disease.
[0013] It is well established that the administration of purified
proteins alone is usually not sufficient to elicit a strong immune
response; isolated antigen generally must be given together with
helper substances called adjuvants. Within these adjuvants, the
administered antigen is protected against rapid degradation, and
the adjuvant provides an extended release of a low level of
antigen.
[0014] As indicated, one of the key events in Alzheimer's Disease
(AD) is the deposition of amyloid as insoluble fibrous masses
(amyloidogenesis) resulting in extracellular neuritic plaques and
deposits around the walls of cerebral blood vessels (for review see
Selkoe, D. J. (1999) Nature. 399, A23-31). The major constituent of
the neuritic plaques and congophilic angiopathy is amyloid .beta.
(A.beta.), although these deposits also contain other proteins such
as glycosaminoglycans and apolipoproteins. A.beta. is
proteolytically cleaved from a much larger glycoprotein known as
Amyloid Precursor Proteins (APPs), which comprises isoforms of
695-770 amino acids with a single hydrophobic transmembrane region.
A.beta. forms a group of peptides up to 43 amino acids in length
showing considerable amino- and carboxy-terminal heterogeneity
(truncation) as well as modifications (Roher, A. E., Palmer, K. C.,
Chau, V., & Ball, M. J. (1988) J. Cell Biol. 107, 2703-2716.
Roher, A. E., Palmer, K. C., Yurewicz, E. C., Ball, M. J., &
Greenberg, B. D. (1993) J. Neurochem. 61, 1916-1926). Prominent
isoforms are A.beta.1-40 and 1-42. It has a high propensity to form
.beta.-sheets aggregating into fibrils, which ultimately leads to
the amyloid. Recent studies demonstrated that a vaccination-induced
reduction in brain amyloid deposits resulted in cognitive
improvements (Schenk, D., Barbour, R., Dunn, W., Gordon, G.,
Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan,
K., et al. (1999) Nature. 400, 173-177).
[0015] We have surprisingly found that self-molecules or
self-antigens presented in a highly ordered and repetitive array
were able to efficiently induce self-specific immune responses, in
particular antibody responses. Moreover, such responses could even
be induced in the absence of adjuvants that otherwise
non-specifically activate antigen presenting cells and other immune
cells.
BRIEF SUMMARY OF THE INVENTION
[0016] The present invention provides compositions, which comprises
highly ordered and repetitive antigen or antigenic determinant
arrays, as well as the processes for their production and their
uses. Thus, the compositions of the invention are useful for the
production of vaccines for the prevention of infectious diseases,
the treatment of allergies and cancers, and to efficiently induce
self-specific immune responses, in particular antibody
responses.
[0017] In a first aspect, the present invention provides a novel
composition comprising, or alternatively consisting of, (A) a
non-natural molecular scaffold and (B) an antigen or antigenic
determinant. The non-natural molecular scaffold comprises, or
alternatively consists of, (i) a core particle selected from the
group consisting of (1) a core particle of non-natural origin and
(2) a core particle of natural origin; and (ii) an organizer
comprising at least one first attachment site, wherein said
organizer is connected to said core particle by at least one
covalent bond. The antigen or antigenic determinant is a self
antigen or a fragment thereof and has at least one second
attachment site which is selected from the group consisting of (i)
an attachment site not naturally occurring with said antigen or
antigenic determinant; and (ii) an attachment site naturally
occurring with said antigen or antigenic determinant. The invention
provides for an ordered and repetitive self antigen array through
an association of the second attachment site to the first
attachment site by way of at least one non-peptide bond. Thus, the
self antigen or self antigenic determinant and the non-natural
molecular scaffold are brought together through this association of
the first and the second attachment site to form an ordered and
repetitive antigen array.
[0018] In a second aspect, the present invention provides a novel
composition comprising, or alternatively consisting of, (A) a
non-natural molecular scaffold and (B) an antigen or antigenic
determinant. The non-natural molecular scaffold comprises, or
alternatively consists of, (i) a core particle and (ii) an
organizer comprising at least one first attachment site, wherein
said core particle is a virus-like particle comprising recombinant
proteins, or fragments thereof, of a bacteriophage, and wherein
said organizer is connected to said core particle by at least one
covalent bond. The antigen or antigenic determinant has at least
one second attachment site which is selected from the group
consisting of (i) an attachment site not naturally occurring with
said antigen or antigenic determinant; and (ii) an attachment site
naturally occurring with said antigen or antigenic determinant. The
invention provides for an ordered and repetitive antigen array
through an association of the second attachment site to the first
attachment site by way of at least one non-peptide bond.
[0019] In a third aspect, the present invention provides a novel
composition comprising, or alternatively consisting of, (A) a
non-natural molecular scaffold and (B) an antigen or antigenic
determinant. The non-natural molecular scaffold comprises, or
alternatively consists of, (i) a core particle selected from the
group consisting of (1) a core particle of non-natural origin and
(2) a core particle of natural origin; and (ii) an organizer
comprising at least one first attachment site, wherein said
organizer is connected to said core particle by at least one
covalent bond. The antigen or antigenic determinant is an amyloid
beta peptide (A.beta..sub.1-42) or a fragment thereof, and has at
least one second attachment site which is selected from the group
consisting of (i) an attachment site not naturally occurring with
said antigen or antigenic determinant; and (ii) an attachment site
naturally occurring with said antigen or antigenic determinant. The
invention provides for an ordered and repetitive antigen array
through an association of the second attachment site to the first
attachment site by way of at least one non-peptide bond.
[0020] In a fourth aspect, the present invention provides a novel
composition comprising, or alternatively consisting of, (A) a
non-natural molecular scaffold and (B) an antigen or antigenic
determinant. The non-natural molecular scaffold comprises, or
alternatively consists of, (i) a core particle selected from the
group consisting of (1) a core particle of non-natural origin and
(2) a core particle of natural origin; and (ii) an organizer
comprising at least one first attachment site, wherein said
organizer is connected to said core particle by at least one
covalent bond. The antigen or antigenic determinant is an
anti-idiotypic antibody or an anti-idiotypic antibody fragment and
has at least one second attachment site which is selected from the
group consisting of (i) an attachment site not naturally occurring
with said antigen or antigenic determinant; and (ii) an attachment
site naturally occurring with said antigen or antigenic
determinant. The invention provides for an ordered and repetitive
antigen array through an association of the second attachment site
to the first attachment site by way of at least one non-peptide
bond.
[0021] Further aspects as well as preferred embodiments and
advantages of the present invention will become apparent in the
following as well as, in particular, in the light of the detailed
description, the examples and the accompanying claims.
[0022] In a preferred embodiment of the present invention, the core
particle is a virus-like particle comprising recombinant proteins
of a RNA-phage, preferably selected from the group consisting of a)
bacteriophage Q.beta.; b) bacteriophage R17; c) bacteriophage fr;
d) bacteriophage GA; e) bacteriophage SP; f) bacteriophage MS2; g)
bacteriophage M11; h) bacteriophage MX1; i) bacteriophage NL95; k)
bacteriophage f2; and 1) bacteriophage PP7. Most preferred are
bacteriophage Q.beta. and bacteriophage fr.
[0023] In another preferred embodiment of the invention, the
recombinant proteins of the RNA-phages comprise wild type coat
proteins.
[0024] In further preferred embodiment of the invention, the
recombinant proteins of the RNA-phages comprise mutant coat
proteins.
[0025] In yet another embodiment, the core particle comprises, or
alternatively consists of, one or more different Hepatitis core
(capsid) proteins (HBcAgs). In a related embodiment, one or more
cysteine residues of these HBcAgs are either deleted or substituted
with another amino acid residue (e.g., a serine residue). In a
specific embodiment, the cysteine residues of the HBcAg used to
prepare compositions of the invention which correspond to amino
acid residues 48 and 107 in SEQ ID NO:134 are either deleted or
substituted with another amino acid residue (e.g., a serine
residue).
[0026] Further, the HBcAg variants used to prepare compositions of
the invention will generally be variants which retain the ability
to associate with other HBcAgs to form dimeric or multimeric
structures that present ordered and repetitive antigen or antigenic
determinant arrays.
[0027] In another embodiment, the non-natural molecular scaffold
comprises, or alternatively consists of, pili or pilus-like
structures that have been either produced from pilin proteins or
harvested from bacteria. When pili or pilus-like structures are
used to prepare compositions of the invention, they may be formed
from products of pilin genes which are naturally resident in the
bacterial cells but have been modified by genetically engineered
(e.g., by homologous recombination) or pilin genes which have been
introduced into these cells.
[0028] In a related embodiment, the core particle comprises, or
alternatively consists of, pili or pilus-like structures that have
been either prepared from pilin proteins or harvested from
bacteria. These core particles may be formed from products of pilin
genes naturally resident in the bacterial cells.
[0029] In a particular embodiment, the organizer may comprise at
least one first attachment site. The first and the second
attachment sites are particularly important elements of
compositions of the invention. In various embodiments of the
invention, the first and/or the second attachment site may be an
antigen and an antibody or antibody fragment thereto; biotin and
avidin; strepavidin and biotin; a receptor and its ligand; a
ligand-binding protein and its ligand; interacting leucine zipper
polypeptides; an amino group and a chemical group reactive thereto;
a carboxyl group and a chemical group reactive thereto; a
sulfhydryl group and a chemical group reactive thereto; or a
combination thereof.
[0030] In a further preferred embodiment, the composition further
comprises an amino acid linker. Preferably the amino acid linker
comprises, or alternatively consists of, the second attachment
site. The second attachment site mediates a directed and ordered
association and binding, respectively, of the antigen to the core
particle. An important function of the amino acid linker is to
further ensure proper display and accessibility of the second
attachment site, and thus to facilitate the binding of the antigen
to the core particle, in particular by way of chemical
cross-linking. Another important property of the amino acid linker
is to further ensure optimal accessibility and, in particular,
reactivity of the second attachment site. These properties of the
amino acid linker are of even more importance for protein
antigens.
[0031] In another preferred embodiment, the amino acid linker is
selected from the group consisting of (a) CGG; (b) N-terminal gamma
1-linker; (c) N-terminal gamma 3-linker; (d) Ig hinge regions; (e)
N-terminal glycine linkers; (f) (G).sub.kC(G).sub.n with n=0-12 and
k=0-5; (g) N-terminal glycine-serine linkers; (h)
(G).sub.kC(G).sub.m(S)l(GGGGS).sub.n with n=0-3, k=0-5, m=0-10,
l=0-2 (SEQ ID NO:424); (i) GGC; (k) GGC-NH2; (l) C-terminal gamma
1-linker; (m) C-terminal gamma 3-linker; (n) C-terminal glycine
linkers; (O) (G).sub.nC(G).sub.k with n=0-12 and k=0-5; (p)
C-terminal glycine-serine linkers; (q)
(G).sub.m(S).sub.l(GGGGS).sub.n(G).sub.oC(G).sub.k with n=0-3,
k=0-5, m=0-10, l=0-2, and o=0-8 (SEQ ID NO:425).
[0032] An important property of glycine and glycine serine linkers
is their flexibility, in particular their structural flexibility,
allowing a wide range of conformations and disfavoring folding into
structures precluding accessibility of the second attachment site.
As glycine and glycine serine linkers contain either no or a
limited amount of side chain residues, they have limited tendency
for engagement into extensive interactions with the antigen, thus,
further ensuring accessibility of the second attachment site.
Serine residues within the glycine serine linkers confer improved
solubility properties to these linkers. Accordingly, the insertion
of one or two amino acids either in tandem or isolation, and in
particular of polar or charged amino acid residues, in the glycine
or glycine serine amino acid linker, is also encompassed by the
teaching of the invention.
[0033] In a further preferred embodiment, the amino acid linker is
either GGC-NH2, GGC-NMe, GGC-N(Me)2, GGC-NHET or GGC-N(Et)2, in
which the C-terminus of the cysteine residue of GGC is amidated.
These amino acid linkers are preferred in particular for peptide
antigens, and in particular for embodiments, in which the antigen
or antigenic determinant with said second attachment site comprises
A.beta. peptides or fragments thereof. Particular preferred is
GGC-NH2. In another embodiment, the amino acid linker is an
Immunoglobulin (Ig) hinge region. Fragments of Ig hinge regions are
also within the scope of the invention, as well as Ig hinge regions
modified with glycine residues. Preferably, the Ig hinge regions
contain only one cysteine residue. It is to be understood, that the
single cysteine residue of the Ig hinge region amino acid linker
can be located at several positions within the linker sequence, and
a man skilled in the art would know how to select them with the
guidance of the teachings of this invention.
[0034] In one embodiment, the invention provides the coupling of
almost any antigen of choice to the surface of a virus, bacterial
pilus, structure formed from bacterial pilin, bacteriophage,
virus-like particle or viral capsid particle. By bringing an
antigen into a quasi-crystalline `virus-like` structure, the
invention exploits the strong antiviral immune reaction of a host
for the production of a highly efficient immune response, i.e., a
vaccination, against the displayed antigen.
[0035] In yet another embodiment, the antigen may be selected from
the group consisting of: (1) a protein suited to induce an immune
response against cancer cells; (2) a protein suited to induce an
immune response against infectious diseases; (3) a protein suited
to induce an immune response against allergens; (4) a protein
suited to induce an improved response against self-antigens; and
(5) a protein suited to induce an immune response in farm animals
or pets. In another embodiment, the first attachment site and/or
the second attachment site are selected from the group comprising:
(1) a genetically engineered lysine residue and (2) a genetically
engineered cysteine residue, two residues that may be chemically
linked together.
[0036] In a yet further preferred embodiment, first attachment site
comprises or is an amino group and said second attachment site
comprises or is a sulfhydryl group. Preferably, the first
attachment site comprises or is a lysine residue and said second
attachment site comprises or is a cysteine residue.
[0037] The invention also includes embodiments where the organizer
particle has only a single first attachment site and the antigen or
antigenic determinant has only a single second attachment site.
Thus, when an ordered and repetitive antigen array is prepared
using such embodiments, each organizer will be bound to a single
antigen or antigenic determinant.
[0038] In a further aspect, the invention provides compositions
comprising, or alternatively consisting of, (a) a non-natural
molecular scaffold comprising (i) a core particle selected from the
group consisting of a core particle of non-natural origin and a
core particle of natural origin, and (ii) an organizer comprising
at least one first attachment site, wherein the core particle
comprises, or alternatively consists of, a virus-like particle, a
bacterial pilus, a pilus-like structure, or a modified HBcAg, or
fragment thereof, and wherein the organizer is connected to the
core particle by at least one covalent bond, and (b) an antigen or
antigenic determinant with at least one second attachment site, the
second attachment site being selected from the group consisting of
(i) an attachment site not naturally occurring with the antigen or
antigenic determinant and (ii) an attachment site naturally
occurring with the antigen or antigenic determinant, wherein the
second attachment site is capable of association through at least
one non-peptide bond to the first attachment site, and wherein the
antigen or antigenic determinant and the scaffold interact through
the association to form an ordered and repetitive antigen
array.
[0039] Other embodiments of the invention include processes for the
production of compositions of the invention and a methods of
medical treatment using vaccine compositions described herein.
[0040] It is to be understood that both the foregoing general
description and the following detailed description are exemplary
and explanatory only and are intended to provide further
explanation of the invention as claimed.
[0041] In a still further aspect, the present invention provides a
composition comprising a bacteriophage Q.beta. coat protein
attached by a covalent bond to phospholipase A2 protein, or a
fragment thereof. In a preferred embodiment, the phospholipase A2
protein, or a fragment thereof, and the bacteriophage Q.beta. coat
protein interact through the covalent bond to form an ordered and
repetitive antigen array. In another preferred embodiment, the
covalent bond is not a peptide bond. In another preferred
embodiment, the phospholipase A2 protein includes an amino acid
selected from the group consisting of the amino acid sequence of
SEQ ID NO:168, the amino acid sequence of SEQ ID NO:169, the amino
acid sequence of SEQ ID NO:170, the amino acid sequence of SEQ ID
NO:171, the amino acid sequence of SEQ ID NO:172, the amino acid
sequence of SEQ ID NO:173, the amino acid sequence of SEQ ID
NO:174, and the amino acid sequence of SEQ ID NO:175.
[0042] The present invention also provides a method of making the
composition comprising combining the bacteriophage Q.beta. coat
protein and the phospholipase A2 protein, wherein the bacteriophage
Q.beta. coat protein and the phospholipase A2 protein interact to
form an antigen array.
[0043] In another aspect, the present invention also provides a
composition comprising a non-natural molecular scaffold comprising
a bacteriophage Q.beta. coat protein, and an organizer comprising
at least one first attachment site, wherein the organizer is
connected to the bacteriophage Q.beta. coat protein by at least one
covalent bond; and phospholipase A2 protein, or a fragment thereof,
or a variant thereof with at least one second attachment site, the
second attachment site being selected from the group consisting of:
an attachment site not naturally occurring with the a phospholipase
A2 protein, or a fragment thereof; and an attachment site naturally
occurring with the a phospholipase A2 protein, or a fragment
thereof, wherein the second attachment site associates through at
least one non-peptide bond to the first attachment site, and
wherein the antigen or antigenic determinant and the scaffold
interact through the association to form an ordered and repetitive
antigen array. In a preferred embodiment, the phospholipase A2
protein includes an amino acid selected from the group consisting
of the amino acid sequence of SEQ ID NO:168, the amino acid
sequence of SEQ ID NO:169, the amino acid sequence of SEQ ID
NO:170, the amino acid sequence of SEQ ID NO:171, the amino acid
sequence of SEQ ID NO:172, the amino acid sequence of SEQ ID
NO:173, the amino acid sequence of SEQ ID NO:174, and the amino
acid sequence of SEQ ID NO:175.
[0044] The present invention also provides a method of making the
composition comprising combining the bacteriophage Q.beta. coat
protein and the phospholipase A2 protein, wherein the bacteriophage
Q.beta. coat protein and the phospholipase A2 protein interact to
form an antigen array. Preferably, the antigen array is ordered
and/or repetitive.
[0045] The present invention also provides a pharmaceutical
composition comprising a phospholipase A2 protein, and a
pharmaceutically acceptable carrier. The present invention also
provides a vaccine composition comprising a phospholipase A2
protein. In a preferred embodiment, the vaccine composition of
claim 31, further comprising at least one adjuvant.
[0046] The present invention also provides a method of treating an
allergy to bee venom, comprising administering the pharmaceutical
composition or the vaccine composition to a subject. As a result of
such administration the subject exhibits a decreased immune
response to the venom.
[0047] The invention also relates to a vaccine for the prevention
of prion-mediated diseases by induction of anti-lymphotoxin-.beta.,
anti-lymphotoxin-.beta. or anti-lymphotoxin-.beta.-receptor
antibodies. The vaccine contains protein carries foreign to the
immunized human or animal coupled to lymphotoxin-.beta. or
fragments thereof, lymphotoxin-.beta. or fragments thereof or the
lymphotoxin-.beta. receptor or fragments thereof. The vaccine is
injected in humans or animals in order to induce antibodies
specific for endogenous lymphotoxin-.beta., lymphotoxin-.beta. or
lymphotoxin-.beta. receptor. These induced anti-lymphotoxin-.beta.,
lymphotoxin-.beta. or anti-lymphotoxin-.beta. receptor antibodies
reduce or eliminate the pool of follicular dendritic cells present
in lymphoid organs. Since prion-replication in lymphoid organs and
transport to the central nervous system are impaired in the absence
of follicular dendritic cells, this treatment inhibits progression
of prion-mediated disease. In addition, blocking lymphotoxin-.beta.
is beneficial for patients with autoimmune diseases such as
diabetes type I.
BRIEF DESCRIPTION OF THE FIGURES
[0048] FIG. 1A-1C Modular eukaryotic expression vectors for
expression of antigens according to the invention (FIG. 1A:SEQ ID
NO:426; FIG. 1B:SEQ ID NO:427; FIG. 1C:SEQ ID NO:428);
[0049] FIG. 2A-2C Cloning, expression and coupling of resistin to
Q.beta. capsid protein (FIG. 2A, SEQ ID NO:429; FIG. 2B, SEQ ID
NO:430);
[0050] FIG. 3A-3B Cloning and expression of lymphotoxin-.beta.
constructs for coupling to virus-like particles and pili.
[0051] FIG. 4A-4B Cloning, expression and coupling of MIF
constructs to Q.beta. capsid protein.
[0052] FIG. 4C ELISA analysis of IgG antibodies specific for MIF in
sera of mice immunized against MIF proteins coupled to Q.beta.
capsid protein.
[0053] FIG. 5 Coupling of MIF constructs to fr capsid protein and
to HBcAg-lys-2cys-Mut capsid protein analyzed by SDS-Page.
[0054] FIG. 6 Cloning and expression of human-C-RANKL.
[0055] FIG. 7 Cloning and expression of prion protein.
[0056] FIG. 8A. ELISA analysis of IgG antibodies specific for
"Angio I" in sera of mice immunized against angiotensin peptides
coupled to Q.beta. capsid protein.
[0057] FIG. 8B. ELISA analysis of IgG antibodies specific for
"Angio II" in sera of mice immunized against angiotensin peptides
coupled to Q.beta. capsid protein.
[0058] FIG. 8C. ELISA analysis of IgG antibodies specific for
"Angio III" in sera of mice immunized against angiotensin peptides
coupled to Q.beta. capsid protein.
[0059] FIG. 8D. ELISA analysis of IgG antibodies specific for
"Angio IV" in sera of mice immunized against angiotensin peptides
coupled to Q.beta. capsid protein.
[0060] FIG. 9A. ELISA analysis of IgG antibodies specific for "Der
p I p52" in sera of mice immunized against Der p I peptides coupled
to Q.beta. capsid protein.
[0061] FIG. 9B. ELISA analysis of IgG antibodies specific for "Der
p I p117" in sera of mice immunized against Der p I peptides
coupled to Q.beta. capsid protein.
[0062] FIG. 10A. ELISA analysis of IgG antibodies specific for
human VEGFR II peptide in sera of mice immunized against human
VEGFR II peptide and the extracellular domain of human VEGFR II
both coupled to Type-1 pili protein.
[0063] FIG. 10B. ELISA analysis of IgG antibodies specific for the
extracellular domain of human VEGFR II in sera of mice immunized
against human VEGFR II peptide and extracellular domain of human
VEGFR II both coupled to Type-1 pili protein.
[0064] FIG. 11. ELISA analysis of IgG antibodies specific for
anti-TNF.beta. protein in sera of mice immunized against full
length HBc-TNF.
[0065] FIG. 12. ELISA analysis of IgG antibodies specific for
anti-TNF.beta. protein in sera of mice immunized against
2cysLys-mut HBcAg1-149 coupled to the 3'TNF II peptide
[0066] FIG. 13A. SDS-PAGE analysis of coupling of "A.beta.1-15" to
Q.beta. capsid protein using the cross-linker SMPH.
[0067] FIG. 13B. SDS-PAGE analysis of coupling of "A.beta.33-42" to
Q.beta. capsid protein using the cross-linker SMPH.
[0068] FIG. 13C. SDS-PAGE analysis of coupling of "A.beta.1-27" to
Q.beta. capsid protein using the cross-linker SMPH.
[0069] FIG. 13D. SDS-PAGE analysis of coupling of "A.beta.1-15" to
Q.beta. capsid protein using the cross-linker Sulfo-GMBS.
[0070] FIG. 13E. SDS-PAGE analysis of coupling of "A.beta.1-15" to
Q.beta. capsid protein using the cross-linker Sulfo-MBS.
[0071] FIG. 14A. ELISA analysis of IgG antibodies specific for
"A.beta.1-15" in sera of mice immunized against "A.beta.1-15"
coupled to Q.beta. capsid protein.
[0072] FIG. 14B. ELISA analysis of IgG antibodies specific for
"A.beta.1-27" in sera of mice immunized against "A.beta.1-27"
coupled to Q.beta. capsid protein.
[0073] FIG. 14C. ELISA analysis of IgG antibodies specific for
"A.beta.33-42" in sera of mice immunized against "A.beta.33-42"
coupled to Q.beta. capsid protein.
[0074] FIG. 15A. SDS-PAGE analysis of coupling of pCC2 to Q.beta.
capsid protein.
[0075] FIG. 15B. SDS-PAGE analysis of coupling of pCA2 to Q.beta.
capsid protein.
[0076] FIG. 15C. SDS-PAGE analysis of coupling of pCB2 to Q.beta.
capsid protein.
[0077] FIG. 16 Coupling of prion peptides to Q.beta. capsid
protein; SDS-Page analysis.
[0078] FIG. 17 A. SDS-PAGE analysis of expression of IL-5 in
bacteria
[0079] FIG. 17 B. Western-Blot analysis of expression of IL-5 and
IL-13 in eukaryotic cells
[0080] FIG. 18 A. SDS-PAGE analysis of coupling of murine VEGFR-2
peptide to Pili.
[0081] FIG. 18 B. SDS-PAGE analysis of coupling of murine VEGFR-2
peptide to Q.beta. capsid protein.
[0082] FIG. 18 C. SDS-PAGE analysis of coupling of murine VEGFR-2
peptide to HBcAg-lys-2cys-Mut.
[0083] FIG. 18 D. ELISA analysis of IgG antibodies specific for
murine VEGFR-2 peptide in sera of mice immunized against murine
VEGFR-2 peptide coupled to Pili.
[0084] FIG. 18 E. ELISA analysis of IgG antibodies specific for
murine VEGFR-2 peptide in sera of mice immunized against murine
VEGFR-2 peptide coupled to Q.beta. capsid protein.
[0085] FIG. 18 F. ELISA analysis of IgG antibodies specific for
murine VEGFR-2 peptide in sera of mice immunized against murine
VEGFR-2 peptide coupled to HBcAg-lys-2cys-Mut.
[0086] FIG. 19 A. SDS-PAGE analysis of coupling of A.beta. 1-15
peptide to HBcAg-lys-2cys-Mut and fr capsid protein.
[0087] FIG. 19 B. ELISA analysis of IgG antibodies specific for
A.beta. 1-15 peptide in sera of mice immunized against A.beta. 1-15
peptide coupled to HBcAg-lys-2cys-Mut or fr capsid protein.
[0088] FIG. 20 ELISA analysis of IgG antibodies specific for human
A.beta. in sera of transgenic APP23 mice immunized with human
A.beta. peptides coupled to Q.beta. capsid protein.
[0089] FIG. 21 SDS-PAGE analysis of coupling of an Fab antibody
fragment to Q.beta. capsid protein.
[0090] FIG. 22 A. SDS-PAGE analysis of coupling of flag peptide
coupled to mutant Q.beta. capsid protein with cross-linker sulfo
GMBS FIG. 22 B. SDS-PAGE analysis of coupling of flag peptide
coupled to mutant Q.beta. capsid protein with cross-linker sulfo
MBS
[0091] FIG. 22 C. SDS-PAGE analysis of coupling of flag peptide
coupled to mutant Q.beta. capsid protein with cross-linker SMPH
[0092] FIG. 22 D. SDS-PAGE analysis of coupling of PLA2-cys protein
coupled to mutant Q.beta. capsid protein with cross-linker SMPH
[0093] FIG. 23 ELISA analysis of immunization with M2 peptide
coupled to mutant Q.beta. capsid protein and fr capsid
[0094] FIG. 24 SDS-PAGE analysis of coupling of DER p1,2 peptide
coupled to mutant Q.beta. capsid protein
[0095] FIG. 25 A Desensitization of allergic mice with PLA2 coupled
to Q.beta.capsid protein: temperature measurements
[0096] FIG. 25 B Desensitization of allergic mice with PLA2-cys
coupled to Q.beta.capsid protein: IgG 2A and Ig E titers
[0097] FIG. 26 SDS-PAGE Analysis and Western-blot analysis of
coupling of PLA2-cys to Q.beta.capsid protein
[0098] FIG. 27 A ELISA analysis of IgG antibodies specific for M2
peptide in sera of mice immunized against M2 peptide coupled to
HBcAg-lys-2cys-Mut, Q.beta.capsid protein, fr capsid protein,
HBcAg-lys-1-183 and M2 eptide fused to HBcAg 1-183
[0099] FIG. 28 A SDS-PAGE Analysis of coupling of anti-idiotypic
IgE mimobody VAE051 to Q.beta.capsid protein
[0100] FIG. 28 B. ELISA analysis of IgG antibodies specific for
anti-idiotypic antibody VAE051 and Human IgE in sera of mice
immunized against VAE051 coupled to Q.beta.capsid protein
DETAILED DESCRIPTION OF THE INVENTION
[0101] 1. Definitions
[0102] Alphavirus: As used herein, the term "alphavirus" refers to
any of the RNA viruses included within the genus Alphavirus.
Descriptions of the members of this genus are contained in Strauss
and Strauss, Microbiol. Rev., 58:491-562 (1994). Examples of
alphaviruses include Aura virus, Bebaru virus, Cabassou virus,
Chikungunya virus, Easter equine encephalomyelitis virus, Fort
morgan virus, Getah virus, Kyzylagach virus, Mayoaro virus,
Middleburg virus, Mucambo virus, Ndumu virus, Pixuna virus, Tonate
virus, Triniti virus, Una virus, Western equine encephalomyelitis
virus, Whataroa virus, Sindbis virus (SIN), Semliki forest virus
(SFV), Venezuelan equine encephalomyelitis virus (VEE), and Ross
River virus.
[0103] Antigen: As used herein, the term "antigen" is a molecule
capable of being bound by an antibody. An antigen is additionally
capable of inducing a humoral immune response and/or cellular
immune response leading to the production of B- and/or
T-lymphocytes. An antigen may have one or more epitopes (B- and
T-epitopes). The specific reaction referred to above is meant to
indicate that the antigen will react, in a highly selective manner,
with its corresponding antibody and not with the multitude of other
antibodies which may be evoked by other antigens.
[0104] Antigenic determinant: As used herein, the term "antigenic
determinant" is meant to refer to that portion of an antigen that
is specifically recognized by either B- or T-lymphocytes.
B-lymphocytes respond to foreign antigenic determinants via
antibody production, whereas T-lymphocytes are the mediator of
cellular immunity. Thus, antigenic determinants or epitopes are
those parts of an antigen that are recognized by antibodies, or in
the context of an MHC, by T-cell receptors.
[0105] Association: As used herein, the term "association" as it
applies to the first and second attachment sites, refers to at
least one non-peptide bond. The nature of the association may be
covalent, ionic, hydrophobic, polar or any combination thereof.
[0106] Attachment Site, First: As used herein, the phrase "first
attachment site" refers to an element of the "organizer", itself
bound to the core particle in a non-random fashion, to which the
second attachment site located on the antigen or antigenic
determinant may associate. The first attachment site may be a
protein, a polypeptide, an amino acid, a peptide, a sugar, a
polynucleotide, a natural or synthetic polymer, a secondary
metabolite or compound (biotin, fluorescein, retinol, digoxigenin,
metal ions, phenylmethylsulfonylfluoride), or a combination
thereof, or a chemically reactive group thereof. Multiple first
attachment sites are present on the surface of the non-natural
molecular scaffold in a repetitive configuration.
[0107] Attachment Site, Second: As used herein, the phrase "second
attachment site" refers to an element associated with the antigen
or antigenic determinant to which the first attachment site of the
"organizer" located on the surface of the non-natural molecular
scaffold may associate. The second attachment site of the antigen
or antigenic determinant may be a protein, a polypeptide, a
peptide, a sugar, a polynucleotide, a natural or synthetic polymer,
a secondary metabolite or compound (biotin, fluorescein, retinol,
digoxigenin, metal ions, phenylmethylsulfonylfluoride), or a
combination thereof, or a chemically reactive group thereof. At
least one second attachment site is present on the antigen or
antigenic determinant. The term "antigen or antigenic determinant
with at least one second attachment site" refers, therefore, to an
antigen or antigenic construct comprising at least the antigen or
antigenic determinant and the second attachment site. However, in
particular for a second attachment site, which is not naturally
occurring within the antigen or antigenic determinant, these
antigen or antigenic constructs comprise an "amino acid linker".
Such an amino acid linker, or also just termed "linker" within this
specification, either associates the antigen or antigenic
determinant with the second attachment site, or more preferably,
already comprises or contains the second attachment site,
typically--but not necessarily--as one amino acid residue,
preferably as a cysteine residue. The term "amino acid linker" as
used herein, however, does not intend to imply that such an amino
acid linker consists exclusively of amino acid residues, even if an
amino acid linker consisting of amino acid residues is a preferred
embodiment of the present invention. The amino acid residues of the
amino acid linker is, preferably, composed of naturally occurring
amino acids or unnatural amino acids known in the art, all-L or
all-D or mixtures thereof. However, an amino acid linker comprising
a molecule with a sulfhydryl group or cysteine residue is also
encompassed within the invention. Such a molecule comprise
preferably a C1-C6 alkyl-, cycloalkyl (C5,C6), aryl or heteroaryl
moiety. Association between the antigen or antigenic determinant or
optionally the second attachment site and the amino acid linker is
preferably by way of at least one covalent bond, more preferably by
way of at least one peptide bond.
[0108] Bound: As used herein, the term "bound" refers to binding or
attachment that may be covalent, e.g., by chemically coupling, or
non-covalent, e.g., ionic interactions, hydrophobic interactions,
hydrogen bonds, etc. Covalent bonds can be, for example, ester,
ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds,
carbon-phosphorus bonds, and the like. The term "bound" is broader
than and includes terms such as "coupled," "fused" and
"attached".
[0109] Core particle: As used herein, the term "core particle"
refers to a rigid structure with an inherent repetitive
organization that provides a foundation for attachment of an
"organizer". A core particle as used herein may be the product of a
synthetic process or the product of a biological process.
[0110] Coat protein(s): As used herein, the term "coat protein(s)"
refers to the protein(s) of a bacteriophage or a RNA-phage capable
of being incorporated within the capsid assembly of the
bacteriophage or the RNA-phage. However, when referring to the
specific gene product of the coat protein gene of RNA-phages the
term "CP" is used. For example, the specific gene product of the
coat protein gene of RNA-phage Q.beta. is referred to as "Q.beta.
CP", whereas the "coat proteins" of bacteriophage Qb comprise the
"Q.beta. CP" as well as the A1 protein.
[0111] Cis-acting: As used herein, the phrase "cis-acting" sequence
refers to nucleic acid sequences to which a replicase binds to
catalyze the RNA-dependent replication of RNA molecules. These
replication events result in the replication of the full-length and
partial RNA molecules and, thus, the alpahvirus subgenomic promoter
is also a "cis-acting" sequence. Cis-acting sequences may be
located at or near the 5' end, 3' end, or both ends of a nucleic
acid molecule, as well as internally.
[0112] Fusion: As used herein, the term "fusion" refers to the
combination of amino acid sequences of different origin in one
polypeptide chain by in-frame combination of their coding
nucleotide sequences. The term "fusion" explicitly encompasses
internal fusions, i.e., insertion of sequences of different origin
within a polypeptide chain, in addition to fusion to one of its
termini.
[0113] Heterologous sequence: As used herein, the term
"heterologous sequence" refers to a second nucleotide sequence
present in a vector of the invention. The term "heterologous
sequence" also refers to any amino acid or RNA sequence encoded by
a heterologous DNA sequence contained in a vector of the invention.
Heterologous nucleotide sequences can encode proteins or RNA
molecules normally expressed in the cell type in which they are
present or molecules not normally expressed therein (e.g., Sindbis
structural proteins).
[0114] Isolated: As used herein, when the term "isolated" is used
in reference to a molecule, the term means that the molecule has
been removed from its native environment. For example, a
polynucleotide or a polypeptide naturally present in a living
animal is not "isolated," but the same polynucleotide or
polypeptide separated from the coexisting materials of its natural
state is "isolated." Further, recombinant DNA molecules contained
in a vector are considered isolated for the purposes of the present
invention. Isolated RNA molecules include in vivo or in vitro RNA
replication products of DNA and RNA molecules. Isolated nucleic
acid molecules further include synthetically produced molecules.
Additionally, vector molecules contained in recombinant host cells
are also isolated. Thus, not all "isolated" molecules need be
"purified."
[0115] Immunotherapeutic: As used herein, the term
"immunotherapeutic" is a composition for the treatment of diseases
or disorders. More specifically, the term is used to refer to a
method of treatment for allergies or a method of treatment for
cancer.
[0116] Individual: As used herein, the term "individual" refers to
multicellular organisms and includes both plants and animals.
Preferred multicellular organisms are animals, more preferred are
vertebrates, even more preferred are mammals, and most preferred
are humans.
[0117] Low or undetectable: As used herein, the phrase "low or
undetectable," when used in reference to gene expression level,
refers to a level of expression which is either significantly lower
than that seen when the gene is maximally induced (e.g., at least
five fold lower) or is not readily detectable by the methods used
in the following examples section.
[0118] Lectin: As used herein, proteins obtained particularly from
the seeds of leguminous plants, but also from many other plant and
animal sources, that have binding sites for specific mono- or
oligosaccharides. Examples include concanavalin A and wheat-germ
agglutinin, which are widely used as analytical and preparative
agents in the study of glycoprotein.
[0119] Mimotope: As used herein, the term "mimotope" refers to a
substance which induces an immune response to an antigen or
antigenic determinant. Generally, the term mimotope will be used
with reference to a particular antigen. For example, a peptide
which elicits the production of antibodies to a phospholipase A2
(PLA2) is a mimotope of the antigenic determinant to which the
antibodies bind. A mimotope may or may not have substantial
structural similarity to or share structural properties with an
antigen or antigenic determinant to which it induces an immune
response. Methods for generating and identifying mimotopes which
induce immune responses to particular antigens or antigenic
determinants are known in the art and are described elsewhere
herein.
[0120] Natural origin: As used herein, the term "natural origin"
means that the whole or parts thereof are not synthetic and exist
or are produced in nature.
[0121] Non-natural: As used herein, the term generally means not
from nature, more specifically, the term means from the hand of
man.
[0122] Non-natural origin: As used herein, the term "non-natural
origin" generally means synthetic or not from nature; more
specifically, the term means from the hand of man.
[0123] Non-natural molecular scaffold: As used herein, the phrase
"non-natural molecular scaffold" refers to any product made by the
hand of man that may serve to provide a rigid and repetitive array
of first attachment sites. Ideally but not necessarily, these first
attachment sites are in a geometric order. The non-natural
molecular scaffold may be organic or non-organic and may be
synthesized chemically or through a biological process, in part or
in whole. The non-natural molecular scaffold is comprised of: (a) a
core particle, either of natural or non-natural origin; and (b) an
organizer, which itself comprises at least one first attachment
site and is connected to a core particle by at least one covalent
bond. In a particular embodiment, the non-natural molecular
scaffold may be a virus, virus-like particle, a bacterial pilus, a
virus capsid particle, a phage, a recombinant form thereof, or
synthetic particle.
[0124] Ordered and repetitive antigen or antigenic determinant
array: As used herein, the term "ordered and repetitive antigen or
antigenic determinant array" generally refers to a repeating
pattern of antigen or antigenic determinant, characterized by a
uniform spacial arrangement of the antigens or antigenic
determinants with respect to the non-natural molecular scaffold. In
one embodiment of the invention, the repeating pattern may be a
geometric pattern. Examples of suitable ordered and repetitive
antigen or antigenic determinant arrays are those which possess
strictly repetitive paracrystalline orders of antigens or antigenic
determinants with spacings of 5 to 15 nanometers.
[0125] Organizer: As used herein, the term "organizer" is used to
refer to an element bound to a core particle in a non-random
fashion that provides a nucleation site for creating an ordered and
repetitive antigen array. An organizer is any element comprising at
least one first attachment site that is bound to a core particle by
at least one covalent bond. An organizer may be a protein, a
polypeptide, a peptide, an amino acid (i.e., a residue of a
protein, a polypeptide or peptide), a sugar, a polynucleotide, a
natural or synthetic polymer, a secondary metabolite or compound
(biotin, fluorescein, retinol, digoxigenin, metal ions,
phenylmethylsulfonylfluoride), or a combination thereof, or a
chemically reactive group thereof. Therefore, the organizer further
ensures formation of an ordered and repetitive antigen array in
accordance with the present invention. In typical embodiments of
the invention, the core particle is modified, e.g. by way of
genetic engineering or chemical reaction, so as to generate a
non-natural molecular scaffold comprising the core particle and the
organizer, the latter being connected to the core particle by at
least one covalent bond. In certain embodiments of the invention,
however, the organizer is selected as being part of the core
particle. Therefore, for those embodiments modification of the core
particle is not necessarily needed to generate a non-natural
molecular scaffold comprising the core particle and the organizer
and to ensure the formation of an ordered and repetitive antigen
array.
[0126] Permissive temperature: As used herein, the phrase
"permissive temperature" refers to temperatures at which an enzyme
has relatively high levels of catalytic activity.
[0127] Pili: As used herein, the term "pili" (singular being
"pilus") refers to extracellular structures of bacterial cells
composed of protein monomers (e.g., pilin monomers) which are
organized into ordered and repetitive patterns. Further, pili are
structures which are involved in processes such as the attachment
of bacterial cells to host cell surface receptors, inter-cellular
genetic exchanges, and cell-cell recognition. Examples of pili
include Type-1 pili, P-pili, F1C pili, S-pili, and 987P-pili.
Additional examples of pili are set out below.
[0128] Pilus-like structure: As used herein, the phrase "pilus-like
structure" refers to structures having characteristics similar to
that of pili and composed of protein monomers. One example of a
"pilus-like structure" is a structure formed by a bacterial cell
which expresses modified pilin proteins that do not form ordered
and repetitive arrays that are essentially identical to those of
natural pili.
[0129] Polypeptide: As used herein the term "polypeptide" refers to
a polymer composed of amino acid residues, generally natural amino
acid residues, linked together through peptide bonds. Although a
polypeptide may not necessarily be limited in size, the term
polypeptide is often used in conjunction with peptide of a size of
about ten to about 50 amino acids.
[0130] Protein: As used herein, the term protein refers to a
polypeptide generally of a size of above 20, more particularly of
above 50 amino acid residues. Proteins generally have a defined
three dimensional structure although they do not necessarily need
to, and are often referred to as folded, in opposition to peptides
and polypeptides which often do not possess a defined
three-dimensional structure, but rather can adopt a large number of
different conformations, and are referred to as unfolded. The
defined three-dimensional structures of proteins is especially
important for the association between the core particle and the
antigen, mediated by the second attachment site, and in particular
by way of chemical cross-linking between the first and second
attachment site using a chemical cross-linker. The amino acid
linker is also intimately related to the structural properties of
proteins in some aspects of the invention.
[0131] Purified: As used herein, when the term "purified" is used
in reference to a molecule, it means that the concentration of the
molecule being purified has been increased relative to molecules
associated with it in its natural environment. Naturally associated
molecules include proteins, nucleic acids, lipids and sugars but
generally do not include water, buffers, and reagents added to
maintain the integrity or facilitate the purification of the
molecule being purified. For example, even if mRNA is diluted with
an aqueous solvent during oligo dT column chromatography, mRNA
molecules are purified by this chromatography if naturally
associated nucleic acids and other biological molecules do not bind
to the column and are separated from the subject mRNA
molecules.
[0132] Receptor: As used herein, the term "receptor" refers to
proteins or glycoproteins or fragments thereof capable of
interacting with another molecule, called the ligand. The ligand
may belong to any class of biochemical or chemical compounds. The
receptor need not necessarily be a membrane-bound protein. Soluble
protein, like e.g., maltose binding protein or retinol binding
protein are receptors as well.
[0133] Residue: As used herein, the term "residue" is meant to mean
a specific amino acid in a polypeptide backbone or side chain.
[0134] Recombinant host cell: As used herein, the term "recombinant
host cell" refers to a host cell into which one or more nucleic
acid molecules of the invention have been introduced.
[0135] Recombinant virus: As used herein, the phrase "recombinant
virus" refers to a virus that is genetically modified by the hand
of man. The phrase covers any virus known in the art. More
specifically, the phrase refers to a an alphavirus genetically
modified by the hand of man, and most specifically, the phrase
refers to a Sinbis virus genetically modified by the hand of
man.
[0136] Restrictive temperature: As used herein, the phrase
"restrictive temperature" refers to temperatures at which an enzyme
has low or undetectable levels of catalytic activity. Both "hot"
and "cold" sensitive mutants are known and, thus, a restrictive
temperature may be higher or lower than a permissive
temperature.
[0137] RNA-dependent RNA replication event: As used herein, the
phrase "RNA-dependent RNA replication event" refers to processes
which result in the formation of an RNA molecule using an RNA
molecule as a template.
[0138] RNA-Dependent RNA polymerase: As used herein, the phrase
"RNA-Dependent RNA polymerase" refers to a polymerase which
catalyzes the production of an RNA molecule from another RNA
molecule. This term is used herein synonymously with the term
"replicase."
[0139] RNA-phage: As used herein, the term "RNA-phage" refers to
RNA viruses infecting bacteria, preferably to single-stranded
positive-sense RNA viruses infecting bacteria.
[0140] Self antigen: As used herein, the term "self antigen" refers
to proteins encoded by the host's DNA and products generated by
proteins or RNA encoded by the host's DNA are defined as self. In
addition, proteins that result from a combination of two or several
self-molecules or that represent a fraction of a self-molecule and
proteins that have a high homology to self-molecules as defined
above (>95%) may also be considered self.
[0141] Temperature-sensitive: As used herein, the phrase
"temperature-sensitive" refers to an enzyme which readily catalyzes
a reaction at one temperature but catalyzes the same reaction
slowly or not at all at another temperature. An example of a
temperature-sensitive enzyme is the replicase protein encoded by
the pCYTts vector, which has readily detectable replicase activity
at temperatures below 34.degree. C. and has low or undetectable
activity at 37.degree. C.
[0142] Transcription: As used herein, the term "transcription"
refers to the production of RNA molecules from DNA templates
catalyzed by RNA polymerase.
[0143] Untranslated RNA: As used herein, the phrase "untranslated
RNA" refers to an RNA sequence or molecule which does not encode an
open reading frame or encodes an open reading frame, or portion
thereof, but in a format in which an amino acid sequence will not
be produced (e.g., no initiation codon is present). Examples of
such molecules are tRNA molecules, rRNA molecules, and
ribozymes.
[0144] Vector: As used herein, the term "vector" refers to an agent
(e.g., a plasmid or virus) used to transmit genetic material to a
host cell. A vector may be composed of either DNA or RNA.
[0145] Virus-like particle: As used herein, the term "virus-like
particle" refers to a structure resembling a virus particle.
Moreover, a virus-like particle in accordance with the invention is
non replicative and noninfectious since it lacks all or part of the
viral genome, in particular the replicative and infectious
components of the viral genome. A virus-like particle in accordance
with the invention may contain nucleic acid distinct from their
genome.
[0146] Virus-like particle of a bacteriophage: As used herein, the
term "virus-like particle of a bacteriophage" refers to a
virus-like particle resembling the structure of a bacteriophage,
being non replicative and noninfectious, and lacking at least the
gene or genes encoding for the replication machinery of the
bacteriophage, and typically also lacking the gene or genes
encoding the protein or proteins responsible for viral attachment
to or entry into the host. This definition should, however, also
encompass virus-like particles of bacteriophages, in which the
aforementioned gene or genes are still present but inactive, and,
therefore, also leading to non-replicative and noninfectious
virus-like particles of a bacteriophage.
[0147] Virus particle: The term "virus particle" as used herein
refers to the morphological form of a virus. In some virus types it
comprises a genome surrounded by a protein capsid; others have
additional structures (e.g., envelopes, tails, etc.).
[0148] One, a, or an: When the terms "one," "a," or "an" are used
in this disclosure, they mean "at least one" or "one or more,"
unless otherwise indicated.
[0149] 2. Compositions of Ordered and Repetitive Antigen or
Antigenic Determinant Arrays and Methods to Make the Same
[0150] The disclosed invention provides compositions comprising an
ordered and repetitive antigen or antigenic determinant array.
Furthermore, the invention conveniently enables the practitioner to
construct ordered and repetitive antigen or antigenic determinant
arrays for various treatment purposes, which includes the
prevention of infectious diseases, the treatment of allergies and
the treatment of cancers.
[0151] Compositions of the invention essentially comprise, or
alternatively consist of, two elements: (1) a non-natural molecular
scaffold; and (2) an antigen or antigenic determinant with at least
one second attachment site capable of association through at least
one non-peptide bond to said first attachment site.
[0152] Compositions of the invention also comprise, or
alternatively consist of, bacterial pilus proteins to which
antigens or antigenic determinants are directly linked.
[0153] The non-natural molecular scaffold comprises, or
alternatively consists of: (a) a core particle selected from the
group consisting of (1) a core particle of non-natural origin and
(2) a core particle of natural origin; and (b) an organizer
comprising at least one first attachment site, wherein said
organizer is connected to said core particle by at least one
covalent bond.
[0154] Compositions of the invention also comprise, or
alternatively consist of, core particles to which antigens or
antigenic determinants are directly linked.
[0155] The antigen or antigenic determinant has at least one second
attachment site which is selected from the group consisting of (a)
an attachment site not naturally occurring with said antigen or
antigenic determinant; and (b) an attachment site naturally
occurring with said antigen or antigenic determinant.
[0156] The invention provides for an ordered and repetitive antigen
array through an association of the second attachment site to the
first attachment site by way of at least one non-peptide bond.
Thus, the antigen or antigenic determinant and the non-natural
molecular scaffold are brought together through this association of
the first and the second attachment site to form an ordered and
repetitive antigen array.
[0157] The practioner may specifically design the antigen or
antigenic determinant and the second attachment site such that the
arrangement of all the antigens or antigenic determinants bound to
the non-natural molecular scaffold or, in certain embodiments, the
core particle will be uniform. For example, one may place a single
second attachment site on the antigen or antigenic determinant at
the carboxyl or amino terminus, thereby ensuring through design
that all antigen or antigenic determinant molecules that are
attached to the non-natural molecular scaffold are positioned in a
uniform way. Thus, the invention provides a convenient means of
placing any antigen or antigenic determinant onto a non-natural
molecular scaffold in a defined order and in a manner which forms a
repetitive pattern.
[0158] As will be clear to those skilled in the art, certain
embodiments of the invention involve the use of recombinant nucleic
acid technologies such as cloning, polymerase chain reaction, the
purification of DNA and RNA, the expression of recombinant proteins
in prokaryotic and eukaryotic cells, etc. Such methodologies are
well known to those skilled in the art and may be conveniently
found in published laboratory methods manuals (e.g., Sambrook, J.
et al., eds., Molecular Cloning, A Laboratory Manual, 2nd. edition,
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
(1989); Ausubel, F. et al., eds., Current Protocols in Molecular
Biology, John H. Wiley & Sons, Inc. (1997)). Fundamental
laboratory techniques for working with tissue culture cell lines
(Celis, J., ed., Cell Biology, Academic Press, 2nd edition, (1998))
and antibody-based technologies (Harlow, E. and Lane, D.,
"Antibodies: A Laboratory Manual," Cold Spring Harbor Laboratory,
Cold Spring Harbor, N.Y. (1988); Deutscher, M. P., "Guide to
Protein Purification," Meth. Enzymol. 128, Academic Press San Diego
(1990); Scopes, R. K., "Protein Purification Principles and
Practice," 3rd ed., Springer-Verlag, New York (1994)) are also
adequately described in the literature, all of which are
incorporated herein by reference.
[0159] A. Core Particles and Non-Natural Molecular Scaffolds
[0160] One element in certain compositions of the invention is a
non-natural molecular scaffold comprising, or alternatively
consisting of, a core particle and an organizer. As used herein,
the phrase "non-natural molecular scaffold" refers to any product
made by the hand of man that may serve to provide a rigid and
repetitive array of first attachment sites. More specifically, the
non-natural molecular scaffold comprises, or alternatively consists
of, (a) a core particle selected from the group consisting of (1) a
core particle of non-natural origin and (2) a core particle of
natural origin; and (b) an organizer comprising at least one first
attachment site, wherein said organizer is connected to said core
particle by at least one covalent bond.
[0161] As will be readily apparent to those skilled in the art, the
core particle of the non-natural molecular scaffold of the
invention is not limited to any specific form. The core particle
may be organic or non-organic and may be synthesized chemically or
through a biological process.
[0162] In one embodiment, a non-natural core particle may be a
synthetic polymer, a lipid micelle or a metal. Such core particles
are known in the art, providing a basis from which to build the
novel non-natural molecular scaffold of the invention. By way of
example, synthetic polymer or metal core particles are described in
U.S. Pat. No. 5,770,380, which discloses the use of a calixarene
organic scaffold to which is attached a plurality of peptide loops
in the creation of an `antibody mimic`, and U.S. Pat. No. 5,334,394
describes nanocrystalline particles used as a viral decoy that are
composed of a wide variety of inorganic materials, including metals
or ceramics. Suitable metals include chromium, rubidium, iron,
zinc, selenium, nickel, gold, silver, platinum. Suitable ceramic
materials in this embodiment include silicon dioxide, titanium
dioxide, aluminum oxide, ruthenium oxide and tin oxide. The core
particles of this embodiment may be made from organic materials
including carbon (diamond). Suitable polymers include polystyrene,
nylon and nitrocellulose. For this type of nanocrystalline
particle, particles made from tin oxide, titanium dioxide or carbon
(diamond) are may also be used. A lipid micelle may be prepared by
any means known in the art. For example micelles may be prepared
according to the procedure of Baiselle and Millar (Biophys. Chem.
4:355-361 (1975)) or Corti et al. (Chem. Phys. Lipids 38:197-214
(1981)) or Lopez et al. (FEBS Lett. 426:314-318 (1998)) or
Topchieva and Karezin (J. Colloid Interface Sci. 213:29-35 (1999))
or Morein et al., (Nature 308:457-460 (1984)), which are all
incorporated herein by reference.
[0163] The core particle may also be produced through a biological
process, which may be natural or non-natural. By way of example,
this type of embodiment may includes a core particle comprising, or
alternatively consisting of, a virus, virus-like particle, a
bacterial pilus, a phage, a viral capsid particle or a recombinant
form thereof. In a more specific embodiment, the core particle may
comprise, or alternatively consist of, recombinant proteins of
Rotavirus, recombinant proteins of Norwalk virus, recombinant
proteins of Alphavirus, recombinant proteins which form bacterial
pili or pilus-like structures, recombinant proteins of Foot and
Mouth Disease virus, recombinant proteins of Retrovirus,
recombinant proteins of Hepatitis B virus (e.g., a HBcAg),
recombinant proteins of Tobacco mosaic virus, recombinant proteins
of Flock House Virus, and recombinant proteins of human
Papillomavirus. The core particle may further comprise, or
alternatively consist of, one or more fragments of such proteins,
as well as variants of such proteins which retain the ability to
associate with each other to form ordered and repetitive antigen or
antigenic determinant arrays.
[0164] As explained in more below, variants of proteins which
retain the ability to associate with each other to form ordered and
repetitive antigen or antigenic determinant arrays may share, for
example, at least 80%, 85%, 90%, 95%, 97%, or 99% identity at the
amino acid level with their wild-type counterparts. Using the HBcAg
having the amino acid sequence shown in SEQ ID NO:89 for
illustration, the invention includes vaccine compositions
comprising HBcAg polypeptides comprising, or alternatively
consisting of, amino acid sequences which are at least 80%, 85%,
90%, 95%, 97%, or 99% identical to the amino acid sequence shown in
SEQ ID NO:89, and forms of this protein which have been processed,
where appropriate, to remove N-terminal leader sequence. These
variants will generally be capable of associating to form dimeric
or multimeric structures. Methods which can be used to determine
whether proteins form such structures comprise gel filtration,
agarose gel electrophoresis, sucrose gradient centrifugation and
electron microscopy (e.g., Koschel, M. et al., J. Virol 73:
2153-2160 (1999)).
[0165] Fragments of proteins which retain the ability to associate
with each other to form ordered and repetitive antigen or antigenic
determinant arrays may comprise, or alternatively consist of,
polypeptides which are 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,
70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170,
180, 190, or 200 amino acids in length. Examples of such protein
fragments include fragments of proteins discussed herein which are
suitable for the preparation of core particles and/or non-natural
molecular scaffolds.
[0166] Whether natural or non-natural, the core particle of the
invention will generally have an organizer that is attached to the
natural or non-natural core particle by at least one covalent bond.
The organizer is an element bound to a core particle in a
non-random fashion that provides a nucleation site for creating an
ordered and repetitive antigen array. Ideally, but not necessarily,
the organizer is associated with the core particle in a geometric
order. Minimally, the organizer comprises a first attachment
site.
[0167] In some embodiments of the invention, the ordered and
repetitive array is formed by association between (1) either core
particles or non-natural molecular scaffolds and (2) either (a) an
antigen or antigenic determinant or (b) one or more antigens or
antigenic determinants. For example, bacterial pili or pilus-like
structures are formed from proteins which are organized into
ordered and repetitive structures. Thus, in many instances, it will
be possible to form ordered arrays of antigens or antigenic
determinants by linking these constituents to bacterial pili or
pilus-like structures either directly or through an organizer.
[0168] As previously stated, the organizer may be any element
comprising at least one first attachment site that is bound to a
core particle by at least one covalent bond. An organizer may be a
protein, a polypeptide, a peptide, an amino acid (i.e., a residue
of a protein, a polypeptide or peptide), a sugar, a polynucleotide,
a natural or synthetic polymer, a secondary metabolite or compound
(biotin, fluorescein, retinol, digoxigenin, metal ions,
phenylmethylsulfonylfluoride), or a combination thereof, or a
chemically reactive group thereof. In a more specific embodiment,
the organizer may comprise a first attachment site comprising an
antigen, an antibody or antibody fragment, biotin, avidin,
strepavidin, a receptor, a receptor ligand, a ligand, a
ligand-binding protein, an interacting leucine zipper polypeptide,
an amino group, a chemical group reactive to an amino group; a
carboxyl group, chemical group reactive to a carboxyl group, a
sulfhydryl group, a chemical group reactive to a sulfhydryl group,
or a combination thereof.
[0169] In one embodiment, the core particle of the non-natural
molecular scaffold comprises a virus, a bacterial pilus, a
structure formed from bacterial pilin, a bacteriophage, a
virus-like particle, a viral capsid particle or a recombinant form
thereof. Any virus known in the art having an ordered and
repetitive coat and/or core protein structure may be selected as a
non-natural molecular scaffold of the invention; examples of
suitable viruses include sindbis and other alphaviruses,
rhabdoviruses (e.g. vesicular stomatitis virus), picomaviruses
(e.g., human rhino virus, Aichi virus), togaviruses (e.g., rubella
virus), orthomyxoviruses (e.g., Thogoto virus, Balken virus, fowl
plague virus), polyomaviruses (e.g., polyomavirus BK, polyomavirus
JC, avian polyomavirus BFDV), parvoviruses, rotaviruses,
bacteriophage Q.beta., bacteriophage R17, bacteriophage M11,
bacteriophage MX1, bacteriophage NL95, bacteriophage fr,
bacteriophage GA, bacteriophage SP, bacteriophage MS2,
bacteriophage f2, bacteriophage PP7, Norwalk virus, foot and mouth
disease virus, a retrovirus, Hepatitis B virus, Tobacco mosaic
virus, Flock House Virus, and human Papilomavirus (for example, see
Table 1 in Bachman, M. F. and Zinkernagel, R. M., Immunol. Today
17:553-558 (1996)).
[0170] In one embodiment, the invention utilizes genetic
engineering of a virus to create a fusion between an ordered and
repetitive viral envelope protein and an organizer comprising a
heterologous protein, peptide, antigenic determinant or a reactive
amino acid residue of choice. Other genetic manipulations known to
those in the art may be included in the construction of the
non-natural molecular scaffold; for example, it may be desirable to
restrict the replication ability of the recombinant virus through
genetic mutation. The viral protein selected for fusion to the
organizer (i.e., first attachment site) protein should have an
organized and repetitive structure. Such an organized and
repetitive structure include paracrystalline organizations with a
spacing of 5-15 nm on the surface of the virus. The creation of
this type of fusion protein will result in multiple, ordered and
repetitive organizers on the surface of the virus. Thus, the
ordered and repetitive organization of the first attachment sites
resulting therefrom will reflect the normal organization of the
native viral protein.
[0171] As will be discussed in more detail herein, in another
embodiment of the invention, the non-natural molecular scaffold is
a recombinant alphavirus, and more specifically, a recombinant
Sinbis virus. Alphaviruses are positive stranded RNA viruses that
replicate their genomic RNA entirely in the cytoplasm of the
infected cell and without a DNA intermediate (Strauss, J. and
Strauss, E., Microbiol. Rev. 58:491-562 (1994)). Several members of
the alphavirus family, Sindbis (Xiong, C. et al., Science
243:1188-1191 (1989); Schlesinger, S., Trends Biotechnol. 11:18-22
(1993)), Semliki Forest Virus (SFV) (Liljestrom, P. & Garoff,
H., Bio/Technology 9:1356-1361 (1991)) and others (Davis, N. L. et
al., Virology 171:189-204 (1989)), have received considerable
attention for use as virus-based expression vectors for a variety
of different proteins (Lundstrom, K., Curr. Opin. Biotechnol.
8:578-582 (1997); Liljestrom, P., Curr. Opin. Biotechnol. 5:495-500
(1994)) and as candidates for vaccine development. Recently, a
number of patents have issued directed to the use of alphaviruses
for the expression of heterologous proteins and the development of
vaccines (see U.S. Pat. Nos. 5,766,602; 5,792,462; 5,739,026;
5,789,245 and 5,814,482). The construction of the alphaviral
scaffold of the invention may be done by means generally known in
the art of recombinant DNA technology, as described by the
aforementioned articles, which are incorporated herein by
reference.
[0172] A variety of different recombinant host cells can be
utilized to produce a viral-based core particle for antigen or
antigenic determinant attachment. For example, Alphaviruses are
known to have a wide host range; Sindbis virus infects cultured
mammalian, reptilian, and amphibian cells, as well as some insect
cells (Clark, H., J. Natl. Cancer Inst. 51:645 (1973); Leake, C.,
J. Gen. Virol. 35:335 (1977); Stollar, V. in The Togaviruses, R. W.
Schlesinger, Ed., Academic Press, (1980), pp. 583-621). Thus,
numerous recombinant host cells can be used in the practice of the
invention. BHK, COS, Vero, HeLa and CHO cells are particularly
suitable for the production of heterologous proteins because they
have the potential to glycosylate heterologous proteins in a manner
similar to human cells (Watson, E. et al., Glycobiology 4:227,
(1994)) and can be selected (Zang, M. et al., Bio/Technology 13:389
(1995)) or genetically engineered (Renner W. et al., Biotech.
Bioeng. 4:476 (1995); Lee K. et al. Biotech. Bioeng. 50:336 (1996))
to grow in serum-free medium, as well as in suspension.
[0173] Introduction of the polynucleotide vectors into host cells
can be effected by methods described in standard laboratory manuals
(see, e.g., Sambrook, J. et al., eds., Molecular Cloning, A
Laboratory Manual, 2nd. edition, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, N.Y. (1989), Chapter 9; Ausubel, F. et
al., eds., Current Protocols in Molecular Biology, John H. Wiley
& Sons, Inc. (1997), Chapter 16), including methods such as
electroporation, DEAE-dextran mediated transfection, transfection,
microinjection, cationic lipid-mediated transfection, transduction,
scrape loading, ballistic introduction, and infection. Methods for
the introduction of exogenous DNA sequences into host cells are
discussed in Felgner, P. et al., U.S. Pat. No. 5,580,859.
[0174] Packaged RNA sequences can also be used to infect host
cells. These packaged RNA sequences can be introduced to host cells
by adding them to the culture medium. For example, the preparation
of non-infective alpahviral particles is described in a number of
sources, including "Sindbis Expression System", Version C
(Invitrogen Catalog No. K750-1).
[0175] When mammalian cells are used as recombinant host cells for
the production of viral-based core particles, these cells will
generally be grown in tissue culture. Methods for growing cells in
culture are well known in the art (see, e.g., Celis, J., ed., Cell
Biology, Academic Press, 2nd edition, (1998); Sambrook, J. et al.,
eds., Molecular Cloning, A Laboratory Manual, 2nd. edition, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989);
Ausubel, F. et al., eds., Current Protocols in Molecular Biology,
John H. Wiley & Sons, Inc. (1997); Freshney, R., Culture of
Animal Cells, Alan R. Liss, Inc. (1983)).
[0176] As will be understood by those in the art, the first
attachment site may be or be a part of any suitable protein,
polypeptide, sugar, polynucleotide, peptide (amino acid), natural
or synthetic polymer, a secondary metabolite or combination thereof
that may serve to specifically attach the antigen or antigenic
determinant of choice to the non-natural molecular scaffold. In one
embodiment, the attachment site is a protein or peptide that may be
selected from those known in the art. For example, the first
attachment site may selected from the following group: a ligand, a
receptor, a lectin, avidin, streptavidin, biotin, an epitope such
as an HA or T7 tag, Myc, Max, immunoglobulin domains and any other
amino acid sequence known in the art that would be useful as a
first attachment site.
[0177] It should be further understood by those in the art that
with another embodiment of the invention, the first attachment site
may be created secondarily to the organizer (i.e., protein or
polypeptide) utilized in constructing the in-frame fusion to the
capsid protein. For example, a protein may be utilized for fusion
to the envelope protein with an amino acid sequence known to be
glycosylated in a specific fashion, and the sugar moiety added as a
result may then serve at the first attachment site of the viral
scaffold by way of binding to a lectin serving as the secondary
attachment site of an antigen. Alternatively, the organizer
sequence may be biotinylated in vivo and the biotin moiety may
serve as the first attachment site of the invention, or the
organizer sequence may be subjected to chemical modification of
distinct amino acid residues in vitro, the modification serving as
the first attachment site.
[0178] In another embodiment of the invention, the first attachment
site is selected to be the JUN-FOS leucine zipper protein domain
that is fused in frame to the Hepatitis B capsid (core) protein
(HBcAg). However, it will be clear to all individuals in the art
that other viral capsid proteins may be utilized in the fusion
protein construct for locating the first attachment site in the
non-natural molecular scaffold of the invention.
[0179] In another embodiment of the invention, the first attachment
site is selected to be a lysine or cysteine residue that is fused
in frame to the HBcAg. However, it will be clear to all individuals
in the art that other viral capsid or virus-like particles may be
utilized in the fusion protein construct for locating the first
attachment in the non-natural molecular scaffold of the
invention.
[0180] The JUN amino acid sequence utilized for the first
attachment site is the following: TABLE-US-00001 (SEQ ID NO: 59)
CGGRIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMN HVGC
[0181] In this instance, the anticipated second attachment site on
the antigen would be the FOS leucine zipper protein domain and the
amino acid sequence would be the following: TABLE-US-00002 (SEQ ID
NO: 60) CGGLTDTLQAETDQVEDEKSALQTEIANLLKEKEKLEFILAAH GGC
[0182] These sequences are derived from the transcription factors
JUN and FOS, each flanked with a short sequence containing a
cysteine residue on both sides. These sequences are known to
interact with each other. The original hypothetical structure
proposed for the JUN-FOS dimer assumed that the hydrophobic side
chains of one monomer interdigitate with the respective side chains
of the other monomer in a zipper-like manner (Landschulz et al.,
Science 240:1759-1764 (1988)). However, this hypothesis proved to
be wrong, and these proteins are known to form an .beta.-helical
coiled coil (O'Shea et al., Science 243:538-542 (1989); O'Shea et
al., Cell 68:699-708 (1992); Cohen & Parry, Trends Biochem.
Sci. 11:245-248 (1986)). Thus, the term "leucine zipper" is
frequently used to refer to these protein domains for more
historical than structural reasons. Throughout this patent, the
term "leucine zipper" is used to refer to the sequences depicted
above or sequences essentially similar to the ones depicted above.
The terms JUN and FOS are used for the respective leucine zipper
domains rather than the entire JUN and FOS proteins.
[0183] As previously stated, the invention includes viral-based
core particles which comprise, or alternatively consist of, a
virus, virus-like particle, a phage, a viral capsid particle or a
recombinant form thereof. Skilled artisans have the knowledge to
produce such core particles and attach organizers thereto. The
production of Hepatitis B virus-like particles and measles viral
capsid particles as core particles is disclosed in Examples 17 to
22 of WO 00/32227, which is explicitly incorporated by reference.
In such embodiments, the JUN leucine zipper protein domain or FOS
leucine zipper protein domain may be used as an organizer, and
hence as a first attachment site, for the non-natural molecular
scaffold of the invention.
[0184] Examples 23-29 provide details of the production of
Hepatitis B core particles carrying an in-frame fused peptide with
a reactive lysine residue and antigens carrying a genetically fused
cysteine residue, as first and second attachment site,
respectively.
[0185] In other embodiments, the core particles used in
compositions of the invention are composed of a Hepatitis B capsid
(core) protein (HBcAg), a fragment of a HBcAg, or other protein or
peptide which can form ordered arrays, which have been modified to
either eliminate or reduce the number of free cysteine residues.
Zhou et al. (J. Virol. 66:5393-5398 (1992)) demonstrated that
HBcAgs which have been modified to remove the naturally resident
cysteine residues retain the ability to associate and form
multimeric structures. Thus, core particles suitable for use in
compositions of the invention include those comprising modified
HBcAgs, or fragments thereof, in which one or more of the naturally
resident cysteine residues have been either deleted or substituted
with another amino acid residue (e.g., a serine residue).
[0186] The HBcAg is a protein generated by the processing of a
Hepatitis B core antigen precursor protein. A number of isotypes of
the HBcAg have been identified. For example, the HBcAg protein
having the amino acid sequence shown in SEQ ID NO:132 is 183 amino
acids in length and is generated by the processing of a 212 amino
acid Hepatitis B core antigen precursor protein. This processing
results in the removal of 29 amino acids from the N-terminus of the
Hepatitis B core antigen precursor protein. Similarly, the HBcAg
protein having the amino acid sequence shown in SEQ ID NO:134 is
185 amino acids in length and is generated by the processing of a
214 amino acid Hepatitis B core antigen precursor protein. The
amino acid sequence shown in SEQ ID NO:134, as compared to the
amino acid sequence shown in SEQ ID NO:132, contains a two amino
acid insert at positions 152 and 153 in SEQ ID NO:134.
[0187] In most instances, vaccine compositions of the invention
will be prepared using the processed form of a HBcAg (i.e., a HBcAg
from which the N-terminal leader sequence (e.g., the first 29 amino
acid residues shown in SEQ ID NO:134) of the Hepatitis B core
antigen precursor protein have been removed).
[0188] Further, when HBcAgs are produced under conditions where
processing will not occur, the HBcAgs will generally be expressed
in "processed" form. For example, bacterial systems, such as E.
coli, generally do not remove the leader sequences, also referred
to as "signal peptides," of proteins which are normally expressed
in eukaryotic cells. Thus, when an E. coli expression system is
used to produce HBcAgs of the invention, these proteins will
generally be expressed such that the N-terminal leader sequence of
the Hepatitis B core antigen precursor protein is not present.
[0189] In one embodiment of the invention, a modified HBcAg
comprising the amino acid sequence shown in SEQ ID NO:134, or
subportion thereof, is used to prepare non-natural molecular
scaffolds. In particular, modified HBcAgs suitable for use in the
practice of the invention include proteins in which one or more of
the cysteine residues at positions corresponding to positions 48,
61, 107 and 185 of a protein having the amino acid sequence shown
in SEQ ID NO:134 have been either deleted or substituted with other
amino acid residues (e.g., a serine residue). As one skilled in the
art would recognize, cysteine residues at similar locations in
HBcAg variants having amino acids sequences which differ from that
shown in SEQ ID NO:134 could also be deleted or substituted with
other amino acid residues. The modified HBcAg variants can then be
used to prepare vaccine compositions of the invention.
[0190] The present invention also includes HBcAg variants which
have been modified to delete or substitute one or more additional
cysteine residues which are not found in polypeptides having the
amino acid sequence shown in SEQ ID NO:134. Examples of such HBcAg
variants have the amino acid sequences shown in SEQ ID NOs:90 and
132. These variant contain cysteines residues at a position
corresponding to amino acid residue 147 in SEQ ID NO:134. Thus, the
vaccine compositions of the invention include compositions
comprising HBcAgs in which cysteine residues not present in the
amino acid sequence shown in SEQ ID NO:134 have been deleted.
[0191] Under certain circumstances (e.g., when a heterobifunctional
cross-linking reagent is used to attach antigens or antigenic
determinants to the non-natural molecular scaffold), the presence
of free cysteine residues in the HBcAg is believed to lead to
covalent coupling of toxic components to core particles, as well as
the cross-linking of monomers to form undefined species.
[0192] Further, in many instances, these toxic components may not
be detectable with assays performed on compositions of the
invention. This is so because covalent coupling of toxic components
to the non-natural molecular scaffold would result in the formation
of a population of diverse species in which toxic components are
linked to different cysteine residues, or in some cases no cysteine
residues, of the HBcAgs. In other words, each free cysteine residue
of each HBcAg will not be covalently linked to toxic components.
Further, in many instances, none of the cysteine residues of
particular HBcAgs will be linked to toxic components. Thus, the
presence of these toxic components may be difficult to detect
because they would be present in a mixed population of molecules.
The administration to an individual of HBcAg species containing
toxic components, however, could lead to a potentially serious
adverse reaction.
[0193] It is well known in the art that free cysteine residues can
be involved in a number of chemical side reactions. These side
reactions include disulfide exchanges, reaction with chemical
substances or metabolites that are, for example, injected or formed
in a combination therapy with other substances, or direct oxidation
and reaction with nucleotides upon exposure to UV light. Toxic
adducts could thus be generated, especially considering the fact
that HBcAgs have a strong tendency to bind nucleic acids. Detection
of such toxic products in antigen-capsid conjugates would be
difficult using capsids prepared using HBcAgs containing free
cysteines and heterobifunctional cross-linkers, since a
distribution of products with a broad range of molecular weight
would be generated. The toxic adducts would thus be distributed
between a multiplicity of species, which individually may each be
present at low concentration, but reach toxic levels when
together.
[0194] In view of the above, one advantage to the use of HBcAgs in
vaccine compositions which have been modified to remove naturally
resident cysteine residues is that sites to which toxic species can
bind when antigens or antigenic determinants are attached to the
non-natural molecular scaffold would be reduced in number or
eliminated altogether. Further, a high concentration of
cross-linker can be used to produce highly decorated particles
without the drawback of generating a plurality of undefined
cross-linked species of HBcAg monomers (i.e., a diverse mixture of
cross-linked monomeric HbcAgs).
[0195] A number of naturally occurring HBcAg variants suitable for
use in the practice of the present invention have been identified.
Yuan et al., (J. Virol. 73:10122-10128 (1999)), for example,
describe variants in which the isoleucine residue at position
corresponding to position 97 in SEQ ID NO:134 is replaced with
either a leucine residue or a phenylalanine residue. The amino acid
sequences of a number of HBcAg variants, as well as several
Hepatitis B core antigen precursor variants, are disclosed in
GenBank reports AAF121240 (SEQ ID NO:89), AF121239 (SEQ ID NO:90),
X85297 (SEQ ID NO:91), X02496 (SEQ ID NO:92), X85305 (SEQ ID
NO:93), X85303 (SEQ ID NO:94), AF151735 (SEQ ID NO:95), X85259 (SEQ
ID NO:96), X85286 (SEQ ID NO:97), X85260 (SEQ ID NO:98), X85317
(SEQ ID NO:99), X85298 (SEQ ID NO:100), AF043593 (SEQ ID NO:101),
M20706 (SEQ ID NO:102), X85295 (SEQ ID NO:103), X80925 (SEQ ID
NO:104), X85284 (SEQ ID NO:105), X85275 (SEQ ID NO:106), X72702
(SEQ ID NO:107), X85291 (SEQ ID NO:108), X65258 (SEQ ID NO:109),
X85302 (SEQ ID NO:110), M32138 (SEQ ID NO:111), X85293 (SEQ ID
NO:112), X85315 (SEQ ID NO:113), U95551 (SEQ ID NO:114), X85256
(SEQ ID NO:115), X85316 (SEQ ID NO:116), X85296 (SEQ ID NO:117),
AB033559 (SEQ ID NO:118), X59795 (SEQ ID NO:119), X85299 (SEQ ID
NO:120), X85307 (SEQ ID NO:121), X65257 (SEQ ID NO:122), X85311
(SEQ ID NO:123), X85301 (SEQ ID NO:124), X85314 (SEQ ID NO:125),
X85287 (SEQ ID NO:126), X85272 (SEQ ID NO:127), X85319 (SEQ ID
NO:128), AB010289 (SEQ ID NO:129), X85285 (SEQ ID NO:130), AB010289
(SEQ ID NO:131), AF121242 (SEQ ID NO:132), M90520 (SEQ ID NO:135),
P03153 (SEQ ID NO:136), AF110999 (SEQ ID NO:137), and M95589 (SEQ
ID NO:138), the disclosures of each of which are incorporated
herein by reference. These HBcAg variants differ in amino acid
sequence at a number of positions, including amino acid residues
which corresponds to the amino acid residues located at positions
12, 13, 21, 22, 24, 29, 32, 33, 35, 38, 40, 42, 44, 45, 49, 51, 57,
58, 59, 64, 66, 67, 69, 74, 77, 80, 81, 87, 92, 93, 97, 98, 100,
103, 105, 106, 109, 113, 116, 121, 126, 130, 133, 135, 141, 147,
149, 157, 176, 178, 182 and 183 in SEQ ID NO:134.
[0196] HBcAgs suitable for use in the present invention may be
derived from any organism so long as they are able to associate to
form an ordered and repetitive antigen array.
[0197] As noted above, generally processed HBcAgs (i.e., those
which lack leader sequences) will be used in the vaccine
compositions of the invention. Thus, when HBcAgs having amino acid
sequence shown in SEQ ID NOs:136, 137, or 138 are used to prepare
vaccine compositions of the invention, generally 30, 35-43, or
35-43 amino acid residues at the N-terminus, respectively, of each
of these proteins will be omitted.
[0198] The present invention includes vaccine compositions, as well
as methods for using these compositions, which employ the above
described variant HBcAgs for the preparation of non-natural
molecular scaffolds.
[0199] Further included within the scope of the invention are
additional HBcAg variants which are capable of associating to form
dimeric or multimeric structures. Thus, the invention further
includes vaccine compositions comprising HBcAg polypeptides
comprising, or alternatively consisting of, amino acid sequences
which are at least 80%, 85%, 90%, 95%, 97%, or 99% identical to any
of the amino acid sequences shown in SEQ ID NOs:89-132 and 134-138,
and forms of these proteins which have been processed, where
appropriate, to remove the N-terminal leader sequence.
[0200] Whether the amino acid sequence of a polypeptide has an
amino acid sequence that is at least 80%, 85%, 90%, 95%, 97%, or
99% identical to one of the amino acid sequences shown in SEQ ID
NOs:89-132 and 134-138, or a subportion thereof, can be determined
conventionally using known computer programs such the Bestfit
program. When using Bestfit or any other sequence alignment program
to determine whether a particular sequence is, for instance, 95%
identical to a reference amino acid sequence according to the
present invention, the parameters are set such that the percentage
of identity is calculated over the full length of the reference
amino acid sequence and that gaps in homology of up to 5% of the
total number of amino acid residues in the reference sequence are
allowed.
[0201] The HBcAg variants and precursors having the amino acid
sequences set out in SEQ ID NOs:89-132 and 134-136 are relatively
similar to each other. Thus, reference to an amino acid residue of
a HBcAg variant located at a position which corresponds to a
particular position in SEQ ID NO:134, refers to the amino acid
residue which is present at that position in the amino acid
sequence shown in SEQ ID NO:134. The homology between these HBcAg
variants is for the most part high enough among Hepatitis B viruses
that infect mammals so that one skilled in the art would have
little difficulty reviewing both the amino acid sequence shown in
SEQ ID NO:134 and that of a particular HBcAg variant and
identifying "corresponding" amino acid residues. For example, the
HBcAg amino acid sequence shown in SEQ ID NO:135, which shows the
amino acid sequence of a HBcAg derived from a virus which infect
woodchucks, has enough homology to the HBcAg having the amino acid
sequence shown in SEQ ID NO:134 that it is readily apparent that a
three amino acid residue insert is present in SEQ ID NO:135 between
amino acid residues 155 and 156 of SEQ ID NO:134.
[0202] The HBcAgs of Hepatitis B viruses which infect snow geese
and ducks differ enough from the amino acid sequences of HBcAgs of
Hepatitis B viruses which infect mammals that alignment of these
forms of this protein with the amino acid sequence shown in SEQ ID
NO:134 is difficult. However, the invention includes vaccine
compositions which comprise HBcAg variants of Hepatitis B viruses
which infect birds, as wells as vaccine compositions which comprise
fragments of these HBcAg variants. HBcAg fragments suitable for use
in preparing vaccine compositions of the invention include
compositions which contain polypeptide fragments comprising, or
alternatively consisting of, amino acid residues selected from the
group consisting of 36-240, 36-269, 44-240, 44-269, 36-305, and
44-305 of SEQ ID NO:137 or 36-240, 36-269, 44-240, 44-269, 36-305,
and 44-305 of SEQ ID NO:138. As one skilled in the art would
recognize, one, two, three or more of the cysteine residues
naturally present in these polypeptides (e.g., the cysteine
residues at position 153 is SEQ ID NO:137 or positions 34, 43, and
196 in SEQ ID NO:138) could be either substituted with another
amino acid residue or deleted prior to their inclusion in vaccine
compositions of the invention.
[0203] In one embodiment, the cysteine residues at positions 48 and
107 of a protein having the amino acid sequence shown in SEQ ID
NO:134 are deleted or substituted with another amino acid residue
but the cysteine at position 61 is left in place. Further, the
modified polypeptide is then used to prepare vaccine compositions
of the invention.
[0204] As set out below in Example 31, the cysteine residues at
positions 48 and 107, which are accessible to solvent, may be
removed, for example, by site-directed mutagenesis. Further, the
inventors have found that the Cys-48-Ser, Cys-107-Ser HBcAg double
mutant constructed as described in Example 31 can be expressed in
E. coli.
[0205] As discussed above, the elimination of free cysteine
residues reduces the number of sites where toxic components can
bind to the HBcAg, and also eliminates sites where cross-linking of
lysine and cysteine residues of the same or of neighboring HBcAg
molecules can occur. The cysteine at position 61, which is involved
in dimer formation and forms a disulfide bridge with the cysteine
at position 61 of another HBcAg, will normally be left intact for
stabilization of HBcAg dimers and multimers of the invention.
[0206] As shown in Example 32, cross-linking experiments performed
with (1) HBcAgs containing free cysteine residues and (2) HBcAgs
whose free cysteine residues have been made unreactive with
iodacetamide, indicate that free cysteine residues of the HBcAg are
responsible for cross-linking between HBcAgs through reactions
between heterobifunctional cross-linker derivatized lysine side
chains, and free cysteine residues. Example 32 also indicates that
cross-linking of HBcAg subunits leads to the formation of high
molecular weight species of undefined size which cannot be resolved
by SDS-polyacrylamide gel electrophoresis.
[0207] When an antigen or antigenic determinant is linked to the
non-natural molecular scaffold through a lysine residue, it may be
advantageous to either substitute or delete one or both of the
naturally resident lysine residues located at positions
corresponding to positions 7 and 96 in SEQ ID NO:134, as well as
other lysine residues present in HBcAg variants. The elimination of
these lysine residues results in the removal of binding sites for
antigens or antigenic determinants which could disrupt the ordered
array and should improve the quality and uniformity of the final
vaccine composition.
[0208] In many instances, when both of the naturally resident
lysine residues at positions corresponding to positions 7 and 96 in
SEQ ID NO:134 are eliminated, another lysine will be introduced
into the HBcAg as an attachment site for an antigen or antigenic
determinant. Methods for inserting such a lysine residue are set
out, for example, in Example 23 below. It will often be
advantageous to introduce a lysine residue into the HBcAg when, for
example, both of the naturally resident lysine residues at
positions corresponding to positions 7 and 96 in SEQ ID NO:134 are
altered and one seeks to attach the antigen or antigenic
determinant to the non-natural molecular scaffold using a
heterobifunctional cross-linking agent.
[0209] The C-terminus of the HBcAg has been shown to direct nuclear
localization of this protein. (Eckhardt et al., J. Virol.
65:575-582 (1991).) Further, this region of the protein is also
believed to confer upon the HBcAg the ability to bind nucleic
acids.
[0210] In some embodiments, vaccine compositions of the invention
will contain HBcAgs which have nucleic acid binding activity (e.g.,
which contain a naturally resident HBcAg nucleic acid binding
domain). HBcAgs containing one or more nucleic acid binding domains
are useful for preparing vaccine compositions which exhibit
enhanced T-cell stimulatory activity. Thus, the vaccine
compositions of the invention include compositions which contain
HBcAgs having nucleic acid binding activity. Further included are
vaccine compositions, as well as the use of such compositions in
vaccination protocols, where HBcAgs are bound to nucleic acids.
These HBcAgs may bind to the nucleic acids prior to administration
to an individual or may bind the nucleic acids after
administration.
[0211] In other embodiments, vaccine compositions of the invention
will contain HBcAgs from which the C-terminal region (e.g., amino
acid residues 145-185 or 150-185 of SEQ ID NO:134) has been removed
and do not bind nucleic acids. Thus, additional modified HBcAgs
suitable for use in the practice of the present invention include
C-terminal truncation mutants. Suitable truncation mutants include
HBcAgs where 1, 5, 10, 15, 20, 25, 30, 34, 35, 36, 37, 38, 39 40,
41, 42 or 48 amino acids have been removed from the C-terminus.
[0212] HBcAgs suitable for use in the practice of the present
invention also include N-terminal truncation mutants. Suitable
truncation mutants include modified HBcAgs where 1, 2, 5, 7, 9, 10,
12, 14, 15, or 17 amino acids have been removed from the
N-terminus.
[0213] Further HBcAgs suitable for use in the practice of the
present invention include N- and C-terminal truncation mutants.
Suitable truncation mutants include HBcAgs where 1, 2, 5, 7, 9, 10,
12, 14, 15, and 17 amino acids have been removed from the
N-terminus and 1, 5, 10, 15, 20, 25, 30, 34, 35, 36, 37, 38, 39 40,
41, 42 or 48 amino acids have been removed from the C-terminus.
[0214] The invention further includes vaccine compositions
comprising HBcAg polypeptides comprising, or alternatively
consisting of, amino acid sequences which are at least 80%, 85%,
90%, 95%, 97%, or 99% identical to the above described truncation
mutants.
[0215] As discussed above, in certain embodiments of the invention,
a lysine residue is introduced as a first attachment site into a
polypeptide which forms the non-natural molecular scaffold. In
preferred embodiments, vaccine compositions of the invention are
prepared using a HBcAg comprising, or alternatively consisting of,
amino acids 1-144 or amino acids 1-149 of SEQ ID NO:134 which is
modified so that the amino acids corresponding to positions 79 and
80 are replaced with a peptide having the amino acid sequence of
Gly-Gly-Lys-Gly-Gly (SEQ ID NO:158) and the cysteine residues at
positions 48 and 107 are either deleted or substituted with another
amino acid residue, while the cysteine at position 61 is left in
place. The invention further includes vaccine compositions
comprising corresponding fragments of polypeptides having amino
acid sequences shown in any of SEQ ID NOs:89-132 and 135-136 which
also have the above noted amino acid alterations.
[0216] The invention further includes vaccine compositions
comprising fragments of a HBcAg comprising, or alternatively
consisting of, an amino acid sequence other than that shown in SEQ
ID NO:134 from which a cysteine residue not present at
corresponding location in SEQ ID NO:134 has been deleted. One
example of such a fragment would be a polypeptide comprising, or
alternatively consisting of, amino acids amino acids 1-149 of SEQ
ID NO:132 where the cysteine residue at position 147 has been
either substituted with another amino acid residue or deleted.
[0217] The invention further includes vaccine compositions
comprising HBcAg polypeptides comprising, or alternatively
consisting of, amino acid sequences which are at least 80%, 85%,
90%, 95%, 97%, or 99% identical to amino acids 1-144 or 1-149 of
SEQ ID NO:134 and corresponding subportions of a polypeptide
comprising an amino acid sequence shown in any of SEQ ID NOs:89-132
or 134-136, as well as to amino acids 1-147 or 1-152 of SEQ ID
NO:158.
[0218] The invention also includes vaccine compositions comprising
HBcAg polypeptides comprising, or alternatively consisting of,
amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or
99% identical to amino acids 36-240, 36-269, 44-240, 44-269,
36-305, and 44-305 of SEQ ID NO:137 or 36-240, 36-269, 44-240,
44-269, 36-305, and 44-305 of SEQ ID NO:138.
[0219] Vaccine compositions of the invention may comprise mixtures
of different HBcAgs. Thus, these vaccine compositions may be
composed of HBcAgs which differ in amino acid sequence. For
example, vaccine compositions could be prepared comprising a
"wild-type" HBcAg and a modified HBcAg in which one or more amino
acid residues have been altered (e.g., deleted, inserted or
substituted). In most applications, however, only one type of a
HBcAg, or at least HBcAgs having essentially equivalent first
attachment sites, will be used because vaccines prepared using such
HBcAgs will present highly ordered and repetitive arrays of
antigens or antigenic determinants. Further, preferred vaccine
compositions of the invention are those which present highly
ordered and repetitive antigen array
[0220] The invention further includes vaccine compositions where
the non-natural molecular scaffold is prepared using a HBcAg fused
to another protein. As discussed above, one example of such a
fusion protein is a HBcAg/FOS fusion. Other examples of HBcAg
fusion proteins suitable for use in vaccine compositions of the
invention include fusion proteins where an amino acid sequence has
been added which aids in the formation and/or stabilization of
HBcAg dimers and multimers. This additional amino acid sequence may
be fused to either the N- or C-terminus of the HBcAg. One example,
of such a fusion protein is a fusion of a HBcAg with the GCN4 helix
region of Saccharomyces cerevisiae (GenBank Accession No. P03069
(SEQ ID NO:154)).
[0221] The helix domain of the GCN4 protein forms homodimers via
non-covalent interactions which can be used to prepare and
stabilize HBcAg dimers and multimers.
[0222] In one embodiment, the invention provides vaccine
compositions prepared using HBcAg fusions proteins comprising a
HBcAg, or fragment thereof, with a GCN4 polypeptide having the
sequence of amino acid residues 227 to 276 in SEQ ID NO:154 fused
to the C-terminus. This GCN4 polypeptide may also be fused to the
N-terminus of the HbcAg.
[0223] HBcAg/src homology 3 (SH3) domain fusion proteins could also
be used to prepare vaccine compositions of the invention. SH3
domains are relatively small domains found in a number of proteins
which confer the ability to interact with specific proline-rich
sequences in protein binding partners (see McPherson, Cell Signal
11:229-238 (1999). HBcAg/SH3 fusion proteins could be used in
several ways. First, the SH3 domain could form a first attachment
site which interacts with a second attachment site of the antigen
or antigenic determinant. Similarly, a proline rich amino acid
sequence could be added to the HBcAg and used as a first attachment
site for an SH3 domain second attachment site of an antigen or
antigenic determinant. Second, the SH3 domain could associate with
proline rich regions introduced into HBcAgs. Thus, SH3 domains and
proline rich SH3 interaction sites could be inserted into either
the same or different HBcAgs and used to form and stabilized dimers
and multimers of the invention.
[0224] In other embodiments, a bacterial pilin, a subportion of a
bacterial pilin, or a fusion protein which contains either a
bacterial pilin or subportion thereof is used to prepare vaccine
compositions of the invention. Examples of pilin proteins include
pilins produced by Escherichia coli, Haemophilus influenzae,
Neisseria meningitidis, Neisseria gonorrhoeae, Caulobacter
crescentus, Pseudomonas stutzeri, and Pseudomonas aeruginosa. The
amino acid sequences of pilin proteins suitable for use with the
present invention include those set out in GenBank reports AJ000636
(SEQ ID NO:139), AJ132364 (SEQ ID NO:140), AF229646 (SEQ ID
NO:141), AF051814 (SEQ ID NO:142), AF051815 (SEQ ID NO:143), and
X00981 (SEQ ID NO:155), the entire disclosures of which are
incorporated herein by reference.
[0225] Bacterial pilin proteins are generally processed to remove
N-terminal leader sequences prior to export of the proteins into
the bacterial periplasm. Further, as one skilled in the art would
recognize, bacterial pilin proteins used to prepare vaccine
compositions of the invention will generally not have the naturally
present leader sequence.
[0226] One specific example of a pilin protein suitable for use in
the present invention is the P-pilin of E. coli (GenBank report
AF237482 (SEQ ID NO:144)). An example of a Type-1 E. coli pilin
suitable for use with the invention is a pilin having the amino
acid sequence set out in GenBank report P04128 (SEQ ID NO:146),
which is encoded by nucleic acid having the nucleotide sequence set
out in GenBank report M27603 (SEQ ID NO:145). The entire
disclosures of these GenBank reports are incorporated herein by
reference. Again, the mature form of the above referenced protein
would generally be used to prepare vaccine compositions of the
invention.
[0227] Bacterial pilins or pilin subportions suitable for use in
the practice of the present invention will generally be able to
associate to form non-natural molecular scaffolds.
[0228] Methods for preparing pili and pilus-like structures in
vitro are known in the art. Bullitt et al., Proc. Natl. Acad. Sci.
USA 93:12890-12895 (1996), for example, describe the in vitro
reconstitution of E. coli P-pili subunits. Further, Eshdat et al.,
J. Bacteriol. 148:308-314 (1981) describe methods suitable for
dissociating Type-1 pili of E. coli and the reconstitution of pili.
In brief, these methods are as follows: pili are dissociated by
incubation at 37.degree. C. in saturated guanidine hydrochloride.
Pilin proteins are then purified by chromatography, after which
pilin dimers are formed by dialysis against 5 mM
tris(hydroxymethyl)aminomethane hydrochloride (pH 8.0). Eshdat et
al. also found that pilin dimers reassemble to form pili upon
dialysis against the 5 mM tris(hydroxymethyl)aminomethane (pH 8.0)
containing 5 mM MgCl2.
[0229] Further, using, for example, conventional genetic
engineering and protein modification methods, pilin proteins may be
modified to contain a first attachment site to which an antigen or
antigenic determinant is linked through a second attachment site.
Alternatively, antigens or antigenic determinants can be directly
linked through a second attachment site to amino acid residues
which are naturally resident in these proteins. These modified
pilin proteins may then be used in vaccine compositions of the
invention.
[0230] Bacterial pilin proteins used to prepare vaccine
compositions of the invention may be modified in a manner similar
to that described herein for HBcAg. For example, cysteine and
lysine residues may be either deleted or substituted with other
amino acid residues and first attachment sites may be added to
these proteins. Further, pilin proteins may either be expressed in
modified form or may be chemically modified after expression.
Similarly, intact pili may be harvested from bacteria and then
modified chemically.
[0231] In another embodiment, pili or pilus-like structures are
harvested from bacteria (e.g., E. coli) and used to form vaccine
compositions of the invention. One example of pili suitable for
preparing vaccine compositions is the Type-1 pilus of E. coli,
which is formed from pilin monomers having the amino acid sequence
set out in SEQ ID NO:146.
[0232] A number of methods for harvesting bacterial pili are known
in the art. Bullitt and Makowski (Biophys. J. 74:623-632 (1998)),
for example, describe a pilus purification method for harvesting
P-pili from E. coli. According to this method, pili are sheared
from hyperpiliated E. coli containing a P-pilus plasmid and
purified by cycles of solubilization and MgCl2 (1.0 M)
precipitation. A similar purification method is set out below in
Example 33.
[0233] Once harvested, pili or pilus-like structures may be
modified in a variety of ways. For example, a first attachment site
can be added to the pili to which antigens or antigen determinants
may be attached through a second attachment site. In other words,
bacterial pili or pilus-like structures can be harvested and
modified to form non-natural molecular scaffolds.
[0234] Pili or pilus-like structures may also be modified by the
attachment of antigens or antigenic determinants in the absence of
a non-natural organizer. For example, antigens or antigenic
determinants could be linked to naturally occurring cysteine
resides or lysine residues. In such instances, the high order and
repetitiveness of a naturally occurring amino acid residue would
guide the coupling of the antigens or antigenic determinants to the
pili or pilus-like structures. For example, the pili or pilus-like
structures could be linked to the second attachment sites of the
antigens or antigenic determinants using a heterobifunctional
cross-linking agent.
[0235] When structures which are naturally synthesized by organisms
(e.g., pili) are used to prepare vaccine compositions of the
invention, it will often be advantageous to genetically engineer
these organisms so that they produce structures having desirable
characteristics. For example, when Type-1 pili of E. coli are used,
the E. coli from which these pili are harvested may be modified so
as to produce structures with specific characteristics. Examples of
possible modifications of pilin proteins include the insertion of
one or more lysine residues, the deletion or substitution of one or
more of the naturally resident lysine residues, and the deletion or
substitution of one or more naturally resident cysteine residues
(e.g., the cysteine residues at positions 44 and 84 in SEQ ID
NO:146).
[0236] Further, additional modifications can be made to pilin genes
which result in the expression products containing a first
attachment site other than a lysine residue (e.g., a FOS or JUN
domain). Of course, suitable first attachment sites will generally
be limited to those which do not prevent pilin proteins from
forming pili or pilus-like structures suitable for use in vaccine
compositions of the invention.
[0237] Pilin genes which naturally reside in bacterial cells can be
modified in vivo (e.g., by homologous recombination) or pilin genes
with particular characteristics can be inserted into these cells.
For examples, pilin genes could be introduced into bacterial cells
as a component of either a replicable cloning vector or a vector
which inserts into the bacterial chromosome. The inserted pilin
genes may also be linked to expression regulatory control sequences
(e.g., a lac operator).
[0238] In most instances, the pili or pilus-like structures used in
vaccine compositions of the invention will be composed of single
type of a pilin subunit. Pili or pilus-like structures composed of
identical subunits will generally be used because they are expected
to form structures which present highly ordered and repetitive
antigen arrays.
[0239] However, the compositions of the invention also include
vaccines comprising pili or pilus-like structures formed from
heterogenous pilin subunits. The pilin subunits which form these
pili or pilus-like structures can be expressed from genes naturally
resident in the bacterial cell or may be introduced into the cells.
When a naturally resident pilin gene and an introduced gene are
both expressed in a cell which forms pili or pilus-like structures,
the result will generally be structures formed from a mixture of
these pilin proteins. Further, when two or more pilin genes are
expressed in a bacterial cell, the relative expression of each
pilin gene will typically be the factor which determines the ratio
of the different pilin subunits in the pili or pilus-like
structures.
[0240] When pili or pilus-like structures having a particular
composition of mixed pilin subunits is desired, the expression of
at least one of the pilin genes can be regulated by a heterologous,
inducible promoter. Such promoters, as well as other genetic
elements, can be used to regulate the relative amounts of different
pilin subunits produced in the bacterial cell and, hence, the
composition of the pili or pilus-like structures.
[0241] In additional, while in most instances the antigen or
antigenic determinant will be linked to bacterial pili or
pilus-like structures by a bond which is not a peptide bond,
bacterial cells which produce pili or pilus-like structures used in
the compositions of the invention can be genetically engineered to
generate pilin proteins which are fused to an antigen or antigenic
determinant. Such fusion proteins which form pili or pilus-like
structures are suitable for use in vaccine compositions of the
invention.
[0242] As already discussed, viral capsids may be used for (1) the
presentation or antigen or antigenic determinants and (2) the
preparation of vaccine compositions of the invention. Particularly,
useful in the practice of the invention are viral capsid proteins,
also referred to herein as "coat proteins," which upon expression
form capsids or capsid-like structures. Thus, these capsid proteins
can form core particles and non-natural molecular scaffolds.
Generally, these capsids or capsid-like structures form ordered and
repetitive arrays which can be used for the presentation of
antigens or antigenic determinants and the preparation of vaccine
compositions of the invention.
[0243] One or more (e.g., one, two, three, four, five, etc.)
antigens or antigenic determinants may be attached by any number of
means to one or more (e.g., one, two, three, four, five, etc.)
proteins which form viral capsids or capsid-like structures (e.g.,
bacteriophage coat proteins), as well as other proteins. For
example, antigens or antigenic determinants may be attached to core
particles using first and second attachment sites. Further, one or
more (e.g., one, two, three, four, five, etc.) heterobifunctional
crosslinkers can be used to attach antigens or antigenic
determinants to one or more proteins which form viral capsids or
capsid-like structures.
[0244] Viral capsid proteins, or fragments thereof may be used, for
example, to prepare core particles and vaccine compositions of the
invention. Bacteriophage Q.beta. coat proteins, for example, can be
expressed recombinantly in E. coli. Further, upon such expression
these proteins spontaneously form capsids. Additionally, these
capsids form ordered and repetitive antigen or antigenic
determinant arrays which can be used for antigen presentation and
the preparation of vaccine compositions. As described below in
Example 38, bacteriophage Q.beta. coat proteins can be used to
prepare vaccine compositions which elicit immunological responses
to antigenic determinants.
[0245] Specific examples of bacteriophage coat proteins which can
be used to prepare compositions of the invention include the coat
proteins of RNA bacteriophages such as bacteriophage Q.beta. (SEQ
ID NO:159; PIR Database, Accession No. VCBPQ.beta. referring to
Q.beta. CP and SEQ ID NO: 217; Accession No. AAA16663 referring to
Q.beta. A1 protein), bacteriophage R17 (SEQ ID NO:160; PIR
Accession No. VCBPR7), bacteriophage fr (SEQ ID NO:161; PIR
Accession No. VCBPFR), bacteriophage GA (SEQ ID NO:162; GenBank
Accession No. NP-040754), bacteriophage SP (SEQ ID NO:163; GenBank
Accession No. CAA30374 referring to SP CP and SEQ ID NO: 254;
Accession No. referring to SP A1 protein), bacteriophage MS2 (SEQ
ID NO:164; PIR Accession No. VCBPM2), bacteriophage M11 (SEQ ID
NO:165; GenBank Accession No. AAC06250), bacteriophage MX1 (SEQ ID
NO:166; GenBank Accession No. AAC14699), bacteriophage NL95 (SEQ ID
NO:167; GenBank Accession No. AAC14704), bacteriophage f2 (SEQ ID
NO: 215; GenBank Accession No. P03611), bacteriophage PP7 (SEQ ID
NO: 253), As one skilled in the art would recognize, any protein
which forms capsids or capsid-like structures can be used for the
preparation of vaccine compositions of the invention. Furthermore,
the A1 protein of bacteriophage Q.beta. or C-terminal truncated
forms missing as much as 100, 150 or 180 amino acids from its
C-terminus may be incorporated in a capsid assembly of Q.beta. coat
proteins. The A1 protein may also be fused to an organizer and
hence a first attachment site, for attachment of Antigens
containing a second attachment site. Generally, the percentage of
A1 protein relative to Q.beta. CP in the capsid assembly will be
limited, in order to insure capsid formation. A1 protein accession
No. AAA16663 (SEQ ID NO: 217).
[0246] Q.beta. coat protein has also been found to self-assemble
into capsids when expressed in E. coli (Kozlovska T M. et al., GENE
137: 133-137 (1993)). The obtained capsids or virus-like particles
showed an icosahedral phage-like capsid structure with a diameter
of 25 nm and T=3 quasi symmetry. Further, the crystal structure of
phage Q.beta. has been solved. The capsid contains 180 copies of
the coat protein, which are linked in covalent pentamers and
hexamers by disulfide bridges (Golmohammadi, R. et al., Structure
4: 543-5554 (1996)). Other RNA phage coat proteins have also been
shown to self-assemble upon expression in a bacterial host
(Kastelein, R A. et al., Gene 23: 245-254 (1983), Kozlovskaya, T M.
et al., Dokl. Akad. Nauk SSSR 287: 452-455 (1986), Adhin, M R. et
al., Virology 170: 238-242 (1989), Ni, C Z., et al., Protein Sci.
5: 2485-2493 (1996), Priano, C. et al., J. Mol. Biol. 249: 283-297
(1995)). The Q.beta. phage capsid contains, in addition to the coat
protein, the so called read-through protein A1 and the maturation
protein A2. A1 is generated by suppression at the UGA stop codon
and has a length of 329 aa. The capsid of phage Q.beta. recombinant
coat protein used in the invention is devoid of the A2 lysis
protein, and contains RNA from the host. The coat protein of RNA
phages is an RNA binding protein, and interacts with the stem loop
of the ribosomal binding site of the replicase gene acting as a
translational repressor during the life cycle of the virus. The
sequence and structural elements of the interaction are known
(Witherell, G W. & Uhlenbeck, O C. Biochemistry 28: 71-76
(1989); Lim F. et al., J. Biol. Chem. 271: 31839-31845 (1996)). The
stem loop and RNA in general are known to be involved in the virus
assembly (Golmohammadi, R. et al., Structure 4: 543-5554
(1996))
[0247] Proteins or protein domains may affect the structure and
assembly of the particle even more then a short peptide. As an
example, proper folding of antigens comprising disulfide bridges
will generally not be possible in the cytoplasm of E. coli, where
the Q.beta. particles are expressed. Likewise, glycosylation is
generally not possible in prokaryotic expression systems. It is
therefore an advantage of the contemplated invention described here
to attach the antigen to the particle by starting with the already
assembled particle and the isolated antigen. This allows expression
of both the particle and the antigen in an expression host
guaranteeing proper folding of the antigen, and proper folding and
assembly of the particle.
[0248] It is a finding of this invention, that one or several
antigen molecules may be attached to one subunit of the capsid of
RNA phages coat proteins. A specific feature of the capsid of the
coat protein of RNA phages and in particular of Q.beta. capsid is
thus the possibility to couple several antigens per subunit. This
allows for the generation of a dense antigen array. Other viral
capsids used for covalent attachment of antigens by way of chemical
cross-linking, such for example a HBcAg modified with a lysine
residue in its major immunodominant region (MIR; WO 00/32227), show
coupling density of maximally 0.5 antigens per subunit. The
distance between the spikes (corresponding to the MIR) of HBcAg is
50 A (Wynne, S A. et al., Mol. Cell 3: 771-780 (1999)), and
therefore an antigen array with distances shorter than 50 A cannot
be generated
[0249] Capsids of Q.beta. coat protein display a defined number of
lysine residues on their surface, with a defined topology with
three lysine residues pointing towards the interior of the capsid
and interacting with the RNA, and four other lysine residues
exposed to the exterior of the capsid. These defined properties
favor the attachment of antigens to the exterior of the particle,
and not to the interior where the lysine residues interact with
RNA. Capsids of other RNA phage coat proteins also have a defined
number of lysine residues on their surface and a defined topology
of these lysine residues. Another advantage of the capsids derived
from RNA phages is their high expression yield in bacteria, that
allows to produce large quantities of material at affordable
cost.
[0250] Another feature of the capsid of Q.beta. coat protein is its
stability. Q.beta. subunits are bound via disulfide bridges to each
other, covalently linking the subunits. Q.beta. capsid protein also
shows unusual resistance to organic solvents and denaturing agents.
Surprisingly, we have observed that DMSO and acetonitrile
concentrations as high as 30%, and Guanidinium concentrations as
high as 1 M could be used without affecting the stability or the
ability to form antigen arrays of the capsid. Thus, theses organic
solvents may be used to couple hydrophobic peptides. The high
stability of the capsid of Q.beta. coat protein is an important
feature pertaining to its use for immunization and vaccination of
mammals and humans in particular. The resistance of the capsid to
organic solvent allows the coupling of antigens not soluble in
aqueous buffers.
[0251] Insertion of a cysteine residue into the N-terminal
.beta.-hairpin of the coat protein of the RNA phage MS-2 has been
described in the U.S. Pat. No. 5,698,424. We note however, that the
presence of an exposed free cysteine residue in the capsid may lead
to oligomerization of capsids by way of disulfide bridge formation.
Other attachments contemplated in U.S. Pat. No. 5,698,424 involve
the formation of disulfide bridges between the antigen and the
Q.beta. particle. Such attachments are labile to sulfhydryl-moiety
containing molecules.
[0252] The reaction between an initial disulfide bridge formed with
a cys-residue on Q.beta. and the antigen containing a free
sulfhydryl residue releases sulfhydryl containing species other
than the antigen. These newly formes sulfhydryl containing species
can react again with other disulfide bridges present on the
particle, thus establishing an equilibrium. Upon reaction with the
disulfide bridge formed on the particle, the antigen may either
form a disulfide bridge with the cys-residue from the particle, or
with the cys-residue of the leaving group molecule which was
forming the initial disulfide bridge on the particle. Moreover, the
other method of attachment described, using a hetero-bifunctional
cross-linker reacting with a cysteine on the Q.beta. particle on
one side, and with a lysine residue on the antigen on the other
side, leads to a random orientation of the antigens on the
particle.
[0253] We further note that, in contrast to the capsid of the
Q.beta. and Fr coat proteins, recombinant MS-2 described in U.S.
Pat. No. 5,698,424 is essentially free of nucleic acids, while RNA
is packaged inside the two capsids mentioned above.
[0254] We describe new and inventive compositions allowing the
formation of robust antigen arrays with variable antigen density.
We show that much higher epitope density can be achieved than
usually obtained with other VLPs. We also disclose compositions
with simultaneous display of several antigens with appropriate
spacing, and compositions wherein the addition of accessory
molecules, enhancing solubility or modifying the capsid in a
suitable and desired way.
[0255] The preparation of compositions of capsids of RNA phage coat
proteins with a high epitope density is disclosed in this
application. As a skilled artisan in the art would know, the
conditions for the assembly of the ordered and repetitive antigen
array depend for a good part on the antigen and on the selection of
a second attachment site on the antigen. In the case of the absence
of a useful second attachment site, such a second attachment has to
be engineered to the antigen.
[0256] A prerequisite in designing a second attachment site, is the
choice of the position at which it should be fused, inserted or
generally engineered. A skilled artisan would know how to find
guidance in selecting the position of the second attachment site. A
crystal structure of the antigen may provide information on the
availability of the C- or N-termini of the molecule (determined for
example from their accessibility to solvent), or on the exposure to
solvent of residues suitable for use as second attachment sites,
such as cysteine residues. Exposed disulfide bridges, as is the
case for Fab fragments, may also be a source of a second attachment
site, since they can be generally converted to single cysteine
residues through mild reduction. In general, in the case where
immunization with a self-antigen is aiming at inhibiting the
interaction of this self-antigen with its natural ligands, the
second attachment site will be added such that it allows generation
of antibodies against the site of interaction with the natural
ligands. Thus, the location of the second attachment site will
selected such, that steric hindrance from the second attachment
site or any amino acid linker containing it, is avoided. In further
embodiments, an antibody response directed at a site distinct from
the interaction site of the self-antigen with its natural ligand is
desired. In such embodiments, the second attachment site may be
selected such that it prevents generation of antibodies against the
interaction site of the self-antigen with its natural ligands.
[0257] Other criteria in selecting the position of the second
attachment site include the oligomerization state of the antigen,
the site of oligomerization, the presence of a cofactor, and the
availability of experimental evidence disclosing sites in the
antigen structure and sequence where modification of the antigen is
compatible with the function of the self-antigen, or with the
generation of antibodies recognizing the self-antigen.
[0258] In some embodiments, engineering of a second attachment site
onto the antigen requires the fusion of an amino acid linker
containing an amino acid suitable as second attachment site
according to the disclosures of this invention. In a preferred
embodiment, the amino acid is cysteine. The selection of the amino
acid linker will be dependent on the nature of the self-antigen, on
its biochemical properties, such as pI, charge distribution,
glycosylation. In general, flexible amino acid linkers are favored.
Examples of amino acid linkers are the hinge region of
Immunoglobulins, glycine serine linkers (GGGGS)n (SEQ ID NO:407),
and glycine linkers (G)n all further containing a cysteine residue
as second attachment site and optionally further glycine residues.
(In the following are examples of said amino acid linkers:
TABLE-US-00003 N-terminal CGDKTHTSPP (SEQ ID NO: 408) gamma 1:
C-terminal DKTHTSPPCG (SEQ ID NO: 409) gamma 1: N-terminal
CGGPKPSTPPGSSGGAP (SEQ ID NO: 410) gamma 3: C-terminal
PKPSTPPGSSGGAPGGCG (SEQ ID NO: 411) gamma 3: N-terminal GCGGGG (SEQ
ID NO: 412) glycine linker: C-terminal GGGGCG (SEQ ID NO: 413))
glycine linker:
[0259] For peptides, GGCG (SEQ ID NO:414) linkers at the C-terminus
of the peptide, or CGG at its N-terminus have shown to be useful.
In general, glycine residues will be inserted between bulky amino
acids and the cysteine to be used as second attachment site.
[0260] A particularly favored method of attachment of antigens to
VLPs, and in particular to capsids of RNA phage coat proteins is
the linking of a lysine residue on the surface of the capsid of RNA
phage coat proteins with a cysteine residue on the antigen. To be
effective as second attachment site, a sulfhydryl group must be
available for coupling. Thus, a cysteine residue has to be in its
reduced state, that is a free cysteine or a cysteine residue with a
free sulfhydryl group has to be available. In the instant where the
cysteine residue to function as second attachment site is in an
oxidized form, for example if it is forming a disulfide bridge,
reduction of this disulfide bridge with e.g. DTT, TCEP or
.beta.-mercaptoethanol is required.
[0261] It is a finding of this application that epitope density on
the capsid of RNA phage coat proteins can be modulated by the
choice of cross-linker and other reaction conditions. For example,
the cross-linkers Sulfo-GMBS and SMPH allow reaching higher epitope
density than the cross-linker Sulfo-MBS under the same reaction
conditions. Derivatization is positively influenced by high
concentration of reactands, and manipulation of the reaction
conditions can be used to control the number of antigens coupled to
RNA phages capsid proteins, and in particular to Q.beta. capsid
protein.
[0262] From theoretical calculation, the maximally achievable
number of globular protein antigens of a size of 17 kDa does not
exceed 0.5. Thus, several of the lysine residues of the capsid of
Q.beta. coat protein will be derivatized with a cross-linker
molecule, yet be devoid of antigen. This leads to the disappearance
of a positive charge, which may be detrimental to the solubility
and stability of the conjugate. By replacing some of the lysine
residues with arginines, such is the case in the disclosed Q.beta.
coat protein mutant, we prevent the excessive disappearance of
positive charges since the arginine residues do not react with the
cross-linker.
[0263] In further embodiments, we disclose a Q.beta. mutant coat
protein with additional lysine residues, suitable for obtaining
high density arrays of antigens.
[0264] The crystal structure of several RNA bacteriophages has been
determined (Golmohammadi, R. et al., Structure 4:543-554 (1996)).
Using such information, one skilled in the art could readily
identify surface exposed residues and modify bacteriophage coat
proteins such that one or more reactive amino acid residues can be
inserted. Thus, one skilled in the art could readily generate and
identify modified forms of bacteriophage coat proteins which can be
used in the practice of the invention. Thus, variants of proteins
which form capsids or capsid-like structures (e.g., coat proteins
of bacteriophage Q.beta., bacteriophage R17, bacteriophage fr,
bacteriophage GA, bacteriophage SP, and bacteriophage MS2) can also
be used to prepare vaccine compositions of the invention.
[0265] Although the sequence of the variants proteins discussed
above will differ from their wild-type counterparts, these variant
proteins will generally retain the ability to form capsids or
capsid-like structures. Thus, the invention further includes
vaccine compositions which contain variants of proteins which form
capsids or capsid-like structures, as well as methods for preparing
such vaccine compositions, individual protein subunits used to
prepare such vaccine compositions, and nucleic acid molecules which
encode these protein subunits. Thus, included within the scope of
the invention are variant forms of wild-type proteins which form
ordered and repetitive antigen arrays (e.g., variants of proteins
which form capsids or capsid-like structures) and retain the
ability to associate and form capsids or capsid-like
structures.
[0266] As a result, the invention further includes vaccine
compositions comprising proteins comprising, or alternatively
consisting of, amino acid sequences which are at least 80%, 85%,
90%, 95%, 97%, or 99% identical to wild-type proteins which form
ordered arrays. In many instances, these proteins will be processed
to remove signal peptides (e.g., heterologous signal peptides).
[0267] Further included within the scope of the invention are
nucleic acid molecules which encode proteins used to prepare
vaccine compositions of the invention.
[0268] In particular embodiments, the invention further includes
vaccine compositions comprising proteins comprising, or
alternatively consisting of, amino acid sequences which are at
least 80%, 85%, 90%, 95%, 97%, or 99% identical to any of the amino
acid sequences shown in SEQ ID NOs:159-167, and forms of these
proteins which have been processed, where appropriate, to remove
the N-terminal leader sequence.
[0269] Proteins suitable for use in the practice of the present
invention also include C-terminal truncation mutants of proteins
which form capsids or capsid-like structures, as well as other
ordered arrays. Specific examples of such truncation mutants
include proteins having an amino acid sequence shown in any of SEQ
ID NOs:159-167 where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino
acids have been removed from the C-terminus. Normally, C-terminal
truncation mutants used in the practice of the invention will
retain the ability to form capsids or capsid-like structures.
[0270] Further proteins suitable for use in the practice of the
present invention also include N-terminal truncation mutants of
proteins which form capsids or capsid-like structures. Specific
examples of such truncation mutants include proteins having an
amino acid sequence shown in any of SEQ ID NOs:159-167 where 1, 2,
5, 7, 9, 10, 12, 14, 15, or 17 amino acids have been removed from
the N-terminus. Normally, N-terminal truncation mutants used in the
practice of the invention will retain the ability to form capsids
or capsid-like structures.
[0271] Additional proteins suitable for use in the practice of the
present invention include--and C-terminal truncation mutants which
form capsids or capsid-like structures. Suitable truncation mutants
include proteins having an amino acid sequence shown in any of SEQ
ID NOs:159-167 where 1, 2, 5, 7, 9, 10, 12, 14, 15, or 17 amino
acids have been removed from the N-terminus and 1, 2, 5, 7, 9, 10,
12, 14, 15, or 17 amino acids have been removed from the
C-terminus. Normally, N-terminal and C-terminal truncation mutants
used in the practice of the invention will retain the ability to
form capsids or capsid-like structures.
[0272] The invention further includes vaccine compositions
comprising proteins comprising, or alternatively consisting of,
amino acid sequences which are at least 80%, 85%, 90%, 95%, 97%, or
99% identical to the above described truncation mutants.
[0273] The invention thus includes vaccine compositions prepared
from proteins which form ordered arrays, methods for preparing
vaccine compositions from individual protein subunits, methods for
preparing these individual protein subunits, nucleic acid molecules
which encode these subunits, and methods for vaccinating and/or
eliciting immunological responses in individuals using vaccine
compositions of the invention.
[0274] B. Construction of an Antigen or Antigenic Determinant with
a Second Attachment Site
[0275] The second element in the compositions of the invention is
an antigen or antigenic determinant possessing at least one second
attachment site capable of association through at least one
non-peptide bond to the first attachment site of the non-natural
molecular scaffold. The invention provides for compositions that
vary according to the antigen or antigenic determinant selected in
consideration of the desired therapeutic effect. Other compositions
are provided by varying the molecule selected for the second
attachment site.
[0276] However, when bacterial pili, or pilus-like structures,
pilin proteins are used to prepare vaccine compositions of the
invention, antigens or antigenic determinants may be attached to
pilin proteins by the expression of pilin/antigen fusion proteins.
Similarly, when proteins other than pilin proteins (e.g., viral
capsid proteins) are used to prepare vaccine compositions of the
invention, antigens or antigenic determinants may be attached to
these non-pilin proteins by the expression of non-pilin
protein/antigen fusion proteins. Antigens or antigenic determinants
may also be attached to bacterial pili, pilus-like structures,
pilin proteins, and other proteins which form ordered arrays
through non-peptide bonds.
[0277] Antigens of the invention may be selected from the group
consisting of the following: (a) proteins suited to induce an
immune response against cancer cells; (b) proteins suited to induce
an immune response against infectious diseases; (c) proteins suited
to induce an immune response against allergens, (d) proteins suited
to induce an immune response in farm animals, and (e) fragments
(e.g., a domain) of any of the proteins set out in (a)-(d).
[0278] In one specific embodiment of the invention, the antigen or
antigenic determinant is one that is useful for the prevention of
infectious disease. Such treatment will be useful to treat a wide
variety of infectious diseases affecting a wide range of hosts,
e.g., human, cow, sheep, pig, dog, cat, other mammalian species and
non-mammalian species as well. Treatable infectious diseases are
well known to those skilled in the art, examples include infections
of viral etiology such as HIV, influenza, Herpes, viral hepatitis,
Epstein Bar, polio, viral encephalitis, measles, chicken pox, etc.;
or infections of bacterial etiology such as pneumonia,
tuberculosis, syphilis, etc.; or infections of parasitic etiology
such as malaria, trypanosomiasis, leishmaniasis, trichomoniasis,
amoebiasis, etc. Thus, antigens or antigenic determinants selected
for the compositions of the invention will be well known to those
in the medical art; examples of antigens or antigenic determinants
include the following: the HIV antigens gp140 and gp160; the
influenaza antigens hemagglutinin, M2 protein and neuraminidase,
Hepatitis B surface antigen, circumsporozoite protein of
malaria.
[0279] In specific embodiments, the invention provides vaccine
compositions suitable for use in methods for preventing and/or
attenuating diseases or conditions which are caused or exacerbated
by "self" gene products (e.g., tumor necrosis factors). Thus,
vaccine compositions of the invention include compositions which
lead to the production of antibodies that prevent and/or attenuate
diseases or conditions caused or exacerbated by "self" gene
products. Examples of such diseases or conditions include graft
versus host disease, IgE-mediated allergic reactions, anaphylaxis,
adult respiratory distress syndrome, Crohn's disease, allergic
asthma, acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma
(NHL), Graves' disease, systemic lupus erythematosus (SLE),
inflammatory autoimmune diseases, myasthenia gravis,
immunoproliferative disease lymphadenopathy (IPL),
angioimmunoproliferative lymphadenopathy (AIL), immunoblastive
lymphadenopathy (IBL), rheumatoid arthritis, diabetes, multiple
sclerosis, Alzheimer disease and osteoporosis.
[0280] In related specific embodiments, compositions of the
invention are an immunotherapeutic that may be used for the
treatment of allergies or cancer.
[0281] The selection of antigens or antigenic determinants for the
preparation of compositions and for use in methods of treatment for
allergies would be known to those skilled in the medical arts
treating such disorders. Representative examples of such antigens
or antigenic determinants include the following: bee venom
phospholipase A2, Bet v I (birch pollen allergen), 5 Dol m V
(white-faced hornet venom allergen), Mellitin and Der p I (House
dust mite allergen), as well as fragments of each which can be used
to elicit immunological responses.
[0282] As indicated, a preferred antigen or antigenic determinant
is Der p I. Der p I is a 25 kD protease found in house dust mite
faecal particles. Der p I represents the major allergic molecule of
house dust mite. Accordingly, 80% of mite allergic patients have
anti-Der p I IgE antibodies. In particular, the peptides p52-72 and
p 117-133, among others, are known to comprise epitopes, which are
recognized by antibodies specific for the native Der p I. IgE
antibodies raised in a polyclonal response to the whole antigen
bind with high affinity to the peptide region 59-94 (L.
Pierson-Mullany et al. (2000) Molecular Immunology). Other regions
also bind IgE with high affinity. The peptide p117-133 contains a
free cysteine at its N-terminus, preferably representing the second
attachment site in accordance with the invention. 3D model assigns
peptides p52-72 and p117-133 to the surface of the whole protein.
However, other fragments of the Der p I protein may comprise B cell
epitopes being preferably suitable for the present invention.
[0283] The selection of antigens or antigenic determinants for
compositions and methods of treatment for cancer would be known to
those skilled in the medical arts treating such disorders.
Representative examples of such types of antigens or antigenic
determinants include the following: Her2 (breast cancer), GD2
(neuroblastoma), EGF-R (malignant glioblastoma), CEA (medullary
thyroid cancer), and CD52 (leukemia), human melanoma protein gp100,
human melanoma protein melan-A/MART-1, tyrosinase, NA17-A nt
protein, MAGE-3 protein, p53 protein, HPV16 E7 protein, as well as
fragments of each which can be used to elicit immunological
responses. Further preferred antigenic determinants useful for
compositions and methods of treatment for cancer are molecules and
antigenic determinants involved in angiogenesis. Angiogenesis, the
formation of new blood vessels, plays an essential role in
physiological and pathophysiological processes such as wound
healing and solid tumor growth, respectively (Folkman, J. (1995)
Nat. medicine 1, 27-31; Folkman, J., and Klagsbrun, M. (1987)
Science 235, 442-446; Martiny-Baron, G., and Marme, D. (1995) Curr.
Opin. Biotechnol. 6, 675-680; Risau, W. (1997) Nature 386,
671-674). Rapidly growing tumors initiate and depend on the
formation of blood vessels to provide the required blood supply.
Thus, antiangiogenic agents might be effective as an anticancer
therapy.
[0284] Among several putative angiogenic factors that have been
identified so far vascular endothelial growth factor (VEGF) is a
potent endothelial cell specific mitogen and a primary stimulant of
the vascularization of many solid tumors. Although recent findings
implicate that a set of angiogenic factors must be perfectly
orchestrated to form functional vessels, it seems that the blockade
of even a single growth factor might limit disease-induced vascular
growth. Thus, blockade of VEGF may be a premium target for
intervention in tumor induced angiogenesis. To target the
endothelium rather than the tumor itself has recently emerged as a
novel strategy to fight tumors (Millauer, B., Shawver, L. K.,
Plate, K. H., Risau, W., and Ullrich, A. (1994) Nature 367,
576-579; Kim, J., Li, B., Winer, J., Armanini, M., Gillett, N.,
Phillip, H. S., Ferrara, N. (1993) Nature 362, 841-844). In
contrast to tumors, which easily mutate target structures
recognized by the immune system, endothelial cells do not usually
escape the immune system or other therapeutic regimens.
[0285] An anti-VEGFR-II antibody (IMC-1C11) and an anti-VEGF
antibody have been disclosed (Lu, D., Kussie, P., Pytowski, B.,
Persaud, K., Bohlen, P., Witte, L., Zhu, Z. (2000) J. Biol. Chem.
275, 14321-14330; Presta, L. G, Chen, H., O'Connor, S J., Chisholm,
V., Meng, Y G., Krummen, L., Winkler, M., Ferrara N. (1997) Cancer
Res. 47, 4593-4599). The former neutralizing monoclonal
anti-VEGFR-2 antibody recognizes an epitope that has been
identified as putative VEGF/VEGFR-II binding site (Piossek, C.,
Schneider-Mergener, J., Schirner, M., Vakalopoulou, E., Germeroth,
L., Thierauch, K. H. (1999) J Biol. Chem. 274, 5612-5619).
[0286] Thus, in another preferred embodiment of the invention, the
antigen or antigenic determinant is a peptide derived from the
VEGFR-II contact site. This provides a composition and a vaccine
composition in accordance with the invention, which may have
antiangiogenic properties useful for the treatment of cancer.
Inhibition of tumor growth in mice using sera specific for VEGFR-2
has been demonstrated (Wei, Y Q., Wang, Q R., Zhao, X., Yang, L.,
Tian, L., Lu, Y., Kang, B., Lu, C J., Huang, M J., Lou, Y Y., Xiao,
F., He, Q M., Shu, J M., Xie, X J., Mao, Y Q., Lei, S., Luo, F.,
Zhou, L Q., Liu, C E., Zhou, H., Jiang, Y., Peng, F., Yuan, L P.,
Li, Q., Wu, Y., Liu, J Y. (2000) Nature Medicine 6, 1160-1165).
Therefore, further preferred antigenic determinants suitable for
inventive compositions and antiangiogenic vaccine compositions in
accordance with the invention comprise either the human VEGFR-II
derived peptide with the sequence CTARTELNVGIDFNWEYPSSKHQHKK (SEQ
ID NO:351), and/or the murine VEGFR-II derived peptide having the
sequence CTARTELNVGLDFTWHSPPSKSHHKK (SEQ ID NO:352), and/or the
relevant extracellular globular domains 1-3 of the VEGFR-II.
[0287] Therefore, in a preferred embodiment of the invention, the
vaccine composition comprises a core particle selected from a
virus-like particle or a bacterial pilus and a VEGFR-II derived
peptide or a fragment thereof as an antigen or antigenic
determinant in accordance with the present invention.
[0288] The selection of antigens or antigenic determinants for
compositions and methods of treatment for other diseases or
conditions associated with self antigens would be also known to
those skilled in the medical arts treating such disorders.
Representative examples of such antigens or antigenic determinants
are, for example, lymphotoxins (e.g. Lymphotoxin .beta. (LT
.beta.), Lymphotoxin .beta. (LT .beta.)), and lymphotoxin
receptors, Receptor activator of nuclear factor kB ligand (RANKL),
vascular endothelial growth factor (VEGF), vascular endothelial
growth factor receptor (VEGF-R), Interleukin-5, Interleukin-17,
Interleukin-13, CCL21, CXCL12, SDF-1, MCP-1, Endoglin, Resistin,
GHRH, LHRH, TRH, MIF, Eotaxin, Bradykinin, BLC, Tumor Necrosis
Factor .beta. and amyloid beta peptide (A.beta.1-42) (SEQ ID NO:
220), as well as fragments of each which can be used to elicit
immunological responses. In a preferred embodiment, the antigen is
the amyloid beta peptide (A.beta.1-42) (DAEFRHDSGYEVHHQKL
VFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 220), or a fragment thereof.
The amyloid beta protein is SEQ ID NO: 218. The amyloid beta
precursor protein is SEQ ID NO: 219.
[0289] In another preferred embodiment of the invention, the
antigen or antigenic determinant is an angiotensin peptide or a
fragment thereof. The term "angiotensin peptide" as used herein,
shall encompass any peptide comprising the sequence, or fragments
thereof, of angiotensinogen, angiotensin I or angiotensin II. The
sequences are as follows: Angiotensinogen: DRVYIHPFHLVIHN (SEQ ID
NO:353); Angiotensin I: DRVYIHPFHL (SEQ ID NO:354); Angiotensin II:
DRVYIHPF (SEQ ID NO:355). Typically, one or more additional amino
acids are added either at the C- or at the N-terminus of the
angiotensin peptide sequences. The sequence of the angiotensin
peptides corresponds to the human sequence, which is identical to
the murine sequence. Therefore, immunization of a human or a mouse
with vaccines or compositions, respectively, comprising such
angiotensin peptides as antigenic determinant in accordance with
the invention, is a vaccination against a self-antigen. Those
additional amino acids are, in particular, valuable for an oriented
and ordered association to the core particle.
[0290] Preferably, the angiotensin peptide has an amino acid
sequence selected from the group consisting of a) the amino acid
sequence of CGGDRVYIHPF (SEQ ID NO:380); b) the amino acid sequence
of CGGDRVYIHPFHL (SEQ ID NO:381); c) the amino acid sequence of
DRVYIHPFHLGGC (SEQ ID NO:382); and d) the amino acid sequence of
CDRVYIHPFH (SEQ ID NO:383).
[0291] Angiotensin I is cleaved from angiotensinogen (14aa) by the
kidney-derived enzyme Renin. Angiotensin I is a biologically
inactive peptide of 10 aa. It is further cleaved at the N-terminus
by angiotensin converting enzyme (ACE) into the biologically active
8aa angiotensin II. This peptide binds to the antgiotensin
receptors AT1I and AT2 which leads to vasoconstriction and
aldosterone release.
[0292] A vaccine in accordance with the present invention
comprising at least one angiotensin peptide may be used for the
treatment of hypertension.
[0293] In a particular embodiment of the invention, the antigen or
antigenic determinant is selected from the group consisting of: (a)
a recombinant protein of HIV, (b) a recombinant protein of
Influenza virus (e.g., an Influenza virus M2 protein or a fragment
thereof), (c) a recombinant protein of Hepatitis C virus, (d) a
recombinant protein of Toxoplasma, (e) a recombinant protein of
Plasmodium falciparum, (f) a recombinant protein of Plasmodium
vivax, (g) a recombinant protein of Plasmodium ovale, (h) a
recombinant protein of Plasmodium malariae, (i) a recombinant
protein of breast cancer cells, (j) a recombinant protein of kidney
cancer cells, (k) a recombinant protein of prostate cancer cells,
(l) a recombinant protein of skin cancer cells, (m) a recombinant
protein of brain cancer cells, (n) a recombinant protein of
leukemia cells, (o) a recombinant profiling, (p) a recombinant
protein of bee sting allergy, (q) a recombinant proteins of nut
allergy, (r) a recombinant proteins of food allergies, (s)
recombinant proteins of asthma, (t) a recombinant protein of
Chlamydia, and (u) a fragment of any of the proteins set out in
(a)-(t).
[0294] Once the antigen or antigenic determinant of the composition
is chosen, at least one second attachment site may be added to the
molecule in preparing to construct the organized and repetitive
array associated with the non-natural molecular scaffold of the
invention. Knowledge of what will constitute an appropriate second
attachment site will be known to those skilled in the art.
Representative examples of second attachment sites include, but are
not limited to, the following: an antigen, an antibody or antibody
fragment, biotin, avidin, strepavidin, a receptor, a receptor
ligand, a ligand, a ligand-binding protein, an interacting leucine
zipper polypeptide, an amino group, a chemical group reactive to an
amino group; a carboxyl group, chemical group reactive to a
carboxyl group, a sulfhydryl group, a chemical group reactive to a
sulfhydryl group, or a combination thereof.
[0295] The association between the first and second attachment
sites will be determined by the characteristics of the respective
molecules selected but will comprise at least one non-peptide bond.
Depending upon the combination of first and second attachment
sites, the nature of the association may be covalent, ionic,
hydrophobic, polar, or a combination thereof.
[0296] In one embodiment of the invention, the second attachment
site may be the FOS leucine zipper protein domain or the JUN
leucine zipper protein domain.
[0297] In a more specific embodiment of the invention, the second
attachment site selected is the FOS leucine zipper protein domain,
which associates specifically with the JUN leucine zipper protein
domain of the non-natural molecular scaffold of the invention. The
association of the JUN and FOS leucine zipper protein domains
provides a basis for the formation of an organized and repetitive
antigen or antigenic determinant array on the surface of the
scaffold. The FOS leucine zipper protein domain may be fused in
frame to the antigen or antigenic determinant of choice at either
the amino terminus, carboxyl terminus or internally located in the
protein if desired.
[0298] Several FOS fusion constructs are provided for exemplary
purposes. Human growth hormone (Example 4), bee venom phospholipase
A2 (PLA2) (Example 9), ovalbumin (Example 10) and HIV gp140
(Example 12).
[0299] In order to simplify the generation of FOS fusion
constructs, several vectors are disclosed that provide options for
antigen or antigenic determinant design and construction (see
Example 6). The vectors pAV1-4 were designed for the expression of
FOS fusion in E. coli; the vectors pAV5 and pAV6 were designed for
the expression of FOS fusion proteins in eukaryotic cells.
Properties of these vectors are briefly described:
[0300] 1. pAV1: This vector was designed for the secretion of
fusion proteins with FOS at the C-terminus into the E. coli
periplasmic space. The gene of interest (g.o.i.) may be ligated
into the StuI/NotI sites of the vector.
[0301] 2. pAV2: This vector was designed for the secretion of
fusion proteins with FOS at the N-terminus into the E. coli
periplasmic space. The gene of interest (g.o.i.) ligated into the
NotI/EcoRV (or NotI/HindIII) sites of the vector.
[0302] 3. pAV3: This vector was designed for the cytoplasmic
production of fusion proteins with FOS at the C-terminus in E.
coli. The gene of interest (g.o.i.) may be ligated into the
EcoRV/NotI sites of the vector.
[0303] 4. pAV4: This vector is designed for the cytoplasmic
production of fusion proteins with FOS at the N-terminus in E.
coli. The gene of interest (g.o.i.) may be ligated into the
NotI/EcoRV (or NotI/HindIII) sites of the vector. The N-terminal
methionine residue is proteolytically removed upon protein
synthesis (Hirel et al., Proc. Natl. Acad. Sci. USA 86:8247-8251
(1989)).
[0304] 5. pAV5: This vector was designed for the eukaryotic
production of fusion proteins with FOS at the C-terminus. The gene
of interest (g.o.i.) may be inserted between the sequences coding
for the hGH signal sequence and the FOS domain by ligation into the
Eco47III/NotI sites of the vector. Alternatively, a gene containing
its own signal sequence may be fused to the FOS coding region by
ligation into the StuI/NotI sites.
[0305] 6. pAV6: This vector was designed for the eukaryotic
production of fusion proteins with FOS at the N-terminus. The gene
of interest (g.o.i.) may be ligated into the NotI/StuI (or
NotI/HindIII) sites of the vector.
[0306] As will be understood by those skilled in the art, the
construction of a FOS-antigen or -antigenic determinant fusion
protein may include the addition of certain genetic elements to
facilitate production of the recombinant protein. Example 4
provides guidance for the addition of certain E. coli regulatory
elements for translation, and Example 7 provides guidance for the
addition of a eukaryotic signal sequence. Other genetic elements
may be selected, depending on the specific needs of the
practioner.
[0307] The invention is also seen to include the production of the
FOS-antigen or FOS-antigenic determinant fusion protein either in
bacterial (Example 5) or eukaryotic cells (Example 8). The choice
of which cell type in which to express the fusion protein is within
the knowledge of the skilled artisan, depending on factors such as
whether post-translational modifications are an important
consideration in the design of the composition.
[0308] As noted previously, the invention discloses various methods
for the construction of a FOS-antigen or FOS-antigenic determinant
fusion protein through the use of the pAV vectors. In addition to
enabling prokaryotic and eukaryotic expression, these vectors allow
the practitioner to choose between N- and C-terminal addition to
the antigen of the FOS leucine zipper protein domain. Specific
examples are provided wherein N- and C-terminal FOS fusions are
made to PLA2 (Example 9) and ovalbumin (Example 10). Example 11
demonstrates the purification of the PLA2 and ovalbumin FOS fusion
proteins.
[0309] In a more specific embodiment, the invention is drawn to an
antigen or antigenic determinant encoded by the HIV genome. More
specifically, the HIV antigen or antigenic determinant is gp140. As
provided for in Examples 11-15, HIV gp140 may be created with a FOS
leucine zipper protein domain and the fusion protein synthesized
and purified for attachment to the non-natural molecular scaffold
of the invention. As one skilled in the art would know, other HIV
antigens or antigenic determinants may be used in the creation of a
composition of the invention.
[0310] In another more specific embodiment, the invention is drawn
to vaccine compositions comprising at least one antigen or
antigenic determinant encoded by an Influenza viral nucleic acid,
and the use of such vaccine compositions to elicit immune
responses. In an even more specific embodiment, the Influenza
antigen or antigenic determinant may be an M2 protein (e.g., an M2
protein having the amino acids shown in SEQ ID NO:213, GenBank
Accession No. P06821, or in SEQ ID NO: 212, PIR Accession No.
MFIV62, or fragment thereof (e.g., amino acids from about 2 to
about 24 in SEQ ID NO:213, the amino acid sequence in SEQ ID
NO:212). Further, influenza antigens or antigenic determinants may
be coupled to non-natural molecular scaffolds or core particles
through either peptide or non-peptide bonds. When Influenza
antigens or antigenic determinants are coupled to non-natural
molecular scaffolds or core particles through peptide bonds, the
molecules which form order and repetitive arrays will generally be
prepared as fusion protein expression products. The more preferred
embodiment is however a composition, wherein the M2 peptide is
coupled by chemical cross-linking, to Q.beta. capsid protein HBcAg
capsid protein or Pili according to the disclosures of the
invention.
[0311] Portions of an M2 protein (e.g., an M2 protein having the
amino acid sequence in SEQ ID NO:213), as well as other proteins
against which an immunological response is sought, suitable for use
with the invention may comprise, or alternatively consist of,
peptides of any number of amino acids in length but will generally
be at least 6 amino acids in length (e.g., peptides 6, 7, 8, 9, 10,
12, 15, 18, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,
90, 95, or 97 amino acids in length).
[0312] In another specific embodiment of the invention, the second
attachment site selected is a cysteine residue, which associates
specifically with a lysine residue of the non-natural molecular
scaffold or core particle of the invention, or the second
attachment site selected is a lysine residue, which associates
specifically with a cysteine residue of the non-natural molecular
scaffold or core particle of the invention. The chemical linkage of
the lysine residue (Lys) and cysteine residue (Cys) provides a
basis for the formation of an organized and repetitive antigen or
antigenic determinant array on the surface of the scaffold or core
particle. The cysteine or lysine residue may be engineered in frame
to the antigen or antigenic determinant of choice at either the
amino terminus, carboxyl terminus or internally located in the
protein if desired. By way of example, PLA2 and HIV gp140 are
provided with a cysteine residue for linkage to a lysine residue
first attachment site.
[0313] In additional specific embodiments, the invention provides
vaccine compositions suitable for use in methods for preventing
and/or attenuating allergic reactions, such as allergic reactions
which lead to anaphylaxis. Thus, vaccine compositions of the
invention include compositions which lead to the production of
antibodies that prevent and/or attenuate allergic reactions. Thus,
in certain embodiments, vaccine compositions of the invention
include compositions which elicit an immunological response against
an allergen. Examples of such allergens include phospholipases such
as the phospholipase A2 (PLA2) proteins of Apis mellifera (SEQ ID
NO:168, GenBank Accession No. 443189; SEQ ID NO:169, GenBank
Accession No. 229378), Apis dorsata (SEQ ID NO:170, GenBank
Accession No. B59055), Apis cerana (SEQ ID NO:171, GenBank
Accession No. A59055), Bombus pennsylvanicus (SEQ ID NO:172 GenBank
Accession No. B56338), and Heloderma suspectum (SEQ ID NO:173,
GenBank Accession No. P80003; SEQ ID NO:174, GenBank Accession No.
S14764; SEQ ID NO:175, GenBank Accession No. 226711).
[0314] Using the amino acid sequence of a PLA2 protein of Apis
mellifera (SEQ ID NO:168) for illustration, peptides of at least
about 60 amino acids in length, which represent any portion of the
whole PLA2 sequence, may also be used in compositions for
preventing and/or attenuating allergic reactions. Examples of such
peptides include peptides which comprise amino acids 1-60 in SEQ ID
NO:168, amino acids 1-70 in SEQ ID NO:168, amino acids 10-70 in SEQ
ID NO:168, amino acids 20-80 in SEQ ID NO:168, amino acids 30-90 in
SEQ ID NO:168, amino acids 40-100 in SEQ ID NO:168, amino acids
47-99 in SEQ ID NO:168, amino acids 50-110 in SEQ ID NO:168, amino
acids 60-120 in SEQ ID NO:168, amino acids 70-130 in SEQ ID NO:168,
or amino acids 90-134 in SEQ ID NO:168, as well corresponding
portions of other PLA2 proteins (e.g., PLA2 proteins described
above). Further examples of such peptides include peptides which
comprise amino acids 1-10 in SEQ ID NO:168, amino acids 5-15 in SEQ
ID NO:168, amino acids 10-20 in SEQ ID NO:168, amino acids 20-30 in
SEQ ID NO:168, amino acids 30-40 in SEQ ID NO:168, amino acids
40-50 in SEQ ID NO:168, amino acids 50-60 in SEQ ID NO:168, amino
acids 60-70 in SEQ ID NO:168, amino acids 70-80 in SEQ ID NO:168,
amino acids 80-90 in SEQ ID NO:168, amino acids 90-100 in SEQ ID
NO:168, amino acids 100-110 in SEQ ID NO:168, amino acids 110-120
in SEQ ID NO:168, or amino acids 120-130 in SEQ ID NO:168, as well
corresponding portions of other PLA2 proteins (e.g., PLA2 proteins
described above).
[0315] Portions of PLA2, as well as portions of other proteins
against which an immunological response is sought, suitable for use
with the invention may comprise, or alternatively consist of,
peptides which are generally at least 6 amino acids in length
(e.g., peptides 6, 7, 8, 9, 10, 12, 15, 18, 20, 25, 30, 35, 40, 45,
50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acids in
length).
[0316] PLA2 peptides (e.g., the full length PLA2 proteins discussed
above, as well as subportions of each) may also be coupled to any
substance (e.g., a Q.beta. capsid protein or fragment thereof)
which allows for the formation of ordered and repetitive antigen
arrays.
[0317] In another aspect of the present invention, the invention
provides compositions being particularly suitable for treating
and/or preventing conditions caused or exacerbated by "self" gene
products.
[0318] In a preferred embodiment of the invention, the antigenic
determinant is RANKL (Receptor activator of NFkB Ligand). RANKL is
also known as TRANCE (TNF-related activation induced cytokine), ODF
(Osteoclast differentiation factor) or OPGL (Osteoprotegerin
ligand). The amino acid sequence of the extracellular part of human
RANKL is shown in SEQ ID No: 221 (RANKL_human: TrEMBL:O14788),
while the amino acid sequence of a human isoform is shown in SEQ ID
No: 222. Sequences for the extracellular part of murine RANKL and
an isoform are shown in SEQ ID No.223 (RANKL_mouse: TrEMBL:O35235),
and in SEQ ID No.224 (RANKL_mouse splice forms: TrEMBL:Q9JJK8 and
TrEMBL:Q9JJK9), respectively.
[0319] It has been shown that RANKL is an essential factor in
osteoclastogenesis. Inhibition of the interaction of RANKL with its
receptor RANK can lead to a suppression of osteoclastogenesis and
thus provide a means to stop excessive bone resorption as seen in
osteoporosis and other conditions. The RANKL/RANK interaction was
inhibited either by a RANK-Fc fusion protein or the soluble decoy
receptor of RANKL, termed osteoprotegerin OPG.
[0320] In the immune system RANKL is expressed on T cells while
RANK is found on antigen-presenting cells. The RANKL-RANK
interaction was shown to be critical for CD40L-independent T-helper
cell activation (Bachmann et al., J. Exp. Med. 7: 1025 (1999)) and
enhance the longevity and adjuvant properties of dendritic cells
(Josien et al., J Exp Med. 191: 495 (2000)).
[0321] In bone RANKL is expressed on stromal cells or osteoblasts,
while RANK is expressed on the osteoclast precursor. The
interaction of RANK and RANKL is crucial for the development of
osteoclast precursors to mature osteoclasts. The interaction can be
blocked by osteoprotegerin.
[0322] OPG-deficient mice develop osteoporosis that can be rescued
by injection of recombinant OPG. This means that OPG is able to
reverse osteoporosis. Thus, inhibition of the RANK-RANKL
interaction by way of injecting this specific embodiment of the
invention may reverse osteoporosis.
[0323] In addition, arterial calcification was observed in OPG k.o.
mice which could be reversed by injection of OPG (Min et al., J.
Exp. Med. 4: 463 (2000)). In an adjuvant-induced arthritis model
OPG injection was able to prevent bone loss and cartilage
destruction, but not inflammation (paw swelling). It is assumed
that activated T cells lead to a RANKL-mediated increase of
osteoclastogenesis and bone loss. OPG inhibits prostate
cancer-induced osteoclastogenesis and prevents prostate tumor
growth in the bone of mice. OPG diminishes advanced bone cancer
pain in mice.
[0324] RANKL is a transmembrane protein of 245 aa belonging to the
TNF-superfamily. Part of the extracellular region (178 aa) can be
shed by a TACE-like protease (Lum et al., J Biol. Chem. 274:13613
(1999)). In addition splice variants lacking the transmembrane
domain have been described (Ikeda et al., Endocrinology 142: 1419
(2001)). The shed part contains the domain highly homologous to
soluble TNF-.beta.. This extracellular domain of RANKL forms
homotrimers as seen for TNF-.beta.. The C-terminus seems to be
involved in the trimer contact site. One cysteine is present in
this region of the sequence.
[0325] We have built a model for the 3-dimensional structure of the
corresponding region of RANKL and found that the naturally present
cysteine may not be accessible in the folded structure for
interaction with a first attachment site on the carrier in
accordance with the present invention. The N-terminus is preferred
for attaching a second attachment site comprising an amino acid
linker with an additional cysteine residue. A human-RANKL construct
with an N terminal amino acid linker containing a cysteine residue
fused to the extracellular part of RANKL is a very preferred
embodiment of the invention. However, an amino-acid linker
containing a cysteine residue as second attachment site and being
fused at the C-terminus of the RANKL sequence or the extracellular
part of RANKL leads to further preferred embodiments of the
invention.
[0326] Human-RANKL constructs, such as the one identified in SEQ ID
NO:320, are generated according to the teachings disclosed in
EXAMPLE 6, and the man skilled in the art are able to compare
murine and human RANKL sequences in a protein sequence alignment to
identify the part of the sequence of human-RANKL to be cloned in
the vectors described in EXAMPLE 6. Fragments containing amino
acids 138-317 and corresponding to the C-terminal region of the
extracellular domain of human RANKL, are particularly favored
embodiments of the invention, and can be modified for coupling to
VLPs and Pili as required according to the teaching of the present
invention. However, other suitable vectors may also be used for
expression in the suitable host described below. Further
human-RANKL constructs, and in particular, the ones comprising the
part of the extracellular region (178 aa),--or fragments
thereof--that can be shed by a TACE-like protease (Lum et al., J
Biol Chem. 274:13613 (1999)), or comprising the sequence
corresponding to the alternative splice variants lacking the
transmembrane domain, as well as conservative fragments thereof,
are intended to be encompassed within the scope of the present
invention. Human C-terminal fragments comprising amino acids
165-317 are also embodiments of the invention. Alternatively,
fragments which encompass the entire extracellular region (amino
acids 71-317) and can be modified for coupling to VLPs and Pili as
required according to the teaching of the present invention, are
also within the scope of the invention.
[0327] RANKL has been expressed in different systems (E. coli,
insect cells, mammalian cells) and shown to be active, and
therefore several expression systems can be used for production of
the antigen of the composition. In the case where expression of the
protein is directed to the periplasm of E. coli, the signal peptide
of RANKL, or of RANKL constructs consisting of the extracellular
part of the protein, and both possibly modified to comprise a
second attachment site in accordance with the invention, is
replaced with a bacterial signal peptide. For expression of the
protein in the cytoplasm of E. coli, RANKL constructs are devoid of
signal peptide.
[0328] In another preferred embodiment of the invention, the
antigenic determinant is MIF or a fragment thereof. MIF is a
cytokine that has been first described in 1966 by its function as
an inhibitor of macrophage migration. It is also known as delayed
early response protein 6 (DER6), glycosylation inhibiting factor or
phenylpyruvate tautomerase. The latter name originates from
enzymatic activity of MIF, however the endogenous substrate has not
been identified.
[0329] MIF has been shown to be implicated in a wide range of
conditions. MIF (mRNA and protein) is upregulated in delayed type
hypersensitivity (DTH) reaction induced by tuberculin, and anti-MIF
antibody inhibits this DTH reaction. MIF is also upregulated in
renal allograft rejection. In a model for ocular autoimmune
disease, experimental autoimmune uveoretinitis (EAU), anti-MIF
treatment caused delay of EAU development. In patients, there is an
increase in serum of MIF, which is also the case in Behcet's
disease patients and patients suffering from iridocyclitis.
Immunization against MIF may provide a way of treatment against
rheumatoid arthritis.
[0330] High serum MIF concentration has been found in atopic
dermatitis patients. In skin lesions, MIF is diffusely expressed
instead of being found in the basal cell layer in controls. MIF
concentration is decreasing after steroid treatment, consistent
with a role of MIF in inflammation. MIF has also been found to
contribute to the establishment of glomerulonephritis. Animals
treated with anti-MIF Antibody show significantly reduced
glomerulonephritis. MIF is pituitary derived, secreted e.g. upon
LPS stimulation, and potentiates endotoxemia. Accordingly, anti-MIF
mAb inhibits endotoxemia and septic shock, while recombinant MIF
markedly increases lethality of peritonitis. MIF is also a
glucocorticoid-induced modulator of cytokine production, and
promotes inflammation.
[0331] MIF is produced by T-cells (Th2), supports proliferation of
T-cells, and anti-MIF-treatment reduces T-cell proliferation and
IgG levels. There is an increased MIF concentration in the
cerebrospinal fluid of multiple sclerosis and neuro-Behcet's
disease patients. High MIF levels were also found in sera of
patients with extended psoriasis. High MIF levels are found in sera
of ulcerative colitis patients but not Crohn's disease
patients.
[0332] High MIF levels have been found in sera of patients with
bronchic asthma. MIF is also upregulated in synovial fluid of
rheumatoid arthritis patients. Anti-MIF treatment was effectively
decreasing rheumatoid arthritis in mouse and rat models (Mikulowska
et al., J. Immunol. 158:5514-7 (1997); Leech et al., Arthritis
Rheum. 41:910-7 (1998), Leech et al. Arthritis Rheum. 43:827-33
(2000), Santos et al., Clin. Exp. Immunol. 123:309-14 (2001)).
Thus, treatment directed at inhibiting MIF activity using a
composition comprising MIF as an antigenic determinant may be
beneficial for the conditions mentioned above.
[0333] MIF from mouse, rat and human consists of 114 amino acid and
contains three conserved cysteines, as shown in SEQ ID No 225
(MIF_rat: SwissProt), in SEQ ID No 226 (MIF_mouse: SwissProt) and
in SEQ ID No 227 (MIF_human: SwissProt). Three subunits form a
homotrimer that is not stabilized by disulfide bonds. The X-ray
structure has been solved and shows three free cysteines (Sun et
al., PNAS 93: 5191-96 (1996)), while some literature data claim the
presence of a disulfide bond. Nonetheless, none of the cysteines
are exposed enough for optimal interaction with a possible first
attachment site present on the carrier. Thus, as the C-terminus of
the protein is exposed in the trimer structure, an amino acid
linker containing a free cysteine residue is, preferably, added at
the C-terminus of the protein, for generation of the second
attachment site in this preferred embodiment of the invention, as
exemplarily described in EXAMPLE 4 for rat-MIF.
[0334] There is only one amino acid change between mouse- and
rat-MIF, and similarly a very high sequence homology (about 90%
sequence identity) between human- and rat-MIF or human- and
mouse-MIF. Human- and mouse-MIF constructs according to the
invention are described and can be generated as disclosed in
EXAMPLE 4. In order to demonstrate the high potency to induce a
self-specific immune response of MIF protein, or fragments thereof,
associated to a core particle in accordance with the present
invention, rat-MIF constructs coupled to Q.beta. capsid protein
were injected in mice. The high antibody titers obtained by
immunizing mice with rat-MIF show that tolerance towards
immunization with self-antigens was overcome by immunizing with MIF
constructs coupled to virus-like particles, and in particular to
Q.beta. capsid protein (EXAMPLE 4). Therefore, compositions in
accordance with the present invention comprising human-MIF protein
associated to a core particle, preferably to pili or a virus-like
particle, and more preferably to a virus-like particle of a
RNA-phage, and even more preferably to RNA-phage Q.beta. or fr,
represent very preferred embodiments of the present invention.
[0335] However, an amino acid linker containing a free cysteine
that is added at the N-terminus of the sequence of MIF leads to
further preferred embodiments of the present invention. MIF has
been expressed in E. coli, purified and shown to be fully
functional (Bernhagen et al., Biochemistry 33: 14144-155 (1994).
Thus, MIF may be, preferably, expressed in E. coli for generating
the preferred embodiments of the invention.
[0336] Tautomerase activity of MIF is inhibited, if the start
methionine is not cleaved from the construct. MIF constructs
expressed in E. coli and described in EXAMPLE 4 show tautomerase
activity. Mutants of MIF where the start methionine is cleaved and
where the proline residue right after the start methionine in the
sequence is mutated to alanine also do not show tautomerase
activity represent further embodiments of the invention and are
intended to be encompassed within the scope of the invention. In
some specific embodiments, immunization with MIF mutants devoid of
tautomerase activity is envisaged.
[0337] In another preferred embodiment of the invention, the
antigenic determinant is Interleukin-17 (IL-17). Human IL-17 is a
32-kDa, disulfide-linked, homodimeric protein with variable
glycosylation (Yao, Z. et al., J. Immunol. 155: 5483-5486 (1995);
Fossiez, F. et al., J. Exp. Med. 183: 2593-2603 (1996)). The
protein comprises 155 amino acids and includes an N-terminal
secretion signal sequence of 19-23 residues. The amino acid
sequence of IL-17 is similar only to a Herpesvirus protein (HSV13)
and is not similar to other cytokines or known proteins. The amino
acid sequence of human IL-17 is shown in SEQ ID No: 228 (ACCESSION
#: AAC50341), The mouse protein sequence is shown in SEQ ID No: 229
(ACCESSION #: AAA37490). Of the large number of tissues and cell
lines evaluated, the mRNA transcript encoding IL-17 has been
detected only in activated T cells and phorbol 12-myristate
13-acetate/ionomycin-stimulated peripheral blood mononuclear cells
(Yao, Z. et al., J. Immunol. 155: 5483-5486 (1995); Fossiez, F. et
al., J. Exp. Med. 183: 2593-2603 (1996)). Both human and mouse
sequences contain 6 cysteine residues.
[0338] The receptor for IL-17 is widely expressed in many tissues
and cell types (Yao, Z. et al., Cytokine 9: 794-800 (1997)).
Although the amino acid sequence of the human IL-17 receptor (866
aa) predicts a protein with a single trans-membrane domain and a
long, 525 aa intracellular domain, the receptor sequence is unique
and is not similar to that of any of the receptors from the
cytokine/growth factor receptor family. This coupled with the lack
of similarity of IL-17 itself to other known proteins indicates
that IL-17 and its receptor may be part of a novel family of
signalling protein and receptors. Clinical studies indicate IL-17
may be involved in many inflammatory diseases. IL-17 is secreted by
synovial T cells from rheumatoid arthritis patients and stimulates
the production of inflammatory mediators (Chabaud, M. et al., J.
Immunol. 161: 409-414 (1998); Chabaud, M. et al., Arthritis Rheum.
42: 963-970 (1999)). High levels of IL-17 have been reported in
patients with rheumatoid arthritis (Ziolkowska M. et al., J.
Immunol. 164:2832-8 (2000)).
[0339] Interleukin 17 has been shown to have an effect on
proteoglycan degradation in murine knee joints (Dudler J. et al.,
Ann Rheum Dis. 59: 529-32 (2000)) and contribute to destruction of
the synovium matrix (Chabaud M. et al., Cytokine. 12:1092-9
(2000)). There are relevant arthritis models in animals for testing
the effect of an immunization against MIF (Chabaud M. et al.,
Cytokine. 12:1092-9 (2000)). Elevated levels of IL-17 mRNA have
been found in mononuclear cells from patients with multiple
sclerosis (Matusevicius, D. et al., Mult. Scler. 5: 101-104
(1999)). Elevated serum levels of IL-17 are observed in patients
suffering Systemic Lupus Erythematosus (Wong C. K. et al., Lupus 9:
589-93 (2000)). In addition, IL-17 mRNA levels are increased in T
cells isolated from lesional psoriatic skin (Teunissen, M. B. et
al., J. Invest. Dermatol. 111: 645-649 (1998)).
[0340] The involvement of IL-17 in rejection of kidney graft has
also been demonstrated (Fossiez F. et al., Int. Rev. Immunol.
16:541-51 (1998)). Evidence for a role of IL-17 in organ allograft
rejection has also been presented by Antonysamy et al. (J. Immunol.
162:577-84 (1999)) who showed IL-17 promotes the functional
differentiation of dendritic cell progenitors. Their findings
suggest a role for IL-17 in allogeneic T cell proliferation that
may be mediated in part via a maturation-inducing effect on DCs.
Furthermore the same group reports (Tang J. L. et al.,
Transplantation 72:348-50 (2001)) a role for IL-17 in the
immunopathogenesis of acute vascular rejection where Interleukin-17
antagonism inhibits acute but not chronic vascular rejection. IL-17
appears to have potential as a novel target for therapeutic
intervention in allograft rejection.
[0341] The above findings suggest IL-17 may play a pivotal role in
the initiation or maintenance of an inflammatory response
(Jovanovic, D. V. et al., J. Immunol. 160: 3513-3521 (1998)).
[0342] The anti-IL-17 monoclonal antibody mAb5 (Schering-Plough
Research Institute) was able to completely inhibit the production
of IL-6 from rheumatoid arthritis (RA) synovium supernatants
following induction by 50 ng/ml of IL-17. An irrelevant mAb MX1 had
no effect in this assay. mAb5 is a mouse IgG1 obtained after
immunization with human rIL-17 (r=recombinant). A concentration of
1 .mu.g/ml of mAb5 was able to completely inhibit the IL-6
production in the assay system (Chabaud, M. et al., J. Immunol.
161: 409-414 (1998)). Thus, immunization against IL-17 provides a
way of treatment for the various conditions described above.
[0343] In another preferred embodiment of the invention, thus, the
composition comprises a linker containing a second attachment site
and being fused to the C-terminus of recombinant IL-17. In further
preferred embodiments of the invention, however, an amino acid
linker containing a free cysteine is fused to the N-terminus of the
sequence corresponding to the sequence of the processed protein, or
inserted at the N-terminus of the sequence of the mature form of
the protein, C-terminally of the signal peptide. For eukaryotic
expression systems, the signal peptide of the IL-17 gene, as it is
the case for the other self-antigens indicated herein, may be
replaced by another signal peptide if required. For expression in
bacteria, the signal peptide is either replaced by a bacterial
signal peptide for soluble expression in the periplasm, or deleted
for expression in the cytoplasm. Constructs of human IL-17 devoid
of signal peptide will preferably comprise residues 24-155, 22-155,
21-155 or 20-155. Constructs of mouse IL-17 devoid of signal
peptide will preferably comprise residues 26-158, 25-158, 24-158 or
27-155. Human IL-17 may be expressed in CV1/EBNA cells; recombinant
hIL-17 has been shown to be secreted in both glycosylated and
nonglycosylated forms (Yao, Z. et al., J. Immunol. 155: 5483-5486
(1995)). IL-17 can also be expressed as hIL-17/Fc fusion protein,
with subsequent cleavage of the IL-17 protein from the fusion
protein. IL-17 may also be expressed in the yeast Pichia pastoris
(Murphy K. P. et. al., Protein Expr Purif. 12: 208-14 (1998)).
Human IL-17 may also be expressed in E. coli. When expression of
IL-17 in E. coli is directed to the periplasm, the signal peptide
of IL-17 is replaced by a bacterial signal peptide. For expression
of the protein in the cytoplasm of E. coli, IL-17 constructs are
devoid of signal peptide.
[0344] In another preferred embodiment of the invention the
antigenic determinant is Interleukin-13 (IL-13). IL-13 is a
cytokine that is secreted by activated T lymphocytes and primarily
impacts monocytes, macrophages, and B cells. The amino acid
sequence of precursor human IL-13 is shown in SEQ ID No: 230 and
the amino acid sequence of processed human IL-13 is shown in SEQ ID
No: 231. The first 20 amino acids of the precursor protein
correspond to the signal peptide, and are absent of the processed
protein. The mouse sequence has also been described, and the
processed amino acid sequence is shown in SEQ ID No: 232 (Brown K.
D. et al., J. Immunol. 142:679-687 (1989)). Depending on the
expression host, the IL-13 construct will comprise the sequence of
the precursor protein, e.g. for expression and secretion in
eukaryotic hosts, or consist of the mature protein, e.g. for
cytoplasmic expression in E. coli. For expression in the periplasm
of E. coli, the signal peptide of IL-13 is replaced by a bacterial
signal peptide.
[0345] IL-13 is a T helper 2-derived cytokine (like IL-4, IL-5)
that has recently been implicated in allergic airway responses
(asthma). Upregulation of IL-13 and IL-13 receptor has been found
in many tumour types (e.g. Hodgkin lymphoma). Interleukin 13 is
secreted by and stimulates the growth of Hodgkin and Reed-Sternberg
cells (Kapp U et al., J Exp Med. 189:1939-46 (1999)). Thus,
immunization against IL-13 provides a way of treating among others
the conditions described above, such as Asthma or Hodgkins
Lymphoma.
[0346] Preferably, the composition comprises an amino acid linker
containing a free cysteine residue and being fused to the N or
C-terminus of the sequence of mature IL-13 to introduce a second
attachment site within the protein. In further preferred
embodiments, an amino acid linker containing a free cysteine is
added to the N-terminus of the mature form of IL-13, since it is
freely accessible according to the NMR structure of IL-13
(Eisenmesser, E. Z. et al., J. Mol. Biol. 310: 231 (2001)). In
again further preferred embodiments, the amino acid linker
containing a free cysteine is fused to the N-terminus of the
sequence corresponding to the sequence of the processed protein, or
inserted at the N-terminus of the sequence of the mature form of
the protein, C-terminally of the signal peptide. In still further
preferred embodiments, an amino acid linker containing a free
cysteine residue is added to the C-terminus of the protein.
[0347] IL-13 may be expressed in E. coli (Eisenmesser E. Z. et al.,
Protein Expr. Purif. 20:186-95 (2000)), or in NS-0 cells
(eukaryotic cell line) (Cannon-Carlson S. et al., Protein Expr.
Purif. 12:239-48 (1998)). EXAMPLE 9 describes constructs and
expression of constructs of murine IL-13, fused to an amino acid
linker containing a cysteine residue, in bacterial and eukaryotic
hosts. Human IL-13 constructs can be generated according to the
teachings of EXAMPLE 9 and yielding the proteins human C-IL-13-F
(SEQ ID NO:330) and human C-IL-13-S (SEQ ID NO:331) after
expression of the fusion proteins and cleavage with Factor Xa, and
enterokinase respectively. The so generated proteins can be coupled
to VLPs and Pili, leading to preferred embodiments of the
invention.
[0348] In yet another embodiment of the invention, the antigenic
determinant is Interleukin-5 (IL-5). IL-5 is a lineage-specific
cytokine for eosinophilopoiesis and plays an important part in
diseases associated with increased number of eosinophils, such as
asthma. The sequence of precursor and processed human IL-5 is
provided in SEQ ID No: 233 and in SEQ ID No: 234, respectively, and
the processed mouse amino acid sequence is shown in SEQ ID No:
235.
[0349] The biological function of IL-5 has been shown in several
studies (Coffman R. L. et al., Science 245: 308-10 (1989); Kopf et
al., Immunity 4:15-24 (1996)), which point to a beneficial effect
of inhibiting IL-5 function in diseases mediated through
eosinophils. Inhibition of the action of IL-5 provides thus a way
of treatment against asthma and other diseases associated with
eosinophils.
[0350] IL-5 forms a dimer, covalently linked by a disulfide bridge.
A single chain (sc) construct has been reported wherein two
monomers of IL-5 are linked by a peptide linker.
[0351] In preferred embodiments of the invention, a peptide linker
containing a free cysteine is added at the N-terminus of the
sequence of the processed form of IL-5. Addition of a linker
containing a free cysteine is also, preferably, envisaged at the
N-terminus of the sequence of the processed form of a scIL-5. In
further preferred embodiments, the amino acid linker containing a
free cysteine is fused to the N-terminus of the sequence
corresponding to the sequence of the processed protein, or inserted
at the N-terminus of the sequence of the mature form of the
protein, C-terminally of the signal peptide.
[0352] In again further preferred embodiments, a linker containing
a free cysteine is fused to the C-terminus of the sequence of IL-5,
or to the C-terminus of a scIL-5 sequence.
[0353] A number of expression systems have been described for IL-5
and can be used in preparing the compositions of the invention. A
bacterial expression system using E. coli has been described by
Proudfoot et al., (Biochem J. 270:357-61 (1990)). In the case where
IL-5 is expressed in the cytoplasm of E. coli, the IL-5 construct
is devoid of a signal peptide. Insect cells may also be used for
producing IL-5 constructs for making the compositions of the
invention (Pierrot C. et al., Biochem. Biophys. Res. Commun.
253:756-60 (1998)). Likewise, Baculovirus expression systems (sf9
cells; Ingley E. et al., Eur. J. Biochem. 196:623-9 (1991) and
Brown P. M. et al., Protein Expr. Purif. 6: 63-71 (1995)) can also
be used. Finally, mammalian expression systems have also been
reported (CHO cells) and can be used in preparing these
compositions of the invention (Kodama S et al., J. Biochem. (Tokyo)
110:693-701 (1991)).
[0354] Baculovirus expression systems (Mitchell et al., Biochem.
Soc. Trans. 21:332S (1993); Kunimoto D Y et al., Cytokine 3:224-30
(1991)) and a mammalian cell expression system using CHO cells
(Kodama S et al., Glycobiology 2:419-27 (1992)) have also been
described for mouse IL-5.
[0355] EXAMPLE 10 describes the expression of murine IL-5
constructs wherein the IL-5 sequence is fused at its N-terminus to
amino acid linkers containing a cysteine residue for coupling to
VLPs and Pili. Human constructs can be generated according to the
teaching of EXAMPLE 10 and yield the proteins human C-IL-5-E (SEQ
ID NO:335), human C-IL-5-F (SEQ ID NO:336) and human C-IL-5-S: (SEQ
ID NO:337) suitable for coupling to VLPs and Pili and leading to
preferred embodiments of the invention.
[0356] In another preferred embodiment of the invention, the
antigenic determinant is CCL-21. CCL-21 is a chemokine of the CC
subfamily that is also known as small inducable cytokine A21, as
exodus-2, as SLD (secondary lymphocyte cytokine), as TCA4
(thymus-derived chemotactic agent 4) or 6Ckine.
[0357] CCL21 inhibits hemopoiesis and stimulates chemotaxis for
thymocytes, activated T-cells and dendritic cells, but not for B
cells, macrophages or neutrophiles. It shows preferential activity
towards naive T cells. It is also a potent mesangial cell
chemoattractant. CCL21 binds to chemokine receptors CCR7 and to
CXCR3 (dependent on species). It can trigger rapid
integrin-dependent arrest of lymphocytes rolling under
physiological shear and is highly expressed by high endothelial
venules.
[0358] Murine CCL21 inhibited tumor growth and angiogenesis in a
human lung cancer SCID mouse model (Arenberg et al., Cancer
Immunol. Immunother. 49: 587-92 (2001)) and a colon carcinoma tumor
model in mice (Vicari et al., J. Immunol. 165: 1992-2000 (2001)).
The angiostatic activity of murine CCL21 was also detected in a rat
corneal micropocket assay (Soto et al., Proc. Natl. Acad. Sci. USA
95: 8205-10 (1998).
[0359] It has been shown that chemokine receptors CCR7 and CXCR4
are upregulated in breast cancer cells and that CCL21 and CXCL12,
the respective ligands, are highly expressed in organs representing
the first destinations of breast cancer metastasis Muller et al.
(Nature 410: 50-6 (2001)). In vitro CCL21-mediated chemotaxis could
be blocked by neutralizing anti-CCL21 antibodies as was
CXCR4-mediated chemotaxis by the respective antibodies. Thus,
immunization against CCL21 provides a way of treatment against
metastatis spread in cancers, more specifically in breast
cancer.
[0360] Secreted CCL21 consist of 110 or 111 aa in mice and humans,
respectively. The respective sequences are shown in SEQ ID No: 236
(Swissprot: SY21_human) and in SEQ ID No: 237 (Swissprot:
SY21_mouse). In contrast to other CC cytokines does CCL21 contain
two more cysteines within an extended region at the C-terminus. It
is assumed that all cysteines are engaged in disulfide bonds.
[0361] In the following, constructs and expression systems are
described for making compositions of the invention comprising the
CCL21 antigenic determinant. In the NMR structure of the homologous
protein eotaxin, both N- and C-terminus are exposed to the solvent.
In some specific embodiments, an amino acid linker containing a
free cysteine residue as a second attachment site is added at the
C-terminus of the protein. A fusion protein with alkaline
phosphatase (at the C-terminus of CCL21) has been expressed and was
shown to be functional, showing that fusions at the C-terminus of
CCL21 are compatible with receptor binding. In other specific
embodiments, the amino acid linker containing a free cysteine is
fused to the N-terminus of the sequence corresponding to the
sequence of the processed protein, or inserted at the N-terminus of
the sequence of the mature form of the protein, C-terminally of the
signal peptide.
[0362] Several expression systems have been described for
production of CCL21 (e.g. Hedrick et al., J Immunol. 159: 1589-93
(1997)). For example, it may expressed in a baculovirus system
(Nagira et al., J. Biol. Chem. 272: 19518-24 (1997)).
[0363] In a related preferred embodiment, the antigenic determinant
is Stromal derived factor-1 (SDF-1), now termed CXCL12. CXCL12 is a
chemokine produced by bone marrow stromal cells and was originally
identified as a stimulatory factor for pre-B cells.
[0364] As already stated above, it has been shown that chemokine
receptors CCR7 and CXCR4 are upregulated in breast cancer cells and
that CCL21 and SDF-1, the respective ligands, are highly expressed
in organs representing the first destinations of breast cancer
metastasis Muller et al. (Nature 410: 50-6 (2001)). In vitro
SDF-1/CXCR4-mediated chemotaxis could be inhibited by neutralizing
anti-SDF-1 and anti-CXCR4 antibodies.
[0365] In a breast cancer metastasis model in SCID mice using the
human MDA-MB-231 breast cancer cell line, a significant decrease in
lung metastasis was observed when mice were treated with anti-CXCR4
antibodies. In the draining lymph nodes a reduction of metastasis
to the inguinal and axillary lymph nodes (38% instead of 100%
metastasis in controls) was observed. Thus, immunization against
CXCL12 provides a way of treatment against metastatis of cancers,
more specifically of breast cancers.
[0366] The SDF-1/CXCR4 chemokine-receptor pair has been shown to
increase the efficacy of homing of more primitive hematopoietic
progenitor cells to be bone marrow. In addition, CXCR4 and SDF-1
are supposed to influence the distribution of chronic lymphocytic
leukemia cells. These cells invariably infiltrate the bone marrow
of patients and it was shown that their migration in the bone
marrow was CXCR4 dependent. Chronic lymphocytic leukemia cells
undergo apoptosis unless they are cocultured with stromal cells.
SDF-1 blocking antibodies could inhibit this protective effect of
stromal cells (Burger et al., Blood 96: 2655-63 (2000)). Immunizing
against CXCL12 thus provides a way of treatment against chronic
lymphocytic leukemia.
[0367] CXCR4 has been shown to be a coreceptor for entry of HIV
into T-cells. SDF-1 inhibits infection of CD4+ cells by X4
(CXCR4-dependent) HIV strains (Oberlin et al., Nature 382:833-5
(1996); Bleul et al., Nature 382:829-33 (1996), Rusconi et al.,
Antivir. Ther. 5:199-204 (2000)). Synthetic peptide analogs of
SDF-1 have been shown to effectively inhibit HIV-1 entry and
infection via the CXCR4 receptor (WO059928A1). Thus, immunization
against CXCL12 provides a way to block HIV entry in T-cells, and
therefore a way of treating AIDS.
[0368] SDF-1-CXCR4 interactions were also reported to play a
central role in CD4+ T cell accumulation in rheumatoid arthritis
synovium (Nanki et al., 2000). Immunization against SDF-1 thus
provides a way of treatment against rheumatoid arthritis.
[0369] Human and murine SDF-1 are known to arise in two forms,
SDF-10 and SDF-1.beta., by differential splicing from a single
gene. They differ in four C-terminal amino acids that are present
in SDF-1.beta. (74 aa) and absent in SDF-1.beta. (70 aa). The
sequence of human is shown in SEQ ID No: 238 (Swissprot:
SDF1_human) and the sequence mouse SDF-1 is shown in SEQ ID No: 239
(Swissprot: SDF1_mouse). SDF-1 contains four conserved cysteines
that form two intra-molecular disulfide bonds. The crystal
structure of SDF shows a non covalently-linked dimer (Dealwis et
al., PNAS 95: 6941-46 (1998)). The SDF-1 structure also shows a
long N-terminal extension.
[0370] Alanine-scanning mutagenesis was used to identify (part of)
the receptor-binding site on SDF-1 (Ohnishi et al., J. Interferon
Cytokine Res. 20: 691-700 (2000)) and Elisseeva et al. (J. Biol.
Chem. 275:26799-805 (2000)) and Heveker et al. (Curr. Biol.
8:369-76 (1998)) described SDF-1 derived peptides inhibiting
receptor binding (and HIV entry).
[0371] In the following, constructs and expression systems suitable
in the generation of the compositions of the invention related to
SDF-1 are described. The N- and C-terminus of SDF-1 are exposed to
the solvent. In specific embodiments, an amino acid linker
containing a cysteine as second attachment site is thus fused to
the C-terminus of the protein sequence, while in other specific
embodiments an amino acid linker containing a cysteine as second
attachment site is fused to the N-terminus of the protein sequence.
The amino acid linker containing a free cysteine is fused to the
N-terminus of the sequence corresponding to the sequence of the
processed protein, or inserted at the N-terminus of the sequence of
the mature form of the protein, C-terminally of the signal peptide.
The genes coding for these specific constructs may be cloned in a
suitable expression vector.
[0372] Expression of SDF-1 in a sendai virus system in chicken
embryonic fibroblasts (Moriya et al., FEBS Lett. 425:105-11 (1998))
has been described as well as expression in E. coli (Holmes et al.,
Prot. Expr. Purif. 21: 367-77 (2001)) and chemical synthesis of
SDF-1 (Dealwis et al., PNAS 95: 6941-46 (2001)).
[0373] In yet another embodiment of the invention, the antigenic
determinant is BLC. B-lymphocyte chemoattractant (BLC, CXCL13) is
expressed in the spleen, Peyer's patches and lymph nodes (Gunn et
al., 1998). Its expression is strongest in the germinal centres,
where B cells undergo somatic mutation and affinity maturation. It
belongs to the CXC chemokine family, and its closest homolog is
GRO.beta._(Gunn et al., Nature 391:799-803 (1998)). Human BLC is
64% homologous to murine BLC. Its receptor is CXCR5. BLC also
shares homology with IL-8. BLC recruits B-cells to follicles in
secondary lymphoid organs such as the spleen and peyer's patches.
BLC is also required for recruitment of B-cells to compartment of
the lymph nodes rich in follicular Dendritic Cells (FDCs) (Ansel et
al., Nature 406:309-314 (2000)). BLC also induces increased
expression of Lymphotoxin-.beta.1.beta.2 (LT?.beta.1.beta.2) on the
recruited B-cells. This provides a positive feed-back loop, since
LT?.beta.1.beta.2 promotes BLC expression (Ansel et al., Nature
406:309-314 (2000)). BLC has also been shown to be able to induce
lymphoid neogenesis (Luther et al., Immunity 12:471-481 (2000)). It
appears that FDCs also express BLC. Thus immunization against BLC
may provide a way of treatment against autoimmune diseases where
lymphoid neogenesis is involved, such as Rheumatoid synovitis and
Rheumatoid arthritis or Type I diabetes.
[0374] A construct of BLC bearing a C-terminal his-tag has been
described, and is functional (Ansel, K. M. et al., J. Exp. Med.
190: 1123-1134 (1999)).
[0375] Thus, in a preferred embodiment of the present invention,
the composition comprises a linker containing a cysteine residue as
second attachment site and being fused at the C-terminus of the BLC
sequence.
[0376] In IL-8, which is homologous to BLC, both N- and C-termini
are free. In a further preferred embodiment, addition of an amino
acid linker containing a cysteine residue as second attachment site
is, therefore, done to the N-terminus of BLC for generation of this
specific composition of the invention.
[0377] In further preferred embodiments of the present invention,
the composition comprises an amino acid linker containing a free
cysteine and being fused to the N-terminus of the sequence
corresponding to the sequence of the processed protein, or inserted
at the N-terminus of the sequence of the mature form of the
protein, C-terminally of the signal peptide. The genes coding for
these specific constructs may be cloned in a suitable expression
vector and expressed accordingly. The sequence of human BLC is
shown in SEQ ID No: 240 (Accession: NP.sub.--006410). Amino acids
1-22 of the sequence are the signal peptide. The mouse sequence is
shown in SEQ ID No: 241 (Accession NP.sub.--061354). Amino acids
1-21 are the signal peptide. Compositions of the invention with BLC
as the antigenic determinant, preferably, use the mature form of
the protein for generating the compositions of the invention.
[0378] In another specific embodiment, the antigenic determinant is
Eotaxin. Eotaxin is a chemokine specific for Chemokine receptor 3,
present on eosinophils, basophils and Th2 cells. Eotaxin seems
however to be highly specific for Eosinophils (Zimmerman et al., J.
Immunol. 165: 5839-46 (2000)). Eosinophil migration is reduced by
70% in the eotaxin-1 knock-out mouse, which however can still
develop eosinophilia (Rothenberg et al., J. Exp. Med. 185: 785-90
(1997)). IL-5 seems to be responsible for the migration of
eosinophils from bone-marrow to blood, and eotaxin for the local
migration in the tissue (Humbles et al., J. Exp. Med. 186: 601-12
(1997)).
[0379] The human genome contains 3 eotaxin genes, eotaxin1-3. They
share 30% homology to each other. Two genes are known so far in the
mouse: eotaxin 1 and eotaxin 2 (Zimmerman et al., J. Immunol. 165:
5839-46 (2000)). They share 38% homology. Murine eotaxin-2 shares
59% homology with human eotaxin-2. In the mouse, eotaxin-1 seems to
be ubiquitously expressed in the gastro-intestinal tract, while
eotaxin-2 seems to be predominantly expressed in the jejunum
(Zimmerman et al., J. Immunol. 165: 5839-46 (2000)). Eotaxin-1 is
present in broncho-alveolar fluid (Teixeira et al., J. Clin.
Invest. 100: 1657-66 (1997)). The sequence of human eotaxin-1 is
shown in SEQ ID No.: 242 (aa 1-23 corresponds to the signal
peptide), the sequence of human eotaxin-2 is shown in SEQ ID No.:
243 (aa 1-26 corresponds to the signal peptide), the sequence of
human eotaxin-3 is shown in SEQ ID No.: 244 (aa 1-23 corresponds to
the signal peptide), the sequence of mouse eotaxin-1 is shown in
SEQ ID No.: 245 (aa 1-23 corresponds to the signal peptide), and
the sequence of mouse eotaxin-2 is shown in SEQ ID No.: 246 (aa
1-23 corresponds to the signal peptide).
[0380] Eotaxin has a MW of 8.3 kDa. It is in equilibrium between
monomers and dimers over a wide range of conditions, with an
estimated Kd of 1.3 mM at 37.degree. C. (Crump et al., J. Biol.
Chem. 273: 22471-9 (1998)). The monomer form is however
predominant. The structure of Eotaxin has been elucidated by NMR
spectroscopy. Binding site to its receptor CCR3 is at the
N-terminus, and the region preceding the first cysteine is crucial
(Crump et al., J. Biol. Chem. 273: 22471-9 (1998)). Peptides of
chemokine receptors bound to Eotaxin confirmed this finding.
Eotaxin has four cysteines forming two disulfide bridges.
Therefore, in a preferred embodiment, the inventive composition
comprises an amino-acid linker containing a cysteine residue as
second attachment site and being, preferably, fused to the
C-terminus of the Eotaxin sequence. In other preferred embodiments,
an amino acid linker containing a free cysteine is fused to the
N-terminus of the sequence corresponding to the sequence of the
processed protein, or inserted at the N-terminus of the sequence of
the mature form of the protein, C-terminally of the signal peptide.
The genes coding for these specific constructs are cloned in a
suitable expression vector.
[0381] Eotaxin can be chemically synthesized (Clark-Lewis et al.,
Biochemistry 30:3128-3135 (1991)). Expression in E. coli has also
been described for Eotaxin-1, in the cytoplasm (Crump et al., J.
Biol. Chem. 273: 22471-9 (1998)). Expression in E. coli as
inclusion bodies with subsequent refolding (Mayer et al.,
Biochemistry 39: 8382-95 (2000)), and Insect cell expression
(Forssmann et al., J. Exp. Med. 185: 2171-6 (1997)) have been
described for Eotaxin-2, and may, moreover, be used to arrive at
the specific embodiments of the invention.
[0382] In yet another specific embodiment of the invention, the
antigenic determinant is Macrophage colony-stimulating factor
(M-CSF or CSF-1). M-CSF or CSF-1 is a regulator of proliferation,
differentiation and survival of macrophages and their bone-marrow
progenitors. The receptor for M-CSF is a cell surface tyrosine
kinase receptor, encoded by the protooncogene cfms. An elevated
expression of M-CSF and its receptor has been associated with poor
prognosis in several epithelial cancers such as breast, uterine and
ovarian cancer. Tumor progression has been studied in a mouse
strain resulting from the crossing of a transgenic mouse
susceptible to mammary cancer (PyMT) with a mouse containing a
recessive null mutation in csf-1 gene. These mice show attenuated
late stage invasive carcinoma and pulmonary metastasis compared to
the PyMT mouse (Lin et al., J. Exp. Med. 193:727-739 (2001)). The
cause seems to be the absence of macrophage recruitment to
neoplastic tissues. Subcutaneous growth of Lewis lung cancer is
also impaired in csf.1 null mice. It is postulated that the
mechanism of macrophage enhancement of tumor growth would be
through angiogenic factors, growth factors and proteases produced
by the macrophages.
[0383] Structural data on the soluble form of M-CSF are available
(crystal structure: Pandit et al., Science 258:1358-62 (1992)), and
show that both the N- and C-termini of the protein are accessible.
However, the N-terminus is close to the site of interaction with
the receptor. In addition, M-CSF is present both in a soluble and
cell surface form, where the transmembrane region is at its
C-terminus. Therefore, in a preferred embodiment of the present
invention, the inventive composition comprises an amino acid linker
containing a cysteine and being, preferably, added at the
C-terminus of M-CSF or fragments thereof, or preferably at the
C-terminus of the soluble form of M-CSF. In further preferred
embodiments, the amino acid linker containing a free cysteine is
fused to the N-terminus of the sequence corresponding to the
sequence of the processed protein or of the soluble form of the
protein, or inserted at the N-terminus of the sequence of the
mature form of the protein or of the soluble form of the protein,
C-terminally of the signal peptide. M-CSF is a dimer, where the two
monomers are linked via an interchain disulfide bridge.
[0384] An expression system in E. coli has been described for an
N-terminal 149 amino acid fragment (functional) of M-CSF (Koths et
al., Mol. Reprod. Dev. 46:31-37 (1997)). This fragment of M-CSF,
preferably modified as outlined above, represents a preferred
antigenic determinant in accordance with the invention.
[0385] The human sequence is shown in SEQ ID No: 247 (Accession:
NP.sub.--000748). Further preferred antigenic determinants of the
present invention comprise the N-terminal fragment consisting of
residue 33-181 or 33-185 of SEQ ID No: 247, corresponding to the
soluble form of the receptor.
[0386] The mouse sequence (Accession. NP.sub.--031804) is shown in
sequence ID No: 248. The mature sequence starts at amino acid 33.
Thus, a preferred antigenic determinant in accordance with the
present invention comprises amino-acid 33-181 or 33-185.
[0387] In another specific embodiment, the antigenic determinant is
Resistin (Res). Passive immunization studies were performed with a
rabbit polyclonal antibodies generated against a fusion protein of
mouse Resistin (mRes) fused to GST, expressed in bacteria. This
passive immunization lead to improved glucose uptake in an animal
obesity/Type II diabetes model (Steppan et al., Nature 409: 307-12
(2001)).
[0388] Resistin (Res) is a 114 aa peptide hormone of approximately
12 KD. It contains 11 cysteine of which the most N-terminal one was
shown to be responsible for the dimerisation of the protein and the
other 10 are believed to be involved in intramolecular disulfide
bonds (Banerjee and Lazar, J. Biol. Chem. 276: 25970-3 (2001)).
Mutation of the first cysteine to alanine abolishes the
dimerisation of mRes.
[0389] It was shown, that mRes with a FLAG tag at its C-terminus
still remains active in an animal model (Steppan et al., Nature
409: 307-12 (2001)), similarly a C-terminally HA tagged
(Haemagglutinin tag) version of resistin was shown to be active in
a tissue culture assay (Kim et al., J. Biol. Chem. 276: 11252-6
(2001)), suggesting that the C-terminus is not very sensitive to
introduced modifications. Thus, in a preferred embodiment, the
inventive composition comprises an amino-acid linker containing a
cysteine residue as second attachment site and being fused at the
C-terminus of the resistin sequence. In further preferred
embodiments, the amino acid linker containing a free cysteine is
fused to the N-terminus of the sequence corresponding to the
sequence of the processed protein, or inserted at the N-terminus of
the sequence of the mature form of the protein, C-terminally of the
signal peptide.
[0390] For a preferred embodiment of the present invention, MRes or
huRes may also be expressed as Fc fusion molecules with a protease
cleavage site inserted between Resistin and the Fc part of the
construct, preferably C-terminally of one or more cysteine residues
of the hinge region of the Fc part of the fusion protein in a
eukaryotic expression system, or more preferably according to the
descriptions and disclosures of EXAMPLE 2. Cleavage of the fusion
protein releases Resistin additionally comprising either an
aminoacid linker containing a cysteine residue as described in
EXAMPLE 2, or part or all of the hinge region of the Fc part of the
fusion protein which comprises a cysteine residue at its
C-terminus, which is suitable for coupling to VLPs or Pili. The
human Resistin sequence is shown in SEQ ID No: 249 (Accession
AF323081). The mouse sequence is shown in SEQ ID No: 250 (Accession
AF323080). A favored embodiment of the invention is human resistin
protein fused at its C-terminus to an amino acid linker containing
a cysteine residue. Human resistin construct can be generated
according to the teachings disclosed in EXAMPLE 2, and by comparing
murine and human Resistin sequences in a protein sequence alignment
to identify the part of the sequence of human Resistin to be cloned
in the vectors described in EXAMPLE 1 and EXAMPLE 2 according to
the teachings of EXAMPLE 2, or in other suitable expression
vectors. Example of human resistin constructs suitable for
generating compositions of the inventions are human resistin-C-Xa:
(SEQ ID NO:325), human resistin-C-EK: (SEQ ID NO:326) and human
resistin-C: (SEQ ID NO:327).
[0391] Human Resistin constructs so generated are a preferred
embodiment of the invention. Vaccination against Resistin using the
aforementioned compositions of the invention may thus provide a way
of treating Type II Diabetes and obesity.
[0392] In another embodiment the antigenic determinant is
Lymphotoxin-.beta.. Immunization against lymphotoxin-.beta. may be
useful in treating Prion mediated disease. Scrapie (a
prion-mediated disease) agent replication is believed to take
mainly place in lymphoid tissues and was shown to depend on
prion-protein expressing follicular dendritic cells (FDCs) (Brown
et al., Nature Med. 11: 1308-1312 (1999)). It was subsequently
shown that mice lacking functional follicular dendritic cells show
an impaired prion replication in spleens and a (small) retardation
of neuroinvasion (Montrasio et al., Science 288: 1257-1259 (2000)).
This was achieved by injecting the mice with a soluble
lymphotoxin-.beta. receptor-Fc-fusion protein (LT.beta.R-Fc). This
soluble receptor construct inhibits the development of FDCs by
interfering with the crucial interaction of lymphotoxin-.beta. on
T, B or NK cells with the lymphotoxin-.beta. receptor on the FDC
precursor cells. Thus, vaccination against lymphotoxin-.beta. (also
called TNF.quadrature.) may provide a vaccine for treatment or
prevention of Creutzfeld-Jakob (variant form) or other
prion-mediated diseases and thus prevent prion replication and
neuroinvasion.
[0393] Immunization against Lymphotoxin-.beta. may also provide a
way of treating diabetes. Transgene expression of soluble
LT.beta.R-Fc fusion protein in nonobese diabetic NOD mice blocked
diabetes development but not insulitis (Ettinger et al., J. Exp.
Med. 193: 1333-40 K (2001)). Wu et al. (J. Exp. Med. 193: 1327-32
(2001)) also used NOD mice to study the involvement of
lymphotoxin-.beta., but instead of transgenic animals they did
inject the LT.beta.R-Fc fusion protein. They saw a strong
inhibition of diabetes development and inhibition of insulitis.
Most interestingly, they could even reverse preexisting insulitis
by the fusion protein treatment. In the pancreas the formation of
lymphoid follicular structures could thus be reversed. Vaccination
against lymphotoxin-.beta. may thus provide a way of treatment
against type-I diabetes.
[0394] The sequence of the extracellular domain of human
lymphotoxin-.beta.is shown in SEQ ID No: 250 (TNFC_human) and the
sequence of the extracellular domain of murine lymphotoxin-.beta.
is shown in SEQ ID No: 251 (TNFC_mouse).
[0395] In a further preferred embodiment, the inventive composition
comprises an amino acid linker containing a free cysteine and being
added to the N-terminus of the sequence corresponding to the
processed form of lymphotoxin-.beta., or inserted between the
N-terminus of the sequence corresponding to the mature form of the
protein, and the signal peptide, C-terminally to the signal
peptide. In further preferred embodiments of the invention, the
extracellular part of lymphotoxin-.beta. is expressed as a fusion
protein either with Glutathione-S-transferase, fused N-terminally
to lymphotoxin-.beta., or with a 6 histidine-tag followed by a
myc-tag, fused again N-terminally to the extracellular part of
lymphotoxin-.beta.. An amino acid spacer containing a protease
cleavage site as well as a linker sequence containing a free
cysteine as attachment site, C-terminally to the protease cleavage
site, are fused to the N-terminus of the sequence of the
extracellular part of lymphotoxin-.beta.. Preferably, the
extracellular part of lymphotoxin-.beta. consists of fragments
corresponding to amino acids 49-306 or 126-306 of
lymphotoxin-.beta.. These specific compositions of the invention
may be cloned and expressed in the pCEP-Pu eukaryotic vector. In
further preferred embodiments, the inventive compositions comprise
an amino acid linker containing a free cysteine residue suitable as
second attachment site, and being fused to the C-terminus of
lymphotoxin-.beta. or lymphotoxin-.beta. fragments. In a
particularly favored embodiment, the amino acid sequence LACGG (SEQ
ID NO:415), comprising the amino acid linker ACGG (SEQ ID NO:416)
which itself contains a cysteine residue for coupling to VLPS and
Pili is fused to the N-terminus of the extracellular part of
lymphotoxin-.beta.: or of a fragment of the extracellular part of
lymphotoxin-.beta., yielding the proteins human C-LT.beta.49-306
(SEQ ID NO:346) and human C-LT.beta.126-306 (SEQ ID NO:347) after
cleavage with enterokinase of the corresponding fusion proteins
expressed either in vector pCEP-SP-GST-EK or vector
pCP-SP-his-myc-EK as described in EXAMPLE 3.
[0396] In a preferred embodiment, the antigen or antigenic
determinant is the prion protein, fragments thereof and in
particular peptides of the prion protein. In one embodiment the
prion protein is the human prion protein. Guidance on how to modify
human prion protein for association with the core particle is given
throughout the application and in particular in EXAMPLE 7. Mouse
prion protein constructs are disclosed, and human prion protein
constructs can also be generated and have, for example, the
sequence of SEQ ID NO:348. Further constructs comprise the whole
human prion protein sequence, and other fragments of the human
prion protein, which are further composition of the invention.
Immunization against prion protein may provide a way of treatment
or prevention of Creutzfeldt-Jakob (variant form) or other
prion-mediated diseases. Immunization using the compositions of the
invention comprising the prion protein may provide a way of
treatment against prion mediated diseases in other animals, and the
corresponding sequences of bovine and sheep prion protein
constructs are given in SEQ ID NO:349 and SEQ ID NO:350,
respectively. The peptides of the human prion protein corresponding
to the murine peptides described in EXAMPLE 8, and of amino acid
sequence CSAMSRPIIHFGSDYEDRYYRENMHR ("human cprplong"; SEQ ID
NO:356) and CGSDYEDRYYRENMHR ("human cprpshort"; SEQ ID NO:357)
lead to preferred embodiments of the invention. These peptides
comprise an N-terminal cysteine residue added for coupling to VLPs
and Pili. Corresponding bovine and sheep peptides are
CSAMSRPLIHFGNDYEDRYYRENMHR ("bovine cprplong"; SEQ ID NO:401) and
CGNDYEDRYYRENMHR ("bovine cprpshort"; SEQ ID NO:402)
CSAMSRPLIHFGNDYEDRYYRENMYR ("sheep cprplong"; SEQ ID NO:403) and
CGNDYEDRYYRENMYR ("sheep cprpshort"; SEQ ID NO:404), all leading to
embodiments of the invention.
[0397] In a further preferred embodiment of the invention, the
antigenic determinant is tumor necrosis factor .beta. (TNF-.beta.),
fragments thereof or peptides of TNF-.beta.. In particular,
peptides or fragments of TNF-.alpha. can be used to induce a
self-specific immune response directed towards the whole protein by
immunizing a human or an animal with vaccines and compositions,
respectively, comprising such peptides or fragments in accordance
with the invention. Preferably, VLPs, bacteriophages or bacterial
pili are used as core particle, to which TNF-.beta., peptides or
fragments thereof are attached according to the invention.
[0398] The following murine peptides are the murine homologs to
human peptides that have been shown to be bound by antibodies
neutralizing the activity of TNF-.alpha. (Yone et al. J. Biol.
Chem. 270: 19509-19515) and were, in a further preferred embodiment
of the invention, modified with cysteine residues for coupling to
VLPs, bacteriophages or bacterial pili.
[0399] MuTNFa peptide: the sequence CGG was added at the N-terminus
of the epitope consisting of amino acid residues 22-32 of mature
murine TNF-.alpha.: CGGVEEQLEWLSQR (SEQ ID NO:358).
[0400] 3'TNF II peptide: the sequence GGC was fused at the
C-terminus of the epitope consisting of amino acid residues 4-22 of
mature murine TNF-.alpha. and glutamine 21 was mutated to glycine.
The sequence of the resulting peptide is: SSQNSSDKPVAHVVANHGVGGC
(SEQ ID NO:359).
[0401] 5'TNF II peptide: a cysteine residue was fused to the
N-terminus of the epitope consisting of amino acid residues 4-22 of
mature murine TNF-.alpha. and glutamine 21 was mutated to glycine.
The sequence of the resulting peptide is: CSSQNSSDKPVAHVVANHGV (SEQ
ID NO:360).
[0402] The corresponding human sequence of the 4-22 epitope is
SSRTPSDKPVAHVVANPQAEGQ (SEQ ID NO:361). Like for the murine
sequence a cysteine is, preferably, fused at the N-terminus of the
epitope, or the sequence GGC is fused at the C-terminus of the
epitope for covalent coupling to VLPs, bacteriophages or bacterial
pili according to the invention. It is, however, within the scope
of the present invention that other cysteine containing sequences
are fused at the N- or C-termini of the epitopes. In general, one
or two glycine residues are preferably inserted between the added
cysteine residue and the sequence of the epitope. Other amino acids
may, however, also be inserted instead of glycine residues, and
these amino acid residues will preferably be small amino acids such
as serine.
[0403] The human sequence corresponding to amino acid residues
22-32 is QLQWLNRRANA (SEQ ID NO:362). Preferably, the sequence CGG
is fused at the N-terminus of the epitope for covalent coupling to
VLPs or bacterial pili according to the invention. Other
TNF-.alpha. epitopes suitable for using in the present invention
have been described and are disclosed for example by Yone et al.
(J. Biol. Chem. 270: 19509-19515).
[0404] The invention further includes compositions which contain
mimotopes of the antigens or antigenic determinants described
herein.
[0405] The specific composition of the invention comprises an
antibody or preferably an antibody fragment presented on a
virus-like particle or pilus for induction of an immune response
against said antibody. Antibodies or antibody fragments which are
produced by lymphoma cells, may be selected for attachment to the
virus-like particle and immunization, in order to induce a
protective immune response against the lymphoma.
[0406] In other further embodiments, an antibody or antibody
fragment mimicking an antigen is attached to the particle. The
mimicking antibody or antibody fragment may be generated by
immunization and subsequent isolation of the mimicking antibody or
antibody fragment by any known method known to the art such as e.g.
hybridoma technology (Gherardi, E. et al., J. Immunol. Methods 126:
61-68 (1990)), phage display (Harrison et al., Methods Enzymol.
267: 83-109 (1996)), ribosome display (Hanes, J. et al., Nat.
Biotechnol. 18: 1287-1292 (2000), yeast two-hybrid (Visintin, M. et
al., Proc. Natl. Acad. Sci. USA 96: 11723-11728 (1999)), yeast
surface display (Boder, E T. & Wittrup, K D. Methods. Enzym.
328: 430-444 (2000)), bacterial surface display (Daugherty, P S. et
al., Protein Eng. 12: 613-621 (1999)). The mimicking antibody may
also be isolated from an antibody library or a naive antibody
library using methods known to the art such as the methods
mentioned above, for example.
[0407] In a further embodiment, an antibody recognizing the
combining site of another antibody, i.e. an anti-idiotypic
antibody, further called the immunizing antibody, may be used. The
antibody recognized by the anti-idiotypic antibody will be further
referred to as the neutralizing antibody. Thus, by immunizing
against the anti-idiotypic antibody, molecules with the specificity
of the neutralizing antibody are generated in situ; we will further
refer to these generated antibodies as the induced antibodies. In
another preferred embodiment, the immunizing antibody is selected
to interact with a ligand molecule of the target molecule against
which immunization is seeked. The ligand molecule may be any
molecule interacting with the target molecule, but will
preferentially interact with the site of the target molecule
against which antibodies should be generated for inhibition of its
function. The ligand molecule may be a natural ligand of the target
molecule, or may be any engineered, designed or isolated ligand
having suitable binding properties.
[0408] The immunizing antibodies may be of human origin, such as
isolated from a naive or immune human antibody library, or may have
been isolated from a library generated from another animal source,
for example of murine origin.
[0409] Coupling of the antibody or antibody fragment to the VLP or
pilus is achieved either by limited reduction of exposed disulfide
bridges (for example of the interchain disulfide bridge between CH1
and C.quadrature. or C.quadrature. in a Fab fragment) or by fusion
of a linker containing a free cysteine residue at the C-terminus of
the antibody or antibody fragment. In a further embodiment, a
linker containing a free cysteine residue is fused to the
N-terminus of the antibody or antibody fragment for attachment to a
VLP or pilus protein.
[0410] A number of vaccine compositions which employ mimotopes are
known in the art, as are methods for generating and identifying
mimotopes of particular epitopes. For example, Arnon et al.,
Immunology 101:555-562 (2000), the entire disclosure of which is
incorporated herein by reference, describe mimotope peptide-based
vaccines against Schistosoma mansoni. The mimotopes uses in these
vaccines were obtained by screening a solid-phase 8mer random
peptide library to identify mimotopes of an epitope recognized by a
protective monoclonal antibody against Schistosoma mansoni.
Similarly, Olszewska et al., Virology 272:98-105 (2000), the entire
disclosure of which is incorporated herein by reference, describe
the identification of synthetic peptides which mimic an epitope of
the measles virus fusion protein and the use of these peptides for
the immunization of mice. In addition, Zuercher et al., Eur. J.
Immunol. 30:128-135 (2000), the entire disclosure of which is
incorporated herein by reference, describe compositions and methods
for oral anti-IgE immunization using epitope-displaying phage. In
particular, epitope-displaying M13 bacteriophages are employed as
carriers for an oral anti-IgE vaccine. The vaccine compositions
tested contain mimotopes and epitopes of the monoclonal anti-IgE
antibody BSW17.
[0411] The invention thus includes vaccine compositions which
contain mimotopes that elicit immunological responses against
particular antigens, as well as individual mimotope/core particle
conjugates and individual mimotope/non-naturally occurring
molecular scaffold conjugates which make up these vaccine
compositions, and the use of these vaccine compositions to elicit
immunological responses against specific antigens or antigenic
determinants. Mimotopes may also be polypeptides, such as
anti-idiotypic antibodies. Therefore, in a further preferred
embodiment of the invention, the antigen or antigenic determinant
is an anti-idiotypic antibody or anti-idiotypic antibody
fragment.
[0412] The invention further includes compositions which contain
mimotopes of the antigens or antigenic determinants described
herein.
[0413] Mimotopes of particular antigens may be generated and
identified by any number of means including the screening of random
peptide phage display libraries (see, e.g., PCT Publication No. WO
97/31948, the entire disclosure of which is incorporated herein by
reference). Screening of such libraries will often be performed to
identify peptides which bind to one or more antibodies having
specificity for a particular antigen.
[0414] Mimotopes suitable for use in vaccine compositions of the
invention may be linear or circular peptides. Mimotopes which are
linear or circular peptides may be linked to non-natural molecular
scaffolds or core particles by a bond which is not a peptide
bond.
[0415] As suggested above, a number of human IgE mimotopes and
epitopes have been identified which elicit immunological responses
against human IgE molecules. (See, e.g., PCT Publication No. WO
97/31948.) Thus, in certain embodiments, vaccine compositions of
the invention include compositions which elicit an immunological
response against immunoglobin molecules (e.g., IgE molecules).
[0416] Peptides which can be used to elicit such immunological
responses include proteins, protein subunits, domains of IgE
molecules, and mimotopes which are capable of eliciting production
of antibodies having specificity for IgE molecules. Generally,
portions of IgE molecules used to prepare vaccine compositions will
be derived from IgE molecules of the species from which the
composition is to be administered. For example, a vaccine
composition intended for administration to humans will often
contain one or more portions of the human IgE molecule, and/or one
or more mimotopes which are capable of eliciting immunological
responses against human IgE molecules.
[0417] In specific embodiments, vaccine compositions of the
invention intended for administration to humans will contain at
least one portion of the constant region of the IgE heavy chain set
out in SEQ ID NO:176; Accession No. AAB59424 (SEQ ID NO: 176). In
more specific embodiments, IgE peptides used to prepare vaccine
compositions of the invention comprise, or alternatively consist
of, peptides having the following amino acid sequences:
TABLE-US-00004 CGGVNLTWSRASG. (SEQ ID NO: 178)
[0418] In additional specific embodiments, vaccine compositions of
the invention will contain at least one mimotope which is capable
of eliciting an immune response that results in the production of
antibodies having specificity for a particular antigen
[0419] Examples of mimotopes of IgE suitable for use in the
preparation of vaccine compositions of the invention include
peptides having the following amino acid sequences: TABLE-US-00005
SEQ ID SEQ ID Mimotope NO Mimotope NO INHRGYWV 179 VKLPWRFYQV 187
RNHRGYWV 180 VWTACGYGRM 188 RSRSGGYWLW 181 GTVSTLS 189 VNLTWSRASG
182 LLDSRYW 190 C.sub..epsilon.H.sub.3 epitope QPAHSLG 191
VNLPWSRASG 183 LWGMQGR 192 VNLTWSFGLE 184 LTLSHPHWVLNHFVS 193
VNLPWSFGLE 185 SMGPDQTLR 194 C.sub..epsilon.H.sub.3 mimotope VNLTWS
195 VNRPWSFGLE 186 GEFCINHRGYWVCGDPA 216
[0420] C. Preparation of the AlphaVaccine Particles
[0421] The invention provides novel compositions and methods for
the construction of ordered and repetitive antigen arrays. As one
of skill in the art would know, the conditions for the assembly of
the ordered and repetitive antigen array depend to a large extent
on the specific choice of the first attachment site of the
non-natural molecular scaffold and the specific choice of the
second attachment site of the antigen or antigenic determinant.
Thus, practitioner choice in the design of the composition (i.e.,
selection of the first and second attachment sites, antigen and
non-natural molecular scaffold) will determine the specific
conditions for the assembly of the AlphaVaccine particle (the
ordered and repetitive antigen array and non-natural molecular
scaffold combined). Information relating to assembly of the
AlphaVaccine particle is well within the working knowledge of the
practitioner, and numerous references exist to aid the practitioner
(e.g., Sambrook, J. et al., eds., Molecular Cloning, A Laboratory
Manual, 2nd. edition, Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, N.Y. (1989); Ausubel, F. et al., eds., Current
Protocols in Molecular Biology, John H. Wiley & Sons, Inc.
(1997); Celis, J., ed., CELL BIOLGY, Academic Press, 2nd edition,
(1998); Harlow, E. and Lane, D., "Antibodies: A Laboratory Manual,"
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1988), all
of which are incorporated herein by reference.
[0422] In a specific embodiment of the invention, the JUN and FOS
leucine zipper protein domains are utilized for the first and
second attachment sites of the invention, respectively. In the
preparation of AlphaVaccine particles, antigen must be produced and
purified under conditions to promote assembly of the ordered and
repetitive antigen array onto the non-natural molecular scaffold.
In the particular JUN/FOS leucine zipper protein domain embodiment,
the FOS-antigen or FOS-antigenic determinant should be treated with
a reducing agent (e.g., Dithiothreitol (DTT)) to reduce or
eliminate the incidence of disulfide bond formation (Example
15).
[0423] For the preparation of the non-natural molecular scaffold
(i.e., recombinant Sinbis virus) of the JUN/FOS leucine zipper
protein domain embodiment, recombinant E2-JUN viral particles
should be concentrated, neutralized and treated with reducing agent
(see Example 16).
[0424] Assembly of the ordered and repetitive antigen array in the
JUN/FOS embodiment is done in the presence of a redox shuffle.
E2-JUN viral particles are combined with a 240 fold molar excess of
FOS-antigen or FOS-antigenic determinant for 10 hours at 4.degree.
C. Subsequently, the AlphaVaccine particle is concentrated and
purified by chromatography (Example 16).
[0425] In another embodiment of the invention, the coupling of the
non-natural molecular scaffold to the antigen or antigenic
determinant may be accomplished by chemical cross-linking. In a
specific embodiment, the chemical agent is a heterobifunctional
cross-linking agent such as .-maleimidocaproic acid
N-hydroxysuccinimide ester (Tanimori et al., J. Pharm. Dyn. 4:812
(1981); Fujiwara et al., J. Immunol. Meth. 45:195 (1981)), which
contains (1) a succinimide group reactive with amino groups and (2)
a maleimide group reactive with SH groups. A heterologous protein
or polypeptide of the first attachment site may be engineered to
contain one or more lysine residues that will serve as a reactive
moiety for the succinimide portion of the heterobifunctional
cross-linking agent. Once chemically coupled to the lysine residues
of the heterologous protein, the maleimide group of the
heterobifunctional cross-linking agent will be available to react
with the SH group of a cysteine residue on the antigen or antigenic
determinant. Antigen or antigenic determinant preparation in this
instance may require the engineering of a cysteine residue into the
protein or polypeptide chosen as the second attachment site so that
it may be reacted to the free maleimide function on the
cross-linking agent bound to the non-natural molecular scaffold
first attachment sites. Thus, in such an instance, the
heterobifunctional cross-linking agent binds to a first attachment
site of the non-natural molecular scaffold and connects the
scaffold to a second binding site of the antigen or antigenic
determinant.
[0426] 3. Compositions, Vaccines, and the Administration Thereof,
and Methods of Treatment
[0427] The invention provides vaccine compositions which may be
used for preventing and/or attenuating diseases or conditions. The
invention further provides vaccination methods for preventing
and/or attenuating diseases or conditions in individuals.
[0428] In one embodiment, the invention provides vaccines for the
prevention of infectious diseases in a wide range of species,
particularly mammalian species such as human, monkey, cow, dog,
cat, horse, pig, etc. Vaccines may be designed to treat infections
of viral etiology such as HIV, influenza, Herpes, viral hepatitis,
Epstein Bar, polio, viral encephalitis, measles, chicken pox, etc.;
or infections of bacterial etiology such as pneumonia,
tuberculosis, syphilis, etc.; or infections of parasitic etiology
such as malaria, trypanosomiasis, leishmaniasis, trichomoniasis,
amoebiasis, etc.
[0429] In another embodiment, the invention provides vaccines for
the prevention of cancer in a wide range of species, particularly
mammalian species such as human, monkey, cow, dog, cat, horse, pig,
etc. Vaccines may be designed to treat all types of cancer:
lymphomas, carcinomas, sarcomas, melanomas, etc.
[0430] In another embodiment of the invention, compositions of the
invention may be used in the design of vaccines for the treatment
of allergies. Antibodies of the IgE isotype are important
components in allergic reactions. Mast cells bind IgE antibodies on
their surface and release histamines and other mediators of
allergic response upon binding of specific antigen to the IgE
molecules bound on the mast cell surface. Inhibiting production of
IgE antibodies, therefore, is a promising target to protect against
allergies. This should be possible by attaining a desired T helper
cell response. T helper cell responses can be divided into type 1
(TH1) and type 2 (TH2) T helper cell responses (Romagnani, Immunol.
Today 18:263-266 (1997)). TH1 cells secrete interferon-gamma and
other cytokines which trigger B cells to produce IgG1-3 antibodies.
In contrast, a critical cytokine produced by TH2 cells is IL-4,
which drived B cells to produce IgG4 and IgE. In many experimental
systems, the development of TH1 and TH2 responses is mutually
exclusive since TH1 cells suppress the induction of TH2 cells and
vice versa. Thus, antigens that trigger a strong TH1 response
simultaneously suppress the development of TH2 responses and hence
the production of IgE antibodies. Interestingly, virtually all
viruses induce a TH1 response in the host and fail to trigger the
production of IgE antibodies (Coutelier et al., J. Exp. Med.
165:64-69 (1987)). This isotype pattern is not restricted to live
viruses but has also been observed for inactivated or recombinant
viral particles (Lo-Man et al., Eur. J. Immunol. 28:1401-1407
(1998)). Thus, by using the processes of the invention (e.g.,
AlphaVaccine Technology), viral particles can be decorated with
various allergens and used for immunization. Due to the resulting
"viral structure" of the allergen, a TH1 response will be elicited,
"protective" IgG1-3 antibodies will be produced, and the production
of IgE antibodies which cause allergic reactions will be prevented.
Since the allergen is presented by viral particles which are
recognized by a different set of helper T cells than the allergen
itself, it is likely that the allergen-specific IgG1-3 antibodies
will be induced even in allergic individuals harboring pre-existing
TH2 cells specific for the allergen. The presence of high
concentrations of IgG antibodies may prevent binding of allergens
to mast cell bound IgE, thereby inhibiting the release of
histamine. Thus, presence of IgG antibodies may protect from IgE
mediated allergic reactions. Typical substances causing allergies
include: grass, ragweed, birch or mountain cedar pollens, house
dust, mites, animal danders, mold, insect venom or drugs (e.g.,
penicillin). Thus, immunization of individuals with
allergen-decorated viral particles should be beneficial not only
before but also after the onset of allergies.
[0431] In specific embodiments, the invention provides methods for
preventing and/or attenuating diseases or conditions which are
caused or exacerbated by "self" gene products (e.g., tumor necrosis
factors), i.e. "self antigens" as used herein. In related
embodiments, the invention provides methods for inducing
immunological responses in individuals which lead to the production
of antibodies that prevent and/or attenuate diseases or conditions
are caused or exacerbated by "self" gene products. Examples of such
diseases or conditions include graft versus host disease,
IgE-mediated allergic reactions, anaphylaxis, adult respiratory
distress syndrome, Crohn's disease, allergic asthma, acute
lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), Graves'
disease, inflammatory autoimmune diseases, myasthenia gravis,
systemic lupus erythematosus (SLE), immunoproliferative disease
lymphadenopathy (IPL), angioimmunoproliferative lymphadenopathy
(AIL), immunoblastive lymphadenopathy (IBL), rheumatoid arthritis,
diabetes, multiple sclerosis, osteoporosis and Alzheimer's
disease.
[0432] As would be understood by one of ordinary skill in the art,
when compositions of the invention are administered to an
individual, they may be in a composition which contains salts,
buffers, adjuvants, or other substances which are desirable for
improving the efficacy of the composition. Examples of materials
suitable for use in preparing pharmaceutical compositions are
provided in numerous sources including Remington's Pharmaceutical
Sciences (Osol, A, ed., Mack Publishing Co., (1990)).
[0433] Compositions of the invention are said to be
"pharmacologically acceptable" if their administration can be
tolerated by a recipient individual. Further, the compositions of
the invention will be administered in a "therapeutically effective
amount" (i.e., an amount that produces a desired physiological
effect).
[0434] The compositions of the present invention may be
administered by various methods known in the art, but will normally
be administered by injection, infusion, inhalation, oral
administration, or other suitable physical methods. The
compositions may alternatively be administered intramuscularly,
intravenously, or subcutaneously. Components of compositions for
administration include sterile aqueous (e.g., physiological saline)
or non-aqueous solutions and suspensions. Examples of non-aqueous
solvents are propylene glycol, polyethylene glycol, vegetable oils
such as olive oil, and injectable organic esters such as ethyl
oleate. Carriers or occlusive dressings can be used to increase
skin permeability and enhance antigen absorption.
[0435] Prion-mediated diseases are an increasing threat for
society. Specifically, prion-induced BSE in cattle represents a
disease that has long been neglected and may affect a great number
of animals throughout Europe. Moreover, a variant form of CJD is
attributed to infection of humans after consumption of meat of
prion-infected cattle. Although the number of infected people has
been relatively low so far, it seems possible that the disease may
become epidemic. However, long-term prognosis for the development
of vCJD may be particular difficult, since incubation times between
infection and overt disease are very long (an estimated 10
years).
[0436] Prions are cellular proteins existing in most mammalian
species. Prion proteins exist in two forms, a normally folded form
that is usually present in healthy individuals (PrPc) and a
misfolded form that causes disease (PrpSc). The current prion
hypotheses postulates that the misfolded prion form PrpSc can
catalyse the refolding of healthy prion PrPc into disease causing
PrpSc (A. Aguzzi, Haematologica 85, 3-10 (2000)). In some rare
instances, this transition may also occur spontaneously, causing
classical CJD in humans. Some mutations in PrPc are associated with
an increase in this spontaneous transition, causing the various
forms of familial CJD. However, PrpSc may also be infectious and
may be transmitted by blood transfusion or via the food chain. The
latter form of prion mediated disease is known as Kuru Kuru and
used to occur in human cannibals. However, since species that are
feeding on their own individuals are not abundant, this form of
orally transmitted disease was too rare to be documented for other
species.
[0437] The massive feeding of cows with beef-products throughout
Europe now changed the situation and numbers of cows infected with
a transmissible form of BSE-causing PrpSc, dramatically increased
in recent years, afflicting hundreds of thousands of cows. This
sudden appearance of massive numbers of BSE-diseased cows caused
great fear in the human population that a similar disease may be
induced in humans. Indeed, in 1996, the first case of a variant
form of CJD was reported that could be attributed to the
consumption of PrpSc infected beef. Until now, this fear has
further increased, since the number of infected humans has
constantly increased during the following years and no cure is in
sight. Moreover, since sheep succumb to a prion-mediated disease
called scrapie and since other mammalian species can be infected
with PrpSc
[0438] Experimentally, it is possible that BSE-like diseases may
occur also in other species. The mechanism of prion transmission
has been studied in great detail. It is now clear that prions first
replicate in the lymphoid organs of infected mice and are
subsequently transported to the central nervous system. Follicular
dendritic cells (FDCs), a rare cell population in lymphoid organs,
seems to be essential for both replication of prion proteins in the
lymphoid organs and transport into the central nervous system (S.
Brandner, M. A. Klein, A. Aguzzi, Transfus Clin Biol 6, 17-23
(1999); F. Montrasio, et al., Science 288, 1257-9 (2000)). FDCs are
a poorly studied cell type but it is now clear that they depend
upon the production of lymphotoxin and/or TNF by B cells for their
development (F. Mackay, J. L. Browning, Nature 395, 26-27 (1998)).
Indeed, mice deficient for lymphotoxin do not exhibit FDCs (M. S.
Matsumoto, et al., Science 264, 703-707 (1996)). Moreover, they
fail to be productively infected with prions and do not succumb to
disease. In addition to FDCs, antibodies may also play a role in
disease progression (S. Brandner, M. A. Klein, A. Aguzzi, Transfus
Clin Biol 6, 17-23 (1999)).
[0439] Recently, it was shown that blocking the LTb pathway using a
Lt receptor Fc fusion molecule not only eliminates FDCs in mice but
also blocks infection with PrPSc (F. Montrasio, et al., Science
288, 1257-9 (2000). Thus, a vaccine that induces antibodies
specific for LTb or its receptor may be able to block transmission
of PrPSc from one individual to another or from the periphery to
the central nervous system.
[0440] However, it is usually difficult if not impossible to induce
antibody responses to self-molecules by conventional vaccination.
One way to improve the efficiency of vaccination is to increase the
degree of repetitiveness of the antigen applied: Unlike isolated
proteins, viruses induce prompt and efficient immune responses in
the absence of any adjuvants both with and without T-cell help
(Bachmann & Zinkemagel, Ann. Rev. Immunol: 15:235-270 (1991)).
Although viruses often consist of few proteins, they are able to
trigger much stronger immune responses than their isolated
components. For B-cell responses, it is known that one crucial
factor for the immunogenicity of viruses is the repetitiveness and
order of surface epitopes. Many viruses exhibit a quasi-crystalline
surface that displays a regular array of epitopes which efficiently
crosslinks epitope-specific immunoglobulins on B cells (Bachmann
& Zinkernagel, Immunol. Today 17:553-558 (1996)). This
crosslinking of surface immunoglobulins on B cells is a strong
activation signal that directly induces cell-cycle progression and
the production of IgM antibodies. Further, such triggered B cells
are able to activate T helper cells, which in turn induce a switch
from IgM to IgG antibody production in B cells and the generation
of long-lived B cell memory--the goal of any vaccination (Bachmann
& Zinkernagel, Ann. Rev. Immunol. 15:235-270 (1997)). Viral
structure is even linked to the generation of anti-antibodies in
autoimmune disease and as a part of the natural response to
pathogens (see Fehr, T., et al., J. Exp. Med. 185:1785-1792
(1997)). Thus, antibodies presented by a highly organized viral
surface are able to induce strong anti-antibody responses.
[0441] The immune system usually fails to produce antibodies
against self-derived structures. For soluble antigens present at
low concentrations, this is due to tolerance at the Th cell level.
Under these conditions, coupling the self-antigen to a carrier that
can deliver T help may break tolerance. For soluble proteins
present at high concentrations or membrane proteins at low
concentration, B and Th cells may be tolerant. However, B cell
tolerance may be reversible (anergy) and can be broken by
administration of the antigen in a highly organized fashion coupled
to a foreign carrier (Bachmann & Zinkemagel, Ann. Rev. Immunol.
15:235-270 (1997). Thus, LTb, LTa or LTb receptor as highly
organized as a virus, a virus like particle or a bacterial pilus
may be able to break B cell tolerance and to induce antibodies
specific for these molecules.
[0442] The present invention is related to the fields of molecular
biology, virology, immunology and medicine. The invention provides
a method that facilitates induction of antibodies specific for
endogenous lymphotoxin (LT)b, LTa or LTb receptor. The invention
also provides a process for producing an antigen or antigenic
determinant that is able to elicit antibodies specific for LTb, LTa
or LTb receptor which is useful for the prevention and therapy of
prion-mediated diseases such as variant Creutzfeld-Jacob disease
(vCJD) or bovine spongioform encephalopathy (BSE) and elimination
of lymphoid organ like structures in autoimmune diseased
tissues.
[0443] The object of the invention is to provide a vaccine that is
able to induce antibodies specific for LTb, LTa or LTb receptor
thereby eliminating FDCs from lymphoid organs. This treatment may
allow preventing infection with PrPSc or spread of PrPSc from the
periphery to the central nervous system. In addition, this
treatment blocks generation of lymphoid organ like structures in
organs targeted by autoimmune disease and may even dissolve such
existing structures, ameliorating disease symptoms.
[0444] LTb, LTa or LTb receptor or fragments thereof are coupled to
a protein carrier that is foreign to the host. In a preferred
embodiment of the invention, LTb, LTa or LTb receptor or fragments
thereof will be coupled to a highly organized structure in order to
render these molecules highly repetitive and organized. The highly
organized structure may be a bacterial pilus, a virus like particle
(VLP) generated by recombinant proteins of the bacteriophage
Q.beta., recombinant proteins of Rotavirus, recombinant proteins of
Norwalkvirus, recombinant proteins of Alphavirus, recombinant
proteins of Foot and Mouth Disease virus, recombinant proteins of
Retrovirus, recombinant proteins of Hepatitis B virus, recombinant
proteins of Tobacco mosaic virus, recombinant proteins of Flock
House Virus, and recombinant proteins of human Papillomavirus. In
order to optimize the three-dimensional arrangement of LTb, LTa or
LTb receptor or fragments thereof on the highly organized
structure, an attachment site, such as a chemically reactive
amino-acid, is introduced into the highly organized structure
(unless it is naturally there) and a binding site, such as a
chemically reactive amino acid, will be introduced on the LTb, LTa
or LTb receptor or fragments (unless it is naturally there). The
presence of an attachment site on the highly organized structure
and a binding site on the LTb, LTa or LTb receptor or fragments
thereof will allow to couple these molecules to the repetitive
structure in an oriented and ordered fashion which is essential for
the induction of efficient B cell responses.
[0445] In an equally preferred embodiment, the attachment site
introduced in the repetitive structure is biotin that specifically
binds streptavidin. Biotin may be introduced by chemical
modification. LTb, LTa or LTb receptor or fragments thereof may be
fused or linked to streptavidin and bound to the biotinylated
repetitive structure.
[0446] Other embodiments of the invention include processes for the
production of the compositions of the invention and methods of
medical treatment using said compositions. It is to be understood
that both the foregoing general description and the following
detailed description are exemplary and explanatory only and are
intended to provide further explanation of the invention as
claimed.
[0447] In addition to vaccine technologies, other embodiments of
the invention are drawn to methods of medical treatment for cancer
and allergies.
[0448] All patents and publications referred to herein are
expressly incorporated by reference in their entirety.
EXAMPLES
[0449] Enzymes and reagents used in the experiments that follow
included: T4 DNA ligase obtained from New England Biolabs; Taq DNA
Polymerase, QIAprep Spin Plasmid Kit, QIAGEN Plasmid Midi Kit,
QiaExII Gel Extraction Kit, QIAquick PCR Purification Kit obtained
from QIAGEN; QuickPrep Micro mRNA Purification Kit obtained from
Pharmacia; SuperScript One-step RT PCR Kit, fetal calf serum (FCS),
bacto-tryptone and yeast extract obtained from Gibco BRL;
Oligonucleotides obtained from Microsynth (Switzerland);
restriction endonucleases obtained from Boehringer Mannheim, New
England Biolabs or MBI Fermentas; Pwo polymerase and dNTPs obtained
from Boehringer Mannheim. HP-1 medium was obtained from Cell
culture technologies (Glattbrugg, Switzerland). All standard
chemicals were obtained from Fluka-Sigma-Aldrich, and all cell
culture materials were obtained from TPP.
[0450] DNA manipulations were carried out using standard
techniques. DNA was prepared according to manufacturer instruction
either from a 2 ml bacterial culture using the QIAprep Spin Plasmid
Kit or from a 50 ml culture using the QIAGEN Plasmid Midi Kit. For
restriction enzyme digestion, DNA was incubated at least 2 hours
with the appropriate restriction enzyme at a concentration of 5-10
units (U) enzyme per mg DNA under manufacturer recommended
conditions (buffer and temperature). Digests with more than one
enzyme were performed simultaneously if reaction conditions were
appropriate for all enzymes, otherwise consecutively. DNA fragments
isolated for further manipulations were separated by
electrophoresis in a 0.7 to 1.5% agarose gel, excised from the gel
and purified with the QiaExII Gel Extraction Kit according to the
instructions provided by the manufacturer. For ligation of DNA
fragments, 100 to 200 pg of purified vector DNA were incubated
overnight with a threefold molar excess of the insert fragment at
16.degree. C. in the presence of 1 U T4 DNA ligase in the buffer
provided by the manufacturer (total volume: 10-20 .mu.l). An
aliquot (0.1 to 0.5 .mu.l) of the ligation reaction was used for
transformation of E. coli XL1-Blue (Stratagene). Transformation was
done by electroporation using a Gene Pulser (BioRAD) and 0.1 cm
Gene Pulser Cuvettes (BioRAD) at 200 Ohm, 25 .mu.F, 1.7 kV. After
electroporation, the cells were incubated with shaking for 1 h in 1
ml S.O.B. medium (Miller, 1972) before plating on selective S.O.B.
agar.
Example 1
Modular Eukaryotic Expression System for Coupling of Antigens to
VLPs
[0451] This system was generated in order to add various amino acid
linker sequences containing a cysteine residue to antigens for
chemical coupling to VLPs.
A. Construction of an EBNA Derived Expression System Encoding a
Cysteine-Containing Amino Acid Linker and Cleavable Fc-Tag:
[0452] pCep-Pu (Wuttke et al. J. Biol. Chem. 276: 36839-48 (2001))
was digested with Kpn I and Bam HI and a new multiple cloning site
was introduced with the annealed oligonucleotides PH37 (SEQ ID
NO:270) and PH38 (SEQ ID NO:271) leading to pCep-MCS.
[0453] A modular system containing a free cysteine flanked by
several glycines, a protease cleavage site and the constant region
of the human IgG1 was generated as follows. pSec2/Hygro B
(Invitrogen Cat. No. V910-20) was digested with Bsp120I and Hind
III and ligated with the annealed oligonucleotides SU7 (SEQ ID
NO:278) and SU8 (SEQ ID NO:279) leading to construct pSec-B-MCS.
pSec-B-MCS was then digested with Nhe I and Hind III and ligated
with the annealed oligonucleotides PH29 (SEQ ID NO:264) and PH30
(SEQ ID NO:265) leading to construct pSec 29/30. The construct
pSec-FL-EK-Fc* was generated by a three fragment ligation of the
following fragments; first pSec 29/30 digested with Eco RI and Hind
III, the annealed oligonucleotides PH31 (SEQ ID NO:266) and PH32
(SEQ ID NO:267) and the BglI/EcoRI fragment of a plasmid
(pSP-Fc*-C1) containing a modified version of the human IgG1
constant region (for details of the hu IgG1 sequence see the
sequence of the final construct pCep-Xa-Fc* see FIG. 1A-1C, SEQ ID
NOS:426, 427 and 428, respectively). The complete sequence of
pCep-Xa-Fc* is given in SEQ ID NO:283. The resulting construct was
named pSec-FL-EK-Fc*. From this plasmid the linker region and the
human IgG1 Fc part was excised by Nhe I, Pme I digestion and cloned
into pCep-MCS digested with Nhe I and Pme I leading to construct
pCep-FL-EK-Fc*. Thus a modular vector, was created where the linker
sequence and the protease cleavage site, which are located between
the Nhe I and Hind III sites, can easily be exchanged with annealed
oligonucleotides. For the generation of cleavable fusion protein
vectors pCep-FL-EK-Fc* was digested with Nhe I and Hind III and the
Factor Xa cleavage site N-terminally flanked with amino acids
GGGGCG (SEQ ID NO:413) was introduced with the annealed
oligonucleotides PH35 (SEQ ID NO:268) and PH36 (SEQ ID NO:269) and
the enterokinase site flanked n-terminally with GGGGCG (SEQ ID
NO:413) was introduced with the annealed oligonucleotides PH39 (SEQ
ID NO:272) and PH40 (SEQ ID NO:273) leading to the constructs
pCep-Xa-Fc* (see FIG. 1A, SEQ ID NO:426) and pCep-EK-Fc* (see FIG.
1B, SEQ ID NO:427) respectively. The construct pCep-SP-EK-Fc* (see
FIG. 1C, SEQ ID NO:428) which in addition contains a eukaryotic
signal peptide was generated by a three fragment ligation of
pCep-EK-Fc* digested Kpn I/Bam HI, the annealed oligos PH41 (SEQ ID
NO:274) and PH42 (SEQ ID NO:275) and the annealed oligos PH43 (SEQ
ID NO:276) and PH44 (SEQ ID NO:277).
B. Large Scale Production of Fusion Proteins:
[0454] For the large scale production of the different fusion
proteins 293-EBNA cells (Invitrogen) were transfected with the
different pCep expression plasmids with Lipofectamine 2000 reagent
(life technologies) according to the manufacturer's recommendation.
24-36 h post transfection the cells were split at a 1 to 3 ratio
under puromycin selection (1 .mu.g/ml) in DMEM supplemented with
10% FCS. The resistant cells were then expanded in selective
medium. For the harvesting of the fusion proteins the resistant
cell population were passed onto poly-L-lysine coated dishes. Once
the cells had reached confluence, they were washed 2 times with PBS
and serum free medium (DMEM) was added to the plates. The tissue
culture supernatant were harvested every 2 to 4 days and replaced
with fresh DMEM medium during a period of up to one month. The
harvested supernatants were kept at 4.degree. C.
C. Purification of the Fusion Proteins:
[0455] The recombinant Fc-fusion proteins were purified by affinity
chromatography using protein A sepharose CL-4B (Amersham Pharmacia
Biotech AG). Briefly chromatography columns were packed with 1-3 ml
protein A resin and the tissue culture supernatants containing the
recombinant proteins were applied to the column with a peristaltic
pump at a flow rate of 0.5-1.5 ml/min. The column was then washed
with 20-50 ml PBS. Depending on the fusion protein the protease
cleavage was performed on the column or the protein was eluted as
described below. Recombinant fusion proteins were eluted with a
citrate/phosphate buffer (pH 3.8) supplemented with 150 mM NaCl and
the fractions containing the protein were pooled and concentrated
with ultrafree centrifugal filters (Millipore).
D. Protease Cleavage of Recombinant Fusion Proteins (Factor Xa,
Enterokinase):
[0456] Eluted recombinant fusion proteins containing the
enterokinase (EK) cleavage site were cleaved using the EKmax system
(Invitrogen) according to the manufacturer's recommendation. The
cleaved Fc part of the fusion protein was removed by incubation
with protein A. The enterokinase was then removed with the EK-Away
system (Invitrogen) according to the manufacturers recommendation.
Similarly fusion proteins containing the factor Xa (Xa) cleavage
site were cleaved using the restriction protease factor Xa cleavage
and removal kit (Roche) according to the manufacturer's
recommendation. The cleaved Fc part was removed by incubation with
protein A and the protease was removed with the streptavidin resin
provided with the kit.
[0457] The different fusion proteins were concentrated with
ultrafree centrifugal filters (Millipore), quantitated by UV
spectrophotometrie and used for subsequent coupling reactions.
[0458] FIG. 1A-1C (SEQ ID NOS:426, 427 and 428, respectively) shows
partial sequences of the different eukaryotic expression vectors
used. Only the modified sequences are shown.
[0459] FIG. 1A (SEQ ID NO:426): pCep-Xa-Fc*: the sequence is shown
from the Bam HI site onwards and different features are shown above
the translated sequence. The arrow indicates the cleavage site of
the factor Xa protease.
[0460] FIG. 1B (SEQ ID NO:427): pCep-EK-Fc*: the sequence is shown
from the Bam HI site onwards and different features are shown above
the translated sequence. The arrow indicates the cleavage site of
the enterokinase. The sequence downstream of the Hind III site is
identical to the one shown in FIG. 1A.
[0461] FIG. 1C (SEQ ID NO:428): pCep-SP-EK-Fc*: the sequence is
shown from the beginning of the signal peptide on and different
features are shown above the translated sequence. The signal
peptide sequence which is cleaved of by the signal peptidase is
shown in bold The arrow indicates the cleavage site of the
enterokinase. The sequence downstream of the Hind III site is
identical to the one shown in FIG. 1A (SEQ ID NO:426).
Example 2
Eukaryotic Expression and Coupling of Mouse Resistin to VLPs and
Pili
A. Cloning of Mouse Resistin:
[0462] Total RNA was isolated from 60 mg mouse adipose tissue using
a Qiagen RNeasy kit according to the manufacturer's recommendation.
The RNA was eluted in 40 .mu.l H.sub.2O. This total RNA was than
used for the reverse transcription with an oligo dT primer using
the ThermoScript.TM. RT-PCR System (Life Technologies) according to
the manufacturer's recommendation. The sample was incubated at
50.degree. C. for 1 h, heated to 85.degree. C. for 5 minutes and
treated for 20 minutes at 37.degree. C. with RNAseH.
[0463] 2 .mu.l of the RT reaction were used for the PCR
amplification of mouse resistin. The PCR was performed using
Platinium TAQ (Life Technologies) according to the manufacturer's
recommendation using primers PH19 (SEQ ID NO:260) and PH20 (SEQ ID
NO:261). Primer PH19 (SEQ ID NO:260) corresponds to positions 58-77
and primer PH20 (SEQ ID NO:261) to positions 454-435 of the mouse
Resistin sequence. The PCR mix was first denatured at 94.degree. C.
for 2 minutes and than 35 cycles were performed as follows: 30
seconds 94.degree. C., 30 seconds 56.degree. C. and 1 minute
72.degree. C., at the end the samples were left for 10 minutes at
72.degree. C. The PCR fragment was purified and subcloned by TA
cloning into the pGEMTeasy vector (Invitrogen) leading to
pGEMT-mRes. In order to add appropriate restriction sites a second
PCR was performed on pGEMT-mRes with the primers PH21 (SEQ ID
NO:262) and PH22 (SEQ ID NO. 263) primers using the same cycling
program as described above. The forward primer (PH21 (SEQ ID
NO:262)) contains a Bam HI site and nucleotides 81-102 of the mouse
Resistin sequence. The reverse primer (PH22 (SEQ ID NO:263))
contains an Xba I site and nucleotides 426-406 of the mouse
Resistin sequence. The indicated positions refer to the mouse
resistin sequence Gene Accession No. AF323080. The PCR product was
purified and digested with Bam HI and Xba I and subcloned into
pcmv-Fc*-C1 digested with Bam HI and Xba I leading to the construct
pcmv-mRes-Fc*.
[0464] The Resistin open reading frame was excised from
pcmv-Res-Fc* by Bam HI/Xba I digestion and cloned into pCep-Xa-Fc*
and pCep-EK-Fc* (see EXAMPLE 1, section B) digested with Bam HI and
Nhe I leading to the constructs pCep-mRes-Xa-Fc* and
pCep-mRes-EK-Fc* respectively.
B. Production, Purification and Cleavage of Resistin
[0465] pCep-mRes-Xa-Fc* and pCep-mRes-EK-Fc* constructs were then
used to transfect 293-EBNA cells for the production of recombinant
proteins as described in EXAMPLE 1, section B. The tissue culture
supernatants were purified as described in EXAMPLE 1, section C.
The purified proteins were then cleaved as described in EXAMPLE 1,
section D. The resulting recombinant proteins were termed
"resistin-C-Xa" or "Res-C-Xa" and "resistin-C-EK" or "Res-C-EK"
according to the vector used (see FIG. 2A and FIG. 2B, SEQ ID
NOS:429 and 430, respectively).
[0466] FIG. 2A and FIG. 2B (SEQ ID NOS:429 and 430, respectively)
show sequence of recombinant mouse Resistin proteins used for
expression and further coupling. Res-C-Xa (FIG. 2A, SEQ ID NO:429)
and Res-C-EK (FIG. 2B, SEQ ID NO:430) are shown as a translated DNA
sequences. The resistin signal sequence which is cleaved upon
protein secretion by the signal peptidase is shown in italic. The
amino acid sequences which result form signal peptidase and
specific protease (factor Xa or enterokinase) cleavage are shown
bold. The bold sequences correspond to the actual protein sequence
which was used for coupling, i.e. SEQ ID NO:280, SEQ ID NO:281, SEQ
ID NO:282 corresponds to an alternative resistin protein construct,
which can also be used for coupling to virus-like particles and
pili in accordance with the invention.
C. Coupling of resistin-C-Xa and resistin-C-EK to Q.beta. Capsid
Protein
[0467] A solution of 0.2 ml of 2 mg/ml Q.beta. capsid protein in 20
mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 5.6
.mu.l of a solution of 100 mM SMPH (Pierce) in DMSO at 25.degree.
C. on a rocking shaker. The reaction solution was subsequently
dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl,
pH 7.4 at 4.degree. C. 8 .mu.l of the dialyzed Q.beta. reaction
mixture was then reacted with 32 .mu.l of resistin-C-Xa solution
(resulting in a final concentration of resistin of 0.39 mg/ml) and
13 .mu.l of the Q.beta. reaction mixture was reacted with 27 .mu.l
resistin-C-EK solution (resulting in a final concentration of
resistin of 0.67 mg/ml) for four hours at 25.degree. C. on a
rocking shaker. Coupling products were analysed by SDS-PAGE (see
FIG. 2C). An additional band of 24 kDa is present in the coupling
reaction, but not in derivatized Q.beta. and resistin,
respectively. The size of 24 kDa corresponds to the expected size
of 24 kDa for the coupled product (14 kDa for Q.beta. plus 10 kDa
for resistin-C-Xa and resistin-C-EK, respectively).
[0468] FIG. 2C shows coupling results of resistin-C-Xa and
resistin-C-EK to Q{tilde over (.beta.)}Coupling products were
analysed on 16% SDS-PAGE gels under reducing conditions. Lane 1:
Molecular weight marker. Lane 2: resistin-C-EK before coupling.
Lane 3: resistin-C-EK-Q.beta. after coupling. Lane 4: Q.beta.
derivatized. Lane 5: resistin-C-Xa before coupling. Lane 6:
resistin-C-Xa-Q.beta. after coupling. Molecular weights of marker
proteins are given on the left margin. Coupled band is indicated by
the arrow.
D. Coupling of resistin-C-Xa and resistin-C-EK to fr Capsid
Protein
[0469] A solution of 0.2 ml of 2 mg/ml fr capsid protein in 20 mM
Hepes, 150 mM NaCl pH 7.4 is reacted for 30 minutes with 5.6 .mu.l
of a solution of 100 mM SMPH (Pierce) in DMSO at 25.degree. C. on a
rocking shaker. The reaction solution is subsequently dialyzed
twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.4
at 4.degree. C. 8 .mu.l of the dialyzed fr capsid protein reaction
mixture is then reacted with 32 .mu.l of resistin-C-Xa solution
(resulting in a final concentration of resistin of 0.39 mg/ml) and
13 .mu.l of the fr capsid protein reaction mixture is reacted with
27 .mu.l resistin-C-EK solution (resulting in a final concentration
of resistin of 0.67 mg/ml) for four hours at 25.degree. C. on a
rocking shaker. Coupling products are analysed by SDS-PAGE under
reducing conditions.
E. Coupling of resistin-C-Xa and resistin-C-EK to
HBcAg-Lys-2cys-mut
[0470] A solution of 0.2 ml of 2 mg/ml HBcAg-Lys-2cys-Mut in 20 mM
Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with 5.6 .mu.l
of a solution of 100 mM SMPH (Pierce) in DMSO at 25.degree. C. on a
rocking shaker. The reaction solution is subsequently dialyzed
twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl, pH 7.2
at 4.degree. C. 8 .mu.l of the dialyzed HBcAg-Lys-2cys-Mut reaction
mixture is then reacted with 32 .mu.l of resistin-C-Xa solution and
13 .mu.l of the HBcAg-Lys-2cys-Mut reaction mixture is reacted with
27 .mu.l resistin-C-EK solution for four hours at 25.degree. C. on
a rocking shaker. Coupling products are analysed by SDS-PAGE.
F. Coupling of resistin-C-Xa and resistin-C-EK to Pili
[0471] A solution of 400 .mu.l of 2.5 mg/ml Type-1 pili of E. coli
in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold
molar excess of cross-linker SMPH diluted from a stock solution in
DMSO (Pierce) at RT on a rocking shaker. The reaction mixture is
desalted on a PD-10 column (Amersham-Pharmacia Biotech). The
protein-containing fractions eluating from the column are pooled,
and 8 .mu.l of the desalted derivatized pili protein is reacted
with 32 .mu.l of resistin-C-Xa solution and 13 .mu.l of the
desalted derivatized pili protein is reacted with 27 .mu.l
resistin-C-EK solution for four hours at 25.degree. C. on a rocking
shaker. Coupling products are analysed by SDS-PAGE.
Example 3
A. Introduction of cys-Containing Linkers, Expression and
Purification of Mouse Lymphotoxin-.beta.
[0472] The extracellular part of mouse lymphotoxin-.beta.
(LT-.beta.) was recombinantly expressed with a CGG amino acid
linker at its N-terminus. The linker contained one cysteine for
coupling to VLP. A long (aa 49-306) and a short version (aa
126-306) of the protein were fused at their N-terminus to either
glutathione S-transferase (GST) or a histidine-myc tag for
purification. An enterokinase (EK) cleavage-site was inserted for
cleavage of the tag.
[0473] Construction of C-LT.beta..sub.49-306 and
C-LT.beta..sub.126-306.
[0474] Mouse LT.beta.49-306 was amplified by PCR with oligos
5'LT.beta. and 3'LT.beta. from a mouse spleen cDNA library inserted
into pFB-LIB. For the PCR reaction, 0.5 .mu.g of each primer and
200 ng of the template DNA was used in the 50 .mu.l reaction
mixture (1 unit of PFX Platinum polymerase, 0.3 mM dNTPs and 2 mM
MgSO.sub.4). The temperature cycles were as follows: 94.degree. C.
for 2 minutes, followed by 25 cycles of 94.degree. C. (15 seconds),
68.degree. C. (30 seconds), 68.degree. C. (1 minute) and followed
by 68.degree. C. for 10 minutes. The PCR product was phosphorylated
with T4 Kinase and ligated into pEntry1A (Life technologies) which
has been cut with EcoRV and has been dephosphorylated. The
resulting plasmid was named pEntry1A-LT.beta..sub.49-306.
[0475] A second PCR reaction was performed with oligos
5'LT.beta.long-NheI and 3'LT.beta.stop-NotI resp.
5'LT.beta.short-NheI and 3'LT.beta.stop-NotI using
pEntry1A-LT.beta.49-306 as a template. Oligos 5'LT.beta.long-NheI
and 5'LT.beta.short-NheI had an internal NheI site and contained
codons for a Cys-Gly-Gly linker and 3'LT.beta.stop-NotI had an
internal NotI site and contained a stop codon. For the second PCR
reaction, 0.5 .mu.g of each primer and 150 ng of the template DNA
was used in the 50 .mu.l reaction mixture (1 unit of PFX Platinum
polymerase, 0.3 mM dNTPs and 2 mM MgSO.sub.4). The temperature
cycles were as follows: 94.degree. C. for 2 minutes, followed by 5
cycles of 94.degree. C. (15 seconds), 50.degree. C. (30 seconds),
68.degree. C. (1 minute), followed by 20 cycles of 94.degree. C.
(15 seconds), 64.degree. C. (30 seconds), 68.degree. C. (1 minute)
and followed by 68.degree. C. for 10 minutes.
[0476] The PCR products were digested with NheI and NotI and
inserted into either pCEP-SP-GST-EK or pCEP-SP-his-myc-EK (Wuttke
et al. J. Biol. Chem. 276: 36839-48 (2001)). Resulting plasmids
were named pCEP-SP-GST-EK-C-LT.beta..sub.49-306 ,
pCEP-SP-GST-EK-C-LT.beta..sub.126-306,
pCEP-SP-his-myc-EK-C-LT.beta..sub.49-306,
pCEP-SP-his-myc-EK-C-LT.beta..sub.126-306, respectively. GST stands
for glutathione-S-transferase, EK for enterokinase, his for a
hexahistidine tag and myc for anti c-myc epitope. The C indicates
the CGG linker containing the additional cysteine.
[0477] All other steps were performed by standard molecular biology
protocols. TABLE-US-00006 Sequence of the oligonucleotides:
5'LT.beta.: (SEQ ID NO: 284) 5'-CTT GGT GCC GCA GGA TCA G-3'
3'LT.beta.: (SEQ ID NO: 285) 5'-CAG ATG GCT GTC ACC CCA C-3'
5'LT.beta.long-NheI: (SEQ ID NO: 286) 5'-GCC CGC TAG CCT GCG GTG
GTC AGG ATC AGG GAC GTC G-3' 5'LT.beta.short-NheI: (SEQ ID NO: 287)
5'-GCC CGC TAG CCT GCG GTG GTT CTC CAG CTG CGG ATT C-3'
3'LT.beta.stop-NotI (SEQ ID NO: 288) 5'-CAA TGA CTG CGG CCG CTT ACC
CCA CCA TCA CCG-3'
[0478] Expression and production of GST-EK-C-LT.beta..sub.49-306,
GST-EK-C-LT.beta..sub.126-306, his-myc-EK-C-LT.beta..sub.49-306 and
his-myc-EK-C-LT.beta..sub.126-306
[0479] The plasmids pCEP-SP-GST-EK-C-LT.beta..sub.49-306,
pCEP-SP-GST-EK-C-LT.beta. 126-306,
pCEP-SP-his-myc-EK-C-LT.beta..sub.49-306 and
pCEP-SP-his-myc-EK-C-LT.beta..sub.126-306 were transfected into
293-EBNA cells (Invitrogen) for protein production as described in
EXAMPLE 1. The resulting proteins were named
GST-EK-C-LT.beta..sub.49-306, GST-EK-C-LT.beta..sub.126-306,
his-myc-EK-C-LT.beta..sub.49-306 and
his-myc-EK-C-LT.beta..sub.126-306.
[0480] The protein sequences of the LT.beta. fusion proteins were
translated from the cDNA sequences: TABLE-US-00007
GST-EK-C-LT.beta..sub.49-306: SEQ ID NO: 289
GST-EK-C-LT.beta..sub.126-306: SEQ ID NO: 290
his-myc-EK-C-LT.beta..sub.49-306: SEQ ID NO: 291
his-myc-EK-C-LT.beta..sub.126-306: SEQ ID NO: 292
[0481] The fusion proteins were analysed on 12% SDS-PAGE gels under
reducing conditions. Gels were blotted onto nitrocellulose
membranes. Membranes were blocked, incubated with a monoclonal
mouse anti-myc antibody or with an anti-GST antibody. Blots were
subsequently incubated with horse radish peroxidase-conjugated goat
anti-mouse IgG or horse radish peroxidase-conjugated rabbit
anti-goat IgG. The results are shown in FIG. 3.
GST-EK-C-LT.beta..sub.49-306 and GST-EK-C-LT.beta..sub.126-306
could be detected with the anti-GST antibody at a molecular weight
of 62 kDa and 48 kDa, respectively.
his-myc-EK-C-LT.beta..sub.49-306 and
his-myc-EK-C-LT.beta..sub.126-306 could be detected with the
anti-myc antibody at 40-56 kDa and 33-39 kDa, respectively.
[0482] FIG. 3A and FIG. 3B show the result of the expression of
LT.beta. fusion proteins. LT.beta. fusion proteins were analysed on
12% SDS-PAGE gels under reducing conditions. Gels were blotted onto
nitrocellulose membranes. Membranes were blocked, incubated either
with a monoclonal mouse anti-myc antibody (dilution 1:2000) (FIG.
3A) or with an anti-GST antibody (dilution 1:2000) (FIG. 3B). Blots
were subsequently incubated with horse radish peroxidase-conjugated
goat anti-mouse IgG (dilutions 1:4000) (FIG. 3A) or horse radish
peroxidase-conjugated rabbit anti-goat IgG (dilutions 1:4000) (FIG.
3B).
A: Lane 1 and 2: his-myc-EK-C-LT.beta..sub.126-306. Lane 3 and 4:
his-myc-EK-C-LT.beta..sub.49-306.
B: Lane 1 and 2: GST-EK-C-LT.beta..sub.126-306. Lane 3 and 4:
GST-EK-C-LT.beta..sub.49-306. Molecular weights of marker proteins
are given on the left margin.
B. Purification of GST-EK-C-LT.beta..sub.49-306,
GST-EK-C-LT.beta..sub.126-306, his-myc-EK-C-LT.beta..sub.49-306 and
his-myc-EK-C-LT.beta..sub.126-306
[0483] GST-EK-C-LT.beta..sub.49-306 and
GST-EK-C-LT.beta..sub.126-306 are purified on glutathione-sepharose
column and his-myc-EK-C-LT.beta..sub.49-306 and
his-myc-EK-C-LT[[.cndot.]].beta..sub.126-306 are purified on Ni-NTA
sepharose column using standard purification protocols. The
purified proteins are cleaved with enterokinase and analysed on a
16% SDS-PAGE gel under reducing conditions
C. Coupling of C-LT.beta..sub.49-306 and C-LT.beta..sub.126-306 to
Q.beta. Capsid Protein
[0484] A solution of 120 .mu.M Q.beta. capsid protein in 20 mM
Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold
molar excess of SMPH (Pierce), diluted from a stock solution in
DMSO, at 25.degree. C. on a rocking shaker. The reaction solution
is subsequently dialyzed twice for 2 hours against 1 L of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed Q.beta.
reaction mixture is then reacted with the C-LT.beta..sub.49-306 and
C-LT.beta..sub.126-306 solution (end concentrations: 60 .mu.M
Q.beta., 60 .mu.M C-LT.beta..sub.49-306 and C-LT.beta..sub.126-306)
for four hours at 25.degree. C. on a rocking shaker. Coupling
products are analysed by SDS-PAGE.
D. Coupling of C-LT.beta..sub.49-06 and C-LT.beta..sub.126-306 to
fr Capsid Protein
[0485] A solution of 120 .mu.M fr capsid in 20 mM Hepes, 150 mM
NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess
of SMPH (Pierce), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed fr capsid protein
reaction mixture is then reacted with the C-LT.beta..sub.49-306 and
C-LT.beta..sub.126-306 solution (end concentrations: 60 .mu.M fr,
60 .mu.M C-LT.beta..sub.49-306 and C-LT.beta..sub.126-306) for four
hours at 25.degree. C. on a rocking shaker. Coupling products are
analysed by SDS-PAGE under reducing conditions.
E. Coupling of C-LT.beta..sub.49-306 and C-LT.beta..sub.126-306 to
HBcAg-Lys-2cys-Mut
[0486] A solution of 120 .mu.M HBcAg-Lys-2cys-Mut capsid in 20 mM
Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold
molar excess of SMPH (Pierce), diluted from a stock solution in
DMSO, at 25.degree. C. on a rocking shaker. The reaction solution
is subsequently dialyzed twice for 2 hours against 1 L of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed
HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the
C-LT.beta..sub.49-306 and C-LT.beta..sub.126-306 solution (end
concentrations: 60 .mu.M HBcAg-Lys-2cys-Mut, 60 .mu.M
C-LT.beta..sub.49-306 and C-LT.beta..sub.126-306) for four hours at
25.degree. C. on a rocking shaker. Coupling products are analysed
by SDS-PAGE.
F. Coupling of C-LT.beta..sub.49-306 and C-LT.beta..sub.126-306 to
Pili
[0487] A solution of 125 .mu.M Type-1 pili of E. coli in 20 mM
Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar
excess of cross-linker SMPH, diluted from a stock solution in DMSO
(Pierce), at RT on a rocking shaker. The reaction mixture is
desalted on a PD-10 column (Amersham-Pharmacia Biotech). The
protein-containing fractions eluting from the column are pooled,
and the desalted derivatized pili protein is reacted with the
C-LT.beta..sub.49-306 and C-LT.beta..sub.126-306 solution (end
concentrations: 60 .mu.M pili, 60 .mu.M C-LT.beta..sub.49-306 and
C-LT.beta..sub.126-306) for four hours at 25.degree. C. on a
rocking shaker. Coupling products are analysed by SDS-PAGE under
reducing conditions.
Example 4
[0488] A. Introduction of Cys-Containing Linkers, Expression,
Purification and Coupling of Rat Macrophage Migration Inhibitory
Factor MIF to Q.beta.
[0489] Rat macrophage migration inhibitory factor (rMIF) was
recombinantly expressed with three different amino acid linkers C1,
C2 and C3 fused at its C-terminus. Each of the linker contained one
cysteine for coupling to VLP.
[0490] Construction of rMIF-C1, rMIF-C2, and rMIF-C3.
[0491] The MCS of pET22b(+) (Novagen, Inc.) was changed to
GTTTAACTTT AAGAAGGAGATATACATATGGATCCGGCTAGCGCTCGAGGGTTTAAACGG
CGGCCGCATGCACC (SEQ ID NO:363) by replacing the original sequence
from the NdeI site to XhoI site with annealed oligos primerMCS-1F
and primerMCS-1R (annealing in 15 mM Tris HCl pH 8 buffer). The
resulting plasmid was termed pMod00, which had NdeI, BamHI, NheI,
XhoI, PmeI and NotI restriction sites in its MCS. The annealed pair
of oligos Bamhis6-EK-Nhe-F and Bamhis6-EKNhe-R and the annealed
pair of oligo1F-C-glycine-linker and oligo1R-C-glycine-linker were
together ligated into BamHI-NotI digested pMod00 plasmid to get
pModEC1, which had an N terminal hexahistidine tag, an enterokinase
cleavage site and a C-terminal amino acid glycine linker containing
one cysteine residue. The annealed pair of oligos Bamhis6-EK-Nhe-F
and Bamhi6-EKNhe R together with the annealed pair of
oligo1F-C-gamma1-linker and oligo1R-C-gamma1-linker were ligated
into BamHI-NotI digested pMod00 plasmid to get pModEC2, which had
an N terminal hexahistidine tag, an enterokinase cleavage site and
a C-terminal 1 linker, derived from the hinge region of human
immunoglobulin .gamma.1, containing one cysteine residue. The
annealed pair of oligos Bamhis6-EK-Nhe-F and Bamhis6-EK-Nhe-R, the
annealed pair of oligo1FA-C-gamma3-linker and
oligo1RA-C-gamma3-linker, and the annealed pair of
oligo1FB-C-gamma3-linker and oligo1RB-C-gamma3-linker were together
ligated into BamHI-NotI digested pMod00 to get pModEC3, which had
an N terminal hexahistidine tag, an enterokinase cleavage site and
a C terminal .gamma.3 linker, containing one cysteine residue,
derived from the hinge region of mouse immunoglobulin
[[.cndot.]].gamma.3.
[0492] pBS-rMIF, which contains the rat MIF cDNA, was amplified by
PCR with oligos rMIF-F and rMIF-Xho-R. rMIF-F had an internal NdeI
site and rMIF-Xho-R had an internal XhoI site. The PCR product was
digested with NdeI and XhoI and ligated into pModEC1, pModEC2 and
pModEC3 digested with the same enzymes. Resulting plasmids were
named pMod-rMIF-C1, pMod-rMIF-C2 and pMod-rMIF-C3,
respectively.
[0493] For the PCR reaction, 15 pmol of each oligo and 1 ng of the
template DNA was used in the 50 .mu.l reaction mixture (2 units of
PFX polymerase, 0.3 mM dNTPs and 2 mM MgSO4). The temperature
cycles were as follows: 94.degree. C. for 2 minutes, followed by 30
cycles of 94.degree. C. (30 seconds), 60.degree. C. (30 seconds),
68.degree. C. (30 seconds) and followed by 68.degree. C. for 2
minutes.
[0494] All other steps were performed by standard molecular biology
protocols. TABLE-US-00008 Sequence of the oligonucleotides:
primerMCS-1F: (SEQ ID NO: 293) 5'-TAT GGA TCC GGC TAG CGC TCG AGG
GTT TAA ACG GCG GCC GCA T-3' primerMCS-1R: (SEQ ID NO:294) 5'-TCG
AAT GCG GCC GCC GTT TAA ACC CTC GAG CGC TAG CCG GAT CCA-3'
Bamhis6-EK-Nhe-F: (SEQ ID NO: 295) 5'-GAT CCA CAC CAC CAC CAC CAC
CAC GGT TCT GGT GAC GAC GAT GAC AAA GCG CTA GCC C-3'
Bamhis6-EK-Nhe-R: (SEQ ID NO: 296) 5'-TCG AGG GCT AGC GCT TTG TCA
TCG TCG TCA CCA GAA CCG TGG TGG TGG TGG TGG TGT G-3'
oligo1F-C-glycine-linker: (SEQ ID NO: 297) 5'-TCG AGG GTG GTG GTG
GTG GTT GCG GTT AAT AAG TTT AAA CGC-3' oligo1R-C-glycine-linker:
(SEQ ID NO: 298) 5'-GGC CGC GTT TAA ACT TAT TAA CCG CAA CCA CCA CCA
CCA CCC-3' oligo1F-C-gamma1-linker: (SEQ ID NO: 299) 5'-TCG AGG ATA
AAA CCC ACA CCT CTC CGC CGT GTG GTT AAT AAG TTT AAA CGC-3'
oligo1R-C-gamma1-linker: (SEQ ID NO: 300) 5'-GGC CGC GTT TAA ACT
TAT TAA CCA CAC GGC GGA GAG GTG TGG GTT TTA TCC-3'
oligo1FA-C-gamma3-linker: (SEQ ID NO: 301) 5'-TCG AGC CGA AAC CGT
CTA CCC CGC CGG GTT CTT CTG-3' oligo1RA-C-gamma3-linker: (SEQ ID
NO: 302) 5'-CAC CAC CAG AAG AAC CCG GCG GGG TAG ACG GTT TCG GC-3'
oligo2FB-C-gamma3-linker: (SEQ ID NO: 303) 5'-GTG GTG CTC CGG GTG
GTT GCG GTT AAT AAG TTT AAA CGC-3' oligo2RB-C-gamma3-linker: (SEQ
ID NO: 304) 5'-GGC CGC GTT TAA ACT TAT TAA CCG CAA CCA CCC GGA G-3'
rMIF-F: (SEQ ID NO: 305) 5'-GGA ATT CCA TAT GCC TAT GTT CAT CGT GAA
CAC-3' rMIF-Xho-R: (SEQ ID NO: 306) 5'-CCC GCT CGA GAG CGA AGG TGG
AAC CGT TC-3'
Expression and Purification of rMIF-Cs
[0495] Competent E. coli BL21 (DE3) cells were transformed with
plasmids pMod-rMIF-C1, pMod-rMIF-C2 and pMod-rMIF-C3. Single
colonies from ampicillin (Amp)-containing agar plates were expanded
in liquid culture (SB with 150 mM MOPS, pH 7.0, 200 ug/ml Amp, 0.5%
glucose) and incubated at 30.degree. C. with 220 rpm shaking
overnight. 1 l of SB (150 mM MOPS, pH 7.0, 200 ug/ml Amp) was then
inoculated 1:50 v/v with the overnight culture and grown to
OD600=2.5 at 30.degree. C. Expression was induced with 2 mM IPTG.
Cells were harvested after overnight culture and centrifuged at
6000 rpm. Cell pellet was suspended in lysis buffer (10 mM
Na.sub.2HPO.sub.4, 30 mM NaCl, 10 mM EDTA and 0.25% Tween-20) with
0.8 mg/ml lysozyme, sonicated and treated with benzonase. 2 ml of
the lysate was then run through a 20 ml Q XL- and a 20 ml SP
XL-column. The proteins rMIF-C1, rMIF-C2 and rMIF-C3 were in the
flow through.
The protein sequences of the rMIF-Cs were translated from the cDNA
sequences.
rMIF-C1: SEQ ID NO:307
rMIF-C2: SEQ ID NO:308
rMIF-C3: SEQ ID NO:309
[0496] Coupling of rMIF-C1 to Q.beta. Capsid Protein
[0497] A solution of 1.48 ml of 6 mg/ml Q.beta. capsid protein in
20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with
14.8 .mu.l of a SMPH (Pierce) (from a 100 mM stock solution
dissolved in DMSO) at 25.degree. C. The reaction solution was
subsequently dialyzed twice for 3 hours against 2 l of 20 mM Hepes,
150 mM NaCl, pH 7.0 at 4.degree. C. A solution of 1.3 ml of 3.6
mg/ml rMIF-C1 protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was
reacted for 1 hour with 9.6 .mu.l of a TCEP (Pierce) (from a 36 mM
stock solution dissolved in H2O) at 25.degree. C. 130 .mu.l of the
derivatized and dialyzed Q.beta. was then reacted with 129 .mu.l of
reduced rMIF-C1 in 241 .mu.l of 20 mM Hepes, 150 mM NaCl, pH 7.0
over night at 25.degree. C.
[0498] Coupling of rMIF-C2 to Q.beta. Capsid Protein
[0499] A solution of 0.9 ml of 5.5 mg/ml Q.beta. capsid protein in
20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 9
.mu.l of a SMPH (Pierce) (from a 100 mM stock solution dissolved in
DMSO) at 25.degree. C. The reaction solution was subsequently
dialyzed twice for 2 hours against 2 l of 20 mM Hepes, 150 mM NaCl,
pH 7.2 at 4.degree. C. A solution of 850 .mu.l of 5.80 mg/ml
rMIF-C2 protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for
1 hour with 8.5 .mu.l of a TCEP (Pierce) (from a 36 mM stock
solution dissolved in H2O) at RT. 80 .mu.l of the derivatized and
dialyzed Q.beta. was then reacted with 85 .mu.l of reduced rMIF-C2
in 335 .mu.l of 20 mM Hepes, 150 mM NaCl, pH 7.2 over night at
25.degree. C.
[0500] Coupling of rMIF-C3 to Q.beta. Capsid Protein
[0501] A solution of 1.48 ml of 6 mg/ml Q.beta. capsid protein in
20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with
14.8 .mu.l of a SMPH (Pierce) (from a 100 mM stock solution
dissolved in DMSO) at 25.degree. C. The reaction solution was
subsequently dialyzed twice for 3 hours against 2 l of 20 mM Hepes,
150 mM NaCl, pH 7.0 at 4.degree. C. A solution of 720 .mu.l of 5.98
mg/ml rMIF-C3 protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was
reacted for 1 hour with 9.5 .mu.l of a TCEP (Pierce) (from a 36 mM
stock solution dissolved in H2O) at 25.degree. C. 130 .mu.l of the
derivatized and dialyzed Q.beta. was then reacted with 80 .mu.l of
reduced rMIF-C3 in 290 .mu.l of 20 mM Hepes, 150 mM NaCl, pH 7.0
over night at 25.degree. C.
[0502] All three coupled products were analysed on 16% SDS-PAGE
gels under reducing conditions. Gels were either stained with
Coomassie Brilliant Blue or blotted onto nitrocellulose membranes.
Membranes were blocked, incubated with a polyclonal rabbit
anti-Q.beta. antiserum (dilution 1:2000) or a purified rabbit
anti-MIF antibody (Torrey Pines Biolabs, Inc.) (dilution 1:2000).
Blots were subsequently incubated with horse radish
peroxidase-conjugated goat anti-rabbit IgG (dilutions 1:2000). The
results are shown in FIG. 4A and FIG. 4B. Coupled products could be
detected in the Coomassie-stained gels (FIG. 4A) and by both
anti-Q.beta. antiserum and the anti-MIF antibody (FIG. 4B) clearly
demonstrated the covalent coupling of all three rMIF variants to
Q.beta. capsid protein.
[0503] FIG. 4A shows the coupling of the MIF constructs to Q.beta.
coupling products were analysed on 16% SDS-PAGE gels under reducing
conditions. The gel was stained with Coomassie Brilliant Blue.
Molecular weights of marker proteins are given on the left
margin.
[0504] FIG. 4B shows the coupling of MIF-C1 to Q.beta. coupling
products were analysed on 16% SDS-PAGE gels under reducing
conditions. Lane 1: MIF-C1 before coupling Lane 2: derivatized
Q.beta. before coupling. Lane 3-5: Q.beta.-MIF-C1. Lanes 1-3 were
stained with Coomassie Brilliant Blue. Lanes 4 and 5 represent
western blots of the coupling reaction developed with an anti-MIF
antiserum and an anti-Q.beta. antiserum, respectively. Molecular
weights of marker proteins are given on the left margin.
[0505] B. Immunization of Mice with MIF-C1 Coupled to Q.beta.
Capsid Protein
[0506] Female Balb/c mice were vaccinated with MIF-C1 coupled to
Q.beta. capsid protein without the addition of adjuvants. 25 .mu.g
of total protein of each sample was diluted in PBS to 200 ul and
injected subcutaneously (100 ml on two ventral sides) on day 0 and
day 14. Mice were bled retroorbitally on day 31 and their serum was
analyzed using a MIF-specific ELISA.
[0507] C. ELISA
[0508] ELISA plates were coated with MIF-C1 at a concentration of 5
.mu.g/ml. The plates were blocked and then incubated with serially
diluted mouse sera. Bound antibodies were detected with
enzymatically labeled anti-mouse IgG antibody. As a control,
preimmune serum of the same mice was also tested. The results are
shown in FIG. 4C. There was a clear reactivity of the mouse sera
raised against MIF-C1 coupled to Q.beta.capsid protein, while the
pre-immune sera did not react with MIF (FIG. 4C and data not
shown). From the dilution series with the antisera against MIF-C1
coupled to Q.beta. capsid protein, a half-maximal titer was reached
at 1:84000.
[0509] Shown on FIG. 4C are the ELISA signals obtained with the
sera of the mice vaccinated with MIF-C1 coupled to Q.beta. capsid
protein. Female Balb/c mice were vaccinated subcutaneously with 25
.mu.g of vaccine in PBS on day 0 and day 14. Serum IgG against
MIF-C1 were measured on day 31. As a control, pre-immune sera from
one of the mice were analyzed. Results for indicated serum
dilutions are shown as optical density at 450 nm. All vaccinated
mice made high IgG antibody titers. No MIF-specific antibodies were
detected in control (pre-immune mouse).
Example 5
Coupling of rMIF-C1 to fr Capsid Protein and HBcAg-lys-2cys-Mut
Capsid Protein
Coupling of rMIF-C1 to fr Capsid Protein
[0510] A solution of 100 .mu.l of 3.1 mg/ml fr capsid protein in 20
mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 3
.mu.l of a 100 mM stock solution of SMPH (Pierce) dissolved in DMSO
at 25.degree. C. In a parallel reaction, fr capsid protein was
first alkylated using iodoacetamid and then reacted with SMPH using
the same reaction conditions described above. The reaction
solutions were subsequently dialyzed twice for 2 hours against 2 l
of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. A solution of
80 .mu.l of 5.7 mg/ml rMIF-C1 protein in 20 mM Hepes, 150 mM NaCl
pH 7.2, was reacted for 1 hour with 1 .mu.l of a 36 mM TCEP
(Pierce) stock solution dissolved in H.sub.2O, at 25.degree. C. 50
.mu.l of the derivatized and dialyzed fr capsid protein and 50
.mu.l of the derivatized, alkylated and dialyzed fr capsid protein
were then reacted each with 17 .mu.l of reduced rMIF-C1 for two
hours at 25.degree. C.
[0511] Coupling products were analysed on 16% SDS-PAGE gels (FIG.
5). An additional band of the expected size of 27 kDa (rMIF-C1:
apparent MW 13 kDa, fr capsid protein apparent MW 14 kDa) and 29
kDa (rMIF-C1: apparent MW 13 kDa, HBcAg-lys-2cys-Mut: apparent MW
15 kDa) can be detected in the coupling reaction but not in the fr
capsid protein and rMIF-C1 solutions, clearly demonstrating
coupling.
Coupling of rMIF-C1 to Hepatitis HBcAg-lys-2cys-Mut Capsid
Protein:
[0512] A solution of 100 .mu.l of 1.2 mg/ml HBcAg-lys-2cys-Mut
capsid protein in 20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for
30 minutes with 1.4 .mu.l of a SMPH (Pierce) (from a 100 mM stock
solution dissolved in DMSO) at 25.degree. C. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 l of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. A solution of 80 .mu.l
of 5.7 mg/ml rMIF-C1 protein in 20 mM Hepes, 150 mM NaCl, pH 7.2
was reacted for 1 hour with 1 .mu.l of a TCEP (Pierce) (from a 36
mM stock solution dissolved in H.sub.2O) at 25.degree. C. 60 .mu.l
of the derivatized and dialyzed HBcAg-lys-2cys-Mut capsid protein
was then reacted with 20 .mu.l of reduced rMIF-C1 for two hours at
25.degree. C.
[0513] Coupling products were analysed on 16% SDS-PAGE gels (FIG.
5) under reducing conditions. An additional band of the expected
size of about 28 kDa (rMIF-C1: apparent MW 13 kDa,
HBcAg-lys-2cys-Mut: apparent MW 15 kDa) can be detected in the
coupling reaction but not in derivatized HBcAg-lys-2cys-Mut or
rMIF-C1, clearly demonstrating coupling.
[0514] The samples loaded on the gel of FIG. 5 were the
following:
[0515] Lane 1: Molecular weight marker. Lane 2: rMIF-C1 before
coupling. Lane 3: rMIF-C1-fr capsid protein after coupling. Lane 4:
derivatized fr capsid protein. Lane 5: rMIF-C1-fr after coupling to
alkylated fr capsid protein. Lane 6: alkylated and derivatized fr
capsid protein. Lane 7: rMIF-HBcAg-lys-2cys-Mut after coupling.
Lane 8 and 9: derivatized HBcAg-lys-2cys-Mut. The gel was stained
with Coomassie Brilliant Blue. Molecular weights of marker proteins
are given on the left margin.
Example 6
A. Introduction of Amino Acid Linkers Containing a Cysteine
Residue, Expression and Purification of Mouse RANKL
[0516] A fragment of the receptor activator of nuclear factor kappa
b ligand (RANKL), which has also been termed osteoclast
differentiation factor, osteoprotegerin ligand and tumor necrosis
factor-related activation-induced cytokine was recombinantly
expressed with an N-terminal linker containing one cysteine for
coupling to VLP.
Construction of Expression Plasmid
[0517] The C-terminal coding region of the RANKL gene was amplified
by PCR with oligos RANKL-UP and RANKL-DOWN. RANKL-UP had an
internal ApaI site and RANKL-DOWN had an internal XhoI site. The
PCR product was digested with ApaI and XhoI and ligated into
pGEX-6p1 (Amersham Pharmacia). The resulting plasmid was named
pGEX-RANKL. All steps were performed by standard molecular biology
protocols and the sequence was verified. The plasmid pGEX-RANKL
codes for a fusion protein of a glutathione
S-transferase-Prescission cleavage site-cysteine-containing amino
acid linker-RANKL (GST-PS-C-RANKL). The cysteine-containing amino
acid linker had the sequence GCGGG. The construct also contains a
hexa-histidine tag between the cysteine containing amino acid
linker and the RANKL sequence. TABLE-US-00009 Oligos: RANKL-UP:
5'CTGCCAGGGGCCCGGGTGCGGCGGTGGCCATCATCACCACCATCACCAG (SEQ ID NO:
316) CGCTTCTCAGGAG-3' RANKL-DOWN:
5'-CCGCTCGAGTTAGTCTATGTCCTGAACTTTGAAAG-3' (SEQ ID NO: 317)
[0518] Protein of GST-PS-C-RANKL (SEQ ID NO:318) and cDNA sequence
of GST-PS-C-RANKL (SEQ ID NO:319) TABLE-US-00010 1 M S P I L G Y W
K I K G L V Q P T R L L L E Y L E 1
atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttcttttggaatatctt-
gaa 26 E K Y E E H L Y E R D E G D K W R N K K F E L G L 76
gaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaatggcgaaacaaaaagtttgaattggg-
tttg 51 E F P N L P Y Y I D G D V K L T Q S M A I I R Y I 151
gagtttcccaatcttccttattatattgatggtgatgttaaattaacacagtctatggccatcatacgtt-
atata 76 A D K H N M L G G C P K E R A E I S M L E G A V L 226
gctgacaagcacaacatgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcgg-
ttttg 101 D I R Y G V S R I A Y S K D F E T L K V D F L S K 301
gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagttgattttctta-
gcaag 126 L P E M L K M F E D R L C H K T Y L N G D H V T H 376
ctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaaacatatttaaatggtgatcatgtaa-
cccat 151 P D F M L Y D A L D V V L Y M D P M C L D A F P K 451
cctgacttcatgttgtatgacgctcttgatgttgttttatacatggacccaatgtgcctggatgcgttcc-
caaaa 176 L V C F K K R I E A I P Q I D K Y L K S S K Y I A 526
ttagtttgttttaaaaaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtata-
tagca 201 W P L Q G W Q A T F G G G D H P P K S D L E V L F 601
tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggatctggaagttc-
tgttc 226 Q G P G C G G G H H H H H H Q R F S G A P A M M E 676
cagGGGCCCGGGTGCGGCGGTGGCCATCATCACCACCATCACCAGC
GCTTCTCAGGAGCTCCAGCTATGATGGAA 251 G S W L D V A Q R G K P E A Q P F
A H L T I N A A 751 GGCTCATGGTTGGATGTGGCCCAGCGAGGCAAGCCTGAGGCCCAG
CCATTTGCACACCTCACCATCAATGCTGCC 276 S I P S G S H K V T L S S W Y H
D R G W A K I S N 826
AGCATCCCATCGGGTTCCCATAAAGTCACTCTGTCCTCTTGGTACC
ACGATCGAGGCTGGGCCAAGATCTCTAAC 301 M T L S N G K L R V N Q D G F Y Y
L Y A N I C F R 901 ATGACGTTAAGCAACGGAAAACTAAGGGTTAACCAAGATGGCTTC
TATTACCTGTACGCCAACATTTGCTTTCGG 326 H H E T S G S V P T D Y L Q L M
V Y V V K T S I K 976
CATCATGAAACATCGGGAAGCGTACCTACAGACTATCTTCAGCTGA
TGGTGTATGTCGTTAAAACCAGCATCAAA 351 I P S S H N L M K G G S T K N W S
G N S E F H F Y 1051 ATCCCAAGTTCTCATAACCTGATGAAAGGAGGGAGCACGAAAAAC
TGGTCGGGCAATTCTGAATTCCACTTTTAT 376 S I N V G G F F K L R A G E E I
S I Q V S N P S L 1126
TCCATAAATGTTGGGGGATTTTTCAAGCTCCGAGCTGGTGAAGAA
ATTAGCATTCAGGTGTCCAACCCTTCCCTG 401 L D P D Q D A T Y F G A F K V Q
D I D * 1201 CTGGATCCGGATCAAGATGCGACGTACTTTGGGGCTTTCAAAGTTC
AGGACATAGACTAACTCGAGCGG
Expression and Purification of C-RANKL
[0519] Competent E. coli BL21 (DE3) Gold pLys cells were
transformed with the plasmid pGEX-RANKL. Single colonies from
kanamycin and chloramphenicol-containing agar plates were expanded
in liquid culture (LB medium, 30 .mu.g/ml kanamycin, 50 .mu.g/ml
chloramphenicol) and incubated at 30.degree. C. with 220 rpm
shaking overnight. 1 l of LB (with 30 ug/ml kanamycin) was then
inoculated 1:100 v/v with the overnight culture and grown to
OD600=1 at 24.degree. C. Expression was induced with 0.4 mM IPTG.
Cells were harvested after 16 h and centrifuged at 5000 rpm. Cell
pellet was suspended in lysis buffer (50 mM Tris-HCl, pH=8; 25%
sucrose; 1 mM EDTA, 1% NaN.sub.3; 10 mM DTT; 5 mM MgCl.sub.2; 1
mg/ml Lysozyme; 0.4 u/ml DNAse) for 30 min. Then 2.5 volumes of
buffer A (50 mM Tris-HCl, pH=8.0; 1% Triton X100; 100 mM NaCl; 0,1%
NaN.sub.3; 10 mM DTT; 1 mM PMSF) were added and incubated at
37.degree. C. for 15 min. The cells were sonicated and pelleted at
9000 rpm for 15 min. The supernatant was immediately used for
GST-affinity chromatography.
[0520] A column GST-Trap FF of 5 ml (Amersham Pharmacia) was
equilibrated in PBS, pH 7.3 (140 mM NaCl, 2.7 mM KCl, 10 mM
Na.sub.2HPO.sub.4, 1.8 mM KH.sub.2PO.sub.4). The supernatant was
loaded on the 5 ml GST-Trap FF column and subsequently the column
was rinsed with 5 column volumes of PBS. The protein GST-PS-C-RANKL
was eluted with 50 mM Tris-HCl, pH=8.0 containing GSH 10 mM.
[0521] The purified GST-PS-C-RANKL protein was digested using the
protease PreScission (Amersham Pharmacia). The digestion was
performed at 37.degree. C. for 1 hour using a molar ratio of 500/1
of GST-PS-C-RANKL to PreScission.
[0522] Furthermore, the reaction of protease digestion was buffer
exchanged using a HiPrep 26/10 desalting column (Amersham
Pharmacia), the fractions containing the proteins were pooled and
immediately used for another step of GST affinity chromatography
using the same conditions reported before. Purification of C-RANKL
was analysed on a SDS-PAGE gel under reducing conditions, shown in
FIG. 6. Molecular weights of marker proteins are given on the left
margin of the gel in the figure. The gel was stained with Coomassie
Brilliant Blue. The cleaved C-RANKL is present in the flow-through
(unbound fraction) while the uncleaved GST-PS-C-RANKL, the cleaved
GST-PS and the PreScission remain bound to the column. C-RANKL
protein of the expected size of 22 kDa was obtained in high
purity.
[0523] The samples loaded on the gel of FIG. 6 were the
following:
[0524] Lane 1: Low molecular weight marker. Lanes 2 and 3: the
supernatant of the cell lysates of the BL21/DE3 cells transformed
with the empty vector pGEX6p1 and pGEX-RANKL respectively, after
sixteen hours of induction with IPTG 0.4 mM. Lane 4: the purified
GST-PS-C-RANKL protein after GST-Trap FF column. Lane 5: the
GST-Trap FF column unbound fraction. Lane 6: the purified
GST-PS-C-RANKL protein after the cleavage with the PreScission
protease. Lane 7: the unbound fraction of the GST-Trap FF column
loaded with the GST-RANKL digestion, which contains the purified
C-RANKL. Lane 8: the bound fraction of the GST-Trap FF column
loaded with the GST-PS-C-RANKL digestion and eluted with GSH.
B. Coupling of C-RANKL to Q.beta. Capsid Protein
[0525] A solution of 120 .mu.M Q.beta. capsid in 20 mM Hepes, 150
mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar
excess of SMPH (Pierce), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed Q.beta. reaction
mixture is then reacted with the C-RANKL solution (end
concentrations: 60 .mu.M Q.beta., 60 .mu.M C-RANKL) for four hours
at 25.degree. C. on a rocking shaker. Coupling products are
analysed by SDS-PAGE.
C. Coupling of C-RANKL to fr Capsid Protein
[0526] A solution of 120 .mu.M fr capsid in 20 mM Hepes, 150 mM
NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar excess
of SMPH (Pierce), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed fr capsid protein
reaction mixture is then reacted with the C-RANKL solution (end
concentrations: 60 .mu.M fr capsid protein, 60 .mu.M C-RANKL) for
four hours at 25.degree. C. on a rocking shaker. Coupling products
are analysed by SDS-PAGE.
D. Coupling of C-RANKL to HBcAg-Lys-2cys-Mut
[0527] A solution of 120 .mu.M HBcAg-Lys-2cys-Mut capsid in 20 mM
Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold
molar excess of SMPH (Pierce), diluted from a stock solution in
DMSO, at 25.degree. C. on a rocking shaker. The reaction solution
is subsequently dialyzed twice for 2 hours against 1 L of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed
HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the
C-RANKL solution (end concentrations: 60 .mu.M HBcAg-Lys-2cys-Mut,
60 .mu.M C-RANKL) for four hours at 25.degree. C. on a rocking
shaker. Coupling products are analysed by SDS-PAGE.
E. Coupling of C-RANKL to Pili
[0528] A solution of 125 .mu.M Type-1 pili of E. coli in 20 mM
Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar
excess of cross-linker SMPH, diluted from a stock solution in DMSO,
at RT on a rocking shaker. The reaction mixture is desalted on a
PD-10 column (Amersham-Pharmacia Biotech). The protein-containing
fractions eluating from the column are pooled, and the desalted
derivatized pili protein is reacted with the C-RANKL solution (end
concentrations: 60 .mu.M pili, 60 .mu.M C-RANKL) for four hours at
25.degree. C. on a rocking shaker. Coupling products are analysed
by SDS-PAGE.
Example 7
A. Introduction of Amino Acid Linker Containing a Cysteine Residue,
Expression and Purification of a Truncated Form of the Mouse Prion
Protein
[0529] A truncated form (aa 121-230) of the mouse prion protein
(termed mPrPt) was recombinantly expressed with a GGGGCG (SEQ ID
NO:413) amino acid linker fused at its C-terminus for coupling to
VLPs and Pili. The protein was fused to the N-terminus of a human
Fc-fragment for purification. An enterokinase (EK) cleavage-site
was introduced behind the EK cleavage site to cleave the Fc-part of
the fusion protein after purification.
[0530] Construction of mPrPt-EK-Fc*.
[0531] Mouse PrPt was amplified by PCR with the primer 5'PrP-BamHI
and 3'PrP-NheI using the plasmid pBPCMVPrP-Fc as a template.
pBPCMVPrP-Fc contained the wild-type sequence of the mouse prion
protein. 5'PrP-BamHI had an internal BamHI site and contained an
ATG and 3'PrP-NheI had an internal NheI site.
[0532] For the PCR reaction, 0.5 .mu.g of each primer and 200 ng of
the template DNA was used in the 50 .mu.l reaction mixture (1 unit
of PFX Platinum polymerase, 0.3 mM dNTPs and 2 mM MgSO4). The
temperature cycles were as follows: 94.degree. C. for 2 minutes,
followed by 5 cycles of 94.degree. C. (15 seconds), 50.degree. C.
(30 seconds), 68.degree. C. (45 seconds), followed by 20 cycles of
94.degree. C. (15 seconds), 64.degree. C. (30 seconds), 68.degree.
C. (45 seconds) and followed by 68.degree. C. for 10 minutes.
[0533] The PCR product was digested with BamHI and NheI and
inserted into pCEP-SP-EK-Fc* containing the GGGGCG (SEQ ID NO:413)
linker sequence at the 5'end of the EK cleavage sequence. The
resulting plasmid was named pCEP-SP-mPrPt-EK-Fc*.
[0534] All other steps were performed by standard molecular biology
protocols. TABLE-US-00011 Oligos: Primer 5'PrP-BamHI 5'-CGG GAT CCC
ACC ATG GTG GGG GGC (SEQ ID NO: 321) CTT GG-3' Primer 3'PrP-NheI
5'-CTA GCT AGC CTG GAT CTT CTC (SEQ ID NO: 322) CCG-3'
Expression and Purification of mPrP.sub.t-EK-Fc*
[0535] Plasmid pCEP-SP-mPrP.sub.t-EK-Fc* was transfected into
293-EBNA cells (Invitrogen) and purified on a Protein A-sepharose
column as described in EXAMPLE 1.
[0536] The protein sequence of the mPrPt-EK-Fc* is identified in
SEQ ID NO:323. mPrPt after cleavage has the sequence as identified
in SEQ ID NO:324 with the GGGGCG (SEQ ID NO:413) linker at its
C-terminus.
[0537] The purified fusion protein mPrPt-EK-Fc* was cleaved with
enterokinase and analysed on a 16% SDS-PAGE gel under reducing
conditions before and after enterokinase cleavage. The gel was
stained with Coomassie Brilliant Blue. The result is shown in FIG.
7. Molecular weights of marker proteins are given on the left
margin of the gel in the figure. The mPrPt-EK-Fc* fusion protein
could be detected as a 50 kDa band. The cleaved mPrPt protein
containing the GGGGCG (SEQ ID NO:413) amino acid linker fused to
its C-terminus could be detected as a broad band between 18 and 25
kDa. The identity of mPrPt was confirmed by western blotting (data
not shown). Thus, mPrPt with a C-terminal amino acid linker
containing a cysteine residue, could be expressed and purified to
be used for coupling to VLPs and Pili.
[0538] The samples loaded on the gel of FIG. 7 were the
following.
Lane 1: Molecular weight marker. Lane 2: mPrP.sub.t-EK-Fc* before
cleavage. Lane 3: mPrP.sub.t after cleavage.
B. Coupling of mPrP.sub.t to Q.beta. Capsid
[0539] A solution of 120 .mu.M Q.beta. capsid in 20 mM Hepes, 150
mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar
excess of SMPH (Pierce), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed Q.beta. reaction
mixture is then reacted with the mPrP.sub.t solution (end
concentrations: 60 .mu.M Q.beta., 60 .mu.M mPrP.sub.t) for four
hours at 25.degree. C. on a rocking shaker. Coupling products are
analysed by SDS-PAGE.
C. Coupling of mPrP.sub.t to fr Capsid Protein
[0540] A solution of 120 .mu.M fr capsid protein in 20 mM Hepes,
150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar
excess of SMPH (Pierce), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed fr reaction
mixture is then reacted with the mPrP.sub.t solution (end
concentrations: 60 .mu.M fr, 60 .mu.M mPrP.sub.t) for four hours at
25.degree. C. on a rocking shaker. Coupling products are analysed
by SDS-PAGE.
D. Coupling of mPrP.sub.t to HBcAg-Lys-2cys-Mut
[0541] A solution of 120 .mu.M HBcAg-Lys-2cys-Mut capsid in 20 mM
Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold
molar excess of SMPH (Pierce), diluted from a stock solution in
DMSO, at 25.degree. C. on a rocking shaker. The reaction solution
is subsequently dialyzed twice for 2 hours against 1 L of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed
HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the
mPrP.sub.t solution (end concentrations: 60 .mu.M
HBcAg-Lys-2cys-Mut, 60 .mu.M mPrP.sub.t) for four hours at
25.degree. C. on a rocking shaker. Coupling products are analysed
by SDS-PAGE.
E. Coupling of mPrP.sub.t to Pili
[0542] A solution of 125 .mu.M Type-1 pili of E. coli in 20 mM
Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar
excess of cross-linker SMPH (Pierce), diluted from a stock solution
in DMSO, at RT on a rocking shaker. The reaction mixture is
desalted on a PD-10 column (Amersham-Pharmacia Biotech). The
protein-containing fractions eluating from the column are pooled,
and the desalted derivatized pili protein is reacted with the
mPrP.sub.t solution (end concentrations: 60 .mu.M pili, 60 .mu.M
mPrP.sub.t) for four hours at 25.degree. C. on a rocking shaker.
Coupling products are analysed by SDS-PAGE.
Example 8
A. Coupling of Prion Peptides to Q.beta. Capsid Protein: Prion
Peptide Vaccines
[0543] The following prion peptides were chemically synthesized:
CSAMSRPMIHFGNDWEDRYYRENMYR ("cprplong"; SEQ ID NO:364) and
CGNDWEDRYYRENMYR ("cprpshort"; SEQ ID NO:365), which comprise an
added N-terminal cysteine residue for coupling to VLPs and Pili,
and used for chemical coupling to Q.beta. as described in the
following.
[0544] A solution of 5 ml of 140 .mu.M Q.beta. capsid protein in 20
mM Hepes. 150 mM NaCl pH 7.4 was reacted for 30 minutes with 108
.mu.l of a 65 mM solution of SMPH (Pierce) in H.sub.2O at
25.degree. C. on a rocking shaker. The reaction solution was
subsequently dialyzed twice for 2 hours against 5 L of 20 mM Hepes,
150 mM NaCl, pH 7.4 at 4.degree. C. 100 .mu.l of the dialyzed
reaction mixture was then reacted either with 1.35 .mu.l of a 2 mM
stock solution (in DMSO) of the peptide cprpshort (1:2
peptide/Q.beta. capsid protein ratio) or with 2.7 .mu.l of the same
stock solution (1:1 peptide/Q.beta. ratio). 1 .mu.l of a 10 mM
stock solution (in DMSO) of the peptide cprplong was reacted with
100 .mu.l of the dialyzed reaction mixture. The coupling reactions
were performed over night at 15.degree. C. in a water bath. The
reaction mixtures were subsequently dialyzed 24 h against 2.times.5
L of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C.
[0545] The coupled products were centrifuged and supernatants and
pellets were analysed on 16% SDS-PAGE gels under reducing
conditions. Gels were stained with Coomassie Brilliant Blue. The
results are shown in FIG. 16. Molecular weights of marker proteins
are given on the left margin of the gel in the figure. The bands at
a molecular weight between 16.5 and 25 kDa clearly demonstrated the
covalent coupling of the peptides cprpshort and cprplong to Q.beta.
capsid protein.
[0546] The samples loaded on the gel of FIG. 16 A were the
following:
[0547] Lane 1: purified Q.beta. capsid protein. Lane 2: derivatized
Q.beta. capsid protein before coupling. Lanes 3-6: Q.beta. capsid
protein-cprpshort couplings with a 1:2 peptide/Q.beta. ratio (lanes
3 and 4) and 1:1 peptide/Q.beta. ratio (lanes 5 and 6). Soluble
fractions (lanes 3 and 5) and insoluble fractions (lanes 4 and 6)
are shown.
[0548] The samples loaded on the gel of FIG. 16 B were the
following:
Lane 1: Molecular weight marker. Lane 2: derivatized Q.beta. capsid
protein before coupling. Lane 3 and 4: Q.beta.capsid
protein-cprplong coupling reactions. Soluble fraction (lane 3) and
insoluble fraction (lane 4) are shown.
B. Coupling of Prion Peptides to fr Capsid Protein
[0549] A solution of 120 .mu.M fr capsid protein in 20 mM Hepes,
150 mM NaCl pH 7.2 is reacted for 30 minutes with a 10 fold molar
excess of SMPH (Pierce)), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed fr reaction
mixture is then reacted with equimolar concentration of peptide
cprpshort or a ration of 1:2 cprplong/fr over night at 16.degree.
C. on a rocking shaker. Coupling products are analysed by
SDS-PAGE.
C. Coupling of Prion Peptides to HBcAg-Lys-2cys-Mut
[0550] A solution of 120 .mu.M HBcAg-Lys-2cys-Mut in 20 mM Hepes,
150 mM NaCl pH 7.2 is reacted for 30 minutes with a 10 fold molar
excess of SMPH (Pierce)), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed HBcAg-Lys-2cys-Mut
reaction mixture is then reacted with equimolar concentration of
peptide cprpshort or a ration of 1:2 cprplong/HBcAg-Lys-2cys-Mut
over night at 16.degree. C. on a rocking shaker. Coupling products
are analysed by SDS-PAGE.
D. Coupling of Prion Peptides to Pili
[0551] A solution of 125 .mu.M Type-1 pili of E. coli in 20 mM
Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar
excess of cross-linker SMPH (Pierce), diluted from a stock solution
in DMSO, at RT on a rocking shaker. The reaction mixture is
desalted on a PD-10 column (Amersham-Pharmacia Biotech). The
protein-containing fractions eluating from the column are pooled,
and the desalted derivatized pili protein is reacted with the prion
peptides in equimolar or in a ratio of 1:2 peptide pili over night
at 16.degree. C. on a rocking shaker. Coupling products are
analysed by SDS-PAGE.
Example 9
Cloning, Expression and Purification of IL-13 to VLPs and Pili
[0552] A. Cloning and Expression of Interleukin 13 (IL-13) with an
N-Terminal Amino Acid Linker Containing a Cysteine Residue for
Coupling to VLPs and Pili
[0553] a) Cloning of Mouse IL-13 (HEK-293T) for Expression in
Mammalian Cells as Fc Fusion Protein
[0554] The DNA for the cloning of IL-13 was isolated by RT-PCR from
in vitro activated splenocytes, which were obtained as following:
CD4+ T cells were isolated from mouse spleen cells and incubated 3
days in IMDM (+5% FCS+10 ng/ml IL4) in 6 well plates which have
been previously coated with anti-CD3 and anti-CD28 antibodies. The
RNA from these cells was used to amplify IL13 by one-step RT-PCR
(Qiagen one-step PCR kit). Primer XhoIL13-R was used for the
reverse transcription of the RNA and the primers NheIL13-F (SEQ ID
NO:338) and XhoIL13-R (SEQ ID NO:339) were used for the PCR
amplification of the IL13 cDNA. Amplified IL13 cDNA was ligated in
a pMOD vector using the NheI/XhoI restriction sites (giving the
vector pMODB1-IL13). pMODB1-Il13 was digested BamHI/XhoI and the
fragment containing IL13 was ligated in the
pCEP-SP-XA-Fc*(.quadrature.xho) vector, an analogue of
pCEP-SP-XA-Fc* where a XhoI site at the end of the Fc sequence has
been removed, which had been previously digested with BamHI/XhoI.
The plasmid resulting from this ligation (pCEP-SP-IL13-Fc) was
sequenced and used to transfect HEK-293T cells. The resulting IL 13
construct encoded by this plasmid had the amino acid sequence
ADPGCGGGGGLA fused at the N-terminus of the IL-13 mature sequence.
This sequence comprises the amino acid linker sequence GCGGGGG
flanked by additional amino acids introduced during the cloning
procedure. IL13-Fc could be purified with Protein-A resin from the
supernatant of the cells transfected with pCEP-SP-IL13-Fc. The
result of the expression is shown on FIG. 17 B (see EXAMPLE 10 for
description of the samples). Mature IL-13 fused at its N-terminus
with the aforementioned amino acid sequence is released upon
cleavage of the fusion protein with Factor-Xa, leading to a protein
called hereinafter "mouse C-IL-13-F" and having a sequence of SEQ
ID NO:328. The result of FIG. 17 B clearly demonstrates expression
of the IL-13 construct.
[0555] b) Cloning of Mouse IL-13 (HEK-293T) for Expression in
Mammalian Cells with GST (Glutathion-S-Transferase) Fused at its
N-Terminus
[0556] The cDNA used for cloning IL-13 with an N-terminal GST
originated from the cDNA of TH2 activated T-cells as described
above (a.). IL-13 was amplified from this cDNA using the primers
Nhelink1IL13-F and IL13StopXhoNot-R. The PCR product was digested
with NheI and XhoI and ligated in the pCEP-SP-GST-EK vector
previously digested with NheI/XhoI. The plasmid which could be
isolated from the ligation (pCEP-SP-GST-IL13) was used to transfect
HEK-293T cells. The resulting IL 13 construct encoded by this
plasmid had the amino acid sequence LACGGGGG (SEQ ID NO:417) fused
at the N-terminus of the IL-13 mature sequence. This sequence
comprises the amino acid linker sequence ACGGGGG (SEQ ID NO:418)
flanked by an additional amino acid introduced during the cloning
procedure. The culture supernatant of the cells transfected with
pCEP-SP-GST-IL13 contained the fusion protein GST-IL13 which could
be purified by Glutathione affinity chromatography according to
standard protocols. Mature IL-13 fused at its N-terminus with
aforementioned amino acid sequence is released upon cleavage of the
fusion protein with enterokinase, leading to a protein called
hereinafter "mouse C-IL-13-S" and having a sequence of SEQ ID
NO:329.
[0557] B. Coupling of Mouse C-IL-13-F, Mouse C-IL-13-S to Q.beta.
Capsid Protein
[0558] A solution of 120 .mu.M Q.beta. capsid in 20 mM Hepes, 150
mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar
excess of SMPH (Pierce), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed Q.beta. reaction
mixture is then reacted with the mouse C-IL-13-F or mouse C-IL-13-S
solution (end concentrations: 60 .mu.M Q.beta.capsid protein, 60
.mu.M mouse C-IL-13-F or mouse C-IL-13-S) for four hours at
25.degree. C. on a rocking shaker. Coupling products are analysed
by SDS-PAGE.
[0559] C. Coupling of Mouse C-IL-13-F, Mouse C-IL-13-S to fr Capsid
Protein
[0560] A solution of 120 .mu.M fr capsid protein in 20 mM Hepes,
150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar
excess of SMPH (Pierce), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed fr reaction
mixture is then reacted with the mouse C-IL-13-F or mouse C-IL-13-S
solution (end concentrations: 60 .mu.M frcapsid protein, 60 .mu.M
mouse C-IL-13-F or mouse C-IL-13-S) for four hours at 25.degree. C.
on a rocking shaker. Coupling products are analysed by
SDS-PAGE.
[0561] D. Coupling of Mouse C-IL-13-F or mouse C-IL-13-S Solution
to HBcAg-Lys-2cys-Mut
[0562] A solution of 120 .mu.M HBcAg-Lys-2cys-Mut capsid in 20 mM
Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold
molar excess of SMPH (Pierce), diluted from a stock solution in
DMSO, at 25.degree. C. on a rocking shaker. The reaction solution
is subsequently dialyzed twice for 2 hours against 1 L of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed
HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the mouse
C-IL-13-F or mouse C-IL-13-S solution (end concentrations: 60 .mu.M
HBcAg-Lys-2cys-Mut, 60 .mu.M mouse C-IL-13-F or mouse C-IL-13-S)
for four hours at 25.degree. C. on a rocking shaker. Coupling
products are analysed by SDS-PAGE.
[0563] E. Coupling of Mouse C-IL-13-F or Mouse C-IL-13-S Solution
to Pili
[0564] A solution of 125 .mu.M Type-1 pili of E. coli in 20 mM
Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar
excess of cross-linker SMPH, diluted from a stock solution in DMSO,
at RT on a rocking shaker. The reaction mixture is desalted on a
PD-10 column (Amersham-Pharmacia Biotech). The protein-containing
fractions eluating from the column are pooled, and the desalted
derivatized pili protein is reacted with the mouse C-IL-13-F or
mouse C-IL-13-S solution (end concentrations: 60 .mu.M pili, 60
.mu.M mouse C-IL-13-F or mouse C-IL-13-S) for four hours at
25.degree. C. on a rocking shaker. Coupling products are analysed
by SDS-PAGE.
Example 10
Cloning and Expression of Interleukin 5 (IL-5) with an N-Terminal
Amino Acid Linker Containing a Cysteine Residue for Coupling to
VLPs and Pili
[0565] A. Cloning of IL-5 for Expression as Inclusion Bodies in E.
coli
[0566] IL-5 was amplified from an ATCC clone (pmIL5-4G; ATCC
number: 37562) by PCR using the following two primers:
Spelinker3-F1 (SEQ ID NO:340) and Il5StopXho-R (SEQ ID NO:342). The
product of this PCR was used as template for a second PCR with the
primers SpeNlinker3-F2 (SEQ ID NO:341) and Il5StopXho-R. The insert
was digested with SpeI and NotI. This insert was ligated into a pET
vector derivative (pMODEC3-8 vector), previously digested with NheI
and NotI (not dephosphorylated), and transformed into E. coli TG1
cells. The IL5 construct generated by cloning into pMODEC3-8 vector
contains at its N-terminus a hexa-histidine tag, followed by an
enterokinase site, an N-terminal gamma 3 amino acid linker
containing a cysteine residue, flanked C-terminally by the sequence
AS and N-terminally by the sequence ALV, and the mature form of the
IL 5 gene. The protein released by cleavage with enterokinase is
called "mouse C-IL-5-E" (SEQ ID NO:332). Plasmid DNA of resulting
clone pMODC6-IL5.2 (also called pMODC6-IL5), whose sequence had
been confirmed by DNA sequencing, was transformed into E. coli
strain BL21.
[0567] Clone pMODC6-IL5/BL21 was grown over night in 5 ml LB
containing 1 mg/L Ampicillin. 2 ml of this culture were diluted in
100 ml terrific broth (TB) containing 1 mg/L Ampicillin. The
culture was induced by adding 0.1 ml of a 1M solution of Ispropyl
.beta.-D-Thiogalactopyranoside (IPTG) when the culture reached an
optical density OD600=0.7. 10 ml samples were taken every 2 h. The
samples were centrifugated 10 min at 4000.times.g. The pellet was
resuspended in 0.5 ml Lysis buffer containing 50 mM Tris-HCl, 2 mM
EDTA, 0.1% triton X-100 (pH8). After having added 20 .mu.l of
Lysozyme (40 mg/ml) and having incubated the tube 30 min at
4.degree. C., the cells were sonicated for 2 min. 100 .mu.l of a 50
mM MgCl2 solution and 1 ml of benzonase were added. The cells were
then incubated 30 min at room temperature and centrifugated 15 min
at 13000.times.g.
[0568] The supernatant was discarded and the pellet was boiled 5
min at 98.degree. C. in 100 .mu.l of SDS loading buffer. 10 .mu.l
of the samples in loading buffer were analyzed by SDS-PAGE under
reducing conditions (FIG. 17 A). The gel of FIG. 17 A clearly
demonstrates expression of the IL-5 construct. The samples loaded
on the gel of FIG. 17 A were the following:
[0569] Lane M: Marker (NEB, Broad range prestained marker). Lane 1:
cell extract of 1 ml culture before induction. Lane 2: cell extract
of 1 ml culture 4 h after induction.
[0570] B. Cloning of IL-5 for Expression in Mammalian Cells
(HEK-293T)
[0571] a) IL-5 Fused at its N-Terminus to an Amino Acid Linker
Containing a Cysteine Residue and Fused at its C-Terminus to the Fc
Fragment
[0572] The template described under (A) (ATCC clone 37562) was used
for the cloning of the following construct. The plasmid pMODB1-IL5
(a pET derivative) was digested with BamHI/XhoI to yield a small
fragment encoding IL5 fused to an N terminal amino acid linker
containing a cysteine. This fragment was ligated in the vector
pCEP-SP-XA-Fc*(.DELTA.Xho) which had previously been digested with
BamHI and XhoI. The ligation was electroporated into E. coli strain
TG1 and plasmid DNA of resulting clone pCEP-SP-IL5-Fc.2, whose
sequence had been confirmed by DNA sequencing, was used to
transfect HEK-293T cells. The resulting IL-5 construct encoded by
this plasmid had the amino acid sequence ADPGCGGGGGLA (SEQ ID
NO:419) fused at the N-terminus of the IL-5 mature sequence. This
sequence comprises the amino acid linker sequence GCGGGGG (SEQ ID
NO:420) containing a cysteine and flanked by additional amino acids
introduced during the cloning procedure. The IL-5 protein released
by cleavage of the fusion protein with Factor-Xa is named
hereinafter "mouse C-IL-5-F" (SEQ ID NO:333).
[0573] After transfection and selection on Puromycin the culture
supernatant was analyzed by Western-Blot (FIG. 17 B) using an
anti-His (mouse) and an anti-mouse IgG antibody conjugated to Horse
raddish peroxidase. The anti-mouse IgG antibody conjugated to Horse
raddish peroxidase also detects Fc-fusion proteins. Purification of
the protein was performed by affinity chromatography on Protein-A
resin. The result of FIG. 17 B clearly demonstrates expression of
the IL-5 construct.
[0574] The samples loaded on the Western-Blot of FIG. 17 B were the
following:
[0575] Lane 1: supernatant of HEK culture expressing IL5-Fc (20
.mu.l). SDS-PAGE was performed under reducing conditions. Lane 2:
supernatant of HEK culture expressing IL13-Fc (20 .mu.l). SDS-PAGE
was performed under non reducing conditions. Lane 3: supernatant of
HEK culture expressing IL5-Fc (20 .mu.l). SDS-PAGE was performed
under non reducing conditions.
[0576] b) IL-5 Cloned with GST (Glutathion-S-Transferase) and an
Amino Acid Linker Containing a Cysteine Residue Fused at its
N-Terminus
[0577] IL-5 (ATCC 37562) was amplified with the primers
Nhe-link1-IL13-F and IL5StopXho-R. After digestion with NheI and
XhoI the insert was ligated into pCEP-SP-GST-EK which had been
previously digested with NheI and XhoI. The resulting plasmid
pCEP-SP-GST-IL5 was sequenced and used for transfection of HEK-293T
cells. The resulting IL-5 construct encoded by this plasmid had the
amino acid sequence LACGGGGG (SEQ ID NO:417) fused at the
N-terminus of the IL-5 mature sequence. This sequence comprises the
amino acid linker sequence ACGGGGG (SEQ ID NO:418) containing a
cysteine residue and flanked by additional amino acids introduced
during the cloning procedure. The protein released by cleavage with
enterokinase was named hereinafter "mouse C-IL-5-S" (SEQ ID
NO:334). The purification of the resulting protein was performed by
affinity chromatography on Glutathione affinity resin.
[0578] C. Coupling of Mouse C-IL-5-F or Mouse C-IL-5-S to Q.beta.
Capsid Protein
[0579] A solution of 120 .mu.M Q.beta. capsid protein in 20 mM
Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold
molar excess of SMPH (Pierce), diluted from a stock solution in
DMSO, at 25.degree. C. on a rocking shaker. The reaction solution
is subsequently dialyzed twice for 2 hours against 1 L of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed Q.beta.
reaction mixture is then reacted with the mouse C-IL-5-F or mouse
C-IL-5-S solution (end concentrations: 60 .mu.M Q.beta.capsid
protein, 60 .mu.M mouse C-IL-5-F or mouse C-IL-5-S) for four hours
at 25.degree. C. on a rocking shaker. Coupling products are
analysed by SDS-PAGE.
[0580] D. Coupling of Mouse C-IL-5-F or Mouse C-IL-5-S to fr Capsid
Protein
[0581] A solution of 120 .mu.M fr capsid protein in 20 mM Hepes,
150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold molar
excess of SMPH (Pierce), diluted from a stock solution in DMSO, at
25.degree. C. on a rocking shaker. The reaction solution is
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed fr reaction
mixture is then reacted with the mouse C-IL-5-F or mouse C-IL-5-S
solution (end concentrations: 60 .mu.M frcapsid protein, 60 .mu.M
mouse C-IL-5-F or mouse C-IL-5-S) for four hours at 25.degree. C.
on a rocking shaker. Coupling products are analysed by
SDS-PAGE.
[0582] E. Coupling of Mouse C-IL-5-F or Mouse C-IL-5-S Solution to
HBcAg-Lys-2cys-Mut
[0583] A solution of 120 .mu.M HBcAg-Lys-2cys-Mut capsid in 20 mM
Hepes, 150 mM NaCl pH 7.2 is reacted for 30 minutes with a 25 fold
molar excess of SMPH (Pierce), diluted from a stock solution in
DMSO, at 25.degree. C. on a rocking shaker. The reaction solution
is subsequently dialyzed twice for 2 hours against 1 L of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. The dialyzed
HBcAg-Lys-2cys-Mut reaction mixture is then reacted with the mouse
C-IL-5-F or mouse C-IL-5-S solution (end concentrations: 60 .mu.M
HBcAg-Lys-2cys-Mut, 60 .mu.M mouse C-IL-5-F or mouse C-IL-5-S) for
four hours at 25.degree. C. on a rocking shaker. Coupling products
are analysed by SDS-PAGE.
[0584] F. Coupling of Mouse C-IL-5-F or Mouse C-IL-5-S Solution to
Pili
[0585] A solution of 125 .mu.M Type-1 pili of E. coli in 20 mM
Hepes, pH 7.4, is reacted for 60 minutes with a 50-fold molar
excess of cross-linker SMPH, diluted from a stock solution in DMSO,
at RT on a rocking shaker. The reaction mixture is desalted on a
PD-10 column (Amersham-Pharmacia Biotech). The protein-containing
fractions eluating from the column are pooled, and the desalted
derivatized pili protein is reacted with the mouse C-IL-5-F or
mouse C-IL-5-S solution (end concentrations: 60 .mu.M pili, 60
.mu.M mouse C-IL-5-F or mouse C-IL-5-S) for four hours at
25.degree. C. on a rocking shaker. Coupling products are analysed
by SDS-PAGE.
Example 11
Introduction of an Amino Acid Linker Containing a Cysteine Residue,
Expression, Purification and Coupling of a Murine Vascular
Endothelial Growth Factor-2 (mVEGFR-2, FLK1) Fragment
[0586] A construct of the murine vascular endothelial growth
factor-2 (mVEGFR-2, FLK-1) comprising its second and third
extracellular domains was recombinantly expressed as a Fc-fusion
protein with an amino acid linker containing a cysteine residue at
its C-terminus for coupling to VLPs and Pili. The protein sequences
of the mVEGFR-2(2-3) was translated from the cDNA sequences of
mouse FLK-1 ((Matthews et al., Proc. Natl. Acad. Sci. USA 88:
9026-9030 (1991)): Accession no.: X59397; Ig-like C2-type domain 2:
amino acid 143-209; Ig-like C2-type domain 3: amino acid 241-306).
The mVEGFR-2 (2-3) construct comprises the sequence of mVEGFR-2
from amino acid proline126 to lysine329 (in the numbering of the
precursor protein). The construct also comprises, in addition to
the Immunoglobulin-like C2-type domains 2 and 3, flanking regions
preceding domain 2 and following domain 3 in the sequence of
mVEGFR-2, to add amino acid spacer moieties. An amino acid linker
containing a cysteine residue was fused to the C-terminus of the
mVEGFR-2 sequence through cloning into pCEP-SP-EK-Fc* vector
(EXAMPLE 1). The fragment of mVEGFR-2 cloned into pCEP-SP-EK-Fc*
vector encoded the following amino acid sequence (SEQ ID NO:345):
TABLE-US-00012 PFIAS VSDQHGIVYI TENKNKTVVI PCRGSISNLN VSLCARYPEK
RFVPDGNRIS WDSEIGFTLP SYMISYAGMV FCEAKINDET YQSIMYIVVV VGYRIYDVIL
SPPHEIELSA GEKLVLNCTA RTELNVGLDF TWHSPPSKSH HKKIVNRDVK PFPGTVAKMF
LSTLTIESVT KSDQGEYTCV ASSGRMIKRN RTFVRVHTKP
[0587] Expression of Recombinant mVEGFR-2(2-3) in Eukaryotic
Cells
[0588] Recombinant mVEGFR-2(2-3) was expressed in EBNA 293 cells
using the pCEP-SP-EK-Fc* vector. The pCEP-SP-EK-Fc* vector has a
BamHI and an NheI sites, encodes an amino acid linker containing
one cysteine residue, an enterokinase cleavage site, and
C-terminally a human Fc region. The mVEGFR-2(2-3) was amplified by
PCR with the primer pair BamH1-FLK1-F and NheI-FLK1-B from a mouse
7-day embryo cDNA (Marathon-Ready cDNA, Clontech). For the PCR
reaction, 10 pmol of each oligo and 0.5 ng of the cDNA (mouse 7-day
embryo cDNA Marathon-Ready cDNA, Clontech) was used in the 50 .mu.l
reaction mixture (1 .mu.l of Advantage 2 polymerase mix
(50.times.), 0.2 mM dNTPs and 5 .mu.l 10.times.cDNA PCR reaction
buffer). The temperature cycles were as follows: 5 cycles a
94.degree. C. for 1 minute, 94.degree. C. for 30 seconds,
54.degree. C. for 30 seconds, 72.degree. C. for 1 minute followed
by 5 cycles of 94.degree. C. (30 seconds), 54.degree. C. (30
seconds), 70.degree. C. (1 minute) and followed by 30 cycles
94.degree. C. (20 seconds), 54.degree. C. (30 seconds) and
68.degree. C. (1 minute). The PCR product was digested with BamHI
and NheI and inserted into the pCEP-SP-EK-Fc* vector digested with
the same enzymes. Resulting plasmid was named
mVEGFR-2(2-3)-pCep-EK-Fc. All other steps were performed by
standard molecular biology protocols. TABLE-US-00013 Oligos: 1.
PrimerBamH1-FLK1-F 5'-CGCGGATCCATTCATCGCCTCTGTC-3' (SEQ ID NO: 343)
2. Primer Nhe1-FLK1-B 5'-CTAGCTAGCTTTGTGTGAACTCGGAC- (SEQ ID NO:
344) 3'
[0589] Transfection and Expression of Recombinant mVEGFR-2(2-3)
[0590] EBNA 293 cells were transfected with the
mVEGFR-2(2-3)-pCep-Ek-Fc construct described above and serum free
supernatant of cells was harvested for purification as described in
EXAMPLE 1.
[0591] Purification of Recombinant mVEGFR-2(2-3)
[0592] Protein A purification of the expressed Fc-EK-mVEGFR-2(2-3)
proteins was performed as described in EXAMPLE 1. Subsequently,
after binding of the fusion protein to Protein A, mVEGFR-2(2-3) was
cleaved from the Fc portion bound to protein A using enterokinase
(EnterokinaseMax, Invitrogen). Digestion was conducted over night
at 37.degree. C. (2.5 units enterokinase/100 .mu.l Protein A beads
with bound fusion protein). The released VEGFR-2(2-3) was separated
from the Fc-portion still bound to protein A beads by short
centrifugation in chromatography columns (Micro Bio Spin, Biorad).
In order to remove the enterokinase the flow through was treated
with enterokinase away (Invitrogen) according to the instructions
of the manufacturer.
Example 12
[0593] Coupling of Murine VEGFR-2 Peptide to Q.beta. Capsid
Protein, HbcAg-lys-2cys-Mut and Pili and Immunization of Mice with
VLP-Peptide and Pili-Peptide Vaccines
[0594] A. Coupling of Murine VEGFR-2 Peptides to VLPs and Pili
[0595] The following peptide was chemically synthesized (by
Eurogentec, Belgium): murine VEGFR-2 peptide
CTARTELNVGLDFTWHSPPSKSHHKK (SEQ ID NO:366) and used for chemical
coupling to Pili as described below.
[0596] Coupling of murine VEGFR-2 peptides to pili: A solution of
1400 .mu.l of 1 mg/ml pili protein in 20 mM Hepes, pH 7.4, was
reacted for 60 minutes with 85 .mu.l of a 100 mM Sulfo-MBS (Pierce)
solution in (H2O) at RT on a rocking shaker. The reaction mixture
was desalted on a PD-10 column (Amersham-Pharmacia Biotech), The
protein-containing fractions eluting from the column were pooled
(containing approximately 1.4 mg protein) and reacted with a
2.5-fold molar excess (final volume) of murine VEGFR-2 peptide
respectively. For example, to 200 .mu.l eluate containing
approximately 0.2 mg derivatized pili, 2.4 .mu.l of a 10 mM peptide
solution (in DMSO) were added. The mixture was incubated for four
hours at 25.degree. C. on a rocking shaker and subsequently
dialyzed against 2 liters of 20 mM Hepes, pH 7.2 overnight at
4.degree. C. Coupling results were analyzed by SDS-PAGE under
reducing conditions and are shown in FIG. 18 A. Supernatant (S) and
pellet (P) of each sample were loaded on the gel, as well pili and
pili derivatized with Sulfo-MBS cross-linker (Pierce). The samples
loaded on the gel of FIG. 18 A were the following:
[0597] Lane 1: Marker proteins; lane 2-5: coupled samples (Pili
murine: Pili coupled to murine peptide; Pili human: Pili coupled to
human peptide); lane 6: pili derivatized with Sulfo-MBS
cross-linker; lane 7-9: three fractions of the eluate of the PD-10
column. Fraction 2 is the peak fraction, fraction 1 and 3 are
fractions taken at the border of the peak. Coupling bands were
clearly visible on the gel, demonstrating the successful coupling
of murine VEGFR-2 to pili.
[0598] Coupling of murine VEGFR-2 peptide to Q.beta.capsid protein:
A solution of 1 ml of 1 mg/ml Q.beta. capsid protein in 20 mM
Hepes, 150 mM NaCl pH 7.4 was reacted for 45 minutes with 20 .mu.l
of 100 mM Sulfo-MBS (Pierce) solution in (H2O) at RT on a rocking
shaker. The reaction solution was subsequently dialyzed twice for 2
hours against 2 L of 20 mM Hepes, pH 7.4 at 4.degree. C. 1000 .mu.l
of the dialyzed reaction mixture was then reacted with 12 .mu.l of
a 10 mM peptide solution (in DMSO) for four hours at 25.degree. C.
on a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, pH 7.4 at
4.degree. C. Coupling results were analyzed by SDS-PAGE under
reducing conditions and are shown in FIG. 18 B. Supernatant (S) of
each sample was loaded on the gel, as well as Q.beta. capsid
protein and Q.beta. capsid protein derivatized with Sulfo-MBS
cross-linker. Coupling was done in duplicate. The following samples
were loaded on the gel:
[0599] Lane 1: Marker proteins; lane 2, 5: Q.beta. capsid protein;
lane 3, 6 Q.beta. capsid protein derivatized with Sulfo-MBS; lane
4, 7: Q.beta. capsid protein coupled to murine VEGFR-2 peptide.
Coupling bands were clearly visible on the gel, demonstrating the
successful coupling of murine VEGFR-2 to Q.beta. capsid
protein.
[0600] Coupling of murine VEGFR-2 peptide to HbcAg-lys-2cys-Mut: A
solution of 3 ml of 0.9 mg/ml cys-free HbcAg capsid protein
(EXAMPLE 31) in PBS, pH 7.4 was reacted for 45 minutes with
37[[,]]0.5 .mu.l of a 100 mM Sulfo-MBS (Pierce) solution in (H2O)
at RT on a rocking shaker. The reaction solution was subsequently
dialyzed overnight against 2 L of 20 mM Hepes, pH 7.4. After buffer
exchange the reaction solution was dialyzed for another 2 hours
against the same buffer. The dialyzed reaction mixture was then
reacted with 3 .mu.l of a 10 mM peptide solution (in DMSO) for 4
hours at 25[[>]].degree. C. on a rocking shaker. The reaction
mixture was subsequently dialyzed against 2 liters of 20 mM Hepes,
pH 7.4 overnight at 4[[>]].degree. C. followed by buffer
exchange and another 2 hours of dialysis against the same buffer.
Coupling results were analyzed by SDS-PAGE under reducing
conditions and are shown in FIG. 18 C. The supernatant (S) of each
sample was loaded on the gel, as well as HbcAg-lys-2cys-Mut protein
and HbcAg-lys-2cys-Mut protein derivatized with Sulfo-MBS
cross-linker. Coupling was done in duplicate. Coupling reactions
were conducted in a 2.5 fold and 10 fold molar excess of peptide.
The following samples were loaded on the gel:
[0601] Lane 1: Marker proteins; lane 2, 5: Q.beta. capsid protein;
lane 3, 6 Q.beta. capsid protein derivatized with Sulfo-MBS; lane
4, 7: Q.beta. capsid protein coupled to murine VEGFR-2 peptide.
Coupling bands were clearly visible on the gel, demonstrating the
successful coupling of murine VEGFR-2 to Q.beta. capsid
protein.
[0602] Coupling of murine VEGFR-2 peptide to HbcAg-lys-2cys-Mut: A
solution of 3 ml of 0.9 mg/ml cys-free HbcAg capsid protein
(EXAMPLE 31) in PBS, pH 7.4 was reacted for 45 minutes with 37.5
.mu.l of a 100 mM Sulfo-MBS (Pierce) solution in (H.sub.2O) at RT
on a rocking shaker. The reaction solution was subsequently
dialyzed overnight against 2 L of 20 mM Hepes, pH 7.4. After buffer
exchange the reaction solution was dialyzed for another 2 hours
against the same buffer. The dialyzed reaction mixture was then
reacted with 3 .mu.l of a 10 mM peptide solution (in DMSO) for 4
hours at 25.degree. C. on a rocking shaker. The reaction mixture
was subsequently dialyzed against 2 liters of 20 mM Hepes, pH 7.4
overnight at 4.degree. C. followed by buffer exchange and another 2
hours of dialysis against the same buffer. Coupling results were
analyzed by SDS-PAGE under reducing conditions and are shown in
FIG. 18 C. The supernatant (S) of each sample was loaded on the
gel, as well as HbcAg-lys-2cys-Mut protein and HbcAg-lys-2cys-Mut
protein derivatized with Sulfo-MBS cross-linker. Coupling was done
in duplicate. Coupling reactions were conducted in a 2.5 fold and
10 fold molar excess of peptide. The following samples were loaded
on the gel:
[0603] Lane 1: Marker proteins; lane 2, 4, 6, 8: Supernatant (S)
and pellet (P) of coupling reactions performed with 10 fold molar
excess of peptide; lane 3, 5, 7, 9: Supernatant (S) and pellet (P)
of coupling reactions performed with 2.5 fold molar excess of
peptide; lane 10: HbcAg-lys-2cys-Mut derivatized with Sulfo-MBS;
lane 11: HbcAg-lys-2cys-Mut.
Coupling bands were clearly visible on the gel, demonstrating the
successful coupling of murine VEGFR-2 to HbcAg-lys-2cys-Mut
protein.
[0604] B. Immunization of Mice:
[0605] Pili-Peptide Vaccine:
[0606] Female C3H-HeJ (Toll-like receptor 4 deficient) and C3H-HeN
(wild-type) mice were vaccinated with the murine VEGFR-2 peptide
coupled to pili protein without the addition of adjuvants.
Approximately 100 .mu.g of total protein of each sample was diluted
in PBS to 200 .mu.l and injected subcutaneously on day 0, day 14
and day 28. Mice were bled retroorbitally on day 14, 28 and day 42
and serum of day 42 was analyzed using a human VEGFR-2 specific
ELISA.
[0607] Q.beta. Capsid Protein-Peptide Vaccine:
[0608] Female Black 6 mice were vaccinated with the murine VEGFR-2
peptide coupled to Q.beta. capsid protein with and without the
addition of adjuvant (Aluminiumhydroxid). Approximately 100 .mu.g
of total protein of each sample was diluted in PBS to 200 .mu.l and
injected subcutaneously on day 0, day 14 and day 28. Mice were bled
retroorbitally on day 14, 28 and day 42 and serum of day 42 was
analyzed using a human VEGFR-2 specific ELISA.
[0609] HbcAg-lys-2cys-Mut Vaccines:
[0610] Female Black 6 mice were vaccinated with the murine VEGFR-2
peptide coupled to HbcAg-lys-2cys-Mut protein with and without the
addition of adjuvant (Aluminiumhydroxid). Approximately 100 .mu.g
of total protein of each sample was diluted in PBS to 200 .mu.l and
injected subcutaneously on day 0, day 14 and day 28. Mice were bled
retroorbitally on day 14, 28 and day 42 and serum of day 42 was
analyzed using a human VEGFR-2 specific ELISA.
[0611] C. ELISA
[0612] Sera of immunized mice were tested in ELISA with immobilized
murine VEGFR-2 peptide. Murine VEGFR-2 peptide was coupled to
bovine RNAse A using the chemical cross-linker Sulfo-SPDP. ELISA
plates were coated with coupled RNAse A at a concentration of 10
.mu.g/ml. The plates were blocked and then incubated with serially
diluted mouse sera. Bound antibodies were detected with
enzymatically labeled anti-mouse IgG antibody. As a control,
preimmune sera of the same mice were also tested. Control ELISA
experiments using sera from mice immunized with uncoupled carrier
showed that the antibodies detected were specific for the
respective peptide. The results are shown in FIG. 4-6.
[0613] Pili-Peptide Vaccine:
[0614] The result of the ELISA is shown in FIG. 18 D. Results for
indicated serum dilutions are shown as optical density at 450 nm.
The average of three mice each (including standard deviations) are
shown. All vaccinated mice made IgG antibody titers against the
murine VEGFR-2 peptide. No difference was noted between mice
deficient for the Toll-like receptor 4 and wild-type mice,
demonstrating the immunogenicity of the self-antigen murine VEGFR-2
peptide, when coupled to pili, in mice. The vaccines injected in
the mice are designating the corresponding analyzed sera.
[0615] Q.beta. Capsid Protein-Peptide Vaccine:
[0616] Results for indicated serum dilutions are shown in FIG. 18 E
as optical density at 450 nm. The average of two mice each
(including standard deviations) are shown. All vaccinated mice made
IgG antibody titers against the murine VEGFR-2 peptide,
demonstrating the immunogenicity of the self-antigen murine VEGFR-2
peptide, when coupled to Q.beta. capsid protein, in mice. The
vaccines injected in the mice are designating the corresponding
analyzed sera.
[0617] HbcAg-lys-2cys-Mut Vaccine:
[0618] Results for indicated serum dilutions are shown in FIG. 18 F
as optical density at 450 nm. The average of three mice each
(including standard deviations) are shown. All vaccinated mice made
IgG antibody titers against the murine VEGFR-2 peptide,
demonstrating the immunogenicity of the self-antigen murine VEGFR-2
peptide, when coupled to Q.beta. capsid protein, in mice. The
vaccines injected in the mice are designating the corresponding
analyzed sera.
Example 13
Coupling of A.beta. 1-15 Peptides to HBc-Ag-lys-2cys-Mut and fr
Capsid Protein
[0619] The following A.beta. peptide was chemically synthesized
(DAEFRHDSGYEVHHQGGC (SEQ ID NO:367)), a peptide which comprises the
amino acid sequence from residue 1-15 of human A.beta., fused at
its C-terminus to the sequence GGC for coupling to VLPs and
Pili.
[0620] A. a.) Coupling of A.beta. 1-15 Peptide to
HBc-Ag-lys-2cys-Mut Using the Cross-Linker SMPH.
[0621] A solution of 833.3 .mu.l of 1.2 mg/ml HBc-Ag-lys-2cys-Mut
protein in 20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30
minutes with 17 .mu.l of a solution of 65 mM SMPH (Pierce) in H2O,
at 25.degree. C. on a rocking shaker. The reaction solution was
subsequently dialyzed twice for 2 hours against 1 L of 20 mM Hepes,
150 mM NaCl, pH 7.4 at 4.degree. C. in a dialysis tubing with
Molecular Weight cutoff 10000 Da. 833.3 .mu.l of the dialyzed
reaction mixture was then reacted with 7.1 .mu.l of a 50 mM peptide
stock solution (peptide stock solution in DMSO) for two hours at
15.degree. C. on a rocking shaker. The reaction mixture was
subsequently dialyzed overnight against 1 liters of 20 mM Hepes,
150 mM NaCl, pH 7.4 at 4.degree. C. The sample was then frozen in
aliquots in liquid Nitrogen and stored at -80.degree. C. until
immunization of the mice.
[0622] b) Coupling of A.beta. 1-15 Peptide to fr Capsid Protein
Using the Cross-Linker SMPH.
[0623] A solution of 500 .mu.l of 2 mg/ml fr capsid protein in 20
mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 23
.mu.l of a solution of 65 mM SMPH (Pierce) in H2O, at 25.degree. C.
on a rocking shaker. The reaction solution was subsequently
dialyzed twice for 2 hours against 1 L of 20 mM Hepes, 150 mM NaCl,
pH 7.4 at 4.degree. C. in a dialysis tubing with Molecular Weight
cutoff 10000 Da. 500 .mu.l of the dialyzed reaction mixture was
then reacted with 5.7 .mu.l of a 50 mM peptide stock solution
(peptide stock solution in DMSO) for two hours at 15.degree. C. on
a rocking shaker. The reaction mixture was subsequently dialyzed
overnight against 1 liter of 20 mM Hepes, 150 mM NaCl, pH 7.4 at
4.degree. C. The sample was then frozen in aliquots in liquid
Nitrogen and stored at -80.degree. C. until immunization of the
mice. Samples of the coupling reaction were analyzed by SDS-PAGE
under reducing conditions.
[0624] The results of the coupling experiments were analyzed by
SDS-PAGE, and are shown in FIG. 19 A. Clear coupling bands
corresponding to the coupling of A.beta. 1-15 either to fr capsid
protein or to HBc-Ag-lys-2cys-Mut were visible on the gel, and are
indicated by arrows in the figure, demonstrating successful
coupling of A.beta. 1-15 to fr capsid protein and to
HBc-Ag-lys-2cys-Mut capsid protein. Multiple coupling bands were
visible for the coupling to fr capsid protein, while mainly one
coupling band was visible for HBc-Ag-lys-2cys-Mut.
[0625] The following samples were loaded on the gel of FIG. 19
A.
[0626] 1: Protein Marker (kDa Marker 7708S BioLabs. Molecular
weight marker bands from the top of the gel: 175, 83, 62, 47.5,
32.5, 25, 16.5, 6.5 kDa). 2: derivatized HBc-Ag-lys-2cys-Mut. 3:
HBc-Ag-lys-2cys-Mut coupled with A.beta.1-15, supernatant of the
sample taken at the end of the coupling reaction, and centrifuged.
4: HBc-Ag-lys-2cys-Mut coupled with A.beta.1-15, pellet of the
sample taken at the end of the coupling reaction, and centrifuged.
5: derivatized fr capsid protein. 6: fr capsid protein coupled with
A.beta.1-15, supernatant of the sample taken at the end of the
coupling reaction, and centrifuged. 4: fr capsid protein coupled
with A.beta.1-15, pellet of the sample taken at the end of the
coupling reaction, and centrifuged.
[0627] A. Immunization of Balb/c Mice
[0628] Female Balb/c mice were vaccinated twice on day 0 and day 14
subcutaneously with either 10 .mu.g of fr capsid protein coupled to
A.beta. 1-15 (Fr-A.beta. 1-15) or 10 .mu.g of HBc-Ag-lys-2cys-Mut
coupled to A.beta. 1-15 (HBc-A.beta.1-15) diluted in sterile PBS.
Mice were bled retroorbitally on day 22 and sera were analysed in
an A.beta.-1-15-specific ELISA.
[0629] C. ELISA
[0630] The A.beta. 1-15 peptide was coupled to bovine RNAse A using
the chemical cross-linker sulfo-SPDP. ELISA plates were coated with
A.beta. 1-15-RNAse conjugate at a concentration of 10 .mu.g/ml. The
plates were blocked and then incubated with serially diluted serum
samples. Bound antibodies were detected with enzymatically labeled
anti-mouse IgG. As a control, serum from a naive mouse was also
tested.
[0631] Shown on FIG. 19 B are the ELISA signals obtained on day 22
with the sera of the mice immunized with vaccines Fr-A.beta. 1-15,
and HBc-A.beta.1-15 respectively. A control serum from a naive
mouse (preimmune serum) was also included. Results from different
serum dilutions are shown as optical density at 450 nm. Average
results from three vaccinated mice each are shown. All vaccinated
mice had A.beta. 1-15-specific IgG antibodies in their serum.
Example 14
Coupling of A.beta. 1-15, A.beta. 1-27 and A.beta. 33-42 Peptides
to Type I Pili
[0632] Coupling of A.beta. 1-15, A.beta. 1-27 and A.beta. 33-42
Peptides to Pili Using the Cross-Linker SMPH.
[0633] The following A.beta. peptides were chemically synthesized:
DAEFRHDSGYEVHHQGGC ("A.beta. 1-15"; SEQ ID NO:367), a peptide which
comprises the amino acid sequence from residue 1-15 of human
A.beta. fused at its C-terminus to the sequence GGC for coupling to
Pili and VLPs, DAEFRHDSGYEVHHQKLVFFAEDVGSNGGC ("A.beta. 1-27"; SEQ
ID NO:368) a peptide which comprises the amino acid sequence from
residue 1-27 of human A.beta. fused at its C-terminus to the
sequence GGC for coupling to Pili and VLPs, and CGHGNKSGLMVGGVVIA
("A.beta.. 33-42"; SEQ ID NO:369) a peptide which comprises the
amino acid sequence from residue 33-42 of A.beta., fused at its
N-terminus to the sequence CGHGNKS (SEQ ID NO:405) for coupling to
Pili and VLPs. All three peptides were used for chemical coupling
to Pili as described in the following.
[0634] A solution of 2 ml of 2 mg/ml Pili in 20 mM Hepes 150 mM
NaCl pH 7.4 was reacted for 45 minutes with 468 .mu.l of a solution
of 33.3 mM SMPH (Pierce) in H2O, at 25.degree. C. on a rocking
shaker. The reaction solution was loaded on a PD10 column
(Pharmacia) and eluted with 6.times.500 .mu.l of 20 mM Hepes 150 mM
NaCl pH 7.4. Fractions were analyzed by dotting on a Nitrocellulose
(Schleicher & Schuell) and stained with Amidoblack. Fractions
3-6 were pooled. The samples were then frozen in aliquots in liquid
Nitrogen and stored at -80.degree. C. until coupling.
[0635] 200 .mu.l of the thawed desalted reaction mixture was then
mixed with 200 .mu.l DMSO and 2.5 .mu.l of each of the
corresponding 50 mM peptide stock solutions in DMSO, for 3.5 hours
at RT on a rocking shaker. 400 .mu.l of the reaction mixture was
subsequently dialyzed three times for one hour against 1 liter of
20 mM Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. in a dialysis
tubing with Molecular Weight cutoff 10000 Da. The samples were then
frozen in aliquots in liquid Nitrogen and stored at -80.degree.
C.
[0636] Sample preparation for SDS-Page was performed as follows:
100 .mu.l of the dialyzed coupling reaction was incubated for 10
minutes in 10% TCA on ice and subsequently centrifuged. The pellet
was resuspended in 50 .mu.l 8.5 M Guanidine-HCl solution and
incubated for 15 minutes at 70.degree. C. The samples were then
precipitated with ethanol, and after a second centrifugation step,
the pellet was resuspended in sample buffer.
[0637] The results of the coupling experiments were analyzed by
SDS-PAGE under reducing conditions. Clear coupling bands were
visible for all three peptides, demonstrating coupling of A.beta.
peptides to Pili.
Example 15
Vaccination of APP23 Mice with A.beta. Peptides Coupled to
Q.beta.capsid Protein
[0638] A. Immunization of APP23 Mice
[0639] Three different A.beta. peptides (A.beta.
1-27-Gly-Gly-Cys-NH2 (SEQ ID NO:421);
H-Cys-Gly-His-Gly-Asn-Lys-Ser-A.beta. 33-42 (SEQ ID NO:422);
A.beta. 1-15-Gly-Gly-Cys-NH2 (SEQ ID NO:422)) were coupled to
Q.beta.capsid protein. The resulting vaccines were termed "Qb-Ab
1-15", "Qb-Ab 1-27" and "Qb-Ab 33-42". 8 months old female APP23
mice which carry a human APP transgene (Sturchler-Pierrat et al.,
Proc. Natl. Acad. Sci. USA 94: 13287-13292 (1997)) were used for
vaccination. The mice were injected subcutaneously with 25 .mu.g
vaccine diluted in sterile PBS and 14 days later boosted with the
same amount of vaccine. Mice were bled from the tail vein before
the start of immunization and 7 days after the booster injection.
The sera were analyzed by ELISA.
[0640] B. ELISA
[0641] A.beta. 1-40 and A.beta. 1-42 peptide stocks were made in
DMSO and diluted in coating buffer before use. ELISA plates were
coated with 0.1 .mu.g/well A.beta. 1-40 or A.beta. 1-42 peptide.
The plates were blocked and then incubated with serially diluted
mouse serum. Bound antibodies were detected with enzymatically
labeled anti-mouse IgG antibody. As a control, sera obtained before
vaccination were also included. The serum dilution showing a mean
three standard deviations above baseline was calculated and defined
as "ELISA titer". All three vaccines tested were immunogenic in
APP23 mice and induced high antibody titers against the A.beta.
peptides 1-40 and/or A.beta. 1-42. The results are shown in FIG.
20. No specific antibodies were detected in preimmune sera of the
same mice (not shown).
[0642] Shown on FIG. 20 are the ELISA signals obtained on day 22
with the sera of the mice immunized with vaccines Fr-A.beta. 1-15,
and HBc-A.beta.1-15 respectively. A control serum from a naive
mouse (preimmune serum) was also included. Results from different
serum dilutions are shown as optical density at 450 nm. Average
results from three vaccinated mice each are shown.
[0643] Mice A21-A30 received the vaccine Qb-Ab 1-15, mice A31-A40
received Qb-Ab 1-27 and mice A41-49 received Qb-Ab 33-42. For each
mouse, A.beta. 1-40 and A.beta. 1-42 peptide-specific serum
antibody titers were determined on day 21 by ELISA. The ELSIA
titers defined as the serum dilution showing a mean three standard
deviations above baseline are shown for individual mice. Mice
vaccinated with Qb-Ab 1-15 or Qb-Ab 1-27 made high antibody titers
against both A.beta. 1-40 and A.beta. 1-42 whereas mice vaccinated
with Qb-Ab 33-42 had only high antibody titers against the A.beta.
1-42 peptide.
Example 16
Coupling of Fab Antibody Fragments to Q.beta. Capsid Protein
[0644] A solution of 4.0 mg/ml Q.beta. capsid protein in 20 mM
Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with a 2.8 mM
SMPH (Pierce) (from a stock solution dissolved in DMSO) at
25.degree. C. on a rocking shaker. The reaction solution was
subsequently dialyzed twice for 2 hours against 2 l of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C.
[0645] The Fab fragment of human IgG, produced by papain digestion
of human IgG, was purchased from Jackson Immunolab. This solution
(11.1 mg/ml) was diluted to a concentration of 2.5 mg/ml in 20 mM
Hepes, 150 mM NaCl pH 7.2 and allowed to react with different
concentrations (0-1000 .mu.M) of either dithiothreitol (DTT) or
tricarboxyethylphosphine (TCEP) for 30 minutes at 25.degree. C.
[0646] Coupling was induced by mixing the derivatized and dialysed
Q.beta. capsid protein solution with non-reduced or reduced Fab
solution (final concentrations: 1.14 mg/ml Q.beta. and 1.78 mg/ml
Fab) and proceeded overnight at 25.degree. C. on a rocking
shaker.
[0647] The reaction products were analysed on 16% SDS-PAGE gels
under reducing conditions. Gels were stained with Coomassie
Brilliant Blue. The results are shown in FIG. 21.
[0648] A coupling product of about 40 kDa could be detected in
samples in which the Fab had been reduced before coupling by
25-1000 .mu.M TCEP and 25-100 .mu.M DTT (FIG. 21, arrow), but not
at 10 .mu.M TCEP, 10 .mu.M DTT or 1000 .mu.M DTT. The coupled band
also reacted with an anti-Q.beta. antiserum (data not shown)
clearly demonstrating the covalent coupling of the Fab fragment to
Q.beta.capsid protein.
The samples loaded on the gel of FIG. 21 were the following:
[0649] Lane 1: Molecular weight marker. Lane 2 and 3: derivatized
Q.beta. capsid protein before coupling. Lane 4-13: Q.beta.-Fab
coupling reactions after reduction of Fab with 4: Q.beta.-Fab
coupling reactions after reduction of Fab with 10 .mu.M TCEP. 5:
Q.beta.-Fab coupling reactions after reduction of Fab with 25 .mu.M
TCEP. 6: Q.beta.-Fab coupling reactions after reduction of Fab with
50 .mu.M TCEP, 7: Q.beta.-Fab coupling reactions after reduction of
Fab with 100 .mu.M TCEP. 8: Q.beta.-Fab coupling reactions after
reduction of Fab with 1000 .mu.M TCEP. 9: Q.beta.-Fab coupling
reactions after reduction of Fab with 10 .mu.M DTT. 10: Q.beta.-Fab
coupling reactions after reduction of Fab with 25 .mu.M DTT. 11:
Q.beta.-Fab coupling reactions after reduction of Fab with 50 .mu.M
DTT. 12: Q.beta.-Fab coupling reactions after reduction of Fab with
100 .mu.M DTT. 13: Q.beta.-Fab coupling reactions after reduction
of Fab with 1000 .mu.M DTT. Lane 14: Fab before coupling. The gel
was stained with Coomassie Brilliant Blue. Molecular weights of
marker proteins are given on the left margin. The arrow indicates
the coupled band.
Example 17
Vaccination of APP23 Mice with A.beta. Peptides Coupled to
Q.beta.capsid Protein
[0650] A. Immunization of APP23 Mice
[0651] Three different A.beta. peptides (A.beta.
1-27-Gly-Gly-Cys-NH2; H-Cys-Gly-His-Gly-Asn-Lys-Ser-A.beta. 33-42;
A.beta. 1-15-Gly-Gly-Cys-NH2) were coupled to Q.beta.capsid
protein. The resulting vaccines were termed "Qb-Ab 1-15", "Qb-Ab
1-27" and "Qb-Ab 33-42". 8 months old female APP23 mice which carry
a human APP transgene (Sturchler-Pierrat et al., Proc. Natl. Acad.
Sci. USA 94: 13287-13292 (1997)) were used for vaccination. The
mice were injected subcutaneously with 25 .mu.g vaccine diluted in
sterile PBS and 14 days later boosted with the same amount of
vaccine. Mice were bled from the tail vein before the start of
immunization and 7 days after the booster injection. The sera were
analyzed by ELISA.
[0652] B. ELISA
[0653] A.beta. 1-40 and A.beta. 1-42 peptide stocks were made in
DMSO and diluted in coating buffer before use. ELISA plates were
coated with 0.1 .mu.g/well A.beta. 1-40 or A.beta. 1-42 peptide.
The plates were blocked and then incubated with serially diluted
mouse serum. Bound antibodies were detected with enzymatically
labeled anti-mouse IgG antibody. As a control, sera obtained before
vaccination were also included. The serum dilution showing a mean
three standard deviations above baseline was calculated and defined
as "ELISA titer". All three vaccines tested were immunogenic in
APP23 mice and induced high antibody titers against the AB peptides
1-40 and/or A.beta. 1-42. The results are shown in FIG. 20. No
specific antibodies were detected in preimmune sera of the same
mice (not shown).
[0654] Shown on FIG. 20 are the ELISA signals obtained on day 22
with the sera of the mice immunized with vaccines Qb-Ab 1-15, Qb-Ab
1-27 and Qb-Ab 33-42, respectively. Mice A21-A30 received the
vaccine Qb-Ab 1-15, mice A31-A40 received Qb-Ab 1-27 and mice
A41-49 received Qb-Ab 33-42. For each mouse, A.beta. 1-40 and
A.beta. 1-42 peptide-specific serum antibody titers were determined
on day 21 by ELISA. The ELSIA titers defined as the serum dilution
showing a mean three standard deviations above baseline are shown
for individual mice. Mice vaccinated with Qb-Ab 1-15 or Qb-Ab 1-27
made high antibody titers against both A.beta. 1-40 and A.beta.
1-42 whereas mice vaccinated with Qb-Ab 33-42 had only high
antibody titers against the A.beta. 1-42 peptide. The very strong
immune responses obtained with the human A.beta. peptides in the
transgenic mice expressing human A.beta. transgene, demonstrate
that by coupling A.beta. peptides to Q.beta.capsid protein,
tolerance towards the self-antigen can be overcome.
Example 18
Construction, Expression and Purification of Mutant Q.beta. Coat
Proteins
[0655] Construction of pQ.beta.-240
[0656] The plasmid pQ.beta.10 (Kozlovska, T M, et al., Gene
137:133-137) was used as an initial plasmid for the construction of
pQ.beta.-240. The mutation Lys13.fwdarw.Arg was created by inverse
PCR. The inverse primers were designed in inverted tail-to-tail
directions: TABLE-US-00014 (SEQ ID NO: 370)
5'-GGTAACATCGGTCGAGATGGAAAACAAACTCTGGTCC-3' and (SEQ ID NO: 371)
5'-GGACCAGAGTTTGTTTTCCATCTCGACCGATGTTACC-3'.
[0657] The products of the first PCR were used as templates for the
second PCR reaction, in which an upstream primer
5'-AGCTCGCCCGGGGATCCTCTAG-3' (SEQ ID NO:372) and a downstream
primer 5'-CGATGCATTTCATCCTT-AGTTATCAATACGCTGGGTTCAG-3' (SEQ ID
NO:373) were used. The product of the second PCR was digested with
XbaI and Mph11031 and cloned into the pQ.beta.10 expression vector,
which was cleaved by the same restriction enzymes. The PCR
reactions were performed with PCR kit reagents and according to
producer protocol (MBI Fermentas, Vilnius, Lithuania).
[0658] Sequencing using the direct label incorporation method
verified the desired mutations. E. coli cells harbouring
pQ.beta.-240 supported efficient synthesis of 14-kD protein co
migrating upon PAGE with control Q.beta. coat protein isolated from
Q.beta. phage particles. TABLE-US-00015 Resulting amino acid
sequence: (SEQ ID NO: 255)
AKLETVTLGNIGRDGKQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSFTQYSTDEERAFVRTELAALLASPLLIDAIDQLNPAY
[0659] Construction of pQ.beta.-243
[0660] The plasmid pQ.beta.10 was used as an initial plasmid for
the construction of pQ.beta.-243. The mutation Asn10.fwdarw.Lys was
created by inverse PCR. The inverse primers were designed in
inverted tail-to-tail directions: TABLE-US-00016 (SEQ ID NO: 374)
5'-GGCAAAATTAGAGACTGTTACTTTAGGTAAGATCGG-3' and (SEQ ID NO: 375)
5'-CCGATCTTACCTAAAGTAACAGTCTCTAATTTTGCC-3'.
[0661] The products of the first PCR were used as templates for the
second PCR reaction, in which an upstream primer
5'-AGCTCGCCCGGGGATCCTCTAG-3' (SEQ ID NO:372) and a downstream
primer 5'-CGATGCATTTCATCCTTAG-TTATCAATACGCTGGGTTCAG-3' (SEQ ID
NO:373) were used. The product of the second PCR was digested with
XbaI and Mph1103I and cloned into the pQ.beta.10 expression vector,
which was cleaved by the same restriction enzymes. The PCR
reactions were performed with PCR kit reagents and according to
producer protocol (MBI Fermentas, Vilnius, Lithuania).
[0662] Sequencing using the direct label incorporation method
verified the desired mutations. E. coli cells harbouring
pQ.beta.-243 supported efficient synthesis of 14-kD protein co
migrating upon PAGE with control Q.beta. coat protein isolated from
Q.beta. phage particles. TABLE-US-00017 Resulting amino acid
sequence: (SEQ ID NO: 256)
AKLETVTLGKIGKDGKQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSFTQYSTDEERAFVRTELAALLASPLLIDAIDQLNPAY
[0663] Construction of pQ[[(]].beta.-250
[0664] The plasmid pQ.beta.-240 was used as an initial plasmid for
the construction of pQ.beta.-250. The mutation Lys2.fwdarw.Arg was
created by site-directed mutagenesis. An upstream primer
5'-GGCCATGGCACGACTCGAGACTGTTACTTTAGG-3' (SEQ ID NO:376) and a
downstream primer 5'-GATTTAGGTGACACTATAG-3' (SEQ ID NO:377) were
used for the synthesis of the mutant PCR-fragment, which was
introduced into the pQ.beta.-185 expression vector at the unique
restriction sites NcoI and HindIII. The PCR reactions were
performed with PCR kit reagents and according to producer protocol
(MBI Fermentas, Vilnius, Lithuania).
[0665] Sequencing using the direct label incorporation method
verified the desired mutations. E. coli cells harbouring
pQ.beta.-250 supported efficient synthesis of 14-kD protein co
migrating upon PAGE with control Q.beta. coat protein isolated from
Q.beta. phage particles. TABLE-US-00018 Resulting amino acid
sequence: (SEQ ID NO: 257)
ARLETVTLGNIGRDGKQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSFTQYSTDEERAFVRTELAALLASPLLIDAIDQLNPAY
[0666] Construction of pQ.beta.[[(]]-251
[0667] The plasmid pQ.beta.10 was used as an initial plasmid for
the construction of pQ.beta.-251. The mutation Lys16.fwdarw.Arg was
created by inverse PCR. The inverse primers were designed in
inverted tail-to-tail directions: TABLE-US-00019 (SEQ ID NO: 378)
5'-GATGGACGTCAAACTCTGGTCCTCAATCCGCGTGGGG-3' and (SEQ ID NO: 379)
5'-CCCCACGCGGATTGAGGACCAGAGTTTGACGTCCATC-3'.
[0668] The products of the first PCR were used as templates for the
second PCR reaction, in which an upstream primer
[0669] 5'-AGCTCGCCCGGGGATCCTCTAG-3' (SEQ ID NO:372) and a
downstream primer
[0670] 5'-CGATGCATTTCATCCTTAGTTATCAATACGCTGGGTTCAG-3' (SEQ ID
NO:373) were used. The product of the second PCR was digested with
XbaI and Mph1103I and cloned into the pQ.beta.10 expression vector,
which was cleaved by the same restriction enzymes. The PCR
reactions were performed with PCR kit reagents and according to
producer protocol (MBI Fermentas, Vilnius, Lithuania).
[0671] Sequencing using the direct label incorporation method
verified the desired mutations. E. coli cells harbouring
pQ.beta.-251 supported efficient synthesis of 14-kD protein co
migrating upon PAGE with control Q.beta. coat protein isolated from
Q.beta. phage particles. The resulting amino acid sequence encoded
by this construct is shown in SEQ. ID NO:259.
[0672] Construction of pQ.beta.-259
[0673] The plasmid pQ.beta.-251 was used as an initial plasmid for
the construction of pQ.beta.-259. The mutation Lys2.fwdarw.Arg was
created by site-directed mutagenesis. An upstream primer
5'-GGCCATGGCACGACTCGAGACTGTTACTTTAGG-3' (SEQ ID NO:376) and a
downstream primer 5'-GATTTAGGTGACACTATAG-3' (SEQ ID NO:377) were
used for the synthesis of the mutant PCR-fragment, which was
introduced into the pQ.beta.-185 expression vector at the unique
restriction sites NcoI and HindIII. The PCR reactions were
performed with PCR kit reagents and according to producer protocol
(MBI Fermentas, Vilnius, Lithuania).
[0674] Sequencing using the direct label incorporation method
verified the desired mutations. E. coli cells harbouring
pQ.beta.-251 supported efficient synthesis of 14-kD protein co
migrating upon PAGE with control Q.beta. coat protein isolated from
Q.beta. phage particles. The resulting amino acid sequence encoded
by this construct is shown in SEQ. ID NO: 259.
[0675] Construction of pQ.beta.-259
[0676] The plasmid pQ.beta.-251 was used as an initial plasmid for
the construction of pQ.beta.-259. The mutation Lys2.fwdarw.Arg was
created by site-directed mutagenesis. An upstream primer
[0677] 5'-GGCCATGGCACGACTCGAGACTGTTACTTTAGG-3' and a downstream
primer 5'-GATTTAGGTGACACTATAG-3' were used for the synthesis of the
mutant PCR-fragment, which was introduced into the pQ.beta.-185
expression vector at the unique restriction sites NcoI and HindIII.
The PCR reactions were performed with PCR kit reagents and
according to producer protocol (MBI Fermentas, Vilnius,
Lithuania).
[0678] Sequencing using the direct label incorporation method
verified the desired mutations. E. coli cells harbouring
pQ.beta.-259 supported efficient synthesis of 14-kD protein co
migrating upon PAGE with control Q.beta. coat protein isolated from
Q.beta. phage particles. TABLE-US-00020 Resulting amino acid
sequence: (SEQ ID NO: 258)
AKLETVTLGNIGKDGKQTLVLNPRGVNPTNGVASLSQAGAVP
ALEKRVTVSVSQPSRNRKNYKVQVKIQNPTACTANGSCDPSVTRQ
KYADVTFSFTQYSTDEERAFVRTELAALLASPLLIDAIDQLNPAY
General Procedures for Expression and Purification of Q.beta. and
Q.beta. Mutants
Expression
[0679] Transform E. coli JM109 with Q-beta expression plasmids.
Inoculate 5 ml of LB liquid medium with 20 .mu.g/ml ampicillin with
clones transformed with Q-beta expression plasmids. Incubate at
37.degree. C. for 16-24 h without shaking.
[0680] Inoculate 100-300 ml of LB medium, containing 20 .mu.g/ml,
1:100 with the prepared inoculum. Incubate at 37.degree. C.
overnight without shaking. Inoculate M9+1% Casamino acids+0.2%
glucose medium in flasks with the prepared inoculum 1:50, incubate
at 37.degree. C. overnight under shaking.
Purification
[0681] Solutions and Buffers for the Purification Procedure:
[0682] 1. Lysis Buffer LB [0683] 50 mM Tris-HCl pH8.0 with 5 mM
EDTA, 0.1% tritonX100 and fresh! prepared PMSF till 5 micrograms
per ml. Without lysozyme and DNAse.
[0684] 2. SAS [0685] Saturated ammonium sulphate in water
[0686] 3. Buffer NET. [0687] 20 mM Tris-HCl, pH 7.8 with 5 mM EDTA
and 150 mM NaCl.
[0688] 4. PEG [0689] 40% (w/v) polyethylenglycol 6000 in NET
[0690] Disruption and Lyses
[0691] Frozen cells were resuspended in LB at 2 ml/g cells. The
mixture was sonicated with 22 kH five times for 15 seconds, with
intervals of 1 min to cool the solution on ice. The lysate was then
centrifuged at 14 000 rpm, for 1 h using a Janecki K 60 rotor. The
centrifugation steps described below were all performed using the
same rotor, except otherwise stated. The supernatant was stored at
4.degree. C., while cell debris were washed twice with LB. After
centrifugation, the supernatants of the lysate and wash fractions
were pooled.
[0692] Fractionation
[0693] A saturated ammonium sulphate solution was added dropwise
under stirring to the above pooled lysate. The volume of the SAS
was adjusted to be one fifth of total volume, to obtain 20% of
saturation. The solution was left standing overnight, and was
centrifuged the next day at 14 000 rpm, for 20 min. The pellet was
washed with a small amount of 20% ammonium sulphate, and
centrifuged again. The obtained supernatants were pooled, and SAS
was added dropwise to obtain 40% of saturation. The solution was
left standing overnight, and was centrifuged the next day at 14 000
rpm, for 20 min. The obtained pellet was solubilised in NET
buffer.
[0694] Chromatography
[0695] The capsid protein resolubilized in NET buffer was loaded on
a Sepharose CL-4B column. Three peaks eluted during chromatography.
The first one mainly contained membranes and membrane fragments,
and was not collected. Capsids were contained in the second peak,
while the third one contained other E. coli proteins.
[0696] The peak fractions were pooled, and the NaCl concentration
was adjusted to a final concentration of 0.65 M. A volume of PEG
solution corresponding to one half of the pooled peak fraction was
added dropwise under stirring. The solution was left to stand
overnight without stirring. The capsid protein was sedimented by
centrifugation at 14 000 rpm for 20 min. It was then solubilized in
a minimal volume of NET and loaded again on the Sepharose CL-4B
column. The peak fractions were pooled, and precipitated with
ammonium sulphate at 60% of saturation (w/v). After centrifugation
and resolubilization in NET buffer, capsid protein was loaded on a
Sepharose CL-6B column for rechromatography.
[0697] Dialysis and Drying
[0698] The peak fractions obtained above were pooled and
extensively dialysed against sterile water, and lyophilized for
storage.
[0699] Expression and Purification Q.beta.-240
[0700] Cells (E. coli JM 109, transformed with the plasmid
pQ.beta.-240) were resuspended in LB, sonicated five times for 15
seconds (water ice jacket) and centrifuged at 13000 rpm for one
hour. The supernatant was stored at 4.degree. C. until further
processing, while the debris were washed 2 times with 9 ml of LB,
and finally with 9 ml of 0.7 M urea in LB. All supernatants were
pooled, and loaded on the Sepharose CL-4B column. The pooled peak
fractions were precipitated with ammonium sulphate and centrifuged.
The resolubilized protein was then purified further on a Sepharose
2B column and finally on a Sepharose 6B column. The capsid peak was
finally extensively dialyzed against water and lyophilized as
described above. The assembly of the coat protein into a capsid was
confirmed by electron microscopy.
[0701] Expression and Purification Q.beta.-243
[0702] Cells (E. coli RR1) were resuspended in LB and processed as
described in the general procedure. The protein was purified by two
successive gel filtration steps on the sepharose CL-4B column and
finally on a sepharose CL-2B column. Peak fractions were pooled and
lyophilized as described above. The assembly of the coat protein
into a capsid was confirmed by electron microscopy.
[0703] Expression and Purification of Q.beta.-250
[0704] Cells (E. coli JM 109, transformed with pQ.beta.-250) were
resuspended in LB and processed as described above. The protein was
purified by gel filtration on a Sepharose CL-4B and finally on a
Sepharose CL-2B column, and lyophilized as described above. The
assembly of the coat protein into a capsid was confirmed by
electron microscopy.
[0705] Expression and Purification of Q.beta.-259
[0706] Cells (E. coli JM 109, transformed with pQ.beta.-259) were
resuspended in LB and sonicated. The debris were washed once with
10 ml of LB and a second time with 10 ml of 0.7 M urea in LB. The
protein was purified by two gel-filtration chromatogaphy steps, on
a Sepharose CL-4 B column. The protein was dialyzed and
lyophilized, as described above. The assembly of the coat protein
into a capsid was confirmed by electron microscopy.
Example 19
Desensitization of Allergic Mice with PLA2 Coupled to Q.beta.Capsid
Protein
[0707] B. Desensitization of Allergic Mice by Vaccination
[0708] Female CBA/J mice (8 weeks old) were sensitized with PLA2:
Per mouse, 0.1 ug PLA2 from Latoxan (France) was adsorbed to 1 mg
Alum (Imject, Pierce) in a total volume of 66 ul by vortexing for
30 min and then injected subcutaneously. This procedure was
repeated every 14 days for a total of four times. This treatment
led to the development of PLA2-specific serum IgE but no IgG2a
antibodies. 1 month after the last sensitization, mice were
injected subcutaneously with 10 ug vaccine consisting of
recombinant PLA2 coupled to Q.beta.capsid protein. One and 2 weeks
later they were again treated with the same amount of vaccine. One
week after the last treatment, mice were bled and then challenged
intraperitoneally with 25 .mu.g PLA2 (Latoxan) and rectal
temperature was measured for 60 min using a calibrated digital
thermometer. As a control sensitized mice which had not been
treated with Q.beta.capsid protein-PLA2 were used. Whereas all
control mice experienced an anaphylactic response reflected in a
dramatic drop in rectal temperature after PLA2 challenge,
vaccinated mice were fully or at least partially protected. Results
are shown in FIG. 25 A.
[0709] B. ELISA
[0710] ELISA plates (Maxisorp, Nunc) were coated with PLA2
(Latoxan) at 5 .mu.g/ml. The plates were blocked and then incubated
with serially diluted serum. For the detection of IgE antibodies,
serum was pretreated with protein G beads (Pharmacia) for 60 min on
a shaker at room temperature. The beads were removed by
centrifugation and the supernatant was used for ELISA. Antibodies
bound to PLA2 were detected with enzymatically labeled anti-mouse
IgG2a or IgE antibodies. ELISA titers were determined at half
maximal optical density (OD50%) and expressed as -log 5 of 100-fold
prediltued sera for IgG2a and as -log 5 of 10-fold prediluted sera
for IgE. For all mice, PLA2-specific IgG2a and IgE in serum were
determined before and at the end of the vaccine treatment.
Vaccination led to a dramatic increase of PLA2-specific IgG2a
whereas no consistent changes in IgE titers were noted. These
results indicate that the vaccination led to an induction of a
Th1-like immune response (reflected by the production of IgG2a).
Results are shown in FIG. 25 B.
[0711] The Anaphylactic response in vaccinated and non-vaccinated
mice is shown in FIG. 25A.
[0712] Mice were sensitized to PLA2 and then treated 3.times.
subcutaneously with 10 .mu.g vaccine consisting of PLA2 coupled to
Q.beta. capsid protein. Control mice were sensitized but not
vaccinated. One week after the last vaccination all mice were
challenged intraperitoneally with 25 .mu.g PLA2 and the
anaphylactic response was monitored by measuring the rectal
temperature for 60 min. Whereas all control mice showed a dramatic
drop in body temperature, vaccinated mice were fully or at least
partially protected from an anaphylactic reaction.
[0713] The induction of PLA2-specific IgG2a by vaccination is shown
in FIG. 25 B.
[0714] Mice were sensitized to PLA2 and then treated 3.times. with
10 ug vaccine consisting of PLA2 coupled to Q.mu.capsid protein.
Control mice were sensitized but not vaccinated. Serum was taken
from sensitized mice before the start of the treatment and after
completion of treatment, before challenge. In vaccinated mice (left
hand of panel) a dramatic increase of PLA2-specific IgG2a was
observed.
Example 20
Expression, Refolding, Purification and Coupling of Pla.sub.2-Cys
(also Called PLA.sub.2 Fusion Protein)
[0715] Expression and Preparation of Inclusion Bodies
[0716] The pET11a Plasmid containing the PLA.sub.2-Cys gene of
example xxx was transformed into E. coli BL21DE3Rill (Stratagene).
An overnight culture was grown in dYT medium containing 100
.mu.g/ml Ampicillin and 15 .mu.g/ml Chloramphenicol. The culture
was diluted in fresh dYT medium containing Ampicillin and
Chloramphenicol, and grown at 37.degree. C. until OD.sub.600 nm=1
was reached. The culture was induced with 1 mM IPTG, and grown for
another 4 hours. Cells were collected by centrifugation, and
resuspended in PBS buffer containing 0.5 mg/ml Lysozyme. After
incubation on ice, cells were sonicated on ice, and MgCl.sub.2
added to a concentration of 10 mM. 6 .mu.l of Benzonase (Merck)
were added to the cell lysate, and the lysate was incubated 30
minutes at RT. Triton was added to a final concentration of 1%, and
the lysate was further incubated for 30 minutes on ice. The
inclusion body (IB) pellet was collected by centrifugation for 10
minutes at 13000 g. The inclusion body pellet was washed in wash
buffer containing 20 mM Tris, 23% sucrose, 1 mM EDTA, pH 8.0. The
IBs were solubilized in 6 M Guanidinium-HCl, 20 mM Tris, pH 8.0,
containing 200 mM DTT. The solubilized IBs were centrifuged at
50000 g and the supernatant dialyzed against 6 M Guanidinium-HCl,
20 mM Tris, pH 8.0 and subsequently against the same buffer
containing 0.1 mM DTT. Oxidized glutathion was added to a final
concentration of 50 mM, and the solubilized IBs were incubated for
1 h. at RT. The solubilized IBs were dialyzed against 6 M
Guanidinium-HCL, 20 mM Tris, pH 8.0. The concentration of the IB
solution was estimated by Bradford analysis and SDS-PAGE.
[0717] B. Refolding and Purification
[0718] The IB solution was added slowly in three portions, every 24
h., to a final concentration of 3 .mu.M, to the refolding buffer
containing 2 mM EDTA, 0.2 mM Benzamidin, 0.2 mM 6 aminocapronic
acid, 0.2 mM Guanidinium-HCl, 0.4 M L-Arginin, pH 6.8, to which 5
mM reduced Glutathion and 0.5 mM oxidized Glutathion were added
prior to initiation of refolding at 4.degree. C. The refolding
solution was concentrated to one half of its volume by
Ultrafiltration using a YM10 membrane (Millipore) and dialyzed
against PBS, pH 7.2, containing 0.1 mM DTT. The protein was further
concentrated by ultrafiltration and loaded onto a Superdex G-75
column (Pharmacia) equilibrated in 20 mM Hepes, 150 mM NaCl, 0.1 mM
DTT, 4.degree. C. for purification. The pH of the equilibration
buffer was adjusted to 7.2 at RT. The monomeric fractions were
pooled.
[0719] C. Coupling
[0720] A solution of 1.5 mg Q.beta. in 0.75 mL 20 mM Hepes, 150 mM
NaCl, pH 7.4 was reacted with 0.06 mL Sulfo-SMPB (Pierce; 31 mM
Stock in H2O) for 45 min. at RT. The reaction mixture was dialyzed
overnight against 20 mM Hepes, 150 mM NaCl, pH 7.4 and 0.75 mL of
this solution were mixed with 1.5 mL of a PLA.sub.2-Cys solution in
0.1 mM DTT (62 .mu.M) and 0.43 mL of 20 mM Hepes, 150 mM NaCl, 137
.mu.M DTT, pH 7.4 adjusted at RT. The coupling reaction was left to
proceed for 4 h. at RT, and the reaction mixture was dialyzed
overnight against 20 mM Hepes, 150 mM NaCl, pH 7.4 using Spectra
Por dialysis tubing, MW cutoff 300 000 Da (Spectrum). The coupling
reaction was analyzed by SDS-PAGE and coomassie staining, and
Western blotting, using either a rabbit anti-bee venom antiserum
(diluted 1:10000), developed with a goat anti-rabbit alkaline
phosphatase conjugate (diluted 1:10000), or a rabbit anti-Q.beta.
antiserum (1:5000), developed with a goat anti-rabbit alkaline
phosphatase conjugate (diluted 1:10000). Samples were run in both
cases under reducing conditions.
[0721] The result of the coupling reaction is shown in FIG. 26.
Bands corresponding to the coupling product of Q.beta. capsid
protein to PLA.sub.2-Cys are clearly visible in the coomassie
stained SDS-PAGE (left panel), the anti-Q.beta. Western Blot
(center panel) and the anti-PLA2 Western blot (right panel) of the
coupling reactions between Q.beta. capsid protein and
PLA.sub.2-Cys, and are indicated by an arrow in the figure. 15
.mu.l of the coupling reactions and 50 .mu.l of the dialyzed
coupling reactions were loaded on the gel.
[0722] Lane 1: Protein marker. 2: Dialyzed coupling reaction 1. 3:
Coupling reaction 1. 4: Coupling reaction 2. 5: coupling reaction
2. 6: Coupling reaction 1. 7: Dialyzed coupling reaction 1. 8:
Protein Marker. 9: Coupling reaction 2. 10: Coupling reaction 1.
11: Dialyed coupling reaction 1. 12: Protein Marker.
Example 21
[0723] Coupling of Anti-Idiotypic IgE Mimobody VAE051 to Q.beta.,
Immunization of Mice and Testing of Antisera
[0724] A solution of 4.0 mg/ml Q.beta. capsid protein in 20 mM
Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 10 fold
molar excess SMPH (Pierce) (from a 100 mM stock solution dissolved
in DMSO) at 25.degree. C. on a rocking shaker. The reaction
solution was subsequently dialyzed twice for 2 hours against 2 l of
20 mM Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. The VAE051
solution (2.4 mg/ml) was reducted with an equimolar concentration
of TCEP for 60 min at 25.degree. C.
[0725] 46 .mu.l of the dialyzed Q.beta. reaction mixture was then
reacted with 340 .mu.l of the TCEP-treated VAE051 solution (2.4
mg/ml) in a total volume of 680 .mu.l of 50 mM sodium acetate
buffer at 16.degree. C. for 2 h on a rocking shaker.
[0726] The reaction products were analysed on 16% SDS-PAGE gels
under reducing conditions. Gels were either stained with Coomassie
Brilliant Blue. The two additional band in the coupling reactions
(which are absent in VAE or Q.beta. solutions) represent the heavy
chain and the light chain of the VAE051 coupled to Q.beta. (FIG. 28
A. Identity of the bands were confirmed by Western blotting with
antibodies specific for heavy and light chains, respectively.
[0727] Immunization of Mice
[0728] The Q.beta.-VAE051 coupling solution was dialysed against 20
mM Hepes, 150 mM NaCl, pH 7.2 using a membrane with a cut-off of
300000 Da. 50 .mu.g of the Q.beta.-VAE051 were injected
intraperitoneal in two female Balb/c mice at day 0 and day 14. Mice
were bled retroorbitally on day 28 and their serum was analyzed
using IgE- and VAE051-specific ELISAs.
[0729] ELISA
[0730] ELISA plates were coated with human IgE at a concentration
of 0.8 .mu.g/ml or with 10 .mu.g/ml VAE051. The plates were blocked
and then incubated with serially diluted mouse sera. Bound
antibodies were detected with enzymatically labeled anti-mouse IgG
antibody (FIG. 28 B).
[0731] Both mice showed high reactivity to VAE051 as well as the
human IgE. Preimmune sera of the same mice did not show any
reactivity against VAE051 and IgE (FIG. 28 B). This demonstrates
that antibodies against the anti-idiotypic IgE mimobody VAE051 have
been produced which also recognize the "parent" molecule IgE.
Example 22
High Occupancy Coupling of DerpI Peptide to wt Q.beta.capsid
Protein Using the Cross-Linker SMPH
[0732] The Derp 1,2 peptide, to which a cysteine was added
N-terminally for coupling, was chemically synthesized and had the
following sequence: H.sub.2N-CQIYPPNANKIREALAQTHSA-COOH (SEQ ID
NO:385). This peptide was used for chemical coupling to wt Q.beta.
capsid protein and as described in the following.
[0733] D. Coupling of Flag Peptide to Q.beta. Capsid Protein
[0734] Q.beta. capsid protein in 20 mM Hepes, 150 mM NaCl, pH 7.2,
at a concentration of 2 mg/ml, was reacted with a 5- or 20-fold
excess of the cross-linker SMPH (Pierce) for 30 min. at 25.degree.
C. on a rocking shaker. The reaction solution was subsequently
dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl,
pH 7.2 at 4.degree. C. The dialyzed reaction mixture was then
reacted with a 5-fold excess of Derp 1,2 peptide for two hours at
25.degree. C. on a rocking shaker.
[0735] The result of the coupling reaction can be seen on FIG. 24.
Coupling bands corresponding to 1, 2 and 3 peptides per subunit,
respectively, are clearly visible on the gel, and are indicated by
arrows. An average of two peptides per subunit were displayed on
the capsid.
[0736] The samples loaded on the gel of FIG. 24 were the
following:
[0737] Lane 1: Protein Marker. 2: Q.beta. capsid protein
derivatized with a 5-fold excess of SMPH. 3: Q.beta. capsid protein
derivatized with a 20-fold excess of SMPH. 4: Coupling reaction of
5-fold derivatized Q.beta. capsid protein. 5: Coupling reaction of
20-fold derivatized Q.beta. capsid protein.
Example 23
Insertion of a Peptide Containing a Lysine Residue into the c/e1
Epitope of HBcAg(1-149)
[0738] The c/e1 epitope (residues 72 to 88) of HBcAg is located in
the tip region on the surface of the Hepatitis B virus capsid
(HBcAg). A part of this region (Proline 79 and Alanine 80) was
genetically replaced by the peptide Gly-Gly-Lys-Gly-Gly (HBcAg-Lys
construct; SEQ ID NO:406). The introduced Lysine residue contains a
reactive amino group in its side chain that can be used for
intermolecular chemical crosslinking of HBcAg particles with any
antigen containing a free cysteine group.
[0739] HBcAg-Lys DNA, having the amino acid sequence shown in SEQ
ID NO:158, was generated by PCRs: The two fragments encoding HBcAg
fragments (amino acid residues 1 to 78 and 81 to 149) were
amplified separately by PCR. The primers used for these PCRs also
introduced a DNA sequence encoding the Gly-Gly-Lys-Gly-Gly (SEQ ID
NO:406) peptide. The HBcAg (1 to 78) fragment was amplified from
pEco63 using primers EcoRIHBcAg(s) and Lys-HBcAg(as). The HBcAg (81
to 149) fragment was amplified from pEco63 using primers
Lys-HBcAg(s) and HBcAg(1-149)Hind(as). Primers Lys-HBcAg(as) and
Lys-HBcAg(s) introduced complementary DNA sequences at the ends of
the two PCR products allowing fusion of the two PCR products in a
subsequent assembly PCR. The assembled fragments were amplified by
PCR using primers EcoRIHBcAg(s) and HbcAg(1-149)Hind(as).
[0740] For the PCRs; 100 pmol of each oligo and 50 ng of the
template DNAs were used in the 50 ml reaction mixtures with 2 units
of Pwo polymerase, 0.1 mM dNTPs and 2 mM MgSO4. For both reactions,
temperature cycling was carried out as follows: 94.degree. C. for 2
minutes; 30 cycles of 94.degree. C. (1 minute), 50.degree. C. (1
minute), 72.degree. C. (2 minutes). TABLE-US-00021 Primer
sequences: EcoRIHBcAg(s): (SEQ ID NO: 79)
(5'-CCGGAATTCATGGACATTGACCCTTATAAAG-3'); Lys-HBcAg(as): (SEQ ID NO:
80) (5'- CCTAGAGCCACCTTTGCCACCATCTTCTAAATTAGTACCCACCCAG GTAGC-3');
Lys-HBcAg(s): (SEQ ID NO: 81) (5'-
GAAGATGGTGGCAAAGGTGGCTCTAGGGACCTAGTAGTCAGTTAT GTC-3');
HBcAg(1-149)Hind(as): (SEQ ID NO: 82)
(5'-CGCGTCCCAAGCTTCTAAACAACAGTAGTCTCCGGAAG-3').
[0741] For fusion of the two PCR fragments by PCR 100 pmol of
primers EcoRIHBcAg(s) and HBcAg(1-49)Hind(as) were used with 100 ng
of the two purified PCR fragments in a 50 ml reaction mixture
containing 2 units of Pwo polymerase, 0.1 mM dNTPs and 2 mM MgSO4.
PCR cycling conditions were: 94.degree. C. for 2 minutes; 30 cycles
of 94.degree. C. (1 minute), 50.degree. C. (1 minute), 72.degree.
C. (2 minutes). The assembled PCR product was analyzed by agarose
gel electrophoresis, purified and digested for 19 hours in an
appropriate buffer with EcoRI and HindIII restriction enzymes. The
digested DNA fragment was ligated into EcoRI/HindIII-digested pKK
vector to generate pKK-HBcAg-Lys expression vector. Insertion of
the PCR product into the vector was analyzed by EcoRI/HindIII
restriction analysis and DNA sequencing of the insert.
Example 24
Expression and Partial Purification of HBcAg-Lys
[0742] E. coli strain XL-1 blue was transformed with pKK-HBcAg-Lys.
1 ml of an overnight culture of bacteria was used to innoculate 100
ml of LB medium containing 100 .mu.g/ml ampicillin. This culture
was grown for 4 hours at 37.degree. C. until an OD at 600 nm of
approximately 0.8 was reached. Induction of the synthesis of
HBcAg-Lys was performed by addition of IPTG to a final
concentration of 1 mM. After induction, bacteria were further
shaken at 37.degree. C. for 16 hours. Bacteria were harvested by
centrifugation at 5000.times.g for 15 minutes. The pellet was
frozen at -20.degree. C. The pellet was thawed and resuspended in
bacteria lysis buffer (10 mM Na2HPO4, pH 7.0, 30 mM NaCl, 0.25%
Tween-20, 10 mM EDTA, 10 mM DTT) supplemented with 200 .mu.g/ml
lysozyme and 10 .mu.l of Benzonase (Merck). Cells were incubated
for 30 minutes at room temperature and disrupted using a French
pressure cell. Triton X-100 was added to the lysate to a final
concentration of 0.2%, and the lysate was incubated for 30 minutes
on ice and shaken occasionally. E. coli cells harboring
pKK-HBcAg-Lys expression plasmid or a control plasmid were used for
induction of HBcAg-Lys expression with IPTG. Prior to the addition
of IPTG, a sample was removed from the bacteria culture carrying
the pKK-HBcAg-Lys plasmid and from a culture carrying the control
plasmid. Sixteen hours after addition of IPTG, samples were again
removed from the culture containing pKK-HBcAg-Lys and from the
control culture. Protein expression was monitored by SDS-PAGE
followed by Coomassie staining.
[0743] The lysate was then centrifuged for 30 minutes at
12,000.times.g in order to remove insoluble cell debris. The
supernatant and the pellet were analyzed by Western blotting using
a monoclonal antibody against HBcAg (YVS1841, purchased from
Accurate Chemical and Scientific Corp., Westbury, N.Y., USA),
indicating that a significant amount of HBcAg-Lys protein was
soluble. Briefly, lysates from E. colicells expressing HBcAg-Lys
and from control cells were centrifuged at 14,000.times.g for 30
minutes. Supernatant (=soluble fraction) and pellet (=insoluble
fraction) were separated and diluted with SDS sample buffer to
equal volumes. Samples were analyzed by SDS-PAGE followed by
Western blotting with anti-HBcAg monoclonal antibody YVS 1841.
[0744] The cleared cell lysate was used for step-gradient
centrifugation using a sucrose step gradient consisting of a 4 ml
65% sucrose solution overlaid with 3 ml 15% sucrose solution
followed by 4 ml of bacterial lysate. The sample was centrifuged
for 3 hrs with 100,000.times.g at 4.degree. C. After
centrifugation, 1 ml fractions from the top of the gradient were
collected and analyzed by SDS-PAGE followed by Coomassie staining.
The HBcAg-Lys protein was detected by Coomassie staining.
[0745] The HBcAg-Lys protein was enriched at the interface between
15 and 65% sucrose indicating that it had formed a capsid particle.
Most of the bacterial proteins remained in the sucrose-free upper
layer of the gradient, therefore step-gradient centrifugation of
the HBcAg-Lys particles led both to enrichment and to a partial
purification of the particles.
Example 25
Chemical Coupling of FLAG Peptide to HbcAg-Lys Using the
Heterobifunctional Cross-Linker SPDP
[0746] Synthetic FLAG peptide with a Cysteine residue at its amino
terminus (amino acid sequence CGGDYKDDDDK (SEQ ID NO:147)) was
coupled chemically to purified HBcAg-Lys particles in order to
elicit an immune response against the FLAG peptide. 600 ml of a 95%
pure solution of HBcAg-Lys particles (2 mg/ml) were incubated for
30 minutes at room temperature with the heterobifunctional
cross-linker N-Succinimidyl 3-(2-pyridyldithio)propionate (SPDP)
(0.5 mM). After completion of the reaction, the mixture was
dialyzed overnight against 1 liter of 50 mM Phosphate buffer (pH
7.2) with 150 mM NaCl to remove free SPDP. Then 500 ml of
derivatized HBcAg-Lys capsid (2 mg/ml) were mixed with 0.1 mM FLAG
peptide (containing an amino-terminal cysteine) in the presence of
10 mM EDTA to prevent metal-catalyzed sulfhydryl oxidation. The
reaction was monitored through the increase of the optical density
of the solution at 343 nm due to the release of pyridine-2-thione
from SPDP upon reaction with the free cysteine of the peptide. The
reaction of derivatized Lys residues with the peptide was complete
after approximately 30 minutes.
[0747] The FLAG decorated particles were injected into mice.
Example 26
Construction of pMPSV-gp140cys
[0748] The gp140 gene was amplified by PCR from pCytTSgp140FOS
using oligos gp140CysEcoRI and SalIgp140. For the PCRs, 100 pmol of
each oligo and 50 ng of the template DNAs were used in the 50 ml
reaction mixtures with 2 units of Pwo polymerase, 0.1 mM dNTPs and
2 mM MgSO4. For both reactions, temperature cycling was carried out
as follows: 94.degree. C. for 2 minutes; 30 cycles of 94.degree. C.
(0.5 minutes), 55.degree. C. (0.5 minutes), 72.degree. C. (2
minutes).
[0749] The PCR product was purified using QiaEXII kit, digested
with SalI/EcoRI and ligated into vector pMPSVHE cleaved with the
same enzymes. TABLE-US-00022 Oligo sequences: Gp140CysEcoRI: (SEQ
ID NO: 83) 5'-GCCGAATTCCTAGCAGCTAGCACCGAATTTATCTAA-3'; SalIgp140:
(SEQ ID NO: 84) 5'-GGTTAAGTCGACATGAGAGTGAAGGAGAAATAT-3'.
Example 27
Expression of pMPSVgp 140Cys
[0750] pMPSVgp140Cys (20 .mu.g) was linearized by restriction
digestion. The reaction was stopped by phenol/chloroform
extraction, followed by an isopropanol precipitation of the
linearized DNA. The restriction digestion was evaluated by agarose
gel electrophoresis. For the transfection, 5.4 .mu.g of linearized
pMPSVgp140-Cys was mixed with 0.6 .mu.g of linearized pSV2Neo in 30
.mu.l H.sub.2O and 30 .mu.l of 1 M CaCl.sub.2 solution was added.
After addition of 60 .mu.l phosphate buffer (50 mM HEPES, 280 mM
NaCl, 1.5 mM Na.sub.2 HPO.sub.4, pH 7.05), the solution was
vortexed for 5 seconds, followed by an incubation at room
temperature for 25 seconds. The solution was immediately added to 2
ml HP-1 medium containing 2% FCS (2% FCS medium). The medium of an
80% confluent BHK21 cell culture (6-well plate) was then replaced
by the DNA containing medium. After an incubation for 5 hours at
37.degree. C. in a CO.sub.2 incubator, the DNA containing medium
was removed and replaced by 2 ml of 15% glycerol in 2% FCS medium.
The glycerol containing medium was removed after a 30 second
incubation phase, and the cells were washed by rinsing with 5 ml of
HP-1 medium containing 10% FCS. Finally 2 ml of fresh HP-1 medium
containing 10% FCS was added.
[0751] Stably transfected cells were selected and grown in
selection medium (HP-1 medium supplemented with G418) at 37.degree.
C. in a CO.sub.2 incubator. When the mixed population was grown to
confluency, the culture was split to two dishes, followed by a 12 h
growth period at 37.degree. C. One dish of the cells was shifted to
30.degree. C. to induce the expression of soluble GP140-FOS. The
other dish was kept at 37.degree. C.
[0752] The expression of soluble GP140-Cys was determined by
Western blot analysis. Culture media (0.5 ml) was
methanol/chloroform precipitated, and the pellet was resuspended in
SDS-PAGE sample buffer. Samples were heated for 5 minutes at
95.degree. C. before being applied to a 15% acrylamide gel. After
SDS-PAGE, proteins were transferred to Protan nitrocellulose
membranes (Schleicher & Schuell, Germany) as described by Bass
and Yang, in Creighton, T. E., ed., Protein Function: A Practical
Approach, 2nd Edn., IRL Press, Oxford (1997), pp. 29-55. The
membrane was blocked with 1% bovine albumin (Sigma) in TBS
(10.times.TBS per liter: 87.7 g NaCl, 66.1 g Trizma hydrochloride
(Sigma) and 9.7 g Trizma base (Sigma), pH 7.4) for 1 hour at room
temperature, followed by an incubation with an anti-GP140 or GP-160
antibody for 1 hour. The blot was washed 3 times for 10 minutes
with TBS-T (TBS with 0.05% Tween20), and incubated for 1 hour with
an alkaline-phosphatase-anti-mouse/rabbit/monkey/human IgG
conjugate. After washing 2 times for 10 minutes with TBS-T and 2
times for 10 minutes with TBS, the development reaction was carried
out using alkaline phosphatase detection reagents (10 ml AP buffer
(100 mM Tris/HCl, 100 mM NaCl, pH 9.5) with 50 .mu.l NBT solution
(7.7% Nitro Blue Tetrazolium (Sigma) in 70% dimethylformamide) and
37 .mu.l of X-Phosphate solution (5% of 5-bromo-4-chloro-3-indolyl
phosphate in dimethylformamide).
Example 28
Purification of gp140Cys
[0753] An anti-gp120 antibody was covalently coupled to a NHS/EDC
activated dextran and packed into a chromatography column. The
supernatant, containing GP140Cys is loaded onto the column and
after sufficient washing, GP140Cys was eluted using 0.1 M HCl. The
eluate was directly neutralized during collection using 1 M Tris pH
7.2 in the collection tubes.
[0754] Disulfide bond formation might occur during purification,
therefore the collected sample is treated with 10 mM DTT in 10 mM
Tris pH 7.5 for 2 hours at 25.degree. C.
[0755] DTT is remove by subsequent dialysis against 10 mM Mes; 80
mM NaCl pH 6.0. Finally GP140Cys is mixed with alphavirus particles
containing the JUN residue in E2 as described in Example 16.
Example 29
Construction of PLA.sub.2-Cys
[0756] The PLA2 gene was amplified by PCR from pAV3PLAfos using
oligos EcoRIPLA and PLA-Cys-hind. For the PCRs, 100 pmol of each
oligo and 50 ng of the template DNAs were used in the 50 ml
reaction mixtures with 2 units of Pwo polymerase, 0.1 mM dNTPs and
2 mM MgSO4. For the reaction, temperature cycling was carried out
as follows: 94.degree. C. for 2 minutes; 30 cycles of 94.degree. C.
(0.5 minutes), 55.degree. C. (0.5 minutes), 72.degree. C. (2
minutes).
[0757] The PCR product was purified using QiaEXII kit, digested
with EcoRI/HindIII and ligated into vector pAV3 cleaved with the
same enzymes. TABLE-US-00023 Oligos EcoRIPLA: (SEQ ID NO: 85)
5'-TAACCGAATTCAGGAGGTAAAAAGATATGG-3' PLA Cys-hind: (SEQ ID NO: 86)
5'-GAAGTAAAGCTTTTAACCACCGCAACCACCAGAAG-3'.
Example 30
Expression and Purification of PLA.sub.2-Cys
[0758] For cytoplasmic production of Cys tagged proteins, E. coli
XL-1-Blue strain was transformed with the vectors pAV3::PLA and
pPLA-Cys. The culture was incubated in rich medium in the presence
of ampicillin at 37.degree. C. with shaking. At an optical density
(550 nm) of, 1 mM IPTG was added and incubation was continued for
another 5 hours. The cells were harvested by centrifugation,
resuspended in an appropriate buffer (e.g., Tris-HCl, pH 7.2, 150
mM NaCl) containing DNase, RNase and lysozyme, and disrupted by
passage through a french pressure cell. After centrifugation
(Sorvall RC-5C, SS34 rotor, 15000 rpm, 10 min, 4.degree. C.), the
pellet was resuspended in 25 ml inclusion body wash buffer (20 mM
tris-HCl, 23% sucrose, 0.5% Triton X-100, 1 mM EDTA, pH8) at
4.degree. C. and recentrifuged as described above. This procedure
was repeated until the supernatant after centrifugation was
essentially clear. Inclusion bodies were resuspended in 20 ml
solubilization buffer (5.5 M guanidinium hydrochloride, 25 mM
tris-HCl, pH 7.5) at room temperature and insoluble material was
removed by centrifugation and subsequent passage of the supernatant
through a sterile filter (0.45 .mu.m). The protein solution was
kept at 4.degree. C. for at least 10 hours in the presence of 10 mM
EDTA and 100 mM DTT and then dialyzed three times against 10
volumes of 5.5 M guanidinium hydrochloride, 25 mM tris-HCl, 10 mM
EDTA, pH 6. The solution was dialyzed twice against 51 2 M urea, 4
mM EDTA, 0.1 M N4Cl, 20 mM sodium borate (pH 8.3) in the presence
of an appropriate redox shuffle (oxidized glutathione/reduced
glutathione; cystine/cysteine). The refolded protein was then
applied to an ion exchange chromatography. The protein was stored
in an appropriate buffer with a pH above 7 in the presence of 2-10
mM DTT to keep the cysteine residues in a reduced form. Prior to
coupling of the protein with the alphavirus particles, DTT was
removed by passage of the protein solution through a Sephadex G-25
gel filtration column.
Example 31
Construction of a HBcAg Devoid of Free Cysteine Residues and
Containing an Inserted Lysine Residue
[0759] A Hepatitis core Antigen (HBcAg), referred to herein as
HBcAg-lys-2cys-Mut, devoid of cysteine residues at positions
corresponding to 48 and 107 in SEQ ID NO:134 and containing an
inserted lysine residue was constructed using the following
methods.
[0760] The two mutations were introduced by first separately
amplifying three fragments of the HBcAg-Lys gene prepared as
described above in Example 23 with the following PCR primer
combinations. PCR methods essentially as described in Example 1 and
conventional cloning techniques were used to prepare the
HBcAg-lys-2cys-Mut gene.
[0761] In brief, the following primers were used to prepare
fragment 1: TABLE-US-00024 Primer 1: EcoRIHBcAg(s) (SEQ ID NO: 148)
CCGGAATTCATGGACATTGACCCTTATAAAG Primer 2: 48as (SEQ ID NO: 149)
GTGCAGTATGGTGAGGTGAGGAATGCTCAGGAGACTC The following primers were
used to prepare fragment 2: Primer 3: 48s (SEQ ID NO: 150)
GSGTCTCCTGAGCATTCCTCACCTCACCATACTGCAC Primer 4: 107as (SEQ ID NO:
151) CTTCCAAAAGTGAGGGAAGAAATGTGAAACCAC
[0762] The following primers were used to prepare fragment 3:
TABLE-US-00025 Primer 5: HBcAg149hind-as (SEQ ID NO: 152)
CGCGTCCCAAGCTTCTAAACAACAGTAGTCTCCGGAAGCGTTGATA G Primer 6: 107s
(SEQ ID NO: 153) GTGGTTTCACATTTCTTCCCTCACTTTTGGAAG
[0763] Fragments 1 and 2 were then combined with PCR primers
EcoRIHBcAg(s) and 107 as to give fragment 4. Fragment 4 and
fragment 3 were then combined with primers EcoRIHBcAg(s) and
HBcAg149hind-as to produce the full length gene. The full length
gene was then digested with the EcoRI (GAATTC) and HindIII (AAGCTT)
enzymes and cloned into the pKK vector (Pharmacia) cut at the same
restriction sites.
Example 32
Blockage of Free Cysteine Residues of a HBcAg Followed by
Cross-Linking
[0764] The free cysteine residues of the HBcAg-Lys prepared as
described above in Example 23 were blocked using Iodacetamide. The
blocked HBcAg-Lys was then cross-linked to the FLAG peptide with
the hetero-bifunctional cross-linker
m-maleimidonbenzoyl-N-hydroxysuccinimide ester (Sulfo-MBS).
[0765] The methods used to block the free cysteine residues and
cross-link the HBcAg-Lys are as follows. HBcAg-Lys (550 .mu.g/ml)
was reacted for 15 minutes at room temperature with Iodacetamide
(Fluka Chemie, Brugg, Switzerland) at a concentration of 50 mM in
phosphate buffered saline (PBS) (50 mM sodium phosphate, 150 mM
sodium chloride), pH 7.2, in a total volume of 1 ml. The so
modified HBcAg-Lys was then reacted immediately with Sulfo-MBS
(Pierce) at a concentration of 330 .mu.M directly in the reaction
mixture of step 1 for 1 hour at room temperature. The reaction
mixture was then cooled on ice, and dialyzed against 1000 volumes
of PBS pH 7.2. The dialyzed reaction mixture was finally reacted
with 300 .mu.M of the FLAG peptide (CGGDYKDDDDK (SEQ ID NO:147))
containing an N-terminal free cysteine for coupling to the
activated HBcAg-Lys, and loaded on SDS-PAGE for analysis.
[0766] The resulting patterns of bands on the SDS-PAGE gel showed a
clear additional band migrating slower than the control HBcAg-Lys
derivatized with the cross-linker, but not reacted with the FLAG
peptide. Reactions done under the same conditions without prior
derivatization of the cysteines with Iodacetamide led to complete
cross-linking of monomers of the HBcAg-Lys to higher molecular
weight species.
Example 33
Isolation and Chemical Coupling of FLAG Peptide to Type-1 Pili of
Escherichia coli Using a Heterobifunctional Cross-Linker
[0767] A. Introduction
[0768] Bacterial pili or fimbriae are filamentous surface
organelles produced by a wide range of bacteria. These organelles
mediate the attachment of bacteria to surface receptors of host
cells and are required for the establishment of many bacterial
infections like cystitis, pyelonephritis, new born meningitis and
diarrhea.
[0769] Pili can be divided in different classes with respect to
their receptor specificity (agglutination of blood cells from
different species), their assembly pathway (extracellular
nucleation, general secretion, chaperone/usher, alternate
chaperone) and their morphological properties (thick, rigid pili;
thin, flexible pili; atypical structures including capsule; curli;
etc). Examples of thick, rigid pili forming a right handed helix
that are assembled via the so called chaperone/usher pathway and
mediate adhesion to host glycoproteins include Type-1 pili, P-pili,
S-pili, F1C-pili, and 987P-pili). The most prominent and best
characterized members of this class of pili are P-pili and Type-1
pili (for reviews on adhesive structures, their assembly and the
associated diseases see Soto, G. E. & Hultgren, S. J., J.
Bacteriol. 181:1059-1071 (1999); Bullitt & Makowski, Biophys.
J. 74:623-632 (1998); Hung, D. L. & Hultgren, S. J., J. Struct,
Biol. 124:201-220 (1998)).
[0770] Type-1 pili are long, filamentous polymeric protein
structures on the surface of E. coli. They possess adhesive
properties that allow for binding to mannose-containing receptors
present on the surface of certain host tissues. Type-1 pili can be
expressed by 70-80% of all E. coli isolates and a single E. coli
cell can bear up to 500 pili. Type-pili reach a length of typically
0.2 to 2 .mu.M with an average number of 1000 protein subunits that
associate to a right-handed helix with 3.125 subunits per turn with
a diameter of 6 to 7 nm and a central hole of 2.0 to 2.5 nm.
[0771] The main Type-1 pilus component, FimA, which represents 98%
of the total pilus protein, is a 15.8 kDa protein. The minor pilus
components FimF, FimG and FimH are incorporated at the tip and in
regular distances along the pilus shaft (Klemm, P. & Krogfelt,
K. A., "Type I fimbriae of Escherichia coli," in: Fimbriae. Klemm,
P. (ed.), CRC Press Inc., (1994) pp. 9-26). FimH, a 29.1 kDa
protein, was shown to be the mannose-binding adhesin of Type-1 pili
(Krogfelt, K. A., et al., Infect. Immun. 58:1995-1998 (1990);
Klemm, P., et al., Mol. Microbiol. 4:553-560 (1990); Hanson, M. S.
& Brinton, C. C. J., Nature 17:265-268 (1988)), and its
incorporation is probably facilitated by FimG and FimF (Klemm, P.
& Christiansen, G., Mol. Gen. Genetics 208:439-445 (1987);
Russell, P. W. & Orndorff, P. E., J. Bacteriol. 174:5923-5935
(1992)). Recently, it was shown that FimH might also form a thin
tip-fibrillum at the end of the pili (Jones, C. H., et al., Proc.
Nat. Acad. Sci. USA 92:2081-2085 (1995)). The order of major and
minor components in the individual mature pili is very similar,
indicating a highly ordered assembly process (Soto, G. E. &
Hultgren, S. J., J. Bacteriol. 181:1059-1071 (1999)).
[0772] P-pili of E. coli are of very similar architecture, have a
diameter of 6.8 nm, an axial hole of 1.5 nm and 3.28 subunits per
turn (Bullitt & Makowski, Biophys. J. 74:623-632 (1998)). The
16.6 kDa PapA is the main component of this pilus type and shows
36% sequence identity and 59% similarity to FimA (see Table 1). As
in Type-1 pili the 36.0 kDa P-pilus adhesin PapG and specialized
adapter proteins make up only a tiny fraction of total pilus
protein. The most obvious difference to Type-1 pili is the absence
of the adhesin as an integral part of the pilus rod, and its
exclusive localization in the tip fibrillium that is connected to
the pilus rod via specialized adapter proteins that Type-1 pili
lack (Hultgren, S. J., et al., Cell 73:887-901 (1993)).
TABLE-US-00026 TABLE 1 Similarity and identity between several
structural pilus proteins of Type-1 and P-pili (in percent). The
adhesins were omitted. Similarity FimA PapA FimI FimF FimG PapE
PapK PapH PapF Identity FimA 59 57 56 44 50 44 46 46 PapA 36 49 48
41 45 49 49 47 FimI 35 31 56 46 40 47 48 48 FimF 34 26 30 40 47 43
49 48 FimG 28 28 28 26 39 39 41 45 PapE 25 23 18 28 22 43 47 54
PapK 24 29 25 28 22 18 49 53 PapH 22 26 22 22 23 24 23 41 PapF 18
22 22 24 28 27 26 21
[0773] Type-1 pili are extraordinary stable hetero-oligomeric
complexes. Neither SDS-treatment nor protease digestions, boiling
or addition of denaturing agents can dissociate Type-1 pili into
their individual protein components. The combination of different
methods like incubation at 100.degree. C. at pH 1.8 was initially
found to allow for the depolymerization and separation of the
components (Eshdat, Y., et al., J. Bacteriol. 148:308-314 (1981);
Brinton, C. C. J., Trans, N.Y. Acad. Sci. 27:1003-1054 (1965);
Hanson, A. S., et al., J. Bacteriol., 170:3350-3358 (1988); Klemm,
P. & Krogfelt, K. A., "Type I fimbriae of Escherichia coli,"
in: Fimbriae. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26).
Interestingly, Type-1 pili show a tendency to break at positions
where FimH is incorporated upon mechanical agitation, resulting in
fragments that present a FimH adhesin at their tips. This was
interpreted as a mechanism of the bacterium to shorten pili to an
effective length under mechanical stress (Klemm, P. & Krogfelt,
K. A., "Type I fimbriae of Escherichia coli," in: Fimbriae. Klemm,
P. (ed.), CRC Press Inc., (1994) pp. 9-26). Despite their
extraordinary stability, Type-1 pili have been shown to unravel
partially in the presence of 50% glycerol; they lose their helical
structure and form an extended and flexible, 2 nm wide protein
chain (Abraham, S. N., et al., J. Bacteriol. 174:5145-5148
(1992)).
[0774] P-pili and Type-1 pili are encoded by single gene clusters
on the E. colichromosome of approximately 10 kb (Klemm, P. &
Krogfelt, K. A., "Type I fimbriae of Escherichia coli," in:
Fimbriae. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26;
Orndorff, P. E. & Falkow, S., J. Bacteriol. 160:61-66 (1984)).
A total of nine genes are found in the Type-1 pilus gene cluster,
and 11 genes in the P-pilus cluster (Hultgren, S. J., et al., Adv.
Prot. Chem. 44:99-123 (1993)). Both clusters are organized quite
similarly.
[0775] The first two fim-genes, fimB and fimE, code for
recombinases involved in the regulation of pilus expression
(McClain, M. S., et al., J. Bacteriol. 173:5308-5314 (1991)). The
main structural pilus protein is encoded by the next gene of the
cluster, fimA (Klemm, P., Euro. J. Biochem. 143:395-400 (1984);
Orndorff, P. E. & Falkow, S., J. Bacteriol. 160:61-66 (1984);
Orndorff, P. E. & Falkow, S., J. Bacteriol. 162:454-457
(1985)). The exact role of fimI is unclear. It has been reported to
be incorporated in the pilus as well (Klemm, P. & Krogfelt, K.
A., "Type I fimbriae of Escherichia coli," in: Fimbriae. Klemm, P.
(ed.), CRC Press Inc., (1994) pp. 9-26). The adjacent fimC codes
not for a structural component of the mature pilus, but for a
so-called pilus chaperone that is essential for the pilus assembly
(Klemm, P., Res. Microbiol. 143:831-838 (1992); Jones, C. H., et
al., Proc. Nat. Acad. Sci. USA 90:8397-8401 (1993)).
[0776] The assembly platform in the outer bacterial membrane to
which the mature pilus is anchored is encoded by fimD (Klemm, P.
& Christiansen, G., Mol. Gen, Genetics 220:334-338 (1990)). The
three minor components of the Type-1 pili, FimF, FimG and FimH are
encoded by the last three genes of the cluster (Klemm, P. &
Christiansen, G., Mol. Gen. Genetics 208:439-445 (1987)). Apart
from fimB and fimE, all genes encode precursor proteins for
secretion into the periplasm via the sec-pathway.
[0777] The similarities between different pili following the
chaperone/usher pathway are not restricted to their morphological
properties. Their genes are also arranged in a very similar manner.
Generally the gene for the main structural subunit is found
directly downstream of the regulatory elements at the beginning of
the gene cluster, followed by a gene for an additional structural
subunit (fimI in the case of Type-1 pili and papH in the case of
P-pili). PapH was shown and FimI is supposed to terminate pilus
assembly (Hultgren, S. J., et al., Cell 73:887-901 (1993)). The two
proteins that guide the process of pilus formation, namely the
specialized pilus chaperone and the outer membrane assembly
platform, are located adjacently downstream. At the end of the
clusters a variable number of minor pilus components including the
adhesins are encoded. The similarities in morphological structure,
sequence (see Table 1), genetic organization and regulation
indicate a close evolutionary relationship and a similar assembly
process for these cell organelles.
[0778] Bacteria producing Type-1 pili show a so-called
phase-variation. Either the bacteria are fully piliated or bald.
This is achieved by an inversion of a 314 bp genomic DNA fragment
containing the fimA promoter, thereby inducing an "all on" or "all
off" expression of the pilus genes (McClain, M. S., et al., J.
Bacteriol. 173:5308-5314 (1991)). The coupling of the expression of
the other structural pilus genes to fimA expression is achieved by
a still unknown mechanism. However, a wide range of studies
elucidated the mechanism that influences the switching between the
two phenotypes.
[0779] The first two genes of the Type-1 pilus cluster, fimB and
fimE encode recombinases that recognize 9 bp DNA segments of dyad
symmetry that flank the invertable fimA promoter. Whereas FimB
switches pilation "on", FimE turns the promoter in the "off"
orientation. The up- or down-regulation of either fimB or fimE
expression therefore controls the position of the so-called
"fim-switch" (McClain, M. S., et al., J. Bacteriol. 173:5308-5314
(1991); Blomfield, I. C., et al., J. Bacteriol. 173:5298-5307
(1991)).
[0780] The two regulatory proteins fimB and fimE are transcribed
from distinct promoters and their transcription was shown to be
influenced by a wide range of different factors including the
integration host factor (IHF) (Blomfield, I. C., et al., Mol.
Microbiol. 23:705-717 (1997)) and the leucine-responsive regulatory
protein (LRP) (Blomfield, I. C., et al., J. Bacteriol. 175:27-36
(1993); Gally, D. L., et al., J. Bacteriol. 175:6186-6193 (1993);
Gally, D. L., et al., Microbiol. 21:725-738 (1996); Roesch, R. L.
& Blomfield, I. C., Mol. Microbiol, 27:751-761 (1998)).
Mutations in the former lock the bacteria either in "on" or "off"
phase, whereas LRP mutants switch with a reduced frequency. In
addition, an effect of leuX on pilus biogenesis has been shown.
This gene is located in the vicinity of the fim-genes on the
chromosome and codes for the minor leucine tRNA species for the UUG
codon. Whereas fimB contains five UUG codons, fimE contains only
two, and enhanced leuX transcription might favor FimB over FimE
expression (Burghoff, R. L., et al., Infect. Immun. 61:1293-1300
(1993); Newman, J. V., et al., FEMS Microbiol. Lett. 122:281-287
(1994); Ritter, A., et al., Mol. Microbial, 25:871-882 (1997)).
[0781] Furthermore, temperature, medium composition and other
environmental factors were shown to influence the activity of FimB
and FimE. Finally, a spontaneous, statistical switching of the fimA
promoter has been reported. The frequency of this spontaneous
switching is approximately 10-3 per generation (Eisenstein, B. I.,
Science 214:337-339 (1981); Abraham, S. M., et al., Proc. Nat.
Acad. Sci, USA 82:5724-5727 (1985)), but is strongly influenced by
the above mentioned factors.
[0782] The genes fimI and fimC are also transcribed from the fimA
promoter, but directly downstream of fimA a DNA segment with a
strong tendency to form secondary structure was identified which
probably represents a partial transcription terminator (Klemm, P.,
Euro. J. Biochem. 143:395-400 (1984)); and is therefore supposed to
severely reduce fimI and fimC transcription. At the 3' end of fimC
an additional promoter controls the fimD transcription; at the 3'
end of fimD the last known fim promoter is located that regulates
the levels of FimF, FimG, and FimH. Thus, all of the minor Type-1
pili proteins are transcribed as a single mRNA (Klemm, P. &
Krogfelt, K. A., "Type I fimbriae of Escherichia coli," in:
Fimbriae. Klemm, P. (ed.), CRC Press Inc., (1994) pp. 9-26). This
ensures a 1:1:1 stoichiometry on mRNA-level, which is probably
maintained on the protein level.
[0783] In the case of P-pili additional regulatory mechanisms were
found when the half-life of mRNA was determined for different
P-pilus genes. The mRNA for papA was extraordinarily long-lived,
whereas the mRNA for papB, a regulatory pilus protein, was encoded
by short-lived mRNA (Naureckiene, S. & Uhlin. B. E., Mol.
Microbiol. 21:55-68 (1996); Nilsson, P., et al., J. Bacterial.
178:683-690 (1996)).
[0784] In the case of Type-1 pili, the gene for the Type-1 pilus
chaperone FimC starts with a GTG instead of an ATG codon, leading
to a reduced translation efficiency. Finally, analysis of the fimH
gene revealed a tendency of the fimH mRNA to form a stem-loop,
which might severely hamper translation. In summary, bacterial
pilus biogenesis is regulated by a wide range of different
mechanisms acting on all levels of protein biosynthesis.
[0785] Periplasmic pilus proteins are generally synthesized as
precursors, containing a N-terminal signal-sequence that allows
translocation across the inner membrane via the Sec-apparatus.
After translocation the precursors are normally cleaved by
signal-peptidase I. Structural Type-1 pilus subunits normally
contain disulfide bonds, their formation is catalyzed by DsbA and
possibly DsbC and DsbG gene products.
[0786] The Type-1 pilus chaperone FimC lacks cysteine residues. In
contrast, the chaperone of P-pili, PapD, is the only member of the
pilus chaperone family that contains a disulfide bond, and the
dependence of P-pili on DsbA has been shown explicitly
(Jacob-Dubuisson, F., et al., Proc. Nat. Acad. Sci. USA
91:11552-11556 (1994)). PapD does not accumulate in the periplasm
of a dsbA strain, indicating that the disturbance of the P-pilus
assembly machinery is caused by the absence of the chaperone
(Jacob-Dubuisson, F., et al., Proc. Nat. Acad. Sci. USA
91:11552-11556 (1994)). This is in accordance with the finding that
Type-1 pili are still assembled in a dsbA strain, albeit to reduced
level (Hultgren, S. J., et al., "Bacterial Adhesion and Their
Assembly", in: Escherichia coli and Salmonella, Neidhardt, F. C.
(ed.) ASM Press, (1996) pp. 2730-2756).
[0787] Type-1 pili as well as P-pili are to 98% made of a single or
main structural subunit termed FimA and PapA, respectively. Both
proteins have a size of .about.15.5 kDa. The additional minor
components encoded in the pilus gene clusters are very similar (see
Table 1). The similarities in sequence and size of the subunits
with the exception of the adhesins suggest that all share an
identical folding motif, and differ only with respect to their
affinity towards each other. Especially the N- and C-terminal
regions of these proteins are well conserved and supposed to play
an important role in chaperone/subunit interactions as well as in
subunit/subunit interactions within the pilus (Soto, G. E. &
Hultgren, S. J., J. Bacteriol. 181:1059-1071 (1999)).
Interestingly, the conserved N-terminal segment can be found in the
middle of the pilus adhesins, indicating a two-domain organization
of the adhesins where the proposed C-terminal domain, starting with
the conserved motif, corresponds to a structural pilus subunit
whereas the N-terminal domain was shown to be responsible for
recognition of host cell receptors (Hultgren, S. J., et al., Proc.
Nat. Acad. Sci. USA 86:4357-4361 (1989); Haslam, D. B., et al.,
Mol. Microbiol. 14:399-409 (1994); Soto, G. E., et al., EMBO J.
17:6155-6167 (1998)). The different subunits were also shown to
influence the morphological properties of the pili. The removal of
several genes was reported to reduce the number of Type-1 or P-pili
or to increase their length, (fimH, papG, papK, fimF, fimG)
(Russell, P. W. & Orndorff, P. E., J. Bacteriol. 174:5923-5935
(1992); Jacob-Dubuisson, R., et al., EMBO J. 12:837-847 (1993);
Soto, G. E. & Hultgren, S. J., J. Bacteriol. 181:1059-1071
(1999)); combination of the gene deletions amplified these effects
or led to a total loss of pilation (Jacob-Dubuisson, R., et al.,
EMBO J. 12:837-847 (1993)).
[0788] In non-fimbrial adhesive cell organelles also assembled via
chaperones/usher systems such as Myf fimbriae and CS3 pili, the
conserved C-terminal region is different. This indirectly proves
the importance of these C-terminal subunit segments for quaternary
interactions (Hultgren, S. J., et al., "Bacterial Adhesion and
Their Assembly", in: Escherichia coli and Salmonella, Neidhardt, F.
C. (ed.) ASM Press, (1996) pp. 2730-2756).
[0789] Gene deletion studies proved that removal of the pilus
chaperones leads to a total loss of piliation in P-pili and Type-1
pili (Lindberg, F., et al., J. Bacteriol. 171:6052-6058 (1989);
Klemm, P., Res. Microbiol. 143:831-838 (1992); Jones, C. H., et
al., Proc. Nat. Acad. Sci. USA 90:8397-8401 (1993)). Periplasmic
extracts of a fimC strain showed the accumulation of the main
subunit FimA, but no pili could be detected (Klemm, P., Res.
Microbiol. 143:831-838 (1992)). Attempts to over-express individual
P-pilus subunits failed and only proteolytically degraded forms
could be detected in the absence of PapD; in addition, the P-pilus
adhesin was purified with the inner membrane fraction in the
absence of the chaperone (Lindberg, F., et al., J. Bacteriol.
171:6052-6058 (1989)). However, co-expression of the structural
pilus proteins and their chaperone allowed the detection of
chaperone/subunit complexes from the periplasm in the case of the
FimC/FimH complex as well as in the case of different Pap-proteins
including the adhesin PapG and the main subunit PapA (Tewari, R.,
et al., J. Biol. Chem. 268:3009-3015 (1993); Lindberg, F., et al.,
J. Bacteriol. 171:6052-6058 (1989)). The affinity of
chaperone/subunit complexes towards their assembly platform has
also been investigated in vitro and was found to differ strongly
(Dodson et al., Proc. Natl. Acad. Sci. USA 90:3670-3674 (1993)).
From these results the following functions were suggested for the
pilus chaperones.
[0790] They are assumed to recognize unfolded pilus subunits,
prevent their aggregation and to provide a "folding template" that
guides the formation of a native structure.
[0791] The folded subunits, which after folding display surfaces
that allow subunit/subunit interactions, are then expected to be
shielded from interacting with other subunits, and to be kept in a
monomeric, assembly-competent state.
[0792] Finally, the pilus chaperones are supposed to allow a
triggered release of the subunits at the outer membrane assembly
location, and, by doing so with different efficiency, influence the
composition and order of the mature pili (see also the separate
section below).
[0793] After subunit release at the outer membrane, the chaperone
is free for another round of substrate binding, folding assistance,
subunit transport through the periplasm and specific delivery to
the assembly site. Since the periplasm lacks energy sources, like
ATP, the whole pilus assembly process must be thermodynamically
driven (Jacob-Dubuisson, F., et al., Proc. Nat. Acad. Sci. USA
91:11552-11556 (1994)). The wide range of different functions
attributed to the pilus chaperones would implicate an extremely
fine tuned cascade of steps.
[0794] Several findings, however, are not readily explained with
the model of pilus chaperone function outlined above. One example
is the existence of multimeric chaperone/subunit complexes
(Striker, R. T., et al., J. Biol. Chem. 269:12233-12239 (1994)),
where one chaperone binds subunit dimers or trimers. It is
difficult to imagine a folding template that can be
"double-booked". The studies on the molecular details of
chaperone/subunit interaction (see below) partially supported the
functions summarized above, but also raised new questions.
[0795] All 31 periplasmic chaperones identified by genetic studies
or sequence analysis so far are proteins of approximately 25 kDa
with conspicuously high pI values around 10. Ten of these
chaperones assist the assembly of rod-like pili, four are involved
in the formation of thin pili, ten are important for the biogenesis
of atypically thin structures (including capsule-like structures)
and two adhesive structures have not been determined so far
(Holmgren, A., et al., EMBO J. 11:1617-1622 (1992); Bonci, A., et
al., J. Mol. Evolution 44:299-309 (1997); Smyth, C. J., et al.,
FEMS Immun. Med Microbiol. 16:127-139 (1996); Hung, D. L. &
Hultgren, S. J., J. Struct, Biol. 124:201-220 (1998)). The pairwise
sequence identity between these chaperones and PapD ranges from 25
to 56%, indicating an identical overall fold (Hung, D. L., et al.,
EMBO J. 15:3792-3805 (1996)).
[0796] The first studies on the mechanism of chaperone/substrate
recognition was based on the observation that the C-termini of all
known pilus chaperones are extremely similar. Synthetic peptides
corresponding to the C-termini of the P-pilus proteins were shown
to bind to PapD in ELISA assays (Kuehn, M. J., et al., Science
262:1234-1241 (1993)). Most importantly, the X-ray structures of
two complexes were solved in which PapD was co-crystallized with
19-residue peptides corresponding to the C-termini of either the
adhesin PapG or the minor pilus component PapK (Kuehn, M. J., et
al., Science 262:1234-1241 (1993); Soto, G. E., et al., EMBO J.
17:6155-6167 (1998)). Both peptides bound in an extended
conformation to a .beta.-strand in the N-terminal chaperone domain
that is oriented towards the inter-domain cleft, thereby extending
a .beta.-sheet by an additional strand. The C-terminal carboxylate
groups of the peptides were anchored via hydrogen-bonds to Arg8 and
Lys112, these two residues are invariant in the family of pilus
chaperones. Mutagenesis studies confirmed their importance since
their exchange against alanine resulted in accumulation of
non-functional pilus chaperone in the periplasm (Slonim, L. N., et
al., EMBO J. 11:4747-4756 (1992)). The crystal structure of PapD
indicates that neither Arg8 nor Lys112 is involved in stabilization
of the chaperone, but completely solvent exposed (Holmgren, A.
& Branden, C. I., Nature 342:248-251 (1989)). On the substrate
side the exchange of C-terminal PapA residues was reported to
abolish P-pilus formation, and similar experiments on the conserved
C-terminal segment of the P-pilus adhesin PapG prevented its
incorporation into the P-pilus (Hultgren, S. J., et al., "Bacterial
Adhesion and Their Assembly", in: Escherichia coli and Salmonella,
Neidhardt, F. C. (ed.) ASM Press, (1996) pp. 2730-2756). All
evidence therefore indicated pilus subunit recognition via the
C-terminal segments of the subunits.
[0797] A more recent study on C-terminal amino acid exchanges of
the P-pilus adhesin PapG gave a more detailed picture. A range of
amino acid substitutions at the positions-2, -4, -6, and -8
relative to the C-terminus were tolerated, but changed pilus
stability (Soto, G. E., et al., EMBO J. 17:6155-6167 (1998)).
[0798] Still, certain problems arise when this model is examined
more closely. Adhesive bacterial structures not assembled to rigid,
rod-like pili lack the conserved C-terminal segments (Hultgren, S.
J., et al., "Bacterial Adhesion and Their Assembly", in:
Escherichia coli and Salmonella, Neidhardt, F. C. (ed.) ASM Press,
(1996) pp. 2730-2756), even though they are also dependent on the
presence of related pilus chaperones. This indicates a different
general role for the C-terminal segments of pilus subunits, namely
the mediation of quaternary interactions in the mature pilus.
Moreover, the attempt to solve the structure of a C-terminal
peptide in complex with the chaperone by NMR was severely hampered
by the weak binding of the peptide to the chaperone (Walse, B., et
al., FEBS Lett. 412:115-120 (1997)); whereas an essential
contribution of the C-terminal segments for chaperone recognition
implies relatively high affinity interactions.
[0799] An additional problem arises if the variability between the
different subunits are taken into account. Even though the
C-terminal segments are conserved, a wide range of conservative
substitutions is found. For example, 15 out of 19 amino acid
residues differ between the two peptides co-crystallized with PapD
(Soto, G. E., et al., EMBO J. 17:6155-6167 (1998)). This has been
explained by the kind of interaction between chaperone and
substrate, that occurs mainly via backbone interactions and not
specifically via side-chain interactions. Then again, the
specificity of the chaperone for certain substrates is not readily
explained. On the contrary to the former argument, the conserved
residues have been taken as a proof for the specificity (Hultgren,
S. J., et al., "Bacterial Adhesion and Their Assembly", in:
Escherichia coli and Salmonella, Neidhardt, F. C. (ed.) ASM Press,
(1996) pp. 2730-2756).
[0800] The outer membrane assembly platform, also termed "usher" in
the literature, is formed by homo-oligomers of FimD or PapC, in the
case of Type-1 and P-pili, respectively (Klemm, P. &
Christiansen, G., Mol. Gen, Genetics 220:334-338 (1990); Thanassi,
D. G., et al., Proc. Nat. Acad. Sei. USA 95:3146-3151 (1998)).
Studies on the elongation of Type-1 fimbriae by electron microscopy
demonstrated an elongation of the pilus from the base (Lowe, M. A.,
et al., J. Bacteriol. 169:157-163 (1987)). In contrast to the
secretion of unfolded subunits into the periplasmic space, the
fully folded proteins have to be translocated through the outer
membrane, possibly in an oligomeric form (Thanassi, D. G., et al.,
Proc. Nat. Acad. Sei. USA 95:3146-3151 (1998)). This requires first
a membrane pore wide enough to allow the passage and second a
transport mechanism that is thermodynamically driven
(Jacob-Dubuisson, F., et al., J. Biol. Chem. 269:12447-12455
(1994)).
[0801] FimD expression alone was shown to have a deleterious effect
on bacterial growth, the co-expression of pilus subunits could
restore normal growth behavior (Klemm, P. & Christiansen, G.,
Mol. Gen, Genetics 220:334-338 (1990)). Based on this it can be
concluded that the ushers probably form pores that are completely
filled by the pilus. Electron microscopy on membrane vesicles in
which PapC had been incorporated confirmed a pore-forming structure
with an inner diameter of 2 nm (Thanassi, D. G., et al., Proc. Nat.
Acad. Sei. USA 95:3146-3151 (1998)). Since the inner diameter of
the pore is too small to allow the passage of a pilus rod, it has
been suggested that the helical arrangement of the mature pilus is
formed at the outside of the bacterial surface. The finding that
glycerol leads to unraveling of pili which then form a protein
chain of approximately 2 nm is in good agreement with this
hypothesis, since an extended chain of subunits might be formed in
the pore as a first step (Abraham, S. N., et al., J. Bacteriol.
174:5145-5148 (1992); Thanassi, D. G., et al., Proc. Nat. Acad.
Sei. USA 95:3146-3151 (1998)). The formation of the helical pilus
rod at the outside of the bacterial membrane might then be the
driving force responsible for translocation of the growing pilus
through the membrane.
[0802] It has also been demonstrated that the usher proteins of
Type-1 and P-pili form ternary complexes with chaperone/subunit
complexes with different affinities (Dodson, K. W., et al., Proc.
Nat. Acad. Sci. USA 90:3670-3674 (1993); Saulino, E. T., et al.,
EMBO J. 17:2177-2185 (1998)). This was interpreted as "kinetic
partitioning" that allows a defined order of pilus proteins in the
pilus. Moreover, it has been suggested that structural proteins
might present a binding surface only compatible with one other type
of pilus protein; this would be another mechanism to achieve a
highly defined order of subunits in the mature pilus (Saulino, E.
T., et al., EMBO J. 17:2177-2185 (1998)).
[0803] B. Production of Type-1 Pili from Escherichia coli
[0804] E. coli strain W3110 was spread on LB (10 g/L tryptone, 5
g/L yeast extract, 5 g/L NaCl, pH 7.5, 1% agar (w/v)) plates and
incubated at 37.degree. C. overnight. A single colony was then used
to inoculate 5 ml of LB starter culture (10 g/L tryptone, 5 g/L
yeast extract, 5 g/L NaCl, pH 7.5). After incubation for 24 hours
under conditions that favor bacteria that produce Type-1 pili
(37.degree. C., without agitation) 5 shaker flasks containing 1
liter LB were inoculated with one milliliter of the starter
culture. The bacterial cultures were then incubated for additional
48 to 72 hours at 37.degree. C. without agitation. Bacteria were
then harvested by centrifugation (5000 rpm, 4.degree. C., 10
minutes) and the resulting pellet was resuspended in 250
milliliters of 10 mM Tris/HCl, pH 7.5. Pili were detached from the
bacteria by 5 minutes agitation in a conventional mixer at 17.000
rpm. After centrifugation for 10 minutes at 10,000 rpm at 4.degree.
C. the pili containing supernatant was collected and 1 M MgCl2 was
added to a final concentration of 100 mM. The solution was kept at
4.degree. C. for 1 hour, and the precipitated pili were then
pelleted by centrifugation (10,000 rpm, 20 minutes, 4.degree. C.).
The pellet was then resuspended in 10 mM HEPES, pH 7.5, and the
pilus solution was then clarified by a final centrifugation step to
remove residual cell debris.
[0805] C. Coupling of FLAG to Purified Type-1 Pili of E. coli Using
m-Maleimidonbenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBS)
[0806] 600 .mu.l of a 95% pure solution of bacterial Type-1 pili (2
mg/ml) were incubated for 30 minutes at room temperature with the
heterobifunctional cross-linker sulfo-MBS (0.5 mM). Thereafter, the
mixture was dialyzed overnight against 1 liter of 50 mM Phosphate
buffer (pH 7.2) with 150 mM NaCl to remove free sulfo-MBS. Then 500
.mu.l of the derivatized pili (2 mg/ml) were mixed with 0.5 mM FLAG
peptide (containing an amino-terminal Cysteine) in the presence of
10 mM EDTA to prevent metal-catalyzed sufhydryloxidation. The
non-coupled peptide was removed by
size-exclusion-chromatography.
Example 34
Construction of an Expression Plasmid for the Expression of Type-1
Pili of Escherichia coli
[0807] The DNA sequence disclosed in GenBank Accession No. U14003,
the entire disclosure of which is incorporated herein by reference,
contains all of the Escherichia coli genes necessary for the
production of type-1 pili from nucleotide number 233947 to
nucleotide number 240543 (the fim gene cluster). This part of the
sequences contains the sequences for the genes fimA, fimI, fimC,
fimD, fimF, fimG, and fimH. Three different PCRs were employed for
the amplification of this part of the E. coli genome and subsequent
cloning into pUC19 (GenBank Accession Nos. L09137 and X02514) as
described below.
[0808] The PCR template was prepared by mixing 10 ml of a glycerol
stock of the E. coli strain W3110 with 90 ml of water and boiling
of the mixture for 10 minutes at 95.degree. C., subsequent
centrifugation for 10 minutes at 14,000 rpm in a bench top
centrifuge and collection of the supernatant.
[0809] Ten ml of the supernatant were then mixed with 50 pmol of a
PCR primer one and 50 pmol of a PCR primer two as defined below.
Then 5 ml of a 10.times.PCR buffer, 0.5 ml of Taq-DNA-Polymerase
and water up to a total of 50 ml were added. All PCRs were carried
out according to the following scheme: 94.degree. C. for 2 minutes,
then 30 cycles of 20 seconds at 94.degree. C., 30 seconds at
55.degree. C., and 2 minutes at 72.degree. C. The PCR products were
then purified by 1% agarose gel-electrophoresis.
[0810] Oligonucleotides with the following sequences with were used
to amplify the sequence from nucleotide number 233947 to nucleotide
number 235863, comprising the fimA, fimI, and fimC genes:
TABLE-US-00027 (SEQ ID NO: 196)
TAGATGATTACGCCAAGCTTATAATAGAAATAGTTTTTTGAAAG GAAAGCAGCATG and (SEQ
ID NO: 197) GTCAAAGGCCTTGTCGACGTTATTCCATTACGCCCGTCATTTTG G
[0811] These two oligonucleotides also contained flanking sequences
that allowed for cloning of the amplification product into puc19
via the restriction sites HindIII and SalI. The resulting plasmid
was termed pFIMAIC (SEQ ID NO:198).
[0812] Oligonucleotides with the following sequences with were used
to amplify the sequence from nucleotide number 235654 to nucleotide
number 238666, comprising the fimD gene: TABLE-US-00028 (SEQ ID NO:
199) AAGATCTTAAGCTAAGCTTGAATTCTCTGACGCTGATTAACC and (SEQ ID NO:
200) ACGTAAAGCATTTCTAGACCGCGGATAGTAATCGTGCTATC.
[0813] These two oligonucleotides also contained flanking sequences
that allowed for cloning of the amplification product into puc19
via the restriction sites HindIII and XbaI, the resulting plasmid
was termed pFIMD (SEQ ID NO:201).
[0814] Oligonucleotides with the following sequences with were used
to amplify the sequence from nucleotide number 238575 nucleotide
number 240543, comprising the fimF, fimG, and fimH gene:
TABLE-US-00029 (SEQ ID NO: 202)
AATTACGTGAGCAAGCTTATGAGAAACAAACCTTTTTATC and (SEQ ID NO: 203)
GACTAAGGCCTTTCTAGATTATTGATAAACAAAAGTCACGC.
[0815] These two oligonucleotides also contained flanking sequences
that allowed for cloning of the amplification product into puc19
via the restriction sites HindIII and XbaI; the resulting plasmid
was termed pFIMFGH. (SEQ ID NO:204).
[0816] The following cloning procedures were subsequently carried
out to generate a plasmid containing all the above-mentioned
fim-genes:
[0817] pFIMAIC was digested EcoRI and HindIII (2237-3982), pFIMD
was digested EcoRI and SstII (2267-5276), pFIMFGH was digested
SstII and HindIII (2327-2231). The fragments were then ligated and
the resulting plasmid, containing all the fim-genes necessary for
pilus formation, was termed pFIMAICDFGH (SEQ ID NO:205).
Example 35
[0818] Construction of an Expression Plasmid for Escherichia coli
Type-1 Pili that Lacks the Adhesion FimH
[0819] The plasmid pFIMAICDFGH (SEQ ID NO:205) was digested with
KpnI, after which a fragment consisting of nucleotide numbers
8895-8509 was isolated by 0.7% agarose gelelectrophoresis and
circularized by self-ligation. The resulting plasmid was termed
pFIMAICDFG (SEQ ID NO: 206), lacks the fimH gene and can be used
for the production of FIMH-free type-1 pili.
Example 36
Expression of Type-1 Pili Using the Plasmid pFIMAICDFGH
[0820] E. coli strain W3110 was transformed with pFIMAICDFGH (SEQ
ID NO:205) and spread on LB (10 g/L tryptone, 5 g/L yeast extract,
5 g/L NaCl, pH 7.5, 1% agar (w/v)) plates containing 100 .mu.g/ml
ampicillin and incubated at 37.degree. C. overnight. A single
colony was then used to inoculate 50 ml of LB-glucose starter
culture (10 g/L tryptone, 5 g/L yeast extract, 1% (w/v) glucose, 5
g/L NaCl, pH 7.5, 100 mg/ml ampicillin). After incubation for 12-16
hours at 37.degree. C. at 150 rpm, a 5 liter shaker flasks
containing 2 liter LB-glucose was inoculated with 20 milliliter of
the starter culture. The bacterial cultures were then incubated for
additional 24 at 37.degree. C. with agitation (150 rpm). Bacteria
were then harvested by centrifugation (5000 rpm, 4.degree. C., 10
minutes) and the resulting pellet was resuspended in 250
milliliters of 10 mM Tris/HCl, pH 8. Pili were detached from the
bacteria by agitation in a conventional mixer at 17,000 rpm for 5
minutes. After centrifugation for 10 minutes at 10,000 rpm, 1 hour,
.degree. C. the supernatant containing pili was collected and 1 M
MgCl2 was added to a final concentration of 100 mM. The solution
was kept at 4.degree. C. for 1 hour, and precipitated pili were
then pelleted by centrifugation (10,000 rpm, 20 minutes, 4.degree.
C.). The pellet was then resuspended in 10 mM HEPES, 30 mM EDTA, pH
7.5, for 30 minutes at room temperature, and the pilus solution was
then clarified by a final centrifugation step to remove residual
cell debris. The preparation was then dialyzed against 20 mM HEPES,
pH 7.4.
Example 37
Coupling of IgE Epitopes and Mimotopes to Type-1 Pili of
Escherichia coli
[0821] A 66 .mu.l aliquot of a 100 uM solution of the
heterobifunctional cross-linker sulfa-MBS was added to 400 .mu.l of
a 95% pure solution of bacterial Type-1 pili (2.5 mg/ml, 20 mM
HEPES, pH 7.4) and subsequently incubated for 45 minutes at room
temperature with agitation. Thereafter, the excess of sulfa-MBS was
removed by size exclusion chromatography using a PD-10 column.
Alternatively, the cross-linker can be removed by dialysis. Then
either 1.3 .mu.l of a solution containing 1.1 mg/ml peptide Ce3epi
(CGGVNLTWSRA SG (SEQ ID NO:207)), or peptide Ce3Mim (CGGVNLPWSFGLE
(SEQ ID NO:208) was added to 1 ml aliquots of the derivatized pili
(1-1.25 mg/ml, 20 mM HEPES pH 7.4). The samples were incubated at
room temperature for 4 h and non-coupled peptide was removed by
dialysis against 2 times 2 l of a buffer containing 20 mM HEPES (pH
7.4). Alternatively, the non-coupled peptide can be removed by
size-exclusion chromatography.
Example 38
Immunization of Mice with a Bee Venom Phospholipase A.sub.2
(PLA.sub.2) Fusion Protein Coupled to Q.beta. Capsid Protein
[0822] A. Preparation of an Alternative Vector for Cytoplasmic
Expression of the Catalytically Inactive Variant of the PLA.sub.2
Gene Fused to the Amino Acid Sequence AAASGGCGG (SEQ ID NO:
209)
[0823] The PLA2 gene construct of example 9 was amplified by PCR
from pAV3PLAfos using oligos ecori_NdeI_pla (sequence below) and
PLA-Cys-hind (Example 29). For the reaction, 100 pmol of each
oligo, and about 1 .mu.g of PAV3PLAfos DNA were used in the 50
.mu.l reaction mixtures with 1.2 units of Pfx DNA polymerase
(Gibco), 1 mM MgSO4, 200 .mu.M dNTPS and Pfx enhancer solution
(Gibco) diluted ten times. For the reaction, temperature cycling
was carried out as follows: 94.degree. C. for 2 minutes, 5 cycles
of 92.degree. C. (0.5 minutes), 58.degree. C. (0.5 minutes),
68.degree. C. (1 minute); 25 cycles of 92.degree. C. (0.5 minutes),
63.degree. C. (0.5 minutes), 68.degree. C. (1 minute). The PCR
product was purified by agarose gel electrophoresis and subsequent
isolation of the fragment using the Qiagen Qiaquick Kit, digested
with enzymes NdeI and HindIII, and cloned into the PET11a vector
(Novagen) digested with the same enzymes. TABLE-US-00030 Oligos:
ecor1_Nde1_pla: (SEQ ID NO: 214) TAACCGAATTCAGGAGGTAAAAACATATGGC
TATCATCTACC.
[0824] The vector encoded a fusion protein having the amino acid
sequence TABLE-US-00031 (SEQ ID NO: 210)
MAIIYPGTLWCGHGNKSSGPNELGRFKHTDACCRTQDMCPDVMSAG
ESKHGLTNTASHTRLSCDCDDKFYDCLKNSADTISSYFVGKMYFNLIDTK
CYKLEHPVTGCGERTEGRCLHYTVDKSKPKVYQWFDLRKYAAASGGCG G.
[0825] Coupling of PLA.sub.2Fusion Protein to Q.beta. Capsid
Protein
[0826] A solution of 600 .mu.l of Q.beta. capsid protein (2 mg/ml
in 20 mM Hepes, pH 7.4) was reacted with 176 .mu.l Sulfo-MBS (13
mg/ml in H2O) for 60 minutes at room temperature, and dialyzed
against 1 L of 20 mM Hepes pH 7.4 O/N at 4.degree. C. The next day,
500 .mu.l of a PLA2 solution (2.5 mg/ml) containing 0.1 mM DTT were
desalted over a 5 ml Hi-Trap column (Pharmacia). Reduced and
desalted PLA2 (60 .mu.l, of a solution of approx. 0.5 mg/ml) was
mixed with activated and dialyzed Q.beta. capsid (25 .mu.l of a 1.5
mg/ml solution) and reacted for four hours at room temperature.
[0827] Capsids of 25-30 nm diameter are clearly visible in electron
microscopy images of Q.beta. capsid protein taken both before and
after coupling to PLA2.
[0828] C. Immunization of Mice with PLA.sub.2 Coupled to Q.beta.
Capsid Protein
[0829] Female Balb/c mice were immunized intravenously on day 0
with 50 .mu.g Q.beta. capsid coupled to PLA.sub.2, and boosted on
day 14 with the same amount of antigen. Mice were bled on day 20
and sera analyzed in an ELISA. A titer of 1:5000 against PLA.sub.2
was obtained.
Example 39
Coupling of IgE Mimotopes and Epitopes to Q.beta. Capsid
Protein
[0830] Human IgE epitopes having the following amino acid sequences
were coupled to Q.beta. capsid protein using the N-terminal
cysteine residue: TABLE-US-00032 Ce3epitope: CGGVNLTWSRASG (SEQ ID
NO: 207) Ce3mimotope: CGGVNLPWSFGLE (SEQ ID NO: 208)
[0831] The coupling reaction was performed using Q.beta. capsid
protein activated with Sulfo-MBS and subsequently dialyzed to
remove excess crosslinker. The respective epitope or mimotope was
diluted into the reaction mixture containing the activated Q.beta.
capsid, and left to react for 4 hours at room temperature. The
reaction mixture was finally dialyzed for 4 hours against PBS, and
injected into mice.
[0832] The following circular mimotope was also coupled to Q.beta.
capsid protein: Ce4mimotope: GEFCINHRGYWVCGDPA (SEQ ID NO:211).
[0833] The mimotope was first reacted with the chemical group
N-succinimidyl-S-acetylthioacetate (SATA), in order to introduce a
protected sulfhydryl group into the mimotope. The protecting group
was subsequently removed by treatment with hydroxylamine, and
immediately reacted with activated Q.beta. capsid protein, for 4
hours at room temperature. The reaction mixture was finally
dialyzed for 4 hours, and injected into mice.
Example 40
Immunization of Mice with HBcAg-Lys Coupled to M2 Peptide
[0834] A. Coupling of M2 Peptide to HBcAg-Lys Capsid Protein
[0835] Synthetic M2 peptide, corresponding to an N-terminal
fragment of the Influenza M2 protein with a cysteine residue at its
C-terminus (SLLTEVETPIRNEWGCRCNGSSDGGGC (SEQ ID NO:212)) was
chemically coupled to purified HBcAg-Lys particles in order to
elicit an immune response against the M2 peptide. Sulfo-MBS (232
.mu.l, 3 mM) was reacted with a solution of 1.4 ml HBcAg-Lys (1.6
mg/ml) in PBS. The mixture was dialyzed overnight against phosphate
buffered saline (PBS). M2 peptide was diluted to a concentration of
24 mg/ml in DMSA; 5 .mu.l of this solution was diluted in 300 .mu.l
PBS, 188 .mu.l of which was added to 312 .mu.l of the dialyzed
activated HBcAg-Lys solution. EDTA (10 .mu.l of a 1 M solution) was
also added to the reaction mixture, after which the reaction was
allowed to proceed for 4 hours at room temperature.
Immunization of Mice with HBcAg-Lys Coupled to M2 Peptide
[0836] Female Balb/c mice were immunized intravenously on day 0
with 50 .mu.g HBcAg-Lys-M2 or M2 peptide alone and boosted 10 days
later with the same amount of antigen. After another 10 days, the
mice were infected intranasally with Influenza virus (50 pfu, PR/8)
and survival of infected mice was monitored. In addition, viral
titers were determined in the lung. Mice primed with M2-HBcAg-Lys
were fully protected and had eliminated the virus by day 7.
Example 41
Coupling of M2 Peptide to Pili, Q.beta. and cys-Free HbcAg-Capsid
Protein and Comparison of the Antibody Titer Obtained by
Immunization of Mice with these Coupled Pili and Capsids with the
Titer Obtained by Immunizing Mice with an N-Terminal Fusion Protein
of the M2 Peptide to HbcAg1-183
[0837] A. Coupling of M2 Peptide to Pili, Q.beta.- and cys-Free
HbcAg-Capsid Protein
[0838] Q.beta.: A solution of 1 ml of 1 mg/ml Q.beta. capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.2 was reacted for 30
minutes with 93 .mu.l of a solution of 13 mg/ml Sulfo-MBS (Pierce)
in H2O at RT on a rocking shaker. The reaction solution was
subsequently dialyzed overnight against 2 L of 20 mM hepes, 150 mM
NaCl, pH 7.2. The dialyzed reaction mixture was then reacted with
58.8 .mu.l of a 25 mM stock solution of M2 peptide (SEQ ID NO:212)
in DMSO for four hours at RT on a rocking shaker. The reaction
mixture was subsequently dialyzed against 2 liters of 20 mM Hepes,
150 mM NaCl, pH 7.2 overnight at 4.degree. C.
[0839] Cys-free HbcAg: A solution of 1.25 ml of 0.8 mg/ml cys-free
HbcAg capsid protein (example 31) in PBS, pH 7.2 was reacted for 30
minutes with 93 .mu.l of a solution of 13 mg/ml Sulfo-MBS (Pierce)
in H2O at RT on a rocking shaker. The reaction solution was
subsequently dialyzed overnight against 2 L of 20 mM Hepes, 150 mM
NaCl, pH 7.2. The dialyzed reaction mixture was then reacted with
58.8 .mu.l of a 25 ml stock solution of M2 peptide (SEQ ID NO:212)
in DMSO for four hours at RT on a rocking shaker. The reaction
mixture was subsequently dialyzed against 2 liters of 20 mM hepes,
150 mM NaCl, ph 7.2 overnight at 4.degree. C.
[0840] Pili: A solution of 400 .mu.l of 2.5 mg/ml pili protein in
20 mM Hepes, pH 7.4, was reacted for 45 minutes with 60 .mu.l of a
100 mM Sulfo-MBS (Pierce) solution in (H2O) at RT on a rocking
shaker. The reaction mixture was desalted on a PD-10 column
(Amersham-Pharmacia Biotech), and the second fraction of 500 .mu.L
protein elating from the column (containing approximately 1 g
protein) was reacted with 58.8 .mu.l of a 25 mM stock solution of
M2 peptide (SEQ ID NO:212) in DMSO for four hours at RT on a
rocking shaker. The reaction mixture was subsequently dialyzed
against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2 overnight at
4.degree. C.
[0841] Genetic fusion of the M2 Peptide to HbcAg1-183
[0842] M2 genetically fused to Hbc: M2 was cloned at the N-terminus
of Hbc as published by Neirynck et. al. Nature Medicine 5: 1157
(1999). MD-HBc was expressed in E. coli and purified by gel
chromatography. The presence of the M2 peptide at the N-terminus of
M2-HBc was confirmed by Edman sequencing.
[0843] Immunization of Mice:
[0844] Female Balb/c mice were vaccinated with M2 peptide coupled
to pili, Q.beta. and cys-free HbcAg protein and with M2 peptide
genetically fused to Hbc immunogen without the addition of
adjuvants. 35 .mu.g protein of each sample were injected
intraperitoneally on day 0 and day 14. Mice were bled on day 27 and
their serum analyzed using a M2-peptide specific ELISA.
[0845] ELISA
[0846] 10 .mu.g/ml M2 peptide coupled to RNAse was coated on an
ELISA plate. The plate was blocked then incubated with serially
diluted mouse sera. Bound antibodies were detected with
enzymatically labeled anti-mouse IgG antibody. As a control,
preimmune sera were also tested. Control ELISA experiments using
sera from mice immunized with unrelated peptides crosslinked to Hbc
or other carriers showed the antibodies detected were specific for
the M2 peptide. The results are shown in FIGS. 27 A and B.
Example 42
Coupling of Angiotensin I and Angiotensin II Peptides to Q.beta.
and Immunization of Mice with Q.beta.-Angiotensin Peptide
Vaccines
[0847] A. Coupling of Angiotensin I and Angiotensin II Peptides to
Q.beta. Capsid Protein
[0848] The following angiotensin peptides were chemically
synthesized: CGGDRVYHPF ("Angio I"; SEQ ID NO:380), CGGDRVYIHPFHL
("Angio II"; SEQ ID NO:381), DRVYIHPFHLGGC ("Angio III"; SEQ ID
NO:382), CDRVYIHPFHL ("Angio IV"; SEQ ID NO:383) and used for
chemical coupling to Q.beta. as described in the following.
[0849] A solution of 5 ml of 2 mg/ml Q.beta. capsid protein in 20
mM Hepes. 150 mM NaCl pH 7.4 was reacted for 30 minutes with 507
.mu.l of a solution of 13 mg/ml Sulfo-MBS (Pierce) in H2O at
25.degree. C. on a rocking shaker. The reaction solution was
subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes,
150 mM NaCl, pH 7.4 at 4.degree. C. 665 ml of the dialyzed reaction
mixture was then reacted with 2.8 ml of each of the corresponding
100 mM peptide stock solution (in DMSO) for two hours at 25.degree.
C. on a rocking shaker. The reaction mixture was subsequently
dialyzed 2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM
NaCl, pH 7.4 at 4.degree. C.
[0850] Immunization of Mice:
[0851] Female Balb/c mice were vaccinated with one of the four
angiotensin peptides coupled to Q.beta. capsid protein without the
addition of adjuvants. 50 .mu.g of total protein of each sample was
diluted in PBS to 200 ml and injected subcutaneously (100 ml on two
ventral sides) on day 0 and day 14. Mice were bled retroorbitally
on day 21 and their serum was analyzed using a
antgiotensin-specific ELISA.
[0852] ELISA
[0853] All four angiotensin peptides were individually coupled to
bovine RNAse A using the chemical cross-linker sulfo-SPDP. ELISA
plates were coated with coupled RNAse preparations at a
concentration of 10 mg/ml. The plates were blocked and then
incubated with serially diluted mouse sera. Bound antibodies were
detected with enzymatically labeled anti-mouse IgG antibody. As a
control, preimmune sera of the same mice were also tested. Control
ELISA experiments using sera from mice immunized with unrelated
peptides crosslinked to Q.beta.or other carriers showed that the
antibodies detected were specific for the respective peptide. The
results are shown in FIG. 8A-8D.
[0854] FIGS. 8A, 8B, 8C and 8D, respectively, show ELISA analyses
of IgG antibodies specific for "Angio I", "Angio II", "Angio III",
and "Angio IV", respectively, in sera of mice immunized against
Angio I-IV coupled to Q.beta.capsid protein. Q.beta.-Angio I,
Q.beta.-Angio II, Q.beta.-Angio III and Q.beta.-Angio IV, as used
in the figures, stand for the vaccine injected in the mice, from
which the sera are derived in accordance with above definition of
the angiotensin peptides.
[0855] Female Balb/c mice were vaccinated subcutaneously with 50 mg
of vaccine in PBS on day 0 and day 14. IgG antibodies in sera of
mice vaccinated with Q.beta.-Angio I, Q.beta.-Angio II,
Q.beta.-Angio III and Q.beta.-Angio IV were measured on day 21
against all four peptides (coupled to RNAse A), i.e. against "Angio
I" (FIG. 8A), "Angio II" (FIG. 8B), "Angio III" (FIG. 8C), and
"Angio IV" (FIG. 8D). As a control, pre-immune sera from the same
mice were analyzed. Results for indicated serum dilutions are shown
as optical density at 450 nm. The average of three mice each
(including standard deviations) is shown. All vaccinated mice made
high IgG antibody titers against all four peptides tested. No
angiotensin-specific antibodies were detected in the controls
(pre-immune mice).
Example 43
Coupling of Angiotensin I and Angiotensin II Peptides to
HBcAg-149-lys-2cys-Mut i.e. cys-Free HBcAg
[0856] The following angiotensin peptides were chemically
synthesized: CGGDRVYIHPF ("Angio I"; SEQ ID NO:380), CGGDRVYIHPFHL
("Angio II"; SEQ ID NO:381), DRVYIHPFHLGGC ("Angio III"; SEQ ID
NO:382), CDRVYIHPFHL ("Angio IV"; SEQ ID NO:383) and are used for
chemical coupling to HBcAg-149-lys-2cys-Mut, i.e. cys-free
HBcAg.
[0857] A solution of 1.25 ml of 0.8 mg/ml HBcAg-149-lys-2cys-Mut
capsid protein (cf. Example 31) in PBS, pH 7.4 is reacted for 30
minutes with 93 .mu.l of a solution of 13 mg/ml Sulfo-MBS (Pierce)
in H.sub.2O at 25.degree. C. on a rocking shaker. The reaction
solution is subsequently dialyzed overnight against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4. After buffer exchange the reaction
solution is dialyzed for another 2 hours. The dialyzed reaction
mixture is then reacted with 1.8 .mu.l of a 100 mM peptide stock
solution (in DMSO) for 2 hours at 25.degree. C. on a rocking
shaker. The reaction mixture is subsequently dialyzed against 2
liters of 20 mM Hepes, 150 mM NaCl, ph 7.4 overnight at 4.degree.
C. followed by buffer exchange and another 2 hours of dialysis.
Example 44
Coupling of Angiotensin I and Angiotensin II Peptides to Type-1
Pili of E. coli
[0858] The following angiotensin peptides were chemically
synthesized: CGGDRVYIHPF ("Angio I"; SEQ ID NO:380), CGGDRVYIHPFHL
("Angio II"; SEQ ID NO:381), DRVYIHPFHLGGC ("Angio III"; SEQ ID
NO:382), CDRVYIHPFHL ("Angio IV"; SEQ ID NO:383) and are used for
chemical coupling to Type-1 pili of E. coli.
[0859] A solution of 400 .mu.l of 2.5 mg/ml Type-1 pili of E. coli
in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with 60 .mu.l of
a 100 mM Sulfo-MBS (Pierce) solution in (H.sub.2O) at RT on a
rocking shaker. The reaction mixture is desalted on a PD-10 column
(Amersham-Pharmacia Biotech), The protein-containing fractions
eluating from the column are pooled (containing approximately 1 mg
protein, i.e. derivatized pili) and reacted with a three-fold molar
excess of peptide. For example, to 500 ul eluate containing
approximately 1 mg derivatized pili, 2.34 ul of a 100 mM peptide
stock solution (in DMSO) is added. The mixture is incubated for
four hours at 25.degree. C. on a rocking shaker and subsequently
dialyzed against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2
overnight at 4.degree. C.
Example 45
Coupling of Der p I Peptides to Q.beta. and Immunization of Mice
with Q.beta.-Der p I Vaccines
[0860] Coupling of Der p I Peptides to Q.beta. Capsid Protein
[0861] The following peptides derived from the house dust mite
allergen Der p I were chemically synthesized:
CGNQSLDLAEQELVDCASQHGCH ("Der p I p52"; aa 52-72, with an
additional cysteine-glycine linker at the N terminus; SEQ ID
NO:384), CQIYPPNANKIREALAQTHSA ("Der p 1 p117"; aa 117-137; SEQ ID
NO:385). These peptides were used for chemical coupling to Q.beta.
as described below.
[0862] 1 ml of a solution consisting of 2 mg/ml Q.beta. capsid
protein in 20 mM Hepes, 150 mM NaCl, pH 7.4 was reacted for 30
minutes with 102 .mu.l of a solution of 13 mg/ml Sulfo-MBS (Pierce)
in H2O at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. 440 .mu.l of the
dialyzed reaction mixture was then reacted with 1.9 .mu.l of a 100
mM peptide stock solution (in DMSO) for two hours at 25.degree. C.
on a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH
7.4 at 4.degree. C.
[0863] Immunization of Mice:
[0864] Female Balb/c mice were vaccinated with one of the two Der p
I peptides coupled to Q.beta. capsid protein without the addition
of adjuvants. Two mice for each vaccine were used. 30 .mu.g of
total protein of each sample was diluted in PBS to 200 .mu.l and
injected subcutaneously on day 0 and day 14. Mice were bled
retroorbitally on day 21 and their serum was analyzed using a Der p
I peptide-specific ELISA.
[0865] ELISA
[0866] The Der p I peptides "Der p I p52" and "Der p I p117" were
individually coupled to bovine RNAse A using the chemical
cross-linker sulfo-SPDP. ELISA plates were coated with coupled
RNAse preparations at a concentration of 10 mg/ml. The plates were
blocked and then incubated with serially diluted mouse sera. Bound
antibodies were detected with enzymatically labeled anti-mouse IgG
antibody. As a control, preimmune sera of the same mice were also
tested. Control ELISA experiments using sera from mice immunized
with unrelated peptides crosslinked to Q.beta. or other carriers
showed that the antibodies detected were specific for the
respective peptide. The results are shown in FIGS. 9A and 9B.
[0867] FIG. 9A and FIG. 9B show ELISA analyses of IgG antibodies
specific for "Der p I p52" (FIG. 9A) and specific for "Der p I
p117" (FIG. 9B) in sera of mice immunized against the Der p I
peptides coupled to Q.beta. capsid protein. "p52" and "p117", as
used in FIGS. 9A and 9B, stand for the vaccine injected in the
mice, from which the sera are derived.
[0868] As a control, pre-immune sera from the same mice were
analyzed (day 0). Results for indicated serum dilutions are shown
as optical density at 450 nm. On day 21, all vaccinated mice made
specific IgG antibodies against the Der p I peptide they were
vaccinated with but not against the other Der p I peptide. No Der p
I peptide-specific antibodies were detected before vaccination (day
0).
[0869] Both Der p I peptide vaccines were highly immunogenic in the
absence of adjuvants. All vaccinated mice made good antibody
responses specific for the peptide in the vaccine preparation.
Example 46
Coupling of Der p 1 Peptides to HBcAg-149-lys-2cys-Mut, i.e.
cys-Free HBcAg
[0870] The following peptides derived from the house dust mite
allergen Der p 1 were chemically synthesized: Der p I p52 (aa
52-72, with an additional cysteine-glycine linker at the N
terminus): CGNQSLDLAEQELVDCASQHGCH (SEQ ID NO:384), Der pI p117 (aa
117-137): CQIYPPNANKIREALAQTHSA (SEQ ID NO:385). These peptides are
used for chemical coupling to HBcAg-149-lys-2cys-Mut, i.e. cys-free
HBcAg.
[0871] A solution of 1.25 ml of 0.8 mg/ml HBcAg-149-lys-2cys-Mut
capsid protein (Example 31) in PBS, pH 7.4 is reacted for 30
minutes with 93 .mu.l of a solution of 13 mg/ml Sulfo-MBS (Pierce)
in H2O at 25.degree. C. on a rocking shaker. The reaction solution
is subsequently dialyzed overnight against 2 L of 20 mM Hepes, 150
mM NaCl, pH 7.4. After buffer exchange the reaction solution is
dialyzed for another 2 hours. The dialyzed reaction mixture is then
reacted with 1.8 .mu.l of a 100 mM peptide stock solution (in DMSO)
for 2 hours at 25.degree. C. on a rocking shaker. The reaction
mixture is subsequently dialyzed against 2 liters of 20 mM Hepes,
150 mM NaCl, ph 7.4 overnight at 4.degree. C. followed by buffer
exchange and another 2 hours of dialysis.
Example 47
Coupling of Der p I Peptides to Type-1 Pili of E. coli
[0872] The following peptides derived from the house dust mite
allergen Der p I were chemically synthesized: Der p I p52 (aa
52-72, with an additional cysteine-glycine linker at the N
terminus) and CGNQSLDLAEQELVDCASQHGCH (SEQ ID NO:384), Der p I p117
(aa 117-137): CQIYPPNANKIREALAQTHSA (SEQ ID NO:385). These peptides
are used for chemical coupling to Type-1 pili of E. coli.
[0873] A solution of 400 .mu.l of 2.5 mg/ml Type-1 pili of E. coli
in 20 mM Hepes, pH 7.4, is reacted for 60 minutes with 60 .mu.l of
a 100 mM Sulfo-MBS (Pierce) solution in (H2O) at RT on a rocking
shaker. The reaction mixture is desalted on a PD-10 column
(Amersham-Pharmacia Biotech), The protein-containing fractions
eluating from the column are pooled (containing approximately 1 mg
protein, i.e. derivatized pili) and reacted with a three-fold molar
excess of peptide. For example, to 500 ul eluate containing
approximately 1 mg derivatized pili, 2.34 ul of a 100 mM peptide
stock solution (in DMSO) is added. The mixture is incubated for
four hours at 25.degree. C. on a rocking shaker and subsequently
dialyzed against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.2
overnight at 4.degree. C.
Example 48
Coupling of HumanVEGFR-II Peptide to Type-1 Pili of E. coli and
Immunization of Mice with Vaccines Comprising Type-1
Pili-HumanVEGFR-II Peptide Arrays
[0874] Coupling of humanVEGFR-II Peptide to Type-1 Pili of E.
coli
[0875] The human VEGFR II peptide with the sequence
CTARTELNVGIDFNWEYPSSKHQHKK (SEQ ID NO:351) was chemically
synthesized and used for chemical coupling to Type-1 pili of E.
coli.
[0876] A solution of 1400 .mu.l of 1 mg/ml pili protein in 20 mM
Hepes, pH 7.4, was reacted for 60 minutes with 85 .mu.l of a 100 mM
Sulfo-MBS (Pierce) solution in (H2O) at RT on a rocking shaker. The
reaction mixture was desalted on a PD-10 column (Amersham-Pharmacia
Biotech). The protein-containing fractions eluting from the column
were pooled (containing approximately 1,4 mg protein) and reacted
with a 2.5-fold molar excess (final volume) of human VEGFR II
peptide. For example, to 200 .mu.l eluate containing approximately
0.2 mg derivatized pili, 2.4 .mu.l of a 10 mM peptide solution (in
DMSO) was added. The mixture was incubated for four hours at
25.degree. C. on a rocking shaker and subsequently dialyzed against
2 liters of 20 mM Hepes, pH 7.2 overnight at 4.degree. C.
[0877] Immunization of Mice
[0878] Female C3H-HeJ (Toll-like receptor 4 deficient, LPS
non-responder mice) and C3H-HeN (wild-type) mice were vaccinated
with the human VEGFR-II peptide coupled to Type-1 pili protein
without the addition of adjuvants. Approximately 100 .mu.g of total
protein of each sample was diluted in PBS to 200 .mu.l and injected
subcutaneously on day 0, day 14 and day 28. Mice were bled
retroorbitally on day 14, 28 and day 42 and serum of day 42 was
analyzed using a human VEGFR-II specific ELISA
[0879] ELISA
[0880] Sera of immunized mice were tested in ELISA with immobilized
human VEGFR-II peptide and the extracellular domain of the human
VEGFR-II (R&D Systems GmbH, Wiesbaden).
[0881] Human VEGFR-II peptide was coupled to bovine RNAse A using
the chemical cross-linker sulfo-SPDP. ELISA plates were coated with
coupled RNAse A at a concentration of 10 .mu.g/ml. The human
extracellular domain of VEGFR-II was adsorbed to the plates at a
concentration of 2 .mu.g/ml. The plates were blocked and then
incubated with serially diluted mouse sera. Bound antibodies were
detected with enzymatically labeled anti-mouse IgG antibody. As a
control, preimmune sera of the same mice were also tested. Control
ELISA experiments using sera from mice immunized with uncoupled
carrier showed that the antibodies detected were specific for the
respective peptide. The results for human VEGFR II peptide coupled
to Type-1 pili are shown in FIG. 10. In particular, FIG. 10A and
FIG. 10B show ELISA analyses of IgG antibodies specific for human
VEGFR II peptide and extracellular domain of human VEGFR II,
respectively, in sera of mice immunized against human VEGFR II
peptide and the extracellular domain of human VEGFR II each coupled
to Type-1 pili protein.
[0882] Female C3H-HeJ (Toll-like receptor 4 deficient,
LPS-nonresponder) and C3H-HeN (wild-type) mice were vaccinated
subcutaneously with 100 ug of vaccine in PBS on day 0, 14 and 28.
Serum IgG against the peptide (coupled to RNAse A) and the
extracellular domain of human VEGFR II were measured on day 42. As
a control, preimmune sera from the same mice were analyzed. Results
for indicated serum dilutions are shown as optical density at 450
nm. The average of three mice each (including standard deviations)
are shown. All vaccinated mice made high IgG antibody titers
against the human VEGFR-II peptide as well as the extracellular
domain of human VEGFR-II (KDR) and no difference was noted between
mice deficient for the Toll-like receptor 4 and wild-type mice. The
latter is remarkable since it demonstrates that formation of high
IgG antibody titers against the human VEGFR-II peptide as well as
the extracellular domain of human VEGFR-II is independent of
endotoxin contaminations.
Example 49
Coupling of HumanVEGFR-II Peptide to Q.beta. Capsid Protein and
Immunization of Mice with Vaccines Comprising Q.beta. Capsid
Protein-HumanVEGFR-II Peptide Arrays
[0883] Coupling of HumanVEGFR-II Peptide to Q.beta. Capsid
Protein
[0884] The human VEGFR II peptide with the sequence
CTARTELNVGIDFNWEYPSSKHQHKK (SEQ ID NO:351) was chemically
synthesized and is used for chemical coupling to Q.beta. capsid
protein.
[0885] A solution of 1 ml of 1 mg/ml Q.beta. capsid protein in 20
mM Hepes, 150 mM NaCl pH 7.4 was reacted for 45 minutes with 20
.mu.l of 100 mM Sulfo-MBS (Pierce) solution in (H2O) at RT on a
rocking shaker. The reaction solution was subsequently dialyzed
twice for 2 hours in 2 L of 20 mM Hepes, pH 7.4 at 4.degree. C.
1000 .mu.l of the dialyzed reaction mixture was then reacted with
12 .mu.l of a 10 mM human VEGFR II peptide solution (in DMSO) for
four hours at 25.degree. C. on a rocking shaker. The reaction
mixture was subsequently dialyzed 2.times.2 hours against 2 liters
of 20 mM Hepes, pH 7.4 at 4.degree. C.
[0886] 1 ml of a solution consisting of 2 mg/ml Q.beta. capsid
protein in 20 mM Hepes, 150 mM NaCl, pH 7.4 was reacted for 30
minutes with 102 .mu.l of a solution of 13 mg/ml Sulfo-MBS (Pierce)
in H2O at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. 440 .mu.l of the
dialyzed reaction mixture was then reacted with 1.9 .mu.l of a 100
mM peptide stock solution (in DMSO) for two hours at 25.degree. C.
on a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH
7.4 at 4.degree. C.
[0887] Immunization of Mice
[0888] C57BL/6 mice are vaccinated with the human VEGFR-II peptide
coupled to Q.beta. protein without the addition of adjuvants.
Approximately 50 .mu.g of total protein of each sample is diluted
in PBS to 200 ul and injected subcutaneously on day 0, day 14 and
day 28. Mice are bled retroorbitally on day 14, 28 and day 42 and
serum of day 42 is analyzed using a human VEGFR-II specific
ELISA
Example 50
Coupling of HumanVEGFR-II Peptide to HBcAg-149-lys-2cys-Mut Capsid
Protein, i.e. cys-Free HBcAg, and Immunization of Mice with
Vaccines Comprising HBcAg-149-lys-2cys-Mut Capsid
Protein-HumanVEGFR-II Peptide Arrays
[0889] Coupling of HumanVEGFR-II Peptide to HBcAg-149-lys-2cys-Mut
Capsid Protein
[0890] The human VEGFR II peptide with the sequence
CTARTELNVGIDFNWEYPSSKHQHKK (SEQ ID NO:351) was chemically
synthesized and is used for chemical coupling to
HBcAg-149-lys-2cys-Mut capsid protein.
[0891] A solution of 3 ml of 0.9 mg/ml cys-free HbcAg capsid
protein (cf. Example 31) in PBS, pH 7.4 is reacted for 45 minutes
with 37.5 .mu.l of 100 mM Sulfo-MBS (Pierce) solution in (H2O) at
RT on a rocking shaker. The reaction solution is subsequently
dialyzed overnight against 2 L of 20 mM Hepes, pH 7.4. After buffer
exchange the reaction solution is dialyzed for another 2 hours. The
dialyzed reaction mixture is then reacted with 3 .mu.l of a 10 mM
human VEGFR II peptide solution (in DMSO) for 4 hours at 25.degree.
C. on a rocking shaker. The reaction mixture is subsequently
dialyzed against 2 liters of 20 mM Hepes, pH 7.4 overnight at
4.degree. C. followed by buffer exchange and another 2 hours of
dialysis.
Example 51
Construction of HBcAg1-183Lys
[0892] Hepatitis core Antigen (HBcAg) 1-183 was modified as
described in Example 23. A part of the c/e1 epitope (residues 72 to
88) region (Proline 79 and Alanine 80) was genetically replaced by
the peptide Gly-Gly-Lys-Gly-Gly (HBcAg1-183Lys construct; SEQ ID
NO:406). The introduced Lysine residue contains a reactive amino
group in its side chain that can be used for intermolecular
chemical crosslinking of HBcAg particles with any antigen
containing a free cysteine group. PCR methods essentially as
described in Example 1 and conventional cloning techniques were
used to prepare the HBcAg1-183Lys gene.
[0893] The Gly-Gly-Lys-Gly-Gly (SEQ ID NO:406) sequence was
inserted by amplifying two separate fragments of the HBcAg gene
from pEco63, as described above in Example 23 and subsequently
fusing the two fragments by PCR to assemble the full length gene.
The following PCR primer combinations were used: TABLE-US-00033
fragment 1: Primer 1: EcoRIHBcAg(s) (see Example 23) Primer 2:
Lys-HBcAg(as) (see Example 23) fragment 2: Primer 3: Lys-HBcAg(s)
(see Example 23) Primer 4: HBcAgwtHindIIII (SEQ ID NO: 386)
CGCGTCCCAAGCTTCTAACATTGAGATTCCCGAGATTG Assembly: Primer 1:
EcoRIHBcAg(s) (see example 23) Primer 2: HBcAgwtHindIIII
[0894] The assembled full length gene was then digested with the
EcoRI (GAATTC) and HindIII (AAGCTT) enzymes and cloned into the pKK
vector (Pharmacia) cut at the same restriction sites.
Example 52
[0895] Coupling of muTNFa Peptide to HBcAg1-183Lys and Immunization
of Mice with Vaccines Comprising HBcAg1-183Lys-muTNFa Peptide
Arrays
[0896] A. Coupling of muTNFa Peptide to HBcAg1-183Lys
[0897] HBcAg1-183Lys at a concentration of 0.6 mg/ml (29 .mu.M) was
treated with iodacetamide as described in Example 32. HBcAg1-183Lys
was then reacted with a fifty-fold excess of the cross-linker
Sulfo-MBS, as described in Example 32, and dialyzed overnight
against 20 mM Hepes, pH 7.2, at 4.degree. C. Activated
(derivatized) HBcAg1-183Lys was reacted with a five-fold molar
excess of the peptide muTNFa (sequence: CGGVEEQLEWLSQR (SEQ ID
NO:387)), diluted directly into the HBcAg1-183Lys solution from a
100 mM stock solution in DMSO) at RT for 4 hours. The coupling
reaction (about 1 ml solution) was dialyzed against 2.times.2
liters of 20 mM HEPES pH 7.2, at 4.degree. C., for 4 hours. The
dialyzed coupling reaction was frozen in aliquots in liquid
nitrogen and stored at -80.degree. C. until immunization of the
mice.
[0898] Immunization
[0899] Two mice (female Balb/c) were immunized intravenously at day
0 and 14 with 100 .mu.g HBcAg1-183Lys coupled to the muTNFa
peptide, per animal, without adjuvant. Antibodies specific for the
muTNFa peptide (coated as a Ribonuclease A conjugate) and for
native TNF.beta. protein (Sigma) in the serum were determined at
day 21 by ELISA.
[0900] ELISA
[0901] Murine TNF.beta. protein (Sigma) was coated at a
concentration of 2 .mu.g/ml. As a control, preimmune sera from the
same mice used for immunization were tested. FIG. 14 shows the
result of the ELISA experiment, demonstrating that immunization
with HBcAg1-183Lys coupled to the muTNFa peptide (Full length
HBc-TNF) generated an immune response specific for the murine
TNF.beta. protein. The sera from mice bled on day 0 (preimmune) and
21 were tested at three different dilutions. Each bar is the
average of the signal obtained with sera from two mice. Thus,
vaccination with HBcAg1-183Lys coupled to the muTNFa peptide
induced an immune response against a self-antigen, since the amino
acid sequence of the muTNFa peptide is derived from the sequence of
mouse TNF.beta. protein.
Example 53
Coupling of 3'TNF II Peptide to 2cysLys-mut HBcAg1-149 and
Immunization of Mice with Vaccines Comprising 2cysLys-mut
HBcAg1-149-3'TNF II Peptide Arrays
[0902] Coupling of the 3'TNF II peptide to 2cysLys-mut
HBcAg1-149
[0903] 2cysLys-mut HBcAg1-149 was reacted at a concentration of 2
mg/ml for 30 min. at RT with a fifty-fold excess of cross-linker in
20 mM Hepes, 150 mM NaCl, pH 7.2. Excess cross-linker was removed
by dialysis overnight, and activated (derivatized) 2cysLys-mut
HBcAg1-149 capsid protein was reacted with a ten-fold excess of
3'TNF II peptide (SEQ: SSQNSSDKPVAHVVANHGVGGC (SEQ ID NO:359),
diluted from a 100 mM stock solution in DMSO) for 4 hours at RT.
The reaction mixture was then dialyzed overnight in a dialysis
tubing with a molecular weight cutoff of 50000 Da, frozen in liquid
nitrogen and stored at -80.degree. C. until immunization of the
mice.
[0904] Immunization of Mice
[0905] 3 Female C3H/HeN mice, 8 weeks of age were vaccinated with
the 3'TNF II peptide coupled to 2cysLys-mut HBcAg1-149 without the
addition of adjuvants. 50 .mu.g of total protein was diluted in PBS
to 200 .mu.l and injected subcutaneously (100 .mu.l on two inguinal
sides) on day 0 and day 14. Mice were bled retroorbitally on day 0
and 21, and their serum were analyzed in an ELISA specific for
murine TNF.beta. protein.
[0906] ELISA
[0907] Murine TNF.beta. protein (Sigma) was coated at a
concentration of 2 .mu.g/ml. As a control, preimmune sera from the
same mice used for immunization were tested FIG. 15 shows the
result of the ELISA, demonstrating that immunization with
2cysLys-mut HBcAg1-149 coupled to the 3'TNF II peptide generated an
immune response specific for the murine TNF.beta. protein. The sera
from mice bled on day 0 (preimmune) and 21 were tested at three
different dilutions. Each bar is the average of the signal obtained
with sera from 3 mice. Thus, vaccination with 2cysLys-mut
HBcAg1-149 coupled to the 3'TNF II peptide induced an immune
response specific for a self-antigen, since the amino acid sequence
of the 3'TNF II peptide is derived from the sequence of murine
TNF.beta. protein.
Example 54
Coupling of A.beta. 1-15, A.beta. 1-27 and A.beta. 33-42 Peptides
to Q.beta. and Immunization of Mice with Vaccines Comprising
Q.beta.-A.beta. Peptide Arrays
A. Coupling of A.beta. 1-15 and A.beta. 33-42 peptides to Q.beta.
Capsid Protein Using the Cross-Linker SMPH.
[0908] The following A.beta. peptides were chemically synthesized:
DAEFRHDSGYEVHHQGGC (abbreviated as "A.beta. 1-15"; SEQ ID NO:367),
a peptide which comprises the amino acid sequence from residue 1-15
of human A.beta., fused at its C-terminus to the sequence GGC for
coupling to Q.beta. capsid protein and CGHGNKSGLMVGGVVIA
(abbreviated as "A.beta. 33-42"; SEQ ID NO:369) a peptide which
comprises the amino acid sequence from residue 33-42 of A.beta.
fused at its N-terminus to the sequence CGHGNKS (SEQ ID NO:405) for
coupling to Q.beta. capsid protein. Both peptides were used for
chemical coupling to Q.beta. as described in the following.
[0909] A solution of 1.5 ml of 2 mg/ml Q.beta. capsid protein in 20
mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 16.6
.mu.l of a solution of 65 mM SMPH (Pierce) in H2O, at 25.degree. C.
on a rocking shaker. The reaction solution was subsequently
dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl,
pH 7.4 at 4.degree. C. in a dialysis tubing with Molecular Weight
cutoff 10000 Da. 450 .mu.l of the dialyzed reaction mixture, which
contains activated (derivatized) Q.beta., was then reacted with 6.5
.mu.l of each of the corresponding 50 mM peptide stock solution (in
DMSO) for two hours at 15.degree. C. on a rocking shaker. 200 .mu.l
of the reaction mixture was subsequently dialyzed overnight against
2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C., and
the next morning for another two hours after change of buffer. The
reaction mixture was then frozen in aliquots in liquid Nitrogen and
stored at -80.degree. C. until immunization of the mice.
[0910] The results of the coupling experiments were analyzed by
SDS-PAGE, and are shown in FIG. 13A and FIG. 13B. The arrows point
to the band corresponding to one, respectively two peptides coupled
to one Q.beta.subunit (FIG. 13A), or one peptide coupled to one
Q.beta.subunit (FIG. 13B). Molecular weights of marker proteins are
given on the left margin of FIG. 13A and FIG. 13B.
[0911] The samples loaded on the gel of FIG. 13A are the
following:
[0912] 1: derivatized Q.beta. 2: Q.beta. coupled with
"A.beta.1-15", supernatant of the sample taken at the end of the
coupling reaction, and centrifuged; 3: Q.beta. coupled with
"A.beta.1-15", pellet of the sample taken at the end of the
coupling reaction, and centrifuged. 4: Q.beta. coupled with
"A.beta.1-15", supernatant of a sample left to stand 24 hours at
4.degree. C., undialyzed and centrifuged. 5: Q.beta. coupled with
"A.beta.1-15", pellet of a sample left to stand 24 hours at
4.degree. C., undialyzed and centrifuged. 6: Q.beta. coupled with
"A.beta.1-15", supernatant of the sample taken after dialysis of
the coupling reaction, and centrifuged.
[0913] The samples loaded on the gel of FIG. 13B are the
following:
[0914] 1: derivatized Q.beta. 2: Q.beta. coupled with
"A.beta.33-42", supernatant of the sample taken at the end of the
coupling reaction, and centrifuged. 3: Q.beta. coupled with
"A.beta.33-42", pellet of the sample taken at the end of the
coupling reaction, and centrifuged. 4: Q.beta. coupled with
"A.beta.33-42", supernatant of a sample left to stand 24 hours at
4.degree. C., undialyzed and centrifuged. 5: Q.beta. coupled with
"A.beta.33-42", pellet of a sample left to stand 24 hours at
4.degree. C., undialyzed and centrifuged. 6: Q.beta. coupled with
"A.beta.33-42", supernatant of the sample taken after dialysis of
the coupling reaction, and centrifuged.
B. Coupling of "A.beta.1-27" Peptide to Q.beta. Capsid Protein
Using the Cross-Linker SMPH.
[0915] The following A.beta. peptide ("A.beta. 1-27"; SEQ ID
NO:368) was chemically synthesized DAEFRHDSGYEVHHQKLVFFAEDVGSNGGC.
This peptide comprises the amino acid sequence from residue 1-27 of
human A.beta., fused at its C-terminus to the sequence GGC for
coupling to Q.beta. capsid protein.
[0916] A first batch of "A.beta.1-27" coupled to Q.beta. capsid
protein, in the following abbreviated as "Q.beta.-A.beta.1-27 batch
1" was prepared as follows:
[0917] A solution of 1.5 ml of 2 mg/ml Q.beta. capsid protein in 20
mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 16.6
.mu.l of a solution of 65 mM SMPH (Pierce) in H2O, at 25.degree. C.
on a rocking shaker. The reaction solution was subsequently
dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl,
pH 7.4 at 4.degree. C. in a dialysis tubing with Molecular Weight
cutoff 10000 Da. 450 .mu.l of the dialyzed reaction mixture was
then reacted with 6.5 .mu.l of a 50 mM peptide stock solution (in
DMSO) for two hours at 15.degree. C. on a rocking shaker. 200 .mu.l
of the sample was then aliquoted, frozen in liquid Nitrogen and
stored at -80.degree. C. until immunization of the mice.
[0918] A second batch of "A.beta. 1-27" coupled to Q.beta. capsid
protein, in the following abbreviated as "Q.beta.-A.beta. 1-27
batch 2" was prepared as follows:
[0919] 500 .mu.l of Q.beta. capsid protein in 20 mM Hepes 150 mM
NaCl pH 7.4 was reacted for 30 minutes with 11.3 .mu.l of a
solution of 32.5 mM SMPH (Pierce) in H2O, at 25.degree. C. on a
rocking shaker. The reaction solution was subsequently dialyzed
twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4
at 4.degree. C. in a dialysis tubing with Molecular Weight cutoff
3500 Da (SnakeSkin, Pierce). The dialyzed reaction mixture was then
reacted with 3.6 .mu.l of a 50 mM peptide stock solution (in DMSO)
for two hours at 15.degree. C. on a rocking shaker. The reaction
mixture was then dialyzed 2.times. against 1120 mM Hepes, 150 mM
NaCl, pH 7.4 for 1 hour and overnight after a last change of
buffer, using a dialysis membrane with a 50000 Da cutoff
(Spectrapor, spectrum). The reaction mixture was then frozen in
aliquots in liquid nitrogen and stored at -80.degree. C. until
immunization of the mice. "Q.beta.-A.beta. 1-27 batch 1" was used
for the first immunization, while "Q.beta.-A.beta. 1-27 batch 2"
was used for the boost.
[0920] The result of the coupling experiment was analyzed by
SDS-PAGE, and is shown in FIG. 13C. The arrow points to the band
corresponding to one peptide coupled to one Q.beta.subunit.
[0921] The samples loaded on the gel of FIG. 13C are the
following:
[0922] M: protein marker. 1: Q.beta.capsid protein 2: derivatized
Q.beta., supernatant of the sample taken at the end of the
derivatization reaction, and centrifuged. 3: derivatized Q.beta.,
pellet of the sample taken at the end of the derivatization
reaction, and centrifuged. 4: Q.beta.coupled with "A.beta.1-27",
supernatant of the sample taken at the end of the coupling
reaction, and centrifuged. 5: Q.beta.coupled with "A.beta.1-27",
pellet of the sample taken at the end of the coupling reaction, and
centrifuged. 6: Q.beta.coupled with "A.beta.1-27", supernatant of
the sample taken after dialysis of the coupling reaction, and
centrifuged. 7: Q.beta.coupled with "A.beta.1-27", pellet of the
sample taken after dialysis of the coupling reaction, and
centrifuged.
C. Coupling of "A.beta. 1-15" Peptide to Q.beta. Capsid Protein
Using the Cross-Linker Sulfo-GMBS
[0923] A solution of 500 .mu.l of 2 mg/ml Q.beta. capsid protein in
20 mM Hepes 150 mM NaCl pH 7.4 was reacted for 30 minutes with 5.5
.mu.l of a solution of 65 mM SMPH (Pierce) in H2O, at 25.degree. C.
on a rocking shaker. The reaction solution was subsequently
dialyzed twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl,
pH 7.4 at 4.degree. C. in a dialysis tubing with Molecular Weight
cutoff 10 000 Da. 500 .mu.l of the dialyzed reaction mixture was
then reacted with 6.5 .mu.l of the 50 mM peptide stock solution (in
DMSO) for two hours at 15.degree. C. on a rocking shaker. 200 .mu.l
of the reaction mixture was subsequently dialyzed overnight against
2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C., and
the next morning for another two hours after change of buffer. The
reaction mixture was then frozen in aliquots in liquid Nitrogen and
stored at -80.degree. C. until immunization of the mice.
[0924] The result of the coupling experiment was analyzed by
SDS-PAGE, and is shown in FIG. 13D. The arrow points to the band
corresponding to one, two and three peptides, respectively, coupled
to one Q.beta.subunit.
[0925] The samples loaded on the gel of FIG. 13D are the
following:
[0926] M: protein marker. 1: derivatized Q.beta. 2: Q.beta.coupled
with "A.beta.1-15", supernatant of the sample taken at the end of
the coupling reaction, and centrifuged. 3: Q.beta.coupled with
"A.beta.1-15", pellet of the sample taken at the end of the
coupling reaction, and centrifuged. 4: Q.beta.coupled with
"A.beta.1-15", supernatant of a sample left to stand 24 hours at
4.degree. C., undialyzed and centrifuged. 5: Q.beta.coupled with
"A.beta.1-15", pellet of a sample left to stand 24 hours at
4.degree. C., undialyzed and centrifuged. 6: Q.beta.coupled with
"A.beta.1-15", supernatant of the sample taken after dialysis of
the coupling reaction, and centrifuged.
D. Coupling of "A.beta. 1-15" to Q.beta. Capsid Protein Using the
Cross-Linker Sulfo-MBS.
[0927] 500 .mu.l of Q.beta. capsid protein in 20 mM Hepes 150 mM
NaCl pH 7.4 was reacted for 30 minutes with 14.7 .mu.l of a
solution of 100 mM Sulfo-MBS (Pierce) in H2O, at 25.degree. C. on a
rocking shaker. The reaction solution was subsequently dialyzed
twice for 2 hours against 2 L of 20 mM Hepes, 150 mM NaCl, pH 7.4
at 4.degree. C. in a dialysis tubing (SnakeSkin, Pierce) with
Molecular Weight cutoff 3500 Da. The dialyzed reaction mixture was
then reacted with 7.2 .mu.l of a 50 mM peptide stock solution (in
DMSO) for two hours at 15.degree. C. on a rocking shaker. The
reaction mixture was then dialyzed 3.times. over 4 hours against
2120 mM Hepes, 150 mM NaCl, pH 7.4 using a dialysis membrane with a
50000 Da cutoff (Spectrapor, spectrum). The reaction mixture was
then frozen in aliquots in liquid nitrogen and stored at
-80.degree. C. until immunization of the mice.
[0928] The result of the coupling experiment was analyzed by
SDS-PAGE, and is shown in FIG. 13E. The arrow points to the band
corresponding to one peptide coupled to one Q.beta.subunit.
[0929] The samples loaded on the gel of FIG. 13E are the
following:
[0930] 1: Q.beta.capsid protein 2: derivatized Q.beta., supernatant
of the sample taken at the end of the derivatization reaction, and
centrifuged. 3: derivatized Q.beta., pellet of the sample taken at
the end of the derivatization reaction, and centrifuged. 4:
derivatized Q.beta., supernatant of the sample taken at the end of
the dialysis of the derivatization reaction, and centrifuged. 5:
derivatized Q.beta., pellet of the sample taken at the end of the
dialysis of the derivatization reaction, and centrifuged. 6:
Q.beta.coupled with "A.beta.1-15", supernatant of the sample taken
at the end of the coupling reaction, and centrifuged. 7:
Q.beta.coupled with "A.beta.1-15", pellet of the sample taken at
the end of the coupling reaction, and centrifuged. 8:
Q.beta.coupled with "A.beta.1-15", supernatant of the sample taken
after dialysis of the coupling reaction, and centrifuged.
E. Immunization of Mice:
[0931] Five groups of female C57BL/6 mice, three mice per group, 8
weeks of age were vaccinated each with one of the five
A.beta.peptide-Q.beta. capsid protein conjugates without the
addition of adjuvant. 25 .mu.g of total protein of each sample was
diluted in PBS to 200 .mu.l and injected subcutaneously on day 0
and day 14. Mice were bled retroorbitally on day 0 (preimmune) and
21 and their serum was analyzed in an ELISA. "A.beta. 1-15" peptide
was coupled to Q.beta. with three different cross-linkers,
resulting in three different vaccine preparations ("Qb-A.beta.1-15
SMPH", "Q.beta.-Ab1-15 SMBS", "Qb-A.beta.1-15 SGMBS"; see ELISA
section for the results).
[0932] F. ELISA
[0933] All three A.beta. peptides were individually coupled to
bovine RNAse A using the chemical cross-linker SPDP as follows: a
solution of 10 mg RNAse A in 2 mL PBS (50 mM Phosphate buffer, 150
mM NaCl pH 7.2) was reacted with 100 .mu.l of a 20 mM SPDP solution
in DMSO, at 25.degree. C. for 60 min. on a rocking shaker. Excess
cross-linker was separated from activated (derivatized) RNAse A by
gel filtration using a PD 10 column (Pharmacia). The protein
containing fractions were pooled and concentrated to a volume of 2
ml using centrifugal filters (5000 MWCO). A sample of 333 .mu.l of
the derivatized RNAse A solution was reacted with 2 .mu.l of the
peptide stock solution (50 mM in DMSO). The coupling reaction was
followed spectrophotometrically.
[0934] ELISA plates were coated with RNAse A coupled to peptide at
a concentration of 10 .mu.g/ml. The plates were blocked and then
incubated with serially diluted mouse sera. Bound antibodies were
detected with enzymatically labeled anti-mouse IgG antibody.
Preimmune sera or control sera from mice immunized with unrelated
peptides conjugated to Q.beta., showed that the antibodies detected
were specific for the respective peptide. FIG. 14A, FIG. 14B and
FIG. 14C, respectively, show ELISA analyses of IgG antibodies
specific for "A.beta. 1-15", "A.beta. 1-27" and "A.beta.33-42",
respectively, in sera of mice immunized against "A.beta. 1-15",
"A.beta. 1-27" and "A.beta.33-42", respectively, coupled to Q.beta.
capsid protein. The denominations on the abscissa stand for the
vaccine injected in the mice from which the sera are derived, and
describe the peptide and the cross-linker used to make the
respective vaccine. All sera were measured against the three
peptides coupled to RNAse A, and the results show that while there
is cross-reactivity between the antibodies raised against peptide
1-15 and 1-27, no such cross reactivity is observed against peptide
33-42, demonstrating the specificity of the immune response.
Likewise, The ELISA titers obtained, expressed as the dilution of
the serum yielding an ELISA signal three standard deviations above
background, were very high, and ranged from 60'000 to 600'000. No
A.beta.peptide-specific antibodies were detected in the controls
(pre-immune mice).
Example 55
Introduction of cys-Containing Linkers, Expression, and
Purification of Anti-Idiotypic IgE Mimobodies and their Coupling to
Q.beta. Capsid Protein
A. Construction of Plasmids for the Expression of Mimobodies for
Coupling to Q.beta. Capsid Protein
[0935] Plasmids were based on the expression plasmid
VAE051-pASK116. This plasmid contains the coding regions for the
heavy chain and for the light chain of the mimobody. The following
primers were used to introduce cys-containing linkers at the
C-terminus of the heavy chain: TABLE-US-00034 Primer CA2F: (SEQ ID
NO: 388) CGGCTCGAGCATCACCATCACCATCACGGTGAAGTTAAACTGCAGCTGGA GTCG
Primer CA1R: (SEQ ID NO: 389)
CATGCCATGGTTAACCACAGGTGTGGGTTTTATCACAAGATTTGGGCTCAA C Primer CB1R:
(SEQ ID NO: 390) CATGCCATGGTTAACCACACGGCGGAGAGGTGTGGGTTTTATCACAAGAT
TTGGGCTCAAC Primer CC1R: (SEQ ID NO: 391)
CCAGAAGAACCCGGCGGGGTAGACGGTTTCGGGCTAGCACAAGATTTGGG CTCAACTC Primer
CC1F: (SEQ ID NO: 392)
CGCCGGGTTCTTCTGGTGGTGCTCCGGGTGGTTGCGGTTAACCATGGAGAA AATAAAGTG
Primer CCR2: (SEQ ID NO: 393) CTCCCGGGTAGAAGTCAC
A.1. Construction of pCA2:
[0936] Primers CA2F and CA1R were used to amplify a 741 bp fragment
encoding part of the heavy chain with an extension encoding the
cys-containing linker sequence. VAE-pASK116 served as template for
the Pfx polymerase (Roche) in the PCR cycler (Robo) at (initial
denaturation at 92.degree. C., cycling: 92.degree. C., 30 s;
48.degree. C., 30 s; 68.degree. C., 60 s) for 5 cycles followed by
30 cycles with 92.degree. C., 30 s; 58.degree. C., 30 s; 68.degree.
C., 1 min. The PCR product of the appropriate size was purified
using the Qiagen PCR purification kit and digested with XhoI and
NcoI according to the recommendation of the manufacturer (Gibco).
The product was purified from an agarose gel with the Qiagen gel
extraction kit. Plasmid VAE-pASK116 was in parallel cleaved with
XhoI and NcoI and a 3.7 kb band purified from agarose gels.
Appropriate aliquots of the XhoI-NcoI digested PCR product and the
plasmid were ligated overnight at 16.degree. C. using T4 DNA ligase
according to the manufacturer's protocol (Gibco). The ligation
product was transformed into competent E. coli XL-1 cells which
were plated on agarose plates containing chloramphenicol. Single
colonies were expanded in LB/chloramphenicol medium, plasmid was
prepared (Qiagen mini plasmid kit) and tested for the presence of
the appropriate XhoI-NcoI insert size after digestion with the
corresponding enzymes. A correspondingly positive plasmid termed
pCA2 was sent for sequencing on both strands which confirmed the
identity of the plasmid including the cys-containing linker.
A.2. Construction of pCB2:
[0937] Primers CA2F and CB1R were used to introduce linker 2 at the
5' end of the heavy chain coding sequence and the same conditions
as described in section A1. The resulting PCR product was 750 bp
and cloned into VAE051-pASK116 as described in section A.1.
A.3. Construction of pCC2:
[0938] Plasmid pCC2 was constructed in a two step procedure: A
first PCR product of 754 bp was amplified using primers CA2F and
CC1R. A second PCR product of 560 bp was produced using primers
CC1F and CC2R. For both PCRs VAE051-pASK116 was used as template
and conditions were as described in section A1. Both PCR products
were isolated from agarose gels, mixed with primers CA2F and CC2R
and a third PCR was performed that resulted in a 1298 bp fragment.
This fragment was isolated and digested with XhoI and NcoI. The
resulting 780 bp fragment was cloned into VAE-pASK100 as described
in section A. 1.
B. Expression of Mimobodies
[0939] Competent E. coli W3110 cells were transformed with plasmids
pCA2, pCB2 and pCC2. Single colonies from chloramphenical agarose
plates were expanded in liquid culture (LB+15 .mu.g/ml
chloramphenicol) overnight at 37.degree. C. 111 of TB medium was
then inoculated 1:50 v/v with the overnight culture and grown to
OD600=3 at 28.degree. C. Expression was induced with 1 mg/l
anhydrotetracyclin. Cells were harvested after overnight culture
and centrifuged at 6000 rpm. Periplasma was isolated from cell
pellets by incubation in lysis buffer supplemented with polymyxin B
sulfate for 2 h at 4.degree. C. Spheroblasts were separated by
centrifugation at 6000 rpm. The resulting supernatant contained the
mimobody and was dialysed against 20 mM Tris, pH 8.0.
C. Purification of Mimobodies
[0940] The introduced his6-tag allowed the purification of mimobody
pCA2 and pCB2 by chromatography on Ni-NTA fast flow (Qiagen)
according the recommendations of the manufacturer. If necessary, a
polishing step on a protein G fast flow column (Amersham Pharmacia
Biotech) followed. Mimobodies were eluted with 0.1 M glycine pH
2.7, immediately neutralized by addition of NaOH and dialysed
against 20 mM Hepes, 150 mM NaCl, pH 7.2. pCC2 was purified by
affinity chromatography on protein G only. Purity was analysed by
SDS-PAGE.
[0941] The protein sequences of the mimobodies were translated from
the cDNA sequences. N-terminal sequences were confirmed by Edman
sequencing of pCA2 and pCB2.
[0942] The sequence of the light chains of pCA2, pCB2 and pCC2 is
the same and as follows: TABLE-US-00035
DIELVVTQPASVSGSPGQSITISCTGTRSDVGGYNYVSWYQQHPGKAPKLMIY (SEQ ID NO:
394) DVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLGVFGGGTKLT
VLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVET
TTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS.
[0943] The sequence of the heavy chain of pCA2 is: TABLE-US-00036
EVKLQLEHHHHHHGEVKLQLESGPGLVKPSETLSLTCTVSGGSISSGGYYWT (SEQ ID NO:
395) WIRQRPGKGLEWIGYIYYSGSTSYNPSLKSRVTMSVDTSKNQFSLRLTSVTAADTAV
YYCARERGETGLYYPYYYIDVWGTGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
NVNHKPSNTKVDKRVEPKSCDKTHTCG.
[0944] The sequence of the heavy chain of pCB2 is: TABLE-US-00037
EVKLQLEHHHHHHGEVKLQLESGPGLVKPSETLSLTCTVSGGSISSGGYYWT (SEQ ID NO:
396) WIRQRPGKGLEWIGYIYYSGSTSYNPSLKSRVTMSVDTSKNQFSLRLTSVTAADTAV
YYCARERGETGLYYPYYYIDVWGTGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
NVNHKPSNTKVDKRVEPKSCDKTHTSPPCG.
[0945] The sequence of the heavy chain of pCC2 is: TABLE-US-00038
EVKLQLEHHHHHHGEVKLQLESGPGLVKPSETLSLTCTVSGGSISSGGYYWT (SEQ ID NO:
397) WIRQRPGKGLEWIGYIYYSGSTSYNPSLKSRVTMSVDTSKNQFSLRLTSVTAADTAV
YYCARERGETGLYYPYYYIDVWGTGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
NVNHKPSNTKVDKRVEPKSCASPKPSTPPGSSGGAPGGC.
D. Coupling of Mimobodies to Q.beta. Capsid Protein D.1. Coupling
of Mimobody pCC2 to Q.beta. Capsid Protein:
[0946] A solution of 1.25 ml of 4.5 mg/ml Q.beta. capsid protein in
20 mM Hepes, 150 mM NaCl pH 7.2 was reacted for 30 minutes with 40
.mu.l of a SMPH solution (Pierce) (from a 100 mM stock solution
dissolved in DMSO) at 25.degree. C. on a rocking shaker. The
reaction solution was subsequently dialyzed twice for 2 hours
against 2 l of 20 mM Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. 6
.mu.l of the dialyzed reaction mixture was then reacted with 30
.mu.l of the pCC2 solution (2.88 mg/ml) for at 25.degree. C. over
night on a rocking shaker.
[0947] The reaction products were analysed on 16% SDS-PAGE gels
under reducing conditions. Gels were either stained with Coomassie
Brilliant Blue or blotted onto nitrocellulose membranes. Membranes
were blocked, incubated with a polyclonal rabbit anti-Qb antiserum
(dilution 1:2000) or a mouse monoclonal anti-Fab-mAb (Jackson
ImmunoResearch) (dilution 1:2000). Blots were subsequently
incubated with horse radish peroxidase-conjugated goat anti-rabbit
IgG or horse radish peroxidase-conjugated goat anti-mouse IgG
(dilutions 1:7000), respectively
[0948] The results are shown in FIG. 13A. Coupling products and
educts were analysed on 16% SDS-PAGE gels under reducing
conditions. In FIG. 13A "pCC2" corresponds to the mimobody before
coupling. "Q.beta. deriv" stands for derivatized Q.beta. before
coupling, "Q.beta.-pCC2" for the product of the coupling reaction.
Gels were either stained with Coomassie Brilliant Blue or blotted
onto nitrocellulose membranes. Membranes were blocked, incubated
with a polyclonal rabbit anti-Q.beta. antiserum (dilution 1:2000)
or an mouse monoclonal anti-Fab-mAb (Jackson ImmunoResearch)
(dilution 1:2000). Blots were subsequently incubated with horse
radish peroxidase-conjugated goat anti-rabbit IgG or horse radish
peroxidase-conjugated goat anti-mouse IgG (dilutions 1:7000),
respectively. Enhanced chemoluminescence (Amersham Pharmacia ELC
kit) was used to visualize the immunoreactive bands. Molecular
weights of marker proteins are given on the left margin.
[0949] A coupling product of about 40 kDa could be detected (FIG.
13A, arrows). Its reactivity with the anti-Q.beta. antiserum and
the anti-Fab antibody recognizing the mimobody clearly demonstrated
the covalent coupling of the mimobody to Q.beta..
D.2. Coupling of Mimobodies pCA2 and pCB2 to Q.beta.Capsid
Protein:
[0950] A solution of 1.25 ml of 4.5 mg/ml Q.beta. capsid protein in
20 mM Hepes, 150 mM NaCl pH 7.4 was reacted for 30 minutes with 40
.mu.l of a SMPH (Pierce) (from a 100 mM stock solution dissolved in
DMSO) at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 l of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. pCA2 (1.2 mg/ml) was
reduced with 20 mM TCEP for 30 min at 25.degree. C., pCB2 (4.2
mg/ml) with 50 mM mercaptoethylamine at 37.degree. C. Both
mimobodies were then dialyzed twice against 20 mM Hepes, 150 mM
NaCl, pH 7.2 at 4.degree. C. Coupling was performed by adding 6
.mu.l of derivatized Q.beta. to 30 .mu.l of mimobody at 25.degree.
C. over night on a rocking shaker.
[0951] The reaction products were analysed on 16% SDS-PAGE gels
under reducing conditions. Gels were either stained with Coomassie
Brilliant Blue or blotted onto nitrocellulose membranes. Membranes
were blocked, incubated with a polyclonal rabbit anti-Qb antiserum
(Cytos, dilution 1:2000) or an mouse monoclonal anti-his6-mAb
(Qiagen) (dilution 1:5000). Blots were subsequently incubated with
horse radish peroxidase-conjugated goat anti-rabbit IgG or horse
radish peroxidase-conjugated goat anti-mouse IgG (dilutions
1:5000), respectively.
[0952] The results are shown in FIG. 13B and FIG. 13C. Coupling
products and educts were analysed on 16% SDS-PAGE gels under
reducing conditions. In FIG. 15A and FIG. 15B "pCA2" and "pCB2"
corresponds to the mimobodies before coupling. "Qb deriv" stands
for derivatized Q.beta. before coupling and "Q.beta.-pCA2" and
"Q.beta.-pCA2" for the products of the coupling reaction. Gels were
either stained with Coomassie Brilliant Blue or blotted onto
nitrocellulose membranes. Membranes were blocked, incubated with a
polyclonal rabbit anti-Qb antiserum (dilution 1:2000) or an mouse
monoclonal anti-his6-mAb (Qiagen) (dilution 1:5000). Blots were
subsequently incubated with horse radish peroxidase-conjugated goat
anti-rabbit IgG or horse radish peroxidase-conjugated goat
anti-mouse IgG (dilutions 1:5000), respectively. Enhanced
chemoluminescence (Amersham Pharmacia ECL kit) was used to
visualize the immunoreactive bands. Molecular weights of marker
proteins are given on the left margin.
[0953] Coupling products of about 40 kDa could be detected for both
the pCA2 and the pCB2 coupling (FIG. 15A and FIG. 15B, arrows). Its
reactivity with the anti-Q.beta. antiserum and the anti-his6
antibody recognizing the heavy chain of the mimobody clearly
demonstrated the covalent coupling of the mimobody to Q.beta..
Example 56
Coupling of Flag Peptides to wt and Mutant Q.beta.capsid Protein
Using the Cross-Linker Sulfo-GMBS
[0954] The Flag peptide, to which a CGG sequence was added
N-terminally for coupling, was chemically synthesized and had the
following sequence: CGGDYKDDDDK (SEQ ID NO:147). This peptide was
used for chemical coupling to wt Q.beta. capsid protein and the
Q.beta. mutant capsid protein as described in the following.
[0955] A. Coupling of Flag Peptide to Q.beta. Capsid Protein
[0956] A solution of 100 .mu.l of 2 mg/ml Q.beta. capsid protein in
20 mM Hepes. 150 mM NaCl pH 7.2 was reacted for 60 minutes with 7
.mu.l of a solution of 65 mM Sulfo-GMBS (Pierce) in H2O at
25.degree. C. on a rocking shaker. The reaction solution was
subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. 100 .mu.l of the dialyzed
reaction mixture was then reacted with 0.58 .mu.l of 100 mM Flag
peptide stock solution (in H.sub.2O) for two hours at 25.degree. C.
on a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH
7.4 at 4.degree. C.
[0957] B. Coupling of Flag Peptide to Q.beta.-240 Capsid
Protein
[0958] A solution of 100 .mu.l of 2 mg/ml Q.beta.-240 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.2 was reacted for 60
minutes with 7 .mu.l of a solution of 65 mM Sulfo-GMBS (Pierce) in
H.sub.2O at 25.degree. C. on a rocking shaker. The reaction
solution was subsequently dialyzed twice for 2 hours against 2 L of
20 mM Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. 100 .mu.l of the
dialyzed reaction mixture was then reacted with 0.58 .mu.l of 100
mM Flag peptide stock solution (in H.sub.2O) for two hours at
25.degree. C. on a rocking shaker. The reaction mixture was
subsequently dialyzed 2.times.2 hours against 2 liters of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C.
[0959] C. Coupling of Flag Peptides to Q.beta.-250 Capsid
Protein
[0960] A solution of 100 .mu.l of 2 mg/ml Q.beta.-250 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.4 was reacted for 60
minutes with 7 .mu.l of a solution of 65 mM Sulfo-GMBS (Pierce) in
H2O at 25.degree. C. on a rocking shaker. The reaction solution was
subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes,
150 mM NaCl, pH 7.2 at 4.degree. C. 100 .mu.l of the dialyzed
reaction mixture was then reacted with 0.58 .mu.l of 00 mM Flag
peptide stock solution (in H.sub.2O) for two hours at 25.degree. C.
on a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH
7.2 at 4.degree. C.
[0961] D. Coupling of Flag Peptides to Q.beta.-259 Capsid
Protein
[0962] A solution of 100 .mu.l of 2 mg/ml Q.beta.-259 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.4 was reacted for 60
minutes with 7 .mu.l of a solution of 65 mM Sulfo-GMBS (Pierce) in
H2O at 25.degree. C. on a rocking shaker. The reaction solution was
subsequently dialyzed twice for 2 hours against 2 L of 20 mM Hepes,
150 mM NaCl, pH 7.4 at 4.degree. C. 100 .mu.l of the dialyzed
reaction mixture was then reacted with 0.58 .mu.l of 100 mM Flag
peptide stock solution (in H.sub.2O) for two hours at 25.degree. C.
on a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH
7.4 at 4.degree. C.
[0963] The results of the coupling reactions of the Q.beta. mutants
240, 250 and 259 to Flag peptide analyzed by SDS-PAGE are shown in
FIG. 22 A. The loading pattern was the following:
[0964] 1. Derivatized Q.beta.-240. 2. Q.beta.-240 coupled to the
Flag peptide. 3. Derivatized Q.beta.-250. 4. Q.beta.-250 coupled to
the Flag peptide. 5. Derivatized Q.beta.-259. 6. Q.beta.-259
coupled to the Flag peptide. 7. Derivatized wt Q.beta.. 8. wt
Q.beta. coupled to the Flag peptide. 9. Protein Marker.
[0965] Comparison of the derivatized reaction with the coupling
reactions shows that for all the mutants and wt, coupling bands
corresponding to 1 and 2 peptides per subunit are visible. The band
corresponding to the uncoupled Q.beta. subunit is very weak,
indicating that nearly all subunits have reacted with at least one
Flag peptide. For the Q.beta.-250 mutant and wt Q.beta., a band
corresponding to three peptides per subunit is visible. The ratio
of the intensities of the band corresponding to two peptides per
subunit and the band corresponding to 1 peptide per subunit is
strongest for wt, with a ratio of 1:1. This ratio is still high for
the Q.beta.-250 mutant, while it is significantly weaker for the
Q.beta.-240 mutant and weakest for the Q.beta.-259 mutant.
Example 57
Coupling of Flag Peptide to Q.beta.capsid Protein Using the
Cross-Linker Sulfo-MBS
[0966] The Flag peptide, to which a CGG sequence was added
N-terminally for coupling, was chemically synthesized and had the
following sequence: CGGDYKDDDDK (SEQ ID NO:147). This peptide was
used for chemical coupling to wt Q.beta. capsid protein and the
Q.beta. mutant capsid protein as described in the following.
[0967] A. Coupling of Flag Peptides to Q.beta. Capsid Protein
[0968] A solution of 100 [[u]].mu.l of 2 mg/ml Q.beta. capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.2 was reacted for 60
minutes with 7 .mu.l of a solution of 65 mM Sulfo-MBS (Pierce) in
H.sub.2O at 25.degree. C. on a rocking shaker. The reaction
solution was subsequently dialyzed twice for 2 hours against 2 L of
20 mM Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. 100 .mu.l of the
dialyzed reaction mixture was then reacted with 0.58 .mu.l of 100
mM Flag peptide stock solution (in H.sub.2O) for two hours at
25.degree. C. on a rocking shaker. The reaction mixture was
subsequently dialyzed 2.times.2 hours against 2 liters of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C.
[0969] B. Coupling of Flag Peptide to Q.beta.-240 Capsid
Protein
[0970] A solution of 100 .mu.l of 2 mg/ml Q.beta.-240 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.2 was reacted for 60
minutes with 7 .mu.l of a solution of 65 mM Sulfo-MBS (Pierce) in
H.sub.2O at 25.degree. C. on a rocking shaker. The reaction
solution was subsequently dialyzed twice for 2 hours against 2 L of
20 mM Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. 100 .mu.l of the
dialyzed reaction mixture was then reacted with 0.58 .mu.l of 100
mM Flag peptide stock solution (in H.sub.2O) for two hours at
25.degree. C. on a rocking shaker. The reaction mixture was
subsequently dialyzed 2.times.2 hours against 2 liters of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C.
[0971] C. Coupling of Flag Peptide to Q.beta.-250 Capsid
Protein
[0972] A solution of 100 .mu.l of 2 mg/ml Q.beta.-250 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.2 was reacted for 60
minutes with 7 .mu.l of a solution of 65 mM Sulfo-MBS (Pierce) in
H.sub.2O at 25.degree. C. on a rocking shaker. The reaction
solution was subsequently dialyzed twice for 2 hours against 2 L of
20 mM Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. 100 .mu.l of the
dialyzed reaction mixture was then reacted with 0.58 .mu.l of 100
mM Flag peptide stock solution (in H.sub.2O) for two hours at
25.degree. C. on a rocking shaker. The reaction mixture was
subsequently dialyzed 2.times.2 hours against 2 liters of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C.
[0973] D. Coupling of Flag Peptides to Q.beta.-259 Capsid
Protein
[0974] A solution of 100 .mu.l of 2 mg/ml Q.beta.-259 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.2 was reacted for 60
minutes with 7 .mu.l of a solution of 65 mM Sulfo-MBS (Pierce) in
H.sub.2O at 25.degree. C. on a rocking shaker. The reaction
solution was subsequently dialyzed twice for 2 hours against 2 L of
20 mM Hepes, 150 mM NaCl, pH 7.2 at 4.degree. C. 100 .mu.l of the
dialyzed reaction mixture was then reacted with 0.58 .mu.l of 100
mM Flag peptide stock solution (in H.sub.2O) for two hours at
25.degree. C. on a rocking shaker. The reaction mixture was
subsequently dialyzed 2.times.2 hours against 2 liters of 20 mM
Hepes, 150 mM NaCl, pH 7.2 at 4[[>]].degree. C.
[0975] The results of the coupling reactions of the Q.beta. mutants
240, 250 and 259 to Flag peptide analyzed by SDS-PAGE are shown in
FIG. 1. The loading pattern was the following:
[0976] 1. Protein Marker. 2. Derivatized Q.beta.-240. 3.
Q.beta.-240 coupled to the Flag peptide. 4. Derivatized
Q.beta.-250. 5. Q.beta.-250 coupled to the Flag peptide. 6.
Derivatized Q.beta.-259. 7. Q.beta.-259 coupled to the Flag
peptide. 8. Derivatized wt Q.beta. 9. wt Q.beta. coupled to the
Flag peptide.
[0977] Comparison of the derivatized reaction with the coupling
reactions shows that for all the mutants and wt, a coupling band
corresponding to 1 peptide per subunit is visible. Bands
corresponding to 2 peptides per subunit are also visible for the
mutant Q.beta.-250 and wt Q.beta.. The ratio of the intensities of
the band corresponding to 1 peptide per subunit and to the
uncoupled subunit, respectively, is higher for the Q.beta.-250
mutant and wt Q.beta.. A weak band corresponding to two peptides
per subunit is visible for the Q.beta.-240 mutant.
Example 58
Coupling of Flag Peptides to Q.beta. Mutants Using the Cross-Linker
SMPH
[0978] The Flag peptide, to which a CGG sequence was added
N-terminally for coupling, was chemically synthesized and had the
following sequence: CGGDYKDDDDK (SEQ ID NO:147). This peptide was
used for chemical coupling to the Q.beta. mutants as described in
the following.
[0979] A Coupling of Flag Peptides to Q.beta.-240 Capsid
Protein
[0980] A solution of 100 .mu.l of 2 mg/ml Q.beta.-240 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.4 was reacted for 30
minutes with 2.94 .mu.l of a solution of 100 mM SMPH (Pierce) in
DMSO at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. 90 .mu.l of the dialyzed
reaction mixture was then reacted with 1.3 .mu.l of 50 mM Flag
peptide stock solution (in DMSO) for two hours at 25.degree. C. on
a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH
7.4 at 4.degree. C.
[0981] B. Coupling of Flag Peptides to Q.beta.-250 Capsid
Protein
[0982] A solution of 100 .mu.l of 2 mg/ml Q.beta.-250 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.4 was reacted for 30
minutes with 2.94 .mu.l of a solution of 100 mM SMPH (Pierce) in
DMSO at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. 90 .mu.l of the dialyzed
reaction mixture was then reacted with 1.3 .mu.l of 50 mM Flag
peptide stock solution (in DMSO) for two hours at 25.degree. C. on
a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH
7.4 at 4.degree. C.
[0983] C. Coupling of Flag Peptide to Q.beta.-259 Capsid
Protein
[0984] A solution of 100 .mu.l of 2 mg/ml Q.beta.-259 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.4 was reacted for 30
minutes with 2.94 .mu.l of a solution of 100 mM SMPH (Pierce) in
DMSO at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. 90 .mu.l of the dialyzed
reaction mixture was then reacted with 1.3 .mu.l of 50 mM Flag
peptide stock solution (in DMSO) for two hours at 25.degree. C. on
a rocking shaker. The reaction mixture was subsequently dialyzed
2.times.2 hours against 2 liters of 20 mM Hepes, 150 mM NaCl, pH
7.4 at 4.degree. C.
[0985] The results of the coupling reactions of the Q.beta. mutants
240, 250 and 259 to Flag peptide analyzed by SDS-PAGE are shown in
FIG. 1. The loading pattern was the following. 1. Protein Marker 2.
Q.beta.-240 coupled to Flag, pellet of the coupling reaction 3.
Q.beta.-240 coupled to Flag, Supernatant of the coupling reaction
4. Q.beta.-240 derivatized with SMPH 5. Q.beta.-250 coupled to
Flag, pellet of the coupling reaction 6. Q.beta.-250 coupled to
Flag, supernatant of the coupling reaction 7. Q.beta.-250
derivatized with SMPH 8. Q.beta.-259 coupled to Flag, pellet of the
coupling reaction 9. Q.beta.-259 coupled to Flag, supernatant of
the coupling reaction 10. Q.beta.-259 derivatized with SMPH.
[0986] Comparison of the derivatized reaction with the coupling
reactions shows that for all the mutants, coupling bands
corresponding to 1, respectively 2 peptides per subunits are
visible. Bands corresponding to three, respectively four peptides
per subunit are also visible for the mutant Q.beta.-250.
Example 59
Coupling of PLA.sub.2-Cys Protein to Mutant Q.beta.capsid
Proteins
[0987] Lyophilized mutant Q.beta.capsid proteins were swollen
overnight in 20 mM Hepes, 150 mM NaCl, pH 7.4.
[0988] A. Coupling of PLA2-Cys Protein to Q.beta.-240 Capsid
Protein
[0989] A solution of 100 .mu.l of 2 mg/ml Q.beta.-240 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.4 was reacted for 30
minutes with 2.94 .mu.l of a solution of 100 mM SMPH (Pierce) in
DMSO at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. 90 .mu.l of the dialyzed
reaction mixture was mixed with 146 .mu.l 20 mM Hepes, 150 mM NaCl,
pH 7.4 and reacted with 85.7 .mu.l of 2.1 mg/ml PLA2-Cys stock
solution for four hours at 25.degree. C. on a rocking shaker. The
reaction mixture was subsequently dialyzed 2.times.2 hours against
2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C.
[0990] B. Coupling of PLA2-Cys Protein to Q.beta.-250 Capsid
Protein
[0991] A solution of 100 .mu.l of 2 mg/ml Q.beta.-250 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.4 was reacted for 30
minutes with 2.94 .mu.l of a solution of 100 mM SMPH (Pierce) in
DMSO at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. 90 .mu.l of the dialyzed
reaction mixture was mixed with 146 .mu.l 120 mM Hepes, 150 mM
NaCl, pH 7.4 and reacted with 85.7 .mu.l of 2.1 mg/ml PLA.sub.2-Cys
stock solution for four hours at 25.degree. C. on a rocking shaker.
The reaction mixture was subsequently dialyzed 2.times.2 hours
against 2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4.degree.
C.
[0992] C. Coupling of PLA2-Cys Protein to Q.beta.-259 Capsid
Protein
[0993] A solution of 100 .mu.l of 2 mg/ml Q.beta.-259 capsid
protein in 20 mM Hepes. 150 mM NaCl pH 7.4 was reacted for 30
minutes with 2.94 .mu.l of a solution of 100 mM SMPH (Pierce) in
DMSO at 25.degree. C. on a rocking shaker. The reaction solution
was subsequently dialyzed twice for 2 hours against 2 L of 20 mM
Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C. 90 .mu.l of the dialyzed
reaction mixture was mixed with 146 .mu.l 20 mM Hepes, 150 mM NaCl,
pH 7.4 and reacted with 85.7 .mu.l of 2.1 mg/ml PLA.sub.2-Cys stock
solution for four hours at 25.degree. C. on a rocking shaker. The
reaction mixture was subsequently dialyzed 2.times.2 hours against
2 liters of 20 mM Hepes, 150 mM NaCl, pH 7.4 at 4.degree. C.
[0994] The results of the coupling experiment analyzed by SDS-PAGE
are shown in FIG. 1. The loading pattern was the following:
[0995] 1. Protein Marker 2. derivatized Q.beta.-240 3. Q.beta.-240
coupled to Pla2Cys, supernatant of the coupling reaction 4.
Q.beta.-240 coupled to PLA2-Cys, pellet of the coupling reaction 5.
derivatized Q.beta.-250 6. Q.beta.-250 coupled to PLA2-Cys,
supernatant of the coupling reaction 7. Q.beta.-250 coupled to
PLA2-Cys, pellet of the coupling reaction 8. derivatized
Q.beta.-259 9. Q.beta.-259 coupled to PLA2-Cys, supernatant of the
coupling reaction 10. Q.beta.-259 coupled to PLA2-Cys, pellet of
the coupling reaction 11. PLA2-Cys.
[0996] Coupling bands (indicated by the arrow in the figure) were
visible for all the mutants, showing that PLA2-Cys protein could be
coupled to all of the mutant Q.beta. capsid proteins.
[0997] All patents and publications referred to herein are
expressly incorporated by reference.
[0998] The entire disclosure of U.S. application Ser. No.
09/449,631 and WO 00/3227, both filed Nov. 30, 1999, are herein
incorporated by reference in their entirety. All publications and
patents mentioned hereinabove are hereby incorporated in their
entireties by reference.
Sequence CWU 0
0
SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 430 <210>
SEQ ID NO 1 <211> LENGTH: 41 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 1
ggggacgcgt gcagcaggta accaccgtta aagaaggcac c 41 <210> SEQ ID
NO 2 <211> LENGTH: 44 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 2 cggtggttac
ctgctgcacg cgttgcttaa gcgacatgta gcgg 44 <210> SEQ ID NO 3
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 3 ccatgaggcc tacgataccc
20 <210> SEQ ID NO 4 <211> LENGTH: 25 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 4
ggcactcacg gcgcgcttta caggc 25 <210> SEQ ID NO 5 <211>
LENGTH: 47 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 5 ccttctttaa cggtggttac ctgctggcaa ccaacgtggt
tcatgac 47 <210> SEQ ID NO 6 <211> LENGTH: 40
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 6 aagcatgctg cacgcgtgtg cggtggtcgg atcgcccggc
40 <210> SEQ ID NO 7 <211> LENGTH: 90 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 7
gggtctagat tcccaaccat tcccttatcc aggctttttg acaacgctat gctccgcgcc
60 catcgtctgc accagctggc ctttgacacc 90 <210> SEQ ID NO 8
<211> LENGTH: 108 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 8 gggtctagaa ggaggtaaaa
aacgatgaaa aagacagcta tcgcgattgc agtggcactg 60 gctggtttcg
ctaccgtagc gcaggccttc ccaaccattc ccttatcc 108 <210> SEQ ID NO
9 <211> LENGTH: 31 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 9 cccgaattcc
tagaagccac agctgccctc c 31 <210> SEQ ID NO 10 <211>
LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 10 cctgcggtgg tctgaccgac accc 24 <210>
SEQ ID NO 11 <211> LENGTH: 41 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 11
ccgcggaaga gccaccgcaa ccaccgtgtg ccgccaggat g 41 <210> SEQ ID
NO 12 <211> LENGTH: 33 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 12 ctatcatcta
gaatgaatag aggattcttt aac 33 <210> SEQ ID NO 13 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Modified ribosome binding site <400> SEQUENCE: 13 aggaggtaaa
aaacg 15 <210> SEQ ID NO 14 <211> LENGTH: 21
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: signal peptide
<400> SEQUENCE: 14 Met Lys Lys Thr Ala Ile Ala Ile Ala Val
Ala Leu Ala Gly Phe Ala 1 5 10 15 Thr Val Ala Gln Ala 20
<210> SEQ ID NO 15 <211> LENGTH: 46 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: modified Fos construct <400>
SEQUENCE: 15 Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp
Gln Val Glu 1 5 10 15 Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala
Asn Leu Leu Lys Glu 20 25 30 Lys Glu Lys Leu Glu Phe Ile Leu Ala
Ala His Gly Gly Cys 35 40 45 <210> SEQ ID NO 16 <211>
LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
peptide linker <400> SEQUENCE: 16 Ala Ala Ala Ser Gly Gly 1 5
<210> SEQ ID NO 17 <211> LENGTH: 6 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: peptide linker <400> SEQUENCE:
17 Gly Gly Ser Ala Ala Ala 1 5 <210> SEQ ID NO 18 <211>
LENGTH: 256 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Fos
fusion construct <400> SEQUENCE: 18 gaattcagga ggtaaaaaac
gatgaaaaag acagctatcg cgattgcagt ggcactggct 60 ggtttcgcta
ccgtagcgca ggcctgggtg ggggcggccg cttctggtgg ttgcggtggt 120
ctgaccgaca ccctgcaggc ggaaaccgac caggtggaag acgaaaaatc cgcgctgcaa
180 accgaaatcg cgaacctgct gaaagaaaaa gaaaagctgg agttcatcct
ggcggcacac 240 ggtggttgct aagctt 256 <210> SEQ ID NO 19
<211> LENGTH: 52 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Fos fusion construct <400> SEQUENCE: 19 Ala Ala
Ala Ser Gly Gly Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala 5 10 15 Glu
Thr Asp Gln Val Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile 20 25
30 Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala
35 40 45 His Gly Gly Cys 50 <210> SEQ ID NO 20 <211>
LENGTH: 261 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Fos
fusion construct <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (22)..(240) <400> SEQUENCE: 20
gaattcagga ggtaaaaaac g atg aaa aag aca gct atc gcg att gca gtg 51
Met Lys Lys Thr Ala Ile Ala Ile Ala Val 1 5 10 gca ctg gct ggt ttc
gct acc gta gcg cag gcc tgc ggt ggt ctg acc 99 Ala Leu Ala Gly Phe
Ala Thr Val Ala Gln Ala Cys Gly Gly Leu Thr 15 20 25 gac acc ctg
cag gcg gaa acc gac cag gtg gaa gac gaa aaa tcc gcg 147 Asp Thr Leu
Gln Ala Glu Thr Asp Gln Val Glu Asp Glu Lys Ser Ala 30 35 40 ctg
caa acc gaa atc gcg aac ctg ctg aaa gaa aaa gaa aag ctg gag 195 Leu
Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu 45 50
55 ttc atc ctg gcg gca cac ggt ggt tgc ggt ggt tct gcg gcc gct 240
Phe Ile Leu Ala Ala His Gly Gly Cys Gly Gly Ser Ala Ala Ala 60 65
70 gggtgtgggg atatcaagct t 261 <210> SEQ ID NO 21 <211>
LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Fos
fusion construct <400> SEQUENCE: 21 Met Lys Lys Thr Ala Ile
Ala Ile Ala Val Ala Leu Ala Gly Phe Ala 1 5 10 15 Thr Val Ala Gln
Ala Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu 20 25 30 Thr Asp
Gln Val Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala 35 40 45
Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala His 50
55 60 Gly Gly Cys Gly Gly Ser Ala Ala Ala 65 70 <210> SEQ ID
NO 22 <211> LENGTH: 196 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Fos fusion construct <220> FEATURE:
<221> NAME/KEY: CDS <222> LOCATION: (34)..(189)
<400> SEQUENCE: 22 gaattcagga ggtaaaaaga tatcgggtgt ggg gcg
gcc gct tct ggt ggt tgc 54 Ala Ala Ala Ser Gly Gly Cys 1 5 ggt ggt
ctg acc gac acc ctg cag gcg gaa acc gac cag gtg gaa gac 102 Gly Gly
Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Val Glu Asp 10 15 20
gaa aaa tcc gcg ctg caa acc gaa atc gcg aac ctg ctg aaa gaa aaa 150
Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys 25
30 35 gaa aag ctg gag ttc atc ctg gcg gca cac ggt ggt tgc taagctt
196 Glu Lys Leu Glu Phe Ile Leu Ala Ala His Gly Gly Cys 40 45 50
<210> SEQ ID NO 23 <211> LENGTH: 52 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fos fusion construct <400>
SEQUENCE: 23 Ala Ala Ala Ser Gly Gly Cys Gly Gly Leu Thr Asp Thr
Leu Gln Ala 1 5 10 15 Glu Thr Asp Gln Val Glu Asp Glu Lys Ser Ala
Leu Gln Thr Glu Ile 20 25 30 Ala Asn Leu Leu Lys Glu Lys Glu Lys
Leu Glu Phe Ile Leu Ala Ala 35 40 45 His Gly Gly Cys 50 <210>
SEQ ID NO 24 <211> LENGTH: 204 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fos fusion construct <400>
SEQUENCE: 24 gaattcagga ggtaaaaaac gatggcttgc ggtggtctga ccgacaccct
gcaggcggaa 60 accgaccagg tggaagacga aaaatccgcg ctgcaaaccg
aaatcgcgaa cctgctgaaa 120 gaaaaagaaa agctggagtt catcctggcg
gcacacggtg gttgcggtgg ttctgcggcc 180 gctgggtgtg gggatatcaa gctt 204
<210> SEQ ID NO 25 <211> LENGTH: 56 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fos fusion construct <400>
SEQUENCE: 25 Lys Thr Met Ala Cys Gly Gly Leu Thr Asp Thr Leu Gln
Ala Glu Thr 1 5 10 15 Asp Gln Val Glu Asp Glu Lys Ser Ala Leu Gln
Thr Glu Ile Ala Asn 20 25 30 Leu Leu Lys Glu Lys Glu Lys Leu Glu
Phe Ile Leu Ala Ala His Gly 35 40 45 Gly Cys Gly Gly Ser Ala Ala
Ala 50 55 <210> SEQ ID NO 26 <211> LENGTH: 26
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 26 Met Ala Thr Gly Ser Arg Thr Ser Leu Leu
Leu Ala Phe Gly Leu Leu 1 5 10 15 Cys Leu Pro Trp Leu Gln Glu Gly
Ser Ala 20 25 <210> SEQ ID NO 27 <211> LENGTH: 262
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Fos fusion
construct <400> SEQUENCE: 27 gaattcaggc ctatggctac aggctcccgg
acgtccctgc tcctggcttt tggcctgctc 60 tgcctgccct ggcttcaaga
gggcagcgct gggtgtgggg cggccgcttc tggtggttgc 120 ggtggtctga
ccgacaccct gcaggcggaa accgaccagg tggaagacga aaaatccgcg 180
ctgcaaaccg aaatcgcgaa cctgctgaaa gaaaaagaaa agctggagtt catcctggcg
240 gcacacggtg gttgctaagc tt 262 <210> SEQ ID NO 28
<211> LENGTH: 52 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Fos fusion construct <400> SEQUENCE: 28 Ala Ala
Ala Ser Gly Gly Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala 5 10 15 Glu
Thr Asp Gln Val Glu Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile 20 25
30 Ala Asn Leu Leu Lys Glu Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala
35 40 45 His Gly Gly Cys 50 <210> SEQ ID NO 29 <211>
LENGTH: 261 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Fos
fusion construct <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (7)..(240) <400> SEQUENCE: 29 gaattc
atg gct aca ggc tcc cgg acg tcc ctg ctc ctg gct ttt ggc 48 Met Ala
Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly 1 5 10 ctg ctc tgc
ctg ccc tgg ctt caa gag ggc agc gct tgc ggt ggt ctg 96 Leu Leu Cys
Leu Pro Trp Leu Gln Glu Gly Ser Ala Cys Gly Gly Leu 15 20 25 30 acc
gac acc ctg cag gcg gaa acc gac cag gtg gaa gac gaa aaa tcc 144 Thr
Asp Thr Leu Gln Ala Glu Thr Asp Gln Val Glu Asp Glu Lys Ser 35 40
45 gcg ctg caa acc gaa atc gcg aac ctg ctg aaa gaa aaa gaa aag ctg
192 Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys
Leu
50 55 60 gag ttc atc ctg gcg gca cac ggt ggt tgc ggt ggt tct gcg
gcc gct 240 Glu Phe Ile Leu Ala Ala His Gly Gly Cys Gly Gly Ser Ala
Ala Ala 65 70 75 gggtgtggga ggcctaagct t 261 <210> SEQ ID NO
30 <211> LENGTH: 78 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Fos fusion construct <400> SEQUENCE: 30
Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu 1 5
10 15 Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Cys Gly Gly Leu Thr
Asp 20 25 30 Thr Leu Gln Ala Glu Thr Asp Gln Val Glu Asp Glu Lys
Ser Ala Leu 35 40 45 Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys
Glu Lys Leu Glu Phe 50 55 60 Ile Leu Ala Ala His Gly Gly Cys Gly
Gly Ser Ala Ala Ala 65 70 75 <210> SEQ ID NO 31 <211>
LENGTH: 44 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 31 cctgggtggg ggcggccgct tctggtggtt
gcggtggtct gacc 44 <210> SEQ ID NO 32 <211> LENGTH: 44
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 32 ggtgggaatt caggaggtaa aaagatatcg
ggtgtggggc ggcc 44 <210> SEQ ID NO 33 <211> LENGTH: 47
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 33 ggtgggaatt caggaggtaa aaaacgatgg
cttgcggtgg tctgacc 47 <210> SEQ ID NO 34 <211> LENGTH:
18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 34 gcttgcggtg gtctgacc 18 <210> SEQ ID
NO 35 <211> LENGTH: 27 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 35 ccaccaagct
tagcaaccac cgtgtgc 27 <210> SEQ ID NO 36 <211> LENGTH:
54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 36 ccaccaagct tgatatcccc acacccagcg
gccgcagaac caccgcaacc accg 54 <210> SEQ ID NO 37 <211>
LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 37 ccaccaagct taggcctccc acacccagcg gc 32
<210> SEQ ID NO 38 <211> LENGTH: 29 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 38
ggtgggaatt caggaggtaa aaaacgatg 29 <210> SEQ ID NO 39
<211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 39 ggtgggaatt caggcctatg
gctacaggct cc 32 <210> SEQ ID NO 40 <211> LENGTH: 27
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 40 ggtgggaatt catggctaca ggctccc 27
<210> SEQ ID NO 41 <211> LENGTH: 59 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 41
gggtctagaa tggctacagg ctcccggacg tccctgctcc tggcttttgg cctgctctg 59
<210> SEQ ID NO 42 <211> LENGTH: 58 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 42
cgcaggcctc ggcactgccc tcttgaagcc agggcaggca gagcaggcca aaagccag 58
<210> SEQ ID NO 43 <211> LENGTH: 402 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Modified bee venom phospholipase A2
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (1)..(402) <400> SEQUENCE: 43 atc atc tac cca ggt
act ctg tgg tgt ggt cac ggc aac aaa tct tct 48 Ile Ile Tyr Pro Gly
Thr Leu Trp Cys Gly His Gly Asn Lys Ser Ser 1 5 10 15 ggt ccg aac
gaa ctc ggc cgc ttt aaa cac acc gac gca tgc tgt cgc 96 Gly Pro Asn
Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys Cys Arg 20 25 30 acc
cag gac atg tgt ccg gac gtc atg tct gct ggt gaa tct aaa cac 144 Thr
Gln Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser Lys His 35 40
45 ggg tta act aac acc gct tct cac acg cgt ctc agc tgc gac tgc gac
192 Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp Cys Asp
50 55 60 gac aaa ttc tac gac tgc ctt aag aac tcc gcc gat acc atc
tct tct 240 Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala Asp Thr Ile
Ser Ser 65 70 75 80 tac ttc gtt ggt aaa atg tat ttc aac ctg atc gat
acc aaa tgt tac 288 Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile Asp
Thr Lys Cys Tyr 85 90 95 aaa ctg gaa cac ccg gta acc ggc tgc ggc
gaa cgt acc gaa ggt cgc 336 Lys Leu Glu His Pro Val Thr Gly Cys Gly
Glu Arg Thr Glu Gly Arg 100 105 110 tgc ctg cac tac acc gtt gac aaa
tct aaa ccg aaa gtt tac cag tgg 384 Cys Leu His Tyr Thr Val Asp Lys
Ser Lys Pro Lys Val Tyr Gln Trp 115 120 125 ttc gac ctg cgc aaa tac
402 Phe Asp Leu Arg Lys Tyr 130 <210> SEQ ID NO 44
<211> LENGTH: 134 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Modified bee venom phospholipase A2 <400>
SEQUENCE: 44 Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn
Lys Ser Ser 1 5 10 15 Gly Pro Asn Glu Leu Gly Arg Phe Lys His Thr
Asp Ala Cys Cys Arg 20 25 30 Thr Gln Asp Met Cys Pro Asp Val Met
Ser Ala Gly Glu Ser Lys His 35 40 45 Gly Leu Thr Asn Thr Ala Ser
His Thr Arg Leu Ser Cys Asp Cys Asp 50 55 60 Asp Lys Phe Tyr Asp
Cys Leu Lys Asn Ser Ala Asp Thr Ile Ser Ser 65 70 75 80 Tyr Phe Val
Gly Lys Met Tyr Phe Asn Leu Ile Asp Thr Lys Cys Tyr
85 90 95 Lys Leu Glu His Pro Val Thr Gly Cys Gly Glu Arg Thr Glu
Gly Arg 100 105 110 Cys Leu His Tyr Thr Val Asp Lys Ser Lys Pro Lys
Val Tyr Gln Trp 115 120 125 Phe Asp Leu Arg Lys Tyr 130 <210>
SEQ ID NO 45 <211> LENGTH: 19 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 45
ccatcatcta cccaggtac 19 <210> SEQ ID NO 46 <211>
LENGTH: 34 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 46 cccacaccca gcggccgcgt atttgcgcag gtcg 34
<210> SEQ ID NO 47 <211> LENGTH: 36 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 47
cggtggttct gcggccgcta tcatctaccc aggtac 36 <210> SEQ ID NO 48
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 48 ttagtatttg cgcaggtcg
19 <210> SEQ ID NO 49 <211> LENGTH: 18 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Primer <400>
SEQUENCE: 49 ccggctccat cggtgcag 18 <210> SEQ ID NO 50
<211> LENGTH: 36 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 50 accaccagaa gcggccgcag
gggaaacaca tctgcc 36 <210> SEQ ID NO 51 <211> LENGTH:
35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 51 cggtggttct gcggccgctg gctccatcgg tgcag 35
<210> SEQ ID NO 52 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 52
ttaaggggaa acacatctgc c 21 <210> SEQ ID NO 53 <211>
LENGTH: 33 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 53 actagtctag aatgagagtg aaggagaaat atc 33
<210> SEQ ID NO 54 <211> LENGTH: 42 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 54
tagcatgcta gcaccgaatt tatctaattc caataattct tg 42 <210> SEQ
ID NO 55 <211> LENGTH: 51 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 55 gtagcaccca
ccaaggcaaa gctgaaagct acccagctcg agaaactggc a 51 <210> SEQ ID
NO 56 <211> LENGTH: 48 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 56 caaagctcct
attcccactg ccagtttctc gagctgggta gctttcag 48 <210> SEQ ID NO
57 <211> LENGTH: 36 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 57 ttcggtgcta
gcggtggctg cggtggtctg accgac 36 <210> SEQ ID NO 58
<211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 58 gatgctgggc ccttaaccgc
aaccaccgtg tgccgcc 37 <210> SEQ ID NO 59 <211> LENGTH:
46 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: JUN amino acid
sequence <400> SEQUENCE: 59 Cys Gly Gly Arg Ile Ala Arg Leu
Glu Glu Lys Val Lys Thr Leu Lys 1 5 10 15 Ala Gln Asn Ser Glu Leu
Ala Ser Thr Ala Asn Met Leu Arg Glu Gln 20 25 30 Val Ala Gln Leu
Lys Gln Lys Val Met Asn His Val Gly Cys 35 40 45 <210> SEQ ID
NO 60 <211> LENGTH: 46 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: FOS amino acid sequence <400> SEQUENCE: 60
Cys Gly Gly Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Val Glu 1 5
10 15 Asp Glu Lys Ser Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys
Glu 20 25 30 Lys Glu Lys Leu Glu Phe Ile Leu Ala Ala His Gly Gly
Cys 35 40 45 <210> SEQ ID NO 61 <211> LENGTH: 33
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 61 ccggaattca tgtgcggtgg tcggatcgcc cgg 33
<210> SEQ ID NO 62 <211> LENGTH: 39 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 62
gtcgctaccc gcggctccgc aaccaacgtg gttcatgac 39 <210> SEQ ID NO
63 <211> LENGTH: 50 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 63 gttggttgcg
gagccgcggg tagcgacatt gacccttata aagaatttgg 50
<210> SEQ ID NO 64 <211> LENGTH: 38 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 64
cgcgtcccaa gcttctacgg aagcgttgat aggatagg 38 <210> SEQ ID NO
65 <211> LENGTH: 33 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 65 ctagccgcgg
gttgcggtgg tcggatcgcc cgg 33 <210> SEQ ID NO 66 <211>
LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 66 cgcgtcccaa gcttttagca accaacgtgg ttcatgac
38 <210> SEQ ID NO 67 <211> LENGTH: 31 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Primer <400>
SEQUENCE: 67 ccggaattca tggacattga cccttataaa g 31 <210> SEQ
ID NO 68 <211> LENGTH: 45 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 68 ccgaccaccg
caacccgcgg ctagcggaag cgttgatagg atagg 45 <210> SEQ ID NO 69
<211> LENGTH: 47 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 69 ctaatggatc cggtgggggc
tgcggtggtc ggatcgcccg gctcgag 47 <210> SEQ ID NO 70
<211> LENGTH: 39 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 70 gtcgctaccc gcggctccgc
aaccaacgtg gttcatgac 39 <210> SEQ ID NO 71 <211>
LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 71 ccggaattca tggacattga cccttataaa g 31
<210> SEQ ID NO 72 <211> LENGTH: 48 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 72
ccgaccaccg cagcccccac cggatccatt agtacccacc caggtagc 48 <210>
SEQ ID NO 73 <211> LENGTH: 45 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 73
gttggttgcg gagccgcggg tagcgaccta gtagtcagtt atgtc 45 <210>
SEQ ID NO 74 <211> LENGTH: 38 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 74
cgcgtcccaa gcttctacgg aagcgttgat aggatagg 38 <210> SEQ ID NO
75 <211> LENGTH: 33 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 75 ctagccgcgg
gttgcggtgg tcggatcgcc cgg 33 <210> SEQ ID NO 76 <211>
LENGTH: 38 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 76 cgcgtcccaa gcttttagca accaacgtgg ttcatgac
38 <210> SEQ ID NO 77 <211> LENGTH: 30 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Primer <400>
SEQUENCE: 77 ccggaattca tggccacact tttaaggagc 30 <210> SEQ ID
NO 78 <211> LENGTH: 38 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer <400> SEQUENCE: 78 cgcgtcccaa
gcttttagca accaacgtgg ttcatgac 38 <210> SEQ ID NO 79
<211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 79 ccggaattca tggacattga
cccttataaa g 31 <210> SEQ ID NO 80 <211> LENGTH: 51
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 80 cctagagcca cctttgccac catcttctaa
attagtaccc acccaggtag c 51 <210> SEQ ID NO 81 <211>
LENGTH: 48 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 81 gaagatggtg gcaaaggtgg ctctagggac
ctagtagtca gttatgtc 48 <210> SEQ ID NO 82 <211> LENGTH:
38 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 82 cgcgtcccaa gcttctaaac aacagtagtc tccggaag
38 <210> SEQ ID NO 83 <211> LENGTH: 36 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Primer <400>
SEQUENCE: 83 gccgaattcc tagcagctag caccgaattt atctaa 36 <210>
SEQ ID NO 84 <211> LENGTH: 33 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 84
ggttaagtcg acatgagagt gaaggagaaa tat 33 <210> SEQ ID NO 85
<211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer <400> SEQUENCE: 85 taaccgaatt caggaggtaa
aaagatatgg 30 <210> SEQ ID NO 86 <211> LENGTH: 35
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
<400> SEQUENCE: 86 gaagtaaagc ttttaaccac cgcaaccacc agaag 35
<210> SEQ ID NO 87 <211> LENGTH: 33 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer <400> SEQUENCE: 87
tcgaatgggc cctcatcttc gtgtgctagt cag 33 <210> SEQ ID NO 88
<211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Fos fusion construct <400> SEQUENCE: 88 Glu Phe
Arg Arg 1 <210> SEQ ID NO 89 <211> LENGTH: 183
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 89 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe
Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr
Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His
Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met
Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile 65 70 75 80
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85
90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly
Arg 100 105 110 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp
Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile
Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val Arg Arg Arg Gly
Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg
Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser Arg Gly
Ser Gln Cys 180 <210> SEQ ID NO 90 <211> LENGTH: 183
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 90 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe
Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr
Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His
Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met
Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Thr 65 70 75 80
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85
90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly
Arg 100 105 110 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp
Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Thr Asn Ala Pro Ile
Leu Ser Thr Leu Pro 130 135 140 Glu Thr Cys Val Ile Arg Arg Arg Gly
Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg
Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser Arg Gly
Ser Gln Cys 180 <210> SEQ ID NO 91 <211> LENGTH: 212
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 91 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile Ser Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 92 <211> LENGTH:
212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 92 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Asn Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile Ser Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 93 <211> LENGTH:
183 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 93 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Thr Asp Phe Phe
Pro Ser Val Arg Asp Leu Leu Asp
20 25 30 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu
His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu
Cys Trp Gly Glu 50 55 60 Leu Met Thr Leu Ala Thr Trp Val Gly Val
Asn Leu Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val Ser Tyr
Val Asn Thr Asn Met Gly Leu Lys 85 90 95 Phe Arg Gln Leu Leu Trp
Phe His Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr Val Ile
Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125 Pro Pro
Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140
Glu Thr Cys Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr 145
150 155 160 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg
Arg Ser 165 170 175 Gln Ser Arg Glu Ser Gln Cys 180 <210> SEQ
ID NO 94 <211> LENGTH: 212 <212> TYPE: PRT <213>
ORGANISM: Hepatitis B virus <400> SEQUENCE: 94 Met Gln Leu
Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val
Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25
30 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
35 40 45 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr
Ala Ser 50 55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His
Cys Ser Pro His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys
Trp Gly Asp Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Gly Asn
Leu Glu Asp Pro Val Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val
Asn Thr Asn Val Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe
His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu
Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155
160 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
165 170 175 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro
Ser Pro 180 185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg
Ser Gln Ser Arg 195 200 205 Glu Ser Gln Cys 210 <210> SEQ ID
NO 95 <211> LENGTH: 212 <212> TYPE: PRT <213>
ORGANISM: Hepatitis B virus <400> SEQUENCE: 95 Met Gln Leu
Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val
Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Asp Met Asp Ile 20 25
30 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
35 40 45 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr
Ala Ser 50 55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His
Cys Ser Pro His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys
Trp Gly Asp Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Gly Asn
Leu Glu Asp Pro Val Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val
Asn Thr Asn Val Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe
His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu
Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155
160 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
165 170 175 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro
Ser Pro 180 185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg
Ser Gln Ser Arg 195 200 205 Glu Ser Gln Cys 210 <210> SEQ ID
NO 96 <211> LENGTH: 212 <212> TYPE: PRT <213>
ORGANISM: Hepatitis B virus <400> SEQUENCE: 96 Met Gln Leu
Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val
Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25
30 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
35 40 45 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr
Ala Ser 50 55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His
Cys Ser Pro Gln 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys
Trp Gly Glu Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Gly Asn
Leu Glu Asp Pro Ile Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val
Asn Thr Asn Met Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe
His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu
Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155
160 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
165 170 175 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro
Ser Pro 180 185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg
Ser Gln Ser Arg 195 200 205 Glu Ser Gln Cys 210 <210> SEQ ID
NO 97 <211> LENGTH: 212 <212> TYPE: PRT <213>
ORGANISM: Hepatitis B virus <400> SEQUENCE: 97 Met Gln Leu
Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val
Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25
30 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
35 40 45 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr
Ala Ser 50 55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His
Cys Ser Pro His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys
Trp Gly Glu Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Val Asn
Leu Glu Asp Pro Ala Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val
Asn Thr Asn Met Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe
His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu
Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155
160 Tyr Lys Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr
165 170 175 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro
Ser Pro 180 185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg
Ser Gln Ser Arg 195 200 205 Gly Ser Gln Cys 210 <210> SEQ ID
NO 98 <211> LENGTH: 183 <212> TYPE: PRT <213>
ORGANISM: Hepatitis B virus <400> SEQUENCE: 98 Met Asp Ile
Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10 15 Ser
Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp 20 25
30 Thr Ala Ser Ala Leu Phe Arg Asp Ala Leu Glu Ser Pro Glu His Cys
35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp
Gly Glu 50 55 60
Leu Met Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ala 65
70 75 80 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly
Leu Lys 85 90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu
Thr Phe Gly Arg 100 105 110 Asp Thr Val Ile Glu Tyr Leu Val Ser Phe
Gly Val Trp Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Ser Asn
Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140 Glu Thr Cys Val Val Arg
Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro
Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln
Ser Arg Glu Ser Gln Cys 180 <210> SEQ ID NO 99 <211>
LENGTH: 183 <212> TYPE: PRT <213> ORGANISM: Hepatitis B
virus <400> SEQUENCE: 99 Met Asp Ile Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu
Met Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala 65 70
75 80 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu
Lys 85 90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr
Phe Gly Arg 100 105 110 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly
Val Trp Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Arg
Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser
Arg Glu Ser Gln Cys 180 <210> SEQ ID NO 100 <211>
LENGTH: 212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B
virus <400> SEQUENCE: 100 Met Gln Leu Phe His Leu Cys Leu Ile
Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys
Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu
Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp
Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala
Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70
75 80 His Thr Ala Leu Arg His Ala Ile Leu Cys Trp Gly Asp Leu Arg
Thr 85 90 95 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile
Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly
Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu
Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe
Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro
Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val
Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190
Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195
200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 101 <211>
LENGTH: 212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B
virus <400> SEQUENCE: 101 Met Gln Leu Phe His Leu Cys Leu Ile
Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys
Leu Gly Trp Leu Trp Asp Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu
Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp
Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala
Leu Phe Arg Asp Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70
75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met
Thr 85 90 95 Leu Ala Thr Trp Val Gly Ala Asn Leu Glu Asp Pro Ala
Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly
Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu
Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe
Gly Val Trp Ile Arg Thr Pro Gln Ala 145 150 155 160 Tyr Arg Pro Pro
Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Cys 165 170 175 Val Val
Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190
Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195
200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 102 <211>
LENGTH: 183 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic human Hepatitus B construct <400> SEQUENCE: 102 Met
Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10
15 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
20 25 30 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu
His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu
Cys Trp Gly Glu 50 55 60 Leu Met Thr Leu Ala Thr Trp Val Gly Val
Asn Leu Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val Ser Tyr
Val Asn Thr Asn Met Gly Leu Lys 85 90 95 Phe Arg Gln Leu Leu Trp
Phe His Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr Val Leu
Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125 Pro Pro
Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140
Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr 145
150 155 160 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg
Arg Ser 165 170 175 Gln Ser Arg Glu Ser Gln Cys 180 <210> SEQ
ID NO 103 <211> LENGTH: 212 <212> TYPE: PRT <213>
ORGANISM: Hepatitis B virus <400> SEQUENCE: 103 Met Gln Leu
Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val
Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25
30 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu
35 40 45 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr
Ala Ser 50 55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His
Cys Ser Pro His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys
Trp Gly Asp Leu Met Ser 85 90 95 Leu Ala Thr Trp Val Gly Val Asn
Leu Glu Asp Pro Ile Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val
Asn Thr Asn Met Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe
His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu
Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala
145 150 155 160 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro
Glu Thr Thr 165 170 175 Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg
Arg Thr Pro Ser Pro 180 185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg
Arg Arg Arg Ser Gln Ser Arg 195 200 205 Glu Ser Gln Cys 210
<210> SEQ ID NO 104 <211> LENGTH: 183 <212> TYPE:
PRT <213> ORGANISM: Hepatitis B virus <400> SEQUENCE:
104 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu
Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr Arg Asp Ala Leu Glu Ser
Pro Glu His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala
Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met Thr Leu Ala Thr Trp Val
Gly Val Asn Leu Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val
Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85 90 95 Phe Arg Gln Leu
Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr
Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125
Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130
135 140 Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg
Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg
Arg Arg Arg Ser 165 170 175 Gln Ser Arg Glu Ser Gln Cys 180
<210> SEQ ID NO 105 <211> LENGTH: 183 <212> TYPE:
PRT <213> ORGANISM: Hepatitis B virus <400> SEQUENCE:
105 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu
Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser
Pro Glu His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala
Ile Leu Cys Trp Gly Asp 50 55 60 Leu Met Thr Leu Ala Thr Trp Val
Gly Val Asn Leu Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val
Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85 90 95 Phe Arg Gln Leu
Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr
Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125
Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130
135 140 Glu Thr Thr Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg
Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg
Arg Arg Arg Ser 165 170 175 Gln Ser Arg Glu Ser Gln Cys 180
<210> SEQ ID NO 106 <211> LENGTH: 183 <212> TYPE:
PRT <213> ORGANISM: Hepatitis B virus <400> SEQUENCE:
106 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu
1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu
Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr Arg Asp Ala Leu Glu Ser
Pro Glu His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala
Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met Thr Leu Ala Thr Trp Val
Gly Ala Asn Leu Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val
Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85 90 95 Phe Arg Gln Leu
Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr
Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125
Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130
135 140 Glu Thr Thr Val Val Arg Arg Arg Gly Arg Thr Pro Arg Arg Arg
Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg
Arg Arg Arg Ser 165 170 175 Gln Ser Arg Glu Ser Gln Cys 180
<210> SEQ ID NO 107 <211> LENGTH: 212 <212> TYPE:
PRT <213> ORGANISM: Hepatitis B virus <400> SEQUENCE:
107 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met
Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu
Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp
Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu Tyr Arg Asp Ala Leu Glu
Ser Pro Glu His Cys Ser Pro His 65 70 75 80 His Thr Ala Leu Arg Gln
Ala Ile Leu Cys Trp Gly Glu Leu Met Thr 85 90 95 Leu Ala Thr Trp
Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp 100 105 110 Leu Val
Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln 115 120 125
Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val 130
135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro
Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu
Pro Glu Thr Thr 165 170 175 Val Val Arg Arg Arg Gly Arg Ser Pro Arg
Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg Arg Arg Ser Gln Ser Pro
Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205 Glu Ser Gln Cys 210
<210> SEQ ID NO 108 <211> LENGTH: 212 <212> TYPE:
PRT <213> ORGANISM: Hepatitis B virus <400> SEQUENCE:
108 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr
1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Gly Met
Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu
Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe Phe Pro Ser Val Arg Asp
Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu Tyr Arg Glu Ala Leu Glu
Ser Pro Glu His Cys Ser Pro His 65 70 75 80 His Thr Ala Leu Arg Gln
Ala Ile Leu Cys Trp Gly Asp Leu Met Thr 85 90 95 Leu Ala Thr Trp
Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp 100 105 110 Leu Val
Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln 115 120 125
Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr Val 130
135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Pro
Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu
Pro Glu Thr Thr 165 170 175 Val Val Arg Arg Arg Gly Arg Ser Pro Arg
Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg Arg Arg Ser Gln Ser Pro
Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205 Glu Ser Gln Cys 210
<210> SEQ ID NO 109 <211> LENGTH: 212 <212> TYPE:
PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 109 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Thr Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ala Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 110 <211> LENGTH:
212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 110 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Phe Glu Cys Ser Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile Ser Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 111 <211> LENGTH:
212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<220> FEATURE: <221> NAME/KEY: UNSURE <222>
LOCATION: 28 <223> OTHER INFORMATION: Xaa may be any amino
acid. <400> SEQUENCE: 111 Met Gln Leu Phe His Leu Cys Leu Ile
Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys
Leu Gly Trp Leu Xaa Asp Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu
Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp
Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala
Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70
75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Ile
Thr 85 90 95 Leu Ser Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Thr
Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly
Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu
Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe
Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro
Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val
Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190
Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Thr Gln Ser Arg 195
200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 112 <211>
LENGTH: 212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B
virus <400> SEQUENCE: 112 Met Gln Leu Phe His Leu Cys Leu Ile
Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys
Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu
Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp
Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Asn Ala Ser 50 55 60 Ala
Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70
75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met
Thr 85 90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala
Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly
Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu
Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe
Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro
Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val
Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190
Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195
200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 113 <211>
LENGTH: 212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B
virus <400> SEQUENCE: 113 Met Gln Leu Phe His Leu Cys Leu Ile
Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys
Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu
Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp
Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala
Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70
75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met
Thr 85 90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala
Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly
Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Cys Cys Leu
Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe
Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro
Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val
Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190
Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195
200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 114
<211> LENGTH: 212 <212> TYPE: PRT <213> ORGANISM:
Hepatitis B virus <400> SEQUENCE: 114 Met Gln Leu Phe His Leu
Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser
Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro
Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45
Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50
55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro
His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp
Pro Ala Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn
Met Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser
Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val
Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg
Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175
Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180
185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser
Arg 195 200 205 Glu Pro Gln Cys 210 <210> SEQ ID NO 115
<211> LENGTH: 212 <212> TYPE: PRT <213> ORGANISM:
Hepatitis B virus <400> SEQUENCE: 115 Met Gln Leu Phe His Leu
Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser
Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro
Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45
Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Ser Thr Ala Ser 50
55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro
His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp
Pro Ala Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn
Met Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser
Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val
Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg
Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175
Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180
185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser
Arg 195 200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 116
<211> LENGTH: 212 <212> TYPE: PRT <213> ORGANISM:
Hepatitis B virus <400> SEQUENCE: 116 Met Gln Leu Phe His Leu
Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser
Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro
Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45
Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50
55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro
His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp
Pro Ala Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn
Met Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser
Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val
Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg
Pro Pro Asn Ala Pro Ile Leu Leu Thr Leu Pro Glu Thr Thr 165 170 175
Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180
185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser
Arg 195 200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 117
<211> LENGTH: 212 <212> TYPE: PRT <213> ORGANISM:
Hepatitis B virus <400> SEQUENCE: 117 Met Gln Leu Phe His Leu
Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser
Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro
Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45
Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50
55 60 Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro
His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp
Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp
Pro Ala Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn
Met Gly Leu Lys Phe Lys Gln 115 120 125 Leu Leu Trp Phe His Ile Ser
Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val
Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg
Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175
Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180
185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser
Arg 195 200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 118
<211> LENGTH: 212 <212> TYPE: PRT <213> ORGANISM:
Hepatitis B virus <400> SEQUENCE: 118 Met Gln Leu Phe His Leu
Cys Leu Ile Ile Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser
Lys Leu Cys Leu Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro
Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45
Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ala 50
55 60 Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys Ser Pro
His 65 70 75 80 His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu
Leu Met Thr 85 90 95 Leu Ala Thr Trp Val Gly Thr Asn Leu Glu Asp
Pro Ala Ser Arg Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn
Met Gly Leu Lys Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser
Cys Leu Thr Phe Gly Arg Glu Thr Val 130 135 140 Leu Glu Tyr Leu Val
Ser Phe Gly Val Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg
Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175
Val Val Arg Arg Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180
185 190 Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser
Arg 195 200 205 Glu Ser Gln Cys 210 <210> SEQ ID NO 119
<211> LENGTH: 183
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 119 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Ser Met Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Tyr
Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr
Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Thr Pro His His
Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met
Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Gln Asp Pro Thr 65 70 75 80
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85
90 95 Phe Arg Gln Leu Leu Trp Phe His Val Ser Cys Leu Thr Phe Gly
Arg 100 105 110 Glu Thr Val Val Glu Tyr Leu Val Ser Phe Gly Val Trp
Ile Arg Thr 115 120 125 Pro Gln Ala Tyr Arg Pro Pro Asn Ala Pro Ile
Leu Ser Thr Leu Pro 130 135 140 Glu Thr Cys Val Val Arg Arg Arg Gly
Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg
Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser Arg Glu
Ser Gln Cys 180 <210> SEQ ID NO 120 <211> LENGTH: 183
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 120 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe
Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr
Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His
Thr Ala Leu Arg His Val Phe Leu Cys Trp Gly Asp 50 55 60 Leu Met
Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Thr 65 70 75 80
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85
90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly
Arg 100 105 110 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp
Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile
Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val Arg Arg Arg Gly
Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg
Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser Arg Glu
Ser Gln Cys 180 <210> SEQ ID NO 121 <211> LENGTH: 212
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 121 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Thr Thr 85
90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 122 <211> LENGTH:
212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 122 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Ile Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 123 <211> LENGTH:
183 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 123 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe
Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr
Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His
Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp 50 55 60 Leu Met
Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Val 65 70 75 80
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Val Gly Leu Lys 85
90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly
Arg 100 105 110 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp
Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile
Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val Arg Arg Arg Gly
Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Ala Arg Arg
Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser Arg Glu
Ser Gln Cys 180 <210> SEQ ID NO 124 <211> LENGTH: 212
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 124 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75
80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Met Asn 85
90 95 Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Val Ser Arg
Asp 100 105 110 Leu Val Val Gly Tyr Val Asn Thr Thr Val Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 125 <211> LENGTH:
183 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 125 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe
Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr
Arg Asp Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His
Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp 50 55 60 Leu Met
Thr Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala 65 70 75 80
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85
90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly
Arg 100 105 110 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp
Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile
Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val Arg Arg Arg Gly
Arg Thr Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg
Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser Arg Glu
Ser Gln Cys 180 <210> SEQ ID NO 126 <211> LENGTH: 212
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 126 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Ala Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
Phe Arg Gln 115 120 125 Ile Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 127 <211> LENGTH:
212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 127 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Thr Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Val Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 128 <211> LENGTH:
212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 128 Met Gln Leu Phe His Leu Cys Leu Ile Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Arg Ile Leu Cys Trp Gly Glu Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg
Asp 100 105 110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys
Phe Arg Gln 115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe
Gly Arg Glu Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val
Trp Ile Arg Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala
Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg
Arg Arg Ser Gln Ser Pro Arg Arg Thr Arg Ser Gln Ser Arg 195 200 205
Glu Ser Gln Cys 210 <210> SEQ ID NO 129 <211> LENGTH:
212 <212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 129 Met Gln Leu Phe His Leu Cys Leu Val Ile
Ser Cys Ser Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu
Gly Trp Leu Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe
Gly Ala Thr Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Asp Phe
Phe Pro Ser Val Arg Asp Leu Leu Asp Thr Ala Ala 50 55 60 Ala Leu
Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80
His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr 85
90 95 Leu Ala Thr Trp Val Gly Asn Asn Leu Glu Asp Pro Ala Ser Arg
Asp 100 105 110
Leu Val Val Asn Tyr Val Asn Thr Asn Met Gly Leu Lys Ile Arg Gln 115
120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr
Val 130 135 140 Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr
Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser
Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg Arg Gly Arg Ser
Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg Arg Arg Ser Gln
Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205 Glu Ser Gln Cys
210 <210> SEQ ID NO 130 <211> LENGTH: 212 <212>
TYPE: PRT <213> ORGANISM: Hepatitis B virus <400>
SEQUENCE: 130 Met Gln Leu Phe His Leu Cys Leu Ile Ile Ser Cys Ser
Cys Pro Thr 1 5 10 15 Val Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu
Trp Gly Met Asp Ile 20 25 30 Asp Pro Tyr Lys Glu Phe Gly Ala Thr
Val Glu Leu Leu Ser Phe Leu 35 40 45 Pro Ser Ala Phe Phe Pro Ser
Val Arg Asp Leu Leu Asp Thr Ala Ser 50 55 60 Ala Leu Tyr Arg Glu
Ala Leu Glu Ser Pro Glu His Cys Ser Pro His 65 70 75 80 His Thr Ala
Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp Leu Met Thr 85 90 95 Leu
Ala Thr Trp Val Gly Val Asn Leu Glu Asp Pro Ala Ser Arg Asp 100 105
110 Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys Phe Arg Gln
115 120 125 Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu
Thr Val 130 135 140 Ile Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg
Thr Pro Pro Ala 145 150 155 160 Tyr Arg Pro Pro Asn Ala Pro Ile Leu
Ser Thr Leu Pro Glu Thr Thr 165 170 175 Val Val Arg Arg Arg Gly Arg
Ser Pro Arg Arg Arg Thr Pro Ser Pro 180 185 190 Arg Arg Arg Arg Ser
Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 195 200 205 Glu Ser Gln
Cys 210 <210> SEQ ID NO 131 <211> LENGTH: 183
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 131 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe
Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ala Ala Leu Tyr
Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His
Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met
Thr Leu Ala Thr Trp Val Gly Asn Asn Leu Glu Asp Pro Ala 65 70 75 80
Ser Arg Asp Leu Val Val Asn Tyr Val Asn Thr Asn Met Gly Leu Lys 85
90 95 Ile Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly
Arg 100 105 110 Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp
Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile
Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val Arg Arg Arg Gly
Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg
Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser Arg Glu
Ser Gln Cys 180 <210> SEQ ID NO 132 <211> LENGTH: 183
<212> TYPE: PRT <213> ORGANISM: Hepatitis B virus
<400> SEQUENCE: 132 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly
Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe
Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr
Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His
Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met
Thr Leu Ala Thr Trp Val Gly Gly Asn Leu Glu Asp Pro Ile 65 70 75 80
Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Met Gly Leu Lys 85
90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly
Arg 100 105 110 Glu Thr Val Ile Glu Tyr Leu Val Ser Phe Gly Val Trp
Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile
Leu Ser Thr Leu Pro 130 135 140 Glu Thr Cys Val Val Arg Arg Arg Gly
Arg Ser Pro Arg Arg Arg Thr 145 150 155 160 Pro Ser Pro Arg Arg Arg
Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser 165 170 175 Gln Ser Arg Gly
Ser Gln Cys 180 <210> SEQ ID NO 133 <211> LENGTH: 3221
<212> TYPE: DNA <213> ORGANISM: Hepatitis B virus
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (1901)..(2458) <400> SEQUENCE: 133 ttccactgcc
ttccaccaag ctctgcagga ccccagagtc aggggtctgt attttcctgc 60
tggtggctcc agttcaggaa cagtaaaccc tgctccgaat attgcctctc acatctcgtc
120 aatctccgcg aggactgggg accctgtgac gaacatggag aacatcacat
caggattcct 180 aggacccctg ctcgtgttac aggcggggtt tttattgttg
acaagaatcc tcacaatacc 240 gcagagtcta gactcgtggt ggacttctct
caattttata gggggatcac ccgtgtgtct 300 tggccaaaat tcgcagtccc
caacctccaa tcactcacca acctcctgtc ctccaatttg 360 tcctggttat
cgctggatgt gtctgcggcg ttttatcata ttcctcttca tcctgctgct 420
atgcctcatc ttcttattgg ttcttctgga ttatcaaggt atgttgcccg tttgtcctct
480 aattccagga tcaacaacaa ccagtacggg accatgcaaa acctgcacga
ctcctgctca 540 aggcaactct atgtttccct catgttgctg tacaaaacct
acggttggaa attgcacctg 600 tattcccatc ccatcgtcct gggctttcgc
aaaataccta tgggagtggg cctcagtccg 660 tttctcttgg ctcagtttac
tagtgccatt tgttcagtgg ttcgtagggc tttcccccac 720 tgtttggctt
tcagctatat ggatgatgtg gtattggggg ccaagtctgt acagcatcgt 780
gagtcccttt ataccgctgt taccaatttt cttttgtctc tgggtataca tttaaaccct
840 aacaaaacaa aaagatgggg ttattcccta aacttcatgg gttacataat
tggaagttgg 900 ggaacattgc cacaggatca tattgtacaa aagatcaaac
actgttttag aaaacttcct 960 gttaacaggc ctattgattg gaaagtatgt
caaagaattg tgggtctttt gggctttgct 1020 gctccattta cacaatgtgg
atatcctgcc ttaatgcctt tgtatgcatg tatacaggct 1080 aaacaggctt
tcactttctc gccaacttac aaggcctttc taagtaaaca gtacatgaac 1140
ctttaccccg ttgctcggca acggcctggt ctgtgccaag tgtttgctga cgcaaccccc
1200 actggttggg gcttggccat aggccatcag cgcatgagtg gaacctttgt
ggctcctctg 1260 ccgatccata ctgcggaact cctagccgct tgtattgctc
gcagccggtc tggagcaaag 1320 ctcatcggaa ctgacaattc tgtcgtcctc
tcgcggaaat atacatcgtt tccatggctg 1380 ctaggctgta ctgccaactg
gatccttcgc gggacgtcct ttgtttacgt cccgtcggcg 1440 ctgaatcccg
cggacgaccc ctctcggggc cgcttgggac tctatcgtcc ccttctccgt 1500
ctgccgttcc agccgaccac ggggcgcacc tctctttacg cggtctcccc gtctgtgcct
1560 tctcatctgc cggtccgtgt gcacttcgct tcacctctgc acgttgcatg
gagaccaccg 1620 tgaacgccca tcagatcctg cccaaggtct tacataagag
gactcttgga ctcccagcaa 1680 tgtcaacgac cgaccttgag gcctacttca
aagactgtgt gtttaaggac tgggaggagc 1740 tgggggagga gattaggtta
aaggtctttg tattaggagg ctgtaggcat aaattggtct 1800 gcgcaccagc
accatgcaac tttttcacct ctgcctaatc atctcttgta catgtcccac 1860
tgttcaagcc tccaagctgt gccttgggtg gctttggggc atg gac att gac cct
1915 Met Asp Ile Asp Pro 1 5 tat aaa gaa ttt gga gct act gtg gag
tta ctc tcg ttt ttg cct tct 1963 Tyr Lys Glu Phe Gly Ala Thr Val
Glu Leu Leu Ser Phe Leu Pro Ser 10 15 20 gac ttc ttt cct tcc gtc
aga gat ctc cta gac acc gcc tca gct ctg 2011 Asp Phe Phe Pro Ser
Val Arg Asp Leu Leu Asp Thr Ala Ser Ala Leu 25 30 35 tat cga gaa
gcc tta gag tct cct gag cat tgc tca cct cac cat act 2059 Tyr Arg
Glu Ala Leu Glu Ser Pro Glu His Cys Ser Pro His His Thr 40 45 50
gca ctc agg caa gcc att ctc tgc tgg ggg gaa ttg atg act cta gct
2107 Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu Leu Met Thr Leu
Ala 55 60 65 acc tgg gtg ggt aat aat ttg gaa gat cca gca tcc agg
gat cta gta 2155 Thr Trp Val Gly Asn Asn Leu Glu Asp Pro Ala Ser
Arg Asp Leu Val 70 75 80 85 gtc aat tat gtt aat act aac atg ggt tta
aag atc agg caa cta ttg 2203 Val Asn Tyr Val Asn Thr Asn Met Gly
Leu Lys Ile Arg Gln Leu Leu
90 95 100 tgg ttt cat ata tct tgc ctt act ttt gga aga gag act gta
ctt gaa 2251 Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg Glu Thr
Val Leu Glu 105 110 115 tat ttg gtc tct ttc gga gtg tgg att cgc act
cct cca gcc tat aga 2299 Tyr Leu Val Ser Phe Gly Val Trp Ile Arg
Thr Pro Pro Ala Tyr Arg 120 125 130 cca cca aat gcc cct atc tta tca
aca ctt ccg gaa act act gtt gtt 2347 Pro Pro Asn Ala Pro Ile Leu
Ser Thr Leu Pro Glu Thr Thr Val Val 135 140 145 aga cga cgg gac cga
ggc agg tcc cct aga aga aga act ccc tcg cct 2395 Arg Arg Arg Asp
Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro 150 155 160 165 cgc
aga cgc aga tct caa tcg ccg cgt cgc aga aga tct caa tct cgg 2443
Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg 170
175 180 gaa tct caa tgt tag tattccttgg actcataagg tgggaaactt
tactgggctt 2498 Glu Ser Gln Cys 185 tattcctcta cagtacctat
ctttaatcct gaatggcaaa ctccttcctt tcctaagatt 2558 catttacaag
aggacattat tgataggtgt caacaatttg tgggccctct cactgtaaat 2618
gaaaagagaa gattgaaatt aattatgcct gctagattct atcctaccca cactaaatat
2678 ttgcccttag acaaaggaat taaaccttat tatccagatc aggtagttaa
tcattacttc 2738 caaaccagac attatttaca tactctttgg aaggctggta
ttctatataa gagggaaacc 2798 acacgtagcg catcattttg cgggtcacca
tattcttggg aacaagagct acagcatggg 2858 aggttggtca ttaaaacctc
gcaaaggcat ggggacgaat ctttctgttc ccaaccctct 2918 gggattcttt
cccgatcatc agttggaccc tgcattcgga gccaactcaa acaatccaga 2978
ttgggacttc aaccccatca aggaccactg gccagcagcc aaccaggtag gagtgggagc
3038 attcgggcca gggctcaccc ctccacacgg cggtattttg gggtggagcc
ctcaggctca 3098 gggcatattg accacagtgt caacaattcc tcctcctgcc
tccaccaatc ggcagtcagg 3158 aaggcagcct actcccatct ctccacctct
aagagacagt catcctcagg ccatgcagtg 3218 gaa 3221 <210> SEQ ID
NO 134 <211> LENGTH: 185 <212> TYPE: PRT <213>
ORGANISM: Hepatitis B virus <400> SEQUENCE: 134 Met Asp Ile
Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10 15 Ser
Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp 20 25
30 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys
35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp
Gly Glu 50 55 60 Leu Met Thr Leu Ala Thr Trp Val Gly Asn Asn Leu
Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val Asn Tyr Val Asn
Thr Asn Met Gly Leu Lys 85 90 95 Ile Arg Gln Leu Leu Trp Phe His
Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr Val Leu Glu Tyr
Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125 Pro Pro Ala Tyr
Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140 Glu Thr
Thr Val Val Arg Arg Arg Asp Arg Gly Arg Ser Pro Arg Arg 145 150 155
160 Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg
165 170 175 Arg Ser Gln Ser Arg Glu Ser Gln Cys 180 185 <210>
SEQ ID NO 135 <211> LENGTH: 188 <212> TYPE: PRT
<213> ORGANISM: Woodchuck hepatitis B virus <400>
SEQUENCE: 135 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ser Ser Tyr
Gln Leu Leu 1 5 10 15 Asn Phe Leu Pro Leu Asp Phe Phe Pro Asp Leu
Asn Ala Leu Val Asp 20 25 30 Thr Ala Thr Ala Leu Tyr Glu Glu Glu
Leu Thr Gly Arg Glu His Cys 35 40 45 Ser Pro His His Thr Ala Ile
Arg Gln Ala Leu Val Cys Trp Asp Glu 50 55 60 Leu Thr Lys Leu Ile
Ala Trp Met Ser Ser Asn Ile Thr Ser Glu Gln 65 70 75 80 Val Arg Thr
Ile Ile Val Asn His Val Asn Asp Thr Trp Gly Leu Lys 85 90 95 Val
Arg Gln Ser Leu Trp Phe His Leu Ser Cys Leu Thr Phe Gly Gln 100 105
110 His Thr Val Gln Glu Phe Leu Val Ser Phe Gly Val Trp Ile Arg Thr
115 120 125 Pro Ala Pro Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr
Leu Pro 130 135 140 Glu His Thr Val Ile Arg Arg Arg Gly Gly Ala Arg
Ala Ser Arg Ser 145 150 155 160 Pro Arg Arg Arg Thr Pro Ser Pro Arg
Arg Arg Arg Ser Gln Ser Pro 165 170 175 Arg Arg Arg Arg Ser Gln Ser
Pro Ser Thr Asn Cys 180 185 <210> SEQ ID NO 136 <211>
LENGTH: 217 <212> TYPE: PRT <213> ORGANISM: Ground
squirrel hepatitis virus <400> SEQUENCE: 136 Met Tyr Leu Phe
His Leu Cys Leu Val Phe Ala Cys Val Pro Cys Pro 1 5 10 15 Thr Val
Gln Ala Ser Lys Leu Cys Leu Gly Trp Leu Trp Asp Met Asp 20 25 30
Ile Asp Pro Tyr Lys Glu Phe Gly Ser Ser Tyr Gln Leu Leu Asn Phe 35
40 45 Leu Pro Leu Asp Phe Phe Pro Asp Leu Asn Ala Leu Val Asp Thr
Ala 50 55 60 Ala Ala Leu Tyr Glu Glu Glu Leu Thr Gly Arg Glu His
Cys Ser Pro 65 70 75 80 His His Thr Ala Ile Arg Gln Ala Leu Val Cys
Trp Glu Glu Leu Thr 85 90 95 Arg Leu Ile Thr Trp Met Ser Glu Asn
Thr Thr Glu Glu Val Arg Arg 100 105 110 Ile Ile Val Asp His Val Asn
Asn Thr Trp Gly Leu Lys Val Arg Gln 115 120 125 Thr Leu Trp Phe His
Leu Ser Cys Leu Thr Phe Gly Gln His Thr Val 130 135 140 Gln Glu Phe
Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Ala Pro 145 150 155 160
Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu His Thr 165
170 175 Val Ile Arg Arg Arg Gly Gly Ser Arg Ala Ala Arg Ser Pro Arg
Arg 180 185 190 Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro
Arg Arg Arg 195 200 205 Arg Ser Gln Ser Pro Ala Ser Asn Cys 210 215
<210> SEQ ID NO 137 <211> LENGTH: 262 <212> TYPE:
PRT <213> ORGANISM: Snow Goose Hepatitis B Virus <400>
SEQUENCE: 137 Met Asp Val Asn Ala Ser Arg Ala Leu Ala Asn Val Tyr
Asp Leu Pro 1 5 10 15 Asp Asp Phe Phe Pro Lys Ile Glu Asp Leu Val
Arg Asp Ala Lys Asp 20 25 30 Ala Leu Glu Pro Tyr Trp Lys Ser Asp
Ser Ile Lys Lys His Val Leu 35 40 45 Ile Ala Thr His Phe Val Asp
Leu Ile Glu Asp Phe Trp Gln Thr Thr 50 55 60 Gln Gly Met His Glu
Ile Ala Glu Ala Ile Arg Ala Val Ile Pro Pro 65 70 75 80 Thr Thr Ala
Pro Val Pro Ser Gly Tyr Leu Ile Gln His Asp Glu Ala 85 90 95 Glu
Glu Ile Pro Leu Gly Asp Leu Phe Lys Glu Gln Glu Glu Arg Ile 100 105
110 Val Ser Phe Gln Pro Asp Tyr Pro Ile Thr Ala Arg Ile His Ala His
115 120 125 Leu Lys Ala Tyr Ala Lys Ile Asn Glu Glu Ser Leu Asp Arg
Ala Arg 130 135 140 Arg Leu Leu Trp Trp His Tyr Asn Cys Leu Leu Trp
Gly Glu Ala Thr 145 150 155 160 Val Thr Asn Tyr Ile Ser Arg Leu Arg
Thr Trp Leu Ser Thr Pro Glu 165 170 175 Lys Tyr Arg Gly Arg Asp Ala
Pro Thr Ile Glu Ala Ile Thr Arg Pro 180 185 190 Ile Gln Val Ala Gln
Gly Gly Arg Lys Thr Ser Thr Ala Thr Arg Lys 195 200 205 Pro Arg Gly
Leu Glu Pro Arg Arg Arg Lys Val Lys Thr Thr Val Val 210 215 220 Tyr
Gly Arg Arg Arg Ser Lys Ser Arg Glu Arg Arg Ala Ser Ser Pro 225 230
235 240 Gln Arg Ala Gly Ser Pro Leu Pro Arg Ser Ser Ser Ser His His
Arg 245 250 255 Ser Pro Ser Pro Arg Lys 260 <210> SEQ ID NO
138 <211> LENGTH: 305 <212> TYPE: PRT <213>
ORGANISM: Duck hepatitis B virus <400> SEQUENCE: 138
Met Trp Asp Leu Arg Leu His Pro Ser Pro Phe Gly Ala Ala Cys Gln 1 5
10 15 Gly Ile Phe Thr Ser Ser Leu Leu Leu Phe Leu Val Thr Val Pro
Leu 20 25 30 Val Cys Thr Ile Val Tyr Asp Ser Cys Leu Cys Met Asp
Ile Asn Ala 35 40 45 Ser Arg Ala Leu Ala Asn Val Tyr Asp Leu Pro
Asp Asp Phe Phe Pro 50 55 60 Lys Ile Asp Asp Leu Val Arg Asp Ala
Lys Asp Ala Leu Glu Pro Tyr 65 70 75 80 Trp Arg Asn Asp Ser Ile Lys
Lys His Val Leu Ile Ala Thr His Phe 85 90 95 Val Asp Leu Ile Glu
Asp Phe Trp Gln Thr Thr Gln Gly Met His Glu 100 105 110 Ile Ala Glu
Ala Leu Arg Ala Ile Ile Pro Ala Thr Thr Ala Pro Val 115 120 125 Pro
Gln Gly Phe Leu Val Gln His Glu Glu Ala Glu Glu Ile Pro Leu 130 135
140 Gly Glu Leu Phe Arg Tyr Gln Glu Glu Arg Leu Thr Asn Phe Gln Pro
145 150 155 160 Asp Tyr Pro Val Thr Ala Arg Ile His Ala His Leu Lys
Ala Tyr Ala 165 170 175 Lys Ile Asn Glu Glu Ser Leu Asp Arg Ala Arg
Arg Leu Leu Trp Trp 180 185 190 His Tyr Asn Cys Leu Leu Trp Gly Glu
Pro Asn Val Thr Asn Tyr Ile 195 200 205 Ser Arg Leu Arg Thr Trp Leu
Ser Thr Pro Glu Lys Tyr Arg Gly Lys 210 215 220 Asp Ala Pro Thr Ile
Glu Ala Ile Thr Arg Pro Ile Gln Val Ala Gln 225 230 235 240 Gly Gly
Arg Asn Lys Thr Gln Gly Val Arg Lys Ser Arg Gly Leu Glu 245 250 255
Pro Arg Arg Arg Arg Val Lys Thr Thr Ile Val Tyr Gly Arg Arg Arg 260
265 270 Ser Lys Ser Arg Glu Arg Arg Ala Pro Thr Pro Gln Arg Ala Gly
Ser 275 280 285 Pro Leu Pro Arg Thr Ser Arg Asp His His Arg Ser Pro
Ser Pro Arg 290 295 300 Glu 305 <210> SEQ ID NO 139
<211> LENGTH: 212 <212> TYPE: PRT <213> ORGANISM:
Haemophilus influenzae <400> SEQUENCE: 139 Met Lys Lys Thr
Leu Leu Gly Ser Leu Ile Leu Leu Ala Phe Ala Gly 1 5 10 15 Asn Val
Gln Ala Ala Ala Asn Ala Asp Thr Ser Gly Thr Val Thr Phe 20 25 30
Phe Gly Lys Val Val Glu Asn Thr Cys Gln Val Asn Gln Asp Ser Glu 35
40 45 Tyr Glu Cys Asn Leu Asn Asp Val Gly Lys Asn His Leu Ser Gln
Gln 50 55 60 Gly Tyr Thr Ala Met Gln Thr Pro Phe Thr Ile Thr Leu
Glu Asn Cys 65 70 75 80 Asn Val Thr Thr Thr Asn Asn Lys Pro Lys Ala
Thr Lys Val Gly Val 85 90 95 Tyr Phe Tyr Ser Trp Glu Ile Ala Asp
Lys Asp Asn Lys Tyr Thr Leu 100 105 110 Lys Asn Ile Lys Glu Asn Thr
Gly Thr Asn Asp Ser Ala Asn Lys Val 115 120 125 Asn Ile Gln Leu Leu
Glu Asp Asn Gly Thr Ala Glu Ile Lys Val Val 130 135 140 Gly Lys Thr
Thr Thr Asp Phe Thr Ser Glu Asn His Asn Gly Ala Gly 145 150 155 160
Ala Asp Pro Val Ala Thr Asn Lys His Ile Ser Ser Leu Thr Pro Leu 165
170 175 Asn Asn Gln Asn Ser Ile Asn Leu His Tyr Ile Ala Gln Tyr Tyr
Ala 180 185 190 Thr Gly Val Ala Glu Ala Gly Lys Val Pro Ser Ser Val
Asn Ser Gln 195 200 205 Ile Ala Tyr Glu 210 <210> SEQ ID NO
140 <211> LENGTH: 139 <212> TYPE: PRT <213>
ORGANISM: Pseudomonas stutzeri <400> SEQUENCE: 140 Met Lys
Ala Gln Met Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile 1 5 10 15
Val Val Ala Ile Ile Gly Ile Leu Ala Ala Ile Ala Leu Pro Ala Tyr 20
25 30 Gln Asp Tyr Thr Val Arg Ser Asn Ala Ala Ala Ala Leu Ala Glu
Ile 35 40 45 Thr Pro Gly Lys Ile Gly Phe Glu Gln Ala Ile Asn Glu
Gly Lys Thr 50 55 60 Pro Ser Leu Thr Ser Thr Asp Glu Gly Tyr Ile
Gly Ile Thr Asp Ser 65 70 75 80 Thr Ser Tyr Cys Asp Val Asp Leu Asp
Thr Ala Ala Asp Gly His Ile 85 90 95 Glu Cys Thr Ala Lys Gly Gly
Asn Ala Gly Lys Phe Asp Gly Lys Thr 100 105 110 Ile Thr Leu Asn Arg
Thr Ala Asp Gly Glu Trp Ser Cys Ala Ser Thr 115 120 125 Leu Asp Ala
Lys Tyr Lys Pro Gly Lys Cys Ser 130 135 <210> SEQ ID NO 141
<211> LENGTH: 59 <212> TYPE: PRT <213> ORGANISM:
Caulobacter crescentus <400> SEQUENCE: 141 Met Thr Lys Phe
Val Thr Arg Phe Leu Lys Asp Glu Ser Gly Ala Thr 1 5 10 15 Ala Ile
Glu Tyr Gly Leu Ile Val Ala Leu Ile Ala Val Val Ile Val 20 25 30
Thr Ala Val Thr Thr Leu Gly Thr Asn Leu Arg Thr Ala Phe Thr Lys 35
40 45 Ala Gly Ala Ala Val Ser Thr Ala Ala Gly Thr 50 55 <210>
SEQ ID NO 142 <211> LENGTH: 173 <212> TYPE: PRT
<213> ORGANISM: Escherichia coli <400> SEQUENCE: 142
Met Ala Val Val Ser Phe Gly Val Asn Ala Ala Pro Thr Ile Pro Gln 1 5
10 15 Gly Gln Gly Lys Val Thr Phe Asn Gly Thr Val Val Asp Ala Pro
Cys 20 25 30 Ser Ile Ser Gln Lys Ser Ala Asp Gln Ser Ile Asp Phe
Gly Gln Leu 35 40 45 Ser Lys Ser Phe Leu Glu Ala Gly Gly Val Ser
Lys Pro Met Asp Leu 50 55 60 Asp Ile Glu Leu Val Asn Cys Asp Ile
Thr Ala Phe Lys Gly Gly Asn 65 70 75 80 Gly Ala Gln Lys Gly Thr Val
Lys Leu Ala Phe Thr Gly Pro Ile Val 85 90 95 Asn Gly His Ser Asp
Glu Leu Asp Thr Asn Gly Gly Thr Gly Thr Ala 100 105 110 Ile Val Val
Gln Gly Ala Gly Lys Asn Val Val Phe Asp Gly Ser Glu 115 120 125 Gly
Asp Ala Asn Thr Leu Lys Asp Gly Glu Asn Val Leu His Tyr Thr 130 135
140 Ala Val Val Lys Lys Ser Ser Ala Val Gly Ala Ala Val Thr Glu Gly
145 150 155 160 Ala Phe Ser Ala Val Ala Asn Phe Asn Leu Thr Tyr Gln
165 170 <210> SEQ ID NO 143 <211> LENGTH: 173
<212> TYPE: PRT <213> ORGANISM: Escherichia coli
<400> SEQUENCE: 143 Met Ala Val Val Ser Phe Gly Val Asn Ala
Ala Pro Thr Ile Pro Gln 1 5 10 15 Gly Gln Gly Lys Val Thr Phe Asn
Gly Thr Val Val Asp Ala Pro Cys 20 25 30 Ser Ile Ser Gln Lys Ser
Ala Asp Gln Ser Ile Asp Phe Gly Gln Leu 35 40 45 Ser Lys Ser Phe
Leu Glu Ala Gly Gly Val Ser Lys Pro Met Asp Leu 50 55 60 Asp Ile
Glu Leu Val Asn Cys Asp Ile Thr Ala Phe Lys Gly Gly Asn 65 70 75 80
Gly Ala Gln Lys Gly Thr Val Lys Leu Ala Phe Thr Gly Pro Ile Val 85
90 95 Asn Gly His Ser Asp Glu Leu Asp Thr Asn Gly Gly Thr Gly Thr
Ala 100 105 110 Ile Val Val Gln Gly Ala Gly Lys Asn Val Val Phe Asp
Gly Ser Glu 115 120 125 Gly Asp Ala Asn Thr Leu Lys Asp Gly Glu Asn
Val Leu His Tyr Thr 130 135 140 Ala Val Val Lys Lys Ser Ser Ala Val
Gly Ala Ala Val Thr Glu Gly 145 150 155 160 Ala Phe Ser Ala Val Ala
Asn Phe Asn Leu Thr Tyr Gln 165 170 <210> SEQ ID NO 144
<211> LENGTH: 172 <212> TYPE: PRT
<213> ORGANISM: Escherichia coli <400> SEQUENCE: 144
Met Ala Val Val Ser Phe Gly Val Asn Ala Ala Pro Thr Thr Pro Gln 1 5
10 15 Gly Gln Gly Arg Val Thr Phe Asn Gly Thr Val Val Asp Ala Pro
Cys 20 25 30 Ser Ile Ser Gln Lys Ser Ala Asp Gln Ser Ile Asp Phe
Gly Gln Leu 35 40 45 Ser Lys Ser Phe Leu Ala Asn Asp Gly Gln Ser
Lys Pro Met Asn Leu 50 55 60 Asp Ile Glu Leu Val Asn Cys Asp Ile
Thr Ala Phe Lys Asn Gly Asn 65 70 75 80 Ala Lys Thr Gly Ser Val Lys
Leu Ala Phe Thr Gly Pro Thr Val Ser 85 90 95 Gly His Pro Ser Glu
Leu Ala Thr Asn Gly Gly Pro Gly Thr Ala Ile 100 105 110 Met Ile Gln
Ala Ala Gly Lys Asn Val Pro Phe Asp Gly Thr Glu Gly 115 120 125 Asp
Pro Asn Leu Leu Lys Asp Gly Asp Asn Val Leu His Tyr Thr Thr 130 135
140 Val Gly Lys Lys Ser Ser Asp Gly Asn Ala Gln Ile Thr Glu Gly Ala
145 150 155 160 Phe Ser Gly Val Ala Thr Phe Asn Leu Ser Tyr Gln 165
170 <210> SEQ ID NO 145 <211> LENGTH: 853 <212>
TYPE: DNA <213> ORGANISM: Escherichia coli <220>
FEATURE: <221> NAME/KEY: CDS <222> LOCATION:
(281)..(829) <400> SEQUENCE: 145 acgtttctgt ggctcgacgc
atcttcctca ttcttctctc caaaaaccac ctcatgcaat 60 ataaacatct
ataaataaag ataacaaata gaatattaag ccaacaaata aactgaaaaa 120
gtttgtccgc gatgctttac ctctatgagt caaaatggcc ccaatgtttc atcttttggg
180 ggaaactgtg cagtgttggc agtcaaactc gttgacaaac aaagtgtaca
gaacgactgc 240 ccatgtcgat ttagaaatag ttttttgaaa ggaaagcagc atg aaa
att aaa act 295 Met Lys Ile Lys Thr 1 5 ctg gca atc gtt gtt ctg tcg
gct ctg tcc ctc agt tct acg acg gct 343 Leu Ala Ile Val Val Leu Ser
Ala Leu Ser Leu Ser Ser Thr Thr Ala 10 15 20 ctg gcc gct gcc acg
acg gtt aat ggt ggg acc gtt cac ttt aaa ggg 391 Leu Ala Ala Ala Thr
Thr Val Asn Gly Gly Thr Val His Phe Lys Gly 25 30 35 gaa gtt gtt
aac gcc gct tgc gca gtt gat gca ggc tct gtt gat caa 439 Glu Val Val
Asn Ala Ala Cys Ala Val Asp Ala Gly Ser Val Asp Gln 40 45 50 acc
gtt cag tta gga cag gtt cgt acc gca tcg ctg gca cag gaa gga 487 Thr
Val Gln Leu Gly Gln Val Arg Thr Ala Ser Leu Ala Gln Glu Gly 55 60
65 gca acc agt tct gct gtc ggt ttt aac att cag ctg aat gat tgc gat
535 Ala Thr Ser Ser Ala Val Gly Phe Asn Ile Gln Leu Asn Asp Cys Asp
70 75 80 85 acc aat gtt gca tct aaa gcc gct gtt gcc ttt tta ggt acg
gcg att 583 Thr Asn Val Ala Ser Lys Ala Ala Val Ala Phe Leu Gly Thr
Ala Ile 90 95 100 gat gcg ggt cat acc aac gtt ctg gct ctg cag agt
tca gct gcg ggt 631 Asp Ala Gly His Thr Asn Val Leu Ala Leu Gln Ser
Ser Ala Ala Gly 105 110 115 agc gca aca aac gtt ggt gtg cag atc ctg
gac aga acg ggt gct gcg 679 Ser Ala Thr Asn Val Gly Val Gln Ile Leu
Asp Arg Thr Gly Ala Ala 120 125 130 ctg acg ctg gat ggt gcg aca ttt
agt tca gaa aca acc ctg aat aac 727 Leu Thr Leu Asp Gly Ala Thr Phe
Ser Ser Glu Thr Thr Leu Asn Asn 135 140 145 gga acc aat acc att ccg
ttc cag gcg cgt tat ttt gca acc ggg gcc 775 Gly Thr Asn Thr Ile Pro
Phe Gln Ala Arg Tyr Phe Ala Thr Gly Ala 150 155 160 165 gca acc ccg
ggt gct gct aat gcg gat gcg acc ttc aag gtt cag tat 823 Ala Thr Pro
Gly Ala Ala Asn Ala Asp Ala Thr Phe Lys Val Gln Tyr 170 175 180 caa
taa cctacctagg ttcagggacg ttca 853 Gln <210> SEQ ID NO 146
<211> LENGTH: 182 <212> TYPE: PRT <213> ORGANISM:
Escherichia coli <400> SEQUENCE: 146 Met Lys Ile Lys Thr Leu
Ala Ile Val Val Leu Ser Ala Leu Ser Leu 1 5 10 15 Ser Ser Thr Thr
Ala Leu Ala Ala Ala Thr Thr Val Asn Gly Gly Thr 20 25 30 Val His
Phe Lys Gly Glu Val Val Asn Ala Ala Cys Ala Val Asp Ala 35 40 45
Gly Ser Val Asp Gln Thr Val Gln Leu Gly Gln Val Arg Thr Ala Ser 50
55 60 Leu Ala Gln Glu Gly Ala Thr Ser Ser Ala Val Gly Phe Asn Ile
Gln 65 70 75 80 Leu Asn Asp Cys Asp Thr Asn Val Ala Ser Lys Ala Ala
Val Ala Phe 85 90 95 Leu Gly Thr Ala Ile Asp Ala Gly His Thr Asn
Val Leu Ala Leu Gln 100 105 110 Ser Ser Ala Ala Gly Ser Ala Thr Asn
Val Gly Val Gln Ile Leu Asp 115 120 125 Arg Thr Gly Ala Ala Leu Thr
Leu Asp Gly Ala Thr Phe Ser Ser Glu 130 135 140 Thr Thr Leu Asn Asn
Gly Thr Asn Thr Ile Pro Phe Gln Ala Arg Tyr 145 150 155 160 Phe Ala
Thr Gly Ala Ala Thr Pro Gly Ala Ala Asn Ala Asp Ala Thr 165 170 175
Phe Lys Val Gln Tyr Gln 180 <210> SEQ ID NO 147 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: FLAG
peptide <400> SEQUENCE: 147 Cys Gly Gly Asp Tyr Lys Asp Asp
Asp Asp Lys 1 5 10 <210> SEQ ID NO 148 <211> LENGTH: 31
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: primer
<400> SEQUENCE: 148 ccggaattca tggacattga cccttataaa g 31
<210> SEQ ID NO 149 <211> LENGTH: 37 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: primer <400> SEQUENCE: 149
gtgcagtatg gtgaggtgag gaatgctcag gagactc 37 <210> SEQ ID NO
150 <211> LENGTH: 37 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: primer <400> SEQUENCE: 150 gsgtctcctg
agcattcctc acctcaccat actgcac 37 <210> SEQ ID NO 151
<211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: primer <400> SEQUENCE: 151 cttccaaaag tgagggaaga
aatgtgaaac cac 33 <210> SEQ ID NO 152 <211> LENGTH: 47
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: primer
<400> SEQUENCE: 152 cgcgtcccaa gcttctaaac aacagtagtc
tccggaagcg ttgatag 47 <210> SEQ ID NO 153 <211> LENGTH:
33 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: primer
<400> SEQUENCE: 153 gtggtttcac atttcttccc tcacttttgg aag 33
<210> SEQ ID NO 154 <211> LENGTH: 281 <212> TYPE:
PRT <213> ORGANISM: Saccharomyces cerevisiae <400>
SEQUENCE: 154 Met Ser Glu Tyr Gln Pro Ser Leu Phe Ala Leu Asn Pro
Met Gly Phe 1 5 10 15 Ser Pro Leu Asp Gly Ser Lys Ser Thr Asn Glu
Asn Val Ser Ala Ser 20 25 30 Thr Ser Thr Ala Lys Pro Met Val Gly
Gln Leu Ile Phe Asp Lys Phe
35 40 45 Ile Lys Thr Glu Glu Asp Pro Ile Ile Lys Gln Asp Thr Pro
Ser Asn 50 55 60 Leu Asp Phe Asp Phe Ala Leu Pro Gln Thr Ala Thr
Ala Pro Asp Ala 65 70 75 80 Lys Thr Val Leu Pro Ile Pro Glu Leu Asp
Asp Ala Val Val Glu Ser 85 90 95 Phe Phe Ser Ser Ser Thr Asp Ser
Thr Pro Met Phe Glu Tyr Glu Asn 100 105 110 Leu Glu Asp Asn Ser Lys
Glu Trp Thr Ser Leu Phe Asp Asn Asp Ile 115 120 125 Pro Val Thr Thr
Asp Asp Val Ser Leu Ala Asp Lys Ala Ile Glu Ser 130 135 140 Thr Glu
Glu Val Ser Leu Val Pro Ser Asn Leu Glu Val Ser Thr Thr 145 150 155
160 Ser Phe Leu Pro Thr Pro Val Leu Glu Asp Ala Lys Leu Thr Gln Thr
165 170 175 Arg Lys Val Lys Lys Pro Asn Ser Val Val Lys Lys Ser His
His Val 180 185 190 Gly Lys Asp Asp Glu Ser Arg Leu Asp His Leu Gly
Val Val Ala Tyr 195 200 205 Asn Arg Lys Gln Arg Ser Ile Pro Leu Ser
Pro Ile Val Pro Glu Ser 210 215 220 Ser Asp Pro Ala Ala Leu Lys Arg
Ala Arg Asn Thr Glu Ala Ala Arg 225 230 235 240 Arg Ser Arg Ala Arg
Lys Leu Gln Arg Met Lys Gln Leu Glu Asp Lys 245 250 255 Val Glu Glu
Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val Ala 260 265 270 Arg
Leu Lys Lys Leu Val Gly Glu Arg 275 280 <210> SEQ ID NO 155
<211> LENGTH: 181 <212> TYPE: PRT <213> ORGANISM:
Escherichia coli <400> SEQUENCE: 155 Met Lys Ile Lys Thr Leu
Ala Ile Val Val Leu Ser Ala Leu Ser Leu 1 5 10 15 Ser Ser Thr Ala
Ala Leu Ala Ala Ala Thr Thr Val Asn Gly Gly Thr 20 25 30 Val His
Phe Lys Gly Glu Val Val Asn Ala Ala Cys Ala Val Asp Ala 35 40 45
Gly Ser Val Asp Gln Thr Val Gln Leu Gly Gln Val Arg Thr Ala Ser 50
55 60 Leu Ala Gln Glu Gly Ala Thr Ser Ser Ala Val Gly Phe Asn Ile
Gln 65 70 75 80 Leu Asn Asp Cys Asp Thr Asn Val Ala Ser Lys Ala Ala
Val Ala Phe 85 90 95 Leu Gly Thr Ala Ile Asp Ala Gly His Thr Asn
Val Leu Ala Leu Gln 100 105 110 Ser Ser Ala Ala Gly Ser Ala Thr Asn
Val Gly Val Gln Ile Leu Asp 115 120 125 Arg Thr Gly Ala Ala Leu Thr
Leu Asp Gly Ala Thr Phe Ser Ser Glu 130 135 140 Thr Thr Leu Asn Asn
Gly Thr Asn Thr Ile Pro Phe Gln Ala Arg Tyr 145 150 155 160 Phe Ala
Gly Ala Ala Thr Pro Gly Ala Ala Asn Ala Asp Ala Thr Phe 165 170 175
Lys Val Gln Tyr Gln 180 <210> SEQ ID NO 156 <211>
LENGTH: 447 <212> TYPE: DNA <213> ORGANISM: Hepatitis B
<220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (1)..(447) <400> SEQUENCE: 156 atg gac att gac cct
tat aaa gaa ttt gga gct act gtg gag tta ctc 48 Met Asp Ile Asp Pro
Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10 15 tcg ttt ttg
cct tct gac ttc ttt cct tcc gta cga gat ctt cta gat 96 Ser Phe Leu
Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 acc
gcc gca gct ctg tat cgg gat gcc tta gag tct cct gag cat tgt 144 Thr
Ala Ala Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys 35 40
45 tca cct cac cat act gca ctc agg caa gca att ctt tgc tgg gga gac
192 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp
50 55 60 tta atg act cta gct acc tgg gtg ggt act aat tta gaa gat
cca gca 240 Leu Met Thr Leu Ala Thr Trp Val Gly Thr Asn Leu Glu Asp
Pro Ala 65 70 75 80 tct agg gac cta gta gtc agt tat gtc aac act aat
gtg ggc cta aag 288 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn
Val Gly Leu Lys 85 90 95 ttc aga caa tta ttg tgg ttt cac att tct
tgt ctc act ttt gga aga 336 Phe Arg Gln Leu Leu Trp Phe His Ile Ser
Cys Leu Thr Phe Gly Arg 100 105 110 gaa acg gtt cta gag tat ttg gtc
tct ttt gga gtg tgg att cgc act 384 Glu Thr Val Leu Glu Tyr Leu Val
Ser Phe Gly Val Trp Ile Arg Thr 115 120 125 cct cca gcc tat aga cca
cca aat gcc cct atc cta tca acg ctt ccg 432 Pro Pro Ala Tyr Arg Pro
Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140 gag act act gtt
gtt 447 Glu Thr Thr Val Val 145 <210> SEQ ID NO 157
<211> LENGTH: 149 <212> TYPE: PRT <213> ORGANISM:
Hepatitis B <400> SEQUENCE: 157 Met Asp Ile Asp Pro Tyr Lys
Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser
Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ala
Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser
Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Asp 50 55
60 Leu Met Thr Leu Ala Thr Trp Val Gly Thr Asn Leu Glu Asp Pro Ala
65 70 75 80 Ser Arg Asp Leu Val Val Ser Tyr Val Asn Thr Asn Val Gly
Leu Lys 85 90 95 Phe Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu
Thr Phe Gly Arg 100 105 110 Glu Thr Val Leu Glu Tyr Leu Val Ser Phe
Gly Val Trp Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn
Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val 145
<210> SEQ ID NO 158 <211> LENGTH: 152 <212> TYPE:
PRT <213> ORGANISM: Hepatitis B <400> SEQUENCE: 158 Met
Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10
15 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp
20 25 30 Thr Ala Ala Ala Leu Tyr Arg Asp Ala Leu Glu Ser Pro Glu
His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu
Cys Trp Gly Asp 50 55 60 Leu Met Thr Leu Ala Thr Trp Val Gly Thr
Asn Leu Glu Asp Gly Gly 65 70 75 80 Lys Gly Gly Ser Arg Asp Leu Val
Val Ser Tyr Val Asn Thr Asn Val 85 90 95 Gly Leu Lys Phe Arg Gln
Leu Leu Trp Phe His Ile Ser Cys Leu Thr 100 105 110 Phe Gly Arg Glu
Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp 115 120 125 Ile Arg
Thr Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser 130 135 140
Thr Leu Pro Glu Thr Thr Val Val 145 150 <210> SEQ ID NO 159
<211> LENGTH: 132 <212> TYPE: PRT <213> ORGANISM:
Bacteriophage Q Beta <400> SEQUENCE: 159 Ala Lys Leu Glu Thr
Val Thr Leu Gly Asn Ile Gly Lys Asp Gly Lys 1 5 10 15 Gln Thr Leu
Val Leu Asn Pro Arg Gly Val Asn Pro Thr Asn Gly Val 20 25 30 Ala
Ser Leu Ser Gln Ala Gly Ala Val Pro Ala Leu Glu Lys Arg Val 35 40
45 Thr Val Ser Val Ser Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys Val
50 55 60 Gln Val Lys Ile Gln Asn Pro Thr Ala Cys Thr Ala Asn Gly
Ser Cys 65 70 75 80 Asp Pro Ser Val Thr Arg Gln Ala Tyr Ala Asp Val
Thr Phe Ser Phe 85 90 95 Thr Gln Tyr Ser Thr Asp Glu Glu Arg Ala
Phe Val Arg Thr Glu Leu 100 105 110 Ala Ala Leu Leu Ala Ser Pro Leu
Leu Ile Asp Ala Ile Asp Gln Leu 115 120 125 Asn Pro Ala Tyr
130 <210> SEQ ID NO 160 <211> LENGTH: 129 <212>
TYPE: PRT <213> ORGANISM: Bacteriophage R 17 <400>
SEQUENCE: 160 Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asn Asp Gly
Gly Thr Gly 1 5 10 15 Asn Val Thr Val Ala Pro Ser Asn Phe Ala Asn
Gly Val Ala Glu Trp 20 25 30 Ile Ser Ser Asn Ser Arg Ser Gln Ala
Tyr Lys Val Thr Cys Ser Val 35 40 45 Arg Gln Ser Ser Ala Gln Asn
Arg Lys Tyr Thr Ile Lys Val Glu Val 50 55 60 Pro Lys Val Ala Thr
Gln Thr Val Gly Gly Val Glu Leu Pro Val Ala 65 70 75 80 Ala Trp Arg
Ser Tyr Leu Asn Met Glu Leu Thr Ile Pro Ile Phe Ala 85 90 95 Thr
Asn Ser Asp Cys Glu Leu Ile Val Lys Ala Met Gln Gly Leu Leu 100 105
110 Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile Ala Ala Asn Ser Gly Ile
115 120 125 Tyr <210> SEQ ID NO 161 <211> LENGTH: 130
<212> TYPE: PRT <213> ORGANISM: Bacteriophage fr
<400> SEQUENCE: 161 Met Ala Ser Asn Phe Glu Glu Phe Val Leu
Val Asp Asn Gly Gly Thr 1 5 10 15 Gly Asp Val Lys Val Ala Pro Ser
Asn Phe Ala Asn Gly Val Ala Glu 20 25 30 Trp Ile Ser Ser Asn Ser
Arg Ser Gln Ala Tyr Lys Val Thr Cys Ser 35 40 45 Val Arg Gln Ser
Ser Ala Asn Asn Arg Lys Tyr Thr Val Lys Val Glu 50 55 60 Val Pro
Lys Val Ala Thr Gln Val Gln Gly Gly Val Glu Leu Pro Val 65 70 75 80
Ala Ala Trp Arg Ser Tyr Met Asn Met Glu Leu Thr Ile Pro Val Phe 85
90 95 Ala Thr Asn Asp Asp Cys Ala Leu Ile Val Lys Ala Leu Gln Gly
Thr 100 105 110 Phe Lys Thr Gly Asn Pro Ile Ala Thr Ala Ile Ala Ala
Asn Ser Gly 115 120 125 Ile Tyr 130 <210> SEQ ID NO 162
<211> LENGTH: 130 <212> TYPE: PRT <213> ORGANISM:
Bacteriophage GA <400> SEQUENCE: 162 Met Ala Thr Leu Arg Ser
Phe Val Leu Val Asp Asn Gly Gly Thr Gly 1 5 10 15 Asn Val Thr Val
Val Pro Val Ser Asn Ala Asn Gly Val Ala Glu Trp 20 25 30 Leu Ser
Asn Asn Ser Arg Ser Gln Ala Tyr Arg Val Thr Ala Ser Tyr 35 40 45
Arg Ala Ser Gly Ala Asp Lys Arg Lys Tyr Ala Ile Lys Leu Glu Val 50
55 60 Pro Lys Ile Val Thr Gln Val Val Asn Gly Val Glu Leu Pro Gly
Ser 65 70 75 80 Ala Trp Lys Ala Tyr Ala Ser Ile Asp Leu Thr Ile Pro
Ile Phe Ala 85 90 95 Ala Thr Asp Asp Val Thr Val Ile Ser Lys Ser
Leu Ala Gly Leu Phe 100 105 110 Lys Val Gly Asn Pro Ile Ala Glu Ala
Ile Ser Ser Gln Ser Gly Phe 115 120 125 Tyr Ala 130 <210> SEQ
ID NO 163 <211> LENGTH: 132 <212> TYPE: PRT <213>
ORGANISM: Bacteriophage SP <400> SEQUENCE: 163 Met Ala Lys
Leu Asn Gln Val Thr Leu Ser Lys Ile Gly Lys Asn Gly 1 5 10 15 Asp
Gln Thr Leu Thr Leu Thr Pro Arg Gly Val Asn Pro Thr Asn Gly 20 25
30 Val Ala Ser Leu Ser Glu Ala Gly Ala Val Pro Ala Leu Glu Lys Arg
35 40 45 Val Thr Val Ser Val Ala Gln Pro Ser Arg Asn Arg Lys Asn
Phe Lys 50 55 60 Val Gln Ile Lys Leu Gln Asn Pro Thr Ala Cys Thr
Arg Asp Ala Cys 65 70 75 80 Asp Pro Ser Val Thr Arg Ser Ala Phe Ala
Asp Val Thr Leu Ser Phe 85 90 95 Thr Ser Tyr Ser Thr Asp Glu Glu
Arg Ala Leu Ile Arg Thr Glu Leu 100 105 110 Ala Ala Leu Leu Ala Asp
Pro Leu Ile Val Asp Ala Ile Asp Asn Leu 115 120 125 Asn Pro Ala Tyr
130 <210> SEQ ID NO 164 <211> LENGTH: 130 <212>
TYPE: PRT <213> ORGANISM: Bacteriophage MS2 <400>
SEQUENCE: 164 Met Ala Ser Asn Phe Thr Gln Phe Val Leu Val Asp Asn
Gly Gly Thr 1 5 10 15 Gly Asp Val Thr Val Ala Pro Ser Asn Phe Ala
Asn Gly Val Ala Glu 20 25 30 Trp Ile Ser Ser Asn Ser Arg Ser Gln
Ala Tyr Lys Val Thr Cys Ser 35 40 45 Val Arg Gln Ser Ser Ala Gln
Asn Arg Lys Tyr Thr Ile Lys Val Glu 50 55 60 Val Pro Lys Val Ala
Thr Gln Thr Val Gly Gly Val Glu Leu Pro Val 65 70 75 80 Ala Ala Trp
Arg Ser Tyr Leu Asn Met Glu Leu Thr Ile Pro Ile Phe 85 90 95 Ala
Thr Asn Ser Asp Cys Glu Leu Ile Val Lys Ala Met Gln Gly Leu 100 105
110 Leu Lys Asp Gly Asn Pro Ile Pro Ser Ala Ile Ala Ala Asn Ser Gly
115 120 125 Ile Tyr 130 <210> SEQ ID NO 165 <211>
LENGTH: 133 <212> TYPE: PRT <213> ORGANISM:
Bacteriophage M11 <400> SEQUENCE: 165 Met Ala Lys Leu Gln Ala
Ile Thr Leu Ser Gly Ile Gly Lys Lys Gly 1 5 10 15 Asp Val Thr Leu
Asp Leu Asn Pro Arg Gly Val Asn Pro Thr Asn Gly 20 25 30 Val Ala
Ala Leu Ser Glu Ala Gly Ala Val Pro Ala Leu Glu Lys Arg 35 40 45
Val Thr Ile Ser Val Ser Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys 50
55 60 Val Gln Val Lys Ile Gln Asn Pro Thr Ser Cys Thr Ala Ser Gly
Thr 65 70 75 80 Cys Asp Pro Ser Val Thr Arg Ser Ala Tyr Ser Asp Val
Thr Phe Ser 85 90 95 Phe Thr Gln Tyr Ser Thr Val Glu Glu Arg Ala
Leu Val Arg Thr Glu 100 105 110 Leu Gln Ala Leu Leu Ala Asp Pro Met
Leu Val Asn Ala Ile Asp Asn 115 120 125 Leu Asn Pro Ala Tyr 130
<210> SEQ ID NO 166 <211> LENGTH: 133 <212> TYPE:
PRT <213> ORGANISM: Bacteriophage MX1 <400> SEQUENCE:
166 Met Ala Lys Leu Gln Ala Ile Thr Leu Ser Gly Ile Gly Lys Asn Gly
1 5 10 15 Asp Val Thr Leu Asn Leu Asn Pro Arg Gly Val Asn Pro Thr
Asn Gly 20 25 30 Val Ala Ala Leu Ser Glu Ala Gly Ala Val Pro Ala
Leu Glu Lys Arg 35 40 45 Val Thr Ile Ser Val Ser Gln Pro Ser Arg
Asn Arg Lys Asn Tyr Lys 50 55 60 Val Gln Val Lys Ile Gln Asn Pro
Thr Ser Cys Thr Ala Ser Gly Thr 65 70 75 80 Cys Asp Pro Ser Val Thr
Arg Ser Ala Tyr Ala Asp Val Thr Phe Ser 85 90 95 Phe Thr Gln Tyr
Ser Thr Asp Glu Glu Arg Ala Leu Val Arg Thr Glu 100 105 110 Leu Lys
Ala Leu Leu Ala Asp Pro Met Leu Ile Asp Ala Ile Asp Asn 115 120 125
Leu Asn Pro Ala Tyr 130 <210> SEQ ID NO 167 <211>
LENGTH: 330 <212> TYPE: PRT <213> ORGANISM:
Bacteriophage NL95
<400> SEQUENCE: 167 Met Ala Lys Leu Asn Lys Val Thr Leu Thr
Gly Ile Gly Lys Ala Gly 1 5 10 15 Asn Gln Thr Leu Thr Leu Thr Pro
Arg Gly Val Asn Pro Thr Asn Gly 20 25 30 Val Ala Ser Leu Ser Glu
Ala Gly Ala Val Pro Ala Leu Glu Lys Arg 35 40 45 Val Thr Val Ser
Val Ala Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys 50 55 60 Val Gln
Ile Lys Leu Gln Asn Pro Thr Ala Cys Thr Lys Asp Ala Cys 65 70 75 80
Asp Pro Ser Val Thr Arg Ser Gly Ser Arg Asp Val Thr Leu Ser Phe 85
90 95 Thr Ser Tyr Ser Thr Glu Arg Glu Arg Ala Leu Ile Arg Thr Glu
Leu 100 105 110 Ala Ala Leu Leu Lys Asp Asp Leu Ile Val Asp Ala Ile
Asp Asn Leu 115 120 125 Asn Pro Ala Tyr Trp Ala Ala Leu Leu Ala Ala
Ser Pro Gly Gly Gly 130 135 140 Asn Asn Pro Tyr Pro Gly Val Pro Asp
Ser Pro Asn Val Lys Pro Pro 145 150 155 160 Gly Gly Thr Gly Thr Tyr
Arg Cys Pro Phe Ala Cys Tyr Arg Arg Gly 165 170 175 Glu Leu Ile Thr
Glu Ala Lys Asp Gly Ala Cys Ala Leu Tyr Ala Cys 180 185 190 Gly Ser
Glu Ala Leu Val Glu Phe Glu Tyr Ala Leu Glu Asp Phe Leu 195 200 205
Gly Asn Glu Phe Trp Arg Asn Trp Asp Gly Arg Leu Ser Lys Tyr Asp 210
215 220 Ile Glu Thr His Arg Arg Cys Arg Gly Asn Gly Tyr Val Asp Leu
Asp 225 230 235 240 Ala Ser Val Met Gln Ser Asp Glu Tyr Val Leu Ser
Gly Ala Tyr Asp 245 250 255 Val Val Lys Met Gln Pro Pro Gly Thr Phe
Asp Ser Pro Arg Tyr Tyr 260 265 270 Leu His Leu Met Asp Gly Ile Tyr
Val Asp Leu Ala Glu Val Thr Ala 275 280 285 Tyr Arg Ser Tyr Gly Met
Val Ile Gly Phe Trp Thr Asp Ser Lys Ser 290 295 300 Pro Gln Leu Pro
Thr Asp Phe Thr Arg Phe Asn Arg His Asn Cys Pro 305 310 315 320 Val
Gln Thr Val Ile Val Ile Pro Ser Leu 325 330 <210> SEQ ID NO
168 <211> LENGTH: 134 <212> TYPE: PRT <213>
ORGANISM: Apis mellifera <400> SEQUENCE: 168 Ile Ile Tyr Pro
Gly Thr Leu Trp Cys Gly His Gly Asn Lys Ser Ser 1 5 10 15 Gly Pro
Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys Cys Arg 20 25 30
Thr His Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser Lys His 35
40 45 Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp Cys
Asp 50 55 60 Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala Asp Thr
Ile Ser Ser 65 70 75 80 Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu Ile
Asp Thr Lys Cys Tyr 85 90 95 Lys Leu Glu His Pro Val Thr Gly Cys
Gly Glu Arg Thr Glu Gly Arg 100 105 110 Cys Leu His Tyr Thr Val Asp
Lys Ser Lys Pro Lys Val Tyr Gln Trp 115 120 125 Phe Asp Leu Arg Lys
Tyr 130 <210> SEQ ID NO 169 <211> LENGTH: 129
<212> TYPE: PRT <213> ORGANISM: Apis mellifera
<400> SEQUENCE: 169 Ile Ile Tyr Pro Gly Thr Leu Trp Cys Gly
His Gly Asn Lys Ser Ser 1 5 10 15 Gly Pro Asn Glu Leu Gly Arg Phe
Lys His Thr Asp Ala Cys Cys Arg 20 25 30 Thr His Asp Met Cys Pro
Asn Val Met Ser Ala Gly Glu Ser Lys His 35 40 45 Gly Leu Thr Asp
Thr Ala Ser Arg Leu Ser Cys Asn Asp Asn Asp Leu 50 55 60 Phe Tyr
Lys Asp Ser Ala Asp Thr Ile Ser Ser Tyr Phe Val Gly Lys 65 70 75 80
Met Tyr Phe Asn Leu Ile Asn Thr Lys Cys Tyr Lys Leu Glu His Pro 85
90 95 Val Thr Gly Cys Gly Glu Arg Thr Glu Gly Arg Cys Leu His Tyr
Thr 100 105 110 Val Asp Lys Ser Lys Pro Lys Val Tyr Gln Trp Phe Asp
Leu Arg Lys 115 120 125 Tyr <210> SEQ ID NO 170 <211>
LENGTH: 134 <212> TYPE: PRT <213> ORGANISM: Apis
dorsata <400> SEQUENCE: 170 Ile Ile Tyr Pro Gly Thr Leu Trp
Cys Gly His Gly Asn Val Ser Ser 1 5 10 15 Ser Pro Asp Glu Leu Gly
Arg Phe Lys His Thr Asp Ser Cys Cys Arg 20 25 30 Ser His Asp Met
Cys Pro Asp Val Met Ser Ala Gly Glu Ser Lys His 35 40 45 Gly Leu
Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp Cys Asp 50 55 60
Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ser Asp Thr Ile Ser Ser 65
70 75 80 Tyr Phe Val Gly Glu Met Tyr Phe Asn Ile Leu Asp Thr Lys
Cys Tyr 85 90 95 Lys Leu Glu His Pro Val Thr Gly Cys Gly Lys Arg
Thr Glu Gly Arg 100 105 110 Cys Leu Asn Tyr Thr Val Asp Lys Ser Lys
Pro Lys Val Tyr Gln Trp 115 120 125 Phe Asp Leu Arg Lys Tyr 130
<210> SEQ ID NO 171 <211> LENGTH: 134 <212> TYPE:
PRT <213> ORGANISM: Apis cerana <400> SEQUENCE: 171 Ile
Ile Tyr Pro Gly Thr Leu Trp Cys Gly His Gly Asn Val Ser Ser 1 5 10
15 Gly Pro Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys Cys Arg
20 25 30 Thr His Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser
Lys His 35 40 45 Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser
Cys Asp Cys Asp 50 55 60 Asp Thr Phe Tyr Asp Cys Leu Lys Asn Ser
Gly Glu Lys Ile Ser Ser 65 70 75 80 Tyr Phe Val Gly Lys Met Tyr Phe
Asn Leu Ile Asp Thr Lys Cys Tyr 85 90 95 Lys Leu Glu His Pro Val
Thr Gly Cys Gly Glu Arg Thr Glu Gly Arg 100 105 110 Cys Leu Arg Tyr
Thr Val Asp Lys Ser Lys Pro Lys Val Tyr Gln Trp 115 120 125 Phe Asp
Leu Arg Lys Tyr 130 <210> SEQ ID NO 172 <211> LENGTH:
136 <212> TYPE: PRT <213> ORGANISM: Bombus
pennsylvanicus <400> SEQUENCE: 172 Ile Ile Tyr Pro Gly Thr
Leu Trp Cys Gly Asn Gly Asn Ile Ala Asn 1 5 10 15 Gly Thr Asn Glu
Leu Gly Leu Trp Lys Glu Thr Asp Ala Cys Cys Arg 20 25 30 Thr His
Asp Met Cys Pro Asp Ile Ile Glu Ala His Gly Ser Lys His 35 40 45
Gly Leu Thr Asn Pro Ala Asp Tyr Thr Arg Leu Asn Cys Glu Cys Asp 50
55 60 Glu Glu Phe Arg His Cys Leu His Asn Ser Gly Asp Ala Val Ser
Ala 65 70 75 80 Ala Phe Val Gly Arg Thr Tyr Phe Thr Ile Leu Gly Thr
Gln Cys Phe 85 90 95 Arg Leu Asp Tyr Pro Ile Val Lys Cys Lys Val
Lys Ser Thr Ile Leu 100 105 110 Arg Glu Cys Lys Glu Tyr Glu Phe Asp
Thr Asn Ala Pro Gln Lys Tyr 115 120 125 Gln Trp Phe Asp Val Leu Ser
Tyr 130 135 <210> SEQ ID NO 173 <211> LENGTH: 142
<212> TYPE: PRT <213> ORGANISM: Heloderma suspectum
<400> SEQUENCE: 173 Gly Ala Phe Ile Met Pro Gly Thr Leu Trp
Cys Gly Ala Gly Asn Ala 1 5 10 15
Ala Ser Asp Tyr Ser Gln Leu Gly Thr Glu Lys Asp Thr Asp Met Cys 20
25 30 Cys Arg Asp His Asp His Cys Ser Asp Thr Met Ala Ala Leu Glu
Tyr 35 40 45 Lys His Gly Met Arg Asn Tyr Arg Pro His Thr Val Ser
His Cys Asp 50 55 60 Cys Asp Asn Gln Phe Arg Ser Cys Leu Met Asn
Val Lys Asp Arg Thr 65 70 75 80 Ala Asp Leu Val Gly Met Thr Tyr Phe
Thr Val Leu Lys Ile Ser Cys 85 90 95 Phe Glu Leu Glu Glu Gly Glu
Gly Cys Val Asp Asn Asn Phe Ser Gln 100 105 110 Gln Cys Thr Lys Ser
Glu Ile Met Pro Val Ala Lys Leu Val Ser Ala 115 120 125 Ala Pro Tyr
Gln Ala Gln Ala Glu Thr Gln Ser Gly Glu Gly 130 135 140 <210>
SEQ ID NO 174 <211> LENGTH: 143 <212> TYPE: PRT
<213> ORGANISM: Heloderma suspectum <400> SEQUENCE: 174
Gly Ala Phe Ile Met Pro Gly Thr Leu Trp Cys Gly Ala Gly Asn Ala 1 5
10 15 Ala Ser Asp Tyr Ser Gln Leu Gly Thr Glu Lys Asp Thr Asp Met
Cys 20 25 30 Cys Arg Asp His Asp His Cys Glu Asn Trp Ile Ser Ala
Leu Glu Tyr 35 40 45 Lys His Gly Met Arg Asn Tyr Tyr Pro Ser Thr
Ile Ser His Cys Asp 50 55 60 Cys Asp Asn Gln Phe Arg Ser Cys Leu
Met Lys Leu Lys Asp Gly Thr 65 70 75 80 Ala Asp Tyr Val Gly Gln Thr
Tyr Phe Asn Val Leu Lys Ile Pro Cys 85 90 95 Phe Glu Leu Glu Glu
Gly Glu Gly Cys Val Asp Trp Asn Phe Trp Leu 100 105 110 Glu Cys Thr
Glu Ser Lys Ile Met Pro Val Ala Lys Leu Val Ser Ala 115 120 125 Ala
Pro Tyr Gln Ala Gln Ala Glu Thr Gln Ser Gly Glu Gly Arg 130 135 140
<210> SEQ ID NO 175 <211> LENGTH: 142 <212> TYPE:
PRT <213> ORGANISM: Heloderma suspectum <400> SEQUENCE:
175 Gly Ala Phe Ile Met Pro Gly Thr Leu Trp Cys Gly Ala Gly Asn Ala
1 5 10 15 Ala Ser Asp Tyr Ser Gln Leu Gly Thr Glu Lys Asp Thr Asp
Met Cys 20 25 30 Cys Arg Asp His Asp His Cys Glu Asn Trp Ile Ser
Ala Leu Glu Tyr 35 40 45 Lys His Gly Met Arg Asn Tyr Tyr Pro Ser
Thr Ile Ser His Cys Asp 50 55 60 Cys Asp Asn Gln Phe Arg Ser Cys
Leu Met Lys Leu Lys Asp Gly Thr 65 70 75 80 Ala Asp Tyr Val Gly Gln
Thr Tyr Phe Asn Val Leu Lys Ile Pro Cys 85 90 95 Phe Glu Leu Glu
Glu Gly Glu Gly Cys Val Asp Trp Asn Phe Trp Leu 100 105 110 Glu Cys
Thr Glu Ser Lys Ile Met Pro Val Ala Lys Leu Val Ser Ala 115 120 125
Ala Pro Tyr Gln Ala Gln Ala Glu Thr Gln Ser Gly Glu Gly 130 135 140
<210> SEQ ID NO 176 <211> LENGTH: 574 <212> TYPE:
PRT <213> ORGANISM: IgE heavy chain <400> SEQUENCE: 176
Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val 1 5
10 15 His Ser Gln Thr Gln Leu Val Gln Ser Gly Ala Glu Val Arg Lys
Pro 20 25 30 Gly Ala Ser Val Arg Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Ile 35 40 45 Asp Ser Tyr Ile His Trp Ile Arg Gln Ala Pro
Gly His Gly Leu Glu 50 55 60 Trp Val Gly Trp Ile Asn Pro Asn Ser
Gly Gly Thr Asn Tyr Ala Pro 65 70 75 80 Arg Phe Gln Gly Arg Val Thr
Met Thr Arg Asp Ala Ser Phe Ser Thr 85 90 95 Ala Tyr Met Asp Leu
Arg Ser Leu Arg Ser Asp Asp Ser Ala Val Phe 100 105 110 Tyr Cys Ala
Lys Ser Asp Pro Phe Trp Ser Asp Tyr Tyr Asn Phe Asp 115 120 125 Tyr
Ser Tyr Thr Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val 130 135
140 Ser Ser Ala Ser Thr Gln Ser Pro Ser Val Phe Pro Leu Thr Arg Cys
145 150 155 160 Cys Lys Asn Ile Pro Ser Asn Ala Thr Ser Val Thr Leu
Gly Cys Leu 165 170 175 Ala Thr Gly Tyr Phe Pro Glu Pro Val Met Val
Thr Trp Asp Thr Gly 180 185 190 Ser Leu Asn Gly Thr Thr Met Thr Leu
Pro Ala Thr Thr Leu Thr Leu 195 200 205 Ser Gly His Tyr Ala Thr Ile
Ser Leu Leu Thr Val Ser Gly Ala Trp 210 215 220 Ala Lys Gln Met Phe
Thr Cys Arg Val Ala His Thr Pro Ser Ser Thr 225 230 235 240 Asp Trp
Val Asp Asn Lys Thr Phe Ser Val Cys Ser Arg Asp Phe Thr 245 250 255
Pro Pro Thr Val Lys Ile Leu Gln Ser Ser Cys Asp Gly Gly Gly His 260
265 270 Phe Pro Pro Thr Ile Gln Leu Leu Cys Leu Val Ser Gly Tyr Thr
Pro 275 280 285 Gly Thr Ile Asn Ile Thr Trp Leu Glu Asp Gly Gln Val
Met Asp Val 290 295 300 Asp Leu Ser Thr Ala Ser Thr Thr Gln Glu Gly
Glu Leu Ala Ser Thr 305 310 315 320 Gln Ser Glu Leu Thr Leu Ser Gln
Lys His Trp Leu Ser Asp Arg Thr 325 330 335 Tyr Thr Cys Gln Val Thr
Tyr Gln Gly His Thr Phe Glu Asp Ser Thr 340 345 350 Lys Lys Cys Ala
Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser 355 360 365 Arg Pro
Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr 370 375 380
Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr 385
390 395 400 Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg
Lys Glu 405 410 415 Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser
Thr Leu Pro Val 420 425 430 Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr
Tyr Gln Cys Arg Val Thr 435 440 445 His Pro His Leu Pro Arg Ala Leu
Met Arg Ser Thr Thr Lys Thr Ser 450 455 460 Gly Pro Arg Ala Ala Pro
Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp 465 470 475 480 Pro Gly Ser
Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe 485 490 495 Met
Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu 500 505
510 Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser
515 520 525 Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu
Trp Glu 530 535 540 Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu
Ala Ala Ser Pro 545 550 555 560 Ser Gln Thr Val Gln Arg Ala Val Ser
Val Asn Pro Gly Lys 565 570 <210> SEQ ID NO 177 <400>
SEQUENCE: 177 000 <210> SEQ ID NO 178 <211> LENGTH: 13
<212> TYPE: PRT <213> ORGANISM: IgE Peptides
<400> SEQUENCE: 178 Cys Gly Gly Val Asn Leu Thr Trp Ser Arg
Ala Ser Gly 1 5 10 <210> SEQ ID NO 179 <211> LENGTH: 8
<212> TYPE: PRT <213> ORGANISM: IgE Mimotype
<400> SEQUENCE: 179 Ile Asn His Arg Gly Tyr Trp Val 1 5
<210> SEQ ID NO 180 <211> LENGTH: 8 <212> TYPE:
PRT <213> ORGANISM: IgE Mimotype <400> SEQUENCE: 180
Arg Asn His Arg Gly Tyr Trp Val 1 5
<210> SEQ ID NO 181 <211> LENGTH: 10 <212> TYPE:
PRT <213> ORGANISM: IgE Mimotype <400> SEQUENCE: 181
Arg Ser Arg Ser Gly Gly Tyr Trp Leu Trp 1 5 10 <210> SEQ ID
NO 182 <211> LENGTH: 10 <212> TYPE: PRT <213>
ORGANISM: IgE Mimotype <400> SEQUENCE: 182 Val Asn Leu Thr
Trp Ser Arg Ala Ser Gly 1 5 10 <210> SEQ ID NO 183
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
IgE Mimotype <400> SEQUENCE: 183 Val Asn Leu Pro Trp Ser Arg
Ala Ser Gly 1 5 10 <210> SEQ ID NO 184 <211> LENGTH: 10
<212> TYPE: PRT <213> ORGANISM: IgE Mimotype
<400> SEQUENCE: 184 Val Asn Leu Thr Trp Ser Phe Gly Leu Glu 1
5 10 <210> SEQ ID NO 185 <211> LENGTH: 10 <212>
TYPE: PRT <213> ORGANISM: IgE Mimotype <400> SEQUENCE:
185 Val Asn Leu Pro Trp Ser Phe Gly Leu Glu 1 5 10 <210> SEQ
ID NO 186 <211> LENGTH: 10 <212> TYPE: PRT <213>
ORGANISM: IgE Mimotype <400> SEQUENCE: 186 Val Asn Arg Pro
Trp Ser Phe Gly Leu Glu 1 5 10 <210> SEQ ID NO 187
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
IgE Mimotype <400> SEQUENCE: 187 Val Lys Leu Pro Trp Arg Phe
Tyr Gln Val 1 5 10 <210> SEQ ID NO 188 <211> LENGTH: 10
<212> TYPE: PRT <213> ORGANISM: IgE Mimotype
<400> SEQUENCE: 188 Val Trp Thr Ala Cys Gly Tyr Gly Arg Met 1
5 10 <210> SEQ ID NO 189 <211> LENGTH: 7 <212>
TYPE: PRT <213> ORGANISM: IgE Mimotype <400> SEQUENCE:
189 Gly Thr Val Ser Thr Leu Ser 1 5 <210> SEQ ID NO 190
<211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM:
IgE Mimotype <400> SEQUENCE: 190 Leu Leu Asp Ser Arg Tyr Trp
1 5 <210> SEQ ID NO 191 <211> LENGTH: 7 <212>
TYPE: PRT <213> ORGANISM: IgE Mimotype <400> SEQUENCE:
191 Gln Pro Ala His Ser Leu Gly 1 5 <210> SEQ ID NO 192
<211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM:
IgE Mimotype <400> SEQUENCE: 192 Leu Trp Gly Met Gln Gly Arg
1 5 <210> SEQ ID NO 193 <211> LENGTH: 15 <212>
TYPE: PRT <213> ORGANISM: IgE Mimotype <400> SEQUENCE:
193 Leu Thr Leu Ser His Pro His Trp Val Leu Asn His Phe Val Ser 1 5
10 15 <210> SEQ ID NO 194 <211> LENGTH: 9 <212>
TYPE: PRT <213> ORGANISM: IgE Mimotype <400> SEQUENCE:
194 Ser Met Gly Pro Asp Gln Thr Leu Arg 1 5 <210> SEQ ID NO
195 <211> LENGTH: 6 <212> TYPE: PRT <213>
ORGANISM: IgE Mimotype <400> SEQUENCE: 195 Val Asn Leu Thr
Trp Ser 1 5 <210> SEQ ID NO 196 <211> LENGTH: 56
<212> TYPE: DNA <213> ORGANISM: Oligonucleotide Primer
<400> SEQUENCE: 196 tagatgatta cgccaagctt ataatagaaa
tagttttttg aaaggaaagc agcatg 56 <210> SEQ ID NO 197
<211> LENGTH: 45 <212> TYPE: DNA <213> ORGANISM:
Oligonucleotide Primer <400> SEQUENCE: 197 gtcaaaggcc
ttgtcgacgt tattccatta cgcccgtcat tttgg 45 <210> SEQ ID NO 198
<211> LENGTH: 4623 <212> TYPE: DNA <213>
ORGANISM: pFIMAIC <400> SEQUENCE: 198 agacgaaagg gcctcgtgat
acgcctattt ttataggtta atgtcatgat aataatggtt 60 tcttagacgt
caggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttattt 120
ttctaaatac attcaaatat gtatccgctc atgagacaat aaccctgata aatgcttcaa
180 taatattgaa aaaggaagag tatgagtatt caacatttcc gtgtcgccct
tattcccttt 240 tttgcggcat tttgccttcc tgtttttgct cacccagaaa
cgctggtgaa agtaaaagat 300 gctgaagatc agttgggtgc acgagtgggt
tacatcgaac tggatctcaa cagcggtaag 360 atccttgaga gttttcgccc
cgaagaacgt tttccaatga tgagcacttt taaagttctg 420 ctatgtggcg
cggtattatc ccgtattgac gccgggcaag agcaactcgg tcgccgcata 480
cactattctc agaatgactt ggttgagtac tcaccagtca cagaaaagca tcttacggat
540 ggcatgacag taagagaatt atgcagtgct gccataacca tgagtgataa
cactgcggcc 600 aacttacttc tgacaacgat cggaggaccg aaggagctaa
ccgctttttt gcacaacatg 660 ggggatcatg taactcgcct tgatcgttgg
gaaccggagc tgaatgaagc cataccaaac 720 gacgagcgtg acaccacgat
gcctgtagca atggcaacaa cgttgcgcaa actattaact 780 ggcgaactac
ttactctagc ttcccggcaa caattaatag actggatgga ggcggataaa 840
gttgcaggac cacttctgcg ctcggccctt ccggctggct ggtttattgc tgataaatct
900 ggagccggtg agcgtgggtc tcgcggtatc attgcagcac tggggccaga
tggtaagccc 960 tcccgtatcg tagttatcta cacgacgggg agtcaggcaa
ctatggatga acgaaataga 1020 cagatcgctg agataggtgc ctcactgatt
aagcattggt aactgtcaga ccaagtttac 1080 tcatatatac tttagattga
tttaaaactt catttttaat ttaaaaggat ctaggtgaag 1140 atcctttttg
ataatctcat gaccaaaatc ccttaacgtg agttttcgtt ccactgagcg 1200
tcagaccccg tagaaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaatc
1260 tgctgcttgc aaacaaaaaa accaccgcta ccagcggtgg tttgtttgcc
ggatcaagag 1320 ctaccaactc tttttccgaa ggtaactggc ttcagcagag
cgcagatacc aaatactgtc 1380 cttctagtgt agccgtagtt aggccaccac
ttcaagaact ctgtagcacc gcctacatac 1440 ctcgctctgc taatcctgtt
accagtggct gctgccagtg gcgataagtc gtgtcttacc 1500 gggttggact
caagacgata gttaccggat aaggcgcagc ggtcgggctg aacggggggt 1560
tcgtgcacac agcccagctt ggagcgaacg acctacaccg aactgagata cctacagcgt
1620 gagctatgag aaagcgccac gcttcccgaa gggagaaagg cggacaggta
tccggtaagc 1680 ggcagggtcg gaacaggaga gcgcacgagg gagcttccag
ggggaaacgc ctggtatctt 1740 tatagtcctg tcgggtttcg ccacctctga
cttgagcgtc gatttttgtg atgctcgtca 1800
ggggggcgga gcctatggaa aaacgccagc aacgcggcct ttttacggtt cctggccttt
1860 tgctggcctt ttgctcacat gttctttcct gcgttatccc ctgattctgt
ggataaccgt 1920 attaccgcct ttgagtgagc tgataccgct cgccgcagcc
gaacgaccga gcgcagcgag 1980 tcagtgagcg aggaagcgga agagcgccca
atacgcaaac cgcctctccc cgcgcgttgg 2040 ccgattcatt aatgcagctg
gcacgacagg tttcccgact ggaaagcggg cagtgagcgc 2100 aacgcaatta
atgtgagtta gctcactcat taggcacccc aggctttaca ctttatgctt 2160
ccggctcgta tgttgtgtgg aattgtgagc ggataacaat ttcacacagg aaacagctat
2220 gaccatgatt acgccaagct tataatagaa atagtttttt gaaaggaaag
cagcatgaaa 2280 attaaaactc tggcaatcgt tgttctgtcg gctctgtccc
tcagttctac agcggctctg 2340 gccgctgcca cgacggttaa tggtgggacc
gttcacttta aaggggaagt tgttaacgcc 2400 gcttgcgcag ttgatgcagg
ctctgttgat caaaccgttc agttaggaca ggttcgtacc 2460 gcatcgctgg
cacaggaagg agcaaccagt tctgctgtcg gttttaacat tcagctgaat 2520
gattgcgata ccaatgttgc atctaaagcc gctgttgcct ttttaggtac ggcgattgat
2580 gcgggtcata ccaacgttct ggctctgcag agttcagctg cgggtagcgc
aacaaacgtt 2640 ggtgtgcaga tcctggacag aacgggtgct gcgctgacgc
tggatggtgc gacatttagt 2700 tcagaaacaa ccctgaataa cggaaccaat
accattccgt tccaggcgcg ttattttgca 2760 accggggccg caaccccggg
tgctgctaat gcggatgcga ccttcaaggt tcagtatcaa 2820 taacctaccc
aggttcaggg acgtcattac gggcagggat gcccaccctt gtgcgataaa 2880
aataacgatg aaaaggaaga gattatttct attagcgtcg ttgctgccaa tgtttgctct
2940 ggccggaaat aaatggaata ccacgttgcc cggcggaaat atgcaatttc
agggcgtcat 3000 tattgcggaa acttgccgga ttgaagccgg tgataaacaa
atgacggtca atatggggca 3060 aatcagcagt aaccggtttc atgcggttgg
ggaagatagc gcaccggtgc cttttgttat 3120 tcatttacgg gaatgtagca
cggtggtgag tgaacgtgta ggtgtggcgt ttcacggtgt 3180 cgcggatggt
aaaaatccgg atgtgctttc cgtgggagag gggccaggga tagccaccaa 3240
tattggcgta gcgttgtttg atgatgaagg aaacctcgta ccgattaatc gtcctccagc
3300 aaactggaaa cggctttatt caggctctac ttcgctacat ttcatcgcca
aatatcgtgc 3360 taccgggcgt cgggttactg gcggcatcgc caatgcccag
gcctggttct ctttaaccta 3420 tcagtaattg ttcagcagat aatgtgataa
caggaacagg acagtgagta ataaaaacgt 3480 caatgtaagg aaatcgcagg
aaataacatt ctgcttgctg gcaggtatcc tgatgttcat 3540 ggcaatgatg
gttgccggac gcgctgaagc gggagtggcc ttaggtgcga ctcgcgtaat 3600
ttatccggca gggcaaaaac aagagcaact tgccgtgaca aataatgatg aaaatagtac
3660 ctatttaatt caatcatggg tggaaaatgc cgatggtgta aaggatggtc
gttttatcgt 3720 gacgcctcct ctgtttgcga tgaagggaaa aaaagagaat
accttacgta ttcttgatgc 3780 aacaaataac caattgccac aggaccggga
aagtttattc tggatgaacg ttaaagcgat 3840 tccgtcaatg gataaatcaa
aattgactga gaatacgcta cagctcgcaa ttatcagccg 3900 cattaaactg
tactatcgcc cggctaaatt agcgttgcca cccgatcagg ccgcagaaaa 3960
attaagattt cgtcgtagcg cgaattctct gacgctgatt aacccgacac cctattacct
4020 gacggtaaca gagttgaatg ccggaacccg ggttcttgaa aatgcattgg
tgcctccaat 4080 gggcgaaagc acggttaaat tgccttctga tgcaggaagc
aatattactt accgaacaat 4140 aaatgattat ggcgcactta cccccaaaat
gacgggcgta atggaataac gtcgactcta 4200 gaggatcccc gggtaccgag
ctcgaattca ctggccgtcg ttttacaacg tcgtgactgg 4260 gaaaaccctg
gcgttaccca acttaatcgc cttgcagcac atcccccttt cgccagctgg 4320
cgtaatagcg aagaggcccg caccgatcgc ccttcccaac agttgcgcag cctgaatggc
4380 gaatggcgcc tgatgcggta ttttctcctt acgcatctgt gcggtatttc
acaccgcata 4440 tggtgcactc tcagtacaat ctgctctgat gccgcatagt
taagccagcc ccgacacccg 4500 ccaacacccg ctgacgcgcc ctgacgggct
tgtctgctcc cggcatccgc ttacagacaa 4560 gctgtgaccg tctccgggag
ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc 4620 gcg 4623
<210> SEQ ID NO 199 <211> LENGTH: 42 <212> TYPE:
DNA <213> ORGANISM: Oligonucleotide Primer <400>
SEQUENCE: 199 aagatcttaa gctaagcttg aattctctga cgctgattaa cc 42
<210> SEQ ID NO 200 <211> LENGTH: 41 <212> TYPE:
DNA <213> ORGANISM: Oligonucleotide Primer <400>
SEQUENCE: 200 acgtaaagca tttctagacc gcggatagta atcgtgctat c 41
<210> SEQ ID NO 201 <211> LENGTH: 5681 <212>
TYPE: DNA <213> ORGANISM: pFIMD <400> SEQUENCE: 201
tcaccgtcat caccgaaacg cgcgagacga aagggcctcg tgatacgcct atttttatag
60 gttaatgtca tgataataat ggtttcttag acgtcaggtg gcacttttcg
gggaaatgtg 120 cgcggaaccc ctatttgttt atttttctaa atacattcaa
atatgtatcc gctcatgaga 180 caataaccct gataaatgct tcaataatat
tgaaaaagga agagtatgag tattcaacat 240 ttccgtgtcg cccttattcc
cttttttgcg gcattttgcc ttcctgtttt tgctcaccca 300 gaaacgctgg
tgaaagtaaa agatgctgaa gatcagttgg gtgcacgagt gggttacatc 360
gaactggatc tcaacagcgg taagatcctt gagagttttc gccccgaaga acgttttcca
420 atgatgagca cttttaaagt tctgctatgt ggcgcggtat tatcccgtat
tgacgccggg 480 caagagcaac tcggtcgccg catacactat tctcagaatg
acttggttga gtactcacca 540 gtcacagaaa agcatcttac ggatggcatg
acagtaagag aattatgcag tgctgccata 600 accatgagtg ataacactgc
ggccaactta cttctgacaa cgatcggagg accgaaggag 660 ctaaccgctt
ttttgcacaa catgggggat catgtaactc gccttgatcg ttgggaaccg 720
gagctgaatg aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca
780 acaacgttgc gcaaactatt aactggcgaa ctacttactc tagcttcccg
gcaacaatta 840 atagactgga tggaggcgga taaagttgca ggaccacttc
tgcgctcggc ccttccggct 900 ggctggttta ttgctgataa atctggagcc
ggtgagcgtg ggtctcgcgg tatcattgca 960 gcactggggc cagatggtaa
gccctcccgt atcgtagtta tctacacgac ggggagtcag 1020 gcaactatgg
atgaacgaaa tagacagatc gctgagatag gtgcctcact gattaagcat 1080
tggtaactgt cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt
1140 taatttaaaa ggatctaggt gaagatcctt tttgataatc tcatgaccaa
aatcccttaa 1200 cgtgagtttt cgttccactg agcgtcagac cccgtagaaa
agatcaaagg atcttcttga 1260 gatccttttt ttctgcgcgt aatctgctgc
ttgcaaacaa aaaaaccacc gctaccagcg 1320 gtggtttgtt tgccggatca
agagctacca actctttttc cgaaggtaac tggcttcagc 1380 agagcgcaga
taccaaatac tgtccttcta gtgtagccgt agttaggcca ccacttcaag 1440
aactctgtag caccgcctac atacctcgct ctgctaatcc tgttaccagt ggctgctgcc
1500 agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc
ggataaggcg 1560 cagcggtcgg gctgaacggg gggttcgtgc acacagccca
gcttggagcg aacgacctac 1620 accgaactga gatacctaca gcgtgagcta
tgagaaagcg ccacgcttcc cgaagggaga 1680 aaggcggaca ggtatccggt
aagcggcagg gtcggaacag gagagcgcac gagggagctt 1740 ccagggggaa
acgcctggta tctttatagt cctgtcgggt ttcgccacct ctgacttgag 1800
cgtcgatttt tgtgatgctc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg
1860 gcctttttac ggttcctggc cttttgctgg ccttttgctc acatgttctt
tcctgcgtta 1920 tcccctgatt ctgtggataa ccgtattacc gcctttgagt
gagctgatac cgctcgccgc 1980 agccgaacga ccgagcgcag cgagtcagtg
agcgaggaag cggaagagcg cccaatacgc 2040 aaaccgcctc tccccgcgcg
ttggccgatt cattaatgca gctggcacga caggtttccc 2100 gactggaaag
cgggcagtga gcgcaacgca attaatgtga gttagctcac tcattaggca 2160
ccccaggctt tacactttat gcttccggct cgtatgttgt gtggaattgt gagcggataa
2220 caatttcaca caggaaacag ctatgaccat gattacgcca agcttgaatt
ctctgacgct 2280 gattaacccg acaccctatt acctgacggt aacagagttg
aatgccggaa cccgggttct 2340 tgaaaatgca ttggtgcctc caatgggcga
aagcacggtt aaattgcctt ctgatgcagg 2400 aagcaatatt acttaccgaa
caataaatga ttatggcgca cttaccccca aaatgacggg 2460 cgtaatggaa
taacgcaggg ggaatttttc gcctgaataa aaagaattga ctgccggggt 2520
gattttaagc cggaggaata atgtcatatc tgaatttaag actttaccag cgaaacacac
2580 aatgcttgca tattcgtaag catcgtttgg ctggtttttt tgtccgactc
gttgtcgcct 2640 gtgcttttgc cgcacaggca cctttgtcat ctgccgacct
ctattttaat ccgcgctttt 2700 tagcggatga tccccaggct gtggccgatt
tatcgcgttt tgaaaatggg caagaattac 2760 cgccagggac gtatcgcgtc
gatatctatt tgaataatgg ttatatggca acgcgtgatg 2820 tcacatttaa
tacgggcgac agtgaacaag ggattgttcc ctgcctgaca cgcgcgcaac 2880
tcgccagtat ggggctgaat acggcttctg tcgccggtat gaatctgctg gcggatgatg
2940 cctgtgtgcc attaaccaca atggtccagg acgctactgc gcatctggat
gttggtcagc 3000 agcgactgaa cctgacgatc cctcaggcat ttatgagtaa
tcgcgcgcgt ggttatattc 3060 ctcctgagtt atgggatccc ggtattaatg
ccggattgct caattataat ttcagcggaa 3120 atagtgtaca gaatcggatt
gggggtaaca gccattatgc atatttaaac ctacagagtg 3180 ggttaaatat
tggtgcgtgg cgtttacgcg acaataccac ctggagttat aacagtagcg 3240
acagatcatc aggtagcaaa aataaatggc agcatatcaa tacctggctt gagcgagaca
3300 taataccgtt acgttcccgg ctgacgctgg gtgatggtta tactcagggc
gatattttcg 3360 atggtattaa ctttcgcggc gcacaattgg cctcagatga
caatatgtta cccgatagtc 3420 aaagaggatt tgccccggtg atccacggta
ttgctcgtgg tactgcacag gtcactatta 3480 aacaaaatgg gtatgacatt
tataatagta cggtgccacc ggggcctttt accatcaacg 3540 atatctatgc
cgcaggtaat agtggtgact tgcaggtaac gatcaaagag gctgacggca 3600
gcacgcagat ttttaccgta ccctattcgt cagtcccgct tttgcaacgt gaagggcata
3660 ctcgttattc cattacggca ggagaatacc gtagtggaaa tgcgcagcag
gaaaaaaccc 3720 gctttttcca gagtacatta ctccacggcc ttccggctgg
ctggacaata tatggtggaa 3780
cgcaactggc ggatcgttat cgtgctttta atttcggtat cgggaaaaac atgggggcac
3840 tgggcgctct gtctgtggat atgacgcagg ctaattccac acttcccgat
gacagtcagc 3900 atgacggaca atcggtgcgt tttctctata acaaatcgct
caatgaatca ggcacgaata 3960 ttcagttagt gggttaccgt tattcgacca
gcggatattt taatttcgct gatacaacat 4020 acagtcgaat gaatggctac
aacattgaaa cacaggacgg agttattcag gttaagccga 4080 aattcaccga
ctattacaac ctcgcttata acaaacgcgg gaaattacaa ctcaccgtta 4140
ctcagcaact cgggcgcaca tcaacactgt atttgagtgg tagccatcaa acttattggg
4200 gaacgagtaa tgtcgatgag caattccagg ctggattaaa tactgcgttc
gaagatatca 4260 actggacgct cagctatagc ctgacgaaaa acgcctggca
aaaaggacgg gatcagatgt 4320 tagcgcttaa cgtcaatatt cctttcagcc
actggctgcg ttctgacagt aaatctcagt 4380 ggcgacatgc cagtgccagc
tacagcatgt cacacgatct caacggtcgg atgaccaatc 4440 tggctggtgt
atacggtacg ttgctggaag acaacaacct cagctatagc gtgcaaaccg 4500
gctatgccgg gggaggcgat ggaaatagcg gaagtacagg ctacgccacg ctgaattatc
4560 gcggtggtta cggcaatgcc aatatcggtt acagccatag cgatgatatt
aagcagctct 4620 attacggagt cagcggtggg gtactggctc atgccaatgg
cgtaacgctg gggcagccgt 4680 taaacgatac ggtggtgctt gttaaagcgc
ctggcgcaaa agatgcaaaa gtcgaaaacc 4740 agacgggggt gcgtaccgac
tggcgtggtt atgccgtgct gccttatgcc actgaatatc 4800 gggaaaatag
agtggcgctg gataccaata ccctggctga taacgtcgat ttagataacg 4860
cggttgctaa cgttgttccc actcgtgggg cgatcgtgcg agcagagttt aaagcgcgcg
4920 ttgggataaa actgctcatg acgctgaccc acaataataa gccgctgccg
tttggggcga 4980 tggtgacatc agagagtagc cagagtagcg gcattgttgc
ggataatggt caggtttacc 5040 tcagcggaat gcctttagcg ggaaaagttc
aggtgaaatg gggagaagag gaaaatgctc 5100 actgtgtcgc caattatcaa
ctgccaccag agagtcagca gcagttatta acccagctat 5160 cagctgaatg
tcgttaaggg ggcgtgatga gaaacaaacc tttttatctt ctgtgcgctt 5220
ttttgtggct ggcggtgagt cacgctttgg ctgcggatag cacgattact atccgcggtc
5280 tagaggatcc ccgggtaccg agctcgaatt cactggccgt cgttttacaa
cgtcgtgact 5340 gggaaaaccc tggcgttacc caacttaatc gccttgcagc
acatccccct ttcgccagct 5400 ggcgtaatag cgaagaggcc cgcaccgatc
gcccttccca acagttgcgc agcctgaatg 5460 gcgaatggcg cctgatgcgg
tattttctcc ttacgcatct gtgcggtatt tcacaccgca 5520 tatggtgcac
tctcagtaca atctgctctg atgccgcata gttaagccag ccccgacacc 5580
cgccaacacc cgctgacgcg ccctgacggg cttgtctgct cccggcatcc gcttacagac
5640 aagctgtgac cgtctccggg agctgcatgt gtcagaggtt t 5681 <210>
SEQ ID NO 202 <211> LENGTH: 40 <212> TYPE: DNA
<213> ORGANISM: Oligonucleotide Primer <400> SEQUENCE:
202 aattacgtga gcaagcttat gagaaacaaa cctttttatc 40 <210> SEQ
ID NO 203 <211> LENGTH: 41 <212> TYPE: DNA <213>
ORGANISM: Oligonucleotide Primer <400> SEQUENCE: 203
gactaaggcc tttctagatt attgataaac aaaagtcacg c 41 <210> SEQ ID
NO 204 <211> LENGTH: 4637 <212> TYPE: DNA <213>
ORGANISM: pFIMFGH <400> SEQUENCE: 204 aaagggcctc gtgatacgcc
tatttttata ggttaatgtc atgataataa tggtttctta 60 gacgtcaggt
ggcacttttc ggggaaatgt gcgcggaacc cctatttgtt tatttttcta 120
aatacattca aatatgtatc cgctcatgag acaataaccc tgataaatgc ttcaataata
180 ttgaaaaagg aagagtatga gtattcaaca tttccgtgtc gcccttattc
ccttttttgc 240 ggcattttgc cttcctgttt ttgctcaccc agaaacgctg
gtgaaagtaa aagatgctga 300 agatcagttg ggtgcacgag tgggttacat
cgaactggat ctcaacagcg gtaagatcct 360 tgagagtttt cgccccgaag
aacgttttcc aatgatgagc acttttaaag ttctgctatg 420 tggcgcggta
ttatcccgta ttgacgccgg gcaagagcaa ctcggtcgcc gcatacacta 480
ttctcagaat gacttggttg agtactcacc agtcacagaa aagcatctta cggatggcat
540 gacagtaaga gaattatgca gtgctgccat aaccatgagt gataacactg
cggccaactt 600 acttctgaca acgatcggag gaccgaagga gctaaccgct
tttttgcaca acatggggga 660 tcatgtaact cgccttgatc gttgggaacc
ggagctgaat gaagccatac caaacgacga 720 gcgtgacacc acgatgcctg
tagcaatggc aacaacgttg cgcaaactat taactggcga 780 actacttact
ctagcttccc ggcaacaatt aatagactgg atggaggcgg ataaagttgc 840
aggaccactt ctgcgctcgg cccttccggc tggctggttt attgctgata aatctggagc
900 cggtgagcgt gggtctcgcg gtatcattgc agcactgggg ccagatggta
agccctcccg 960 tatcgtagtt atctacacga cggggagtca ggcaactatg
gatgaacgaa atagacagat 1020 cgctgagata ggtgcctcac tgattaagca
ttggtaactg tcagaccaag tttactcata 1080 tatactttag attgatttaa
aacttcattt ttaatttaaa aggatctagg tgaagatcct 1140 ttttgataat
ctcatgacca aaatccctta acgtgagttt tcgttccact gagcgtcaga 1200
ccccgtagaa aagatcaaag gatcttcttg agatcctttt tttctgcgcg taatctgctg
1260 cttgcaaaca aaaaaaccac cgctaccagc ggtggtttgt ttgccggatc
aagagctacc 1320 aactcttttt ccgaaggtaa ctggcttcag cagagcgcag
ataccaaata ctgtccttct 1380 agtgtagccg tagttaggcc accacttcaa
gaactctgta gcaccgccta catacctcgc 1440 tctgctaatc ctgttaccag
tggctgctgc cagtggcgat aagtcgtgtc ttaccgggtt 1500 ggactcaaga
cgatagttac cggataaggc gcagcggtcg ggctgaacgg ggggttcgtg 1560
cacacagccc agcttggagc gaacgaccta caccgaactg agatacctac agcgtgagct
1620 atgagaaagc gccacgcttc ccgaagggag aaaggcggac aggtatccgg
taagcggcag 1680 ggtcggaaca ggagagcgca cgagggagct tccaggggga
aacgcctggt atctttatag 1740 tcctgtcggg tttcgccacc tctgacttga
gcgtcgattt ttgtgatgct cgtcaggggg 1800 gcggagccta tggaaaaacg
ccagcaacgc ggccttttta cggttcctgg ccttttgctg 1860 gccttttgct
cacatgttct ttcctgcgtt atcccctgat tctgtggata accgtattac 1920
cgcctttgag tgagctgata ccgctcgccg cagccgaacg accgagcgca gcgagtcagt
1980 gagcgaggaa gcggaagagc gcccaatacg caaaccgcct ctccccgcgc
gttggccgat 2040 tcattaatgc agctggcacg acaggtttcc cgactggaaa
gcgggcagtg agcgcaacgc 2100 aattaatgtg agttagctca ctcattaggc
accccaggct ttacacttta tgcttccggc 2160 tcgtatgttg tgtggaattg
tgagcggata acaatttcac acaggaaaca gctatgacca 2220 tgattacgcc
aagcttatga gaaacaaacc tttttatctt ctgtgcgctt ttttgtggct 2280
ggcggtgagt cacgctttgg ctgcggatag cacgattact atccgcggct atgtcaggga
2340 taacggctgt agtgtggccg ctgaatcaac caattttact gttgatctga
tggaaaacgc 2400 ggcgaagcaa tttaacaaca ttggcgcgac gactcctgtt
gttccatttc gtattttgct 2460 gtcaccctgt ggtaatgccg tttctgccgt
aaaggttggg tttactggcg ttgcagatag 2520 ccacaatgcc aacctgcttg
cacttgaaaa tacggtgtca gcggcttcgg gactgggaat 2580 acagcttctg
aatgagcagc aaaatcaaat accccttaat gctccatcgt ccgcgctttc 2640
gtggacgacc ctgacgccgg gtaaaccaaa tacgctgaat ttttacgccc ggctaatggc
2700 gacacaggtg cctgtcactg cggggcatat caatgccacg gctaccttca
ctcttgaata 2760 tcagtaactg gagatgctca tgaaatggtg caaacgtggg
tatgtattgg cggcaatatt 2820 ggcgctcgca agtgcgacga tacaggcagc
cgatgtcacc atcacggtga acggtaaggt 2880 cgtcgccaaa ccgtgtacgg
tttccaccac caatgccacg gttgatctcg gcgatcttta 2940 ttctttcagt
cttatgtctg ccggggcggc atcggcctgg catgatgttg cgcttgagtt 3000
gactaattgt ccggtgggaa cgtcgagggt cactgccagc ttcagcgggg cagccgacag
3060 taccggatat tataaaaacc aggggaccgc gcaaaacatc cagttagagc
tacaggatga 3120 cagtggcaac acattgaata ctggcgcaac caaaacagtt
caggtggatg attcctcaca 3180 atcagcgcac ttcccgttac aggtcagagc
attgacagta aatggcggag ccactcaggg 3240 aaccattcag gcagtgatta
gcatcaccta tacctacagc tgaacccgaa gagatgattg 3300 taatgaaacg
agttattacc ctgtttgctg tactgctgat gggctggtcg gtaaatgcct 3360
ggtcattcgc ctgtaaaacc gccaatggta ccgctatccc tattggcggt ggcagcgcca
3420 atgtttatgt aaaccttgcg cccgtcgtga atgtggggca aaacctggtc
gtggatcttt 3480 cgacgcaaat cttttgccat aacgattatc cggaaaccat
tacagactat gtcacactgc 3540 aacgaggctc ggcttatggc ggcgtgttat
ctaatttttc cgggaccgta aaatatagtg 3600 gcagtagcta tccatttcct
accaccagcg aaacgccgcg cgttgtttat aattcgagaa 3660 cggataagcc
gtggccggtg gcgctttatt tgacgcctgt gagcagtgcg ggcggggtgg 3720
cgattaaagc tggctcatta attgccgtgc ttattttgcg acagaccaac aactataaca
3780 gcgatgattt ccagtttgtg tggaatattt acgccaataa tgatgtggtg
gtgcctactg 3840 gcggctgcga tgtttctgct cgtgatgtca ccgttactct
gccggactac cctggttcag 3900 tgccaattcc tcttaccgtt tattgtgcga
aaagccaaaa cctggggtat tacctctccg 3960 gcacaaccgc agatgcgggc
aactcgattt tcaccaatac cgcgtcgttt tcacctgcac 4020 agggcgtcgg
cgtacagttg acgcgcaacg gtacgattat tccagcgaat aacacggtat 4080
cgttaggagc agtagggact tcggcggtga gtctgggatt aacggcaaat tatgcacgta
4140 ccggagggca ggtgactgca gggaatgtgc aatcgattat tggcgtgact
tttgtttatc 4200 aataatctag aggatccccg ggtaccgagc tcgaattcac
tggccgtcgt tttacaacgt 4260 cgtgactggg aaaaccctgg cgttacccaa
cttaatcgcc ttgcagcaca tccccctttc 4320 gccagctggc gtaatagcga
agaggcccgc accgatcgcc cttcccaaca gttgcgcagc 4380 ctgaatggcg
aatggcgcct gatgcggtat tttctcctta cgcatctgtg cggtatttca 4440
caccgcatat ggtgcactct cagtacaatc tgctctgatg ccgcatagtt aagccagccc
4500 cgacacccgc caacacccgc tgacgcgccc tgacgggctt gtctgctccc
ggcatccgct 4560 tacagacaag ctgtgaccgt ctccgggagc tgcatgtgtc
agaggttttc accgtcatca 4620 ccgaaacgcg cgagacg 4637 <210> SEQ
ID NO 205 <211> LENGTH: 9299
<212> TYPE: DNA <213> ORGANISM: pFIMAICDFGH <400>
SEQUENCE: 205 cgagacgaaa gggcctcgtg atacgcctat ttttataggt
taatgtcatg ataataatgg 60 tttcttagac gtcaggtggc acttttcggg
gaaatgtgcg cggaacccct atttgtttat 120 ttttctaaat acattcaaat
atgtatccgc tcatgagaca ataaccctga taaatgcttc 180 aataatattg
aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc cttattccct 240
tttttgcggc attttgcctt cctgtttttg ctcacccaga aacgctggtg aaagtaaaag
300 atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc
aacagcggta 360 agatccttga gagttttcgc cccgaagaac gttttccaat
gatgagcact tttaaagttc 420 tgctatgtgg cgcggtatta tcccgtattg
acgccgggca agagcaactc ggtcgccgca 480 tacactattc tcagaatgac
ttggttgagt actcaccagt cacagaaaag catcttacgg 540 atggcatgac
agtaagagaa ttatgcagtg ctgccataac catgagtgat aacactgcgg 600
ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt ttgcacaaca
660 tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa
gccataccaa 720 acgacgagcg tgacaccacg atgcctgtag caatggcaac
aacgttgcgc aaactattaa 780 ctggcgaact acttactcta gcttcccggc
aacaattaat agactggatg gaggcggata 840 aagttgcagg accacttctg
cgctcggccc ttccggctgg ctggtttatt gctgataaat 900 ctggagccgg
tgagcgtggg tctcgcggta tcattgcagc actggggcca gatggtaagc 960
cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat gaacgaaata
1020 gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca
gaccaagttt 1080 actcatatat actttagatt gatttaaaac ttcattttta
atttaaaagg atctaggtga 1140 agatcctttt tgataatctc atgaccaaaa
tcccttaacg tgagttttcg ttccactgag 1200 cgtcagaccc cgtagaaaag
atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa 1260 tctgctgctt
gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg ccggatcaag 1320
agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata ccaaatactg
1380 tccttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca
ccgcctacat 1440 acctcgctct gctaatcctg ttaccagtgg ctgctgccag
tggcgataag tcgtgtctta 1500 ccgggttgga ctcaagacga tagttaccgg
ataaggcgca gcggtcgggc tgaacggggg 1560 gttcgtgcac acagcccagc
ttggagcgaa cgacctacac cgaactgaga tacctacagc 1620 gtgagctatg
agaaagcgcc acgcttcccg aagggagaaa ggcggacagg tatccggtaa 1680
gcggcagggt cggaacagga gagcgcacga gggagcttcc agggggaaac gcctggtatc
1740 tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg
tgatgctcgt 1800 caggggggcg gagcctatgg aaaaacgcca gcaacgcggc
ctttttacgg ttcctggcct 1860 tttgctggcc ttttgctcac atgttctttc
ctgcgttatc ccctgattct gtggataacc 1920 gtattaccgc ctttgagtga
gctgataccg ctcgccgcag ccgaacgacc gagcgcagcg 1980 agtcagtgag
cgaggaagcg gaagagcgcc caatacgcaa accgcctctc cccgcgcgtt 2040
ggccgattca ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc
2100 gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta
cactttatgc 2160 ttccggctcg tatgttgtgt ggaattgtga gcggataaca
atttcacaca ggaaacagct 2220 atgaccatga ttacgccaag cttataatag
aaatagtttt ttgaaaggaa agcagcatga 2280 aaattaaaac tctggcaatc
gttgttctgt cggctctgtc cctcagttct acagcggctc 2340 tggccgctgc
cacgacggtt aatggtggga ccgttcactt taaaggggaa gttgttaacg 2400
ccgcttgcgc agttgatgca ggctctgttg atcaaaccgt tcagttagga caggttcgta
2460 ccgcatcgct ggcacaggaa ggagcaacca gttctgctgt cggttttaac
attcagctga 2520 atgattgcga taccaatgtt gcatctaaag ccgctgttgc
ctttttaggt acggcgattg 2580 atgcgggtca taccaacgtt ctggctctgc
agagttcagc tgcgggtagc gcaacaaacg 2640 ttggtgtgca gatcctggac
agaacgggtg ctgcgctgac gctggatggt gcgacattta 2700 gttcagaaac
aaccctgaat aacggaacca ataccattcc gttccaggcg cgttattttg 2760
caaccggggc cgcaaccccg ggtgctgcta atgcggatgc gaccttcaag gttcagtatc
2820 aataacctac ccaggttcag ggacgtcatt acgggcaggg atgcccaccc
ttgtgcgata 2880 aaaataacga tgaaaaggaa gagattattt ctattagcgt
cgttgctgcc aatgtttgct 2940 ctggccggaa ataaatggaa taccacgttg
cccggcggaa atatgcaatt tcagggcgtc 3000 attattgcgg aaacttgccg
gattgaagcc ggtgataaac aaatgacggt caatatgggg 3060 caaatcagca
gtaaccggtt tcatgcggtt ggggaagata gcgcaccggt gccttttgtt 3120
attcatttac gggaatgtag cacggtggtg agtgaacgtg taggtgtggc gtttcacggt
3180 gtcgcggatg gtaaaaatcc ggatgtgctt tccgtgggag aggggccagg
gatagccacc 3240 aatattggcg tagcgttgtt tgatgatgaa ggaaacctcg
taccgattaa tcgtcctcca 3300 gcaaactgga aacggcttta ttcaggctct
acttcgctac atttcatcgc caaatatcgt 3360 gctaccgggc gtcgggttac
tggcggcatc gccaatgccc aggcctggtt ctctttaacc 3420 tatcagtaat
tgttcagcag ataatgtgat aacaggaaca ggacagtgag taataaaaac 3480
gtcaatgtaa ggaaatcgca ggaaataaca ttctgcttgc tggcaggtat cctgatgttc
3540 atggcaatga tggttgccgg acgcgctgaa gcgggagtgg ccttaggtgc
gactcgcgta 3600 atttatccgg cagggcaaaa acaagagcaa cttgccgtga
caaataatga tgaaaatagt 3660 acctatttaa ttcaatcatg ggtggaaaat
gccgatggtg taaaggatgg tcgttttatc 3720 gtgacgcctc ctctgtttgc
gatgaaggga aaaaaagaga ataccttacg tattcttgat 3780 gcaacaaata
accaattgcc acaggaccgg gaaagtttat tctggatgaa cgttaaagcg 3840
attccgtcaa tggataaatc aaaattgact gagaatacgc tacagctcgc aattatcagc
3900 cgcattaaac tgtactatcg cccggctaaa ttagcgttgc cacccgatca
ggccgcagaa 3960 aaattaagat ttcgtcgtag cgcgaattct ctgacgctga
ttaacccgac accctattac 4020 ctgacggtaa cagagttgaa tgccggaacc
cgggttcttg aaaatgcatt ggtgcctcca 4080 atgggcgaaa gcacggttaa
attgccttct gatgcaggaa gcaatattac ttaccgaaca 4140 ataaatgatt
atggcgcact tacccccaaa atgacgggcg taatggaata acgcaggggg 4200
aatttttcgc ctgaataaaa agaattgact gccggggtga ttttaagccg gaggaataat
4260 gtcatatctg aatttaagac tttaccagcg aaacacacaa tgcttgcata
ttcgtaagca 4320 tcgtttggct ggtttttttg tccgactcgt tgtcgcctgt
gcttttgccg cacaggcacc 4380 tttgtcatct gccgacctct attttaatcc
gcgcttttta gcggatgatc cccaggctgt 4440 ggccgattta tcgcgttttg
aaaatgggca agaattaccg ccagggacgt atcgcgtcga 4500 tatctatttg
aataatggtt atatggcaac gcgtgatgtc acatttaata cgggcgacag 4560
tgaacaaggg attgttccct gcctgacacg cgcgcaactc gccagtatgg ggctgaatac
4620 ggcttctgtc gccggtatga atctgctggc ggatgatgcc tgtgtgccat
taaccacaat 4680 ggtccaggac gctactgcgc atctggatgt tggtcagcag
cgactgaacc tgacgatccc 4740 tcaggcattt atgagtaatc gcgcgcgtgg
ttatattcct cctgagttat gggatcccgg 4800 tattaatgcc ggattgctca
attataattt cagcggaaat agtgtacaga atcggattgg 4860 gggtaacagc
cattatgcat atttaaacct acagagtggg ttaaatattg gtgcgtggcg 4920
tttacgcgac aataccacct ggagttataa cagtagcgac agatcatcag gtagcaaaaa
4980 taaatggcag catatcaata cctggcttga gcgagacata ataccgttac
gttcccggct 5040 gacgctgggt gatggttata ctcagggcga tattttcgat
ggtattaact ttcgcggcgc 5100 acaattggcc tcagatgaca atatgttacc
cgatagtcaa agaggatttg ccccggtgat 5160 ccacggtatt gctcgtggta
ctgcacaggt cactattaaa caaaatgggt atgacattta 5220 taatagtacg
gtgccaccgg ggccttttac catcaacgat atctatgccg caggtaatag 5280
tggtgacttg caggtaacga tcaaagaggc tgacggcagc acgcagattt ttaccgtacc
5340 ctattcgtca gtcccgcttt tgcaacgtga agggcatact cgttattcca
ttacggcagg 5400 agaataccgt agtggaaatg cgcagcagga aaaaacccgc
tttttccaga gtacattact 5460 ccacggcctt ccggctggct ggacaatata
tggtggaacg caactggcgg atcgttatcg 5520 tgcttttaat ttcggtatcg
ggaaaaacat gggggcactg ggcgctctgt ctgtggatat 5580 gacgcaggct
aattccacac ttcccgatga cagtcagcat gacggacaat cggtgcgttt 5640
tctctataac aaatcgctca atgaatcagg cacgaatatt cagttagtgg gttaccgtta
5700 ttcgaccagc ggatatttta atttcgctga tacaacatac agtcgaatga
atggctacaa 5760 cattgaaaca caggacggag ttattcaggt taagccgaaa
ttcaccgact attacaacct 5820 cgcttataac aaacgcggga aattacaact
caccgttact cagcaactcg ggcgcacatc 5880 aacactgtat ttgagtggta
gccatcaaac ttattgggga acgagtaatg tcgatgagca 5940 attccaggct
ggattaaata ctgcgttcga agatatcaac tggacgctca gctatagcct 6000
gacgaaaaac gcctggcaaa aaggacggga tcagatgtta gcgcttaacg tcaatattcc
6060 tttcagccac tggctgcgtt ctgacagtaa atctcagtgg cgacatgcca
gtgccagcta 6120 cagcatgtca cacgatctca acggtcggat gaccaatctg
gctggtgtat acggtacgtt 6180 gctggaagac aacaacctca gctatagcgt
gcaaaccggc tatgccgggg gaggcgatgg 6240 aaatagcgga agtacaggct
acgccacgct gaattatcgc ggtggttacg gcaatgccaa 6300 tatcggttac
agccatagcg atgatattaa gcagctctat tacggagtca gcggtggggt 6360
actggctcat gccaatggcg taacgctggg gcagccgtta aacgatacgg tggtgcttgt
6420 taaagcgcct ggcgcaaaag atgcaaaagt cgaaaaccag acgggggtgc
gtaccgactg 6480 gcgtggttat gccgtgctgc cttatgccac tgaatatcgg
gaaaatagag tggcgctgga 6540 taccaatacc ctggctgata acgtcgattt
agataacgcg gttgctaacg ttgttcccac 6600 tcgtggggcg atcgtgcgag
cagagtttaa agcgcgcgtt gggataaaac tgctcatgac 6660 gctgacccac
aataataagc cgctgccgtt tggggcgatg gtgacatcag agagtagcca 6720
gagtagcggc attgttgcgg ataatggtca ggtttacctc agcggaatgc ctttagcggg
6780 aaaagttcag gtgaaatggg gagaagagga aaatgctcac tgtgtcgcca
attatcaact 6840 gccaccagag agtcagcagc agttattaac ccagctatca
gctgaatgtc gttaaggggg 6900 cgtgatgaga aacaaacctt tttatcttct
gtgcgctttt ttgtggctgg cggtgagtca 6960 cgctttggct gcggatagca
cgattactat ccgcggctat gtcagggata acggctgtag 7020 tgtggccgct
gaatcaacca attttactgt tgatctgatg gaaaacgcgg cgaagcaatt 7080
taacaacatt ggcgcgacga ctcctgttgt tccatttcgt attttgctgt caccctgtgg
7140 taatgccgtt tctgccgtaa aggttgggtt tactggcgtt gcagatagcc
acaatgccaa 7200 cctgcttgca cttgaaaata cggtgtcagc ggcttcggga
ctgggaatac agcttctgaa 7260 tgagcagcaa aatcaaatac cccttaatgc
tccatcgtcc gcgctttcgt ggacgaccct 7320 gacgccgggt aaaccaaata
cgctgaattt ttacgcccgg ctaatggcga cacaggtgcc 7380
tgtcactgcg gggcatatca atgccacggc taccttcact cttgaatatc agtaactgga
7440 gatgctcatg aaatggtgca aacgtgggta tgtattggcg gcaatattgg
cgctcgcaag 7500 tgcgacgata caggcagccg atgtcaccat cacggtgaac
ggtaaggtcg tcgccaaacc 7560 gtgtacggtt tccaccacca atgccacggt
tgatctcggc gatctttatt ctttcagtct 7620 tatgtctgcc ggggcggcat
cggcctggca tgatgttgcg cttgagttga ctaattgtcc 7680 ggtgggaacg
tcgagggtca ctgccagctt cagcggggca gccgacagta ccggatatta 7740
taaaaaccag gggaccgcgc aaaacatcca gttagagcta caggatgaca gtggcaacac
7800 attgaatact ggcgcaacca aaacagttca ggtggatgat tcctcacaat
cagcgcactt 7860 cccgttacag gtcagagcat tgacagtaaa tggcggagcc
actcagggaa ccattcaggc 7920 agtgattagc atcacctata cctacagctg
aacccgaaga gatgattgta atgaaacgag 7980 ttattaccct gtttgctgta
ctgctgatgg gctggtcggt aaatgcctgg tcattcgcct 8040 gtaaaaccgc
caatggtacc gctatcccta ttggcggtgg cagcgccaat gtttatgtaa 8100
accttgcgcc cgtcgtgaat gtggggcaaa acctggtcgt ggatctttcg acgcaaatct
8160 tttgccataa cgattatccg gaaaccatta cagactatgt cacactgcaa
cgaggctcgg 8220 cttatggcgg cgtgttatct aatttttccg ggaccgtaaa
atatagtggc agtagctatc 8280 catttcctac caccagcgaa acgccgcgcg
ttgtttataa ttcgagaacg gataagccgt 8340 ggccggtggc gctttatttg
acgcctgtga gcagtgcggg cggggtggcg attaaagctg 8400 gctcattaat
tgccgtgctt attttgcgac agaccaacaa ctataacagc gatgatttcc 8460
agtttgtgtg gaatatttac gccaataatg atgtggtggt gcctactggc ggctgcgatg
8520 tttctgctcg tgatgtcacc gttactctgc cggactaccc tggttcagtg
ccaattcctc 8580 ttaccgttta ttgtgcgaaa agccaaaacc tggggtatta
cctctccggc acaaccgcag 8640 atgcgggcaa ctcgattttc accaataccg
cgtcgttttc acctgcacag ggcgtcggcg 8700 tacagttgac gcgcaacggt
acgattattc cagcgaataa cacggtatcg ttaggagcag 8760 tagggacttc
ggcggtgagt ctgggattaa cggcaaatta tgcacgtacc ggagggcagg 8820
tgactgcagg gaatgtgcaa tcgattattg gcgtgacttt tgtttatcaa taatctagaa
8880 ggatccccgg gtaccgagct cgaattcact ggccgtcgtt ttacaacgtc
gtgactggga 8940 aaaccctggc gttacccaac ttaatcgcct tgcagcacat
ccccctttcg ccagctggcg 9000 taatagcgaa gaggcccgca ccgatcgccc
ttcccaacag ttgcgcagcc tgaatggcga 9060 atggcgcctg atgcggtatt
ttctccttac gcatctgtgc ggtatttcac accgcatatg 9120 gtgcactctc
agtacaatct gctctgatgc cgcatagtta agccagcccc gacacccgcc 9180
aacacccgct gacgcgccct gacgggcttg tctgctcccg gcatccgctt acagacaagc
9240 tgtgaccgtc tccgggagct gcatgtgtca gaggttttca ccgtcatcac
cgaaacgcg 9299 <210> SEQ ID NO 206 <211> LENGTH: 8464
<212> TYPE: DNA <213> ORGANISM: pFIMAICDFG <400>
SEQUENCE: 206 cgagacgaaa gggcctcgtg atacgcctat ttttataggt
taatgtcatg ataataatgg 60 tttcttagac gtcaggtggc acttttcggg
gaaatgtgcg cggaacccct atttgtttat 120 ttttctaaat acattcaaat
atgtatccgc tcatgagaca ataaccctga taaatgcttc 180 aataatattg
aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc cttattccct 240
tttttgcggc attttgcctt cctgtttttg ctcacccaga aacgctggtg aaagtaaaag
300 atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc
aacagcggta 360 agatccttga gagttttcgc cccgaagaac gttttccaat
gatgagcact tttaaagttc 420 tgctatgtgg cgcggtatta tcccgtattg
acgccgggca agagcaactc ggtcgccgca 480 tacactattc tcagaatgac
ttggttgagt actcaccagt cacagaaaag catcttacgg 540 atggcatgac
agtaagagaa ttatgcagtg ctgccataac catgagtgat aacactgcgg 600
ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt ttgcacaaca
660 tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa
gccataccaa 720 acgacgagcg tgacaccacg atgcctgtag caatggcaac
aacgttgcgc aaactattaa 780 ctggcgaact acttactcta gcttcccggc
aacaattaat agactggatg gaggcggata 840 aagttgcagg accacttctg
cgctcggccc ttccggctgg ctggtttatt gctgataaat 900 ctggagccgg
tgagcgtggg tctcgcggta tcattgcagc actggggcca gatggtaagc 960
cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat gaacgaaata
1020 gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca
gaccaagttt 1080 actcatatat actttagatt gatttaaaac ttcattttta
atttaaaagg atctaggtga 1140 agatcctttt tgataatctc atgaccaaaa
tcccttaacg tgagttttcg ttccactgag 1200 cgtcagaccc cgtagaaaag
atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa 1260 tctgctgctt
gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg ccggatcaag 1320
agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata ccaaatactg
1380 tccttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca
ccgcctacat 1440 acctcgctct gctaatcctg ttaccagtgg ctgctgccag
tggcgataag tcgtgtctta 1500 ccgggttgga ctcaagacga tagttaccgg
ataaggcgca gcggtcgggc tgaacggggg 1560 gttcgtgcac acagcccagc
ttggagcgaa cgacctacac cgaactgaga tacctacagc 1620 gtgagctatg
agaaagcgcc acgcttcccg aagggagaaa ggcggacagg tatccggtaa 1680
gcggcagggt cggaacagga gagcgcacga gggagcttcc agggggaaac gcctggtatc
1740 tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg
tgatgctcgt 1800 caggggggcg gagcctatgg aaaaacgcca gcaacgcggc
ctttttacgg ttcctggcct 1860 tttgctggcc ttttgctcac atgttctttc
ctgcgttatc ccctgattct gtggataacc 1920 gtattaccgc ctttgagtga
gctgataccg ctcgccgcag ccgaacgacc gagcgcagcg 1980 agtcagtgag
cgaggaagcg gaagagcgcc caatacgcaa accgcctctc cccgcgcgtt 2040
ggccgattca ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg ggcagtgagc
2100 gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta
cactttatgc 2160 ttccggctcg tatgttgtgt ggaattgtga gcggataaca
atttcacaca ggaaacagct 2220 atgaccatga ttacgccaag cttataatag
aaatagtttt ttgaaaggaa agcagcatga 2280 aaattaaaac tctggcaatc
gttgttctgt cggctctgtc cctcagttct acagcggctc 2340 tggccgctgc
cacgacggtt aatggtggga ccgttcactt taaaggggaa gttgttaacg 2400
ccgcttgcgc agttgatgca ggctctgttg atcaaaccgt tcagttagga caggttcgta
2460 ccgcatcgct ggcacaggaa ggagcaacca gttctgctgt cggttttaac
attcagctga 2520 atgattgcga taccaatgtt gcatctaaag ccgctgttgc
ctttttaggt acggcgattg 2580 atgcgggtca taccaacgtt ctggctctgc
agagttcagc tgcgggtagc gcaacaaacg 2640 ttggtgtgca gatcctggac
agaacgggtg ctgcgctgac gctggatggt gcgacattta 2700 gttcagaaac
aaccctgaat aacggaacca ataccattcc gttccaggcg cgttattttg 2760
caaccggggc cgcaaccccg ggtgctgcta atgcggatgc gaccttcaag gttcagtatc
2820 aataacctac ccaggttcag ggacgtcatt acgggcaggg atgcccaccc
ttgtgcgata 2880 aaaataacga tgaaaaggaa gagattattt ctattagcgt
cgttgctgcc aatgtttgct 2940 ctggccggaa ataaatggaa taccacgttg
cccggcggaa atatgcaatt tcagggcgtc 3000 attattgcgg aaacttgccg
gattgaagcc ggtgataaac aaatgacggt caatatgggg 3060 caaatcagca
gtaaccggtt tcatgcggtt ggggaagata gcgcaccggt gccttttgtt 3120
attcatttac gggaatgtag cacggtggtg agtgaacgtg taggtgtggc gtttcacggt
3180 gtcgcggatg gtaaaaatcc ggatgtgctt tccgtgggag aggggccagg
gatagccacc 3240 aatattggcg tagcgttgtt tgatgatgaa ggaaacctcg
taccgattaa tcgtcctcca 3300 gcaaactgga aacggcttta ttcaggctct
acttcgctac atttcatcgc caaatatcgt 3360 gctaccgggc gtcgggttac
tggcggcatc gccaatgccc aggcctggtt ctctttaacc 3420 tatcagtaat
tgttcagcag ataatgtgat aacaggaaca ggacagtgag taataaaaac 3480
gtcaatgtaa ggaaatcgca ggaaataaca ttctgcttgc tggcaggtat cctgatgttc
3540 atggcaatga tggttgccgg acgcgctgaa gcgggagtgg ccttaggtgc
gactcgcgta 3600 atttatccgg cagggcaaaa acaagagcaa cttgccgtga
caaataatga tgaaaatagt 3660 acctatttaa ttcaatcatg ggtggaaaat
gccgatggtg taaaggatgg tcgttttatc 3720 gtgacgcctc ctctgtttgc
gatgaaggga aaaaaagaga ataccttacg tattcttgat 3780 gcaacaaata
accaattgcc acaggaccgg gaaagtttat tctggatgaa cgttaaagcg 3840
attccgtcaa tggataaatc aaaattgact gagaatacgc tacagctcgc aattatcagc
3900 cgcattaaac tgtactatcg cccggctaaa ttagcgttgc cacccgatca
ggccgcagaa 3960 aaattaagat ttcgtcgtag cgcgaattct ctgacgctga
ttaacccgac accctattac 4020 ctgacggtaa cagagttgaa tgccggaacc
cgggttcttg aaaatgcatt ggtgcctcca 4080 atgggcgaaa gcacggttaa
attgccttct gatgcaggaa gcaatattac ttaccgaaca 4140 ataaatgatt
atggcgcact tacccccaaa atgacgggcg taatggaata acgcaggggg 4200
aatttttcgc ctgaataaaa agaattgact gccggggtga ttttaagccg gaggaataat
4260 gtcatatctg aatttaagac tttaccagcg aaacacacaa tgcttgcata
ttcgtaagca 4320 tcgtttggct ggtttttttg tccgactcgt tgtcgcctgt
gcttttgccg cacaggcacc 4380 tttgtcatct gccgacctct attttaatcc
gcgcttttta gcggatgatc cccaggctgt 4440 ggccgattta tcgcgttttg
aaaatgggca agaattaccg ccagggacgt atcgcgtcga 4500 tatctatttg
aataatggtt atatggcaac gcgtgatgtc acatttaata cgggcgacag 4560
tgaacaaggg attgttccct gcctgacacg cgcgcaactc gccagtatgg ggctgaatac
4620 ggcttctgtc gccggtatga atctgctggc ggatgatgcc tgtgtgccat
taaccacaat 4680 ggtccaggac gctactgcgc atctggatgt tggtcagcag
cgactgaacc tgacgatccc 4740 tcaggcattt atgagtaatc gcgcgcgtgg
ttatattcct cctgagttat gggatcccgg 4800 tattaatgcc ggattgctca
attataattt cagcggaaat agtgtacaga atcggattgg 4860 gggtaacagc
cattatgcat atttaaacct acagagtggg ttaaatattg gtgcgtggcg 4920
tttacgcgac aataccacct ggagttataa cagtagcgac agatcatcag gtagcaaaaa
4980 taaatggcag catatcaata cctggcttga gcgagacata ataccgttac
gttcccggct 5040 gacgctgggt gatggttata ctcagggcga tattttcgat
ggtattaact ttcgcggcgc 5100 acaattggcc tcagatgaca atatgttacc
cgatagtcaa agaggatttg ccccggtgat 5160 ccacggtatt gctcgtggta
ctgcacaggt cactattaaa caaaatgggt atgacattta 5220 taatagtacg
gtgccaccgg ggccttttac catcaacgat atctatgccg caggtaatag 5280
tggtgacttg caggtaacga tcaaagaggc tgacggcagc acgcagattt ttaccgtacc
5340 ctattcgtca gtcccgcttt tgcaacgtga agggcatact cgttattcca
ttacggcagg 5400
agaataccgt agtggaaatg cgcagcagga aaaaacccgc tttttccaga gtacattact
5460 ccacggcctt ccggctggct ggacaatata tggtggaacg caactggcgg
atcgttatcg 5520 tgcttttaat ttcggtatcg ggaaaaacat gggggcactg
ggcgctctgt ctgtggatat 5580 gacgcaggct aattccacac ttcccgatga
cagtcagcat gacggacaat cggtgcgttt 5640 tctctataac aaatcgctca
atgaatcagg cacgaatatt cagttagtgg gttaccgtta 5700 ttcgaccagc
ggatatttta atttcgctga tacaacatac agtcgaatga atggctacaa 5760
cattgaaaca caggacggag ttattcaggt taagccgaaa ttcaccgact attacaacct
5820 cgcttataac aaacgcggga aattacaact caccgttact cagcaactcg
ggcgcacatc 5880 aacactgtat ttgagtggta gccatcaaac ttattgggga
acgagtaatg tcgatgagca 5940 attccaggct ggattaaata ctgcgttcga
agatatcaac tggacgctca gctatagcct 6000 gacgaaaaac gcctggcaaa
aaggacggga tcagatgtta gcgcttaacg tcaatattcc 6060 tttcagccac
tggctgcgtt ctgacagtaa atctcagtgg cgacatgcca gtgccagcta 6120
cagcatgtca cacgatctca acggtcggat gaccaatctg gctggtgtat acggtacgtt
6180 gctggaagac aacaacctca gctatagcgt gcaaaccggc tatgccgggg
gaggcgatgg 6240 aaatagcgga agtacaggct acgccacgct gaattatcgc
ggtggttacg gcaatgccaa 6300 tatcggttac agccatagcg atgatattaa
gcagctctat tacggagtca gcggtggggt 6360 actggctcat gccaatggcg
taacgctggg gcagccgtta aacgatacgg tggtgcttgt 6420 taaagcgcct
ggcgcaaaag atgcaaaagt cgaaaaccag acgggggtgc gtaccgactg 6480
gcgtggttat gccgtgctgc cttatgccac tgaatatcgg gaaaatagag tggcgctgga
6540 taccaatacc ctggctgata acgtcgattt agataacgcg gttgctaacg
ttgttcccac 6600 tcgtggggcg atcgtgcgag cagagtttaa agcgcgcgtt
gggataaaac tgctcatgac 6660 gctgacccac aataataagc cgctgccgtt
tggggcgatg gtgacatcag agagtagcca 6720 gagtagcggc attgttgcgg
ataatggtca ggtttacctc agcggaatgc ctttagcggg 6780 aaaagttcag
gtgaaatggg gagaagagga aaatgctcac tgtgtcgcca attatcaact 6840
gccaccagag agtcagcagc agttattaac ccagctatca gctgaatgtc gttaaggggg
6900 cgtgatgaga aacaaacctt tttatcttct gtgcgctttt ttgtggctgg
cggtgagtca 6960 cgctttggct gcggatagca cgattactat ccgcggctat
gtcagggata acggctgtag 7020 tgtggccgct gaatcaacca attttactgt
tgatctgatg gaaaacgcgg cgaagcaatt 7080 taacaacatt ggcgcgacga
ctcctgttgt tccatttcgt attttgctgt caccctgtgg 7140 taatgccgtt
tctgccgtaa aggttgggtt tactggcgtt gcagatagcc acaatgccaa 7200
cctgcttgca cttgaaaata cggtgtcagc ggcttcggga ctgggaatac agcttctgaa
7260 tgagcagcaa aatcaaatac cccttaatgc tccatcgtcc gcgctttcgt
ggacgaccct 7320 gacgccgggt aaaccaaata cgctgaattt ttacgcccgg
ctaatggcga cacaggtgcc 7380 tgtcactgcg gggcatatca atgccacggc
taccttcact cttgaatatc agtaactgga 7440 gatgctcatg aaatggtgca
aacgtgggta tgtattggcg gcaatattgg cgctcgcaag 7500 tgcgacgata
caggcagccg atgtcaccat cacggtgaac ggtaaggtcg tcgccaaacc 7560
gtgtacggtt tccaccacca atgccacggt tgatctcggc gatctttatt ctttcagtct
7620 tatgtctgcc ggggcggcat cggcctggca tgatgttgcg cttgagttga
ctaattgtcc 7680 ggtgggaacg tcgagggtca ctgccagctt cagcggggca
gccgacagta ccggatatta 7740 taaaaaccag gggaccgcgc aaaacatcca
gttagagcta caggatgaca gtggcaacac 7800 attgaatact ggcgcaacca
aaacagttca ggtggatgat tcctcacaat cagcgcactt 7860 cccgttacag
gtcagagcat tgacagtaaa tggcggagcc actcagggaa ccattcaggc 7920
agtgattagc atcacctata cctacagctg aacccgaaga gatgattgta atgaaacgag
7980 ttattaccct gtttgctgta ctgctgatgg gctggtcggt aaatgcctgg
tcattcgcct 8040 gtaaaaccgc caatggtacc gagctcgaat tcactggccg
tcgttttaca acgtcgtgac 8100 tgggaaaacc ctggcgttac ccaacttaat
cgccttgcag cacatccccc tttcgccagc 8160 tggcgtaata gcgaagaggc
ccgcaccgat cgcccttccc aacagttgcg cagcctgaat 8220 ggcgaatggc
gcctgatgcg gtattttctc cttacgcatc tgtgcggtat ttcacaccgc 8280
atatggtgca ctctcagtac aatctgctct gatgccgcat agttaagcca gccccgacac
8340 ccgccaacac ccgctgacgc gccctgacgg gcttgtctgc tcccggcatc
cgcttacaga 8400 caagctgtga ccgtctccgg gagctgcatg tgtcagaggt
tttcaccgtc atcaccgaaa 8460 cgcg 8464 <210> SEQ ID NO 207
<211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM:
Ce3epitope <400> SEQUENCE: 207 Cys Gly Gly Val Asn Leu Thr
Trp Ser Arg Ala Ser Gly 1 5 10 <210> SEQ ID NO 208
<211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM:
Ce3mimotope <400> SEQUENCE: 208 Cys Gly Gly Val Asn Leu Pro
Trp Ser Phe Gly Leu Glu 1 5 10 <210> SEQ ID NO 209
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Bee venom phospholipase A2 cloning vector <400> SEQUENCE: 209
Ala Ala Ala Ser Gly Gly Cys Gly Gly 1 5 <210> SEQ ID NO 210
<211> LENGTH: 145 <212> TYPE: PRT <213> ORGANISM:
PLA2 fusion protein <400> SEQUENCE: 210 Met Ala Ile Ile Tyr
Pro Gly Thr Leu Trp Cys Gly His Gly Asn Lys 1 5 10 15 Ser Ser Gly
Pro Asn Glu Leu Gly Arg Phe Lys His Thr Asp Ala Cys 20 25 30 Cys
Arg Thr Gln Asp Met Cys Pro Asp Val Met Ser Ala Gly Glu Ser 35 40
45 Lys His Gly Leu Thr Asn Thr Ala Ser His Thr Arg Leu Ser Cys Asp
50 55 60 Cys Asp Asp Lys Phe Tyr Asp Cys Leu Lys Asn Ser Ala Asp
Thr Ile 65 70 75 80 Ser Ser Tyr Phe Val Gly Lys Met Tyr Phe Asn Leu
Ile Asp Thr Lys 85 90 95 Cys Tyr Lys Leu Glu His Pro Val Thr Gly
Cys Gly Glu Arg Thr Glu 100 105 110 Gly Arg Cys Leu His Tyr Thr Val
Asp Lys Ser Lys Pro Lys Val Tyr 115 120 125 Gln Trp Phe Asp Leu Arg
Lys Tyr Ala Ala Ala Ser Gly Gly Cys Gly 130 135 140 Gly 145
<210> SEQ ID NO 211 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Ce4mimotope <400> SEQUENCE: 211 Gly
Glu Phe Cys Ile Asn His Arg Gly Tyr Trp Val Cys Gly Asp Pro 1 5 10
15 Ala <210> SEQ ID NO 212 <211> LENGTH: 27 <212>
TYPE: PRT <213> ORGANISM: Synthetic M2 Peptide <400>
SEQUENCE: 212 Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Glu
Trp Gly Cys 1 5 10 15 Arg Cys Asn Gly Ser Ser Asp Gly Gly Gly Cys
20 25 <210> SEQ ID NO 213 <211> LENGTH: 97 <212>
TYPE: PRT <213> ORGANISM: Matrix protein M2 <400>
SEQUENCE: 213 Met Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn
Glu Trp Gly 1 5 10 15 Cys Arg Cys Asn Gly Ser Ser Asp Pro Leu Ala
Ile Ala Ala Asn Ile 20 25 30 Ile Gly Ile Leu His Leu Ile Leu Trp
Ile Leu Asp Arg Leu Phe Phe 35 40 45 Lys Cys Ile Tyr Arg Arg Phe
Lys Tyr Gly Leu Lys Gly Gly Pro Ser 50 55 60 Thr Glu Gly Val Pro
Lys Ser Met Arg Glu Glu Tyr Arg Lys Glu Gln 65 70 75 80 Gln Ser Ala
Val Asp Ala Asp Asp Gly His Phe Val Ser Ile Glu Leu 85 90 95 Glu
<210> SEQ ID NO 214 <211> LENGTH: 42 <212> TYPE:
DNA <213> ORGANISM: Oligonucleotide <400> SEQUENCE: 214
taaccgaatt caggaggtaa aaacatatgg ctatcatcta cc 42 <210> SEQ
ID NO 215 <211> LENGTH: 129 <212> TYPE: PRT <213>
ORGANISM: Bacteriophage f2 <400> SEQUENCE: 215 Ala Ser Asn
Phe Thr Gln Phe Val Leu Val Asn Asp Gly Gly Thr Gly 1 5 10 15
Asn Val Thr Val Ala Pro Ser Asn Phe Ala Asn Gly Val Ala Glu Trp 20
25 30 Ile Ser Ser Asn Ser Arg Ser Gln Ala Tyr Lys Val Thr Cys Ser
Val 35 40 45 Arg Gln Ser Ser Ala Gln Asn Arg Lys Tyr Thr Ile Lys
Val Glu Val 50 55 60 Pro Lys Val Ala Thr Gln Thr Val Gly Gly Val
Glu Leu Pro Val Ala 65 70 75 80 Ala Trp Arg Ser Tyr Leu Asn Leu Glu
Leu Thr Ile Pro Ile Phe Ala 85 90 95 Thr Asn Ser Asp Cys Glu Leu
Ile Val Lys Ala Met Gln Gly Leu Leu 100 105 110 Lys Asp Gly Asn Pro
Ile Pro Ser Ala Ile Ala Ala Asn Ser Gly Ile 115 120 125 Tyr
<210> SEQ ID NO 216 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Circular Mimotope <400> SEQUENCE:
216 Gly Glu Phe Cys Ile Asn His Arg Gly Tyr Trp Val Cys Gly Asp Pro
1 5 10 15 Ala <210> SEQ ID NO 217 <211> LENGTH: 329
<212> TYPE: PRT <213> ORGANISM: Bacteriophage Q-beta
<400> SEQUENCE: 217 Met Ala Lys Leu Glu Thr Val Thr Leu Gly
Asn Ile Gly Lys Asp Gly 1 5 10 15 Lys Gln Thr Leu Val Leu Asn Pro
Arg Gly Val Asn Pro Thr Asn Gly 20 25 30 Val Ala Ser Leu Ser Gln
Ala Gly Ala Val Pro Ala Leu Glu Lys Arg 35 40 45 Val Thr Val Ser
Val Ser Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys 50 55 60 Val Gln
Val Lys Ile Gln Asn Pro Thr Ala Cys Thr Ala Asn Gly Ser 65 70 75 80
Cys Asp Pro Ser Val Thr Arg Gln Ala Tyr Ala Asp Val Thr Phe Ser 85
90 95 Phe Thr Gln Tyr Ser Thr Asp Glu Glu Arg Ala Phe Val Arg Thr
Glu 100 105 110 Leu Ala Ala Leu Leu Ala Ser Pro Leu Leu Ile Asp Ala
Ile Asp Gln 115 120 125 Leu Asn Pro Ala Tyr Trp Thr Leu Leu Ile Ala
Gly Gly Gly Ser Gly 130 135 140 Ser Lys Pro Asp Pro Val Ile Pro Asp
Pro Pro Ile Asp Pro Pro Pro 145 150 155 160 Gly Thr Gly Lys Tyr Thr
Cys Pro Phe Ala Ile Trp Ser Leu Glu Glu 165 170 175 Val Tyr Glu Pro
Pro Thr Lys Asn Arg Pro Trp Pro Ile Tyr Asn Ala 180 185 190 Val Glu
Leu Gln Pro Arg Glu Phe Asp Val Ala Leu Lys Asp Leu Leu 195 200 205
Gly Asn Thr Lys Trp Arg Asp Trp Asp Ser Arg Leu Ser Tyr Thr Thr 210
215 220 Phe Arg Gly Cys Arg Gly Asn Gly Tyr Ile Asp Leu Asp Ala Thr
Tyr 225 230 235 240 Leu Ala Thr Asp Gln Ala Met Arg Asp Gln Lys Tyr
Asp Ile Arg Glu 245 250 255 Gly Lys Lys Pro Gly Ala Phe Gly Asn Ile
Glu Arg Phe Ile Tyr Leu 260 265 270 Lys Ser Ile Asn Ala Tyr Cys Ser
Leu Ser Asp Ile Ala Ala Tyr His 275 280 285 Ala Asp Gly Val Ile Val
Gly Phe Trp Arg Asp Pro Ser Ser Gly Gly 290 295 300 Ala Ile Pro Phe
Asp Phe Thr Lys Phe Asp Lys Thr Lys Cys Pro Ile 305 310 315 320 Gln
Ala Val Ile Val Val Pro Arg Ala 325 <210> SEQ ID NO 218
<211> LENGTH: 770 <212> TYPE: PRT <213> ORGANISM:
Amyloid-Beta Protein (Homo Sapiens) <400> SEQUENCE: 218 Met
Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg 1 5 10
15 Ala Leu Glu Val Pro Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro
20 25 30 Gln Ile Ala Met Phe Cys Gly Arg Leu Asn Met His Met Asn
Val Gln 35 40 45 Asn Gly Lys Trp Asp Ser Asp Pro Ser Gly Thr Lys
Thr Cys Ile Asp 50 55 60 Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln
Glu Val Tyr Pro Glu Leu 65 70 75 80 Gln Ile Thr Asn Val Val Glu Ala
Asn Gln Pro Val Thr Ile Gln Asn 85 90 95 Trp Cys Lys Arg Gly Arg
Lys Gln Cys Lys Thr His Pro His Phe Val 100 105 110 Ile Pro Tyr Arg
Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu 115 120 125 Val Pro
Asp Lys Cys Lys Phe Leu His Gln Glu Arg Met Asp Val Cys 130 135 140
Glu Thr His Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu 145
150 155 160 Lys Ser Thr Asn Leu His Asp Tyr Gly Met Leu Leu Pro Cys
Gly Ile 165 170 175 Asp Lys Phe Arg Gly Val Glu Phe Val Cys Cys Pro
Leu Ala Glu Glu 180 185 190 Ser Asp Asn Val Asp Ser Ala Asp Ala Glu
Glu Asp Asp Ser Asp Val 195 200 205 Trp Trp Gly Gly Ala Asp Thr Asp
Tyr Ala Asp Gly Ser Glu Asp Lys 210 215 220 Val Val Glu Val Ala Glu
Glu Glu Glu Val Ala Glu Val Glu Glu Glu 225 230 235 240 Glu Ala Asp
Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu 245 250 255 Glu
Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile 260 265
270 Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Val Arg
275 280 285 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala
Met Ile 290 295 300 Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys
Ala Pro Phe Phe 305 310 315 320 Tyr Gly Gly Cys Gly Gly Asn Arg Asn
Asn Phe Asp Thr Glu Glu Tyr 325 330 335 Cys Met Ala Val Cys Gly Ser
Ala Met Ser Gln Ser Leu Leu Lys Thr 340 345 350 Thr Gln Glu Pro Leu
Ala Arg Asp Pro Val Lys Leu Pro Thr Thr Ala 355 360 365 Ala Ser Thr
Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro Gly Asp 370 375 380 Glu
Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala 385 390
395 400 Lys His Arg Glu Arg Met Ser Gln Val Met Arg Glu Trp Glu Glu
Ala 405 410 415 Glu Arg Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys
Ala Val Ile 420 425 430 Gln His Phe Gln Glu Lys Val Glu Ser Leu Glu
Gln Glu Ala Ala Asn 435 440 445 Glu Arg Gln Gln Leu Val Glu Thr His
Met Ala Arg Val Glu Ala Met 450 455 460 Leu Asn Asp Arg Arg Arg Leu
Ala Leu Glu Asn Tyr Ile Thr Ala Leu 465 470 475 480 Gln Ala Val Pro
Pro Arg Pro Arg His Val Phe Asn Met Leu Lys Lys 485 490 495 Tyr Val
Arg Ala Glu Gln Lys Asp Arg Gln His Thr Leu Lys His Phe 500 505 510
Glu His Val Arg Met Val Asp Pro Lys Lys Ala Ala Gln Ile Arg Ser 515
520 525 Gln Val Met Thr His Leu Arg Val Ile Tyr Glu Arg Met Asn Gln
Ser 530 535 540 Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Glu
Ile Gln Asp 545 550 555 560 Glu Val Asp Glu Leu Leu Gln Lys Glu Gln
Asn Tyr Ser Asp Asp Val 565 570 575 Leu Ala Asn Met Ile Ser Glu Pro
Arg Ile Ser Tyr Gly Asn Asp Ala 580 585 590 Leu Met Pro Ser Leu Thr
Glu Thr Lys Thr Thr Val Glu Leu Leu Pro 595 600 605 Val Asn Gly Glu
Phe Ser Leu Asp Asp Leu Gln Pro Trp His Ser Phe 610 615 620 Gly Ala
Asp Ser Val Pro Ala Asn Thr Glu Asn Glu Val Glu Pro Val 625 630 635
640 Asp Ala Arg Pro Ala Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser
645 650 655 Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys
Met Asp 660 665 670 Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His
His Gln Lys Leu 675 680 685 Val Phe Phe Ala Glu Asp Val Gly Ser Asn
Lys Gly Ala Ile Ile Gly 690 695 700 Leu Met Val Gly Gly Val Val Ile
Ala Thr Val Ile Val Ile Thr Leu 705 710 715 720
Val Met Leu Lys Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val 725
730 735 Glu Val Asp Ala Ala Val Thr Pro Glu Glu Arg His Leu Ser Lys
Met 740 745 750 Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys Phe Phe
Glu Gln Met 755 760 765 Gln Asn 770 <210> SEQ ID NO 219
<211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM:
Beta-Amyloid Peptide Precursor (Homo Sapiens) <400> SEQUENCE:
219 Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys
1 5 10 15 Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His
His Gln 20 25 30 Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn
Lys Gly Ala Ile 35 40 45 Ile Gly Leu Met Val Gly Gly Val Val Ile
Ala Thr Val Ile Ile Ile 50 55 60 Thr Leu Val Met Leu Lys Lys Gln
Tyr Thr Ser Asn His His Gly Val 65 70 75 80 Val Glu <210> SEQ
ID NO 220 <211> LENGTH: 42 <212> TYPE: PRT <213>
ORGANISM: Amyloid Beta Peptide <400> SEQUENCE: 220 Asp Ala
Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 1 5 10 15
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 20
25 30 Gly Leu Met Val Gly Gly Val Val Ile Ala 35 40 <210> SEQ
ID NO 221 <211> LENGTH: 249 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 221 Tyr Phe Arg Ala
Gln Met Asp Pro Asn Arg Ile Ser Glu Asp Gly Thr 1 5 10 15 His Cys
Ile Tyr Arg Ile Leu Arg Leu His Glu Asn Ala Asp Phe Gln 20 25 30
Asp Thr Thr Leu Glu Ser Gln Asp Thr Lys Leu Ile Pro Asp Ser Cys 35
40 45 Arg Arg Ile Lys Gln Ala Phe Gln Gly Ala Val Gln Lys Glu Leu
Gln 50 55 60 His Ile Val Gly Ser Gln His Ile Arg Ala Glu Lys Ala
Met Val Asp 65 70 75 80 Gly Ser Trp Leu Asp Leu Ala Lys Arg Ser Lys
Leu Glu Ala Gln Pro 85 90 95 Phe Ala His Leu Thr Ile Asn Ala Thr
Asp Ile Pro Ser Gly Ser His 100 105 110 Lys Val Ser Leu Ser Ser Trp
Tyr His Asp Arg Gly Trp Ala Lys Ile 115 120 125 Ser Asn Met Thr Phe
Ser Asn Gly Lys Leu Ile Val Asn Gln Asp Gly 130 135 140 Phe Tyr Tyr
Leu Tyr Ala Asn Ile Cys Phe Arg His His Glu Thr Ser 145 150 155 160
Gly Asp Leu Ala Thr Glu Tyr Leu Gln Leu Met Val Tyr Val Thr Lys 165
170 175 Thr Ser Ile Lys Ile Pro Ser Ser His Thr Leu Met Lys Gly Gly
Ser 180 185 190 Thr Lys Tyr Trp Ser Gly Asn Ser Glu Phe His Phe Tyr
Ser Ile Asn 195 200 205 Val Gly Gly Phe Phe Lys Leu Arg Ser Gly Glu
Glu Ile Ser Ile Glu 210 215 220 Val Ser Asn Pro Ser Leu Leu Asp Pro
Asp Gln Asp Ala Thr Tyr Phe 225 230 235 240 Gly Ala Phe Lys Val Arg
Asp Ile Asp 245 <210> SEQ ID NO 222 <211> LENGTH: 244
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 222 Met Asp Pro Asn Arg Ile Ser Glu Asp Gly
Thr His Cys Ile Tyr Arg 1 5 10 15 Ile Leu Arg Leu His Glu Asn Ala
Asp Phe Gln Asp Thr Thr Leu Glu 20 25 30 Ser Gln Asp Thr Lys Leu
Ile Pro Asp Ser Cys Arg Arg Ile Lys Gln 35 40 45 Ala Phe Gln Gly
Ala Val Gln Lys Glu Leu Gln His Ile Val Gly Ser 50 55 60 Gln His
Ile Arg Ala Glu Lys Ala Met Val Asp Gly Ser Trp Leu Asp 65 70 75 80
Leu Ala Lys Arg Ser Lys Leu Glu Ala Gln Pro Phe Ala His Leu Thr 85
90 95 Ile Asn Ala Thr Asp Ile Pro Ser Gly Ser His Lys Val Ser Leu
Ser 100 105 110 Ser Trp Tyr His Asp Arg Gly Trp Ala Lys Ile Ser Asn
Met Thr Phe 115 120 125 Ser Asn Gly Lys Leu Ile Val Asn Gln Asp Gly
Phe Tyr Tyr Leu Tyr 130 135 140 Ala Asn Ile Cys Phe Arg His His Glu
Thr Ser Gly Asp Leu Ala Thr 145 150 155 160 Glu Tyr Leu Gln Leu Met
Val Tyr Val Thr Lys Thr Ser Ile Lys Ile 165 170 175 Pro Ser Ser His
Thr Leu Met Lys Gly Gly Ser Thr Lys Tyr Trp Ser 180 185 190 Gly Asn
Ser Glu Phe His Phe Tyr Ser Ile Asn Val Gly Gly Phe Phe 195 200 205
Lys Leu Arg Ser Gly Glu Glu Ile Ser Ile Glu Val Ser Asn Pro Ser 210
215 220 Leu Leu Asp Pro Asp Gln Asp Ala Thr Tyr Phe Gly Ala Phe Lys
Val 225 230 235 240 Arg Asp Ile Asp <210> SEQ ID NO 223
<211> LENGTH: 247 <212> TYPE: PRT <213> ORGANISM:
Mus musculus <400> SEQUENCE: 223 Tyr Phe Arg Ala Gln Met Asp
Pro Asn Arg Ile Ser Glu Asp Ser Thr 1 5 10 15 His Cys Phe Tyr Arg
Ile Leu Arg Leu His Glu Asn Ala Gly Leu Gln 20 25 30 Asp Ser Thr
Leu Glu Ser Glu Asp Thr Leu Pro Asp Ser Cys Arg Arg 35 40 45 Met
Lys Gln Ala Phe Gln Gly Ala Val Gln Lys Glu Leu Gln His Ile 50 55
60 Val Gly Pro Gln Arg Phe Ser Gly Ala Pro Ala Met Met Glu Gly Ser
65 70 75 80 Trp Leu Asp Val Ala Gln Arg Gly Lys Pro Glu Ala Gln Pro
Phe Ala 85 90 95 His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser Gly
Ser His Lys Val 100 105 110 Thr Leu Ser Ser Trp Tyr His Asp Arg Gly
Trp Ala Lys Ile Ser Asn 115 120 125 Met Thr Leu Ser Asn Gly Lys Leu
Arg Val Asn Gln Asp Gly Phe Tyr 130 135 140 Tyr Leu Tyr Ala Asn Ile
Cys Phe Arg His His Glu Thr Ser Gly Ser 145 150 155 160 Val Pro Thr
Asp Tyr Leu Gln Leu Met Val Tyr Val Val Lys Thr Ser 165 170 175 Ile
Lys Ile Pro Ser Ser His Asn Leu Met Lys Gly Gly Ser Thr Lys 180 185
190 Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile Asn Val Gly
195 200 205 Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser Ile Gln
Val Ser 210 215 220 Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr
Tyr Phe Gly Ala 225 230 235 240 Phe Lys Val Gln Asp Ile Asp 245
<210> SEQ ID NO 224 <211> LENGTH: 199 <212> TYPE:
PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 224
Met Lys Gln Ala Phe Gln Gly Ala Val Gln Lys Glu Leu Gln His Ile 1 5
10 15 Val Gly Pro Gln Arg Phe Ser Gly Ala Pro Ala Met Met Glu Gly
Ser 20 25 30 Trp Leu Asp Val Ala Gln Arg Gly Lys Pro Glu Ala Gln
Pro Phe Ala 35 40 45 His Leu Thr Ile Asn Ala Ala Ser Ile Pro Ser
Gly Ser His Lys Val 50 55 60 Thr Leu Ser Ser Trp Tyr His Asp Arg
Gly Trp Ala Lys Ile Ser Asn 65 70 75 80 Met Thr Leu Ser Asn Gly Lys
Leu Arg Val Asn Gln Asp Gly Phe Tyr 85 90 95 Tyr Leu Tyr Ala Asn
Ile Cys Phe Arg His His Glu Thr Ser Gly Ser 100 105 110 Val Pro Thr
Asp Tyr Leu Gln Leu Met Val Tyr Val Val Lys Thr Ser
115 120 125 Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys Gly Gly Ser
Thr Lys 130 135 140 Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr Ser
Ile Asn Val Gly 145 150 155 160 Gly Phe Phe Lys Leu Arg Ala Gly Glu
Glu Ile Ser Ile Gln Val Ser 165 170 175 Asn Pro Ser Leu Leu Asp Pro
Asp Gln Asp Ala Thr Tyr Phe Gly Ala 180 185 190 Phe Lys Val Gln Asp
Ile Asp 195 <210> SEQ ID NO 225 <211> LENGTH: 114
<212> TYPE: PRT <213> ORGANISM: Rattus sp. <400>
SEQUENCE: 225 Pro Met Phe Ile Val Asn Thr Asn Val Pro Arg Ala Ser
Val Pro Glu 1 5 10 15 Gly Phe Leu Ser Glu Leu Thr Gln Gln Leu Ala
Gln Ala Thr Gly Lys 20 25 30 Pro Ala Gln Tyr Ile Ala Val His Val
Val Pro Asp Gln Leu Met Thr 35 40 45 Phe Ser Gly Thr Ser Asp Pro
Cys Ala Leu Cys Ser Leu His Ser Ile 50 55 60 Gly Lys Ile Gly Gly
Ala Gln Asn Arg Asn Tyr Ser Lys Leu Leu Cys 65 70 75 80 Gly Leu Leu
Ser Asp Arg Leu His Ile Ser Pro Asp Arg Val Tyr Ile 85 90 95 Asn
Tyr Tyr Asp Met Asn Ala Ala Asn Val Gly Trp Asn Gly Ser Thr 100 105
110 Phe Ala <210> SEQ ID NO 226 <211> LENGTH: 114
<212> TYPE: PRT <213> ORGANISM: Mus musculus
<400> SEQUENCE: 226 Pro Met Phe Ile Val Asn Thr Asn Val Pro
Arg Ala Ser Val Pro Glu 1 5 10 15 Gly Phe Leu Ser Glu Leu Thr Gln
Gln Leu Ala Gln Ala Thr Gly Lys 20 25 30 Pro Ala Gln Tyr Ile Ala
Val His Val Val Pro Asp Gln Leu Met Thr 35 40 45 Phe Ser Gly Thr
Asn Asp Pro Cys Ala Leu Cys Ser Leu His Ser Ile 50 55 60 Gly Lys
Ile Gly Gly Ala Gln Asn Arg Asn Tyr Ser Lys Leu Leu Cys 65 70 75 80
Gly Leu Leu Ser Asp Arg Leu His Ile Ser Pro Asp Arg Val Tyr Ile 85
90 95 Asn Tyr Tyr Asp Met Asn Ala Ala Asn Val Gly Trp Asn Gly Ser
Thr 100 105 110 Phe Ala <210> SEQ ID NO 227 <211>
LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Homo
sapiens <400> SEQUENCE: 227 Pro Met Phe Ile Val Asn Thr Asn
Val Pro Arg Ala Ser Val Pro Asp 1 5 10 15 Gly Phe Leu Ser Glu Leu
Thr Gln Gln Leu Ala Gln Ala Thr Gly Lys 20 25 30 Pro Pro Gln Tyr
Ile Ala Val His Val Val Pro Asp Gln Leu Met Ala 35 40 45 Phe Gly
Gly Ser Ser Glu Pro Cys Ala Leu Cys Ser Leu His Ser Ile 50 55 60
Gly Lys Ile Gly Gly Ala Gln Asn Arg Ser Tyr Ser Lys Leu Leu Cys 65
70 75 80 Gly Leu Leu Ala Glu Arg Leu Arg Ile Ser Pro Asp Arg Val
Tyr Ile 85 90 95 Asn Tyr Tyr Asp Met Asn Ala Ala Asn Val Gly Trp
Asn Asn Ser Thr 100 105 110 Phe Ala <210> SEQ ID NO 228
<211> LENGTH: 155 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 228 Met Thr Pro Gly Lys Thr Ser
Leu Val Ser Leu Leu Leu Leu Leu Ser 1 5 10 15 Leu Glu Ala Ile Val
Lys Ala Gly Ile Thr Ile Pro Arg Asn Pro Gly 20 25 30 Cys Pro Asn
Ser Glu Asp Lys Asn Phe Pro Arg Thr Val Met Val Asn 35 40 45 Leu
Asn Ile His Asn Arg Asn Thr Asn Thr Asn Pro Lys Arg Ser Ser 50 55
60 Asp Tyr Tyr Asn Arg Ser Thr Ser Pro Trp Asn Leu His Arg Asn Glu
65 70 75 80 Asp Pro Glu Arg Tyr Pro Ser Val Ile Trp Glu Ala Lys Cys
Arg His 85 90 95 Leu Gly Cys Ile Asn Ala Asp Gly Asn Val Asp Tyr
His Met Asn Ser 100 105 110 Val Pro Ile Gln Gln Glu Ile Leu Val Leu
Arg Arg Glu Pro Pro His 115 120 125 Cys Pro Asn Ser Phe Arg Leu Glu
Lys Ile Leu Val Ser Val Gly Cys 130 135 140 Thr Cys Val Thr Pro Ile
Val His His Val Ala 145 150 155 <210> SEQ ID NO 229
<211> LENGTH: 158 <212> TYPE: PRT <213> ORGANISM:
Mus musculus <400> SEQUENCE: 229 Met Ser Pro Gly Arg Ala Ser
Ser Val Ser Leu Met Leu Leu Leu Leu 1 5 10 15 Leu Ser Leu Ala Ala
Thr Val Lys Ala Ala Ala Ile Ile Pro Gln Ser 20 25 30 Ser Ala Cys
Pro Asn Thr Glu Ala Lys Asp Phe Leu Gln Asn Val Lys 35 40 45 Val
Asn Leu Lys Val Phe Asn Ser Leu Gly Ala Lys Val Ser Ser Arg 50 55
60 Arg Pro Ser Asp Tyr Leu Asn Arg Ser Thr Ser Pro Trp Thr Leu His
65 70 75 80 Arg Asn Glu Asp Pro Asp Arg Tyr Pro Ser Val Ile Trp Glu
Ala Gln 85 90 95 Cys Arg His Gln Arg Cys Val Asn Ala Glu Gly Lys
Leu Asp His His 100 105 110 Met Asn Ser Val Leu Ile Gln Gln Glu Ile
Leu Val Leu Lys Arg Glu 115 120 125 Pro Glu Ser Cys Pro Phe Thr Phe
Arg Val Glu Lys Met Leu Val Gly 130 135 140 Val Gly Cys Thr Cys Val
Ala Ser Ile Val Arg Gln Ala Ala 145 150 155 <210> SEQ ID NO
230 <211> LENGTH: 132 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 230 Met Ala Leu Leu
Leu Thr Thr Val Ile Ala Leu Thr Cys Leu Gly Gly 1 5 10 15 Phe Ala
Ser Pro Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Glu Leu 20 25 30
Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys 35
40 45 Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr
Cys 50 55 60 Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser
Ala Ile Glu 65 70 75 80 Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro
His Lys Val Ser Ala 85 90 95 Gly Gln Phe Ser Ser Leu His Val Arg
Asp Thr Lys Ile Glu Val Ala 100 105 110 Gln Phe Val Lys Asp Leu Leu
Leu His Leu Lys Lys Leu Phe Arg Glu 115 120 125 Gly Arg Phe Asn 130
<210> SEQ ID NO 231 <211> LENGTH: 112 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 231
Gly Pro Val Pro Pro Ser Thr Ala Leu Arg Glu Leu Ile Glu Glu Leu 1 5
10 15 Val Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser
Met 20 25 30 Val Trp Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala
Ala Leu Glu 35 40 45 Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile
Glu Lys Thr Gln Arg 50 55 60 Met Leu Ser Gly Phe Cys Pro His Lys
Val Ser Ala Gly Gln Phe Ser 65 70 75 80 Ser Leu His Val Arg Asp Thr
Lys Ile Glu Val Ala Gln Phe Val Lys 85 90 95 Asp Leu Leu Leu His
Leu Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn 100 105 110
<210> SEQ ID NO 232 <211> LENGTH: 111 <212> TYPE:
PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 232
Gly Pro Val Pro Arg Ser Val Ser Leu Pro Leu Thr Leu Lys Glu Leu 1 5
10 15 Ile Glu Glu Leu Ser Asn Ile Thr Gln Asp Gln Thr Pro Leu Cys
Asn 20 25 30 Gly Ser Met Val Trp Ser Val Asp Leu Ala Ala Gly Gly
Phe Cys Val 35 40 45 Ala Leu Asp Ser Leu Thr Asn Ile Ser Asn Cys
Asn Ala Ile Tyr Arg 50 55 60 Thr Gln Arg Ile Leu His Gly Leu Cys
Asn Arg Lys Ala Pro Thr Thr 65 70 75 80 Val Ser Ser Leu Pro Asp Thr
Lys Ile Glu Val Ala His Phe Ile Thr 85 90 95 Lys Leu Leu Ser Tyr
Thr Lys Gln Leu Phe Arg His Gly Pro Phe 100 105 110 <210> SEQ
ID NO 233 <211> LENGTH: 134 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 233 Met Arg Met Leu
Leu His Leu Ser Leu Leu Ala Leu Gly Ala Ala Tyr 1 5 10 15 Val Tyr
Ala Ile Pro Thr Glu Ile Pro Thr Ser Ala Leu Val Lys Glu 20 25 30
Thr Leu Ala Leu Leu Ser Thr His Arg Thr Leu Leu Ile Ala Asn Glu 35
40 45 Thr Leu Arg Ile Pro Val Pro Val His Lys Asn His Gln Leu Cys
Thr 50 55 60 Glu Glu Ile Phe Gln Gly Ile Gly Thr Leu Glu Ser Gln
Thr Val Gln 65 70 75 80 Gly Gly Thr Val Glu Arg Leu Phe Lys Asn Leu
Ser Leu Ile Lys Lys 85 90 95 Tyr Ile Asp Gly Gln Lys Lys Lys Cys
Gly Glu Glu Arg Arg Arg Val 100 105 110 Asn Gln Phe Leu Asp Tyr Leu
Gln Glu Phe Leu Gly Val Met Asn Thr 115 120 125 Glu Trp Ile Ile Glu
Ser 130 <210> SEQ ID NO 234 <211> LENGTH: 115
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 234 Ile Pro Thr Glu Ile Pro Thr Ser Ala Leu
Val Lys Glu Thr Leu Ala 1 5 10 15 Leu Leu Ser Thr His Arg Thr Leu
Leu Ile Ala Asn Glu Thr Leu Arg 20 25 30 Ile Pro Val Pro Val His
Lys Asn His Gln Leu Cys Thr Glu Glu Ile 35 40 45 Phe Gln Gly Ile
Gly Thr Leu Glu Ser Gln Thr Val Gln Gly Gly Thr 50 55 60 Val Glu
Arg Leu Phe Lys Asn Leu Ser Leu Ile Lys Lys Tyr Ile Asp 65 70 75 80
Gly Gln Lys Lys Lys Cys Gly Glu Glu Arg Arg Arg Val Asn Gln Phe 85
90 95 Leu Asp Tyr Leu Gln Glu Phe Leu Gly Val Met Asn Thr Glu Trp
Ile 100 105 110 Ile Glu Ser 115 <210> SEQ ID NO 235
<211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM:
Mus musculus <400> SEQUENCE: 235 Met Glu Ile Pro Met Ser Thr
Val Val Lys Glu Thr Leu Thr Gln Leu 1 5 10 15 Ser Ala His Arg Ala
Leu Leu Thr Ser Asn Glu Thr Met Arg Leu Pro 20 25 30 Val Pro Thr
His Lys Asn His Gln Leu Cys Ile Gly Glu Ile Phe Gln 35 40 45 Gly
Leu Asp Ile Leu Lys Asn Gln Thr Val Arg Gly Gly Thr Val Glu 50 55
60 Met Leu Phe Gln Asn Leu Ser Leu Ile Lys Lys Tyr Ile Asp Arg Gln
65 70 75 80 Lys Glu Lys Cys Gly Glu Glu Arg Arg Arg Thr Arg Gln Phe
Leu Asp 85 90 95 Tyr Leu Gln Glu Phe Leu Gly Val Met Ser Thr Glu
Trp Ala Met Glu 100 105 110 Gly <210> SEQ ID NO 236
<211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 236 Ser Asp Gly Gly Ala Gln Asp
Cys Cys Leu Lys Tyr Ser Gln Arg Lys 1 5 10 15 Ile Pro Ala Lys Val
Val Arg Ser Tyr Arg Lys Gln Glu Pro Ser Leu 20 25 30 Gly Cys Ser
Ile Pro Ala Ile Leu Phe Leu Pro Arg Lys Arg Ser Gln 35 40 45 Ala
Glu Leu Cys Ala Asp Pro Lys Glu Leu Trp Val Gln Gln Leu Met 50 55
60 Gln His Leu Asp Lys Thr Pro Ser Pro Gln Lys Pro Ala Gln Gly Cys
65 70 75 80 Arg Lys Asp Arg Gly Ala Ser Lys Thr Gly Lys Lys Gly Lys
Gly Ser 85 90 95 Lys Gly Cys Lys Arg Thr Glu Arg Ser Gln Thr Pro
Lys Gly Pro 100 105 110 <210> SEQ ID NO 237 <211>
LENGTH: 110 <212> TYPE: PRT <213> ORGANISM: Mus
musculus <400> SEQUENCE: 237 Ser Asp Gly Gly Gly Gln Asp Cys
Cys Leu Lys Tyr Ser Gln Lys Lys 1 5 10 15 Ile Pro Tyr Ser Ile Val
Arg Gly Tyr Arg Lys Gln Glu Pro Ser Leu 20 25 30 Gly Cys Pro Ile
Pro Ala Ile Leu Phe Ser Pro Arg Lys His Ser Lys 35 40 45 Pro Glu
Leu Cys Ala Asn Pro Glu Glu Gly Trp Val Gln Asn Leu Met 50 55 60
Arg Arg Leu Asp Gln Pro Pro Ala Pro Gly Lys Gln Ser Pro Gly Cys 65
70 75 80 Arg Lys Asn Arg Gly Thr Ser Lys Ser Gly Lys Lys Gly Lys
Gly Ser 85 90 95 Lys Gly Cys Lys Arg Thr Glu Gln Thr Gln Pro Ser
Arg Gly 100 105 110 <210> SEQ ID NO 238 <211> LENGTH:
74 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 238 Asp Gly Lys Pro Val Ser Leu Ser Tyr Arg
Cys Pro Cys Arg Phe Phe 1 5 10 15 Glu Ser His Val Ala Arg Ala Asn
Val Lys His Leu Lys Ile Leu Asn 20 25 30 Thr Pro Asn Cys Ala Leu
Gln Ile Val Ala Arg Leu Lys Asn Asn Asn 35 40 45 Arg Gln Val Cys
Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu 50 55 60 Glu Lys
Ala Leu Asn Lys Arg Phe Lys Met 65 70 <210> SEQ ID NO 239
<211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM:
Mus musculus <400> SEQUENCE: 239 Asp Gly Lys Pro Val Ser Leu
Ser Tyr Arg Cys Pro Cys Arg Phe Phe 1 5 10 15 Glu Ser His Ile Ala
Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn 20 25 30 Thr Pro Asn
Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn 35 40 45 Arg
Gln Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu 50 55
60 Glu Lys Ala Leu Asn Lys 65 70 <210> SEQ ID NO 240
<211> LENGTH: 109 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 240 Met Lys Phe Ile Ser Thr Ser
Leu Leu Leu Met Leu Leu Val Ser Ser 1 5 10 15 Leu Ser Pro Val Gln
Gly Val Leu Glu Val Tyr Tyr Thr Ser Leu Arg 20 25 30 Cys Arg Cys
Val Gln Glu Ser Ser Val Phe Ile Pro Arg Arg Phe Ile 35 40 45 Asp
Arg Ile Gln Ile Leu Pro Arg Gly Asn Gly Cys Pro Arg Lys Glu 50 55
60 Ile Ile Val Trp Lys Lys Asn Lys Ser Ile Val Cys Val Asp Pro
Gln
65 70 75 80 Ala Glu Trp Ile Gln Arg Met Met Glu Val Leu Arg Lys Arg
Ser Ser 85 90 95 Ser Thr Leu Pro Val Pro Val Phe Lys Arg Lys Ile
Pro 100 105 <210> SEQ ID NO 241 <211> LENGTH: 109
<212> TYPE: PRT <213> ORGANISM: Mus musculus
<400> SEQUENCE: 241 Met Arg Leu Ser Thr Ala Thr Leu Leu Leu
Leu Leu Ala Ser Cys Leu 1 5 10 15 Ser Pro Gly His Gly Ile Leu Glu
Ala His Tyr Thr Asn Leu Lys Cys 20 25 30 Arg Cys Ser Gly Val Ile
Ser Thr Val Val Gly Leu Asn Ile Ile Asp 35 40 45 Arg Ile Gln Val
Thr Pro Pro Gly Asn Gly Cys Pro Lys Thr Glu Val 50 55 60 Val Ile
Trp Thr Lys Met Lys Lys Val Ile Cys Val Asn Pro Arg Ala 65 70 75 80
Lys Trp Leu Gln Arg Leu Leu Arg His Val Gln Ser Lys Ser Leu Ser 85
90 95 Ser Thr Pro Gln Ala Pro Val Ser Lys Arg Arg Ala Ala 100 105
<210> SEQ ID NO 242 <211> LENGTH: 97 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 242
Met Lys Val Ser Ala Ala Leu Leu Trp Leu Leu Leu Ile Ala Ala Ala 1 5
10 15 Phe Ser Pro Gln Gly Leu Ala Gly Pro Ala Ser Val Pro Thr Thr
Cys 20 25 30 Cys Phe Asn Leu Ala Asn Arg Lys Ile Pro Leu Gln Arg
Leu Glu Ser 35 40 45 Tyr Arg Arg Ile Thr Ser Gly Lys Cys Pro Gln
Lys Ala Val Ile Phe 50 55 60 Lys Thr Lys Leu Ala Lys Asp Ile Cys
Ala Asp Pro Lys Lys Lys Trp 65 70 75 80 Val Gln Asp Ser Met Lys Tyr
Leu Asp Gln Lys Ser Pro Thr Pro Lys 85 90 95 Pro <210> SEQ ID
NO 243 <211> LENGTH: 119 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 243 Met Ala Gly Leu
Met Thr Ile Val Thr Ser Leu Leu Phe Leu Gly Val 1 5 10 15 Cys Ala
His His Ile Ile Pro Thr Gly Ser Val Val Ile Pro Ser Pro 20 25 30
Cys Cys Met Phe Phe Val Ser Lys Arg Ile Pro Glu Asn Arg Val Val 35
40 45 Ser Tyr Gln Leu Ser Ser Arg Ser Thr Cys Leu Lys Ala Gly Val
Ile 50 55 60 Phe Thr Thr Lys Lys Gly Gln Gln Phe Cys Gly Asp Pro
Lys Gln Glu 65 70 75 80 Trp Val Gln Arg Tyr Met Lys Asn Leu Asp Ala
Lys Gln Lys Lys Ala 85 90 95 Ser Pro Arg Ala Arg Ala Val Ala Val
Lys Gly Pro Val Gln Arg Tyr 100 105 110 Pro Gly Asn Gln Thr Thr Cys
115 <210> SEQ ID NO 244 <211> LENGTH: 94 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
244 Met Met Gly Leu Ser Leu Ala Ser Ala Val Leu Leu Ala Ser Leu Leu
1 5 10 15 Ser Leu His Leu Gly Thr Ala Thr Arg Gly Ser Asp Ile Ser
Lys Thr 20 25 30 Cys Cys Phe Gln Tyr Ser His Lys Pro Leu Pro Trp
Thr Trp Val Arg 35 40 45 Ser Tyr Glu Phe Thr Ser Asn Ser Cys Ser
Gln Arg Ala Val Ile Phe 50 55 60 Thr Thr Lys Arg Gly Lys Lys Val
Cys Thr His Pro Arg Lys Lys Trp 65 70 75 80 Val Gln Lys Tyr Ile Ser
Leu Leu Lys Thr Pro Lys Gln Leu 85 90 <210> SEQ ID NO 245
<211> LENGTH: 97 <212> TYPE: PRT <213> ORGANISM:
Mus musculus <400> SEQUENCE: 245 Met Gln Ser Ser Thr Ala Leu
Leu Phe Leu Leu Leu Thr Val Thr Ser 1 5 10 15 Phe Thr Ser Gln Val
Leu Ala His Pro Gly Ser Ile Pro Thr Ser Cys 20 25 30 Cys Phe Ile
Met Thr Ser Lys Lys Ile Pro Asn Thr Leu Leu Lys Ser 35 40 45 Tyr
Lys Arg Ile Thr Asn Asn Arg Cys Thr Leu Lys Ala Ile Val Phe 50 55
60 Lys Thr Arg Leu Gly Lys Glu Ile Cys Ala Asp Pro Lys Lys Lys Trp
65 70 75 80 Val Gln Asp Ala Thr Lys His Leu Asp Gln Lys Leu Gln Thr
Pro Lys 85 90 95 Pro <210> SEQ ID NO 246 <211> LENGTH:
119 <212> TYPE: PRT <213> ORGANISM: Mus musculus
<400> SEQUENCE: 246 Met Ala Gly Ser Ala Thr Ile Val Ala Gly
Leu Leu Leu Leu Val Ala 1 5 10 15 Cys Ala Cys Cys Ile Phe Pro Ile
Asp Ser Val Thr Ile Pro Ser Ser 20 25 30 Cys Cys Thr Ser Phe Ile
Ser Lys Lys Ile Pro Glu Asn Arg Val Val 35 40 45 Ser Tyr Gln Leu
Ala Asn Gly Ser Ile Cys Pro Lys Ala Gly Val Ile 50 55 60 Phe Ile
Thr Lys Lys Gly His Lys Ile Cys Thr Asp Pro Lys Leu Leu 65 70 75 80
Trp Val Gln Arg His Ile Gln Lys Leu Asp Ala Lys Lys Asn Gln Pro 85
90 95 Ser Lys Gly Ala Lys Ala Val Arg Thr Lys Phe Ala Val Gln Arg
Arg 100 105 110 Arg Gly Asn Ser Thr Glu Val 115 <210> SEQ ID
NO 247 <211> LENGTH: 553 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 247 Met Thr Ala Pro
Gly Ala Ala Gly Arg Cys Pro Pro Thr Thr Trp Leu 1 5 10 15 Gly Ser
Leu Leu Leu Leu Val Cys Leu Leu Ala Ser Arg Ser Ile Thr 20 25 30
Glu Glu Val Ser Glu Tyr Cys Ser His Met Ile Gly Ser Gly His Leu 35
40 45 Gln Ser Leu Gln Arg Leu Ile Asp Ser Gln Met Glu Thr Ser Cys
Gln 50 55 60 Ile Thr Phe Glu Phe Val Asp Gln Glu Gln Leu Lys Asp
Pro Val Cys 65 70 75 80 Tyr Leu Lys Lys Ala Phe Leu Leu Val Gln Asp
Ile Met Glu Asp Thr 85 90 95 Met Arg Phe Arg Asp Asn Thr Pro Asn
Ala Ile Ala Ile Val Gln Leu 100 105 110 Gln Glu Leu Ser Leu Arg Leu
Lys Ser Cys Phe Thr Lys Asp Tyr Glu 115 120 125 Glu His Asp Lys Ala
Cys Val Arg Thr Phe Tyr Glu Thr Pro Leu Gln 130 135 140 Leu Leu Glu
Lys Val Lys Asn Val Phe Asn Glu Thr Lys Asn Leu Leu 145 150 155 160
Asp Lys Asp Trp Asn Ile Phe Ser Lys Asn Cys Asn Asn Ser Phe Ala 165
170 175 Glu Cys Ser Ser Gln Asp Val Val Thr Lys Pro Asp Cys Asn Cys
Leu 180 185 190 Tyr Pro Lys Ala Ile Pro Ser Ser Asp Pro Ala Ser Val
Ser Pro His 195 200 205 Gln Pro Leu Ala Pro Ser Met Ala Pro Val Ala
Gly Leu Thr Trp Glu 210 215 220 Asp Ser Glu Gly Thr Glu Gly Ser Ser
Leu Leu Pro Gly Glu Gln Pro 225 230 235 240 Leu His Thr Val Asp Pro
Gly Ser Ala Lys Gln Arg Pro Pro Arg Ser 245 250 255 Thr Cys Gln Ser
Phe Glu Pro Pro Glu Thr Pro Val Val Lys Asp Ser 260 265 270 Thr Ile
Gly Gly Ser Pro Gln Pro Arg Pro Ser Val Gly Ala Phe Asn 275 280 285
Pro Gly Met Glu Asp Ile Leu Asp Ser Ala Met Gly Thr Asn Trp Val 290
295 300 Pro Glu Glu Ala Ser Gly Glu Ala Ser Glu Ile Pro Val Pro Gln
Gly 305 310 315 320
Thr Glu Leu Ser Pro Ser Arg Pro Gly Gly Gly Ser Met Gln Thr Glu 325
330 335 Pro Ala Arg Pro Ser Asn Phe Leu Ser Ala Ser Ser Pro Leu Pro
Ala 340 345 350 Ser Ala Lys Gly Gln Gln Pro Ala Asp Val Thr Gly Thr
Ala Leu Pro 355 360 365 Arg Val Gly Pro Val Arg Pro Thr Gly Gln Asp
Trp Asn His Thr Pro 370 375 380 Gln Lys Thr Asp His Pro Ser Ala Leu
Leu Arg Asp Pro Pro Glu Pro 385 390 395 400 Gly Ser Pro Arg Ile Ser
Ser Pro Arg Pro Gln Gly Leu Ser Asn Pro 405 410 415 Ser Thr Leu Ser
Ala Gln Pro Gln Leu Ser Arg Ser His Ser Ser Gly 420 425 430 Ser Val
Leu Pro Leu Gly Glu Leu Glu Gly Arg Arg Ser Thr Arg Asp 435 440 445
Arg Arg Ser Pro Ala Glu Pro Glu Gly Gly Pro Ala Ser Glu Gly Ala 450
455 460 Ala Arg Pro Leu Pro Arg Phe Asn Ser Val Pro Leu Thr Asp Thr
His 465 470 475 480 Glu Arg Gln Ser Glu Gly Ser Ser Ser Pro Gln Leu
Gln Glu Ser Val 485 490 495 Phe His Leu Leu Val Pro Ser Val Ile Leu
Val Leu Leu Ala Val Gly 500 505 510 Gly Leu Leu Phe Tyr Arg Trp Arg
Arg Arg Ser His Gln Glu Pro Gln 515 520 525 Arg Ala Asp Ser Pro Leu
Glu Gln Pro Glu Gly Ser Pro Leu Thr Gln 530 535 540 Asp Asp Arg Gln
Val Glu Leu Pro Val 545 550 <210> SEQ ID NO 248 <211>
LENGTH: 552 <212> TYPE: PRT <213> ORGANISM: Mus
musculus <400> SEQUENCE: 248 Met Thr Ala Arg Gly Ala Ala Gly
Arg Cys Pro Ser Ser Thr Trp Leu 1 5 10 15 Gly Ser Arg Leu Leu Leu
Val Cys Leu Leu Met Ser Arg Ser Ile Ala 20 25 30 Lys Glu Val Ser
Glu His Cys Ser His Met Ile Gly Asn Gly His Leu 35 40 45 Lys Val
Leu Gln Gln Leu Ile Asp Ser Gln Met Glu Thr Ser Cys Gln 50 55 60
Ile Ala Phe Glu Phe Val Asp Gln Glu Gln Leu Asp Asp Pro Val Cys 65
70 75 80 Tyr Leu Lys Lys Ala Phe Phe Leu Val Gln Asp Ile Ile Asp
Glu Thr 85 90 95 Met Arg Phe Lys Asp Asn Thr Pro Asn Ala Asn Ala
Thr Glu Arg Leu 100 105 110 Gln Glu Leu Ser Asn Asn Leu Asn Ser Cys
Phe Thr Lys Asp Tyr Glu 115 120 125 Glu Gln Asn Lys Ala Cys Val Arg
Thr Phe His Glu Thr Pro Leu Gln 130 135 140 Leu Leu Glu Lys Ile Lys
Asn Phe Phe Asn Glu Thr Lys Asn Leu Leu 145 150 155 160 Glu Lys Asp
Trp Asn Ile Phe Thr Lys Asn Cys Asn Asn Ser Phe Ala 165 170 175 Lys
Cys Ser Ser Arg Asp Val Val Thr Lys Pro Asp Cys Asn Cys Leu 180 185
190 Tyr Pro Lys Ala Thr Pro Ser Ser Asp Pro Ala Ser Ala Ser Pro His
195 200 205 Gln Pro Pro Ala Pro Ser Met Ala Pro Leu Ala Gly Leu Ala
Trp Asp 210 215 220 Asp Ser Gln Arg Thr Glu Gly Ser Ser Leu Leu Pro
Ser Glu Leu Pro 225 230 235 240 Leu Arg Ile Glu Asp Pro Gly Ser Ala
Lys Gln Arg Pro Pro Arg Ser 245 250 255 Thr Cys Gln Thr Leu Glu Ser
Thr Glu Gln Pro Asn His Gly Asp Arg 260 265 270 Leu Thr Glu Asp Ser
Gln Pro His Pro Ser Ala Gly Gly Pro Val Pro 275 280 285 Gly Val Glu
Asp Ile Leu Glu Ser Ser Leu Gly Thr Asn Trp Val Leu 290 295 300 Glu
Glu Ala Ser Gly Glu Ala Ser Glu Gly Phe Leu Thr Gln Glu Ala 305 310
315 320 Lys Phe Ser Pro Ser Thr Pro Val Gly Gly Ser Ile Gln Ala Glu
Thr 325 330 335 Asp Arg Pro Arg Ala Leu Ser Ala Ser Pro Phe Pro Lys
Ser Thr Glu 340 345 350 Asp Gln Lys Pro Val Asp Ile Thr Asp Arg Pro
Leu Thr Glu Val Asn 355 360 365 Pro Met Arg Pro Ile Gly Gln Thr Gln
Asn Asn Thr Pro Glu Lys Thr 370 375 380 Asp Gly Thr Ser Thr Leu Arg
Glu Asp His Gln Glu Pro Gly Ser Pro 385 390 395 400 His Ile Ala Thr
Pro Asn Pro Gln Arg Val Ser Asn Ser Ala Thr Pro 405 410 415 Val Ala
Gln Leu Leu Leu Pro Lys Ser His Ser Trp Gly Ile Val Leu 420 425 430
Pro Leu Gly Glu Leu Glu Gly Lys Arg Ser Thr Arg Asp Arg Arg Ser 435
440 445 Pro Ala Glu Leu Glu Gly Gly Ser Ala Ser Glu Gly Ala Ala Arg
Pro 450 455 460 Val Ala Arg Phe Asn Ser Ile Pro Leu Thr Asp Thr Gly
His Val Glu 465 470 475 480 Gln His Glu Gly Ser Ser Asp Pro Gln Ile
Pro Glu Ser Val Phe His 485 490 495 Leu Leu Val Pro Gly Ile Ile Leu
Val Leu Leu Thr Val Gly Gly Leu 500 505 510 Leu Phe Tyr Lys Trp Lys
Trp Arg Ser His Arg Asp Pro Gln Thr Leu 515 520 525 Asp Ser Ser Val
Gly Arg Pro Glu Asp Ser Ser Leu Thr Gln Asp Glu 530 535 540 Asp Arg
Gln Val Glu Leu Pro Val 545 550 <210> SEQ ID NO 249
<211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 249 Met Lys Ala Leu Cys Leu Leu
Leu Leu Pro Val Leu Gly Leu Leu Val 1 5 10 15 Ser Ser Lys Thr Leu
Cys Ser Met Glu Glu Ala Ile Asn Glu Arg Ile 20 25 30 Gln Glu Val
Ala Gly Ser Leu Ile Phe Arg Ala Ile Ser Ser Ile Gly 35 40 45 Leu
Glu Cys Gln Ser Val Thr Ser Arg Gly Asp Leu Ala Thr Cys Pro 50 55
60 Arg Gly Phe Ala Val Thr Gly Cys Thr Cys Gly Ser Ala Cys Gly Ser
65 70 75 80 Trp Asp Val Arg Ala Glu Thr Thr Cys His Cys Gln Cys Ala
Gly Met 85 90 95 Asp Trp Thr Gly Ala Arg Cys Cys Arg Val Gln Pro
100 105 <210> SEQ ID NO 250 <211> LENGTH: 114
<212> TYPE: PRT <213> ORGANISM: Mus musculus
<400> SEQUENCE: 250 Met Lys Asn Leu Ser Phe Pro Leu Leu Phe
Leu Phe Phe Leu Val Pro 1 5 10 15 Glu Leu Leu Gly Ser Ser Met Pro
Leu Cys Pro Ile Asp Glu Ala Ile 20 25 30 Asp Lys Lys Ile Lys Gln
Asp Phe Asn Ser Leu Phe Pro Asn Ala Ile 35 40 45 Lys Asn Ile Gly
Leu Asn Cys Trp Thr Val Ser Ser Arg Gly Lys Leu 50 55 60 Ala Ser
Cys Pro Glu Gly Thr Ala Val Leu Ser Cys Ser Cys Gly Ser 65 70 75 80
Ala Cys Gly Ser Trp Asp Ile Arg Glu Glu Lys Val Cys His Cys Gln 85
90 95 Cys Ala Arg Ile Asp Trp Thr Ala Ala Arg Cys Cys Lys Leu Gln
Val 100 105 110 Ala Ser <210> SEQ ID NO 251 <211>
LENGTH: 174 <212> TYPE: PRT <213> ORGANISM: Homo
sapiens <400> SEQUENCE: 251 Gln Asp Gln Gly Gly Leu Val Thr
Glu Thr Ala Asp Pro Gly Ala Gln 1 5 10 15 Ala Gln Gln Gly Leu Gly
Phe Gln Lys Leu Pro Glu Glu Glu Pro Glu 20 25 30 Thr Asp Leu Ser
Pro Gly Leu Pro Ala Ala His Leu Ile Gly Ala Pro 35 40 45 Leu Lys
Gly Gln Gly Leu Gly Trp Glu Thr Thr Lys Glu Gln Ala Phe 50 55 60
Leu Thr Ser Gly Thr Gln Phe Ser Asp Ala Glu Gly Leu Ala Leu Pro 65
70 75 80 Gln Asp Gly Leu Tyr Tyr Leu Tyr Cys Leu Val Gly Tyr Arg
Gly Arg 85 90 95 Ala Pro Pro Gly Gly Gly Asp Pro Gln Gly Arg Ser
Val Thr Leu Arg 100 105 110 Ser Ser Leu Tyr Arg Ala Gly Gly Ala Tyr
Gly Pro Gly Thr Pro Glu 115 120 125 Leu Leu Leu Glu Gly Ala Glu Thr
Val Thr Pro Val Leu Asp Pro Ala
130 135 140 Arg Arg Gln Gly Tyr Gly Pro Leu Trp Tyr Thr Ser Val Gly
Phe Gly 145 150 155 160 Gly Leu Val Gln Leu Arg Arg Gly Glu Arg Val
Tyr Val Asn 165 170 <210> SEQ ID NO 252 <211> LENGTH:
258 <212> TYPE: PRT <213> ORGANISM: Mus musculus
<400> SEQUENCE: 252 Gln Asp Gln Gly Arg Arg Val Glu Lys Ile
Ile Gly Ser Gly Ala Gln 1 5 10 15 Ala Gln Lys Arg Leu Asp Asp Ser
Lys Pro Ser Cys Ile Leu Pro Ser 20 25 30 Pro Ser Ser Leu Ser Glu
Thr Pro Asp Pro Arg Leu His Pro Gln Arg 35 40 45 Ser Asn Ala Ser
Arg Asn Leu Ala Ser Thr Ser Gln Gly Pro Val Ala 50 55 60 Gln Ser
Ser Arg Glu Ala Ser Ala Trp Met Thr Ile Leu Ser Pro Ala 65 70 75 80
Ala Asp Ser Thr Pro Asp Pro Gly Val Gln Gln Leu Pro Lys Gly Glu 85
90 95 Pro Glu Thr Asp Leu Asn Pro Glu Leu Pro Ala Ala His Leu Ile
Gly 100 105 110 Ala Trp Met Ser Gly Gln Gly Leu Ser Trp Glu Ala Ser
Gln Glu Glu 115 120 125 Ala Phe Leu Arg Ser Gly Ala Gln Phe Ser Pro
Thr His Gly Leu Ala 130 135 140 Leu Pro Gln Asp Gly Val Tyr Tyr Leu
Tyr Cys His Val Gly Tyr Arg 145 150 155 160 Gly Arg Thr Pro Pro Ala
Gly Arg Ser Arg Ala Arg Ser Leu Thr Leu 165 170 175 Arg Ser Ala Leu
Tyr Arg Ala Gly Gly Ala Tyr Gly Arg Gly Ser Pro 180 185 190 Glu Leu
Leu Leu Glu Gly Ala Glu Thr Val Thr Pro Val Val Asp Pro 195 200 205
Ile Gly Tyr Gly Ser Leu Trp Tyr Thr Ser Val Gly Phe Gly Gly Leu 210
215 220 Ala Gln Leu Arg Ser Gly Glu Arg Val Tyr Val Asn Ile Ser His
Pro 225 230 235 240 Asp Met Val Asp Tyr Arg Arg Gly Lys Thr Phe Phe
Gly Ala Val Met 245 250 255 Val Gly <210> SEQ ID NO 253
<211> LENGTH: 128 <212> TYPE: PRT <213> ORGANISM:
RNA-phage PP7 <400> SEQUENCE: 253 Met Ser Lys Thr Ile Val Leu
Ser Val Gly Glu Ala Thr Arg Thr Leu 1 5 10 15 Thr Glu Ile Gln Ser
Thr Ala Asp Arg Gln Ile Phe Glu Glu Lys Val 20 25 30 Gly Pro Leu
Val Gly Arg Leu Arg Leu Thr Ala Ser Leu Arg Gln Asn 35 40 45 Gly
Ala Lys Thr Ala Tyr Arg Val Asn Leu Lys Leu Asp Gln Ala Asp 50 55
60 Val Val Asp Cys Ser Thr Ser Val Cys Gly Glu Leu Pro Lys Val Arg
65 70 75 80 Tyr Thr Gln Val Trp Ser His Asp Val Thr Ile Val Ala Asn
Ser Thr 85 90 95 Glu Ala Ser Arg Lys Ser Leu Tyr Asp Leu Thr Lys
Ser Leu Val Ala 100 105 110 Thr Ser Gln Val Glu Asp Leu Val Val Asn
Leu Val Pro Leu Gly Arg 115 120 125 <210> SEQ ID NO 254
<211> LENGTH: 330 <212> TYPE: PRT <213> ORGANISM:
RNA-phage SP A1 protein <400> SEQUENCE: 254 Ala Lys Leu Asn
Gln Val Thr Leu Ser Lys Ile Gly Lys Asn Gly Asp 1 5 10 15 Gln Thr
Leu Thr Leu Thr Pro Arg Gly Val Asn Pro Thr Asn Gly Val 20 25 30
Ala Ser Leu Ser Glu Ala Gly Ala Val Pro Ala Leu Glu Lys Arg Val 35
40 45 Thr Val Ser Val Ala Gln Pro Ser Arg Asn Arg Lys Asn Phe Lys
Val 50 55 60 Gln Ile Lys Leu Gln Asn Pro Thr Ala Cys Thr Arg Asp
Ala Cys Asp 65 70 75 80 Pro Ser Val Thr Arg Ser Ala Phe Ala Asp Val
Thr Leu Ser Phe Thr 85 90 95 Ser Tyr Ser Thr Asp Glu Glu Arg Ala
Leu Ile Arg Thr Glu Leu Ala 100 105 110 Ala Leu Leu Ala Asp Pro Leu
Ile Val Asp Ala Ile Asp Asn Leu Asn 115 120 125 Pro Ala Tyr Trp Ala
Ala Leu Leu Val Ala Ser Ser Gly Gly Gly Asp 130 135 140 Asn Pro Ser
Asp Pro Asp Val Pro Val Val Pro Asp Val Lys Pro Pro 145 150 155 160
Asp Gly Thr Gly Arg Tyr Lys Cys Pro Phe Ala Cys Tyr Arg Leu Gly 165
170 175 Ser Ile Tyr Glu Val Gly Lys Glu Gly Ser Pro Asp Ile Tyr Glu
Arg 180 185 190 Gly Asp Glu Val Ser Val Thr Phe Asp Tyr Ala Leu Glu
Asp Phe Leu 195 200 205 Gly Asn Thr Asn Trp Arg Asn Trp Asp Gln Arg
Leu Ser Asp Tyr Asp 210 215 220 Ile Ala Asn Arg Arg Arg Cys Arg Gly
Asn Gly Tyr Ile Asp Leu Asp 225 230 235 240 Ala Thr Ala Met Gln Ser
Asp Asp Phe Val Leu Ser Gly Arg Tyr Gly 245 250 255 Val Arg Lys Val
Lys Phe Pro Gly Ala Phe Gly Ser Ile Lys Tyr Leu 260 265 270 Leu Asn
Ile Gln Gly Asp Ala Trp Leu Asp Leu Ser Glu Val Thr Ala 275 280 285
Tyr Arg Ser Tyr Gly Met Val Ile Gly Phe Trp Thr Asp Ser Lys Ser 290
295 300 Pro Gln Leu Pro Thr Asp Phe Thr Gln Phe Asn Ser Ala Asn Cys
Pro 305 310 315 320 Val Gln Thr Val Ile Ile Ile Pro Ser Leu 325 330
<210> SEQ ID NO 255 <211> LENGTH: 132 <212> TYPE:
PRT <213> ORGANISM: QB 240 <400> SEQUENCE: 255 Ala Lys
Leu Glu Thr Val Thr Leu Gly Asn Ile Gly Arg Asp Gly Lys 1 5 10 15
Gln Thr Leu Val Leu Asn Pro Arg Gly Val Asn Pro Thr Asn Gly Val 20
25 30 Ala Ser Leu Ser Gln Ala Gly Ala Val Pro Ala Leu Glu Lys Arg
Val 35 40 45 Thr Val Ser Val Ser Gln Pro Ser Arg Asn Arg Lys Asn
Tyr Lys Val 50 55 60 Gln Val Lys Ile Gln Asn Pro Thr Ala Cys Thr
Ala Asn Gly Ser Cys 65 70 75 80 Asp Pro Ser Val Thr Arg Gln Lys Tyr
Ala Asp Val Thr Phe Ser Phe 85 90 95 Thr Gln Tyr Ser Thr Asp Glu
Glu Arg Ala Phe Val Arg Thr Glu Leu 100 105 110 Ala Ala Leu Leu Ala
Ser Pro Leu Leu Ile Asp Ala Ile Asp Gln Leu 115 120 125 Asn Pro Ala
Tyr 130 <210> SEQ ID NO 256 <211> LENGTH: 132
<212> TYPE: PRT <213> ORGANISM: Qb 243 <400>
SEQUENCE: 256 Ala Lys Leu Glu Thr Val Thr Leu Gly Lys Ile Gly Lys
Asp Gly Lys 1 5 10 15 Gln Thr Leu Val Leu Asn Pro Arg Gly Val Asn
Pro Thr Asn Gly Val 20 25 30 Ala Ser Leu Ser Gln Ala Gly Ala Val
Pro Ala Leu Glu Lys Arg Val 35 40 45 Thr Val Ser Val Ser Gln Pro
Ser Arg Asn Arg Lys Asn Tyr Lys Val 50 55 60 Gln Val Lys Ile Gln
Asn Pro Thr Ala Cys Thr Ala Asn Gly Ser Cys 65 70 75 80 Asp Pro Ser
Val Thr Arg Gln Lys Tyr Ala Asp Val Thr Phe Ser Phe 85 90 95 Thr
Gln Tyr Ser Thr Asp Glu Glu Arg Ala Phe Val Arg Thr Glu Leu 100 105
110 Ala Ala Leu Leu Ala Ser Pro Leu Leu Ile Asp Ala Ile Asp Gln Leu
115 120 125 Asn Pro Ala Tyr 130 <210> SEQ ID NO 257
<211> LENGTH: 132 <212> TYPE: PRT <213> ORGANISM:
Qb 250 <400> SEQUENCE: 257 Ala Arg Leu Glu Thr Val Thr Leu
Gly Asn Ile Gly Arg Asp Gly Lys 1 5 10 15 Gln Thr Leu Val Leu Asn
Pro Arg Gly Val Asn Pro Thr Asn Gly Val
20 25 30 Ala Ser Leu Ser Gln Ala Gly Ala Val Pro Ala Leu Glu Lys
Arg Val 35 40 45 Thr Val Ser Val Ser Gln Pro Ser Arg Asn Arg Lys
Asn Tyr Lys Val 50 55 60 Gln Val Lys Ile Gln Asn Pro Thr Ala Cys
Thr Ala Asn Gly Ser Cys 65 70 75 80 Asp Pro Ser Val Thr Arg Gln Lys
Tyr Ala Asp Val Thr Phe Ser Phe 85 90 95 Thr Gln Tyr Ser Thr Asp
Glu Glu Arg Ala Phe Val Arg Thr Glu Leu 100 105 110 Ala Ala Leu Leu
Ala Ser Pro Leu Leu Ile Asp Ala Ile Asp Gln Leu 115 120 125 Asn Pro
Ala Tyr 130 <210> SEQ ID NO 258 <211> LENGTH: 132
<212> TYPE: PRT <213> ORGANISM: Qb 259 <400>
SEQUENCE: 258 Ala Arg Leu Glu Thr Val Thr Leu Gly Asn Ile Gly Lys
Asp Gly Arg 1 5 10 15 Gln Thr Leu Val Leu Asn Pro Arg Gly Val Asn
Pro Thr Asn Gly Val 20 25 30 Ala Ser Leu Ser Gln Ala Gly Ala Val
Pro Ala Leu Glu Lys Arg Val 35 40 45 Thr Val Ser Val Ser Gln Pro
Ser Arg Asn Arg Lys Asn Tyr Lys Val 50 55 60 Gln Val Lys Ile Gln
Asn Pro Thr Ala Cys Thr Ala Asn Gly Ser Cys 65 70 75 80 Asp Pro Ser
Val Thr Arg Gln Lys Tyr Ala Asp Val Thr Phe Ser Phe 85 90 95 Thr
Gln Tyr Ser Thr Asp Glu Glu Arg Ala Phe Val Arg Thr Glu Leu 100 105
110 Ala Ala Leu Leu Ala Ser Pro Leu Leu Ile Asp Ala Ile Asp Gln Leu
115 120 125 Asn Pro Ala Tyr 130 <210> SEQ ID NO 259
<211> LENGTH: 132 <212> TYPE: PRT <213> ORGANISM:
Qb 251 <400> SEQUENCE: 259 Ala Lys Leu Glu Thr Val Thr Leu
Gly Asn Ile Gly Lys Asp Gly Arg 1 5 10 15 Gln Thr Leu Val Leu Asn
Pro Arg Gly Val Asn Pro Thr Asn Gly Val 20 25 30 Ala Ser Leu Ser
Gln Ala Gly Ala Val Pro Ala Leu Glu Lys Arg Val 35 40 45 Thr Val
Ser Val Ser Gln Pro Ser Arg Asn Arg Lys Asn Tyr Lys Val 50 55 60
Gln Val Lys Ile Gln Asn Pro Thr Ala Cys Thr Ala Asn Gly Ser Cys 65
70 75 80 Asp Pro Ser Val Thr Arg Gln Lys Tyr Ala Asp Val Thr Phe
Ser Phe 85 90 95 Thr Gln Tyr Ser Thr Asp Glu Glu Arg Ala Phe Val
Arg Thr Glu Leu 100 105 110 Ala Ala Leu Leu Ala Ser Pro Leu Leu Ile
Asp Ala Ile Asp Gln Leu 115 120 125 Asn Pro Ala Tyr 130 <210>
SEQ ID NO 260 <211> LENGTH: 20 <212> TYPE: DNA
<213> ORGANISM: PH19 <400> SEQUENCE: 260 taagtcctct
gccacgtacc 20 <210> SEQ ID NO 261 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: PH20 <400>
SEQUENCE: 261 tggaaaccac gctcacttcc 20 <210> SEQ ID NO 262
<211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM:
PH21 <400> SEQUENCE: 262 cgggatccgg gatgaagaac ctttcatttc 30
<210> SEQ ID NO 263 <211> LENGTH: 31 <212> TYPE:
DNA <213> ORGANISM: PH22 <400> SEQUENCE: 263 gcctctagag
aggaagcgac ctgcagctta c 31 <210> SEQ ID NO 264 <211>
LENGTH: 46 <212> TYPE: DNA <213> ORGANISM: PH29
<400> SEQUENCE: 264 ctagcgggag ggggtggatg tggggacgac
tacaaggatg acgaca 46 <210> SEQ ID NO 265 <211> LENGTH:
46 <212> TYPE: DNA <213> ORGANISM: PH30 <400>
SEQUENCE: 265 agcttgtcgt catccttgta gtcgtcccca catccacccc ctcccg 46
<210> SEQ ID NO 266 <211> LENGTH: 45 <212> TYPE:
DNA <213> ORGANISM: PH31 <400> SEQUENCE: 266 agcttactca
cacatgccca ccgtgcccag cacctgaagc cgagg 45 <210> SEQ ID NO 267
<211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM:
PH32 <400> SEQUENCE: 267 cggcttcagg tgctgggcac ggtgggcatg
tgtgagta 38 <210> SEQ ID NO 268 <211> LENGTH: 37
<212> TYPE: DNA <213> ORGANISM: PH35 <400>
SEQUENCE: 268 ctagcgggag ggggtggatg tgggatcgaa ggtcgca 37
<210> SEQ ID NO 269 <211> LENGTH: 37 <212> TYPE:
DNA <213> ORGANISM: PH36 <400> SEQUENCE: 269 agcttgcgac
cttcgatccc acatccaccc cctcccg 37 <210> SEQ ID NO 270
<211> LENGTH: 43 <212> TYPE: DNA <213> ORGANISM:
PH37 <400> SEQUENCE: 270 cgggatccag cagctgggct cgaggtgcta
gctttgttta aac 43 <210> SEQ ID NO 271 <211> LENGTH: 55
<212> TYPE: DNA <213> ORGANISM: PH38 <400>
SEQUENCE: 271 gatcgtttaa acaaacaaag ctagcacctc gagcccagct
gctggatccc ggtac 55 <210> SEQ ID NO 272 <211> LENGTH:
37 <212> TYPE: DNA <213> ORGANISM: PH39 <400>
SEQUENCE: 272 ctagcgggag ggggtggatg tggggacgat gacgaca 37
<210> SEQ ID NO 273 <211> LENGTH: 37 <212> TYPE:
DNA <213> ORGANISM: PH40 <400> SEQUENCE: 273 agcttgtcgt
catcgtcccc acatccaccc cctcccg 37 <210> SEQ ID NO 274
<211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM:
PH41 <400> SEQUENCE: 274 catggagaca gacacactcc tgctatgggt 30
<210> SEQ ID NO 275 <211> LENGTH: 39 <212> TYPE:
DNA <213> ORGANISM: PH42 <400> SEQUENCE: 275
gcagtaccca tagcaggagt gtgtctgtct ccatggtac 39 <210> SEQ ID NO
276 <211> LENGTH: 37 <212> TYPE: DNA <213>
ORGANISM: PH43 <400> SEQUENCE: 276 actgctgctc tgggttccag
gttccactgg tgacgcg 37 <210> SEQ ID NO 277 <211> LENGTH:
36 <212> TYPE: DNA <213> ORGANISM: PH44 <400>
SEQUENCE: 277 gatccgcgtc accagtggaa cctggaaccc agagca 36
<210> SEQ ID NO 278 <211> LENGTH: 40 <212> TYPE:
DNA <213> ORGANISM: SU7 <400> SEQUENCE: 278 agcttgcgga
tccaggatat cggctcgagg ttctagagtg 40 <210> SEQ ID NO 279
<211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM:
SU8 <400> SEQUENCE: 279 ggcccactct agaacctcga gccgatatcc
tggatccgca 40 <210> SEQ ID NO 280 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Resistin-C-Xa
construct <400> SEQUENCE: 280 Ser Ser Met Pro Leu Cys Pro Ile
Asp Glu Ala Ile Asp Lys Lys Ile 1 5 10 15 Lys Gln Asp Phe Asn Ser
Leu Phe Pro Asn Ala Ile Lys Asn Ile Gly 20 25 30 Leu Asn Cys Trp
Thr Val Ser Ser Arg Gly Lys Leu Ala Ser Cys Pro 35 40 45 Glu Gly
Thr Ala Val Leu Ser Cys Ser Cys Gly Ser Ala Cys Gly Ser 50 55 60
Trp Asp Ile Arg Glu Glu Lys Val Cys His Cys Gln Cys Ala Arg Ile 65
70 75 80 Asp Trp Thr Ala Ala Arg Cys Cys Lys Leu Gln Val Ala Ser
Ser Leu 85 90 95 Ala Gly Gly Gly Gly Cys Gly Ile Glu Gly Arg 100
105 <210> SEQ ID NO 281 <211> LENGTH: 107 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Resistin-C-EK construct
<400> SEQUENCE: 281 Ser Ser Met Pro Leu Cys Pro Ile Asp Glu
Ala Ile Asp Lys Lys Ile 1 5 10 15 Lys Gln Asp Phe Asn Ser Leu Phe
Pro Asn Ala Ile Lys Asn Ile Gly 20 25 30 Leu Asn Cys Trp Thr Val
Ser Ser Arg Gly Lys Leu Ala Ser Cys Pro 35 40 45 Glu Gly Thr Ala
Val Leu Ser Cys Ser Cys Gly Ser Ala Cys Gly Ser 50 55 60 Trp Asp
Ile Arg Glu Glu Lys Val Cys His Cys Gln Cys Ala Arg Ile 65 70 75 80
Asp Trp Thr Ala Ala Arg Cys Cys Lys Leu Gln Val Ala Ser Ser Leu 85
90 95 Ala Gly Gly Gly Gly Cys Gly Asp Asp Asp Asp 100 105
<210> SEQ ID NO 282 <211> LENGTH: 103 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Resistin-GCG construct <400>
SEQUENCE: 282 Ser Ser Met Pro Leu Cys Pro Ile Asp Glu Ala Ile Asp
Lys Lys Ile 1 5 10 15 Lys Gln Asp Phe Asn Ser Leu Phe Pro Asn Ala
Ile Lys Asn Ile Gly 20 25 30 Leu Asn Cys Trp Thr Val Ser Ser Arg
Gly Lys Leu Ala Ser Cys Pro 35 40 45 Glu Gly Thr Ala Val Leu Ser
Cys Ser Cys Gly Ser Ala Cys Gly Ser 50 55 60 Trp Asp Ile Arg Glu
Glu Lys Val Cys His Cys Gln Cys Ala Arg Ile 65 70 75 80 Asp Trp Thr
Ala Ala Arg Cys Cys Lys Leu Gln Val Ala Ser Ser Leu 85 90 95 Ala
Gly Gly Gly Gly Cys Gly 100 <210> SEQ ID NO 283 <211>
LENGTH: 10285 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: pCep Xa Fc construct <220> FEATURE: <221>
NAME/KEY: misc_feature <222> LOCATION: (9872)..(9872)
<223> OTHER INFORMATION: n is a, c, g, or t <400>
SEQUENCE: 283 gccccgccgc cggacgaact aaacctgact acggcatctc
tgccccttct tcgctggtac 60 gaggagcgct tttgttttgt attcggggca
gtgcatgtaa tcccttcagt tggttggtac 120 aacttgccaa ctgggccctg
ttccacatgt gacacggggg gggaccaaac acaaaggggt 180 tctctgactg
tagttgacat ccttataaat ggatgtgcac atttgccaac actgagtggc 240
tttcatcctg gagcagactt tgcatgctgt ggactgcaac acaacattgc ctttatgtgt
300 aactcttggc tgaagctctt acaccaatgc tgggggacat gtacctccca
ggggcccagg 360 aagactacgg gaggctacac caacgtcaat cagaggggcc
tgtgtagcta ccgataagcg 420 gaccctcaag agggcattag caatagtgtt
tataaggccc ccttgttaac cctaaacggg 480 tagcatatgc ttcccgggta
gtagtatata ctatccagac taaccctaat tcaatagcat 540 atgttaccca
acgggaagca tatgctatcg aattagggtt agtaaaaggg tcctaaggaa 600
cagcgatatc tcccacccca tgagctgtca cggttttatt tacatggggt caggattcca
660 cgagggtagt gaaccatttt agtcacaagg gcagtggctg aagatcaagg
agcgggcagt 720 gaactctcct gaatcttcgc ctgcttcttc attctccttc
gtttagctaa tagaataact 780 gctgagttgt gaacagtaag gtgtatgtga
ggtgctcgaa aacaaggttt caggtgacgc 840 ccccagaata aaatttggac
ggggggttca gtggtggcat tgtgctatga caccaatata 900 accctcacaa
accccttggg caataaatac tagtgtagga atgaaacatt ctgaatatct 960
ttaacaatag aaatccatgg ggtggggaca agccgtaaag actggatgtc catctcacac
1020 gaatttatgg ctatgggcaa cacataatcc tagtgcaata tgatactggg
gttattaaga 1080 tgtgtcccag gcagggacca agacaggtga accatgttgt
tacactctat ttgtaacaag 1140 gggaaagaga gtggacgccg acagcagcgg
actccactgg ttgtctctaa cacccccgaa 1200 aattaaacgg ggctccacgc
caatggggcc cataaacaaa gacaagtggc cactcttttt 1260 tttgaaattg
tggagtgggg gcacgcgtca gcccccacac gccgccctgc ggttttggac 1320
tgtaaaataa gggtgtaata acttggctga ttgtaacccc gctaaccact gcggtcaaac
1380 cacttgccca caaaaccact aatggcaccc cggggaatac ctgcataagt
aggtgggcgg 1440 gccaagatag gggcgcgatt gctgcgatct ggaggacaaa
ttacacacac ttgcgcctga 1500 gcgccaagca cagggttgtt ggtcctcata
ttcacgaggt cgctgagagc acggtgggct 1560 aatgttgcca tgggtagcat
atactaccca aatatctgga tagcatatgc tatcctaatc 1620 tatatctggg
tagcataggc tatcctaatc tatatctggg tagcatatgc tatcctaatc 1680
tatatctggg tagtatatgc tatcctaatt tatatctggg tagcataggc tatcctaatc
1740 tatatctggg tagcatatgc tatcctaatc tatatctggg tagtatatgc
tatcctaatc 1800 tgtatccggg tagcatatgc tatcctaata gagattaggg
tagtatatgc tatcctaatt 1860 tatatctggg tagcatatac tacccaaata
tctggatagc atatgctatc ctaatctata 1920 tctgggtagc atatgctatc
ctaatctata tctgggtagc ataggctatc ctaatctata 1980 tctgggtagc
atatgctatc ctaatctata tctgggtagt atatgctatc ctaatttata 2040
tctgggtagc ataggctatc ctaatctata tctgggtagc atatgctatc ctaatctata
2100 tctgggtagt atatgctatc ctaatctgta tccgggtagc atatgctatc
ctcatgcata 2160 tacagtcagc atatgatacc cagtagtaga gtgggagtgc
tatcctttgc atatgccgcc 2220 acctcccaag ggggcgtgaa ttttcgctgc
ttgtcctttt cctgcatgct ggttgctccc 2280 attcttaggt gaatttaagg
aggccaggct aaagccgtcg catgtctgat tgctcaccag 2340 gtaaatgtcg
ctaatgtttt ccaacgcgag aaggtgttga gcgcggagct gagtgacgtg 2400
acaacatggg tatgcccaat tgccccatgt tgggaggacg aaaatggtga caagacagat
2460 ggccagaaat acaccaacag cacgcatgat gtctactggg gatttattct
ttagtgcggg 2520 ggaatacacg gcttttaata cgattgaggg cgtctcctaa
caagttacat cactcctgcc 2580 cttcctcacc ctcatctcca tcacctcctt
catctccgtc atctccgtca tcaccctccg 2640 cggcagcccc ttccaccata
ggtggaaacc agggaggcaa atctactcca tcgtcaaagc 2700 tgcacacagt
caccctgata ttgcaggtag gagcgggctt tgtcataaca aggtccttaa 2760
tcgcatcctt caaaacctca gcaaatatat gagtttgtaa aaagaccatg aaataacaga
2820 caatggactc ccttagcggg ccaggttgtg ggccgggtcc aggggccatt
ccaaagggga 2880 gacgactcaa tggtgtaaga cgacattgtg gaatagcaag
ggcagttcct cgccttaggt 2940 tgtaaaggga ggtcttacta cctccatata
cgaacacacc ggcgacccaa gttccttcgt 3000 cggtagtcct ttctacgtga
ctcctagcca ggagagctct taaaccttct gcaatgttct 3060
caaatttcgg gttggaacct ccttgaccac gatgctttcc aaaccaccct ccttttttgc
3120 gcctgcctcc atcaccctga ccccggggtc cagtgcttgg gccttctcct
gggtcatctg 3180 cggggccctg ctctatcgct cccgggggca cgtcaggctc
accatctggg ccaccttctt 3240 ggtggtattc aaaataatcg gcttccccta
cagggtggaa aaatggcctt ctacctggag 3300 ggggcctgcg cggtggagac
ccggatgatg atgactgact actgggactc ctgggcctct 3360 tttctccacg
tccacgacct ctccccctgg ctctttcacg acttcccccc ctggctcttt 3420
cacgtcctct accccggcgg cctccactac ctcctcgacc ccggcctcca ctacctcctc
3480 gaccccggcc tccactgcct cctcgacccc ggcctccacc tcctgctcct
gcccctcctg 3540 ctcctgcccc tcctcctgct cctgcccctc ctgcccctcc
tgctcctgcc cctcctgccc 3600 ctcctgctcc tgcccctcct gcccctcctg
ctcctgcccc tcctgcccct cctcctgctc 3660 ctgcccctcc tgcccctcct
cctgctcctg cccctcctgc ccctcctgct cctgcccctc 3720 ctgcccctcc
tgctcctgcc cctcctgccc ctcctgctcc tgcccctcct gctcctgccc 3780
ctcctgctcc tgcccctcct gctcctgccc ctcctgcccc tcctgcccct cctcctgctc
3840 ctgcccctcc tgctcctgcc cctcctgccc ctcctgcccc tcctgctcct
gcccctcctc 3900 ctgctcctgc ccctcctgcc cctcctgccc ctcctcctgc
tcctgcccct cctgcccctc 3960 ctcctgctcc tgcccctcct cctgctcctg
cccctcctgc ccctcctgcc cctcctcctg 4020 ctcctgcccc tcctgcccct
cctcctgctc ctgcccctcc tcctgctcct gcccctcctg 4080 cccctcctgc
ccctcctcct gctcctgccc ctcctcctgc tcctgcccct cctgcccctc 4140
ctgcccctcc tgcccctcct cctgctcctg cccctcctcc tgctcctgcc cctcctgctc
4200 ctgcccctcc cgctcctgct cctgctcctg ttccaccgtg ggtccctttg
cagccaatgc 4260 aacttggacg tttttggggt ctccggacac catctctatg
tcttggccct gatcctgagc 4320 cgcccggggc tcctggtctt ccgcctcctc
gtcctcgtcc tcttccccgt cctcgtccat 4380 ggttatcacc ccctcttctt
tgaggtccac tgccgccgga gccttctggt ccagatgtgt 4440 ctcccttctc
tcctaggcca tttccaggtc ctgtacctgg cccctcgtca gacatgattc 4500
acactaaaag agatcaatag acatctttat tagacgacgc tcagtgaata cagggagtgc
4560 agactcctgc cccctccaac agccccccca ccctcatccc cttcatggtc
gctgtcagac 4620 agatccaggt ctgaaaattc cccatcctcc gaaccatcct
cgtcctcatc accaattact 4680 cgcagcccgg aaaactcccg ctgaacatcc
tcaagatttg cgtcctgagc ctcaagccag 4740 gcctcaaatt cctcgtcccc
ctttttgctg gacggtaggg atggggattc tcgggacccc 4800 tcctcttcct
cttcaaggtc accagacaga gatgctactg gggcaacgga agaaaagctg 4860
ggtgcggcct gtgaggatca gcttatcgat gataagctgt caaacatgag aattcttgaa
4920 gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata
ataatggttt 4980 cttagacgtc aggtggcact tttcggggaa atgtgcgcgg
aacccctatt tgtttatttt 5040 tctaaataca ttcaaatatg tatccgctca
tgagacaata accctgataa atgcttcaat 5100 aatattgaaa aaggaagagt
atgagtattc aacatttccg tgtcgccctt attccctttt 5160 ttgcggcatt
ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 5220
ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga
5280 tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt
aaagttctgc 5340 tatgtggcgc ggtattatcc cgtgttgacg ccgggcaaga
gcaactcggt cgccgcatac 5400 actattctca gaatgacttg gttgagtact
caccagtcac agaaaagcat cttacggatg 5460 gcatgacagt aagagaatta
tgcagtgctg ccataaccat gagtgataac actgcggcca 5520 acttacttct
gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 5580
gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg
5640 acgagcgtga caccacgatg cctgcagcaa tggcaacaac gttgcgcaaa
ctattaactg 5700 gcgaactact tactctagct tcccggcaac aattaataga
ctggatggag gcggataaag 5760 ttgcaggacc acttctgcgc tcggcccttc
cggctggctg gtttattgct gataaatctg 5820 gagccggtga gcgtgggtct
cgcggtatca ttgcagcact ggggccagat ggtaagccct 5880 cccgtatcgt
agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 5940
agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact
6000 catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc
taggtgaaga 6060 tcctttttga taatctcatg accaaaatcc cttaacgtga
gttttcgttc cactgagcgt 6120 cagaccccgt agaaaagatc aaaggatctt
cttgagatcc tttttttctg cgcgtaatct 6180 gctgcttgca aacaaaaaaa
ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 6240 taccaactct
ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc 6300
ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc
6360 tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg
tgtcttaccg 6420 ggttggactc aagacgatag ttaccggata aggcgcagcg
gtcgggctga acggggggtt 6480 cgtgcacaca gcccagcttg gagcgaacga
cctacaccga actgagatac ctacagcgtg 6540 agctatgaga aagcgccacg
cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 6600 gcagggtcgg
aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 6660
atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag
6720 gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc
ctggcctttt 6780 gctgcgccgc gtgcggctgc tggagatggc ggacgcgatg
gatatgttct gccaagggtt 6840 ggtttgcgca ttcacagttc tccgcaagaa
ttgattggct ccaattcttg gagtggtgaa 6900 tccgttagcg aggccatcca
gcctcgcgtc gaactagatg atccgctgtg gaatgtgtgt 6960 cagttagggt
gtggaaagtc cccaggctcc ccagcaggca gaagtatgca aagcatgcat 7020
ctcaattagt cagcaaccag gtgtggaaag tccccaggct ccccagcagg cagaagtatg
7080 caaagcatgc atctcaatta gtcagcaacc atagtcccgc ccctaactcc
gcccatcccg 7140 cccctaactc cgcccagttc cgcccattct ccgccccatg
gctgactaat tttttttatt 7200 tatgcagagg ccgaggccgc ctcggcctct
gagctattcc agaagtagtg aggaggcttt 7260 tttggagggt gaccgccacg
accggtgccg ccaccatccc ctgacccacg cccctgaccc 7320 ctcacaagga
gacgaccttc catgaccgag tacaagccca cggtgcgcct cgccacccgc 7380
gacgacgtcc cccgggccgt acgcaccctc gccgccgcgt tcgccgacta ccccgccacg
7440 cgccacaccg tcgaccccga ccgccacatc gaacgcgtca ccgagctgca
agaactcttc 7500 ctcacgcgcg tcgggctcga catcggcaag gtgtgggtcg
cggacgacgg cgccgcggtg 7560 gcggtctgga ccacgccgga gagcgtcgaa
gcgggggcgg tgttcgccga gatcggcccg 7620 cgcatggccg agttgagcgg
ttcccggctg gccgcgcagc aacagatgga aggcctcctg 7680 gcgccgcacc
ggcccaagga gcccgcgtgg ttcctggcca ccgtcggcgt ctcgcccgac 7740
caccagggca agggtctggg cagcgccgtc gtgctccccg gagtggaggc ggccgagcgc
7800 gccggggtgc ccgccttcct ggagacctcc gcgccccgca acctcccctt
ctacgagcgg 7860 ctcggcttca ccgtcaccgc cgacgtcgag tgcccgaagg
accgcgcgac ctggtgcatg 7920 acccgcaagc ccggtgcctg acgcccgccc
cacgacccgc agcgcccgac cgaaaggagc 7980 gcacgacccg gtccgacggc
ggcccacggg tcccaggggg gtcgacctcg aaacttgttt 8040 attgcagctt
ataatggtta caaataaagc aatagcatca caaatttcac aaataaagca 8100
tttttttcac tgcattctag ttgtggtttg tccaaactca tcaatgtatc ttatcatgtc
8160 tggatcgatc cgaacccctt cctcgaccaa ttctcatgtt tgacagctta
tcatcgcaga 8220 tccgggcaac gttgttgcat tgctgcaggc gcagaactgg
taggtatgga agatctatac 8280 attgaatcaa tattggcaat tagccatatt
agtcattggt tatatagcat aaatcaatat 8340 tggctattgg ccattgcata
cgttgtatct atatcataat atgtacattt atattggctc 8400 atgtccaata
tgaccgccat gttgacattg attattgact agttattaat agtaatcaat 8460
tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac ttacggtaaa
8520 tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa
tgacgtatgt 8580 tcccatagta acgccaatag ggactttcca ttgacgtcaa
tgggtggagt atttacggta 8640 aactgcccac ttggcagtac atcaagtgta
tcatatgcca agtccgcccc ctattgacgt 8700 caatgacggt aaatggcccg
cctggcatta tgcccagtac atgaccttac gggactttcc 8760 tacttggcag
tacatctacg tattagtcat cgctattacc atggtgatgc ggttttggca 8820
gtacaccaat gggcgtggat agcggtttga ctcacgggga tttccaagtc tccaccccat
8880 tgacgtcaat gggagtttgt tttggcacca aaatcaacgg gactttccaa
aatgtcgtaa 8940 taaccccgcc ccgttgacgc aaatgggcgg taggcgtgta
cggtgggagg tctatataag 9000 cagagctcgt ttagtgaacc gtcagatctc
tagaagctgg gtaccgggat ccagcagctg 9060 ggctcgaggt gctagcggga
gggggtggat gtgggatcga aggtcgcaag cttactcaca 9120 catgcccacc
gtgcccagca cctgaagccg agggggcacc gtcagtcttc ctcttccccc 9180
caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc gtggtggtgg
9240 acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc
gtggaggtgc 9300 ataatgccaa gacaaagccg cgggaggagc agtacaacag
cacgtaccgt gtggtcagcg 9360 tcctcaccgt cctgcaccag gactggctga
atggcaagga gtacaagtgc aaggtctcca 9420 acaaagccct cccagcctcc
atcgagaaaa ccatctccaa agccaaaggg cagccccgag 9480 aaccacaggt
gtacaccctg cccccatccc gggatgagct gaccaagaac caggtcagcc 9540
tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg gagagcaatg
9600 ggcagccgga gaacaactac aagaccacgc ctcccgtgtt ggactccgac
ggctccttct 9660 tcctctacag caagctcacc gtggacaaga gcaggtggca
gcaggggaac gtcttctcat 9720 gctccgtgat gcatgaggct ctgcacaacc
actacacgca gaagagcctc tccctgtctc 9780 cgggtaaatg actcgaggcc
cgaacaaaaa ctcatctcag aagaggatct gaatagcgcc 9840 gtcgaccatc
atcatcatca tcattgagtt tnaacgatcc agacatgata agatacattg 9900
atgagtttgg acaaaccaca actagaatgc agtgaaaaaa atgctttatt tgtgaaattt
9960 gtgatgctat tgctttattt gtaaccatta taagctgcaa taaacaagtt
aacaacaaca 10020 attgcattca ttttatgttt caggttcagg gggaggtggg
gaggtttttt aaagcaagta 10080 aaacctctac aaatgtggta tggctgatta
tgatccggct gcctcgcgcg tttcggtgat 10140 gacggtgaaa acctctgaca
catgcagctc ccggagacgg tcacagcttg tctgtaagcg 10200 gatgccggga
gcagacaagc ccgtcagggc gcgtcagcgg gtgttggcgg gtgtcggggc 10260
gcagccatga ccggtcgact ctaga 10285 <210> SEQ ID NO 284
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: 5'LT oligonucleotide <400> SEQUENCE: 284
cttggtgccg caggatcag 19 <210> SEQ ID NO 285 <211>
LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: 3'LT
oligonucleotide <400> SEQUENCE: 285 cagatggctg tcaccccac 19
<210> SEQ ID NO 286 <211> LENGTH: 37 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: 5'LT long-NheI oligonucleotide
<400> SEQUENCE: 286 gcccgctagc ctgcggtggt caggatcagg gacgtcg
37 <210> SEQ ID NO 287 <211> LENGTH: 37 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: 5'LT short-NheI
oligonucleotide <400> SEQUENCE: 287 gcccgctagc ctgcggtggt
tctccagctg cggattc 37 <210> SEQ ID NO 288 <211> LENGTH:
33 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: 3'LT stop-NotI
oligonucleotide <400> SEQUENCE: 288 caatgactgc ggccgcttac
cccaccatca ccg 33 <210> SEQ ID NO 289 <211> LENGTH: 504
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION:
GST-EK-C-LT-beta-49-306 fusion protein <400> SEQUENCE: 289
Ala Pro Leu Val Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly 1 5
10 15 Leu Val Gln Pro Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys
Tyr 20 25 30 Glu Glu His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp
Arg Asn Lys 35 40 45 Lys Phe Glu Leu Gly Leu Glu Phe Pro Asn Leu
Pro Tyr Tyr Ile Asp 50 55 60 Gly Asp Val Lys Leu Thr Gln Ser Met
Ala Ile Ile Arg Tyr Ile Ala 65 70 75 80 Asp Lys His Asn Met Leu Gly
Gly Cys Pro Lys Glu Arg Ala Glu Ile 85 90 95 Ser Met Leu Glu Gly
Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg 100 105 110 Ile Ala Tyr
Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser 115 120 125 Lys
Leu Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys 130 135
140 Thr Tyr Leu Asn Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr
145 150 155 160 Asp Ala Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys
Leu Asp Ala 165 170 175 Phe Pro Lys Leu Val Cys Phe Lys Lys Arg Ile
Glu Ala Ile Pro Gln 180 185 190 Ile Asp Lys Tyr Leu Lys Ser Ser Lys
Tyr Ile Ala Trp Pro Leu Gln 195 200 205 Gly Trp Gln Ala Thr Phe Gly
Gly Gly Asp His Pro Pro Lys Ala Ser 210 215 220 Met Thr Gly Gly Gln
Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp Asp 225 230 235 240 Lys Leu
Ala Cys Gly Gly Gln Asp Gln Gly Arg Arg Val Glu Lys Ile 245 250 255
Ile Gly Ser Gly Ala Gln Ala Gln Lys Arg Leu Asp Asp Ser Lys Pro 260
265 270 Ser Cys Ile Leu Pro Ser Pro Ser Ser Leu Ser Glu Thr Pro Asp
Pro 275 280 285 Arg Leu His Pro Gln Arg Ser Asn Ala Ser Arg Asn Leu
Ala Ser Thr 290 295 300 Ser Gln Gly Pro Val Ala Gln Ser Ser Arg Glu
Ala Ser Ala Trp Met 305 310 315 320 Thr Ile Leu Ser Pro Ala Ala Asp
Ser Thr Pro Asp Pro Gly Val Gln 325 330 335 Gln Leu Pro Lys Gly Glu
Pro Glu Thr Asp Leu Asn Pro Glu Leu Pro 340 345 350 Ala Ala His Leu
Ile Gly Ala Trp Met Ser Gly Gln Gly Leu Ser Trp 355 360 365 Glu Ala
Ser Gln Glu Glu Ala Phe Leu Arg Ser Gly Ala Gln Phe Ser 370 375 380
Pro Thr His Gly Leu Ala Leu Pro Gln Asp Gly Val Tyr Tyr Leu Tyr 385
390 395 400 Cys His Val Gly Tyr Arg Gly Arg Thr Pro Pro Ala Gly Arg
Ser Arg 405 410 415 Ala Arg Ser Leu Thr Leu Arg Ser Ala Leu Tyr Arg
Ala Gly Gly Ala 420 425 430 Tyr Gly Arg Gly Ser Pro Glu Leu Leu Leu
Glu Gly Ala Glu Thr Val 435 440 445 Thr Pro Val Val Asp Pro Ile Gly
Tyr Gly Ser Leu Trp Tyr Thr Ser 450 455 460 Val Gly Phe Gly Gly Leu
Ala Gln Leu Arg Ser Gly Glu Arg Val Tyr 465 470 475 480 Val Asn Ile
Ser His Pro Asp Met Val Asp Tyr Arg Arg Gly Lys Thr 485 490 495 Phe
Phe Gly Ala Val Met Val Gly 500 <210> SEQ ID NO 290
<211> LENGTH: 427 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: GST-EK-C-LT_126-306 fusion protein <400>
SEQUENCE: 290 Ala Pro Leu Val Met Ser Pro Ile Leu Gly Tyr Trp Lys
Ile Lys Gly 1 5 10 15 Leu Val Gln Pro Thr Arg Leu Leu Leu Glu Tyr
Leu Glu Glu Lys Tyr 20 25 30 Glu Glu His Leu Tyr Glu Arg Asp Glu
Gly Asp Lys Trp Arg Asn Lys 35 40 45 Lys Phe Glu Leu Gly Leu Glu
Phe Pro Asn Leu Pro Tyr Tyr Ile Asp 50 55 60 Gly Asp Val Lys Leu
Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala 65 70 75 80 Asp Lys His
Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile 85 90 95 Ser
Met Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg 100 105
110 Ile Ala Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser
115 120 125 Lys Leu Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys
His Lys 130 135 140 Thr Tyr Leu Asn Gly Asp His Val Thr His Pro Asp
Phe Met Leu Tyr 145 150 155 160 Asp Ala Leu Asp Val Val Leu Tyr Met
Asp Pro Met Cys Leu Asp Ala 165 170 175 Phe Pro Lys Leu Val Cys Phe
Lys Lys Arg Ile Glu Ala Ile Pro Gln 180 185 190 Ile Asp Lys Tyr Leu
Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln 195 200 205 Gly Trp Gln
Ala Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ala Ser 210 215 220 Met
Thr Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp Asp 225 230
235 240 Lys Leu Ala Cys Gly Gly Ser Pro Ala Ala Asp Ser Thr Pro Asp
Pro 245 250 255 Gly Val Gln Gln Leu Pro Lys Gly Glu Pro Glu Thr Asp
Leu Asn Pro 260 265 270 Glu Leu Pro Ala Ala His Leu Ile Gly Ala Trp
Met Ser Gly Gln Gly 275 280 285 Leu Ser Trp Glu Ala Ser Gln Glu Glu
Ala Phe Leu Arg Ser Gly Ala 290 295 300 Gln Phe Ser Pro Thr His Gly
Leu Ala Leu Pro Gln Asp Gly Val Tyr 305 310 315 320 Tyr Leu Tyr Cys
His Val Gly Tyr Arg Gly Arg Thr Pro Pro Ala Gly 325 330 335 Arg Ser
Arg Ala Arg Ser Leu Thr Leu Arg Ser Ala Leu Tyr Arg Ala 340 345 350
Gly Gly Ala Tyr Gly Arg Gly Ser Pro Glu Leu Leu Leu Glu Gly Ala 355
360 365 Glu Thr Val Thr Pro Val Val Asp Pro Ile Gly Tyr Gly Ser Leu
Trp 370 375 380 Tyr Thr Ser Val Gly Phe Gly Gly Leu Ala Gln Leu Arg
Ser Gly Glu 385 390 395 400 Arg Val Tyr Val Asn Ile Ser His Pro Asp
Met Val Asp Tyr Arg Arg 405 410 415 Gly Lys Thr Phe Phe Gly Ala Val
Met Val Gly 420 425 <210> SEQ ID NO 291 <211> LENGTH:
311
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION:
his-myc-EK-C-LT_49-306 fusion protein <400> SEQUENCE: 291 Ala
Pro Leu Val His His His His His His Gly Pro Leu Val Asp Val 1 5 10
15 Ala Ser Asn Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Ala Ser Met
20 25 30 Thr Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp
Asp Lys 35 40 45 Leu Ala Cys Gly Gly Gln Asp Gln Gly Arg Arg Val
Glu Lys Ile Ile 50 55 60 Gly Ser Gly Ala Gln Ala Gln Lys Arg Leu
Asp Asp Ser Lys Pro Ser 65 70 75 80 Cys Ile Leu Pro Ser Pro Ser Ser
Leu Ser Glu Thr Pro Asp Pro Arg 85 90 95 Leu His Pro Gln Arg Ser
Asn Ala Ser Arg Asn Leu Ala Ser Thr Ser 100 105 110 Gln Gly Pro Val
Ala Gln Ser Ser Arg Glu Ala Ser Ala Trp Met Thr 115 120 125 Ile Leu
Ser Pro Ala Ala Asp Ser Thr Pro Asp Pro Gly Val Gln Gln 130 135 140
Leu Pro Lys Gly Glu Pro Glu Thr Asp Leu Asn Pro Glu Leu Pro Ala 145
150 155 160 Ala His Leu Ile Gly Ala Trp Met Ser Gly Gln Gly Leu Ser
Trp Glu 165 170 175 Ala Ser Gln Glu Glu Ala Phe Leu Arg Ser Gly Ala
Gln Phe Ser Pro 180 185 190 Thr His Gly Leu Ala Leu Pro Gln Asp Gly
Val Tyr Tyr Leu Tyr Cys 195 200 205 His Val Gly Tyr Arg Gly Arg Thr
Pro Pro Ala Gly Arg Ser Arg Ala 210 215 220 Arg Ser Leu Thr Leu Arg
Ser Ala Leu Tyr Arg Ala Gly Gly Ala Tyr 225 230 235 240 Gly Arg Gly
Ser Pro Glu Leu Leu Leu Glu Gly Ala Glu Thr Val Thr 245 250 255 Pro
Val Val Asp Pro Ile Gly Tyr Gly Ser Leu Trp Tyr Thr Ser Val 260 265
270 Gly Phe Gly Gly Leu Ala Gln Leu Arg Ser Gly Glu Arg Val Tyr Val
275 280 285 Asn Ile Ser His Pro Asp Met Val Asp Tyr Arg Arg Gly Lys
Thr Phe 290 295 300 Phe Gly Ala Val Met Val Gly 305 310 <210>
SEQ ID NO 292 <211> LENGTH: 234 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: his-myc-EK-C-LT_126-306 fusion
protein <400> SEQUENCE: 292 Ala Pro Leu Val His His His His
His His Gly Pro Leu Val Asp Val 1 5 10 15 Ala Ser Asn Glu Gln Lys
Leu Ile Ser Glu Glu Asp Leu Ala Ser Met 20 25 30 Thr Gly Gly Gln
Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp Asp Lys 35 40 45 Leu Ala
Cys Gly Gly Ser Pro Ala Ala Asp Ser Thr Pro Asp Pro Gly 50 55 60
Val Gln Gln Leu Pro Lys Gly Glu Pro Glu Thr Asp Leu Asn Pro Glu 65
70 75 80 Leu Pro Ala Ala His Leu Ile Gly Ala Trp Met Ser Gly Gln
Gly Leu 85 90 95 Ser Trp Glu Ala Ser Gln Glu Glu Ala Phe Leu Arg
Ser Gly Ala Gln 100 105 110 Phe Ser Pro Thr His Gly Leu Ala Leu Pro
Gln Asp Gly Val Tyr Tyr 115 120 125 Leu Tyr Cys His Val Gly Tyr Arg
Gly Arg Thr Pro Pro Ala Gly Arg 130 135 140 Ser Arg Ala Arg Ser Leu
Thr Leu Arg Ser Ala Leu Tyr Arg Ala Gly 145 150 155 160 Gly Ala Tyr
Gly Arg Gly Ser Pro Glu Leu Leu Leu Glu Gly Ala Glu 165 170 175 Thr
Val Thr Pro Val Val Asp Pro Ile Gly Tyr Gly Ser Leu Trp Tyr 180 185
190 Thr Ser Val Gly Phe Gly Gly Leu Ala Gln Leu Arg Ser Gly Glu Arg
195 200 205 Val Tyr Val Asn Ile Ser His Pro Asp Met Val Asp Tyr Arg
Arg Gly 210 215 220 Lys Thr Phe Phe Gly Ala Val Met Val Gly 225 230
<210> SEQ ID NO 293 <211> LENGTH: 43 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: MCS-1F primer <400> SEQUENCE:
293 tatggatccg gctagcgctc gagggtttaa acggcggccg cat 43 <210>
SEQ ID NO 294 <211> LENGTH: 45 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: MCS-1R primer <400> SEQUENCE:
294 tcgaatgcgg ccgccgttta aaccctcgag cgctagccgg atcca 45
<210> SEQ ID NO 295 <211> LENGTH: 58 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Bamhis6-EK-Nhe-F oligonucleotide
<400> SEQUENCE: 295 gatccacacc accaccacca ccacggttct
ggtgacgacg atgacaaagc gctagccc 58 <210> SEQ ID NO 296
<211> LENGTH: 58 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Bamhis6-EK-Nhe-R oligonucleotide <400> SEQUENCE:
296 tcgagggcta gcgctttgtc atcgtcgtca ccagaaccgt ggtggtggtg gtggtgtg
58 <210> SEQ ID NO 297 <211> LENGTH: 42 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: oligo1F-C-glycine-linker
<400> SEQUENCE: 297 tcgagggtgg tggtggtggt tgcggttaat
aagtttaaac gc 42 <210> SEQ ID NO 298 <211> LENGTH: 42
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION:
oligo1R-C-glycine-linker <400> SEQUENCE: 298 ggccgcgttt
aaacttatta accgcaacca ccaccaccac cc 42 <210> SEQ ID NO 299
<211> LENGTH: 51 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: oligo1F-C-gamma1-linker <400> SEQUENCE: 299
tcgaggataa aacccacacc tctccgccgt gtggttaata agtttaaacg c 51
<210> SEQ ID NO 300 <211> LENGTH: 51 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: oligo1R-C-gamma1-linker <400>
SEQUENCE: 300 ggccgcgttt aaacttatta accacacggc ggagaggtgt
gggttttatc c 51 <210> SEQ ID NO 301 <211> LENGTH: 36
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION:
oligo1FA-C-gamma3-linker <400> SEQUENCE: 301 tcgagccgaa
accgtctacc ccgccgggtt cttctg 36 <210> SEQ ID NO 302
<211> LENGTH: 38 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: oligo1RA-C-gamma3-linker <400> SEQUENCE: 302
caccaccaga agaacccggc ggggtagacg gtttcggc 38 <210> SEQ ID NO
303 <211> LENGTH: 39 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: oligo2FB-C-gamma3-linker <400> SEQUENCE:
303
gtggtgctcc gggtggttgc ggttaataag tttaaacgc 39 <210> SEQ ID NO
304 <211> LENGTH: 37 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: oligo2RB-C-gamma3-linker <400> SEQUENCE:
304 ggccgcgttt aaacttatta accgcaacca cccggag 37 <210> SEQ ID
NO 305 <211> LENGTH: 33 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: rMIF-F oligonucleotide <400> SEQUENCE: 305
ggaattccat atgcctatgt tcatcgtgaa cac 33 <210> SEQ ID NO 306
<211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: rMIF-Xho-R oligonucleotide <400> SEQUENCE: 306
cccgctcgag agcgaaggtg gaaccgttc 29 <210> SEQ ID NO 307
<211> LENGTH: 124 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: rMIF-C1 <400> SEQUENCE: 307 Met Pro Met Phe Ile
Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro 1 5 10 15 Glu Gly Phe
Leu Ser Glu Leu Thr Gln Gln Leu Ala Gln Ala Thr Gly 20 25 30 Lys
Pro Ala Gln Tyr Ile Ala Val His Val Val Pro Asp Gln Leu Met 35 40
45 Thr Phe Ser Gly Thr Ser Asp Pro Cys Ala Leu Cys Ser Leu His Ser
50 55 60 Ile Gly Lys Ile Gly Gly Ala Gln Asn Arg Asn Tyr Ser Lys
Leu Leu 65 70 75 80 Cys Gly Leu Leu Ser Asp Arg Leu His Ile Ser Pro
Asp Arg Val Tyr 85 90 95 Ile Asn Tyr Tyr Asp Met Asn Ala Ala Asn
Val Gly Trp Asn Gly Ser 100 105 110 Thr Phe Ala Leu Glu Gly Gly Gly
Gly Gly Cys Gly 115 120 <210> SEQ ID NO 308 <211>
LENGTH: 127 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
rMIF-C2 <400> SEQUENCE: 308 Met Pro Met Phe Ile Val Asn Thr
Asn Val Pro Arg Ala Ser Val Pro 1 5 10 15 Glu Gly Phe Leu Ser Glu
Leu Thr Gln Gln Leu Ala Gln Ala Thr Gly 20 25 30 Lys Pro Ala Gln
Tyr Ile Ala Val His Val Val Pro Asp Gln Leu Met 35 40 45 Thr Phe
Ser Gly Thr Ser Asp Pro Cys Ala Leu Cys Ser Leu His Ser 50 55 60
Ile Gly Lys Ile Gly Gly Ala Gln Asn Arg Asn Tyr Ser Lys Leu Leu 65
70 75 80 Cys Gly Leu Leu Ser Asp Arg Leu His Ile Ser Pro Asp Arg
Val Tyr 85 90 95 Ile Asn Tyr Tyr Asp Met Asn Ala Ala Asn Val Gly
Trp Asn Gly Ser 100 105 110 Thr Phe Ala Leu Glu Asp Lys Thr His Thr
Ser Pro Pro Cys Gly 115 120 125 <210> SEQ ID NO 309
<211> LENGTH: 135 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: rMIF-C3 <400> SEQUENCE: 309 Met Pro Met Phe Ile
Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro 1 5 10 15 Glu Gly Phe
Leu Ser Glu Leu Thr Gln Gln Leu Ala Gln Ala Thr Gly 20 25 30 Lys
Pro Ala Gln Tyr Ile Ala Val His Val Val Pro Asp Gln Leu Met 35 40
45 Thr Phe Ser Gly Thr Ser Asp Pro Cys Ala Leu Cys Ser Leu His Ser
50 55 60 Ile Gly Lys Ile Gly Gly Ala Gln Asn Arg Asn Tyr Ser Lys
Leu Leu 65 70 75 80 Cys Gly Leu Leu Ser Asp Arg Leu His Ile Ser Pro
Asp Arg Val Tyr 85 90 95 Ile Asn Tyr Tyr Asp Met Asn Ala Ala Asn
Val Gly Trp Asn Gly Ser 100 105 110 Thr Phe Ala Leu Glu Pro Lys Pro
Ser Thr Pro Pro Gly Ser Ser Gly 115 120 125 Gly Ala Pro Gly Gly Cys
Gly 130 135 <210> SEQ ID NO 310 <211> LENGTH: 124
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 310 Met Pro Met Phe Ile Val Asn Thr Asn Val
Pro Arg Ala Ser Val Pro 1 5 10 15 Asp Gly Phe Leu Ser Glu Leu Thr
Gln Gln Leu Ala Gln Ala Thr Gly 20 25 30 Lys Pro Pro Gln Tyr Ile
Ala Val His Val Val Pro Asp Gln Leu Met 35 40 45 Ala Phe Gly Gly
Ser Ser Glu Pro Cys Ala Leu Cys Ser Leu His Ser 50 55 60 Ile Gly
Lys Ile Gly Gly Ala Gln Asn Arg Ser Tyr Ser Lys Leu Leu 65 70 75 80
Cys Gly Leu Leu Ala Glu Arg Leu Arg Ile Ser Pro Asp Arg Val Tyr 85
90 95 Ile Asn Tyr Tyr Asp Met Asn Ala Ala Asn Val Gly Trp Asn Asn
Ser 100 105 110 Thr Phe Ala Leu Glu Gly Gly Gly Gly Gly Cys Gly 115
120 <210> SEQ ID NO 311 <211> LENGTH: 123 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
311 Pro Met Phe Ile Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro Asp
1 5 10 15 Gly Phe Leu Ser Glu Leu Thr Gln Gln Leu Ala Gln Ala Thr
Gly Lys 20 25 30 Pro Pro Gln Tyr Ile Ala Val His Val Val Pro Asp
Gln Leu Met Ala 35 40 45 Phe Gly Gly Ser Ser Glu Pro Cys Ala Leu
Cys Ser Leu His Ser Ile 50 55 60 Gly Lys Ile Gly Gly Ala Gln Asn
Arg Ser Tyr Ser Lys Leu Leu Cys 65 70 75 80 Gly Leu Leu Ala Glu Arg
Leu Arg Ile Ser Pro Asp Arg Val Tyr Ile 85 90 95 Asn Tyr Tyr Asp
Met Asn Ala Ala Asn Val Gly Trp Asn Asn Ser Thr 100 105 110 Phe Ala
Leu Glu Gly Gly Gly Gly Gly Cys Gly 115 120 <210> SEQ ID NO
312 <211> LENGTH: 127 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 312 Met Pro Met Phe
Ile Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro 1 5 10 15 Asp Gly
Phe Leu Ser Glu Leu Thr Gln Gln Leu Ala Gln Ala Thr Gly 20 25 30
Lys Pro Pro Gln Tyr Ile Ala Val His Val Val Pro Asp Gln Leu Met 35
40 45 Ala Phe Gly Gly Ser Ser Glu Pro Cys Ala Leu Cys Ser Leu His
Ser 50 55 60 Ile Gly Lys Ile Gly Gly Ala Gln Asn Arg Ser Tyr Ser
Lys Leu Leu 65 70 75 80 Cys Gly Leu Leu Ala Glu Arg Leu Arg Ile Ser
Pro Asp Arg Val Tyr 85 90 95 Ile Asn Tyr Tyr Asp Met Asn Ala Ala
Asn Val Gly Trp Asn Asn Ser 100 105 110 Thr Phe Ala Leu Glu Asp Lys
Thr His Thr Ser Pro Pro Cys Gly 115 120 125 <210> SEQ ID NO
313 <211> LENGTH: 126 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 313 Pro Met Phe Ile
Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro Asp 1 5 10 15
Gly Phe Leu Ser Glu Leu Thr Gln Gln Leu Ala Gln Ala Thr Gly Lys 20
25 30 Pro Pro Gln Tyr Ile Ala Val His Val Val Pro Asp Gln Leu Met
Ala 35 40 45 Phe Gly Gly Ser Ser Glu Pro Cys Ala Leu Cys Ser Leu
His Ser Ile 50 55 60 Gly Lys Ile Gly Gly Ala Gln Asn Arg Ser Tyr
Ser Lys Leu Leu Cys 65 70 75 80 Gly Leu Leu Ala Glu Arg Leu Arg Ile
Ser Pro Asp Arg Val Tyr Ile 85 90 95 Asn Tyr Tyr Asp Met Asn Ala
Ala Asn Val Gly Trp Asn Asn Ser Thr 100 105 110 Phe Ala Leu Glu Asp
Lys Thr His Thr Ser Pro Pro Cys Gly 115 120 125 <210> SEQ ID
NO 314 <211> LENGTH: 135 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 314 Met Pro Met Phe
Ile Val Asn Thr Asn Val Pro Arg Ala Ser Val Pro 1 5 10 15 Asp Gly
Phe Leu Ser Glu Leu Thr Gln Gln Leu Ala Gln Ala Thr Gly 20 25 30
Lys Pro Pro Gln Tyr Ile Ala Val His Val Val Pro Asp Gln Leu Met 35
40 45 Ala Phe Gly Gly Ser Ser Glu Pro Cys Ala Leu Cys Ser Leu His
Ser 50 55 60 Ile Gly Lys Ile Gly Gly Ala Gln Asn Arg Ser Tyr Ser
Lys Leu Leu 65 70 75 80 Cys Gly Leu Leu Ala Glu Arg Leu Arg Ile Ser
Pro Asp Arg Val Tyr 85 90 95 Ile Asn Tyr Tyr Asp Met Asn Ala Ala
Asn Val Gly Trp Asn Asn Ser 100 105 110 Thr Phe Ala Leu Glu Pro Lys
Pro Ser Thr Pro Pro Gly Ser Ser Gly 115 120 125 Gly Ala Pro Gly Gly
Cys Gly 130 135 <210> SEQ ID NO 315 <211> LENGTH: 134
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 315 Pro Met Phe Ile Val Asn Thr Asn Val Pro
Arg Ala Ser Val Pro Asp 1 5 10 15 Gly Phe Leu Ser Glu Leu Thr Gln
Gln Leu Ala Gln Ala Thr Gly Lys 20 25 30 Pro Pro Gln Tyr Ile Ala
Val His Val Val Pro Asp Gln Leu Met Ala 35 40 45 Phe Gly Gly Ser
Ser Glu Pro Cys Ala Leu Cys Ser Leu His Ser Ile 50 55 60 Gly Lys
Ile Gly Gly Ala Gln Asn Arg Ser Tyr Ser Lys Leu Leu Cys 65 70 75 80
Gly Leu Leu Ala Glu Arg Leu Arg Ile Ser Pro Asp Arg Val Tyr Ile 85
90 95 Asn Tyr Tyr Asp Met Asn Ala Ala Asn Val Gly Trp Asn Asn Ser
Thr 100 105 110 Phe Ala Leu Glu Pro Lys Pro Ser Thr Pro Pro Gly Ser
Ser Gly Gly 115 120 125 Ala Pro Gly Gly Cys Gly 130 <210> SEQ
ID NO 316 <211> LENGTH: 62 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: RANKL-UP oligonucleotide <400> SEQUENCE:
316 ctgccagggg cccgggtgcg gcggtggcca tcatcaccac catcaccagc
gcttctcagg 60 ag 62 <210> SEQ ID NO 317 <211> LENGTH:
35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: RANKL-down
oligonucleotide <400> SEQUENCE: 317 ccgctcgagt tagtctatgt
cctgaacttt gaaag 35 <210> SEQ ID NO 318 <211> LENGTH:
419 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: GST-PS-C-RANKL
construct <400> SEQUENCE: 318 Met Ser Pro Ile Leu Gly Tyr Trp
Lys Ile Lys Gly Leu Val Gln Pro 1 5 10 15 Thr Arg Leu Leu Leu Glu
Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 20 25 30 Tyr Glu Arg Asp
Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 35 40 45 Gly Leu
Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys 50 55 60
Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn 65
70 75 80 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met
Leu Glu 85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg
Ile Ala Tyr Ser 100 105 110 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe
Leu Ser Lys Leu Pro Glu 115 120 125 Met Leu Lys Met Phe Glu Asp Arg
Leu Cys His Lys Thr Tyr Leu Asn 130 135 140 Gly Asp His Val Thr His
Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 145 150 155 160 Val Val Leu
Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 165 170 175 Val
Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 180 185
190 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala
195 200 205 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Glu
Val Leu 210 215 220 Phe Gln Gly Pro Gly Cys Gly Gly Gly His His His
His His His Gln 225 230 235 240 Arg Phe Ser Gly Ala Pro Ala Met Met
Glu Gly Ser Trp Leu Asp Val 245 250 255 Ala Gln Arg Gly Lys Pro Glu
Ala Gln Pro Phe Ala His Leu Thr Ile 260 265 270 Asn Ala Ala Ser Ile
Pro Ser Gly Ser His Lys Val Thr Leu Ser Ser 275 280 285 Trp Tyr His
Asp Arg Gly Trp Ala Lys Ile Ser Asn Met Thr Leu Ser 290 295 300 Asn
Gly Lys Leu Arg Val Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala 305 310
315 320 Asn Ile Cys Phe Arg His His Glu Thr Ser Gly Ser Val Pro Thr
Asp 325 330 335 Tyr Leu Gln Leu Met Val Tyr Val Val Lys Thr Ser Ile
Lys Ile Pro 340 345 350 Ser Ser His Asn Leu Met Lys Gly Gly Ser Thr
Lys Asn Trp Ser Gly 355 360 365 Asn Ser Glu Phe His Phe Tyr Ser Ile
Asn Val Gly Gly Phe Phe Lys 370 375 380 Leu Arg Ala Gly Glu Glu Ile
Ser Ile Gln Val Ser Asn Pro Ser Leu 385 390 395 400 Leu Asp Pro Asp
Gln Asp Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln 405 410 415 Asp Ile
Asp <210> SEQ ID NO 319 <211> LENGTH: 1269 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: GST-PS-C-RANKL construct
<400> SEQUENCE: 319 atgtccccta tactaggtta ttggaaaatt
aagggccttg tgcaacccac tcgacttctt 60 ttggaatatc ttgaagaaaa
atatgaagag catttgtatg agcgcgatga aggtgataaa 120 tggcgaaaca
aaaagtttga attgggtttg gagtttccca atcttcctta ttatattgat 180
ggtgatgtta aattaacaca gtctatggcc atcatacgtt atatagctga caagcacaac
240 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg
agcggttttg 300 gatattagat acggtgtttc gagaattgca tatagtaaag
actttgaaac tctcaaagtt 360 gattttctta gcaagctacc tgaaatgctg
aaaatgttcg aagatcgttt atgtcataaa 420 acatatttaa atggtgatca
tgtaacccat cctgacttca tgttgtatga cgctcttgat 480 gttgttttat
acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa 540
aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca
600 tggcctttgc agggctggca agccacgttt ggtggtggcg accatcctcc
aaaatcggat 660 ctggaagttc tgttccaggg gcccgggtgc ggcggtggcc
atcatcacca ccatcaccag 720 cgcttctcag gagctccagc tatgatggaa
ggctcatggt tggatgtggc ccagcgaggc 780 aagcctgagg cccagccatt
tgcacacctc accatcaatg ctgccagcat cccatcgggt 840 tcccataaag
tcactctgtc ctcttggtac cacgatcgag gctgggccaa gatctctaac 900
atgacgttaa gcaacggaaa actaagggtt aaccaagatg gcttctatta cctgtacgcc
960 aacatttgct ttcggcatca tgaaacatcg ggaagcgtac ctacagacta
tcttcagctg 1020
atggtgtatg tcgttaaaac cagcatcaaa atcccaagtt ctcataacct gatgaaagga
1080 gggagcacga aaaactggtc gggcaattct gaattccact tttattccat
aaatgttggg 1140 ggatttttca agctccgagc tggtgaagaa attagcattc
aggtgtccaa cccttccctg 1200 ctggatccgg atcaagatgc gacgtacttt
ggggctttca aagttcagga catagactaa 1260 ctcgagcgg 1269 <210>
SEQ ID NO 320 <211> LENGTH: 185 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 320 Gly
Cys Gly Gly Gly Gln His Ile Arg Ala Glu Lys Ala Met Val Asp 1 5 10
15 Gly Ser Trp Leu Asp Leu Ala Lys Arg Ser Lys Leu Glu Ala Gln Pro
20 25 30 Phe Ala His Leu Thr Ile Asn Ala Thr Asp Ile Pro Ser Gly
Ser His 35 40 45 Lys Val Ser Leu Ser Ser Trp Tyr His Asp Arg Gly
Trp Ala Lys Ile 50 55 60 Ser Asn Met Thr Phe Ser Asn Gly Lys Leu
Ile Val Asn Gln Asp Gly 65 70 75 80 Phe Tyr Tyr Leu Tyr Ala Asn Ile
Cys Phe Arg His His Glu Thr Ser 85 90 95 Gly Asp Leu Ala Thr Glu
Tyr Leu Gln Leu Met Val Tyr Val Thr Lys 100 105 110 Thr Ser Ile Lys
Ile Pro Ser Ser His Thr Leu Met Lys Gly Gly Ser 115 120 125 Thr Lys
Tyr Trp Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile Asn 130 135 140
Val Gly Gly Phe Phe Lys Leu Arg Ser Gly Glu Glu Ile Ser Ile Glu 145
150 155 160 Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr
Tyr Phe 165 170 175 Gly Ala Phe Lys Val Arg Asp Ile Asp 180 185
<210> SEQ ID NO 321 <211> LENGTH: 29 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer 5'PrP-BamHI <400>
SEQUENCE: 321 cgggatccca ccatggtggg gggccttgg 29 <210> SEQ ID
NO 322 <211> LENGTH: 24 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Primer 3'PrP-NheI <400> SEQUENCE: 322
ctagctagcc tggatcttct cccg 24 <210> SEQ ID NO 323 <211>
LENGTH: 350 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
mPrPt-EK-Fc construct <400> SEQUENCE: 323 Met Val Gly Gly Leu
Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg 1 5 10 15 Pro Met Ile
His Phe Gly Asn Asp Trp Glu Asp Arg Tyr Tyr Arg Glu 20 25 30 Asn
Met Tyr Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln 35 40
45 Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Ile
50 55 60 Lys Gln His Thr Val Thr Thr Thr Thr Lys Gly Glu Asn Phe
Thr Glu 65 70 75 80 Thr Asp Val Lys Met Met Glu Arg Val Val Glu Gln
Met Cys Val Thr 85 90 95 Gln Tyr Gln Lys Glu Ser Gln Ala Tyr Tyr
Asp Gly Arg Ser Arg Leu 100 105 110 Ala Gly Gly Gly Gly Cys Gly Asp
Asp Asp Asp Lys Leu Thr His Thr 115 120 125 Cys Pro Pro Cys Pro Ala
Pro Glu Ala Glu Gly Ala Pro Ser Val Phe 130 135 140 Leu Phe Pro Pro
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 145 150 155 160 Glu
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val 165 170
175 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
180 185 190 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
Ser Val 195 200 205 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys 210 215 220 Lys Val Ser Asn Lys Ala Leu Pro Ala Ser
Ile Glu Lys Thr Ile Ser 225 230 235 240 Lys Ala Lys Gly Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu Pro Pro 245 250 255 Ser Arg Asp Glu Leu
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 260 265 270 Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 275 280 285 Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 290 295
300 Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
305 310 315 320 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
Ala Leu His 325 330 335 Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys 340 345 350 <210> SEQ ID NO 324 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: mPrPt
construct <400> SEQUENCE: 324 Met Val Gly Gly Leu Gly Gly Tyr
Met Leu Gly Ser Ala Met Ser Arg 1 5 10 15 Pro Met Ile His Phe Gly
Asn Asp Trp Glu Asp Arg Tyr Tyr Arg Glu 20 25 30 Asn Met Tyr Arg
Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln 35 40 45 Tyr Ser
Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Ile 50 55 60
Lys Gln His Thr Val Thr Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu 65
70 75 80 Thr Asp Val Lys Met Met Glu Arg Val Val Glu Gln Met Cys
Val Thr 85 90 95 Gln Tyr Gln Lys Glu Ser Gln Ala Tyr Tyr Asp Gly
Arg Ser Arg Leu 100 105 110 Ala Gly Gly Gly Gly Cys Gly Asp Asp Asp
Asp Lys 115 120 <210> SEQ ID NO 325 <211> LENGTH: 102
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: human
resistin-C-Xa construct <400> SEQUENCE: 325 Ser Ser Lys Thr
Leu Cys Ser Met Glu Glu Ala Ile Asn Glu Arg Ile 1 5 10 15 Gln Glu
Val Ala Gly Ser Leu Ile Phe Arg Ala Ile Ser Ser Ile Gly 20 25 30
Leu Glu Cys Gln Ser Val Thr Ser Arg Gly Asp Leu Ala Thr Cys Pro 35
40 45 Arg Gly Phe Ala Val Thr Gly Cys Thr Cys Gly Ser Ala Cys Gly
Ser 50 55 60 Trp Asp Val Arg Ala Glu Thr Thr Cys His Cys Gln Cys
Ala Gly Met 65 70 75 80 Asp Trp Thr Gly Ala Arg Cys Cys Arg Val Gln
Pro Gly Gly Gly Gly 85 90 95 Cys Gly Ile Glu Gly Arg 100
<210> SEQ ID NO 326 <211> LENGTH: 103 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: human resistin-C-EK construct
<400> SEQUENCE: 326 Ser Ser Lys Thr Leu Cys Ser Met Glu Glu
Ala Ile Asn Glu Arg Ile 1 5 10 15 Gln Glu Val Ala Gly Ser Leu Ile
Phe Arg Ala Ile Ser Ser Ile Gly 20 25 30 Leu Glu Cys Gln Ser Val
Thr Ser Arg Gly Asp Leu Ala Thr Cys Pro 35 40 45 Arg Gly Phe Ala
Val Thr Gly Cys Thr Cys Gly Ser Ala Cys Gly Ser 50 55 60 Trp Asp
Val Arg Ala Glu Thr Thr Cys His Cys Gln Cys Ala Gly Met 65 70 75 80
Asp Trp Thr Gly Ala Arg Cys Cys Arg Val Gln Pro Gly Gly Gly Gly 85
90 95 Cys Gly Asp Asp Asp Asp Lys 100
<210> SEQ ID NO 327 <211> LENGTH: 98 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: human resisitin-C construct
<400> SEQUENCE: 327 Ser Ser Lys Thr Leu Cys Ser Met Glu Glu
Ala Ile Asn Glu Arg Ile 1 5 10 15 Gln Glu Val Ala Gly Ser Leu Ile
Phe Arg Ala Ile Ser Ser Ile Gly 20 25 30 Leu Glu Cys Gln Ser Val
Thr Ser Arg Gly Asp Leu Ala Thr Cys Pro 35 40 45 Arg Gly Phe Ala
Val Thr Gly Cys Thr Cys Gly Ser Ala Cys Gly Ser 50 55 60 Trp Asp
Val Arg Ala Glu Thr Thr Cys His Cys Gln Cys Ala Gly Met 65 70 75 80
Asp Trp Thr Gly Ala Arg Cys Cys Arg Val Gln Pro Gly Gly Gly Gly 85
90 95 Cys Gly <210> SEQ ID NO 328 <211> LENGTH: 132
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: mouse C-IL-13-F
construct <400> SEQUENCE: 328 Ala Asp Pro Gly Cys Gly Gly Gly
Gly Gly Leu Ala Gly Pro Val Pro 1 5 10 15 Arg Ser Val Ser Leu Pro
Leu Thr Leu Lys Glu Leu Ile Glu Glu Leu 20 25 30 Ser Asn Ile Thr
Gln Asp Gln Thr Pro Leu Cys Asn Gly Ser Met Val 35 40 45 Trp Ser
Val Asp Leu Ala Ala Gly Gly Phe Cys Val Ala Leu Asp Ser 50 55 60
Leu Thr Asn Ile Ser Asn Cys Asn Ala Ile Tyr Arg Thr Gln Arg Ile 65
70 75 80 Leu His Gly Leu Cys Asn Arg Lys Ala Pro Thr Thr Val Ser
Ser Leu 85 90 95 Pro Asp Thr Lys Ile Glu Val Ala His Phe Ile Thr
Lys Leu Leu Ser 100 105 110 Tyr Thr Lys Gln Leu Phe Arg His Gly Pro
Phe Leu Glu Val Leu Ala 115 120 125 Ile Glu Gly Arg 130 <210>
SEQ ID NO 329 <211> LENGTH: 119 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: mouse C-IL-13-S construct
<400> SEQUENCE: 329 Leu Ala Cys Gly Gly Gly Gly Gly Gly Pro
Val Pro Arg Ser Val Ser 1 5 10 15 Leu Pro Leu Thr Leu Lys Glu Leu
Ile Glu Glu Leu Ser Asn Ile Thr 20 25 30 Gln Asp Gln Thr Pro Leu
Cys Asn Gly Ser Met Val Trp Ser Val Asp 35 40 45 Leu Ala Ala Gly
Gly Phe Cys Val Ala Leu Asp Ser Leu Thr Asn Ile 50 55 60 Ser Asn
Cys Asn Ala Ile Tyr Arg Thr Gln Arg Ile Leu His Gly Leu 65 70 75 80
Cys Asn Arg Lys Ala Pro Thr Thr Val Ser Ser Leu Pro Asp Thr Lys 85
90 95 Ile Glu Val Ala His Phe Ile Thr Lys Leu Leu Ser Tyr Thr Lys
Gln 100 105 110 Leu Phe Arg His Gly Pro Phe 115 <210> SEQ ID
NO 330 <211> LENGTH: 133 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: human C-IL-13-F construct <400> SEQUENCE:
330 Ala Asp Pro Gly Cys Gly Gly Gly Gly Gly Leu Ala Gly Pro Val Pro
1 5 10 15 Pro Ser Thr Ala Leu Arg Glu Leu Ile Glu Glu Leu Val Asn
Ile Thr 20 25 30 Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser Met
Val Trp Ser Ile 35 40 45 Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala
Leu Glu Ser Leu Ile Asn 50 55 60 Val Ser Gly Cys Ser Ala Ile Glu
Lys Thr Gln Arg Met Leu Ser Gly 65 70 75 80 Phe Cys Pro His Lys Val
Ser Ala Gly Gln Phe Ser Ser Leu His Val 85 90 95 Arg Asp Thr Lys
Ile Glu Val Ala Gln Phe Val Lys Asp Leu Leu Leu 100 105 110 His Leu
Lys Lys Leu Phe Arg Glu Gly Arg Phe Asn Leu Glu Val Leu 115 120 125
Ala Ile Glu Gly Arg 130 <210> SEQ ID NO 331 <211>
LENGTH: 120 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: human
C-IL-13-S construct <400> SEQUENCE: 331 Leu Ala Cys Gly Gly
Gly Gly Gly Gly Pro Val Pro Pro Ser Thr Ala 1 5 10 15 Leu Arg Glu
Leu Ile Glu Glu Leu Val Asn Ile Thr Gln Asn Gln Lys 20 25 30 Ala
Pro Leu Cys Asn Gly Ser Met Val Trp Ser Ile Asn Leu Thr Ala 35 40
45 Gly Met Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys
50 55 60 Ser Ala Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys
Pro His 65 70 75 80 Lys Val Ser Ala Gly Gln Phe Ser Ser Leu His Val
Arg Asp Thr Lys 85 90 95 Ile Glu Val Ala Gln Phe Val Lys Asp Leu
Leu Leu His Leu Lys Lys 100 105 110 Leu Phe Arg Glu Gly Arg Phe Asn
115 120 <210> SEQ ID NO 332 <211> LENGTH: 136
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: mouse C-IL-5-E
construct <400> SEQUENCE: 332 Ala Leu Val Gly Cys Gly Gly Pro
Lys Pro Ser Thr Pro Pro Gly Ser 1 5 10 15 Ser Gly Gly Ala Pro Ala
Ser Met Glu Ile Pro Met Ser Thr Val Val 20 25 30 Lys Glu Thr Leu
Thr Gln Leu Ser Ala His Arg Ala Leu Leu Thr Ser 35 40 45 Asn Glu
Thr Met Arg Leu Pro Val Pro Thr His Lys Asn His Gln Leu 50 55 60
Cys Ile Gly Glu Ile Phe Gln Gly Leu Asp Ile Leu Lys Asn Gln Thr 65
70 75 80 Val Arg Gly Gly Thr Val Glu Met Leu Phe Gln Asn Leu Ser
Leu Ile 85 90 95 Lys Lys Tyr Ile Asp Arg Gln Lys Glu Lys Cys Gly
Glu Glu Arg Arg 100 105 110 Arg Thr Arg Gln Phe Leu Asp Tyr Leu Gln
Glu Phe Leu Gly Val Met 115 120 125 Ser Thr Glu Trp Ala Met Glu Gly
130 135 <210> SEQ ID NO 333 <211> LENGTH: 134
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: mouse C-IL-5-F
construct <400> SEQUENCE: 333 Ala Asp Pro Gly Cys Gly Gly Gly
Gly Gly Leu Ala Met Glu Ile Pro 1 5 10 15 Met Ser Thr Val Val Lys
Glu Thr Leu Thr Gln Leu Ser Ala His Arg 20 25 30 Ala Leu Leu Thr
Ser Asn Glu Thr Met Arg Leu Pro Val Pro Thr His 35 40 45 Lys Asn
His Gln Leu Cys Ile Gly Glu Ile Phe Gln Gly Leu Asp Ile 50 55 60
Leu Lys Asn Gln Thr Val Arg Gly Gly Thr Val Glu Met Leu Phe Gln 65
70 75 80 Asn Leu Ser Leu Ile Lys Lys Tyr Ile Asp Arg Gln Lys Glu
Lys Cys 85 90 95 Gly Glu Glu Arg Arg Arg Thr Arg Gln Phe Leu Asp
Tyr Leu Gln Glu 100 105 110 Phe Leu Gly Val Met Ser Thr Glu Trp Ala
Met Glu Gly Leu Glu Val 115 120 125 Leu Ala Ile Glu Gly Arg 130
<210> SEQ ID NO 334 <211> LENGTH: 121 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE:
<223> OTHER INFORMATION: mouse C-IL-5-S construct <400>
SEQUENCE: 334 Leu Ala Cys Gly Gly Gly Gly Gly Met Glu Ile Pro Met
Ser Thr Val 1 5 10 15 Val Lys Glu Thr Leu Thr Gln Leu Ser Ala His
Arg Ala Leu Leu Thr 20 25 30 Ser Asn Glu Thr Met Arg Leu Pro Val
Pro Thr His Lys Asn His Gln 35 40 45 Leu Cys Ile Gly Glu Ile Phe
Gln Gly Leu Asp Ile Leu Lys Asn Gln 50 55 60 Thr Val Arg Gly Gly
Thr Val Glu Met Leu Phe Gln Asn Leu Ser Leu 65 70 75 80 Ile Lys Lys
Tyr Ile Asp Arg Gln Lys Glu Lys Cys Gly Glu Glu Arg 85 90 95 Arg
Arg Thr Arg Gln Phe Leu Asp Tyr Leu Gln Glu Phe Leu Gly Val 100 105
110 Met Ser Thr Glu Trp Ala Met Glu Gly 115 120 <210> SEQ ID
NO 335 <211> LENGTH: 138 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: human C-IL-5-E construct <400> SEQUENCE:
335 Ala Leu Val Gly Cys Gly Gly Pro Lys Pro Ser Thr Pro Pro Gly Ser
1 5 10 15 Ser Gly Gly Ala Pro Ala Ser Ile Pro Thr Glu Ile Pro Thr
Ser Ala 20 25 30 Leu Val Lys Glu Thr Leu Ala Leu Leu Ser Thr His
Arg Thr Leu Leu 35 40 45 Ile Ala Asn Glu Thr Leu Arg Ile Pro Val
Pro Val His Lys Asn His 50 55 60 Gln Leu Cys Thr Glu Glu Ile Phe
Gln Gly Ile Gly Thr Leu Glu Ser 65 70 75 80 Gln Thr Val Gln Gly Gly
Thr Val Glu Arg Leu Phe Lys Asn Leu Ser 85 90 95 Leu Ile Lys Lys
Tyr Ile Asp Gly Gln Lys Lys Lys Cys Gly Glu Glu 100 105 110 Arg Arg
Arg Val Asn Gln Phe Leu Asp Tyr Leu Gln Glu Phe Leu Gly 115 120 125
Val Met Asn Thr Glu Trp Ile Ile Glu Ser 130 135 <210> SEQ ID
NO 336 <211> LENGTH: 136 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: human C-IL-5-F construct <400> SEQUENCE:
336 Ala Asp Pro Gly Cys Gly Gly Gly Gly Gly Leu Ala Ile Pro Thr Glu
1 5 10 15 Ile Pro Thr Ser Ala Leu Val Lys Glu Thr Leu Ala Leu Leu
Ser Thr 20 25 30 His Arg Thr Leu Leu Ile Ala Asn Glu Thr Leu Arg
Ile Pro Val Pro 35 40 45 Val His Lys Asn His Gln Leu Cys Thr Glu
Glu Ile Phe Gln Gly Ile 50 55 60 Gly Thr Leu Glu Ser Gln Thr Val
Gln Gly Gly Thr Val Glu Arg Leu 65 70 75 80 Phe Lys Asn Leu Ser Leu
Ile Lys Lys Tyr Ile Asp Gly Gln Lys Lys 85 90 95 Lys Cys Gly Glu
Glu Arg Arg Arg Val Asn Gln Phe Leu Asp Tyr Leu 100 105 110 Gln Glu
Phe Leu Gly Val Met Asn Thr Glu Trp Ile Ile Glu Ser Leu 115 120 125
Glu Val Leu Ala Ile Glu Gly Arg 130 135 <210> SEQ ID NO 337
<211> LENGTH: 123 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: human C-IL-5-S construct <400> SEQUENCE: 337 Leu
Ala Cys Gly Gly Gly Gly Gly Ile Pro Thr Glu Ile Pro Thr Ser 1 5 10
15 Ala Leu Val Lys Glu Thr Leu Ala Leu Leu Ser Thr His Arg Thr Leu
20 25 30 Leu Ile Ala Asn Glu Thr Leu Arg Ile Pro Val Pro Val His
Lys Asn 35 40 45 His Gln Leu Cys Thr Glu Glu Ile Phe Gln Gly Ile
Gly Thr Leu Glu 50 55 60 Ser Gln Thr Val Gln Gly Gly Thr Val Glu
Arg Leu Phe Lys Asn Leu 65 70 75 80 Ser Leu Ile Lys Lys Tyr Ile Asp
Gly Gln Lys Lys Lys Cys Gly Glu 85 90 95 Glu Arg Arg Arg Val Asn
Gln Phe Leu Asp Tyr Leu Gln Glu Phe Leu 100 105 110 Gly Val Met Asn
Thr Glu Trp Ile Ile Glu Ser 115 120 <210> SEQ ID NO 338
<211> LENGTH: 27 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: primer NheIL13-F <400> SEQUENCE: 338 Cys Thr Ala
Gly Cys Thr Ala Gly Cys Cys Gly Gly Gly Cys Cys Gly 1 5 10 15 Gly
Thr Gly Cys Cys Ala Ala Gly Ala Thr Cys 20 25 <210> SEQ ID NO
339 <211> LENGTH: 26 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: primer XhoIL13-R <400> SEQUENCE: 339
tttctcgagg aaggggccgt ggcgaa 26 <210> SEQ ID NO 340
<211> LENGTH: 55 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: primer Spelinker3-F1 <400> SEQUENCE: 340
ccccgccggg ttcttctggc ggtgctccgg ctagcatgga gattcccatg agcac 55
<210> SEQ ID NO 341 <211> LENGTH: 52 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Primer SpeNlinker3-F2 <400>
SEQUENCE: 341 ttttactagt tggttgcggc ggcccgaaac cgagcacccc
gccgggttct tc 52 <210> SEQ ID NO 342 <211> LENGTH: 49
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Primer
IL5StopXho-R <400> SEQUENCE: 342 ttttgcggcc gcgtttaaac
tcgagttatt agccttccat tgcccactc 49 <210> SEQ ID NO 343
<211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer BamH1-FLK1-F <400> SEQUENCE: 343
cgcggatcca ttcatcgcct ctgtc 25 <210> SEQ ID NO 344
<211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Primer Nhe1-FLK1-B <400> SEQUENCE: 344
ctagctagct ttgtgtgaac tcggac 26 <210> SEQ ID NO 345
<211> LENGTH: 205 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: mVEGFR-2 (2-3) fragment <400> SEQUENCE: 345 Pro
Phe Ile Ala Ser Val Ser Asp Gln His Gly Ile Val Tyr Ile Thr 1 5 10
15 Glu Asn Lys Asn Lys Thr Val Val Ile Pro Cys Arg Gly Ser Ile Ser
20 25 30 Asn Leu Asn Val Ser Leu Cys Ala Arg Tyr Pro Glu Lys Arg
Phe Val 35 40 45 Pro Asp Gly Asn Arg Ile Ser Trp Asp Ser Glu Ile
Gly Phe Thr Leu 50 55 60 Pro Ser Tyr Met Ile Ser Tyr Ala Gly Met
Val Phe Cys Glu Ala Lys 65 70 75 80 Ile Asn Asp Glu Thr Tyr Gln Ser
Ile Met Tyr Ile Val Val Val Val 85 90 95
Gly Tyr Arg Ile Tyr Asp Val Ile Leu Ser Pro Pro His Glu Ile Glu 100
105 110 Leu Ser Ala Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr
Glu 115 120 125 Leu Asn Val Gly Leu Asp Phe Thr Trp His Ser Pro Pro
Ser Lys Ser 130 135 140 His His Lys Lys Ile Val Asn Arg Asp Val Lys
Pro Phe Pro Gly Thr 145 150 155 160 Val Ala Lys Met Phe Leu Ser Thr
Leu Thr Ile Glu Ser Val Thr Lys 165 170 175 Ser Asp Gln Gly Glu Tyr
Thr Cys Val Ala Ser Ser Gly Arg Met Ile 180 185 190 Lys Arg Asn Arg
Thr Phe Val Arg Val His Thr Lys Pro 195 200 205 <210> SEQ ID
NO 346 <211> LENGTH: 263 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: human C-LT_49-306 fragment <400> SEQUENCE:
346 Leu Ala Cys Gly Gly Gln Asp Gln Gly Arg Arg Val Glu Lys Ile Ile
1 5 10 15 Gly Ser Gly Ala Gln Ala Gln Lys Arg Leu Asp Asp Ser Lys
Pro Ser 20 25 30 Cys Ile Leu Pro Ser Pro Ser Ser Leu Ser Glu Thr
Pro Asp Pro Arg 35 40 45 Leu His Pro Gln Arg Ser Asn Ala Ser Arg
Asn Leu Ala Ser Thr Ser 50 55 60 Gln Gly Pro Val Ala Gln Ser Ser
Arg Glu Ala Ser Ala Trp Met Thr 65 70 75 80 Ile Leu Ser Pro Ala Ala
Asp Ser Thr Pro Asp Pro Gly Val Gln Gln 85 90 95 Leu Pro Lys Gly
Glu Pro Glu Thr Asp Leu Asn Pro Glu Leu Pro Ala 100 105 110 Ala His
Leu Ile Gly Ala Trp Met Ser Gly Gln Gly Leu Ser Trp Glu 115 120 125
Ala Ser Gln Glu Glu Ala Phe Leu Arg Ser Gly Ala Gln Phe Ser Pro 130
135 140 Thr His Gly Leu Ala Leu Pro Gln Asp Gly Val Tyr Tyr Leu Tyr
Cys 145 150 155 160 His Val Gly Tyr Arg Gly Arg Thr Pro Pro Ala Gly
Arg Ser Arg Ala 165 170 175 Arg Ser Leu Thr Leu Arg Ser Ala Leu Tyr
Arg Ala Gly Gly Ala Tyr 180 185 190 Gly Arg Gly Ser Pro Glu Leu Leu
Leu Glu Gly Ala Glu Thr Val Thr 195 200 205 Pro Val Val Asp Pro Ile
Gly Tyr Gly Ser Leu Trp Tyr Thr Ser Val 210 215 220 Gly Phe Gly Gly
Leu Ala Gln Leu Arg Ser Gly Glu Arg Val Tyr Val 225 230 235 240 Asn
Ile Ser His Pro Asp Met Val Asp Tyr Arg Arg Gly Lys Thr Phe 245 250
255 Phe Gly Ala Val Met Val Gly 260 <210> SEQ ID NO 347
<211> LENGTH: 186 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: human C-LT_126-306 fragment <400> SEQUENCE: 347
Leu Ala Cys Gly Gly Ser Pro Ala Ala Asp Ser Thr Pro Asp Pro Gly 1 5
10 15 Val Gln Gln Leu Pro Lys Gly Glu Pro Glu Thr Asp Leu Asn Pro
Glu 20 25 30 Leu Pro Ala Ala His Leu Ile Gly Ala Trp Met Ser Gly
Gln Gly Leu 35 40 45 Ser Trp Glu Ala Ser Gln Glu Glu Ala Phe Leu
Arg Ser Gly Ala Gln 50 55 60 Phe Ser Pro Thr His Gly Leu Ala Leu
Pro Gln Asp Gly Val Tyr Tyr 65 70 75 80 Leu Tyr Cys His Val Gly Tyr
Arg Gly Arg Thr Pro Pro Ala Gly Arg 85 90 95 Ser Arg Ala Arg Ser
Leu Thr Leu Arg Ser Ala Leu Tyr Arg Ala Gly 100 105 110 Gly Ala Tyr
Gly Arg Gly Ser Pro Glu Leu Leu Leu Glu Gly Ala Glu 115 120 125 Thr
Val Thr Pro Val Val Asp Pro Ile Gly Tyr Gly Ser Leu Trp Tyr 130 135
140 Thr Ser Val Gly Phe Gly Gly Leu Ala Gln Leu Arg Ser Gly Glu Arg
145 150 155 160 Val Tyr Val Asn Ile Ser His Pro Asp Met Val Asp Tyr
Arg Arg Gly 165 170 175 Lys Thr Phe Phe Gly Ala Val Met Val Gly 180
185 <210> SEQ ID NO 348 <211> LENGTH: 117 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Modified human prion
protein fragment <400> SEQUENCE: 348 Val Gly Gly Leu Gly Gly
Tyr Met Leu Gly Ser Ala Met Ser Arg Pro 1 5 10 15 Ile Ile His Phe
Gly Ser Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn 20 25 30 Met His
Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Met Asp Glu Tyr 35 40 45
Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Ile Lys 50
55 60 Gln His Thr Val Thr Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu
Thr 65 70 75 80 Asp Val Lys Met Met Glu Arg Val Val Glu Gln Met Cys
Ile Thr Gln 85 90 95 Tyr Glu Arg Glu Ser Gln Ala Tyr Tyr Gln Arg
Gly Arg Leu Ala Gly 100 105 110 Gly Gly Gly Cys Gly 115 <210>
SEQ ID NO 349 <211> LENGTH: 117 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Modified bovine prion protein
fragment <400> SEQUENCE: 349 Val Gly Gly Leu Gly Gly Tyr Met
Leu Gly Ser Ala Met Ser Arg Pro 1 5 10 15 Leu Ile His Phe Gly Ser
Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn 20 25 30 Met His Arg Tyr
Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr 35 40 45 Ser Asn
Gln Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Val Lys 50 55 60
Glu His Thr Val Thr Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr 65
70 75 80 Asp Ile Lys Met Met Glu Arg Val Val Glu Gln Met Cys Ile
Thr Gln 85 90 95 Tyr Gln Arg Glu Ser Gln Ala Tyr Tyr Gln Arg Gly
Arg Leu Ala Gly 100 105 110 Gly Gly Gly Cys Gly 115 <210> SEQ
ID NO 350 <211> LENGTH: 117 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Modified sheep prion protein fragment
<400> SEQUENCE: 350 Val Gly Gly Leu Gly Gly Tyr Met Leu Gly
Ser Ala Met Ser Arg Pro 1 5 10 15 Leu Ile His Phe Gly Asn Asp Tyr
Glu Asp Arg Tyr Tyr Arg Glu Asn 20 25 30 Met Tyr Arg Tyr Pro Asn
Gln Val Tyr Tyr Arg Pro Val Asp Arg Tyr 35 40 45 Ser Asn Gln Asn
Asn Phe Val His Asp Cys Val Asn Ile Thr Val Lys 50 55 60 Gln His
Thr Val Thr Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr 65 70 75 80
Asp Ile Lys Ile Met Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln 85
90 95 Tyr Gln Arg Glu Ser Gln Ala Tyr Tyr Gln Arg Gly Arg Leu Ala
Gly 100 105 110 Gly Gly Gly Cys Gly 115 <210> SEQ ID NO 351
<211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <220> FEATURE: <223> OTHER INFORMATION:
VEGFR-II derived peptide <400> SEQUENCE: 351 Cys Thr Ala Arg
Thr Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu 1 5 10 15 Tyr Pro
Ser Ser Lys His Gln His Lys Lys 20 25 <210> SEQ ID NO 352
<211> LENGTH: 26 <212> TYPE: PRT
<213> ORGANISM: Artificial <220> FEATURE: <223>
OTHER INFORMATION: Murine VEGFR-II derived peptide <400>
SEQUENCE: 352 Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Leu Asp Phe
Thr Trp His 1 5 10 15 Ser Pro Pro Ser Lys Ser His His Lys Lys 20 25
<210> SEQ ID NO 353 <211> LENGTH: 14 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Angiotensinogen <400>
SEQUENCE: 353 Asp Arg Val Tyr Ile His Pro Phe His Leu Val Ile His
Asn 1 5 10 <210> SEQ ID NO 354 <211> LENGTH: 10
<212> TYPE: PRT <213> ORGANISM: Artificial <220>
FEATURE: <223> OTHER INFORMATION: Angiotensin I <400>
SEQUENCE: 354 Asp Arg Val Tyr Ile His Pro Phe His Leu 1 5 10
<210> SEQ ID NO 355 <211> LENGTH: 8 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Angiotensin II <400> SEQUENCE:
355 Asp Arg Val Tyr Ile His Pro Phe 1 5 <210> SEQ ID NO 356
<211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <220> FEATURE: <223> OTHER INFORMATION:
cprplong <400> SEQUENCE: 356 Cys Ser Ala Met Ser Arg Pro Ile
Ile His Phe Gly Ser Asp Tyr Glu 1 5 10 15 Asp Arg Tyr Tyr Arg Glu
Asn Met His Arg 20 25 <210> SEQ ID NO 357 <211> LENGTH:
16 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<220> FEATURE: <223> OTHER INFORMATION: cprpshort
<400> SEQUENCE: 357 Cys Gly Ser Asp Tyr Glu Asp Arg Tyr Tyr
Arg Glu Asn Met His Arg 1 5 10 15 <210> SEQ ID NO 358
<211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
MuTNFa Peptide <400> SEQUENCE: 358 Cys Gly Gly Val Glu Glu
Gln Leu Glu Trp Leu Ser Gln Arg 1 5 10 <210> SEQ ID NO 359
<211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
3'TNF II Peptide <400> SEQUENCE: 359 Ser Ser Gln Asn Ser Ser
Asp Lys Pro Val Ala His Val Val Ala Asn 1 5 10 15 His Gly Val Gly
Gly Cys 20 <210> SEQ ID NO 360 <211> LENGTH: 20
<212> TYPE: PRT <213> ORGANISM: Artificial <220>
FEATURE: <223> OTHER INFORMATION: 5'TNF II Peptide
<400> SEQUENCE: 360 Cys Ser Ser Gln Asn Ser Ser Asp Lys Pro
Val Ala His Val Val Ala 1 5 10 15 Asn His Gly Val 20 <210>
SEQ ID NO 361 <211> LENGTH: 22 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <220> FEATURE: <223>
OTHER INFORMATION: 4-22 epitope <400> SEQUENCE: 361 Ser Ser
Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn 1 5 10 15
Pro Gln Ala Glu Gly Gln 20 <210> SEQ ID NO 362 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<220> FEATURE: <223> OTHER INFORMATION: amino acid
residues 22-32 <400> SEQUENCE: 362 Gln Leu Gln Trp Leu Asn
Arg Arg Ala Asn Ala 1 5 10 <210> SEQ ID NO 363 <211>
LENGTH: 74 <212> TYPE: DNA <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: pET22b(+)
<400> SEQUENCE: 363 gtttaacttt aagaaggaga tatacatatg
gatccggcta gcgctcgagg gtttaaacgg 60 cggccgcatg cacc 74 <210>
SEQ ID NO 364 <211> LENGTH: 26 <212> TYPE: PRT
<213> ORGANISM: Artificial <220> FEATURE: <223>
OTHER INFORMATION: cprplong prion peptide <400> SEQUENCE: 364
Cys Ser Ala Met Ser Arg Pro Met Ile His Phe Gly Asn Asp Trp Glu 1 5
10 15 Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg 20 25 <210> SEQ
ID NO 365 <211> LENGTH: 16 <212> TYPE: PRT <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: cprpshort prion peptide <400> SEQUENCE: 365 Cys
Gly Asn Asp Trp Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg 1 5 10
15 <210> SEQ ID NO 366 <211> LENGTH: 26 <212>
TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: murine VEGFR-2 peptide <400>
SEQUENCE: 366 Cys Thr Ala Arg Thr Glu Leu Asn Val Gly Leu Asp Phe
Thr Trp His 1 5 10 15 Ser Pro Pro Ser Lys Ser His His Lys Lys 20 25
<210> SEQ ID NO 367 <211> LENGTH: 18 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: ABeta 1-15 <400> SEQUENCE: 367
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Gly 1 5
10 15 Gly Cys <210> SEQ ID NO 368 <211> LENGTH: 30
<212> TYPE: PRT <213> ORGANISM: Artificial <220>
FEATURE: <223> OTHER INFORMATION: ABeta 1-27 <400>
SEQUENCE: 368 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His
His Gln Lys 1 5 10 15 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn
Gly Gly Cys 20 25 30 <210> SEQ ID NO 369 <211> LENGTH:
17 <212> TYPE: PRT <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: ABeta 33-42
<400> SEQUENCE: 369 Cys Gly His Gly Asn Lys Ser Gly Leu Met
Val Gly Gly Val Val Ile 1 5 10 15 Ala <210> SEQ ID NO 370
<211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
inverse primer <400> SEQUENCE: 370 ggtaacatcg gtcgagatgg
aaaacaaact ctggtcc 37 <210> SEQ ID NO 371 <211> LENGTH:
37 <212> TYPE: DNA <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: inverse primer
<400> SEQUENCE: 371 ggaccagagt ttgttttcca tctcgaccga tgttacc
37 <210> SEQ ID NO 372 <211> LENGTH: 22 <212>
TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: upstream primer <400>
SEQUENCE: 372 agctcgcccg gggatcctct ag 22 <210> SEQ ID NO 373
<211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
downstream primer <400> SEQUENCE: 373 cgatgcattt catccttagt
tatcaatacg ctgggttcag 40 <210> SEQ ID NO 374 <211>
LENGTH: 36 <212> TYPE: DNA <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: inverse primer
<400> SEQUENCE: 374 ggcaaaatta gagactgtta ctttaggtaa gatcgg
36 <210> SEQ ID NO 375 <211> LENGTH: 36 <212>
TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: inverse primer <400> SEQUENCE:
375 ccgatcttac ctaaagtaac agtctctaat tttgcc 36 <210> SEQ ID
NO 376 <211> LENGTH: 33 <212> TYPE: DNA <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: Upstream primer <400> SEQUENCE: 376 ggccatggca
cgactcgaga ctgttacttt agg 33 <210> SEQ ID NO 377 <211>
LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: Downstream
primer <400> SEQUENCE: 377 gatttaggtg acactatag 19
<210> SEQ ID NO 378 <211> LENGTH: 37 <212> TYPE:
DNA <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Inverse primer <400> SEQUENCE:
378 gatggacgtc aaactctggt cctcaatccg cgtgggg 37 <210> SEQ ID
NO 379 <211> LENGTH: 37 <212> TYPE: DNA <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: Inverse primer <400> SEQUENCE: 379 ccccacgcgg
attgaggacc agagtttgac gtccatc 37 <210> SEQ ID NO 380
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
Angio I <400> SEQUENCE: 380 Cys Gly Gly Asp Arg Val Tyr Ile
His Pro Phe 1 5 10 <210> SEQ ID NO 381 <211> LENGTH: 13
<212> TYPE: PRT <213> ORGANISM: Artificial <220>
FEATURE: <223> OTHER INFORMATION: Angio II <400>
SEQUENCE: 381 Cys Gly Gly Asp Arg Val Tyr Ile His Pro Phe His Leu 1
5 10 <210> SEQ ID NO 382 <211> LENGTH: 13 <212>
TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Angio III <400> SEQUENCE: 382
Asp Arg Val Tyr Ile His Pro Phe His Leu Gly Gly Cys 1 5 10
<210> SEQ ID NO 383 <211> LENGTH: 11 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Angio IV <400> SEQUENCE: 383
Cys Asp Arg Val Tyr Ile His Pro Phe His Leu 1 5 10 <210> SEQ
ID NO 384 <211> LENGTH: 23 <212> TYPE: PRT <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: Der p I p52; aa 52-72 <400> SEQUENCE: 384 Cys
Gly Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp Cys 1 5 10
15 Ala Ser Gln His Gly Cys His 20 <210> SEQ ID NO 385
<211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION: Der
p 1 p117; aa 117-137 <400> SEQUENCE: 385 Cys Gln Ile Tyr Pro
Pro Asn Ala Asn Lys Ile Arg Glu Ala Leu Ala 1 5 10 15 Gln Thr His
Ser Ala 20 <210> SEQ ID NO 386 <211> LENGTH: 38
<212> TYPE: DNA <213> ORGANISM: Artificial <220>
FEATURE: <223> OTHER INFORMATION: HBcAgwtHindIIII <400>
SEQUENCE: 386 cgcgtcccaa gcttctaaca ttgagattcc cgagattg 38
<210> SEQ ID NO 387 <211> LENGTH: 14 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: muTNFa peptide <400> SEQUENCE:
387 Cys Gly Gly Val Glu Glu Gln Leu Glu Trp Leu Ser Gln Arg 1 5 10
<210> SEQ ID NO 388 <211> LENGTH: 54 <212> TYPE:
DNA <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Primer CA2F <400> SEQUENCE:
388 cggctcgagc atcaccatca ccatcacggt gaagttaaac tgcagctgga gtcg 54
<210> SEQ ID NO 389
<211> LENGTH: 52 <212> TYPE: DNA <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
Primer CA1R <400> SEQUENCE: 389 catgccatgg ttaaccacag
gtgtgggttt tatcacaaga tttgggcaca ac 52 <210> SEQ ID NO 390
<211> LENGTH: 61 <212> TYPE: DNA <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
Primer CB1R <400> SEQUENCE: 390 catgccatgg ttaaccacac
ggcggagagg tgtgggtttt atcacaagat ttgggctcaa 60 c 61 <210> SEQ
ID NO 391 <211> LENGTH: 58 <212> TYPE: DNA <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: Primer CC1R <400> SEQUENCE: 391 ccagaagaac
ccggcggggt agacggtttc gggctagcac aagatttggg ctcaactc 58 <210>
SEQ ID NO 392 <211> LENGTH: 60 <212> TYPE: DNA
<213> ORGANISM: Artificial <220> FEATURE: <223>
OTHER INFORMATION: Primer CC1F <400> SEQUENCE: 392 cgccgggttc
ttctggtggt gctccgggtg gttgcggtta accatggaga aaataaagag 60
<210> SEQ ID NO 393 <211> LENGTH: 18 <212> TYPE:
DNA <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Primer CCR2 <400> SEQUENCE:
393 ctcccgggta gaagtcac 18 <210> SEQ ID NO 394 <211>
LENGTH: 219 <212> TYPE: PRT <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: Light chains of
pCA2, pCB2 and pCC2 <400> SEQUENCE: 394 Asp Ile Glu Leu Val
Val Thr Gln Pro Ala Ser Val Ser Gly Ser Pro 1 5 10 15 Gly Gln Ser
Ile Thr Ile Ser Cys Thr Gly Thr Arg Ser Asp Val Gly 20 25 30 Gly
Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro 35 40
45 Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn
50 55 60 Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr
Ile Ser 65 70 75 80 Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys
Ser Ser Tyr Thr 85 90 95 Ser Ser Ser Thr Leu Gly Val Phe Gly Gly
Gly Thr Lys Leu Thr Val 100 105 110 Leu Gly Gln Pro Lys Ala Ala Pro
Ser Val Thr Leu Phe Pro Pro Ser 115 120 125 Ser Glu Glu Leu Gln Ala
Asn Lys Ala Thr Leu Val Cys Leu Ile Ser 130 135 140 Asp Phe Tyr Pro
Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser 145 150 155 160 Pro
Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn 165 170
175 Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp
180 185 190 Lys Ser His Lys Ser Tyr Ser Cys Gln Val Thr His Glu Gly
Ser Thr 195 200 205 Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210
215 <210> SEQ ID NO 395 <211> LENGTH: 251 <212>
TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Heavy chain of pCA2 <400>
SEQUENCE: 395 Glu Val Lys Leu Gln Leu Glu His His His His His His
Gly Glu Val 1 5 10 15 Lys Leu Gln Leu Glu Ser Gly Pro Gly Leu Val
Lys Pro Ser Glu Thr 20 25 30 Leu Ser Leu Thr Cys Thr Val Ser Gly
Gly Ser Ile Ser Ser Gly Gly 35 40 45 Tyr Tyr Trp Thr Trp Ile Arg
Gln Arg Pro Gly Lys Gly Leu Glu Trp 50 55 60 Ile Gly Tyr Ile Tyr
Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu 65 70 75 80 Lys Ser Arg
Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 85 90 95 Leu
Arg Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 100 105
110 Ala Arg Glu Arg Gly Glu Thr Gly Leu Tyr Tyr Pro Tyr Tyr Tyr Ile
115 120 125 Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser Ala
Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn
Ser Gly Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu 225 230
235 240 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Gly 245 250
<210> SEQ ID NO 396 <211> LENGTH: 254 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Heavy chain of pCB2 <400>
SEQUENCE: 396 Glu Val Lys Leu Gln Leu Glu His His His His His His
Gly Glu Val 1 5 10 15 Lys Leu Gln Leu Glu Ser Gly Pro Gly Leu Val
Lys Pro Ser Glu Thr 20 25 30 Leu Ser Leu Thr Cys Thr Val Ser Gly
Gly Ser Ile Ser Ser Gly Gly 35 40 45 Tyr Tyr Trp Thr Trp Ile Arg
Gln Arg Pro Gly Lys Gly Leu Glu Trp 50 55 60 Ile Gly Tyr Ile Tyr
Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu 65 70 75 80 Lys Ser Arg
Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser 85 90 95 Leu
Arg Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys 100 105
110 Ala Arg Glu Arg Gly Glu Thr Gly Leu Tyr Tyr Pro Tyr Tyr Tyr Ile
115 120 125 Asp Val Trp Gly Thr Gly Thr Thr Val Thr Val Ser Ser Ala
Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn
Ser Gly Ala Leu Thr Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu 225 230
235 240 Pro Lys Ser Cys Asp Lys Thr His Thr Ser Pro Pro Cys Gly 245
250 <210> SEQ ID NO 397 <211> LENGTH: 263 <212>
TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Heavy chain of pCC2 <400>
SEQUENCE: 397 Glu Val Lys Leu Gln Leu Glu His His His His His His
Gly Glu Val 1 5 10 15 Lys Leu Gln Leu Glu Ser Gly Pro Gly Leu Val
Lys Pro Ser Glu Thr 20 25 30 Leu Ser Leu Thr Cys Thr Val Ser Gly
Gly Ser Ile Ser Ser Gly Gly 35 40 45 Tyr Tyr Trp Thr Trp Ile Arg
Gln Arg Pro Gly Lys Gly Leu Glu Trp 50 55 60 Ile Gly Tyr Ile Tyr
Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu
65 70 75 80 Lys Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln
Phe Ser 85 90 95 Leu Arg Leu Thr Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys 100 105 110 Ala Arg Glu Arg Gly Glu Thr Gly Leu Tyr
Tyr Pro Tyr Tyr Tyr Ile 115 120 125 Asp Val Trp Gly Thr Gly Thr Thr
Val Thr Val Ser Ser Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185
190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
Lys Arg Val Glu 225 230 235 240 Pro Lys Ser Cys Ala Ser Pro Lys Pro
Ser Thr Pro Pro Gly Ser Ser 245 250 255 Gly Gly Ala Pro Gly Gly Cys
260 <210> SEQ ID NO 398 <211> LENGTH: 23 <212>
TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: TNF-alpha attachment <400>
SEQUENCE: 398 Cys Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His
Val Val Ala 1 5 10 15 Asn Pro Gln Ala Glu Gly Gln 20 <210>
SEQ ID NO 399 <211> LENGTH: 25 <212> TYPE: PRT
<213> ORGANISM: Artificial <220> FEATURE: <223>
OTHER INFORMATION: TNF-alpha attachment <400> SEQUENCE: 399
Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn 1 5
10 15 Pro Gln Ala Glu Gly Gln Gly Gly Cys 20 25 <210> SEQ ID
NO 400 <211> LENGTH: 14 <212> TYPE: PRT <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: TNF-alpha attachment <400> SEQUENCE: 400 Cys Gly
Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala 1 5 10 <210>
SEQ ID NO 401 <211> LENGTH: 26 <212> TYPE: PRT
<213> ORGANISM: Bovine <220> FEATURE: <223> OTHER
INFORMATION: cprplong <400> SEQUENCE: 401 Cys Ser Ala Met Ser
Arg Pro Leu Ile His Phe Gly Asn Asp Tyr Glu 1 5 10 15 Asp Arg Tyr
Tyr Arg Glu Asn Met His Arg 20 25 <210> SEQ ID NO 402
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Bovine <220> FEATURE: <223> OTHER INFORMATION:
cprpshort <400> SEQUENCE: 402 Cys Gly Asn Asp Tyr Glu Asp Arg
Tyr Tyr Arg Glu Asn Met His Arg 1 5 10 15 <210> SEQ ID NO 403
<211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM:
Sheep <220> FEATURE: <223> OTHER INFORMATION: cprplong
<400> SEQUENCE: 403 Cys Ser Ala Met Ser Arg Pro Leu Ile His
Phe Gly Asn Asp Tyr Glu 1 5 10 15 Asp Arg Tyr Tyr Arg Glu Asn Met
Tyr Arg 20 25 <210> SEQ ID NO 404 <211> LENGTH: 16
<212> TYPE: PRT <213> ORGANISM: Sheep <220>
FEATURE: <223> OTHER INFORMATION: cprpshort <400>
SEQUENCE: 404 Cys Gly Asn Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn
Met Tyr Arg 1 5 10 15 <210> SEQ ID NO 405 <211> LENGTH:
7 <212> TYPE: PRT <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: ABeta
N-terminus fused <400> SEQUENCE: 405 Cys Gly His Gly Asn Lys
Ser 1 5 <210> SEQ ID NO 406 <211> LENGTH: 5 <212>
TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: HBcAg1-183Lys construct <400>
SEQUENCE: 406 Gly Gly Lys Gly Gly 1 5 <210> SEQ ID NO 407
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
Glycine serine linkers <400> SEQUENCE: 407 Gly Gly Gly Gly
Ser 1 5 <210> SEQ ID NO 408 <211> LENGTH: 10
<212> TYPE: PRT <213> ORGANISM: Artificial <220>
FEATURE: <223> OTHER INFORMATION: N-terminal gamma 1
<400> SEQUENCE: 408 Cys Gly Asp Lys Thr His Thr Ser Pro Pro 1
5 10 <210> SEQ ID NO 409 <211> LENGTH: 10 <212>
TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: C-terminal gamma 1 <400>
SEQUENCE: 409 Asp Lys Thr His Thr Ser Pro Pro Cys Gly 1 5 10
<210> SEQ ID NO 410 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: N-terminal gamma 3 <400>
SEQUENCE: 410 Cys Gly Gly Pro Lys Pro Ser Thr Pro Pro Gly Ser Ser
Gly Gly Ala 1 5 10 15 Pro <210> SEQ ID NO 411 <211>
LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: C-terminal
gamma 3 <400> SEQUENCE: 411 Pro Lys Pro Ser Thr Pro Pro Gly
Ser Ser Gly Gly Ala Pro Gly Gly 1 5 10 15 Cys Gly <210> SEQ
ID NO 412 <211> LENGTH: 6 <212> TYPE: PRT <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: N-terminal glycine linker <400> SEQUENCE: 412
Gly Cys Gly Gly Gly Gly 1 5 <210> SEQ ID NO 413
<211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
C-terminal glycine linker <400> SEQUENCE: 413 Gly Gly Gly Gly
Cys Gly 1 5 <210> SEQ ID NO 414 <211> LENGTH: 4
<212> TYPE: PRT <213> ORGANISM: Artificial <220>
FEATURE: <223> OTHER INFORMATION: C-terminal peptide linker
<400> SEQUENCE: 414 Gly Gly Cys Gly 1 <210> SEQ ID NO
415 <211> LENGTH: 5 <212> TYPE: PRT <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: Lymphotoxin-Beta linker <400> SEQUENCE: 415 Leu
Ala Cys Gly Gly 1 5 <210> SEQ ID NO 416 <211> LENGTH: 4
<212> TYPE: PRT <213> ORGANISM: Artificial <220>
FEATURE: <223> OTHER INFORMATION: Amino acid linker
<400> SEQUENCE: 416 Ala Cys Gly Gly 1 <210> SEQ ID NO
417 <211> LENGTH: 8 <212> TYPE: PRT <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: N-terminal IL-13 <400> SEQUENCE: 417 Leu Ala Cys
Gly Gly Gly Gly Gly 1 5 <210> SEQ ID NO 418 <211>
LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: Amino acid
linker <400> SEQUENCE: 418 Ala Cys Gly Gly Gly Gly Gly 1 5
<210> SEQ ID NO 419 <211> LENGTH: 12 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: N-terminal IL-5 <400>
SEQUENCE: 419 Ala Asp Pro Gly Cys Gly Gly Gly Gly Gly Leu Ala 1 5
10 <210> SEQ ID NO 420 <211> LENGTH: 7 <212>
TYPE: PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Amino acid linker <400>
SEQUENCE: 420 Gly Cys Gly Gly Gly Gly Gly 1 5 <210> SEQ ID NO
421 <211> LENGTH: 31 <212> TYPE: PRT <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: Amidated ABeta 1-27 <220> FEATURE: <221>
NAME/KEY: MOD_RES <222> LOCATION: (31)..(31) <223>
OTHER INFORMATION: AMIDATION <400> SEQUENCE: 421 Asp Ala Glu
Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 1 5 10 15 Leu
Val Phe Phe Ala Glu Asp Val Gly Ser Asn Gly Gly Cys Xaa 20 25 30
<210> SEQ ID NO 422 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Hydrogenated ABeta 33-42 <220>
FEATURE: <221> NAME/KEY: MOD_RES <222> LOCATION:
(1)..(1) <223> OTHER INFORMATION: Xaa=Hydrogen <400>
SEQUENCE: 422 Xaa Cys Gly His Gly Asn Lys Ser Gly Leu Met Val Gly
Gly Val Val 1 5 10 15 Ile <210> SEQ ID NO 423 <211>
LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: Amidated ABeta
1-15 <220> FEATURE: <221> NAME/KEY: MOD_RES <222>
LOCATION: (19)..(19) <223> OTHER INFORMATION: AMIDATION
<400> SEQUENCE: 423 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
Glu Val His His Gln Gly 1 5 10 15 Gly Cys Xaa <210> SEQ ID NO
424 <211> LENGTH: 9 <212> TYPE: PRT <213>
ORGANISM: Artificial <220> FEATURE: <223> OTHER
INFORMATION: Amino acid linker <400> SEQUENCE: 424 Gly Cys
Gly Ser Gly Gly Gly Gly Ser 1 5 <210> SEQ ID NO 425
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
Artificial <220> FEATURE: <223> OTHER INFORMATION:
Amino acid linker <400> SEQUENCE: 425 Gly Ser Gly Gly Gly Gly
Ser Gly Cys Gly 1 5 10 <210> SEQ ID NO 426 <211>
LENGTH: 745 <212> TYPE: DNA <213> ORGANISM: Artificial
<220> FEATURE: <223> OTHER INFORMATION: pCep-Xa-Fc*
construct <400> SEQUENCE: 426 gatccagcag ctgggctcga
ggtgctagcg ggagggggtg gatgtgggat cgaaggtcgc 60 aagcttactc
acacatgccc accgtgccca gcacctgaag ccgagggggc accgtcagtc 120
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
180 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg
gtacgtggac 240 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg
agcagtacaa cagcacgtac 300 cgtgtggtca gcgtcctcac cgtcctgcac
caggactggc tgaatggcaa ggagtacaag 360 tgcaaggtct ccaacaaagc
cctcccagcc tccatcgaga aaaccatctc caaagccaaa 420 gggcagcccc
gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag 480
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
540 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gttggactcc 600 gacggctcct tcttcctcta cagcaagctc accgtggaca
agagcaggtg gcagcagggg 660 aacgtcttct catgctccgt gatgcatgag
gctctgcaca accactacac gcagaagagc 720 ctctccctgt ctccgggtaa atgac
745 <210> SEQ ID NO 427 <211> LENGTH: 96 <212>
TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: pCep-EK-Fc* construct <400>
SEQUENCE: 427 gatccagcag ctgggctcga ggtgctagcg ggagggggtg
gatgtgggga cgatgacgac 60 aagcttactc acacatgccc accgtgccca gcacct 96
<210> SEQ ID NO 428 <211> LENGTH: 144 <212> TYPE:
DNA <213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: pCep-SP-EK-Fc* construct <400>
SEQUENCE: 428 atggagacag acacactcct gctatgggta ctgctgctct
gggttccagg ttccactggt 60 gacgcggatc cagcagctgg gctcgaggtg
ctagcgggag ggggtggatg tggggacgat 120 gacgacaagc ttactcacac atgc
144
<210> SEQ ID NO 429 <211> LENGTH: 399 <212> TYPE:
DNA <213> ORGANISM: Mouse <220> FEATURE: <223>
OTHER INFORMATION: Resistin protein Res-C-Xa <400> SEQUENCE:
429 ggatccggga tgaagaacct ttcatttccc ctccttttcc ttttcttcct
tgtccctgaa 60 ctgctgggct ccagcatgcc actgtgtccc atcgatgaag
ccatcgacaa gaagatcaaa 120 caagacttca actccctgtt tccaaatgca
ataaagaaca ttggcttaaa ttgctggaca 180 gtctcctcca gagggaagtt
ggcctcctgc ccagaaggca cagcagtctt gagctgctcc 240 tgtggctctg
cctgtggctc gtgggacatt cgtgaagaaa aagtgtgtca ctgccagtgt 300
gcaaggatag actggacagc agcccgctgc tgtaagctgc aggtcgcttc ctctctagcg
360 ggagggggtg gatgtgggat cgaaggtcgc aagcttact 399 <210> SEQ
ID NO 430 <211> LENGTH: 399 <212> TYPE: DNA <213>
ORGANISM: Mouse <220> FEATURE: <223> OTHER INFORMATION:
Resistin protein Res-C-EK <400> SEQUENCE: 430 ggatccggga
tgaagaacct ttcatttccc ctccttttcc ttttcttcct tgtccctgaa 60
ctgctgggct ccagcatgcc actgtgtccc atcgatgaag ccatcgacaa gaagatcaaa
120 caagacttca actccctgtt tccaaatgca ataaagaaca ttggcttaaa
ttgctggaca 180 gtctcctcca gagggaagtt ggcctcctgc caagaaggca
cagcagtctt gagctgctcc 240 tgtggctctg cctctggctc gtgggacatt
cgtgaagaaa aagtgtgtca ctgccagtgt 300 gcaaggatag actggacagc
agcccgctgc tgtaagctgc aggtcgcttc ctctctagcg 360 ggagggggtg
gatgtgggga cgatgacgac aagcttact 399
* * * * *